{"docstore/metadata": {"afb9b040-6326-42a5-83fb-cf44aa93e06d": {"doc_hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100"}, "1036a4f8-3485-4d30-a6cb-aa4f9bc3a0a5": {"doc_hash": "6941abde4d2e85a01de135dbfae1ff50ce2987d5409f92e506b75fc89a9fec40", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "052cbc8d-fa9f-42fb-83e9-5766d8e788a4": {"doc_hash": "c3aaf46100e63f01ac093a3719a66aecdb5f833253e823b2db33dd2ba719eca1", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "43458db4-244a-48b3-8e1d-af78647d3291": {"doc_hash": "9294ae825a372fcea62da3ede49728d4f592118c840eca08f654146591029123", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "d80d93c7-46e6-4a61-bae0-ebca359a0f81": {"doc_hash": "2e551012b3c1da3fb262f9376c0eebcd96f57234dff1de5eba7e211c0a35bf5f", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "4158e382-6845-4f03-9e03-1bb0da38247c": {"doc_hash": "6e5e46c32f6e93d8e1a1b91a202a5b7203ddc0879438932242ee10fc1f40167e", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "c685d16f-0229-44b6-a640-095ba85eb828": {"doc_hash": "3852ace7075dcae95f4c04efec66582fbf7acdc5425ede5bf9d682b1f9d32082", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "19fb4a23-a91f-476a-82c9-8a3e749927fb": {"doc_hash": "c833ef9e763d9c7d23b12491a7aa72f74cc7d6c82f48f560267b74cd2bed0786", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "f4953596-7d02-4fe0-8879-9e16292174ab": {"doc_hash": "636af05ca4be22ddcb0babe7c70b60be8527d692310f7790f073821f1bf3e889", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "236b8a33-9489-48f1-ae41-b2025f3ccdaf": {"doc_hash": "134a34e8eed110b88120808ec7b92281f2338c8b677d97236c31267fe2ed8cf2", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "7f5fc362-b2f0-41bd-b2a3-1c0c6e3b9830": {"doc_hash": "52cfacb86485fa9b0d3589c25fca863225f7caa8a29150193480eb8d69142bfc", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "1ad76d80-f31b-433e-bc05-c6580728a784": {"doc_hash": "d89e381a51902ed5fcd8383111dd8b336a97ea4c520b3efedcfe47a2ce65a50d", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "1ac7f708-6fc9-4cd4-8800-0e058f5f38ee": {"doc_hash": "477dd5bbc9fc7ee972feab8283a950837109adf0efcf8b6321c8cc20579bc91a", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "4489c10f-77ce-47f6-ba54-5265142fac28": {"doc_hash": "416d01bc054a988140434b2d0ab0c78d82ac90c140647bac06f99ae2431834a8", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "ddb3c7a4-47d7-46b0-b4ba-962f9da7b55b": {"doc_hash": "e39ec2df6c54b25570df020279b475987b8494220587e222d579c88c9d03fccb", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "a6ca6a4a-ad94-41e2-9994-d92271b399aa": {"doc_hash": "22c3eaa8c5a6e176a612b799805a0ec33a98c38139b7e8c9c1595b67d745f726", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "99135879-8373-4bb8-8700-abfc7ed740b6": {"doc_hash": "4ba1d797c2df239c08215382a17fe55e640ed6064648b8e9b4f77a5709eedd2f", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "0b151272-b5f3-46f1-9fa4-8281dc1b54f3": {"doc_hash": "6305c6510d771bc8f72aad41abd7839c6478a0318ce5adf3d69a5e54322dec83", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "ecafb81d-90b8-4b6c-9cad-5cdf3884e661": {"doc_hash": "aecf88a3ebe7e53f54d19110eec2433b14f2d8343fa1ab30d61392da10f6d6be", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "eb46cca4-1e07-48d1-b2b0-a9e5c2e17106": {"doc_hash": "b04a2d523359faad4f1dcfd4850e4e3d37196d8be61025b81ae2db0930836f73", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "a9692c7a-ee28-44ac-b19b-1bd19e41c25b": {"doc_hash": "1388f83138901a153910da0c9e18c2cd5ffb19468bfe4907f38ae78bffb779d0", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "ad805fd6-1618-4255-a9cc-6be22582b2fd": {"doc_hash": "b34227b22d09c558481c650fda1afbc0a5dfc2bc7e65bf27b546f848e93ecd12", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "aede0b6a-4ecb-491a-8d8c-290df566cb1a": {"doc_hash": "8867981ca054fa75b3b017cf9c1a845a9e81690a94b2ea719a703b162417deac", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "25c75933-341f-4f40-bff4-164b65b2d1f2": {"doc_hash": "51daf0aca388949f1b3a30769931138bcad4a699afee8801da3685d5a3006c49", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "d5186346-bc1c-456b-8eca-6e392508db4a": {"doc_hash": "2af02ff8add799b71d88f43db4def9d816dd2f26acc11efe482b5b382fe340f8", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "1b8cbd76-01c7-443f-ad43-0b4ccd2350ef": {"doc_hash": "71f3ef4c56f249d4b0038d9fcd21e0cd55448c71fe71579305f725825aca9d11", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "449a6cce-d131-41e8-9502-e32a621694bf": {"doc_hash": "b9d78dbe1d94ebcadaf8d0b2edfa343f03a4269295f5315c63b506a7bbc63d46", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "103d247a-c0df-4b31-b219-83173b72fb65": {"doc_hash": "997fb8524d50aecdc5f707e9497a892d6ca5998a42698f3258fa8e288b0bd411", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "e8d2eacc-9f37-4d14-ba67-dfcf08f7d1ee": {"doc_hash": "b2e16a2e9beaf85de2db208711de81a4344b7d2310a6752402b64f216dd60c83", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "c5b0e74a-7ae2-4afb-b7fc-8cee366a3e91": {"doc_hash": "dbeb4011b0bbd4a5b1adbb26b3c79148769beb7e15406b7ad0ab3f2c2e7bb21e", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "b17bc647-e238-4e04-a2c5-cc6659c0c0f0": {"doc_hash": "ceb498dfaac92032153d36d976e51ffb2130efd1a7f4359bff96e5b45dff8ea2", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "8479a90a-1221-4e8b-abcf-7fc084c4021c": {"doc_hash": "c50dde396d447f778003abfda4aa9f21991da59e0f8a6e959da46b50b4c7dccd", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "f4448a73-5eb5-4ba1-8068-5bfda83b79cb": {"doc_hash": "8d98dd57abefcd7559140069e138e2d06c3554208eea0053c3055c39e2e526bb", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "45c4adb3-6a9d-47c1-b73e-add0b14a913c": {"doc_hash": "e9014d9630e96d53085c1e975bc8d70ffcb812b3e5ead169f5879f59c59ef785", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "daa465cc-2819-48f3-aa86-5d356cd5d569": {"doc_hash": "8bdbf90ee2e1ace2afd82a9b1e760f17214658864f34e9900f4a1e70cec1bf76", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "ee99db64-dd02-4b8b-b523-3f332e1a9456": {"doc_hash": "215eb69cdb443d69a1fcbbb33dcebd1bae3f9b1ba3d57c848876352e1ac7c170", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "59c7b1bd-6874-4dc4-a60b-d76951e40ca5": {"doc_hash": "928a6e2d556a6cad5e82ae62e828fd98a7a3b58b87b38ea91b4af203f119de0f", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "69ba04b1-ec0b-4f35-9c26-0dc6e2180114": {"doc_hash": "15ea1fd873ac6d5f7bc55660ef4cb68d9c320697f9e2bd3d35e0ac11bffd1fac", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "e32cab25-cf9e-4ce9-bc0a-1763e97caf72": {"doc_hash": "02b4ba398885004d407eee6205706e6a607a6b53860d0c76dbba76861effb5e3", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "24a37567-78f2-405e-ab36-09f0f98f53a7": {"doc_hash": "9ca005f8a421e9484460328f1d2427e67792bcc3b865f0abd5784c6f227f29c1", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "49c0e777-a6c0-4529-974a-1d52c86e4cd8": {"doc_hash": "88347395bcc9af06f0e9ed699120a44b8e58e6751d850a7d021aaa79ab6580ab", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "40baa07a-bdda-403d-b422-81e5ef472ba7": {"doc_hash": "e7950ccf235ca0f0baca04c917ed9fd17b12727843a32299ad8c37197128c50a", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "4a587a50-e6bc-4dcb-90fa-2f15d08c055a": {"doc_hash": "5b389ff47ba24e99ae4503c0d0f3f077d3bce23369cbf4165f2fbb96e5d642bf", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "14d7c90d-0e4a-4de3-b1d1-6fd8b1bd90bb": {"doc_hash": "74c0f0df0cc4dda4044a80f76236165f9a72b07f7d0495768c15714eaf947132", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "71f7b1c0-17cc-4e46-ba75-d40b74faf6cf": {"doc_hash": "da05a5b4bfc66e386b990fc024d32e42cac0e1ca7777b5dff690122e9722a841", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "6f2369d1-2979-4dfa-97cc-197840df09bc": {"doc_hash": "9af4bf1b2d6609fb24b342b2a1cec1ac6c5bd832fe3ad4c1b398c29e19eb5f33", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "0bfa73c0-65f0-4b6b-bd9d-bb1d70cd71e6": {"doc_hash": "46c8baaba7d382fe8f0a394c0d0fe15e0f0597cb6fcb3da901c94861b5007118", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "8b8c5c2b-d62f-4c3d-b88c-ff0b905bb01f": {"doc_hash": "1e188780ed6ea3008b683025f5787fc956bf03878396983a1816bd709c8b9614", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "f4d8731f-de36-422e-b47c-dde8f7d43c3a": {"doc_hash": "88671cd5509a082b5c63f44b0c050f0c99eef949ec31e541500d2293d8259bef", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "e54d1f30-7e17-4486-a9d6-9c317842cca2": {"doc_hash": "5b39f6168e0cc5323b14a39757893da6ecc9adc1f3182ceb0985acf2d9da4789", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "00529685-51ce-451c-9738-58689422bda1": {"doc_hash": "30f507858ab58a63b86563e27d50cc89dd8233cf1ab74051d56dc911e89d82df", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "eb23ea85-cec7-47c9-b7ac-c1994897aa74": {"doc_hash": "87bdfd779102dfcca5fb4fb3156630440b8dfccb54327d12fa2012b2dd5994cc", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "9cb11c9f-ab42-4032-9247-42891281c397": {"doc_hash": "d5b416268f71bc6fb00facd4084e4ebd53bb1c5cc634630b50081db123ac0bde", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "937519ce-0dad-48f6-8445-232d1f32866e": {"doc_hash": "acd97c76c3c0e91cf650e94dcfe6bb54ab3622b9eba9fddaad38c64ad897bcde", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "61f7f586-3fbd-4224-9f4d-ee339ef1ba5a": {"doc_hash": "c8b79b0f066e4a07c584ec38d96a59178a4f25a5cad1c907cce6426e123819dc", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "68d17695-6053-4a48-af47-35705201d333": {"doc_hash": "94128a4ebe9608705183b4f278fdbffc55cd6416e22e357e4391bf7e92ba5844", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "0d3f64cc-bd9f-4fd3-a1b9-3a10ed44b518": {"doc_hash": "5ed4c2b582c2a4b5027a807c86e4bef0ba1a53b014ae91a4eaf57a43b2685c27", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "9be33f89-e3d7-44cc-a1dc-67347895e4c1": {"doc_hash": "4f2d381e9243974f3819e6bb13cb4dde14e698fea85ffda1a3d252737bad3ea9", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "91d2c834-1bb8-459b-a791-c98887609019": {"doc_hash": "61d46d44102569cb4b45e4d06e93adabce5ac7e81d5ca23a88d81d3e24a49323", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "d16802c4-9be4-46da-9d90-7b95036ad451": {"doc_hash": "2aec09ef2240a9417ca352aaad69e8856456395e4193461fe4f6adf1eca3b228", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "1a0fd09c-bdda-4bd5-90a5-c829def51fda": {"doc_hash": "ddeadd2572bca6f0be83d400403480a925fe866f347a73efd5702d5e066d5752", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "690b7103-f38e-46da-8511-f9e7835a084c": {"doc_hash": "5821d285f56d82f2924ac6cd49f36abd78d79b8ed7aa2d0a157819dd9b4eff88", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "acb4dec0-79a4-454e-9289-7cdfd94ceb21": {"doc_hash": "81f0c026b193f7f566c6c2a5c8ec9ea1b06d4308402c9ebcd74a7c6545b5437e", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "30f154ac-54d0-457c-af30-6373dace70ba": {"doc_hash": "f99e81427a65994110beb99117e51a40a7f7a6d008973b9fbbc3b6f1a677ee51", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "6a4be7fb-c4e3-4b91-bf58-ffbb5cd7248d": {"doc_hash": "90070b6f640477d03be155cf1b154343f55fc88c392536213fef7b1eab5a576f", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "961e12af-4d2f-4f75-8018-8e3ababf2bd7": {"doc_hash": "2eab85cda44b2c6f76231baa6e98d8e54a9680448e958197fbd0905e3c9a56bf", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "9407dfbb-c851-4b9d-9004-7d81b463b5e3": {"doc_hash": "408f48667d8e9549165151f6d7a0ab32c380f4891301c68f7807a1f951623a32", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "c161b1ee-d189-455b-b78b-d089d9154a45": {"doc_hash": "60c6f882262f96df96192a3fffc718cb8705610a8b630f14d6788757130ec722", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "3b67ef33-19f3-4cb6-8fb3-d6d9259afe2f": {"doc_hash": "a404e890cd807faf3b8d582760aa1eb64d677e3e33db2deca3339119e992dbba", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "a177ca05-4dea-44f4-970e-ee783b7bfc0a": {"doc_hash": "4c4d86d17e8635aa42b7e0131c5426fea001debe8199e2c0b3760140e896a738", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "0ffec63e-c37c-4c72-a712-3b7fccaef9d2": {"doc_hash": "44e5b4c76b7f05fa4d19de298411956bb7cafac13518fee80bc104b563ae639a", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "9692b485-7b15-4800-9659-f813ae362532": {"doc_hash": "94088a28b8d9ff71e25efaac6ee82f12dcf0f8d371dbbf6de4c92a5dbc565019", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "28ac60bc-bda8-4b08-9942-5edd029b9670": {"doc_hash": "75fa30f2921751d08a0ca6d2da90e9a58021d850652ef8f27420b049d08b4747", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "dcaeca5c-1ee8-430a-b687-58e0a3fbd310": {"doc_hash": "a9f4b1860a333f2c63a8f9e8960ecf983beacb3273495b11fc2590e9415c8e8f", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "288eccf3-d9f1-4b5f-b044-b3a3675208cd": {"doc_hash": "13039942b75dbae7c4f65fd836b55843cd9ab42f9fe6e60f83c88f2697ff58d3", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "6b69d05c-f395-4901-91a4-5faccc2bc2fc": {"doc_hash": "24291050f282181e759a6c073546f82fa6a5c409d8740d0dd77cf6892f054fa4", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "56edb2ea-d832-48e1-a724-94a83e10b95d": {"doc_hash": "defe78cc4ea3dd2b93a0c4637361b99b1ab081bcb0ae07b07373d9ab5c629886", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "649ce2f9-13db-4093-815f-4d5af1186966": {"doc_hash": "28dedf3083c9d648d9a82e56baf82468b9c4fee44268b2854fb53fdd222ed6f2", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "bfdedacb-6f1d-4f5e-b6ee-75f18a47fa8c": {"doc_hash": "42b7fc4d3f702c1e78017ed89ae4b3b58a36f493790c28a29b5fb507b111947f", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "4a3edce0-e362-4db2-92d1-94bbf0f25f97": {"doc_hash": "393e31abb82b3191286a666c106619719350d7c922f27e1a53840c05de3268c3", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "cfd4b491-08f1-4d60-991a-3eda0c66750c": {"doc_hash": "4e49708f25ec4e69c72b0af413d299940241554ac1afdc91c22f45d93bb88fab", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "b71c35c2-6518-44ff-b2aa-949152b438ca": {"doc_hash": "e678605d05c0dfddb9f65625631a037f4d5d89e2797000912a99780888e3836d", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "5080571c-37c9-4a9c-b04b-c760b4384c72": {"doc_hash": "f023ef604a84a9ca40f001d7abc117b8d7922a869840460a1fa7bf52700d9b6c", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "e368f399-145d-4986-8c5e-ae5edf99d1d5": {"doc_hash": "c6d5961f077bd9378f2f965ef4e7c2112fc3067e2fd6495f9c76a92b8a64d445", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "ba1ba382-5680-4b70-a172-f20f39d3bb6e": {"doc_hash": "26231ae58ceb299a19f21cbfdf4f0686fba7c836e0d9944f45a8981036d1c4b8", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "9cb65691-478a-473a-a029-9031f6181067": {"doc_hash": "d31396d7dcb4d125280a124ebd9c1f7b84e882a48296832a3e987d83aa15db34", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "36601084-14f5-4891-8843-cf3da093f2e2": {"doc_hash": "1c20c86093e4014d0004101c84f365208d867cd4d45996bccd8e03c1d0e0ec6d", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "e08820ea-03f2-4a04-8f1e-5c0d71cfb10d": {"doc_hash": "bcfd998907aad009cd50e556c2fdb96299dbbd25929242cd94fe88ed3a36765b", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "ced1544d-e977-49eb-8e8c-8e4cbe90fdec": {"doc_hash": "f3e7e96c259c4d6a400f68263b9ff30fcadd4224c3aad427ebaa35ec5f3fafb1", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "1a3b97b9-209d-46ef-a814-1918e1b13f3f": {"doc_hash": "f1e98e6e89d8eb1359e312409a0683a466a5f7de5b85c56271a155ffc6d850ed", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "76f7a18e-9e55-4515-9a86-faabbfbcbd4e": {"doc_hash": "179e73fd921cff0794cd16ee71ad24514858071e1d1be70caba473d28f765c62", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "75a48158-a4bc-4389-a621-57493449b494": {"doc_hash": "63df019a4871e40d931190993324440721bed5cf6e11cd0ae4e2c6b142fb31c0", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "7dca7282-c74c-4730-b0c3-c7facfe84305": {"doc_hash": "202e333f45466c1aa344d1187486f4ff210b3a017233c90b1d7d1af1b815175c", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "0a0a3d38-b758-4655-978a-349506737657": {"doc_hash": "355ed9b33fd96405019ad3559bbc54c964a0c01659c3f47fcbb79989559b350f", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "ddc8d27b-f612-4146-8ed4-87c59233eec7": {"doc_hash": "6d909c841c230a4a09fa61a1c5f28e114d0d956d46b45a221d3cfe223f3e5187", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "28150757-f102-44c2-81a0-4a3d80492343": {"doc_hash": "40602464137268987933d87b1ccec7a7dc1fc50bc2d31bb73bb7a2b244d74e05", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "9fd9ffa0-ff02-4dad-9d1a-43b06a4f2526": {"doc_hash": "3a877ad097c905db2fdd74bb2a0e4223b314d085ee49b2a4da53c1fceada8dee", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "42409b83-d018-4272-8c0e-0b419cae7e82": {"doc_hash": "0db263e433180deed40e2b91eb4fe28668d39276f925474d43ca7ac906dedbca", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "e6e4c1ed-008e-43c0-9157-6a944babce8f": {"doc_hash": "928f696dcf8d4203c564a1a0bf35de074ea68312ed93fa3147a5858f295c1fe4", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "fafb8693-ecdb-4afc-b535-4ed2d173d0a5": {"doc_hash": "92ec58bb9ddbe0405d3c68e99d065e26b9b226f4e12f4f4c3d96ffa5aa0f2e28", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "936e113b-929f-4223-8c9b-818105a8cc6b": {"doc_hash": "aeb2f57184f25756692275945544ccbf56233588017443fdea30f72a039a65f8", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "1b241987-b338-4b9d-8276-91acd4d8a4e4": {"doc_hash": "d6b9ea077fc6a63f9d9adc9f2d0651e478fc4bc94a6aa53ee7aab28bda82789c", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "47f9d7a3-2e00-4c5c-a277-57af3f134ee2": {"doc_hash": "1da8e6d812087386c016e71afa2ad2fe2a208ca6685c91ef17ac8958f0cdb795", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "43d54893-d8e8-4be2-845a-935680a75dc3": {"doc_hash": "f02ab1ddfc415e25380f410e125aaf63665a138a99ac5691b640f9449c21a2a0", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "2f6ef761-f940-4459-a9e9-aa0324c39d73": {"doc_hash": "fb6655c6fecd1881166b4775917173390c4634b2a8d24c3e2401ed7a8dfbd6e8", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "cbd14bdd-47db-47d3-8db0-9cf973e24878": {"doc_hash": "b286f83045868ec78a35383d7dfb69e249a06f40f664357cb99b2be15ba39e0d", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "4117d508-400d-456d-b3f1-52d90a14a586": {"doc_hash": "d6b3065ab7488e71c46df8e865ea3126db019a79ae004d654825244cd7a3e84d", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "39ecc645-2496-4cab-97f7-339e1dff17bb": {"doc_hash": "653e09c257f9f6d8e43c001ff62a6cfdec071e79b75d1010aa4d36e5b9ade2ec", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "8ca16fd9-8388-4140-b3c5-d260c925b00b": {"doc_hash": "1e38538b7e3bb4659f4f9f01dc71ab0895f1be71d2ffd4557dbaa943675cae25", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "f395d788-fb73-4df3-b4d7-a9b7e7295919": {"doc_hash": "6e40b9a71628c68199d55953be9179126aa76fbb8809bb460f1eaa8cd5b2fbf9", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "2d0f803e-a067-4c27-8108-2d5ee25030e8": {"doc_hash": "4b8f7c683c10d98ce7b61f5aabded2b2c6b1104ef6600c08ade33664b30a25a0", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "85d49957-ae50-466a-8c85-6d029bf7295f": {"doc_hash": "03dbedd3788103530d968ac027c55f1a94ef51f43443002aa2c3ff593764cf2e", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "685897a8-6be3-45c8-9972-c7e3dee7c261": {"doc_hash": "7f60f7f75b1fec8d195166c5b2781e207724f11aa56f7d6b0fcdabc44baf1ffa", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "e919736f-026a-497d-a57a-d9e914102879": {"doc_hash": "7fac413f310f4e563fab8114ce18a93aa1acb55ce608e2e4e110321a4b24f4d2", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "62fbd0d4-0d75-4298-8ab6-3d8b39d03334": {"doc_hash": "03d3d593439d8ec401e22db1cffeadc377577dd0f40903f32ddbd838d30de62c", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "5e62b029-8891-4b2b-b0bb-d9c998a907dc": {"doc_hash": "f3196554bb8e9860fbf15e25afab3a8b22960a61f315d11e326ab7bf4d2fcda5", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "f8dadadf-2830-4e78-a001-1bdfab2bf5fb": {"doc_hash": "52df1b3b0032aec63f638e685e28441b41bb327e255771ae079ad8e411032d4e", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "4066d87e-0092-45ec-b530-31e17778ef3e": {"doc_hash": "8874a8cfe7477d19a01aaab346db802438b18dee0ade74617d16a49f85d486d1", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "f3888ea3-4c0d-491a-bc9d-4df171f4602a": {"doc_hash": "1be8049daf03cef9e6512884179f862e9042241640d74e459a20eff3a7a3bcbc", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "e4e1aa3d-c9b9-4dfb-b74e-941e7d91ce55": {"doc_hash": "611b27f0216111f13110e16064056ba1e70a105664c527b357a8c361e0d4998e", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "972c0f03-1969-4128-96a5-cc324384f60c": {"doc_hash": "de7558df69e518850d1baeae5674876e3774232bcebe5cced44fbc513e570799", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "57edc9ec-0116-4bc5-aece-44adab3723a4": {"doc_hash": "5d673afd7f40112de34aa0ab2948505642d45bf56b0ddb1c4ada5cb6f06766fe", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "f5aaa0ab-09ee-4a4b-ac0f-3afee52f7b6b": {"doc_hash": "a6a0dea97cee158f3252b098b59a2d44246e45aee90fef4044d0c2ecf3c53ddd", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "2a769a85-a4a1-4035-a56e-651cbbb29a3a": {"doc_hash": "f86379c02b4eed94c06887d640dfb685cb31613d087ab7c1a7a837b45d0d2f35", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "1ca669ab-3103-419f-954a-6a9bed6946f1": {"doc_hash": "580298b30fa452f325b4d26b2564a12ca144ef2cd15fe331dc04ad59235a6773", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "ed28d78a-bfe1-4e4d-aeb6-f735250f7d43": {"doc_hash": "1892ebfb1b0f4337873a9ae997cdfed086c9a7740e6ccd7d55f48fc5abb82393", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "7d9bc5ff-f858-4ca5-a1a7-02609294c7a2": {"doc_hash": "322e07c1983a3b3fa2e9e2724145a488d0579ff86e4df021fb76d7d0b638006a", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "94507c4d-a376-4aee-940c-f069bda93e75": {"doc_hash": "17a3eb134aba9db1e9a22609e1e9400ee24bf9a7a0871b64b2ed1bccf9286d0d", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "bbed5a8c-886c-4f8e-a434-3e8635945b52": {"doc_hash": "1a3465e1cb5b853b10aecfd45825e93b7c947e663983d6b95e21cf1bb96ebd3c", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "cc81e3a0-aa8a-4556-9b03-c0a093c91302": {"doc_hash": "5ef8634b0e4aa9ffacaac0f700448a123e05ac91c67c3bd1abd17698429f75a2", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "a9355efb-ad67-44eb-b4ca-72994217a088": {"doc_hash": "3859f9b607d183ba4e30914d437c0f221f995960be07cfaff689687a7e79d091", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "9b2fe97e-e211-426c-abf6-a9ff248071ab": {"doc_hash": "1c96213f0baf6797a98b8ca0a9a63d6cc96a2d228a70b6bcd1a3ac98817b1e5f", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "b0fee0bb-948b-41b4-a18f-204cb0140cb3": {"doc_hash": "c773639ceb370cf73b69196d47c2cd2aed75b531967a49fac132c49a0b7da8e8", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "c6630ff4-f3ef-4204-9883-711d7685995a": {"doc_hash": "a1bef85118dad385bdd99d06f80c0b50bee4504c9d24a96424633d95e7a58a39", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "00a56089-0956-4078-8a0a-02b888f08c2c": {"doc_hash": "39c8db7382581f75f8b7a25a20f0d6c1f6d21f8e4e30da81b5bbb54d4285e0f6", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "11e0291a-7412-4c7b-906f-27ad7188631e": {"doc_hash": "be52983be28fa37470462655b2c4ffcf7b4496c7cccc8f66355de9476fd76fa4", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "cfaa5827-9140-45c1-a536-639ea9fdf92e": {"doc_hash": "3bc3636bd3be5ae916432bed996213dad89bb56de472374a0f1382c34a8d065e", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "1053b498-b6b2-4e1d-a0ba-d0ad8da908ae": {"doc_hash": "5ebd90b1054915dca1ddd6273fff52ee8d082ac1876216a69a782d6a11843c72", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "60c0aaa9-5f40-4fbc-bdd8-6fe51181f6a2": {"doc_hash": "3b3a7ca8d4334848214045fd1f7dc5df65bca7113c4a09d08532ed4a325b3653", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "d415fc58-0e1d-4d0a-bcbc-f61170701876": {"doc_hash": "b42efdded02520a939dacdde4f8441e631ad253ed06a4a1d90632638e5c747fe", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "2adb8e6f-9152-4417-8ddd-4748f3ab3d6e": {"doc_hash": "c2e5700836b464b1154635a57b9ce16c81fa4f2b5547b8389dc939d63ef32129", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "dd78f9cd-07c6-4f4c-92ba-3ce65df77e9b": {"doc_hash": "ddf0f5ec892ef61f2f88add847e213d69a67bd261a65a070409783424543dac7", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "37306512-b166-48ce-8ec1-6d617a833ac9": {"doc_hash": "02ffc33be26c35bb25bd64168714473fc5f589a44d769700016436a0888eea75", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "3c29c57a-b9c0-4f36-ac8d-2ec9a1f2b020": {"doc_hash": "f3e2cbe6f3ce622b875c77db80230a6b986d4ce208fa5500fb474947763619db", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "8c8fe47b-c642-4052-8f16-d2c8d2ce9458": {"doc_hash": "0b6a453ed2d3884646faf143447d35d934ea7a0ecee7e0fc09003a912e90c504", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "0fbcd7b5-6e4b-4a84-8f71-02ce8ce7173b": {"doc_hash": "89096889f66fef0db49697403e2f9d92ecedfe61a4c19cf53995916a7766bc66", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "c84f13da-ce73-47e9-aadd-31d13db6533e": {"doc_hash": "1728cf2aacd4f577bfc384570e1ec6cb03d3d3fa6d257609adedd542fdf53719", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "54fe4d0d-8f14-439d-adab-cafb9c57d862": {"doc_hash": "508d02864bdde1672094bd8ef5e0d7f0334c535d3c1db31fa59aee1b36487ee6", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "e0f20e7a-9885-4a78-b9f5-d6c7b02b1dfb": {"doc_hash": "aa710fa1fb396d0836ab7ed6a6f7fb3c3c78e19d6472de9d369012c6bfe426b1", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "3eb08217-0b56-40e7-b585-d9cd98dd376b": {"doc_hash": "f48f4569b3b2ee3b94b7d346b223d23dad2c95bfbbbec32c986403cf07469ad7", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "fccb0447-15d5-462d-b4fa-fb371fe7192d": {"doc_hash": "496d1982498f79cd062421cdaefc935eeeefb3d8a6f27782ffe1b2a109c7994f", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "d0e57b5b-06e8-4917-88de-19c754283d0b": {"doc_hash": "c047a65d1d7567d437850708c20337f40352571d4c93a4bff67a61a27d520771", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "39c76bfa-1c0d-459d-b92b-aafeb82c530f": {"doc_hash": "4facd241b142b959330d4c6f757676663e9096ff72e75e1856cb7c455fa52989", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "b59ee300-57d8-4a28-94aa-1c9a3d7f93ad": {"doc_hash": "4d991d02a9947d37d7d9529b9e2099213b196f4f6a149817038ed162ae11d481", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "32e8a32f-4e2d-4dea-9c55-f16df2df9a98": {"doc_hash": "999042b47a3279720941d531193758918ca90c41a2f24520459b3bda68c193df", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "27feed5c-1a29-4060-9413-32a8e1c84ccd": {"doc_hash": "0c4985b51644ac785fc01a7ff7d50aa00e349066ee18cd513792e3abecb13b2e", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "9887439d-a408-4ca3-8fcb-1c8234128c66": {"doc_hash": "efad0274219a90704bb2529c038c9e42ed42bda15599fc4b11d9992b4264aaaf", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "04a9b834-4bf4-4a4f-a360-4514a947785b": {"doc_hash": "834f59813af23765b44d02a070d348e07749d5bedb2af235e750dbf62da4ba6a", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "f3bb362e-b548-4a6b-b0ee-36cca203cbce": {"doc_hash": "65beea76856b542a0742d7924c251a0c912ba1682b29584f58c570fc756d2fc4", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "50e1fbc6-ce92-4407-b3ee-1236bf051cb6": {"doc_hash": "b3e902e9d81e889e7f552a8d9ddc95d8a7286abd7102c5b9f73c07ad462ea299", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "713c32b8-2196-49a5-9a53-ca53a0676fde": {"doc_hash": "dec1ff1a94090337e6d254aca165fc04deff02efbdabeb0910d5bed423e6afcb", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "255105fb-6aef-4034-b7c8-19428baa2b26": {"doc_hash": "57e0197d84c32527f47a6914c80864b85f562da4dfa74378ff728508f3f318fb", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "4ef969b0-03f1-469f-8653-e2cbc4668112": {"doc_hash": "190873e9177d97ebee39f7a5d064b6a9049496b6d001a1edbed5824a1b7e4ab9", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "1a4812e1-28d6-468f-86ac-8ce53cebd625": {"doc_hash": "70adaabd78ef478af8bb56ac3f71c5e1d654973f48c3e9f38a0b2288582e3a12", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "14b7a12a-641e-4648-9dca-60a535a97025": {"doc_hash": "d18500b488e388c289547e182010f48dbda5562b512b11858a5261fcfffabea4", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "b3d574ea-c88e-4e89-a6d1-e85ac3587dfb": {"doc_hash": "455d07a42961c458db29633677eed40b4a6ad78aef7c279e295c8303b73fcb0d", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "b7dd20e2-c7fa-46fe-9ab0-ef6f2e374f23": {"doc_hash": "c6bff8b28e2df28a5bed38c5e991a1140b71f982fc68f5e2dc9e2ead2436201d", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "ee974b0e-438c-4280-b3e6-ec22c700d4dc": {"doc_hash": "ba19d36014aec07d00c27a4f63037600cc44b5fe81ef677545618c7ca56ea789", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "653f14f5-48db-4fa7-b2ca-754d8a7f4497": {"doc_hash": "fca4408eb243c2a9e6049b712dba5fdbaadc849f16367a2a2810c4c2f09910be", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "3d71dba8-8788-40f7-b748-b1efe293bfc2": {"doc_hash": "51bcb4b28da220b9eb549078cde3cd36b68cb53ff448771860b606345acc2541", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "40a9ed84-8fbc-464a-b243-576444978912": {"doc_hash": "3e12ab2c5d55455ea0ba372a47c4f70089a2b3288c39d61332eae9b613b7fc15", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "4820a60d-7c6e-422c-8fb4-d65d67aaad21": {"doc_hash": "44383faa85d5779a77112f921126c065bfe0ae8f24bb4fa89553e24288a965f4", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "d8f545c2-4b4d-499d-be28-520d710af962": {"doc_hash": "c8080664e926872c8c40b16e7cda793ce981f73aa46fe6889e8f1b5f3124bd02", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "e7a52c70-826c-44e8-abef-54480625ddfb": {"doc_hash": "2d36d88ac79ad505e230242212135623815b4ffbf3567f007a621e00306b2895", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "e224655b-9379-4af3-99b0-5d50cb96489f": {"doc_hash": "9b4ef9559991dd02ec0ca6e51d8113fcee34bf8bde016c7ec45bfd4d7eff6056", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "532068e0-122a-408d-9acc-6be26d94d2a6": {"doc_hash": "2d18d7ffed530a9b65b7588c0f355d4442703c0772a98cb88953239b81972f3b", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "7cd6511e-bc6a-4254-baec-f7b36239c34e": {"doc_hash": "69ece462d167e9f912290d29c58af0912740ed15268382b14a040475050488ce", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "848dd453-5336-4ef9-b445-4508dcbb0ad4": {"doc_hash": "98e1b4b84616a28c839e4d00f6fb0874ae4736761b1c66181c0a7bea497d321a", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "990c7852-628c-49d8-b18f-141e7e0d4417": {"doc_hash": "68c20f653946f12e48600846125bc4ce7f2fe6cd3f01402bb6853a229ba4d117", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "65d74546-e665-421f-a2d2-f6ae5d2544de": {"doc_hash": "398aea3397b7680bcf467434d442b4e8caff9c246c04c111f13a806b89cb1b8d", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "019ef2a0-55d9-4563-8be3-bcb58b6810ea": {"doc_hash": "2bb534c9949f85e1ad79f3061c3a0e10e5a84ec60055608dd1ee3cc762285935", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "980db64e-92c2-47c0-8d6c-f1d967bd5535": {"doc_hash": "ed02e9829b106e654a5e5aa9a39039009fe841293b1a58c21767009da14603a1", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "4d1e1223-80da-4d4e-92c9-7c998f55e656": {"doc_hash": "dcda10cf82b7485db6440fbff87457d065c6d7d98cb0534b20ffed9d62ad078e", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "9937b0e1-4130-432e-8d55-cc1aea6411f9": {"doc_hash": "8bf82984906b4ac3649d75bfdffe58fed0ba5fc348d84e7e39138bfeec99993c", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "53916f59-fff6-497f-82c6-4b7831eed5c1": {"doc_hash": "96259949b80c425929d92dc7a7faed7e57ce3ce1a6bb9f9fe362756c1c75abd5", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "43c217ae-86ed-4b41-aa49-efe0219b8ef4": {"doc_hash": "0251e6ed8cc728e3c189634649344926144aa1af772669f951048077a41e4997", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "3ad3447d-121a-4927-b435-36ded6bdc526": {"doc_hash": "0f49c165580a2a5ae8093e212aa97c6dc828851ad4780f5c9df530b33c5b253c", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "18e5cd46-9c56-48b3-a643-27847ea52e77": {"doc_hash": "ae7c4f8f2b54f7f1890c36dcc72577cb54257ce69a7dd41938988eddff01aafb", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "d00b99f9-6510-463a-90b9-1f8e3745dc11": {"doc_hash": "b12b301d6df51155452821c27cca03c1da78cfdb920103906cd1e3d8527d2061", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "43e6c42e-71b3-4523-a906-d599c04a21fd": {"doc_hash": "ce035e84517153199906569aaf2f63e32043fb6eca417f504260758e192d2fab", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "57481040-2e71-4a0b-b48b-7be0a81156f8": {"doc_hash": "af2ee902b28cb54d2996756e6c3de0921964dc78ed6cdd9796465a63997bfc03", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "501aa4df-f3f5-409d-adbd-ea2532add26f": {"doc_hash": "e0a600204aca6d5991b98ffe197bdb92ad580f1e441b1eb0c63ce63312fea8df", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "0fcb2b47-0b13-4d84-893a-961eee50260d": {"doc_hash": "d0870a2ecf5d34b94a00923583291281196b38c0a516d336e8d70e02b4a0d536", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "3b8517c0-5e2c-4ff2-8847-77ebe7162328": {"doc_hash": "41447ed38422a503367badeb6364c62812c71cb1c35548872b2cb99ffc45a1a2", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "1dce9361-c062-49ba-809a-3183a280c0c8": {"doc_hash": "cbaae55dfb07d4c27df05e21bf2cd4a006de17760394335c4263d38c92d4f217", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "ffb16ab1-8580-4243-a4c9-7d31c12a621b": {"doc_hash": "7956c4d38e5efe28c48747c55a2807fb443dd514167d1db8826a32e83fc5d89d", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "73637211-3e06-4849-a900-ba6c48bf8e5e": {"doc_hash": "744305a2259c0c6c226379f4fea738e63a9bf41b12dcf92b53efcbc4483cf53d", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "99c04a38-ede0-4d32-97d5-7dadfd17ace1": {"doc_hash": "80d06caf8e3a53aa725f5749ebe3f50e39dfb1060a3348ba23aa56c7e322bd48", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "2a0c2f99-1b79-412c-9dcf-007eba999855": {"doc_hash": "8a06753355c3922ae780ec13f4c1711a90d1a4f656c452ad18647571f5890d38", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "ae640b64-0210-4262-936c-6ca16f261f76": {"doc_hash": "1e8ead4972b00f36cd8e8938130fb81509970fafa1b325512dae8197761d7466", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "0a5edce9-d52a-4176-91b9-8b64198a61fc": {"doc_hash": "04b23feebe3702217805f36d6916c06bae9bdb5c42b9eaf00d118ec2d3a31e52", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "bedabdb3-df05-4d9f-a051-cef8ffa5f871": {"doc_hash": "3d4504baa9d268b2b3146c69f09fe42346a765c4d36322b9df3a4a84a0d8c9dd", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "5aae2931-fc70-4fe0-a893-ad7f219dae57": {"doc_hash": "97a718259963c55ee46009c16b366aba704a3b5934453c683f90bf0c2af41778", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "9dba4efe-88d4-4301-87fc-e0cefea78bd6": {"doc_hash": "a8ff69b64ce5524256d0ae490795fa657eb701bd3ef0327a6c3f866719113ab6", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "d50917b1-8db6-496f-abb6-272260bb0986": {"doc_hash": "a3cfaf1c9fc69e4495f6e5273e44d3367c1d689dfabc6a24941d3d01033875ad", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "447c65af-0137-497f-946d-b395640da62b": {"doc_hash": "d46dfeef61202c05c4d0bef7d5bce70b96e82536483a6120ab9a5e424d0ebd82", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "fca67361-d74c-4b9b-b58b-894379487234": {"doc_hash": "1031906aa0fbeb3dec01c0f5309f98b9615617f530539372b8bcea59fdb94f37", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "8b36e6fd-cb6b-4055-a0bb-44e3be63eb43": {"doc_hash": "f26395f5e4b0edf5cb702dafe78aae8843ca634d28fd6f2a4e7f829947f37e83", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "629a39b7-a00e-4058-b941-a8dfa0f516f3": {"doc_hash": "54db8b29837ddfe4bc58db2f05f6001d752e2bb925f46e09944d90c87661f0fe", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "040a1177-7e5f-4891-9d1b-fe7d3b12463d": {"doc_hash": "bd45ae71e633152000f234812ec88ca37217a7287ffa871095b739374a45570a", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "b59f1c00-1560-4736-9c6a-13ff264e444f": {"doc_hash": "7c536a6cd895d994f48e209d94c9a29af034e693b93612bca47f33d27c1c4178", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "48959635-c9a5-4b2e-b695-55d12cc9b70c": {"doc_hash": "dbf25d8f79aaf2076ce139d255a40590665a57218a044b27ac4b2d65af9a2231", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "df8c28d5-68b9-4a2b-bac6-f889ef058960": {"doc_hash": "fe19c52050ab58af7489a1fba5b0a9358b8c9a5d424ef3a10604e80608199056", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "72b7497b-2899-4c2a-95f5-245037f81c02": {"doc_hash": "9a4deb4fd23f7b513a517831c9487c9ee5fabca045a958267540a96b195151fe", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "bdbe6b3e-f76a-416d-8bd9-659c8f90ddd4": {"doc_hash": "55f03e90e65ce20d7fe12c3fc99a11ecbe72ef2d1e9edaa65f620ec6c62abfad", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "547143f7-db83-4697-96fd-c28eb0f3bc82": {"doc_hash": "6aeb5a631c42a6c94de619143ba00ddf044c1cb8f0934fd13a8d5f8e88b78251", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "4ca98578-7a73-4367-a1ef-5e5bece82d63": {"doc_hash": "da38a9c5932e0918156ea9ebfa994fa179fa522f9b23742845c348f9a9741008", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "95809b13-84ed-4a84-aa5d-c2d92ef30a04": {"doc_hash": "e6d37fdc74fd53b03a379b75550085ad2bb0350529d562ca570409eadca68bbc", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "4a22e37b-54b8-4b90-a44f-1131c4c3f46d": {"doc_hash": "20555cd2ca7a014cf7f08fa5de9c8913d30e3b0faade0c96a2349e5e9360a7da", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "f196db6c-c458-4c3c-8d17-ac0ab9465e3f": {"doc_hash": "66b1cb09fc2f2aa9bfbf1de356df6f106485ed5d8085406b9305caa3016baf03", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "182780ec-7bf9-4666-bb0b-75b8036439d2": {"doc_hash": "f1aef59f0e87d8d0a994771762be3c51b7ed624421ffdbd49f9225c8f646ddea", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "b7abb64d-ecb9-446f-b6a0-32feba4452f7": {"doc_hash": "cb907dc01b7d029e755fe102f1cec51645d0a388e767736a137a3521ebb3a639", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "0b23df02-efed-499a-ad31-077d7f011f61": {"doc_hash": "f1db712cf7e8e4a03e4f296495d87c044a87fd2edc83e8f4f5dc33ce77b70588", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "bb9c554f-88e7-47ef-96c0-b7c88c3d5e05": {"doc_hash": "2645e6f6ad8ae053e52cbdc5b939a47427d30b2f517cb89a1c1baf1d9cd1aaeb", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "9e80edf3-85ca-432c-9447-b5d431ef6d20": {"doc_hash": "74a678c320ada7f11f8da13379ca1353628c0902d5edaf4e76e16fa9706f0b88", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "434127b6-661a-4fb4-9190-7d84d683c97f": {"doc_hash": "9c0c149a714dfd79af72fdf74bddafe667ebabf24cb4cfda6f526e4b9fdc20b0", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "4d58d043-4f92-4584-9a95-db18d0194ae0": {"doc_hash": "cd4b9ffb7ef062a443139e5232cbc0dab20162f510e1a33cb30346ab21c2b3d8", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "18a79015-7dd2-43b2-9df3-39072348e97e": {"doc_hash": "5e2e0fc10064110f03fce05410810af2b27a67b8b5425e38ceedb82e7fc6b134", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "2face4b7-6f07-479a-8169-11c8b114894b": {"doc_hash": "38f5c5aa706072b1b23d03aa50546bd02c4cdf21134f65af21756202fd546fa7", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "bb5374f9-ece3-4db3-8927-63ed09f1a2e6": {"doc_hash": "d3787febcec20cd1b71ed2dd633fbc1d31de80e4684d0f003930ab9594dfc2ca", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "325551bf-cd86-471a-be73-e7c314b050db": {"doc_hash": "46a510972967e76aadbe588ef6dbe21479186507a4bd0c2d610de46c92e2af75", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "ad6609e2-4bd6-44b9-bfa9-bffa78f18567": {"doc_hash": "18d56c4461c727ed68f370c94f36e4b8fae429ac380aba0989a86b99f909084e", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "cc48a589-3ca6-4f8c-9990-381bf7af79c2": {"doc_hash": "e43d5b7d785021dcf2ab8598d8609b81f2fbb300547f2eec75889808942ce0b8", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "8dea17a3-171a-42b8-8102-c350832c7102": {"doc_hash": "71b2ce6277be93368858e3b4547b6f561a24071db36ee28e3863de60617d5ebf", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "509b7404-7fac-4152-855b-6cd1cbfdadba": {"doc_hash": "113a0c4db2ecef22b8cf7e40f9dfcaca2bf4b35c038fdb888174bbb8ea137443", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "fcfe8dfd-b23d-4542-9943-5e9120852dc6": {"doc_hash": "57ce1e589619b02c4279558e391a55da638a1f98b8e41dfd83c1bd955b99f89c", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "7f72b190-57d5-47bc-b152-ed7eb7a3f8df": {"doc_hash": "78c19cd0f55c353faee5c91e6ea3e7e1be9b8659fa711fc788ba2f323e01dfb3", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "5bddc74c-3192-4eeb-84cb-7ab375b0d84b": {"doc_hash": "89286683d7b05fc3b76d25ded693a38ce85048a01d45f08ea339bfc751d3a617", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "792001b1-621e-4e93-850f-d4d4f7eee655": {"doc_hash": "fa77eece9182a4b6a69f1e40002c84981d1e85fcc547115d8ce40eedcf7b1f07", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "52ff2706-6c8b-4998-a57b-3df0f649c2dd": {"doc_hash": "6870f47223e2cb7da36adf4c7606cf898a3fd897cebd695a26c10719d8058d5c", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "c20f7eba-bab5-4b9a-81dd-9fa4a4b2be6b": {"doc_hash": "b3067dcb6cd6262f972b5f095084c8ac493ad4c45b712b7daf64d48d8c9dbb65", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "9f23fc7d-7226-4a59-9650-a4e5a9a9c4e5": {"doc_hash": "083c26053e92ec80c849d76abec70d71f7500681df49ff489d76a5bde0b04f49", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "12d4f45e-74ca-4008-a0ed-28f655fae283": {"doc_hash": "7e722e85afee91f09426444fa3a31156a15a71309c0e6f57eacd932f3ca3755f", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "2cee667e-a67a-40b9-b2a3-596a2882f35b": {"doc_hash": "4159ce581c6a3d77eeda111977bd03ec59ce2a01b20defea107d57cbcd1d1721", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "05319213-e034-405d-916f-acc33384a011": {"doc_hash": "959c5d3744cb8ebe698a2fc3e62faf665c1b2acecca9da6ab8ca7b460af4ab65", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "f1fb7cf0-faab-420b-b017-60c5e17c2a8b": {"doc_hash": "e46c1d18471664c3acc32826790731fa6030c76a7d6841f5befd75f01ac42053", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "5b3d43df-9ab3-44e5-bdd3-d1da43112b1c": {"doc_hash": "b920dc862e9efee3358a2847fb27cf402f662e91c12dd87cc7ed6f84275fc781", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "38caee37-180e-4b0c-9dc3-0038efc65b84": {"doc_hash": "121aa923b6cbade7586a6be7ccc31a27db2dd0af39460aa5b5e2d9ef87c89f57", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "5374afa9-5f59-48ba-9ff0-6353db66dec9": {"doc_hash": "0864d4ecae2ab8b99c4e228b2660734cb285b59ebd7f6b399a33e3681ae0eac4", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "70386e3e-0ffd-4dca-aeb5-f6b2e432cc98": {"doc_hash": "4158db85d24ae3000bcd51d2861e897df3c880025ca27540bb74672435cd6942", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "4ff5cb4c-5f6e-4c95-9f62-3ec45ae59fea": {"doc_hash": "6072a6909a5c25e943e6a34e99cae6cae92da35476657d5b02009b8d01aa1d72", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "1e13093d-54f6-4e0f-8ade-e1246a76a0f5": {"doc_hash": "c866786b76b22f960c8ffe7f9de45ffc5265215dc2a5129c9789b3d783e031c2", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "590ea2b3-1acb-4bc4-8f00-0d11cd8e100a": {"doc_hash": "b6e1de837ca7a8792fc0f6909ccf8413fdb39940a69f6628292d99219b5a5bc6", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "301f1ef3-abbf-43a4-a9ed-db41588bec7c": {"doc_hash": "cfb58f4e68583e9aaca1eb1ef740a18b834c8d83770204cadf13031038cb7b51", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "053147ef-9e39-49ea-9a2d-a9e5809be524": {"doc_hash": "490bdaae77a365edeba121a8d08664da3ab03a019c60ed24a7b563af9d7b73fa", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "b6768563-f8f2-4888-b4c3-8ad41cad23ff": {"doc_hash": "67a15ede93fcd4997f283a1604739906d98649b3987115258b23ca0fda179b38", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "316858bc-b366-46c2-8760-670ab4b880d0": {"doc_hash": "5a154cbb2e7c8a996e6ca76caf241025f88ad297a52e9f281f7667a8b384da36", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "287ac444-df08-41e0-a01e-c8aef2afa6ce": {"doc_hash": "e5b1e6c7862fc7886da8e9ce08eb8da5912e9e6074a58e78fa5b312a6d6a8695", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "bb8eff95-18df-4789-84d8-9afe0c1482f2": {"doc_hash": "05674b418d9b2c4304e4af1deac69bebf30835a1226faf7ffdbb0750d5109e46", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "d47bdbd4-451d-45a8-875b-cfb6e9df257a": {"doc_hash": "a26e2deab689efabe702028c1670726e9dfac51c2e5ddea3a112c4d86afd3e67", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "ee852c4c-7e25-424d-a503-28a158b59444": {"doc_hash": "3b005b79a8816e966bcae8bd3ddb393b8a7069e6092c99c114cf512487e4c28f", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "0ee8b7ad-9655-40f2-acbf-5d802afe50b0": {"doc_hash": "8f5475a42b778328390c999f2eb2843aafbbc1420e6a69ac383964fb574ea62e", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "d1bbf538-19da-4eaa-a283-12ec27565ef8": {"doc_hash": "d9a00e0becfe3863b89cb2cc415cd3d7fa121379a1780a0d090092641494fa6c", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "be163f8a-f99c-46b0-9f8d-aad7093e34f0": {"doc_hash": "e8b70a9b053e03df0bc57ef18e4d19c35b1c1fff8bc9e44f6e90a67b7260829b", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "f1330769-5221-4b15-8f72-4b352c249455": {"doc_hash": "84491714fcda35124b8ba49ffe9cda363887f993a11cee6a76c6ad1bf1568b45", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "03a9d552-7665-468e-aa4e-ea67146e55aa": {"doc_hash": "1fe64ce17b74a0567a805e5d63a5cb6473d02055c455f7e48a395e05170e9425", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "b6184f38-a493-4641-9867-f75845bd5b41": {"doc_hash": "3291d25412a0186d5d7a4f9460d2df567e52e312237ff6d50ee97b009d8b1067", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "5144c4bc-c318-413d-b751-09541e4c8fb4": {"doc_hash": "688eb8fcee7ce4e60a34185f94315145e25ad8bab1a9304791f3d84302263f1d", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "dda1f4e2-b735-4b4e-985a-8627419c5587": {"doc_hash": "32659b1f6e2d11943b2ba66ca86b58a5afd8a881bab02825a70f8ba3dd7ba17b", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "ae013a5a-6816-4183-bcff-ab09d23142ac": {"doc_hash": "11a4c67fc5a10ed0562b3eb16f233184e2a3c6c76fc7d8e1c3ff87ff7de052dd", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "c66dae90-73dd-45c5-bd42-a112fbb68f37": {"doc_hash": "96490035f11f53832f7993b2d436c7fed0058bc44bd01859f59b024b46dd1ee5", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "ef6c0fba-cc33-4d7a-9d09-0f7e671e3175": {"doc_hash": "1c264d10fd4f19fb2a846d72c78137a9eb97fa1cee896e808980e648da482142", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "c22fcf0b-3a5e-464f-824a-d4cc09fa7d4f": {"doc_hash": "4f80dbca48376b87a64dbfb74e0684690240ef2de85c9efaab31bb42c99038c5", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "cbae228d-276d-492f-bd05-518d623a5f26": {"doc_hash": "d7bad91280ff5de7afa1e352844ec68a10cc4075283828d0f10da2911cbcb21d", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "1a7d110e-2a45-457a-99df-fbc22fdbf4c4": {"doc_hash": "edd2fef6f5d24c7a115b856b60cbea9b83308f8ff8b28a0c73c253f1ba1ebfcd", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "de30defa-b6e4-4c02-8bf6-4d821664b776": {"doc_hash": "56104da15211a935c0280f46e4c4cdcbb4994ee29f91590857963c4995737428", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "ca75fa2d-ecab-4b75-b875-3eefa9cac1c3": {"doc_hash": "275067ad0d8b12ed5da9e342fe1eb305e2d81bd273dc569453685f822623c682", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "a8abea84-fbe2-4f3e-926d-f3f6a3fa15a9": {"doc_hash": "8f9d091638e362c1ef130466a47e12b2ea5c797422dcbe99d4325053a3c8741e", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "0cd11053-59b9-4bd1-aa0f-ce84f91393d4": {"doc_hash": "d06a0af4dc24098fbb2401126dce24da4dc1c5f818262e7ffbf0697e59e2e871", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "4a1c028c-1af7-46de-afc8-4d3e3802f39d": {"doc_hash": "404bed608ab1ae60a2defad3c3b0c023f2545bc3eefbc577f591aec9dc839db1", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "b8387343-4baf-4167-a241-ad3a25091c81": {"doc_hash": "ba088e56d5632bab025cfe12c395a051d59067ef8c990dcc69a93120303af50c", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "af2dc654-25ff-4759-b6be-2068914f8083": {"doc_hash": "fd39922203262a49bd5f7114d7816a240db6faace25dfc9ff690e5321b4fe9b4", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "62f01751-8868-4ae7-8262-0df65a02a61e": {"doc_hash": "aa61a93a9a0760b9b9cd72518bbd2e966d63c92646a4bfda5f850c3cfeaffef0", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "9631a34f-a0bf-4223-b105-125997254604": {"doc_hash": "f5ef926876347522a2544adbf54b056cde689d3f7980e5bd39b3bf5465b12e2b", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "a0e4ced8-b15f-45aa-a2d4-5b57b2469e12": {"doc_hash": "9410bbeb8510b142417c251dd73d31475a651b2c7f0fd6b042df7ac0329b44d0", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "6fa65883-c39b-49c5-9cc8-3ce0161c6d05": {"doc_hash": "eb5f4aadedb10fd67465e8c0c0015fc725dfbc0f1d77f4b14bc942b04058eb41", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "897af07f-4bbd-4172-a260-a5d8bb3f2510": {"doc_hash": "4258ba33add60f17cc0dcc6204510cbe28aa49e6271be3863d65f68031a460b3", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "8c0b4cd7-60fc-45b2-9e6d-1cd679734c3e": {"doc_hash": "19994d77a65b77a5d233c86a2172571c8cfaaaeeeb792093250ca5d61653cc17", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "a60b7ae8-db95-45e4-868d-411a6f58ef0a": {"doc_hash": "7cda110e3cac9fa39f3dc914a990806c62fa426c169d711d794862bf8c97d453", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "693ee3df-41dd-4ff0-8bac-31eef592b4ef": {"doc_hash": "bdaa67fe3d9cb23523aaab66619438ac1087c2341f9033eb5b24523860d39d3e", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "9220026d-2817-42c4-a3a7-095f18210c16": {"doc_hash": "9406177848c9b66cb27af90e77b6d87f18ccfc1b13e7a9a6bc0d38cabdabfe32", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "871a98a7-4a42-431b-8c91-cb8218432b0c": {"doc_hash": "a776daaeccad50887caf951c00047d5baf8e58a027b494d683ae2dc75a960f37", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "e6b6078c-b089-4fae-8dd3-e5490fe5baac": {"doc_hash": "d80785d6b1c97390fd88111896ebf39a0b26fae75d54266f4d147598782415cb", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "2f763fe1-8e09-45f7-b808-2160e2062a17": {"doc_hash": "3c900dcda2e7f3b5d70298bc879a1c83a5ac2bd651f5c9bf78f26763ae1bdc91", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}, "579fc8b1-66fb-4aa7-95a8-a46340cb77e4": {"doc_hash": "68e5ba90a7441d244b481d145eabff78c8fe016bf5450cb6a83d026dedb5fb39", "ref_doc_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d"}}, "docstore/data": {"1036a4f8-3485-4d30-a6cb-aa4f9bc3a0a5": {"__data__": {"id_": "1036a4f8-3485-4d30-a6cb-aa4f9bc3a0a5", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "052cbc8d-fa9f-42fb-83e9-5766d8e788a4", "node_type": "1", "metadata": {}, "hash": "2acbbdb3c99631622809a3f654d0121f71aa7f2dfae085c46d0e096b938a351c", "class_name": "RelatedNodeInfo"}}, "text": "# NASEMSO National Model EMS Clinical Guidelines\n\n# NASEMSO National Model EMS Clinical Guidelines\n\nMarch 2022\n\nVERSION 3.0\n\nThese guidelines will be maintained by the National Association of State EMS Officials (NASEMSO) to facilitate the creation of state and local EMS system clinical guidelines, protocols, or operating procedures. System medical directors and other leaders are invited to harvest content as will be useful. These guidelines are either evidence-based or consensus-based and have been formatted for use by field EMS professionals.\n\nNASEMSO Medical Directors Council\n\nwww.nasemso.org\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Contents\n\n|INTRODUCTION|6|\n|---|---|\n|PURPOSE AND NOTES|7|\n|TARGET AUDIENCE|8|\n|WHAT IS NEW IN THE 2022 EDITION|8|\n|ACKNOWLEDGEMENTS|8|\n|UNIVERSAL CARE|9|\n|UNIVERSAL CARE GUIDELINE|9|\n|FUNCTIONAL NEEDS|19|\n|PATIENT REFUSALS|23|\n|CARDIOVASCULAR|26|\n|ADULT AND PEDIATRIC SYNCOPE AND NEAR SYNCOPE|26|\n|CHEST PAIN/ACUTE CORONARY SYNDROME (ACS)/ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)|31|\n|BRADYCARDIA|35|\n|IMPLANTABLE VENTRICULAR ASSIST DEVICES|39|\n|TACHYCARDIA WITH A PULSE|42|\n|SUSPECTED STROKE/TRANSIENT ISCHEMIC ATTACK|48|\n|GENERAL MEDICAL|51|\n|ABDOMINAL PAIN|51|\n|ABUSE AND MALTREATMENT|55|\n|AGITATED OR VIOLENT PATIENT/BEHAVIORAL EMERGENCY|59|\n|ANAPHYLAXIS AND ALLERGIC REACTION|66|\n|ALTERED MENTAL STATUS|71|\n|BACK PAIN|75|\n|END-OF-LIFE CARE/HOSPICE CARE|78|\n|HYPERGLYCEMIA|81|\n|HYPOGLYCEMIA|84|\n|NAUSEA-VOMITING|89|\n|PAIN MANAGEMENT|93|\n|SEIZURES|101|\n|SHOCK|107|\n|SICKLE CELL PAIN CRISIS|114|\n|RESUSCITATION|117|\n|CARDIAC ARREST (VF/VT/ASYSTOLE/PEA)|117|\n|ADULT POST-ROSC (RETURN OF SPONTANEOUS CIRCULATION) CARE|126|\n|DETERMINATION OF DEATH/WITHHOLDING RESUSCITATIVE EFFORTS|130|\n|DO NOT RESUSCITATE STATUS/ADVANCE DIRECTIVES/HEALTHCARE POWER OF ATTORNEY (POA) STATUS|133|\n|TERMINATION OF RESUSCITATIVE EFFORTS|136|\n\nRev.", "start_char_idx": 0, "end_char_idx": 1902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "052cbc8d-fa9f-42fb-83e9-5766d8e788a4": {"__data__": {"id_": "052cbc8d-fa9f-42fb-83e9-5766d8e788a4", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1036a4f8-3485-4d30-a6cb-aa4f9bc3a0a5", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "6941abde4d2e85a01de135dbfae1ff50ce2987d5409f92e506b75fc89a9fec40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43458db4-244a-48b3-8e1d-af78647d3291", "node_type": "1", "metadata": {}, "hash": "5a9aab5bf6e92d5a40db85db6d8fca50bc6500d58e04a8d854ca44beaa45d220", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# NASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## RESUSCITATION IN TRAUMATIC CARDIAC ARREST\n\nPage Number: 141\n\n## PEDIATRIC-SPECIFIC GUIDELINES\n\nPage Number: 144\n\n### BRIEF RESOLVED UNEXPLAINED EVENT (BRUE) & ACUTE EVENTS IN INFANTS\n\nPage Number: 144\n\n### PEDIATRIC RESPIRATORY DISTRESS (BRONCHIOLITIS)\n\nPage Number: 150\n\n### PEDIATRIC RESPIRATORY DISTRESS (CROUP)\n\nPage Number: 155\n\n### NEONATAL RESUSCITATION\n\nPage Number: 159\n\n## OB/GYN\n\nPage Number: 165\n\n### CHILDBIRTH\n\nPage Number: 165\n\n### ECLAMPSIA/PRE-ECLAMPSIA\n\nPage Number: 171\n\n### OBSTETRICAL AND GYNECOLOGICAL CONDITIONS\n\nPage Number: 175\n\n## RESPIRATORY\n\nPage Number: 178\n\n### AIRWAY MANAGEMENT\n\nPage Number: 178\n\n### RESPIRATORY DISTRESS (INCLUDES BRONCHOSPASM, PULMONARY EDEMA)\n\nPage Number: 190\n\n### MECHANICAL VENTILATION (INVASIVE)\n\nPage Number: 198\n\n### TRACHEOSTOMY MANAGEMENT\n\nPage Number: 203\n\n## TRAUMA\n\nPage Number: 208\n\n### GENERAL TRAUMA MANAGEMENT\n\nPage Number: 208\n\n### BLAST INJURIES\n\nPage Number: 215\n\n### BURNS\n\nPage Number: 218\n\n### CRUSH INJURY/CRUSH SYNDROME\n\nPage Number: 222\n\n### EXTREMITY TRAUMA/EXTERNAL HEMORRHAGE MANAGEMENT\n\nPage Number: 225\n\n### FACIAL/DENTAL TRAUMA\n\nPage Number: 230\n\n### HEAD INJURY\n\nPage Number: 233\n\n### HIGH THREAT CONSIDERATIONS/ACTIVE SHOOTER SCENARIO\n\nPage Number: 238\n\n### SPINAL CARE\n\nPage Number: 241\n\n### TRAUMA MASS CASUALTY INCIDENT\n\nPage Number: 249\n\n## TOXINS AND ENVIRONMENTAL\n\nPage Number: 252\n\n### POISONING/OVERDOSE UNIVERSAL CARE\n\nPage Number: 252\n\n### ACETYLCHOLINESTERASE INHIBITORS (CARBAMATES, NERVE AGENTS, ORGANOPHOSPHATES) EXPOSURE\n\nPage Number: 260\n\n### RADIATION EXPOSURE\n\nPage Number: 271\n\n### TOPICAL CHEMICAL BURN\n\nPage Number: 275\n\n### STIMULANT POISONING/OVERDOSE\n\nPage Number: 279\n\n### CYANIDE EXPOSURE\n\nPage Number: 283\n\n### BETA BLOCKER POISONING/OVERDOSE\n\nPage Number: 287\n\n### BITES AND ENVENOMATION\n\nPage Number: 291\n\n### CALCIUM CHANNEL BLOCKER POISONING/OVERDOSE\n\nPage Number: 295\n\n### OPIOID POISONING/OVERDOSE\n\nPage Number: 303\n\n### AIRWAY RESPIRATORY IRRITANTS\n\nPage Number: 308\n\n### RIOT CONTROL AGENTS\n\nPage Number: 317\n\n### HYPERTHERMIA/HEAT EXPOSURE\n\nPage Number: 320\n\n### HYPOTHERMIA/COLD EXPOSURE\n\nPage Number: 326\n\n### DROWNING\n\nPage Number: 333\n\nRev. March 2022\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### DIVE (SCUBA) INJURY/ACCIDENTS\n\n337\n\n### ALTITUDE ILLNESS\n\n341\n\n### CONDUCTED ELECTRICAL WEAPON INJURY (I.E., TASER\u00ae)\n\n345\n\n### ELECTRICAL INJURIES\n\n348\n\n### LIGHTNING/LIGHTNING STRIKE INJURY\n\n352\n\n### APPENDICES\n\n357\n\n#### I. AUTHOR, REVIEWER AND STAFF INFORMATION\n\n357\n\n#### II. UNIVERSAL DOCUMENTATION GUIDELINE\n\n363\n\n#### III. MEDICATIONS\n\n377\n\n#### IV. APPROVED ABBREVIATIONS\n\n394\n\n#### V. BURN AND BURN FLUID CHARTS\n\n398\n\n#### VI. NEUROLOGIC STATUS ASSESSMENT\n\n404\n\n#### VII. ABNORMAL VITAL SIGNS\n\n405\n\n#### VIII.", "start_char_idx": 1903, "end_char_idx": 4808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43458db4-244a-48b3-8e1d-af78647d3291": {"__data__": {"id_": "43458db4-244a-48b3-8e1d-af78647d3291", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "052cbc8d-fa9f-42fb-83e9-5766d8e788a4", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "c3aaf46100e63f01ac093a3719a66aecdb5f833253e823b2db33dd2ba719eca1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d80d93c7-46e6-4a61-bae0-ebca359a0f81", "node_type": "1", "metadata": {}, "hash": "b28b17a2e1332d7f8a4a33cb986888d06f4221b575412a32c1a6636f9073049b", "class_name": "RelatedNodeInfo"}}, "text": "UNIVERSAL DOCUMENTATION GUIDELINE\n\n363\n\n#### III. MEDICATIONS\n\n377\n\n#### IV. APPROVED ABBREVIATIONS\n\n394\n\n#### V. BURN AND BURN FLUID CHARTS\n\n398\n\n#### VI. NEUROLOGIC STATUS ASSESSMENT\n\n404\n\n#### VII. ABNORMAL VITAL SIGNS\n\n405\n\n#### VIII. EVIDENCE-BASED GUIDELINES: GRADE METHODOLOGY\n\n406\n\n#### IX. 2022 NATIONAL GUIDELINE FOR THE FIELD TRIAGE OF INJURED PATIENTS\n\n407\n\nRev. March 2022\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\nNASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\nThis publication was developed with funding from the National Highway Traffic Safety Administration\n(NHTSA), Office of Emergency Medical Services (Cooperative Agreement 693JJ92050001-0002) and the\nHealth Resources and Services Administration/Maternal and Child Health Bureau/EMS for Children\nprogram. The opinions, findings, and conclusions expressed in this publication are those of the authors and\nnot necessarily those of the United States Government. The United States Government assumes no liability\nfor its content or use thereof. If trade or manufacturers\u2019 names or products are mentioned, it is because\nthey are considered essential to the object of the publication and should not be construed as an\nendorsement. The United States Government does not endorse products or manufacturers. For more\ninformation, please visit EMS.gov and HRSA.gov.\n\nRev. March 2022\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# Introduction\n\nWe are honored to present the third edition of the National Association of State EMS Officials (NASEMSO) National Model EMS Clinical Guidelines and want to thank the entire EMS community for contributing to its evolution. The inaugural edition, released in September 2014, has been warmly welcomed by EMS clinicians, agencies, medical directors, and healthcare organizations in our nation as well as abroad. The creation of this document is a pinnacle event in the practice of EMS medicine as it fulfilled a recommendation in The Future of Emergency Care: Emergency Medical Services at the Crossroads published by the Institute of Medicine (now the National Academies of Sciences) in 2007. Specifically, this report states \u201cNHTSA, in partnership with professional organizations, should convene a panel of individuals with multidisciplinary expertise to develop evidence-based model prehospital care protocols for the treatment, triage, and transport of patients.\u201d\n\nThe National Association of State EMS Officials (NASEMSO) recognizes the need for national EMS clinical guidelines to help state EMS systems ensure a more standardized approach to the practice of patient care now and, as experience dictates, the adoption of future practices. The value of EMS clinicians to the patient has no boundaries as magnified by the historic 2019 novel coronavirus pandemic as well as other interjurisdictional and global responses. Model EMS clinical guidelines promote uniformity in EMS medicine which, in turn, fosters a more consistent skilled practice as EMS clinicians move across healthcare systems. They also provide a standard to EMS medical directors upon which to base practice. Supported by initial and subsequent grant funding from NHTSA\u2019s Office of Emergency Medical Services (OEMS) and the Health Resources and Services Administration (HRSA) Maternal and Child Health Bureau\u2019s EMS for Children program, NASEMSO continues to authorize its Medical Directors Council to partner with national stakeholder organizations with expertise in EMS medical direction and subject matter experts to create a unified set of patient care guidelines. For those aspects of clinical care where evidence-based guidelines derived in accordance with the national evidence-based guideline model process were not available, consensus-based clinical guidelines are developed utilizing current available research.\n\nThe NASEMSO Model EMS Clinical Guidelines are not mandatory, are not meant to be all-inclusive, nor are they meant to determine local scope of practice. The focus of these guidelines is solely patient-centric. As such, they are designed to provide a resource for EMS clinical practice, appropriate patient care, safety of patients and clinicians, and outcomes regardless of the existing resources and capabilities within an EMS system. This document provides a clinical standard that can be used as is or adapted for use on a state, regional, local, or organizational level to enhance patient care and to set benchmark performance of EMS practice. The Guidelines should be adapted to align with federal, state, regional, and jurisdictional laws and regulations. NASEMSO\u2019s ongoing support of this project underlines the critical evolution of the model EMS clinical guidelines as new EMS research and evidence-based patient care measures emerge.\n\nWe are most grateful to be able to partner with a group of talented, committed individuals in this worthwhile endeavor.", "start_char_idx": 4570, "end_char_idx": 9476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d80d93c7-46e6-4a61-bae0-ebca359a0f81": {"__data__": {"id_": "d80d93c7-46e6-4a61-bae0-ebca359a0f81", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43458db4-244a-48b3-8e1d-af78647d3291", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "9294ae825a372fcea62da3ede49728d4f592118c840eca08f654146591029123", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4158e382-6845-4f03-9e03-1bb0da38247c", "node_type": "1", "metadata": {}, "hash": "541ddd7e9c5adaf6d08f09262b0321afb388a054ae9736a679790fe82c89fe24", "class_name": "RelatedNodeInfo"}}, "text": "The focus of these guidelines is solely patient-centric. As such, they are designed to provide a resource for EMS clinical practice, appropriate patient care, safety of patients and clinicians, and outcomes regardless of the existing resources and capabilities within an EMS system. This document provides a clinical standard that can be used as is or adapted for use on a state, regional, local, or organizational level to enhance patient care and to set benchmark performance of EMS practice. The Guidelines should be adapted to align with federal, state, regional, and jurisdictional laws and regulations. NASEMSO\u2019s ongoing support of this project underlines the critical evolution of the model EMS clinical guidelines as new EMS research and evidence-based patient care measures emerge.\n\nWe are most grateful to be able to partner with a group of talented, committed individuals in this worthwhile endeavor.\n\nCarol Cunningham, M.D. Co-Principal Investigator\n\nRichard Kamin, M.D. Co-Principal Investigator\n\nRev. March 2022\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\nPurpose and Notes\n\nThese guidelines are intended to help state EMS systems ensure a more standardized approach to the practice of patient care, and to encompass evidence-based guidelines (EBG) as they are developed. The long-term goal is to develop a full range of evidence-based clinical guidelines for the practice of EMS medicine. However, until there is a sufficient body of evidence to fully support this goal, there is a need for this interim expert, consensus-based step.\n\nThe National Model EMS Clinical Guidelines can fill a significant gap in uniform clinical guidance for EMS patient care, while also providing input to the evidence-based guideline (EBG) development process. These guidelines will be maintained by the Medical Directors Council of the National Association of State EMS Officials (NASEMSO) and will be reviewed and updated periodically. As EBG material is developed, it will be substituted for the consensus-based guidelines now comprising the majority of the content of this document. In the interim, additional consensus-based guidelines will also be added as the need is identified.\n\nFor guidelines to be considered for inclusion, they must be presented in the format followed by all guidelines in the document. Universal Care and Poisoning/Overdose Universal Care guidelines are included to reduce the need for extensive reiteration of basic assessment and other considerations in every guideline. The appendices contain material such as neurologic status assessment and burn assessment tools to which many guidelines refer to increase consistency in internal standardization and to reduce duplication.\n\nWhile some specific guidelines have been included for pediatric patients, considerations of patient age and size (pediatric, geriatric, and bariatric) have been interwoven in the guidelines throughout the document. Where IV access and drug routing are specified, it is intended to include IO access and drug routing when IV access and drug routing is not possible. Generic medication names are utilized throughout the guidelines. A complete list of these, along with respective brand names, may be found in Appendix III. \u201cMedications\u201d.\n\nAccurate and quality data collection is crucial to the advancement of EMS and a critical element of EMS research. The National EMS Information System (NEMSIS) has the unique ability to unify EMS data on a national scope to fulfill this need. Each guideline, therefore, is also listed by the closest NEMSIS Version 3 Label and Code corresponding to it, listed in parentheses below the guideline name. Quality assurance (QA) and/or continued performance improvement (CPI) programs are an indispensable element of medical direction as they facilitate the identification of gaps and potential avenues of their resolution within an EMS system. The National EMS Quality Alliance (NEMSQA) Performance Measures is a resource for these programs. This edition of the NASEMSO National Model EMS Clinical Guidelines incorporates many of the NEMSQA performance measures into the key performance measures associated with each clinical guideline.\n\nRev. March 2022\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\nTarget Audience\n\nWhile this material is intended to be integrated into an EMS system\u2019s operational guidance materials by its medical director and other leaders, it is written with the intention that it will be consumed by field EMS clinicians. To the degree possible, it has been assembled in a format useful for guidance and quick reference so that leaders may adopt it in whole or in part, harvesting and integrating as they deem appropriate to the format of their guideline, protocol, or procedure materials. Any set of guidelines must determine a balance between education and patient care. This document purposefully focuses on the patient care aspect of EMS response. This does not preclude the individual medical director from using these guidelines and including additional education as well as incorporation of state, local, or jurisdictional operational procedures.", "start_char_idx": 8565, "end_char_idx": 13703, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4158e382-6845-4f03-9e03-1bb0da38247c": {"__data__": {"id_": "4158e382-6845-4f03-9e03-1bb0da38247c", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d80d93c7-46e6-4a61-bae0-ebca359a0f81", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "2e551012b3c1da3fb262f9376c0eebcd96f57234dff1de5eba7e211c0a35bf5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c685d16f-0229-44b6-a640-095ba85eb828", "node_type": "1", "metadata": {}, "hash": "0fb404fb234f9466929cbfacc7513221574602ed809bacd5085c83ded4761cc0", "class_name": "RelatedNodeInfo"}}, "text": "Rev. March 2022\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\nTarget Audience\n\nWhile this material is intended to be integrated into an EMS system\u2019s operational guidance materials by its medical director and other leaders, it is written with the intention that it will be consumed by field EMS clinicians. To the degree possible, it has been assembled in a format useful for guidance and quick reference so that leaders may adopt it in whole or in part, harvesting and integrating as they deem appropriate to the format of their guideline, protocol, or procedure materials. Any set of guidelines must determine a balance between education and patient care. This document purposefully focuses on the patient care aspect of EMS response. This does not preclude the individual medical director from using these guidelines and including additional education as well as incorporation of state, local, or jurisdictional operational procedures.\n\nWhat is New in the 2022 Edition\n\nAll of the 2017 guidelines have been reviewed and updated, and additional guidelines and new evidence-based guidelines have been added to this edition. While some of the new material has been added as guidelines in the appropriate chapter, other topics have been incorporated into a previously existing guideline. New guidelines have been added to the 2022 edition for the following clinical conditions or scenarios:\n\nBrief Resolved Unexplained Event (BRUE) & Acute Events in Infants\nResuscitation in Traumatic Cardiac Arrest\nTracheostomy Management\nTrauma Mass Casualty Incident\n\nIn addition, with the permission and assistance of the American College of Surgeons \u2013 Committee on Trauma, we have included the 2022 National Guideline for the Field Triage of Injured Patients as Appendix IX.\n\nAcknowledgements\n\nThe authors of this document are NASEMSO Medical Director Council members partnered with representatives of seven EMS medical director stakeholder organizations. The stakeholder organizations are the American Academy of Emergency Medicine (AAEM), the American Academy of Pediatrics (AAP), the American College of Emergency Physicians (ACEP), the American College of Surgeons Committee on Trauma (ACS-COT), the Air Medical Physician Association (AMPA), and the National Association of EMS Physicians (NAEMSP). In honor and gratitude, the authors of the inaugural NASEMSO National Model EMS Clinical Guidelines are also included. Their invaluable contributions and expertise to build the foundation of this evolutionary document will always be deeply respected and appreciated.\n\nRev. March 2022\n---\n# NASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Universal Care\n\n### Universal Care Guideline\n\n### Aliases\n\nPatient assessment\n\nPatient history\n\nPhysical assessment\n\nPrimary survey\n\nSecondary survey\n\n### Patient Care Goals\n\nFacilitate appropriate initial assessment and management of any EMS patient and link to appropriate specific guidelines as dictated by the findings within the Universal Care guideline\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nAll patient encounters with and care delivery by EMS personnel\n\n#### Exclusion Criteria\n\nNone\n\n### Patient Management\n\nAssessment\n\nAssess scene safety\n\nEvaluate for hazards to EMS personnel, patient, bystanders\nSafely remove patient from hazards prior to beginning medical care\nDetermine number of patients\nDetermine mechanism of injury or potential source of illness\nRequest additional resources if needed and weigh the benefits of waiting for additional resources against rapid transport to definitive care\nConsider declaration of mass casualty incident if needed\n\nUse appropriate personal protective equipment (PPE)\n\nConsider suspected or confirmed hazards on scene\nConsider suspected or confirmed highly contagious infectious disease (e.g., contact [bodily fluids], droplet, airborne)\n\nWear high-visibility, retro-reflective apparel when deemed appropriate (e.g., operations at night or in darkness, on or near roadways)\nConsider cervical spine stabilization and/or spinal care if traumatic injury suspected. [See Spine Care Guideline]\nPrimary survey\n(Airway, Breathing, Circulation (ABC) is cited below; although there are specific circumstances where Circulation, Airway, Breathing (CAB) may be indicated, such as for cardiac arrest, or Massive hemorrhage, Airway, Respirations, Circulation, Hypothermia and head injury (MARCH) may be indicated for trauma or major arterial bleeding)\n\n________________________Go To TOC\n\n## Universal Care\n\nRev. March 2022\n\nUniversal Care Guideline\n\n9\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\na. Airway (assess for patency and open the airway as indicated) \u2013 go to Airway Management Guideline\n\ni. Patient is unable to maintain airway patency\u2014open airway\n\n1. Head tilt/chin lift\n\n2. Jaw thrust\n\n3. Suction\n\n4.", "start_char_idx": 12754, "end_char_idx": 17609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c685d16f-0229-44b6-a640-095ba85eb828": {"__data__": {"id_": "c685d16f-0229-44b6-a640-095ba85eb828", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4158e382-6845-4f03-9e03-1bb0da38247c", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "6e5e46c32f6e93d8e1a1b91a202a5b7203ddc0879438932242ee10fc1f40167e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19fb4a23-a91f-476a-82c9-8a3e749927fb", "node_type": "1", "metadata": {}, "hash": "34a672c28c616a3ae95462d600645fe485b9d8e78723525f9c64f5d4471589b1", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nUniversal Care Guideline\n\n9\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\na. Airway (assess for patency and open the airway as indicated) \u2013 go to Airway Management Guideline\n\ni. Patient is unable to maintain airway patency\u2014open airway\n\n1. Head tilt/chin lift\n\n2. Jaw thrust\n\n3. Suction\n\n4. Consider use of the appropriate airway management adjuncts and devices: oral airway, nasal airway, supraglottic\nairway device or endotracheal tube\n\n5. For patients with laryngectomies or tracheostomies, remove all objects or clothing that may obstruct the opening of\nthese devices, maintain the flow of prescribed oxygen, and reposition the head and/or neck\n\nb. Breathing\n\ni. Evaluate rate, breath sounds, accessory muscle use, retractions, patient positioning, oxygen saturation\n\nii. Provide supplemental oxygen as appropriate to achieve the target of 94\u201398% oxygen saturation (SPO2) based upon\nclinical presentation and assessment of ventilation (e.g., EtCO2)\n\niii. Apnea (not breathing) \u2013 go to Airway Management Guideline\n\nc. Circulation\n\ni. Control any major external bleeding [See General Trauma Management Guideline and/or Extremity Trauma/External\nHemorrhage Management Guideline]\n\nii. Assess pulse\n\n1. If none \u2013 go to Resuscitation Section\n\n2. Assess rate and quality of carotid and radial pulses\n\niii. Evaluate perfusion by assessing skin color and temperature\n\n1. Evaluate capillary refill\n\nd. Disability\n\ni. Evaluate patient responsiveness: AVPU (Alert, Verbal, Painful, Unresponsive)\n\nii. Evaluate gross motor and sensory function in all extremities\n\niii. Check blood glucose in patients with altered mental status (AMS) or suspected stroke. If blood glucose is less than\n60 mg/dL \u2013 go to Hypoglycemia Guideline\n\niv. If acute stroke suspected \u2013 go to Suspected Stroke/Transient Ischemic Attack Guideline\n\ne. Expose patient for exam as appropriate to complaint\n\ni. Be considerate of patient modesty\n\nii. Keep patient warm\n\n6. Assess for urgency of transport\n\n7. Secondary survey\n\nThe performance of the secondary survey should not delay transport in critical patients. See also secondary survey\nspecific to individual complaints in other protocols. Secondary surveys should be tailored to patient presentation and chief\ncomplaint. The following are suggested considerations for secondary survey assessment:\n\na. Head\n\ni. Pupils\n\nii. Ears\n\niii. Naso-oropharynx\n\niv. Skull and scalp\n\n________________________ Go To TOC\n\nUniversal Care Rev. March 2022\n\nUniversal Care Guideline 10\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n**8. Obtain baseline vital signs (an initial full set of vital signs is required: pulse, blood pressure, respiratory rate, neurologic status assessment and obtain pulse oximetry if indicated)**\n\na. Neurologic status assessment [See Appendix VII. Neurologic Status Assessment] involves establishing a baseline and then trending any change in patient neurologic status\n\ni. Glasgow Coma Score (GCS) is frequently used, but there are often errors in applying and calculating this score. With this in consideration, a more simple field approach may be as valid as GCS. Either AVPU or only the motor component of the GCS may more effectively serve in this capacity\n\nii. Sternal rub as a stimulus is discouraged\n\nb. Patients with cardiac or respiratory complaints\n\ni. Pulse oximetry\n\nii. 12-lead electrocardiogram (EKG) should be obtained promptly in patients with cardiac or suspected cardiac complaints\n\niii. Continuous cardiac monitoring, if available\n\niv. Consider waveform capnography for patients with respiratory complaints (essential for critical patients and those patients who require invasive airway management)\n\nc. Patient with altered mental status\n\ni. Check blood glucose. If low, go to Hypoglycemia Guideline\n\nii. Consider waveform capnography (essential for critical patients and those patients who require invasive airway management) or digital capnometry\n\nd. Stable patients should have at least two sets of pertinent vital signs. Ideally, one set should be taken shortly before arrival at receiving facility\n\ne. Critical patients should have pertinent vital signs frequently monitored\n\n## Go To TOC\n\nUniversal Care Rev.", "start_char_idx": 17273, "end_char_idx": 21496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19fb4a23-a91f-476a-82c9-8a3e749927fb": {"__data__": {"id_": "19fb4a23-a91f-476a-82c9-8a3e749927fb", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c685d16f-0229-44b6-a640-095ba85eb828", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "3852ace7075dcae95f4c04efec66582fbf7acdc5425ede5bf9d682b1f9d32082", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4953596-7d02-4fe0-8879-9e16292174ab", "node_type": "1", "metadata": {}, "hash": "299edbaccdd8628668fab02f1742142f8687041782851a38fcefc348a83948db", "class_name": "RelatedNodeInfo"}}, "text": "12-lead electrocardiogram (EKG) should be obtained promptly in patients with cardiac or suspected cardiac complaints\n\niii. Continuous cardiac monitoring, if available\n\niv. Consider waveform capnography for patients with respiratory complaints (essential for critical patients and those patients who require invasive airway management)\n\nc. Patient with altered mental status\n\ni. Check blood glucose. If low, go to Hypoglycemia Guideline\n\nii. Consider waveform capnography (essential for critical patients and those patients who require invasive airway management) or digital capnometry\n\nd. Stable patients should have at least two sets of pertinent vital signs. Ideally, one set should be taken shortly before arrival at receiving facility\n\ne. Critical patients should have pertinent vital signs frequently monitored\n\n## Go To TOC\n\nUniversal Care Rev. March 2022 Universal Care Guideline 11\n---\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n### 9. Obtain OPQRST history:\n\na. Onset of symptoms\n\nb. Provocation: location; any exacerbating or alleviating factors\n\nc. Quality of pain\n\nd. Radiation of pain\n\ne. Severity of symptoms: pain scale\n\nf. Time of onset and circumstances around onset\n\n### 10. Obtain SAMPLE history:\n\na. Symptoms\n\nb. Allergies: medication, environmental, and foods\n\nc. Medications: prescription and over the counter; bring containers to ED if possible\n\nd. Past medical history\n\ni. Look for medical alert tags, portable medical records, advance directives\n\nii. Look for medical devices/implants (some common ones may be dialysis shunt, insulin pump, pacemaker, central\nvenous access port, gastric tubes, urinary catheter)\n\niii. For females of childbearing age, inquire of potential or recent pregnancy.\n\ne. Last oral intake\n\nf. Events leading up to the 911 call\n\nIn patients with syncope, seizure, altered mental status, or acute stroke, consider bringing the witness to the\nhospital or obtain their contact phone number to provide to ED care team\n\n### Treatment and Interventions\n\n1. Administer oxygen as appropriate with a target of achieving 94\u201398% saturation and select the appropriate method of\noxygen delivery to mitigate or treat hypercarbia associated with hypoventilation\n\n2. Place appropriate monitoring equipment as dictated by assessment; these may include:\n\na. Continuous pulse oximetry\n\nb. Cardiac rhythm monitoring\n\nc. Waveform capnography or digital capnometry\n\nd. Carbon monoxide assessment\n\n3. Establish vascular access if indicated or in patients who are at risk for clinical deterioration.\n\na. If IO is to be used for a conscious patient, consider the use of 0.5 mg/kg of lidocaine 0.1 mg/mL with slow push\nthrough IO needle to a maximum of 40 mg to mitigate pain from IO medication administration\n\n4. Monitor pain scale if appropriate\n\n5. Monitor agitation-sedation scale if appropriate\n\n6. Reassess patient\n\n### Transfer of Care\n\n1. The content and quality of information provided during the transfer of patient care to another party is critical\nfor seamless patient care and maintenance of patient safety\n\n2. Ideally, a completed electronic or written medical record should be provided to the next caregiver at the time of\ntransfer of care\n\nUniversal Care\n\nRev.", "start_char_idx": 20646, "end_char_idx": 23863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4953596-7d02-4fe0-8879-9e16292174ab": {"__data__": {"id_": "f4953596-7d02-4fe0-8879-9e16292174ab", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19fb4a23-a91f-476a-82c9-8a3e749927fb", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "c833ef9e763d9c7d23b12491a7aa72f74cc7d6c82f48f560267b74cd2bed0786", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "236b8a33-9489-48f1-ae41-b2025f3ccdaf", "node_type": "1", "metadata": {}, "hash": "1b2468d09fbe93a680f1bccee36f491b7b9970bedac0d3da152ade63befaea6d", "class_name": "RelatedNodeInfo"}}, "text": "Establish vascular access if indicated or in patients who are at risk for clinical deterioration.\n\na. If IO is to be used for a conscious patient, consider the use of 0.5 mg/kg of lidocaine 0.1 mg/mL with slow push\nthrough IO needle to a maximum of 40 mg to mitigate pain from IO medication administration\n\n4. Monitor pain scale if appropriate\n\n5. Monitor agitation-sedation scale if appropriate\n\n6. Reassess patient\n\n### Transfer of Care\n\n1. The content and quality of information provided during the transfer of patient care to another party is critical\nfor seamless patient care and maintenance of patient safety\n\n2. Ideally, a completed electronic or written medical record should be provided to the next caregiver at the time of\ntransfer of care\n\nUniversal Care\n\nRev. March 2022\n\nUniversal Care Guideline\n\n12\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n### Transfer of Care\n\nIf provision of the completed medical record is not possible at the time of transfer of care, a verbal report and an abbreviated written run report should be provided to the next caregiver\nThe information provided during the transfer of care should include, but is not limited to:\n\nPatient\u2019s full name\nAge\nChief complaint\nHistory of present illness/Mechanism of injury\nPast medical history\nMedications\nAllergies\nVital signs with documented times\nPatient assessment and interventions along with the timing of any medication or intervention and the patient\u2019s response to such interventions\n\nThe verbal or abbreviated written run report provided at the time of transfer of care does not take the place of or negate the requirement for the provision of a complete electronic or written medical record of the care provided by EMS personnel\n\n### Patient Safety Considerations\n\nRoutine use of lights and sirens is not warranted\nEven when lights and sirens are in use, always limit speeds to level that is safe for the emergency vehicle being driven and road conditions on which it is being operated\nBe aware of legal issues and patient rights as they pertain to and impact patient care (e.g., patients with functional needs or children with special healthcare needs)\nBe aware of potential need to adjust management based on patient age and comorbidities, including medication dosages\nThe maximum weight-based dose of medication administered to a pediatric patient should not exceed the maximum adult dose except where specifically stated in a patient care guideline\nMedical direction should be contacted when mandated or as needed\nConsider air medical transport, if available, for patients with time-critical conditions where ground transport time exceeds 30 minutes\n\n### Notes/Educational Pearls\n\n#### Key Considerations\n\nPediatrics: use a weight-based assessment tool (length-based tape or other system) to estimate patient weight and guide medication therapy and adjunct choice\n\nAlthough the defined age varies by state, the pediatric population is generally defined by those patients who weigh up to 40 kg or up to 14 years of age, whichever comes first\nConsider using the pediatric assessment triangle (appearance, work of breathing, circulation) when first approaching a child to help with assessment\n\nGeriatrics: although the defined age varies by state, the geriatric population is generally defined as those patients who are 65 years old or more\n\nIn these patients, as well as all adult patients, reduced medication dosages may apply to patients with renal disease (i.e., on dialysis or a diagnosis of chronic renal insufficiency) or hepatic disease (i.e., severe cirrhosis or end-stage liver disease)\n\nUniversal Care\n\nRev. March 2022\n\nUniversal Care Guideline\n\n13\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n3. Co-morbidities: reduced medication dosages may apply to patients with renal disease (i.e., on dialysis or a diagnosis of chronic renal insufficiency) or hepatic disease (i.e., severe cirrhosis or end-stage liver disease)\n\n4. Vital Signs:\n\na. Oxygen\n\ni. Administer oxygen as appropriate with a target of achieving 94\u201398% saturation\n\nii. Supplemental oxygen administration is warranted to patients with oxygen saturations below this level and titrated based upon clinical condition, clinical response, and geographic location and altitude\n\niii. The method of oxygen delivery should minimize or treat hypercarbia associated with hypoventilation (e.g., non-invasive positive airway pressure devices)\n\nb. Normal vital signs (See Table 1. Normal Vital Signs)\n\ni. Hypotension is considered a systolic blood pressure less than the lower limit on the chart\n\nii. Tachycardia is considered a pulse above the upper limit on the chart\n\niii. Bradycardia is considered a pulse below the lower limit on the chart\n\niv.", "start_char_idx": 23091, "end_char_idx": 27838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "236b8a33-9489-48f1-ae41-b2025f3ccdaf": {"__data__": {"id_": "236b8a33-9489-48f1-ae41-b2025f3ccdaf", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4953596-7d02-4fe0-8879-9e16292174ab", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "636af05ca4be22ddcb0babe7c70b60be8527d692310f7790f073821f1bf3e889", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f5fc362-b2f0-41bd-b2a3-1c0c6e3b9830", "node_type": "1", "metadata": {}, "hash": "a335244331d260b4e49cfbe0120141f6bb3dc3eef2771560879e2f0bbf2b31b0", "class_name": "RelatedNodeInfo"}}, "text": "Vital Signs:\n\na. Oxygen\n\ni. Administer oxygen as appropriate with a target of achieving 94\u201398% saturation\n\nii. Supplemental oxygen administration is warranted to patients with oxygen saturations below this level and titrated based upon clinical condition, clinical response, and geographic location and altitude\n\niii. The method of oxygen delivery should minimize or treat hypercarbia associated with hypoventilation (e.g., non-invasive positive airway pressure devices)\n\nb. Normal vital signs (See Table 1. Normal Vital Signs)\n\ni. Hypotension is considered a systolic blood pressure less than the lower limit on the chart\n\nii. Tachycardia is considered a pulse above the upper limit on the chart\n\niii. Bradycardia is considered a pulse below the lower limit on the chart\n\niv. Tachypnea is considered a respiratory rate above the upper limit on the chart\n\nv. Bradypnea is considered a respiratory rate below the lower limit on the chart\n\nc. Hypertension. Although abnormal, may be an expected finding in many patients\n\ni. Unless an intervention is specifically suggested based on the patient\u2019s complaint or presentation, the hypertension should be documented, but otherwise, no intervention should be taken acutely to normalize the blood pressure\n\nii. The occurrence of symptoms (e.g., chest pain, dyspnea, vision change, headache, focal weakness or change in sensation, altered mental status) in patients with hypertension should be considered concerning, and care should be provided appropriate with the patient\u2019s complaint or presentation\n\n5. Secondary Survey: if patient has critical primary survey problems, it may not be possible to complete\n\n6. Critical Patients: proactive patient management should occur simultaneously with assessment\n\na. Ideally, one clinician should be assigned to exclusively monitor and facilitate patient-focused care\n\nb. Other than lifesaving interventions that prevent deterioration en route, treatment and Interventions should be initiated as soon as practical, but should not impede extrication or delay transport to definitive care\n\n7. Air Medical Transport: air transport of trauma patients should generally be reserved for higher acuity trauma patients where there is a significant time saved over ground transport, where the appropriate destination is not accessible by ground due to systemic or logistical issues, and for patients who meet the American College of Surgeons Committee on Trauma (ACS-COT) 2022 National Guideline for the Field Triage of Injured Patients anatomic, physiologic, and situational high-acuity triage criteria. In selected circumstances, air medical resources may be helpful for non-trauma care (e.g., stroke, STEMI when geographically constrained)\n\n8. Additional Protective Measures for the EMS Clinician: Due to suspected or confirmed hazards and/or highly infectious contagious diseases, traditional patient treatment and care delivery may be altered due to recommendations by federal, state, local or jurisdictional officials\n\n________________________ Go To TOC\n\nUniversal Care Rev. March 2022 Universal Care Guideline 14\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Pertinent Assessment Findings\n\nRefer to individual guidelines\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914075 \u2013 General - Universal Patient Care/Initial Patient Contact\n\n### Key Documentation Elements\n\nAt least two sets of vital signs should be documented for every patient\nAll patient interventions and response to care should be documented\nAll major changes in clinical status including, but not limited to, vital signs and data from monitoring equipment, should be documented\n\n### Performance Measures\n\nAbnormal vital signs should be addressed and reassessed\nResponse to therapy provided should be documented including pain scale or agitation-sedation scale (e.g., Richmond Agitation-Sedation Scale (RASS)) reassessment if appropriate\nLimit scene time for patients with time-critical illness or injury unless clinically indicated\nAppropriate utilization of air medical services\nBlood glucose level obtained when indicated\nCompliance with provision of critical information during patient transfer of care\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nGo To TOC\n\nUniversal Care\n\nRev. March 2022\n\nUniversal Care Guideline\n\n15\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n**Table 1.", "start_char_idx": 27062, "end_char_idx": 31591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f5fc362-b2f0-41bd-b2a3-1c0c6e3b9830": {"__data__": {"id_": "7f5fc362-b2f0-41bd-b2a3-1c0c6e3b9830", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "236b8a33-9489-48f1-ae41-b2025f3ccdaf", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "134a34e8eed110b88120808ec7b92281f2338c8b677d97236c31267fe2ed8cf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ad76d80-f31b-433e-bc05-c6580728a784", "node_type": "1", "metadata": {}, "hash": "8d08a9aec329d626b4e9ffd10c87a77a212dfbe1d16c61877b177ab5b50909c5", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nUniversal Care Guideline\n\n15\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n**Table 1. Normal Vital Signs**\n|Age|Pulse-Awake (beats/minute)|Pulse-Sleeping (beats/minute)|Respiratory Rate (breaths/minute)|Systolic BP (mmHg)|\n|---|---|---|---|---|\n|Preterm less than 1 kg|120\u2013160| |30\u201360|39\u201359|\n|Preterm 1\u20133 kg|120\u2013160| |30\u201360|60\u201376|\n|Newborn|100\u2013205|85\u2013160|30\u201360|67\u201384|\n|Up to 1 year|100\u2013190|90\u2013160|30\u201360|72\u2013104|\n|1\u20132 years|100\u2013190|90\u2013160|24\u201340|86\u2013106|\n|2\u20133 years|98\u2013140|60\u2013120|24\u201340|86\u2013106|\n|3\u20134 years|80\u2013140|60\u2013100|24\u201340|89\u2013112|\n|4\u20135 years|80\u2013140|60\u2013100|22\u201334|89\u2013112|\n|5\u20136 years|75\u2013140|58\u201390|22\u201334|89\u2013112|\n|6\u201310 years|75\u2013140|58\u201390|18\u201330|97\u2013115|\n|10\u201312 years|75\u2013118|58\u201390|18\u201330|102\u2013120|\n|12\u201313 years|60\u2013100|58\u201390|15\u201320|110\u2013131|\n|13\u201315 years|60\u2013100|50\u201390|15\u201320|110\u2013131|\n|15 years or older|60\u2013100|50\u201390|15\u201320|110\u2013131|\n\nSource: Extrapolated from the 2020 American Heart Association Pediatric Advanced Life Support\u2019s tables from the Nursing Care of the Critically Ill Child, and from Web Box 1: Existing reference ranges for respiratory rate and heart rate in the appendix of the article by Fleming, et al, published in Lancet\n\nNote: While many factors affect blood pressure (e.g., pain, activity, hydration), it is imperative to rapidly recognize hypotension, especially in children. For children of the ages 1\u201310, hypotension is present if the systolic blood pressure is less than 70 mmHg + (child\u2019s age in years x 2) mmHg.\n\n________________________\n\nGo To TOC\n\nUniversal Care\n\nRev. March 2022\n\nUniversal Care Guideline\n\n16\n---\n## Table 2. Glasgow Coma Scale\n\n|ADULT GLASGOW COMA SCALE|PEDIATRIC GLASGOW COMA SCALE|\n|---|---|\n|Eye Opening (4)|Eye Opening (4)|\n|Spontaneous|Spontaneous|\n|To Speech|To Speech|\n|To Pain|To Pain|\n|None|None|\n|Best Motor Response (6)|Best Motor Response (6)|\n|Obeys Commands|Spontaneous Movement|\n|Localizes Pain|Withdraws to Touch|\n|Withdraws from Pain|Withdraws from Pain|\n|Abnormal Flexion|Abnormal Flexion|\n|Abnormal Extension|Abnormal Extension|\n|None|None|\n|Verbal Response (5)|Verbal Response (5)|\n|Oriented|Coos, Babbles|\n|Confused|Irritable Cry|\n|Inappropriate|Cries to Pain|\n|Incomprehensible|Moans to Pain|\n|None|None|\n\nSource: https://www.cdc.gov/masstrauma/resources/gcs.pdf\n\n### References\n\n2020 Pediatric Advanced Life Support Provider Manual, American Heart Association, 2020\nBass, R. R., Lawner, B., Lee, D. and Nable, J. V. 2015 Medical oversight of EMS systems, in Emergency Medical\nServices: Clinical Practice and Systems Oversight, Second Edition (eds D. C. Cone, J. H. Brice, T. R. Delbridge and\nJ. B. Myers), John Wiley & Sons, Ltd, Chichester, UK\nBledsoe BE, Porter RS, Cherry RA. Paramedic Care: Principles & Practice, Volume 3, 4th Ed. Brady, 2012\nDuckworth, Rom, EMS Trauma Care: ABCs vs. MARCH, Rescue Digest, September 1, 2017\nEmergency Cardiovascular Care: For Healthcare Providers. American Heart Association, 2020.", "start_char_idx": 31459, "end_char_idx": 34378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ad76d80-f31b-433e-bc05-c6580728a784": {"__data__": {"id_": "1ad76d80-f31b-433e-bc05-c6580728a784", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f5fc362-b2f0-41bd-b2a3-1c0c6e3b9830", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "52cfacb86485fa9b0d3589c25fca863225f7caa8a29150193480eb8d69142bfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ac7f708-6fc9-4cd4-8800-0e058f5f38ee", "node_type": "1", "metadata": {}, "hash": "21268c99c27114364da5a1eb200c888fbdf462e255f8ff771f743698d862949a", "class_name": "RelatedNodeInfo"}}, "text": "2015 Medical oversight of EMS systems, in Emergency Medical\nServices: Clinical Practice and Systems Oversight, Second Edition (eds D. C. Cone, J. H. Brice, T. R. Delbridge and\nJ. B. Myers), John Wiley & Sons, Ltd, Chichester, UK\nBledsoe BE, Porter RS, Cherry RA. Paramedic Care: Principles & Practice, Volume 3, 4th Ed. Brady, 2012\nDuckworth, Rom, EMS Trauma Care: ABCs vs. MARCH, Rescue Digest, September 1, 2017\nEmergency Cardiovascular Care: For Healthcare Providers. American Heart Association, 2020.\nFleming, S, et al, Normal ranges of heart rate and respiratory rate in children from birth to 18 years: a systematic\nreview of observational studies, Lancet, March 19, 2011,377(9770),1011\u20131018\nGerecht, Ryan, et al, \u201cUnderstanding when to Request a Helicopter for Your Patient\u201d, Journal of EMS, October 3,\n2014. https://www.jems.com/operations/ambulances-vehicle-ops/understanding-when-request-helicopter-yo/.\nAccessed March 11, 2022\nGill M, Steele R, Windemuth R, Green SM. A comparison of five simplified scales to the out-of-hospital Glasgow\nComa Scale for the prediction of traumatic brain injury outcomes. Acad Emerg Med. 2006;13(9):968\u201373\nHaziinski, MF, Children are Different, Nursing Care of the Critically Ill Child, 3rd ed, Mosby, 2013,1\u201318\n\n________________________ Go To TOC\n\nUniversal Care Rev. March 2022\n\n### Universal Care Guideline\n\n17\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n10. Kupas, D. Lights and Siren Use by Emergency Medical Services (EMS): Above All Do No Harm. National Highway\nTraffic Safety Administration Contract DTNH22-14-F-00579. Published May 2017\n\n11. National Association of State Emergency Medical Services Officials. State model rules for the regulation of air\nmedical services. September 2016\n\n12. O\u2019Driscoll BR, Howard LS, Davison AG. BTS guideline for emergency oxygen use in adult patients. Thorax\n2008;63:vi1-vi68\n\n13. Thomas SH, Brown KM, Oliver ZJ, Spaite DW, Sahni R, Weik TS, et al. An evidence-based guideline for the air\nmedical transportation of trauma patients. Prehosp Emerg Care 2014;18 Suppl 1:35\u201344\n\n14. U.S. Fire Administration. Traffic incident management systems, FA-330. March 2012.\nhttps://www.usfa.fema.gov/downloads/pdf/publications/fa_330.pdf.\nAccessed March 11, 2022\n\nRevision Date March 24, 2022\n\n________________________ Go To TOC\n\nUniversal Care Rev. March 2022\n\nUniversal Care Guideline 18\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Functional Needs\n\nAliases: Developmental delay, Disabled, Handicapped, Impaired, Mental Illness, Intellectual Disability, Special needs\n\n### Patient Care Goals\n\nTo meet and maintain the additional support required for patients with functional needs during the delivery of prehospital care\n\n### Patient Presentation\n\n|Inclusion Criteria|Patients who are identified by the World Health Organization\u2019s International Classification of Functioning, Disability, and Health that have experienced a decrement in health resulting in some degree of disability. According to the U.S.", "start_char_idx": 33874, "end_char_idx": 36928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ac7f708-6fc9-4cd4-8800-0e058f5f38ee": {"__data__": {"id_": "1ac7f708-6fc9-4cd4-8800-0e058f5f38ee", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ad76d80-f31b-433e-bc05-c6580728a784", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "d89e381a51902ed5fcd8383111dd8b336a97ea4c520b3efedcfe47a2ce65a50d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4489c10f-77ce-47f6-ba54-5265142fac28", "node_type": "1", "metadata": {}, "hash": "904cb2bc32cdd275b1f04ef91d1dd90fe33fc4f80b3e0181a0ff12a37fb6b883", "class_name": "RelatedNodeInfo"}}, "text": "March 2012.\nhttps://www.usfa.fema.gov/downloads/pdf/publications/fa_330.pdf.\nAccessed March 11, 2022\n\nRevision Date March 24, 2022\n\n________________________ Go To TOC\n\nUniversal Care Rev. March 2022\n\nUniversal Care Guideline 18\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Functional Needs\n\nAliases: Developmental delay, Disabled, Handicapped, Impaired, Mental Illness, Intellectual Disability, Special needs\n\n### Patient Care Goals\n\nTo meet and maintain the additional support required for patients with functional needs during the delivery of prehospital care\n\n### Patient Presentation\n\n|Inclusion Criteria|Patients who are identified by the World Health Organization\u2019s International Classification of Functioning, Disability, and Health that have experienced a decrement in health resulting in some degree of disability. According to the U.S. Department of Health and Human Services, this includes, but is not limited to, individuals with physical, sensory, mental health, and cognitive and/or intellectual disabilities affecting their ability to function independently without assistance|\n|---|---|\n|Exclusion Criteria|None noted|\n\n### Patient Management\n\nAssessment\n\nIdentify the functional need by means of information from the patient, the patient\u2019s family, bystanders, medic alert bracelets or documents, or the patient\u2019s adjunct assistance devices\nThe physical examination should not be intentionally abbreviated, although the way the exam is performed may need to be modified to accommodate the specific needs of the patient\n\nTreatment and Interventions\n\nMedical care should not intentionally be reduced or abbreviated during the triage, treatment, and transport of patients with functional needs, although the way the care is provided may need to be modified to accommodate the specific needs of the patient\n\nPatient Safety Considerations\n\nFor patients with communication barriers (language or sensory), it may be desirable to obtain secondary confirmation of pertinent data (e.g., allergies) from the patient\u2019s family, interpreters, or written or electronic medical records. The family members can be an excellent source of information and the presence of a family member can have a calming influence on some of these patients\n\n________________________Go To TOC\n\nUniversal Care Rev. March 2022\n\nFunctional Needs 19\n---\n# NASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Notes/Educational Pearls\n\n### Key Considerations\n\n1. Communication Barriers\n\na. Language Barriers:\n\ni. Expressive and/or receptive aphasia\n\nii. Nonverbal\n\niii. Fluency in a different language than that of the EMS professional\n\niv. Examples of tools to overcome language barriers include:\n\nTransport of an individual who is fluent in the patient\u2019s language along with the patient to the hospital\nMedical translation cards\nTelephone-accessible services with live language interpreters\nMethods through which the patient augments his/her communication skills (e.g., eye blinking, nodding) should be noted, utilized as able, and communicated to the receiving facility\nElectronic applications for translation\n\nb. Sensory Barriers:\n\ni. Visual impairment\n\nii. Auditory impairment\n\niii. Examples of tools to overcome sensory barriers include:\n\nBraille communication card\nSign language\nLip reading\nHearing aids\nWritten communication\n\n2. Physical Barriers:\n\na. Ambulatory impairment (e.g., limb amputation, bariatric)\n\nb. Neuromuscular impairment\n\n3. Cognitive Barriers:\n\na. Mental illness\n\nb. Developmental challenge or delay\n\n### Pertinent Assessment Findings\n\n1. Assistance Adjuncts. Examples of devices that facilitate the activities of daily living for the patient with functional needs include, but are not limited to:\n\na. Extremity prostheses\n\nb. Hearing aids\n\nc. Magnifiers\n\nd. Tracheostomy speaking valves\n\ne. White or sensory canes\n\nf. Wheelchairs or motorized scooters\n\n2. Service Animals\n\nAs defined by the American Disabilities Act, \u201cany guide dog, signal dog, or other animal individually trained to do work or perform tasks for the benefit of an individual with a disability, including, but not limited to guiding individuals with impaired vision, alerting individuals with\n\nUniversal Care\n\nRev.", "start_char_idx": 36044, "end_char_idx": 40281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4489c10f-77ce-47f6-ba54-5265142fac28": {"__data__": {"id_": "4489c10f-77ce-47f6-ba54-5265142fac28", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ac7f708-6fc9-4cd4-8800-0e058f5f38ee", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "477dd5bbc9fc7ee972feab8283a950837109adf0efcf8b6321c8cc20579bc91a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddb3c7a4-47d7-46b0-b4ba-962f9da7b55b", "node_type": "1", "metadata": {}, "hash": "1c5a3875497ffa7ec14ec863a7fd920ef4048ad10bb3e27152d903a3edc7a822", "class_name": "RelatedNodeInfo"}}, "text": "Cognitive Barriers:\n\na. Mental illness\n\nb. Developmental challenge or delay\n\n### Pertinent Assessment Findings\n\n1. Assistance Adjuncts. Examples of devices that facilitate the activities of daily living for the patient with functional needs include, but are not limited to:\n\na. Extremity prostheses\n\nb. Hearing aids\n\nc. Magnifiers\n\nd. Tracheostomy speaking valves\n\ne. White or sensory canes\n\nf. Wheelchairs or motorized scooters\n\n2. Service Animals\n\nAs defined by the American Disabilities Act, \u201cany guide dog, signal dog, or other animal individually trained to do work or perform tasks for the benefit of an individual with a disability, including, but not limited to guiding individuals with impaired vision, alerting individuals with\n\nUniversal Care\n\nRev. March 2022\n\nFunctional Needs\n\n20\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\nImpaired hearing to intruders or sounds, providing minimal protection or rescue work, pulling a wheelchair, or fetching\ndropped items\n\na. Services animals are not classified as a pet and should, by law, always be permitted to accompany the patient with\nthe following exceptions:\n\ni. A public entity may ask an individual with a disability to remove a service animal from the premises if:\n\n1. The animal is out of control and the animal's handler does not take effective action to control it; or\n\n2. The animal is not housebroken\n\nb. Service animals are not required to wear a vest or a leash. It is illegal to make a request for special identification\nor documentation from the service animal\u2019s partner. EMS clinicians may only ask the patient if the service animal is\nrequired because of a disability and the form of assistance the animal has been trained to perform.\n\nc. EMS clinicians are not responsible for the care of the service animal. If the patient is incapacitated and cannot\npersonally care for the service animal, a decision can be made whether to transport the animal in this situation.\n\nd. Animals that solely provide emotional support, comfort, or companionship do not qualify as service animals\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914063 \u2013 General - Individualized Patient Protocol\n9914165 \u2013 Other\n\n### Key Documentation Elements\n\nDocument all barriers in the NEMSIS element \u201ceHistory.01 \u2013 Barriers to Patient Care\u201d (NEMSIS Required National Element)\nDocument specific physical barriers in the appropriate exam elements (e.g., \u201cblind\u201d under Eye Assessment; or paralysis,\nweakness, or speech problems under Neurological Assessment)\nDocument any of the following, as appropriate in the narrative:\n\nLanguage barriers:\n\nThe patient\u2019s primary language of fluency\nThe identification of the person assisting with the communication\nThe methods through which the patient augments his/her communication skills\n\nSensory barriers:\n\nThe methods through which the patient augments his/her communication skills\nWritten communication between the patient and the EMS professional is part of the medical record, even if it is\non a scrap sheet of paper, and it should be retained with the same collation, storage, and confidentiality policies\nand procedures that are applicable to the written or electronic patient care report\n\nAssistance adjuncts (devices that facilitate the activities of life for the patient)\n\n### Performance Measure\n\nAccuracy of key data elements (chief complaint, past medical history, medication, allergies)\nUtilization of the appropriate adjuncts to overcome communication barriers\n\n________________________ Go To TOC\n\n## Universal Care\n\nRev. March 2022\n\n## Functional Needs\n\n21\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nDocumentation of the patient\u2019s functional need and avenue exercised to support the patient\nDocumentation of complete and accurate transfer of information regarding the functional need to the receiving\nfacility\nBarriers documented under \u201ceHistory.01\u2014Barriers to Patient Care\u201d\n\nReferences\n\nInternational classification of functioning, disability, and health. Presented at: 54th World Health Assembly, WHA\n54.21, Agenda Item 13.9; May 21, 2001\nU.S. Department of Health and Human Services, Office of the Assistant Secretary of Preparedness and Response.\nFEMA\u2019s Functional Needs Support Services Guidance. 2012. http://www.phe.gov/Preparedness/planning/abc/Documents/fema-fnss.pdf.\nAccessed August 18, 2017\nUS Department of Labor. Americans with Disabilities Act; 28 Code of Federal Regulations Part 35. July 23, 2010\nUS Department of Labor. Americans with Disabilities Act; 42 U.S. Code, Chapter 126.", "start_char_idx": 39522, "end_char_idx": 44141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddb3c7a4-47d7-46b0-b4ba-962f9da7b55b": {"__data__": {"id_": "ddb3c7a4-47d7-46b0-b4ba-962f9da7b55b", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4489c10f-77ce-47f6-ba54-5265142fac28", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "416d01bc054a988140434b2d0ab0c78d82ac90c140647bac06f99ae2431834a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6ca6a4a-ad94-41e2-9994-d92271b399aa", "node_type": "1", "metadata": {}, "hash": "0eb2e5642cbae2e12e2634b8954c7ed560df60b2e2331dabdbfe2f08b145b960", "class_name": "RelatedNodeInfo"}}, "text": "Presented at: 54th World Health Assembly, WHA\n54.21, Agenda Item 13.9; May 21, 2001\nU.S. Department of Health and Human Services, Office of the Assistant Secretary of Preparedness and Response.\nFEMA\u2019s Functional Needs Support Services Guidance. 2012. http://www.phe.gov/Preparedness/planning/abc/Documents/fema-fnss.pdf.\nAccessed August 18, 2017\nUS Department of Labor. Americans with Disabilities Act; 28 Code of Federal Regulations Part 35. July 23, 2010\nUS Department of Labor. Americans with Disabilities Act; 42 U.S. Code, Chapter 126. 1990\nUS Department of Labor. Americans with Disabilities Act; Amendments Act; 42 U.S. Code. 2008\n\nRevision Date\n\nMarch 11, 2022\n\nUniversal Care\n\nRev. March 2022\n\nFunctional Needs\n\n22\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Patient Refusals\n\n### Aliases\n\nAgainst medical advice\n\nRefusal of treatment\n\nRefusal of transport\n\n## Patient Care Goals/Patient Presentation (Overview)\n\nIf an individual (or the parent or legal guardian of the individual) refuses secondary care and/or ambulance\ntransport to a hospital after prehospital clinicians have been called to the scene, clinicians should determine\nthe patient\u2019s capacity to make decisions. Competency is generally a legal status of a person\u2019s ability to make\ndecisions. However, state laws vary in the definition of competency and its impact upon authority.\nTherefore, one should consult with the respective state EMS office for clarification on legal definitions and\npatient rights.\n\n## Patient Management\n\n### Assessment\n\n#### Decision-Making Capacity\n\na. An individual who is alert, oriented, and can understand the circumstances surrounding his/her illness or\nimpairment, as well as the possible risks associated with refusing treatment and/or transport, typically is\nconsidered to have decision-making capacity\n\nb. The individual\u2019s judgment must also not be significantly impaired by illness, injury, or drugs/alcohol\nintoxication. Individuals who have attempted suicide, verbalized suicidal intent, or had other factors that lead\nEMS clinicians to suspect suicidal intent, should not be regarded as having decision-making capacity and may not\ndecline transport to a medical facility\n\n### Treatment and Interventions\n\nObtain a complete set of vital signs and complete an initial assessment, paying particular attention to the\nindividual\u2019s neurologic and mental status\nDetermine the individual\u2019s capacity to make a valid judgment concerning the extent of his/her illness or injury; if\nthe EMS clinician has doubts about whether the individual has the mental capacity to refuse or if the patient lacks\ncapacity, the EMS clinician should contact medical direction\nIf patient has capacity, clearly explain to the individual and all responsible parties the possible risks and overall\nconcerns with regards to refusing care and that they may reengage the EMS system if needed\nPerform appropriate medical care with the consent of the individual\nComplete the patient care report clearly documenting the initial assessment findings and the discussions with all\ninvolved individuals regarding the possible consequences of refusing additional prehospital care and/or\ntransportation\n\n## Notes/Educational Pearls\n\n### Key Considerations\n\nAn adult or emancipated minor who has demonstrated possessing sufficient mental capacity for making decisions has\nthe right to determine the course of his/her medical care, including the refusal of care\n\n________________________Go To TOC\n\nUniversal Care Rev. March 2022\n\nPatient Refusals 23\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n2. Individuals must be advised of the risks and consequences resulting from refusal of medical care to enable an informed decision regarding consent or refusal of treatment\n\n3. An individual determined to lack decision-making capacity by EMS clinicians should not be allowed to refuse care against medical advice or to be released at the scene. Mental illness, drugs, alcohol intoxication, or physical/mental impairment may significantly impair an individual\u2019s decision-making capacity. Individuals who have attempted suicide, verbalized suicidal intent, or had other factors that lead EMS clinicians to suspect suicidal intent, should not be regarded as having demonstrated sufficient decision-making capacity\n\n4. The determination of decision-making capacity may be challenged by communication barriers or cultural differences\n\n5. EMS clinicians should not put themselves in danger by attempting to treat and/or transport an individual who refuses care. Law enforcement personnel should be requested if needed\n\n6. Always act in the best interest of the patient. EMS clinicians, with the support of direct medical oversight, must strike a balance between abandoning the patient and forcing care\n\n7.", "start_char_idx": 43601, "end_char_idx": 48422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6ca6a4a-ad94-41e2-9994-d92271b399aa": {"__data__": {"id_": "a6ca6a4a-ad94-41e2-9994-d92271b399aa", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddb3c7a4-47d7-46b0-b4ba-962f9da7b55b", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "e39ec2df6c54b25570df020279b475987b8494220587e222d579c88c9d03fccb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99135879-8373-4bb8-8700-abfc7ed740b6", "node_type": "1", "metadata": {}, "hash": "146049191acbdd51a23fc024913faf0505039996b28127e89bf911636512068f", "class_name": "RelatedNodeInfo"}}, "text": "An individual determined to lack decision-making capacity by EMS clinicians should not be allowed to refuse care against medical advice or to be released at the scene. Mental illness, drugs, alcohol intoxication, or physical/mental impairment may significantly impair an individual\u2019s decision-making capacity. Individuals who have attempted suicide, verbalized suicidal intent, or had other factors that lead EMS clinicians to suspect suicidal intent, should not be regarded as having demonstrated sufficient decision-making capacity\n\n4. The determination of decision-making capacity may be challenged by communication barriers or cultural differences\n\n5. EMS clinicians should not put themselves in danger by attempting to treat and/or transport an individual who refuses care. Law enforcement personnel should be requested if needed\n\n6. Always act in the best interest of the patient. EMS clinicians, with the support of direct medical oversight, must strike a balance between abandoning the patient and forcing care\n\n7. Special Considerations \u2013 Minors\n\nIt is preferable for minors to have a parent or legal guardian who can provide consent for treatment on behalf of the child\n\na. All states allow healthcare clinicians to provide emergency treatment when a parent is not available to provide consent. This is known as the emergency exception rule or the doctrine of implied consent. For minors, this doctrine means that the EMS clinician can presume consent and proceed with appropriate treatment and transport if the following six conditions are met:\n\ni. The child is suffering from an emergent condition that places their life or health in danger\nii. The child\u2019s legal guardian is unavailable or unable to provide consent for treatment or transport\niii. Treatment or transport cannot be safely delayed until consent can be obtained\niv. The EMS clinician administers only treatment for emergency conditions that pose an immediate threat to the child\nv. As a rule, when the EMS clinician\u2019s authority to act is in doubt, EMS clinicians should always do what they believe to be in the best interest of the minor\nvi. If a minor is injured or ill and no parent contact is possible, the EMS clinician may contact medical direction for additional instructions\n\nQuality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914189 \u2013 General - Refusal of Care\n\nKey Documentation Elements\n\nDocument patient capacity with:\nAll barriers to patient care in the NEMSIS element \u201ceHistory.01\u2014Barriers to Patient Care\u201d (a Required National Element of NEMSIS)\nExam fields for \u201ceExam.19\u2014Mental Status\u201d and \u201ceExam.20\u2014Neurological Assessment\u201d\nVitals for level of responsiveness and Glasgow Coma Scale\nAlcohol and drug use indicators\n\nGo To TOC\n\nUniversal Care Rev. March 2022 Patient Refusals 24\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nBlood glucose level (as appropriate to situation and patient history)\nPatient Age\nMinors who are not emancipated and adults with a legal guardian: guardian name, contact, and relationship\nAny efforts made to contact guardians if contact could not be made\nWhat the patient\u2019s plan is after refusal of care and/or transport\nWho will be with the patient after EMS departs\nPatient was advised that they can change their mind and EMS can be contacted again at any time\nPatient was advised of possible risks to their health resulting from refusing care and/or transport\nPatient voices understanding of risks. A quotation of the patient\u2019s actual words, stating they understand, is best\nReason for patient refusing care. A quotation of the patient\u2019s actual words, stating they understand, is best\nMedical direction contact\nAny assessments and treatments performed\n\nPerformance Measures\n\nPatient decision-making capacity was determined and documented\nMedical direction was contacted as indicated by EMS agency protocol\nGuardians contacted or efforts to contact the guardians for minor patients who are not or cannot be confirmed to be\nemancipated\n\nReferences\n\nPatient Autonomy and Destination Factors in Emergency Medical Services (EMS) and EMS-Affiliated Mobile Integrated\nHealthcare/Community Paramedicine Programs. Acep.org.\n\nRevised October 2015. Accessed March 11, 2022\n\nRevision Date\n\nMarch 11, 2022\n\n________________________\n\nGo To TOC\n\nUniversal Care\n\nRev. March 2022\n\nPatient Refusals\n\n25\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# Cardiovascular - Adult and Pediatric Syncope and Near Syncope\n\n## Aliases\n\nLoss of consciousness\n\n## Patient Care Goals\n\nStabilize and resuscitate when necessary\nInitiate monitoring and diagnostic procedures\nTransfer for further evaluation\n\n## Patient Presentation\n\nSyncope is heralded by both the loss of consciousness and the loss of postural tone and resolves spontaneously without medical interventions.", "start_char_idx": 47400, "end_char_idx": 52266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99135879-8373-4bb8-8700-abfc7ed740b6": {"__data__": {"id_": "99135879-8373-4bb8-8700-abfc7ed740b6", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6ca6a4a-ad94-41e2-9994-d92271b399aa", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "22c3eaa8c5a6e176a612b799805a0ec33a98c38139b7e8c9c1595b67d745f726", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b151272-b5f3-46f1-9fa4-8281dc1b54f3", "node_type": "1", "metadata": {}, "hash": "4eecb4fcb7ae0259da89b98c47accd4541737bbdeed53d99de3ed80b0f042341", "class_name": "RelatedNodeInfo"}}, "text": "Acep.org.\n\nRevised October 2015. Accessed March 11, 2022\n\nRevision Date\n\nMarch 11, 2022\n\n________________________\n\nGo To TOC\n\nUniversal Care\n\nRev. March 2022\n\nPatient Refusals\n\n25\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# Cardiovascular - Adult and Pediatric Syncope and Near Syncope\n\n## Aliases\n\nLoss of consciousness\n\n## Patient Care Goals\n\nStabilize and resuscitate when necessary\nInitiate monitoring and diagnostic procedures\nTransfer for further evaluation\n\n## Patient Presentation\n\nSyncope is heralded by both the loss of consciousness and the loss of postural tone and resolves spontaneously without medical interventions. Syncope typically is abrupt in onset and resolves equally quickly. EMS clinicians may find the patient awake and alert on initial evaluation\n\nNear syncope is defined as the prodromal symptoms of syncope. The symptoms that can precede syncope last for seconds to minutes with signs and symptoms that may include pallor, sweating, lightheadedness, visual changes, or weakness. It may be described by the patient as \"nearly blacking out\" or \"nearly fainting\".\n\nRapid first aid during the onset may improve symptoms and prevent syncope\n\n## Inclusion Criteria\n\nAbrupt loss of consciousness with loss of postural tone\nProdromal symptoms of syncope\n\n## Exclusion Criteria\n\nConditions other than the above, including:\n\nPatients with alternate and obvious cause of loss of consciousness (e.g., trauma \u2013 See Head Injury Guideline)\nPatients with ongoing mental status changes or coma should be treated per the Altered Mental Status Guideline\nPatients with persistent new neurologic deficit [See Suspected Stroke/Transient Ischemic Attack Guideline]\n\n## Patient Management - Assessment\n\n### Pertinent History\n\nReview the patient\u2019s past medical history including a history of:\n\nCardiovascular disease (e.g., cardiac disease/stroke, valvular disease, hypertrophic cardiomyopathy, mitral valve prolapse)\nSeizure\nRecent trauma\nActive cancer diagnosis\n\n________________________ Go To TOC\n\nCardiovascular - Rev. March 2022 - Adult and Pediatric Syncope and Near Syncope - 26\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n### Dysrhythmias including prior electrophysiology studies/pacemaker and/or implantable cardioverter defibrillator (ICD)\n\n### History of syncope\n\n### History of thrombosis or emboli\n\nHistory of Present Illness, including:\n\nConditions leading to the event: after transition from recumbent/sitting to standing; occurring with strenuous exercise (notably in the young and seemingly healthy)\n\nSyncope that occurs during exercise often indicates an ominous cardiac cause. Patients should be evaluated in the emergency department\n\nPatient complaints before or after the event including prodromal symptoms\n\nHistory of symptoms described by others on scene, including seizures or shaking, presence of pulse/breathing (if noted), duration of the event, events that lead to the resolution of the event\n\nReview of Systems:\n\nCurrent medications (new medications, changes in doses)\n\nFluid losses (nausea/vomiting/diarrhea) and fluid intake\n\nLast menstrual period/pregnant\n\nOccult blood loss (gastrointestinal (GI)/genitourinary (GU))\n\nPalpitations\n\nUnilateral Leg swelling, history of recent travel, prolonged immobilization, malignancy\n\nPertinent Physical Exam including:\n\nAttention to vital signs and evaluation for trauma\n\nNote overall patient appearance, diaphoresis, pallor\n\nDetailed neurologic exam (including stroke screening and mental status)\n\nHeart, lung, abdominal, and extremity exam\n\nAdditional Evaluation:\n\nCardiac monitoring\nOxygen saturation (SPO2)\nOngoing vital signs\n12-lead EKG\nBlood glucose level (BGL)\n\n## Treatment and Interventions:\n\nShould be directed at abnormalities discovered in the physical exam or on additional examination and may include management of cardiac dysrhythmias, cardiac ischemia/infarct, hemorrhage, shock, etc.\nManage airway as indicated\nOxygen as appropriate\nEvaluate for hemorrhage and treat for shock if indicated\nEstablish IV access\nFluid bolus if appropriate\nCardiac monitor\n12-lead EKG\nMonitor for and treat arrhythmias (if present, refer to appropriate guideline)\n\nGo To TOC\n\nCardiovascular\n\nRev. March 2022\n\nAdult and Pediatric Syncope and Near Syncope\n\n27\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Patient Safety Considerations:\n\n1. Patients suffering from syncope due to arrhythmia may experience recurrent arrhythmias and should therefore be placed on a cardiac monitor\n\n2.", "start_char_idx": 51619, "end_char_idx": 56146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b151272-b5f3-46f1-9fa4-8281dc1b54f3": {"__data__": {"id_": "0b151272-b5f3-46f1-9fa4-8281dc1b54f3", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99135879-8373-4bb8-8700-abfc7ed740b6", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "4ba1d797c2df239c08215382a17fe55e640ed6064648b8e9b4f77a5709eedd2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecafb81d-90b8-4b6c-9cad-5cdf3884e661", "node_type": "1", "metadata": {}, "hash": "333e900d12a58faaf783930250c687beff3cac775d9e938ed1221ce27f55ef8b", "class_name": "RelatedNodeInfo"}}, "text": "Manage airway as indicated\nOxygen as appropriate\nEvaluate for hemorrhage and treat for shock if indicated\nEstablish IV access\nFluid bolus if appropriate\nCardiac monitor\n12-lead EKG\nMonitor for and treat arrhythmias (if present, refer to appropriate guideline)\n\nGo To TOC\n\nCardiovascular\n\nRev. March 2022\n\nAdult and Pediatric Syncope and Near Syncope\n\n27\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Patient Safety Considerations:\n\n1. Patients suffering from syncope due to arrhythmia may experience recurrent arrhythmias and should therefore be placed on a cardiac monitor\n\n2. Geriatric patients suffering falls from standing may sustain significant injury and should be diligently screened for trauma. [General Trauma Management Guideline]\n\n### Notes/Educational Pearls\n\n#### Key Considerations\n\n1. By being most proximate to the scene and to the patient\u2019s presentation, EMS clinicians are commonly in a unique position to identify the cause of syncope. Consideration of potential causes, ongoing monitoring of vitals and cardiac rhythm and detailed exam and history are essential pieces of information to pass on to hospital clinicians\n\n2. For patients where a lower risk etiology is suspected, e.g., vasovagal syncope, decisions regarding delayed or non-transport should be made in consultation with medical direction\n\n3. High-risk causes of syncope include, but are not limited to, the following:\n\nCardiovascular\n\nMyocardial infarction\nAortic stenosis\nHypertrophic cardiomyopathy (consider in young patient with unexplained syncope during exertion)\nPulmonary embolus\nAortic dissection\nDysrhythmia\nMitral valve prolapse is associated with higher risk for sudden death\n\nNeurovascular\n\nIntracranial hemorrhage\nTransient ischemic attack or stroke\nVertebral basilar insufficiency\n\nHemorrhagic\n\nRuptured ectopic pregnancy\nGI bleed\nAortic rupture\n\n4. Consider high-risk 12-lead EKG features including, but not limited to:\n\nEvidence of QT prolongation (generally over 500 msec)\nDelta waves\nBrugada syndrome (incomplete right bundle branch block (RBBB) pattern in V1/V2 with ST segment elevation)\nHypertrophic obstructive cardiomyopathy\n\n### Pertinent Assessment Findings\n\n1. 12-lead EKG findings\n\n2. Evidence of alternate etiology, including seizure\n\n3. Evidence of cardiac dysfunction (e.g., evidence of congestive heart failure (CHF), arrhythmia)\n\n4. Evidence of hemorrhage\n\n5. Evidence of neurologic compromise\n\n________________________Go To TOC\n\nCardiovascular Rev. March 2022 Adult and Pediatric Syncope and Near Syncope 28\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n###### Evidence of trauma\n\n###### Initial and ongoing cardiac rhythm\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914149 \u2013 Medical \u2013 Syncope\n\n#### Key Documentation Elements\n\nPresenting cardiac rhythm\nCardiac rhythm present when patient is symptomatic\nAny cardiac rhythm changes\nBlood pressure\nPulse\nBlood glucose level (BGL)\nSymptoms immediately preceding event\nPatient status on EMS arrival: recovered or still symptomatic\n\n#### Performance Measures\n\nAcquisition of 12-lead EKG\nApplication of cardiac monitor\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nStroke \u2014 01: Suspected Stroke Receiving Prehospital Stroke Assessment\n\n#### References\n\nAnderson JB, Willis M, Lancaster H, Leonard K, Thomas C. The evaluation and management of pediatric syncope.\nPediatr Neurol. 2016; 55:6\u201313\nhttps://doi.org/10.1016/j.pediatrneurol.2015.10.018\n\nBenditt DG, Adkisson WO. Approach to the patient with syncope. Cardiol Clin. 2013;31(1):9\u201325\nDovgalyuk J, Holstege C, Mattu A, Brady WJ. The electrocardiogram in the patient with syncope. Am J Emerg Med.\n2007; 25:688\u2013701\nFischer J, Choo CS. Pediatric syncope: cases from the emergency department. Emerg Med Clin North Am.", "start_char_idx": 55541, "end_char_idx": 59469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecafb81d-90b8-4b6c-9cad-5cdf3884e661": {"__data__": {"id_": "ecafb81d-90b8-4b6c-9cad-5cdf3884e661", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b151272-b5f3-46f1-9fa4-8281dc1b54f3", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "6305c6510d771bc8f72aad41abd7839c6478a0318ce5adf3d69a5e54322dec83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb46cca4-1e07-48d1-b2b0-a9e5c2e17106", "node_type": "1", "metadata": {}, "hash": "e708924ff2f27cacc96ac04662ae918d7d22e9772861edd8667ffb57e7230e70", "class_name": "RelatedNodeInfo"}}, "text": "Pediatr Neurol. 2016; 55:6\u201313\nhttps://doi.org/10.1016/j.pediatrneurol.2015.10.018\n\nBenditt DG, Adkisson WO. Approach to the patient with syncope. Cardiol Clin. 2013;31(1):9\u201325\nDovgalyuk J, Holstege C, Mattu A, Brady WJ. The electrocardiogram in the patient with syncope. Am J Emerg Med.\n2007; 25:688\u2013701\nFischer J, Choo CS. Pediatric syncope: cases from the emergency department. Emerg Med Clin North Am.\n2010;28(3):501\u201316\nHerbert M, Spangler M, Swadron S, Mason J. Emergency Medicine Reviews and Perspectives (EM:RAP). C3 Continuous\nCore Content Podcast. Syncope \u2013 Introduction. November 2016.\nhttps://www.emrap.org/episode/c3syncope/syncope.\nAccessed March 11, 2022\n\nHuff JS, Decker WW, Quinn JV, Perron AD, Napoli AM, Peeters S, et al; American College of Emergency Physicians.\nClinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency\ndepartment with syncope. Ann Emerg Med. 2007;49(4):431\u201344\n\nKessler C, Tristan JM, De Lorenzo R. The emergency department approach to syncope: evidence-based guidelines and\nprediction rules. Emerg Med Clin North Am. 2010;28(3):248\u2013500\n\nKhoo C, Chakrabarti S, Arbour L, Krahn AD. Recognizing life-threatening causes of syncope. Cardiol Clin.\n2013;31(1):51\u201366\n\n________________________ Go To TOC\n\nCardiovascular Rev. March 2022\n\nAdult and Pediatric Syncope and Near Syncope 29\n---\n# NASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n9. Orman R, Mattu A; Emergency Medicine Reviews and Perspectives (EMRAP). Spring Forward into PE. Cardiology Corner \u2013 Syncope. March 2016.\n\nhttps://www.emrap.org/episode/springforward/cardiology. Accessed March 11, 2022\n\n10. Ouyang H, Quinn J. Diagnosis and management of syncope in the emergency department. Emerg Med Clin North Am. 2010;28(3):471.485\n\nRevision Date: March 11, 2022\n\nGo To TOC\n\n## Cardiovascular\n\nRev. March 2022\n\n### Adult and Pediatric Syncope and Near Syncope\n\n30\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Chest Pain/Acute Coronary Syndrome (ACS)/ST-segment Elevation Myocardial Infarction (STEMI)\n\nAliases\n\nHeart attack Myocardial infarction (MI)\n\nPatient Care Goals\n\nIdentify ST-elevation myocardial infarction (STEMI) quickly\nDetermine the time of symptom onset\nActivate hospital-based STEMI system of care\nMonitor vital signs and cardiac rhythm and be prepared to provide CPR and defibrillation if needed\nAdminister appropriate medications\nTransport to appropriate facility\n\nPatient Presentation\n\nInclusion Criteria\n\nChest pain or discomfort in other areas of the body (e.g., arm, jaw, epigastrium) of suspected cardiac origin,\nshortness of breath, associated or unexplained sweating, nausea, vomiting, or dizziness. Atypical or unusual\nsymptoms are more common in women, the elderly, and diabetic patients. May also present with CHF, syncope, and/or\nshock\nChest pain associated sympathomimetic use (e.g., cocaine, methamphetamine)\nSome patients will present with likely non-cardiac chest pain and otherwise have a low likelihood of ACS (e.g.,\nblunt trauma to the chest of a child).", "start_char_idx": 59065, "end_char_idx": 62151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb46cca4-1e07-48d1-b2b0-a9e5c2e17106": {"__data__": {"id_": "eb46cca4-1e07-48d1-b2b0-a9e5c2e17106", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecafb81d-90b8-4b6c-9cad-5cdf3884e661", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "aecf88a3ebe7e53f54d19110eec2433b14f2d8343fa1ab30d61392da10f6d6be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9692c7a-ee28-44ac-b19b-1bd19e41c25b", "node_type": "1", "metadata": {}, "hash": "addf2a7060d52cca13f57ad0bbff22a6a2026250c8c456296c1a6dc59d44ce30", "class_name": "RelatedNodeInfo"}}, "text": "Atypical or unusual\nsymptoms are more common in women, the elderly, and diabetic patients. May also present with CHF, syncope, and/or\nshock\nChest pain associated sympathomimetic use (e.g., cocaine, methamphetamine)\nSome patients will present with likely non-cardiac chest pain and otherwise have a low likelihood of ACS (e.g.,\nblunt trauma to the chest of a child). For these patients, defer the administration of aspirin (ASA) and nitrates\nper the Pain Management Guideline\n\nExclusion Criteria\n\nNone noted\n\nPatient Management\n\nAssessment, Treatment, and Interventions\n\nSigns and symptoms include chest pain, congestive heart failure (CHF), syncope, shock, symptoms similar to a\npatient\u2019s previous MI\nAssess the patient\u2019s cardiac rhythm and immediately address pulseless rhythms, symptomatic tachycardia, or\nsymptomatic bradycardia [See Cardiovascular Section and Resuscitation Section]\nIf the patient is dyspneic, hypoxemic, or has obvious signs of heart failure, EMS clinicians should administer\noxygen as appropriate with a target of achieving 94\u201398% saturation [Refer to Universal Care Guideline]\nThe 12-lead EKG is the primary diagnostic tool that identifies a STEMI; it is imperative that EMS clinicians\nroutinely acquire a 12-lead EKG within 10 minutes for all patients exhibiting signs and symptoms of ACS\n\nGo To TOC\n\nCardiovascular\n\nRev. March 2022\n\nChest Pain/Acute Coronary Syndrome (ACS)/ST-segment Elevation Myocardial Infarction (STEMI)\n\n31\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\na. The EKG may be transmitted for remote interpretation by a physician or screened for STEMI by properly trained EMS clinicians or other healthcare providers with or without the assistance of computer-interpretation\n\nb. Advance notification should be provided to the receiving hospital for patients identified as having a STEMI\n\nc. Performance of serial EKGs is encouraged for symptomatic patients with EKGs initially non-diagnostic for STEMI\n\nd. All EKGs should be made available to treating personnel at the receiving hospital, whether hand delivered as hard copy or transmitted from the field\n\n5. Administer aspirin; chewable, non-enteric-coated aspirin preferred (162\u2013325 mg)\n\n6. Establish IV access\n\n7. Nitroglycerin 0.4 mg sublingual (SL), can repeat q (quaque, every) 3\u20135 minutes if SBP greater than 100 mmHg\n\na. The use of nitrates should be avoided in any patient who has used a phosphodiesterase inhibitor within the past 48 hours\n\nb. Examples include sildenafil (Viagra\u00ae, Revatio\u00ae), vardenafil (Levitra\u00ae, Staxyn\u00ae), tadalafil (Cialis\u00ae, Adcirca\u00ae) which are used for erectile dysfunction and pulmonary hypertension. Also avoid use in patients receiving intravenous epoprostenol (Flolan\u00ae) or treprostenil (Remodulin\u00ae) which is used for pulmonary hypertension.\n\nc. Care should always be taken when giving nitroglycerin when the patient\u2019s blood pressure is marginal. If used in this setting, the clinician should weigh the risk and benefit of nitrate administration over the administration of an opiate analgesic and be ready to respond to hypotension with fluid bolus or pressor\n\n8. The location of the infarct does not preclude the use of nitrates. Right-sided leads are of no additional value if an inferior STEMI has been diagnosed and such findings (presumed RV infarct) do not preclude the use of nitroglycerin: however, continually monitor the patient\u2019s hemodynamic status and be prepared to resuscitate if hypotension occurs\n\n9. If the pain is unresponsive to nitrates, opiates are an acceptable alternative. Morphine should be used with caution in unstable angina (UA)/non-STEMI due to an association with increased mortality\n\n10. Transport and destination decisions should be based on local resources and system of care\n\n11. Early notification to receiving facility of any changes in patient condition or serial EKGs\n\n### Patient Safety Considerations\n\n1. Observe for signs of clinical deterioration: dysrhythmias, chest pain, shortness of breath, decreased level of consciousness/syncope, or other signs of shock/hypotension\n\n2. Perform serial 12-lead EKGs (especially if clinical changes are noted)\n\n3. Consider placing defibrillator pads on high-risk patients\n\n4.", "start_char_idx": 61786, "end_char_idx": 65992, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9692c7a-ee28-44ac-b19b-1bd19e41c25b": {"__data__": {"id_": "a9692c7a-ee28-44ac-b19b-1bd19e41c25b", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb46cca4-1e07-48d1-b2b0-a9e5c2e17106", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "b04a2d523359faad4f1dcfd4850e4e3d37196d8be61025b81ae2db0930836f73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad805fd6-1618-4255-a9cc-6be22582b2fd", "node_type": "1", "metadata": {}, "hash": "35228ed3b79aa42108e83b7291c76062fa01350954e23777df0543d2efa9aad5", "class_name": "RelatedNodeInfo"}}, "text": "If the pain is unresponsive to nitrates, opiates are an acceptable alternative. Morphine should be used with caution in unstable angina (UA)/non-STEMI due to an association with increased mortality\n\n10. Transport and destination decisions should be based on local resources and system of care\n\n11. Early notification to receiving facility of any changes in patient condition or serial EKGs\n\n### Patient Safety Considerations\n\n1. Observe for signs of clinical deterioration: dysrhythmias, chest pain, shortness of breath, decreased level of consciousness/syncope, or other signs of shock/hypotension\n\n2. Perform serial 12-lead EKGs (especially if clinical changes are noted)\n\n3. Consider placing defibrillator pads on high-risk patients\n\n4. Consider configuring monitor/defibrillator to allow automatic VT/VF alert\n\n5. Consider configuring monitor/defibrillator to allow ST-segment trending if available\n\n### Notes/Educational Pearls\n\nKey Considerations\n\nAcute coronary syndrome may present with atypical pain, vague or only generalized complaints.\n\n________________________\n\nGo To TOC\n\n#### Cardiovascular\n\nRev. March 2022\n\nChest Pain/Acute Coronary Syndrome (ACS)/ST-segment Elevation Myocardial Infarction (STEMI)\n\n32\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nIschemic burden time is a risk for morbidity and mortality, EMS can help decrease first medical contact to intervention time/reflow by efficient scripting/training of safely minimizing scene time\n\n## Pertinent Assessment Findings\n\nA complete medication list should be obtained from each patient. It is especially important for the treating physician and healthcare providers to be informed if the patient is taking beta-blockers, calcium channel blockers, clonidine, digoxin, blood thinners (anticoagulants), and medications for the treatment of erectile dysfunction or pulmonary hypertension\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914117 \u2013 Medical - Cardiac Chest Pain\n9914143 \u2013 Medical - ST-Elevation Myocardial Infarction (STEMI)\n\n## Key Documentation Elements\n\nThe time of symptom onset\nThe time of patient contact by EMS to the time of 12-lead EKG acquisition\nThe time aspirin (ASA) administered, or reason why not given\nThe time of STEMI notification\n\n## Performance Measures\n\nThe time of patient contact by the first medical contact to the time of 12-lead EKG acquisition within 10 minutes\nThe time from first diagnostic 12-lead EKG to STEMI notification\nConfirmation patient received ASA (taken prior to EMS arrival, advised by dispatch, given by EMS, or substantiated by other pertinent negatives)\nThe time of a STEMI patient\u2019s ultimate arrival to a receiving hospital\nThe time of EMS notification to the time of activation of a cardiac catheterization laboratory\nThe time of arrival at the percutaneous coronary intervention (PCI) center to the time of cardiac catheterization (door-to-balloon time) or if patient not transported directly to PCI center, the time of arrival at receiving hospital to thrombolytics\nThe time of prehospital 12-lead EKG acquisition to the time of device deployment (formerly EKG-to-balloon time)\nNOTE: These measures can only be evaluated if EMS documentation can be combined with information provided by the receiving hospital\n\n## References\n\nBosson KN, Kaji AH, Niemann JT, et al The utility of prehospital EKG transmission in a large EMS system. Prehosp Emerg Care. 2015;19(4):496\u2013503\nDe Champlain F, Boothroyd LJ, Vadeboncoeur A, et al. Computerized interpretation of the prehospital electrocardiogram: predictive value for ST-segment elevation myocardial infarction and impact on on-scene time. CJEM. 2014;16(2):94\u2013105\nMeine TJ, Roe MT, Chen AY, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE quality improvement initiative. Am Heart J. 2005;149(6):1043\u20139\n\n________________________\n\nGo To TOC\n\nCardiovascular\n\nRev. March 2022\n\nChest Pain/Acute Coronary Syndrome (ACS)/ST-segment Elevation Myocardial Infarction (STEMI)\n\n33\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n4. Mission: Lifeline EMS Recognition.", "start_char_idx": 65253, "end_char_idx": 69476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad805fd6-1618-4255-a9cc-6be22582b2fd": {"__data__": {"id_": "ad805fd6-1618-4255-a9cc-6be22582b2fd", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9692c7a-ee28-44ac-b19b-1bd19e41c25b", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "1388f83138901a153910da0c9e18c2cd5ffb19468bfe4907f38ae78bffb779d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aede0b6a-4ecb-491a-8d8c-290df566cb1a", "node_type": "1", "metadata": {}, "hash": "517d73130370e94802c04d4300489b9606dec88d047e18eaceaefd51758830c0", "class_name": "RelatedNodeInfo"}}, "text": "Computerized interpretation of the prehospital electrocardiogram: predictive value for ST-segment elevation myocardial infarction and impact on on-scene time. CJEM. 2014;16(2):94\u2013105\nMeine TJ, Roe MT, Chen AY, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE quality improvement initiative. Am Heart J. 2005;149(6):1043\u20139\n\n________________________\n\nGo To TOC\n\nCardiovascular\n\nRev. March 2022\n\nChest Pain/Acute Coronary Syndrome (ACS)/ST-segment Elevation Myocardial Infarction (STEMI)\n\n33\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n4. Mission: Lifeline EMS Recognition. American Heart Association. Heart.org.\n\nhttps://www.heart.org/en/professional/quality-improvement/mission-lifeline/mission-lifeline-ems-recognition. Accessed March 11, 2022\n\n5. Nam J, Caners K, Bowen JM, O\u2019Reilly D. Systematic review and meta-analysis of the benefits of out-of-hospital\n12-lead EKG and advance notification in ST-segment elevation myocardial infarction patients. Ann Emerg Med.\n2014;64(2):176\u201386\n\n6. O\u2019Connor RE, Abudulaziz AAS, Brady WJ, et al. Part 9: acute coronary syndromes. Circulation. 2015;132(18 Suppl\n2):S483\u2013500\n\n7. Robichaud L, Ross D, Proulx M-H, et al. Prehospital Nitroglycerin Safety in Inferior ST Elevation Myocardial\nInfarction. Prehospital Emergency Care. 2016;20(1):76\u201381. doi:10.3109/10903127.2015.1037480\n\n8. Squire BT, Tamaryo-Sarver JH, Rashi P, Koenig W, Niemann JT. Effect of prehospital cardiac catheterization lab\nactivation on door-to-balloon time, mortality, and false-positive activation. Prehosp Emerg Care.\n2014;18(1):1\u20138\n\n9. Verbeek PR, Ryan D, Turner L, Craig AM. Serial prehospital 12-lead electrocardiograms increase identification of\nST-segment elevation myocardial infarction. Prehosp Emerg Care. 2012;16(1):109\u201314\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nCardiovascular Rev.", "start_char_idx": 68811, "end_char_idx": 70735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aede0b6a-4ecb-491a-8d8c-290df566cb1a": {"__data__": {"id_": "aede0b6a-4ecb-491a-8d8c-290df566cb1a", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad805fd6-1618-4255-a9cc-6be22582b2fd", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "b34227b22d09c558481c650fda1afbc0a5dfc2bc7e65bf27b546f848e93ecd12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25c75933-341f-4f40-bff4-164b65b2d1f2", "node_type": "1", "metadata": {}, "hash": "a010a4e75f9dac1ce52abe7007de228ba9dc43b780b727692d780052b4919c87", "class_name": "RelatedNodeInfo"}}, "text": "Prehospital Emergency Care. 2016;20(1):76\u201381. doi:10.3109/10903127.2015.1037480\n\n8. Squire BT, Tamaryo-Sarver JH, Rashi P, Koenig W, Niemann JT. Effect of prehospital cardiac catheterization lab\nactivation on door-to-balloon time, mortality, and false-positive activation. Prehosp Emerg Care.\n2014;18(1):1\u20138\n\n9. Verbeek PR, Ryan D, Turner L, Craig AM. Serial prehospital 12-lead electrocardiograms increase identification of\nST-segment elevation myocardial infarction. Prehosp Emerg Care. 2012;16(1):109\u201314\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nCardiovascular Rev. March 2022\n\nChest Pain/Acute Coronary Syndrome (ACS)/ST-segment Elevation Myocardial Infarction (STEMI) 34\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Bradycardia\n\n### Aliases\n\nHeart block\n\nJunctional rhythm\n\n### Patient Care Goals\n\nMaintain adequate perfusion\nTreat underlying cause:\n\nHypoxia\nShock\nSecond- or third-degree atrioventricular (AV) block\nToxin exposure (beta-blocker, calcium channel blocker, organophosphates, digoxin)\nElectrolyte disorder\nHypoglycemia\nIncreased intracranial pressure (ICP)\nOther\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nHeart rate less than 60 beats per minute (BPM) with either symptoms (altered mental status (AMS), chest pain\n(CP), congestive heart failure (CHF), seizure, syncope, shock, pallor, diaphoresis) or evidence of hemodynamic\ninstability\nThe major EKG rhythms classified as bradycardia include:\n\nSinus bradycardia\nSecond-degree AV block\n\nType I-Wenckebach/Mobitz I\nType II-Mobitz II\n\nThird-degree AV block, complete heart block\nVentricular escape rhythms\n\nSee additional inclusion criteria for pediatric patients\n\n#### Exclusion Criteria\n\nNone noted\n\n### Patient Management\n\n#### Assessment, Treatment, and Interventions\n\nAdult Management\n\nManage airway as necessary\nAdminister oxygen as appropriate with a target of achieving 94\u201398% saturation\nInitiate monitoring and perform 12-lead EKG\nEstablish IV access\nCheck blood glucose and treat hypoglycemia per the Hypoglycemia Guideline and Hyperglycemia Guideline\n\nGo To TOC\n\n### Cardiovascular\n\nRev. March 2022\n\n## Bradycardia\n\n35\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nf. Consider the following additional therapies if bradycardia and symptoms or hemodynamic instability continue:\n\ni. Atropine 1 mg IV q 3\u20135 minutes (maximum total dose of 3 mg)\n\nii. Vasopressor medications (in order of preference)\n\nEpinephrine IV drip 0.02\u20130.2 mcg/kg/min titrated to a MAP greater than 65 mmHg OR\nEpinephrine by push dose (dilute boluses): for example, prepare 10 mcg/mL by adding 1 mL of 0.1 mg/mL epinephrine to 9 mL of normal saline, then administer 10\u201320 mcg boluses (1\u20132 mL) q 2 minutes titrated MAP greater than 65 mmHg OR\nNorepinephrine 0.02\u20130.4 mcg/kg/minute IV titrated to a MAP greater than 65 mmHg\n\niii. Transcutaneous Pacing \u2013 If pacing is performed, consider sedation or pain control\n\n2.", "start_char_idx": 70142, "end_char_idx": 73103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25c75933-341f-4f40-bff4-164b65b2d1f2": {"__data__": {"id_": "25c75933-341f-4f40-bff4-164b65b2d1f2", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aede0b6a-4ecb-491a-8d8c-290df566cb1a", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8867981ca054fa75b3b017cf9c1a845a9e81690a94b2ea719a703b162417deac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5186346-bc1c-456b-8eca-6e392508db4a", "node_type": "1", "metadata": {}, "hash": "d44918cd4d9b838571ad4583e4ce2846be0d4bb05fb6bd101eb6156691a45009", "class_name": "RelatedNodeInfo"}}, "text": "Vasopressor medications (in order of preference)\n\nEpinephrine IV drip 0.02\u20130.2 mcg/kg/min titrated to a MAP greater than 65 mmHg OR\nEpinephrine by push dose (dilute boluses): for example, prepare 10 mcg/mL by adding 1 mL of 0.1 mg/mL epinephrine to 9 mL of normal saline, then administer 10\u201320 mcg boluses (1\u20132 mL) q 2 minutes titrated MAP greater than 65 mmHg OR\nNorepinephrine 0.02\u20130.4 mcg/kg/minute IV titrated to a MAP greater than 65 mmHg\n\niii. Transcutaneous Pacing \u2013 If pacing is performed, consider sedation or pain control\n\n2. Pediatric Management\n\nTreatment is only indicated for patients who are symptomatic (pale/cyanotic, diaphoretic, altered mental status, hypoxic)\n\na. For infants and newborns, initiate chest compressions for heart rate less than 60 BPM and signs of poor perfusion (altered mental status, hypoxia, hypotension, weak pulse, delayed capillary refill, cyanosis)\n\nb. Manage airway and assist ventilations as necessary with minimally interrupted chest compressions using a compression-to-ventilation ratio 15:2 (30:2 if single clinician is present)\n\nc. Administer oxygen as appropriate with a target of achieving 94\u201398% saturation\n\nd. Initiate monitoring and perform 12-lead EKG\n\ne. Establish IV access\n\nf. Check blood glucose and treat hypoglycemia per the Hypoglycemia Guideline\n\ng. Consider the following additional therapies if bradycardia and symptoms or hemodynamic instability continue:\n\ni. Epinephrine by push dose (dilute boluses). For example, prepare 10 mcg/mL by adding 1 mL of 0.1 mg/mL epinephrine to 9 mL of normal saline, then administer 0.01 mg/kg (0.1 mL/kg) maximum single dose 10 mcg (1 mL) q 3\u20135 minutes titrated to MAP greater than 65 mmHg\n\nii. Also consider atropine 0.01\u20130.02 mg/kg IV with minimum dose of 0.1 mg if increased vagal tone or cholinergic drug toxicity to maximum initial dose of 0.5 mg (maximum total dose of 3 mg)\n\niii. Transcutaneous pacing: If pacing is performed, consider sedation or pain control\n\niv. Epinephrine may be used for bradycardia and poor perfusion unresponsive to ventilation and oxygenation\n\nIt is reasonable to administer atropine for bradycardia caused by increased vagal tone or cholinergic drug toxicity\n\nPatient Safety Considerations\n\nIf pacing is performed, consider sedation or pain control\n\nGo To TOC\n\nCardiovascular\n\nRev.", "start_char_idx": 72568, "end_char_idx": 74883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5186346-bc1c-456b-8eca-6e392508db4a": {"__data__": {"id_": "d5186346-bc1c-456b-8eca-6e392508db4a", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25c75933-341f-4f40-bff4-164b65b2d1f2", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "51daf0aca388949f1b3a30769931138bcad4a699afee8801da3685d5a3006c49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b8cbd76-01c7-443f-ad43-0b4ccd2350ef", "node_type": "1", "metadata": {}, "hash": "ef2258d06be3dd57a794168a57f4b74379d5cf54c7ddd2e660aa4231ef35b392", "class_name": "RelatedNodeInfo"}}, "text": "Also consider atropine 0.01\u20130.02 mg/kg IV with minimum dose of 0.1 mg if increased vagal tone or cholinergic drug toxicity to maximum initial dose of 0.5 mg (maximum total dose of 3 mg)\n\niii. Transcutaneous pacing: If pacing is performed, consider sedation or pain control\n\niv. Epinephrine may be used for bradycardia and poor perfusion unresponsive to ventilation and oxygenation\n\nIt is reasonable to administer atropine for bradycardia caused by increased vagal tone or cholinergic drug toxicity\n\nPatient Safety Considerations\n\nIf pacing is performed, consider sedation or pain control\n\nGo To TOC\n\nCardiovascular\n\nRev. March 2022\n\nBradycardia\n\n36\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Notes/Educational Pearls\n\n### Key Considerations\n\nObserve for signs of decreased end-organ perfusion: chest pain (CP), shortness of breath (SOB), decreased level of\nconsciousness, syncope, or other signs of shock/hypotension\nPatients who have undergone cardiac transplant will not respond to atropine\nConsider potential culprit medications including beta-blockers, calcium channel blockers, sodium channel\nblockers/anti-depressants, digoxin, and clonidine\n\nIf medication overdose is considered, refer to appropriate guideline in the Toxins and Environmental Section\n\nThe differential diagnosis includes the following: myocardial infarction (MI), hypoxia, pacemaker failure,\nhypothermia, sinus bradycardia, athletes, head injury with increased intracranial pressure (ICP), stroke, spinal\ncord lesion, sick sinus syndrome, AV blocks, overdose, cholinergic nerve agents\nConsider hyperkalemia in the patient with wide complex bradycardia\nBradycardia should be managed via the least invasive manner possible, escalating care as needed\n\nThird-degree heart block or the denervated heart (as in cardiac transplant) may not respond to atropine and in\nthese cases, proceed quickly to chronotropic agents (such as epinephrine or dopamine) or transcutaneous pacing\n\nDopamine is not indicated for pediatric patients\nIn cases of impending hemodynamic collapse, proceed directly to transcutaneous pacing\nFor shock that is suspected to be from sepsis, norepinephrine is preferred over dopamine due to its reduced\nrisk of arrhythmias and its lower mortality rate\n\nBe aware of acute coronary syndrome as a cause of bradycardia in adult patients\nWhen dosing medications for pediatric patients, dose should be weight-based for non-obese patients and based on\nideal body weight for obese patients\nAlthough dopamine is often recommended for the treatment of symptomatic bradycardia, recent research suggests\nthat patients in cardiogenic or septic shock treated with norepinephrine have a lower mortality rate compared to\nthose treated with dopamine\nCaution: Norepinephrine can theoretically cause reflex bradycardia\n\n### Pertinent Assessment Findings\n\nNone noted\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914115 \u2013 Medical - Bradycardia\n\n### Key Documentation Elements\n\nCardiac rhythm/rate\nTime, dose, and response of medications given\nPacing: Time started or stopped, rate, joules, capture, and response rate\nPatient weight\nPediatric length-based tape color (for pediatrics who fit on tape)\n\n________________________ Go To TOC\n\n## Cardiovascular\n\nRev. March 2022\n\n## Bradycardia\n\n37\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n### Performance Measures\n\nBlood sugar obtained\nCorrect medication(s) and dose given for patient condition, age, and weight\nCorrect application and use of cardiac pacing\nUse of sedation or pain management with cardiac pacing\n\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nHypoglycemia\u201401: Treatment Administered for Hypoglycemia\nPediatrics\u201403: Documentation of Estimated Weight in Kilograms\n\n### References\n\nBerg KM, Soar J, Andersen LW, et al. Adult Advanced Life Support: 2020 International Consensus on\nCardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.\nCirculation. 2020;142(16_suppl_1): S92-S139.", "start_char_idx": 74263, "end_char_idx": 78429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b8cbd76-01c7-443f-ad43-0b4ccd2350ef": {"__data__": {"id_": "1b8cbd76-01c7-443f-ad43-0b4ccd2350ef", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5186346-bc1c-456b-8eca-6e392508db4a", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "2af02ff8add799b71d88f43db4def9d816dd2f26acc11efe482b5b382fe340f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "449a6cce-d131-41e8-9502-e32a621694bf", "node_type": "1", "metadata": {}, "hash": "5a20b9a3bc147cfef2cbb0c713adaa91aec156e3765c1a60d0d2badc59f37dac", "class_name": "RelatedNodeInfo"}}, "text": "Adult Advanced Life Support: 2020 International Consensus on\nCardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.\nCirculation. 2020;142(16_suppl_1): S92-S139. doi:10.1161/CIR.0000000000000893\nBrady W, Swart G, Mao R, Aufderheide TP. The efficacy of atropine in the treatment of hemodynamically unstable\nbradycardia and atrioventricular block: prehospital and emergency department considerations. Resuscitation.\n1999;41(1):47\u201355\nDe Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock.\nN Engl J Med. 2010; 362:779\u201389\nDe Backer, Daniel et al. \u201cDopamine versus norepinephrine in the treatment of septic shock: a meta-analysis*.\u201d\nCritical care medicine vol. 40,3 (2012): 725-30. doi:10.1097/CCM.0b013e31823778ee\nGottlieb M. Bolus dose of epinephrine for refractory post-arrest hypotension. CJEM. 2017; 10:1\u20135\nKleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support. Circulation.\n2010;122(18 Suppl.3): S876-S908\nLink MS, Berkow PJ, Kudenchuk HR, et. al. Part 7: adult advanced cardiovascular life support. Circulation.\n2015;132(18 Suppl 2): S444\u201364\nMarik, Paul E., Dopamine increases mortality in pediatric septic shock. Current Best Evidence. January 01, 2016;\n168:253-256 doi.org/10.1016/j.jpeds.2015.10.073\nSherbino J, Verbeek PR, MacDonald RD, Sawadsky BV, McDonald AC, Morrison LJ. Prehospital transcutaneous cardiac\npacing for symptomatic bradycardia or bradyasystolic cardiac arrest: a systematic review. Resuscitation.\n2006;70(2):193\u2013200\nWeingart S. Push-dose pressors for immediate blood pressure control. Clin Exp Emerg Med. 2015;2(2):131\u2013132\nXu, Xudong, Xu, Xianghua and Wu, Yueying. \"Norepinephrine was superior in death risk reducing and hemodynamics\ncompared to dopamine in treatment of patients with septic shock\" Pteridines, 2021;32(1):5-10.\n\n### Revision Date\n\nMarch 11, 2022\n\n________________________ Go To TOC\n\nCardiovascular Rev.", "start_char_idx": 78220, "end_char_idx": 80204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "449a6cce-d131-41e8-9502-e32a621694bf": {"__data__": {"id_": "449a6cce-d131-41e8-9502-e32a621694bf", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b8cbd76-01c7-443f-ad43-0b4ccd2350ef", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "71f3ef4c56f249d4b0038d9fcd21e0cd55448c71fe71579305f725825aca9d11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "103d247a-c0df-4b31-b219-83173b72fb65", "node_type": "1", "metadata": {}, "hash": "09c06931a7d437a8cd08357ac14eaa462b3b71054f61efc60d50a13961dc1dce", "class_name": "RelatedNodeInfo"}}, "text": "Prehospital transcutaneous cardiac\npacing for symptomatic bradycardia or bradyasystolic cardiac arrest: a systematic review. Resuscitation.\n2006;70(2):193\u2013200\nWeingart S. Push-dose pressors for immediate blood pressure control. Clin Exp Emerg Med. 2015;2(2):131\u2013132\nXu, Xudong, Xu, Xianghua and Wu, Yueying. \"Norepinephrine was superior in death risk reducing and hemodynamics\ncompared to dopamine in treatment of patients with septic shock\" Pteridines, 2021;32(1):5-10.\n\n### Revision Date\n\nMarch 11, 2022\n\n________________________ Go To TOC\n\nCardiovascular Rev. March 2022 Bradycardia 38\n---\n# Implantable Ventricular Assist Devices\n\n## Aliases\n\nBiventricular assist device (BiVAD), Left ventricular assist device (LVAD), Right ventricular assist device (RVAD),\nVentricular assist device (VAD)\n\n## Patient Care Goals\n\nRapid identification of, and interventions for, cardiovascular compromise in patients with VADs\nRapid identification of, and interventions for, VAD-related malfunctions or complications\n\n## Patient Presentation\n\n### Inclusion Criteria\n\nAdult patients that have had an implantable ventricular assist device (VAD), including a left ventricular assist\ndevice (LVAD), right ventricular assist device (RVAD), or biventricular-assist device (BiVAD) and have symptoms of\ncardiovascular compromise\nPatients with VADs that are in cardiac arrest\nPatients with VADs that are experiencing a medical or injury-related event not involving the cardiovascular system\nor VAD malfunction\n\n### Exclusion Criteria\n\nAdult patients who do not have a VAD in place\n\n## Patient Management\n\n### Assessment\n\nAssess for possible pump malfunction\n\nAssess for alarms\nAuscultate for pump sound \u201chum\u201d\nSigns of hypoperfusion including pallor, diaphoresis, altered mental status\n\nIf the VAD pump has malfunctioned:\n\nUtilize available resources to troubleshoot potential VAD malfunctions and to determine appropriate corrective\nactions to restore normal VAD function:\n\nContact the patient\u2019s VAD-trained companion, if available\nContact the patient\u2019s VAD coordinator, using the phone number on the device\nCheck all the connections to system controller\nChange VAD batteries, and/or change system controller if indicated\nHave patient stop all activity and assess for patient tolerance\nFollow appropriate cardiovascular condition-specific protocol(s) as indicated\n\n### Treatment and Interventions\n\nManage airway as indicated\nCardiac monitoring\nIV access\nAcquire 12-lead EKG\n\n________________________ Go To TOC\n\nCardiovascular Rev. March 2022\n\nImplantable Ventricular Assist Devices 39\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n5. If patient is experiencing VAD-related complications or cardiovascular problems, expedite transport to the medical\nfacility where VAD was placed if patient\u2019s clinical condition and time allows\n\n6. If patient has a functioning VAD and is experiencing a non-cardiovascular-related problem, transport to a facility\nthat is appropriate for the patient\u2019s main presenting problem without manipulating the device\n\n7. If patient has a functioning VAD and is hypoperfused:\n\na. Administer IV fluids (30 mL/kg isotonic fluid; maximum of 1 liter) over less than 15 minutes, using a push-pull\nmethod of drawing up the fluid in a syringe and pushing it through the IV\n\nb. May repeat up to 3 times based on patient\u2019s condition and clinical impression for a total cumulative dose not to\nexceed 3 L\n\n8. If patient is in full cardiac arrest:\n\na. CPR should not be performed if there is any evidence the pump is still functioning. The decision whether to perform\nCPR should be made based upon best clinical judgment in consultation with the patient\u2019s VAD-trained companion and the\nVAD coordinator (or direct medical oversight if VAD coordinator unavailable)\n\nb. CPR may be initiated only where:\n\ni. You have confirmed the pump has stopped and troubleshooting efforts to restart it have failed, and\n\nii. The patient is unresponsive and has no detectable signs of life\n\nNotes/Educational Pearls\n\n1. You do not need to disconnect the controller or batteries to:\n\na. Defibrillate or cardiovert\n\nb. Acquire a 12-lead EKG\n\n2. Automatic non-invasive cuff blood pressures may be difficult to obtain due to the narrow pulse pressure created by\nthe continuous flow pump\n\n3.", "start_char_idx": 79642, "end_char_idx": 83927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "103d247a-c0df-4b31-b219-83173b72fb65": {"__data__": {"id_": "103d247a-c0df-4b31-b219-83173b72fb65", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "449a6cce-d131-41e8-9502-e32a621694bf", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "b9d78dbe1d94ebcadaf8d0b2edfa343f03a4269295f5315c63b506a7bbc63d46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8d2eacc-9f37-4d14-ba67-dfcf08f7d1ee", "node_type": "1", "metadata": {}, "hash": "baed1043b5372d4f1e0d587b2f4d58829cdde2402997cc198eb845ebd85426ce", "class_name": "RelatedNodeInfo"}}, "text": "If patient is in full cardiac arrest:\n\na. CPR should not be performed if there is any evidence the pump is still functioning. The decision whether to perform\nCPR should be made based upon best clinical judgment in consultation with the patient\u2019s VAD-trained companion and the\nVAD coordinator (or direct medical oversight if VAD coordinator unavailable)\n\nb. CPR may be initiated only where:\n\ni. You have confirmed the pump has stopped and troubleshooting efforts to restart it have failed, and\n\nii. The patient is unresponsive and has no detectable signs of life\n\nNotes/Educational Pearls\n\n1. You do not need to disconnect the controller or batteries to:\n\na. Defibrillate or cardiovert\n\nb. Acquire a 12-lead EKG\n\n2. Automatic non-invasive cuff blood pressures may be difficult to obtain due to the narrow pulse pressure created by\nthe continuous flow pump\n\n3. Flow though many VAD devices is not pulsatile, and patients may not have a palpable pulse or accurate pulse\noximetry\n\n4. The blood pressure, if measurable, may not be an accurate measure of perfusion\n\n5. Ventricular fibrillation, ventricular tachycardia, or asystole/PEA may be the patient\u2019s \u201cnormal\u201d underlying rhythm.\nEvaluate clinical condition and provide care in consultation with VAD coordinator\n\n6. The patient\u2019s travel bag should always accompany them with back-up controller and spare batteries\n\n7. If feasible, bring the patient\u2019s power module, cable, and display module to the hospital\n\n8. All patients should carry a spare pump controller with them\n\n9. The most common cause for VAD alarms is low batteries or battery failures\n\n10. Although automatic non-invasive blood pressure cuffs are often ineffective in measuring systolic and diastolic\npressure, if they do obtain a measurement, the MAP is usually accurate\n\n11. Other VAD complications:\n\na. Infection\n\nb. Stroke/Transient ischemic attack (TIA)\n\nc. Bleeding\n\nd. Arrhythmias\n\ne. Cardiac tamponade\n\nGo To TOC\n\nCardiovascular\n\nRev. March 2022\n\nImplantable Ventricular Assist Devices\n\n40\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914065 \u2013 General - Indwelling Medical Devices/Equipment\n9914069 \u2013 General - Medical Device Malfunction\n\n### Key Documentation Elements\n\nInformation gained from the VAD control box indicating any specific device malfunctions\nInterventions performed to restore a malfunctioning VAD to normal function\nTime of notification to and instructions from VAD-trained companion and/or VAD coordinator\n\n### Performance Measures\n\nIdentify and mitigate any correctable VAD malfunctions\nPerform CPR for patients in cardiac arrest when indicated\n\n## References\n\nGarg S, Ayers CR, Fitzsimmons C, et al. In-hospital cardiopulmonary arrests in patients with left ventricular\nassist devices. J Card Fail. 2014;20(12):899\u2013904\nMabvuure NT, Rodrigues JN. External cardiac compression during cardiopulmonary resuscitation with left\nventricular assist devices. Interact Cardiovasc Thorac Surg. 2014;19(2):286\u20139\nMechem M. Prehospital assessment and management of patients with ventricular-assist devices. Prehosp Emerg\nCare. 2013;17(2):223\u20139\nShinar Z, Bellezzo J, Stahovich M, Cheskes S, Chillcott S, Dembitsky W. Chest compressions may be safe in\narresting patients with left ventricular assist devices (LVADs). Resuscitation. 2014;85(5):702\u20134\nSepsis: SIRS 4 Criteria, Severe Sepsis Criteria and Treatment Nursing Jobs Exam The Beginner's Guide to\nIntensive Care: A Handbook for Junior Doctors and Allied Professionals. Nurses Notes. 2021. https://nursingjobsexam.com/sepsis-sirs-criteria-severe-sepsis-criteria/.\nAccessed March 11, 2022\n\nRevision Date: March 11, 2022\n\n________________________ Go To TOC\n\nCardiovascular Rev.", "start_char_idx": 83069, "end_char_idx": 86879, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8d2eacc-9f37-4d14-ba67-dfcf08f7d1ee": {"__data__": {"id_": "e8d2eacc-9f37-4d14-ba67-dfcf08f7d1ee", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "103d247a-c0df-4b31-b219-83173b72fb65", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "997fb8524d50aecdc5f707e9497a892d6ca5998a42698f3258fa8e288b0bd411", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5b0e74a-7ae2-4afb-b7fc-8cee366a3e91", "node_type": "1", "metadata": {}, "hash": "b57ba8fd32477538896a50b43a8e142b1f12dcd84b79a08f252ae16cd63eaedf", "class_name": "RelatedNodeInfo"}}, "text": "Prehosp Emerg\nCare. 2013;17(2):223\u20139\nShinar Z, Bellezzo J, Stahovich M, Cheskes S, Chillcott S, Dembitsky W. Chest compressions may be safe in\narresting patients with left ventricular assist devices (LVADs). Resuscitation. 2014;85(5):702\u20134\nSepsis: SIRS 4 Criteria, Severe Sepsis Criteria and Treatment Nursing Jobs Exam The Beginner's Guide to\nIntensive Care: A Handbook for Junior Doctors and Allied Professionals. Nurses Notes. 2021. https://nursingjobsexam.com/sepsis-sirs-criteria-severe-sepsis-criteria/.\nAccessed March 11, 2022\n\nRevision Date: March 11, 2022\n\n________________________ Go To TOC\n\nCardiovascular Rev. March 2022 Implantable Ventricular Assist Devices 41\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nTachycardia with a Pulse\n\n### Aliases\n\nAtrial fibrillation (A-FIB) - Atrial flutter\n\nSupraventricular tachycardia (SVT) - Multifocal atrial tachycardia (MAT)\n\nTorsades - Ventricular tachycardia (VT)\n\n### Patient Care Goals\n\nMaintain adequate oxygenation, ventilation, and perfusion\nControl ventricular rate\nRestore regular sinus rhythm in unstable patient\nSearch for underlying cause:\n\nMedications (caffeine, diet pills, thyroid, decongestants)\nDrugs (cocaine, amphetamines)\nHistory of dysrhythmia\nCongestive heart failure (CHF)\n\n### Patient Presentation\n\nPatients will manifest elevated heart rate for age and may or may not also present with associated signs or symptoms such as palpitations, dyspnea, chest pain, syncope/near-syncope, hemodynamic compromise, altered mental status, or other signs of end organ malperfusion\n\n### Inclusion Criteria\n\nHeart rate greater than 100 BPM in adults or relative tachycardia in pediatric patients\n\n### Exclusion Criteria\n\nSinus tachycardia\n\n### Patient Management\n\n#### Assessment, Treatments, and Interventions\n\nAdult Management\n\nManage airway as necessary\nAdminister oxygen as appropriate with a target of achieving 94\u201398% saturation\nInitiate monitoring and perform 12-lead EKG\nEstablish IV access\nCheck blood glucose and treat hypoglycemia per the Hypoglycemia Guideline\nConsider the following additional therapies if tachycardia with signs and symptoms or hemodynamic instability continues:\n\nRegular Narrow Complex Tachycardia \u2013 Stable (SVT)\n\nPerform vagal maneuvers\nAdenosine 6 mg IV (proximal site) followed by 10 mL fluid bolus\n\nIf tachycardia continues, give adenosine 12 mg IV\nA third dose of adenosine, 12 mg IV, can be given\n\nDiltiazem 0.25 mg/kg slowly IV over 2 minutes\n\nGo To TOC\n\nCardiovascular\n\nRev. March 2022\n\nTachycardia with a Pulse\n\n42\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n#### Tachycardia with a Pulse\n\na. After 15 minutes, a second dose of diltiazem 0.35 mg/kg IV may be given if needed\n\nb. For patients older than 65 years old, recommend maximum initial dose of diltiazem 10 mg IV and a maximum second\ndose of 20 mg\n\nMetoprolol 5 mg IV given over 1\u20132 minutes. May repeat as needed q 5 minutes for a total of 3 doses\n\nVerapamil 2.5\u20135 mg IV given over 2 minutes. May repeat with verapamil 5\u201310 mg after 15\u201330 minutes.\n\n##### Regular Narrow Complex Tachycardia \u2013 Unstable\n\n1. Deliver a synchronized shock based on manufacturer\u2019s recommendations\n\n2. For responsive patients, consider sedation and analgesia\n\n##### Irregular Narrow Complex Tachycardia \u2013 Stable (atrial fibrillation (A-FIB), atrial flutter, multifocal atrial\ntachycardia)\n\n1.", "start_char_idx": 86258, "end_char_idx": 89653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5b0e74a-7ae2-4afb-b7fc-8cee366a3e91": {"__data__": {"id_": "c5b0e74a-7ae2-4afb-b7fc-8cee366a3e91", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8d2eacc-9f37-4d14-ba67-dfcf08f7d1ee", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "b2e16a2e9beaf85de2db208711de81a4344b7d2310a6752402b64f216dd60c83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b17bc647-e238-4e04-a2c5-cc6659c0c0f0", "node_type": "1", "metadata": {}, "hash": "370316974c49def5bfbbc09eff940392e1e48984a8fc263a6523c42290e2389c", "class_name": "RelatedNodeInfo"}}, "text": "May repeat as needed q 5 minutes for a total of 3 doses\n\nVerapamil 2.5\u20135 mg IV given over 2 minutes. May repeat with verapamil 5\u201310 mg after 15\u201330 minutes.\n\n##### Regular Narrow Complex Tachycardia \u2013 Unstable\n\n1. Deliver a synchronized shock based on manufacturer\u2019s recommendations\n\n2. For responsive patients, consider sedation and analgesia\n\n##### Irregular Narrow Complex Tachycardia \u2013 Stable (atrial fibrillation (A-FIB), atrial flutter, multifocal atrial\ntachycardia)\n\n1. Diltiazem 0.25 mg/kg slowly IV over 2 minutes\n\na. After 15 minutes, a second dose of diltiazem 0.35 mg/kg IV may be given if needed\n\nb. For patients older than 65 years old, recommend maximum initial dose of diltiazem 10 mg IV and a maximum second\ndose of 20 mg\n\n2. Metoprolol 5 mg IV given over 1\u20132 minutes. May repeat as needed q 5 minutes for a total of 3 doses\n\n##### Irregular Narrow Complex Tachycardia \u2013 Unstable\n\n1. Deliver a synchronized shock based on manufacturer\u2019s recommendation\n\n2. For responsive patients, consider sedation\n\n##### Regular Wide Complex Tachycardia \u2013 Stable (ventricular tachycardia, supraventricular tachycardia, atrial\nfibrillation/flutter with aberrancy, accelerated idioventricular rhythms, pre-excited tachycardias with accessory\npathways)\n\n1. Amiodarone 150 mg IV over 10 minutes\n\na. May repeat once as needed\n\n2. Procainamide 20\u201350 mg/min until arrhythmia suppressed, hypotension ensues, QRS duration increases greater than\n50%, or maximum dose 17 mg/kg given\n\na. Maintenance infusion: 1\u20134 mg/min\n\nb. Avoid if prolonged QT or CHF\n\n3. Lidocaine 1\u20131.5 mg/kg IV\n\na. May be repeated at 5-minute intervals for a maximum dose of 3 mg/kg IV\n\n4. Adenosine 6 mg IV (proximal site) followed by 10 mL fluid bolus\n\na. If monomorphic tachycardia continues, give adenosine 12 mg IV\n\n##### Regular Wide Complex Tachycardia \u2013 Unstable\n\n1. Deliver a synchronized shock based on manufacturer\u2019s recommendation\n\n2. For responsive patients, consider sedation\n\n##### Irregular Wide Complex Tachycardia \u2013 Stable (A-FIB with aberrancy, pre-excited A-FIB (i.e., A-FIB using an accessory\npathway), multifocal atrial tachycardia (MAT) or polymorphic VT/torsades de pointes\n\n1.", "start_char_idx": 89177, "end_char_idx": 91340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b17bc647-e238-4e04-a2c5-cc6659c0c0f0": {"__data__": {"id_": "b17bc647-e238-4e04-a2c5-cc6659c0c0f0", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5b0e74a-7ae2-4afb-b7fc-8cee366a3e91", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "dbeb4011b0bbd4a5b1adbb26b3c79148769beb7e15406b7ad0ab3f2c2e7bb21e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8479a90a-1221-4e8b-abcf-7fc084c4021c", "node_type": "1", "metadata": {}, "hash": "64020ddec1d6e3dfa591570fedfba6b5fb1f7e56bb55065b6cddc690a8865846", "class_name": "RelatedNodeInfo"}}, "text": "Lidocaine 1\u20131.5 mg/kg IV\n\na. May be repeated at 5-minute intervals for a maximum dose of 3 mg/kg IV\n\n4. Adenosine 6 mg IV (proximal site) followed by 10 mL fluid bolus\n\na. If monomorphic tachycardia continues, give adenosine 12 mg IV\n\n##### Regular Wide Complex Tachycardia \u2013 Unstable\n\n1. Deliver a synchronized shock based on manufacturer\u2019s recommendation\n\n2. For responsive patients, consider sedation\n\n##### Irregular Wide Complex Tachycardia \u2013 Stable (A-FIB with aberrancy, pre-excited A-FIB (i.e., A-FIB using an accessory\npathway), multifocal atrial tachycardia (MAT) or polymorphic VT/torsades de pointes\n\n1. Procainamide 20\u201350 mg/min until arrhythmia suppressed, hypotension ensues, QRS duration increases greater than\n50%, or maximum dose 17 mg/kg given\n\na. Maintenance infusion: 1\u20134 mg/min\n\nb. Avoid if prolonged QT or CHF\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Cardiovascular\n\n### Tachycardia with a Pulse\n\n44\n\n#### If torsades, give magnesium 1\u20132 g IV over 10 minutes\n\n#### Amiodarone 150 mg IV over 10 minutes\n\na. May repeat once as needed\n\nb. Administration of amiodarone, if needed, should follow procainamide in patients with Wolff\u2013Parkinson\u2013White\nsyndrome\n\n#### Irregular Wide Complex Tachycardia \u2013 Unstable\n\nDeliver a synchronized shock based on manufacturer\u2019s recommendation\nFor responsive patients, consider sedation\n\n#### Pediatric Management\n\nManage airway as necessary\nAdminister oxygen as appropriate with a target of achieving 94\u201398% saturation\nInitiate monitoring and perform 12-lead EKG\nEstablish IV access\nCheck blood glucose and treat hypoglycemia per the Hypoglycemia Guideline\nConsider the following additional therapies if tachycardia and symptoms or hemodynamic instability continue:\n\n#### Regular Narrow Complex Tachycardia \u2013 Stable (SVT)\n\nPerform vagal maneuvers\nAdenosine 0.1 mg/kg (maximum of 6 mg)\na. If unsuccessful, may repeat with 0.2 mg/kg (maximum of 12 mg)\n\n#### Regular Narrow Complex Tachycardia \u2013 Unstable\n\nDeliver a synchronized shock: 0.5\u20131 J/kg for the first dose\nRepeat doses should be 2 J/kg\n\n#### Regular, Wide Complex Tachycardia \u2014 Stable\n\nConsider adenosine 0.1 mg/kg (maximum of 6 mg) for SVT with aberrancy\nOtherwise give amiodarone 5 mg/kg IV (maximum of 150 mg) over 10 minutes\n\n#### Regular, Wide Complex Tachycardia \u2013 Unstable\n\nSynchronized cardioversion 0.5\u20131.0 J/kg\n\n### Notes/Educational Pearls\n\n#### Key Considerations\n\nCauses:\na. Hypovolemia\n\nb. Hypoxia\n\nc. Hydrogen (acidosis)\n\nd. Myocardial infarction\n\ne. Hypokalemia/Hyperkalemia\n\nf. Hypoglycemia\n\ng. Hypothermia\n\nh. Toxins/Overdose\n\ni. Tamponade\n\nj. Tension pneumothorax\n\nk. Thrombus \u2013 central or peripheral\n\nl. Trauma\n\nm. Hyperthyroidism\n\n________________________\n\nGo To TOC\n\n### Rev. March 2022\n---\n## NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n2. A-FIB rarely requires cardioversion in the field. As it is difficult to ascertain the onset of this rhythm, the risk of stroke needs to be considered prior to cardioversion\n\n3.", "start_char_idx": 90725, "end_char_idx": 93734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8479a90a-1221-4e8b-abcf-7fc084c4021c": {"__data__": {"id_": "8479a90a-1221-4e8b-abcf-7fc084c4021c", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b17bc647-e238-4e04-a2c5-cc6659c0c0f0", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "ceb498dfaac92032153d36d976e51ffb2130efd1a7f4359bff96e5b45dff8ea2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4448a73-5eb5-4ba1-8068-5bfda83b79cb", "node_type": "1", "metadata": {}, "hash": "1a071570746370ef7e100f0c0c2e2b2c48fba20c22b739ebb1fcb00b3dcbd6de", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n---\n## NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n2. A-FIB rarely requires cardioversion in the field. As it is difficult to ascertain the onset of this rhythm, the risk of stroke needs to be considered prior to cardioversion\n\n3. A wide-complex irregular rhythm should be considered pre-excited A-FIB; extreme care must be taken in these patients\n\na. Characteristic EKG findings include a short PR interval and, in some cases, a delta wave\nb. Avoid AV nodal blocking agents such as adenosine, calcium channel blockers, digoxin, and possibly beta-blockers in patients with pre-excitation A-FIB (e.g., Wolff-Parkinson-White Syndrome, Lown-Ganong-Levine Syndrome) because these drugs may cause a paradoxical increase in the ventricular response\nc. Blocking the AV node in some of these patients may lead to impulses that are transmitted exclusively down the accessory pathway, which can result in ventricular fibrillation\nd. Amiodarone or procainamide may be used as an alternative\n\n4. Amiodarone or procainamide can be used as a rate-controlling agent for patients who are intolerant of or unresponsive to other agents, such as patients with CHF who may not otherwise tolerate diltiazem or metoprolol\n\na. Caution should be exercised in those who are not receiving anticoagulation, as amiodarone can promote cardioversion\n\n5. Administer metoprolol to patients with SBP greater than 120 mmHg\n\na. Worsening CHF, chronic obstructive pulmonary disease (COPD), asthma, as well as hypotension and bradycardia can occur with use of metoprolol\n\n6. Biphasic waveforms have been proven to convert A-FIB at lower energies and higher rates of success than monophasic waveforms\n\na. Strategies include dose escalation (70, 120, 150, 170 joules (J) for biphasic or 100, 200, 300, 360 J for monophasic) versus beginning with single high energy/highest success rate for single shock delivered\n\n7. Studies in infants and children have demonstrated the effectiveness of adenosine for the treatment of hemodynamically stable or unstable SVT\n\n8. Adenosine should be considered the preferred medication for stable SVT\n\na. Verapamil may be considered as alternative therapy in older children but should not be routinely used in infants\nb. Procainamide or amiodarone given by a slow IV infusion with careful hemodynamic monitoring may be considered for refractory SVT\n\n### Pertinent Assessment Findings\n\nNone noted\n\n### Patient Safety Considerations\n\n1. Only use one antidysrhythmic at a time\n2. Patients who receive beta-blockers (e.g., metoprolol) with calcium channel blockers (e.g., diltiazem) are at increased risk for hypotension and bradycardia\n3. If using cardioversion, consider sedation and pain control\n4. With irregular wide complex tachycardia (A-FIB with aberrancy such as Wolff-Parkinson-White and Lown-Ganong Levine), avoid use of AV nodal blocking agents (e.g., adenosine, calcium channel blockers, beta-blockers)\n5. Patients with Wolff\u2013Parkinson\u2013White should be given procainamide prior to amiodarone\n\n|Cardiovascular Tachycardia with a Pulse|Rev.", "start_char_idx": 93477, "end_char_idx": 96543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4448a73-5eb5-4ba1-8068-5bfda83b79cb": {"__data__": {"id_": "f4448a73-5eb5-4ba1-8068-5bfda83b79cb", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8479a90a-1221-4e8b-abcf-7fc084c4021c", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "c50dde396d447f778003abfda4aa9f21991da59e0f8a6e959da46b50b4c7dccd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45c4adb3-6a9d-47c1-b73e-add0b14a913c", "node_type": "1", "metadata": {}, "hash": "ac9a82d79fd02d93fc3b01f87f7bd7f2a927034c4a38fa7b48281342d7b7affe", "class_name": "RelatedNodeInfo"}}, "text": "Only use one antidysrhythmic at a time\n2. Patients who receive beta-blockers (e.g., metoprolol) with calcium channel blockers (e.g., diltiazem) are at increased risk for hypotension and bradycardia\n3. If using cardioversion, consider sedation and pain control\n4. With irregular wide complex tachycardia (A-FIB with aberrancy such as Wolff-Parkinson-White and Lown-Ganong Levine), avoid use of AV nodal blocking agents (e.g., adenosine, calcium channel blockers, beta-blockers)\n5. Patients with Wolff\u2013Parkinson\u2013White should be given procainamide prior to amiodarone\n\n|Cardiovascular Tachycardia with a Pulse|Rev. March 2022|45|\n|---|---|---|\n\n________________________ Go To TOC\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914147 \u2013 Medical - Supraventricular Tachycardia (including A-FIB)\n9914151 \u2013 Medical - Ventricular Tachycardia (with pulse)\n9914199 \u2013 Medical-Tachycardia\n\n### Key Documentation Elements\n\nInitial rhythm and all rhythm changes\nTime, dose, and response to medications given\nCardioversion times, synchronization, attempts, joules, and response\nObtain monitor strips after each intervention\nPatient weight\nPediatric length-based tape color (for pediatrics who fit on tape)\nHistory of event supporting treatment of underlying causes\n\n### Performance Measures\n\nTime to clinical improvement from patient contact\nBlood sugar obtained\nCorrect medication(s) and dose given for patient condition, age, and weight\nCorrect cardioversion joules delivered given patient weight and/or condition\nUse of sedation for responsive patient\n\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nHypoglycemia\u201401: Treatment Administered for Hypoglycemia\nPediatrics\u201403: Documentation of Estimated Weight in Kilograms\n\n### References\n\nDeSouza IS, Martindale JL, Sinert R. Antidysrhythmic drug therapy for the termination of stable, monomorphic\nventricular tachycardia: a systematic review. Emerg Med J. 2015;32(2):161\u20137\nFengler BT, Brady WJ, Plautz CU. Atrial fibrillation in the Wolff-Parkinson-White Syndrome: EKG recognition and\ntreatment in the ED. Am J Emerg Med. 2007;25(5):576\u201383\nFuster V, Ryd\u00e9n LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial\nfibrillation \u2013 executive summary. Rev Port Cardiol. Apr;26(4):383\u2013446\nLink MS, Berkow LC, Kudenchuk HR, et al. Part 7: adult advanced cardiovascular life support. Circulation.\n2015;132(18 Suppl 2):S444\u201364\nLong B, Koyfman A. Best clinical practice: emergency medicine management of stable monomorphic ventricular\ntachycardia. J Emerg Med. Epub 2016 Oct 15. 2017;4(15):484\u2013492. doi:10.1016/j.jemermed.2016.09.010.\nMcNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the\nrole of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med.\n2003;139(12):1018\u201333\n\nGo To TOC\n\n## Cardiovascular\n\nRev. March 2022\n\n## Tachycardia with a Pulse\n\n46\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n7. Ortiz M, Martin A, Arribas F, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone\nfor the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Hear J. 2017;38(17):1329\u201335\n\n8. Somberg JC, Bailin SJ, Haffajee CI, et al.", "start_char_idx": 95932, "end_char_idx": 99406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45c4adb3-6a9d-47c1-b73e-add0b14a913c": {"__data__": {"id_": "45c4adb3-6a9d-47c1-b73e-add0b14a913c", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4448a73-5eb5-4ba1-8068-5bfda83b79cb", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8d98dd57abefcd7559140069e138e2d06c3554208eea0053c3055c39e2e526bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "daa465cc-2819-48f3-aa86-5d356cd5d569", "node_type": "1", "metadata": {}, "hash": "d90ccc168750ef95f375897eddbc21b2a103b492a4f637fd582c700685d61004", "class_name": "RelatedNodeInfo"}}, "text": "Management of atrial fibrillation: review of the evidence for the\nrole of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med.\n2003;139(12):1018\u201333\n\nGo To TOC\n\n## Cardiovascular\n\nRev. March 2022\n\n## Tachycardia with a Pulse\n\n46\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n7. Ortiz M, Martin A, Arribas F, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone\nfor the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Hear J. 2017;38(17):1329\u201335\n\n8. Somberg JC, Bailin SJ, Haffajee CI, et al. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous\nformulation) for incessant ventricular tachycardia. Am J Cardiol. 2002;90(8):853\u20139\n\n9. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with\natrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American\nHeart Association task force on practice guidelines. Circulation. 2011; 123:104\u201323\n\n10. Zimetbaum P, Reynolds MR, Ho KK, et al. Impact of a practice guideline for patients with atrial fibrillation on\nmedical resource utilization and costs. Am J Cardiol, 2003;92(6):677\u201381\n\nRevision Date March 11, 2022\n\n________________________\n\nGo To TOC\n\nCardiovascular\n\nTachycardia with a Pulse\n\nRev. March 2022\n\n47\n---\n# Suspected Stroke/Transient Ischemic Attack\n\n## Aliases\n\nCerebrovascular accident (CVA) - Transient ischemic attack (TIA)\n\n## Patient Care Goals\n\nDetect neurological deficits\nDetermine eligibility for transport to a stroke center\nIdentify patients who have potentially sustained a stroke involving a large vessel occlusion (LVO)\n\n## Patient Presentation\n\nNeurologic deficit such as facial droop, localized weakness, gait disturbance, slurred speech, altered mentation, sudden onset of dizziness/vertigo\nHemiparesis or hemiplegia\nDysconjugate gaze, forced or crossed gaze (if patient is unable to voluntarily respond to exam, makes no discernible effort to respond, or is unresponsive)\nSevere headache, neck pain/stiffness, difficulty seeing\n\n## Inclusion Criteria\n\nPatient has signs and symptoms consistent with stroke or transient ischemic attack (TIA)\n\n## Exclusion Criteria\n\nIf glucose less than 60 mg/dL (deciliter), treat per the Hypoglycemia Guideline\nIf trauma and Glasgow Coma Score (GCS) less than or equal to 13, treat per the Head Injury Guideline and General Trauma Management Guideline\n\n## Patient Management\n\n### Assessment\n\nUse a validated prehospital stroke scale that may include, but is not limited to:\n\nFacial smile/grimace \u2013 ask patient to smile\nArm drift \u2013 close eyes and hold out arms for count of 10 seconds\nSpeech \u2013 ask patient to say \u201cYou can\u2019t teach an old dog new tricks\u201d\n\nUse a validated prehospital stroke severity scale that may include, but is not limited to:\n\nVision changes\nSensory neglect\nAphasia\n\nPertinent historical data includes:\n\nHistory \u2013 \u201clast known well\u201d and source of that information\nNeurologic status assessment [See Appendix VII. Neurologic Status Assessment]\nPatient is taking warfarin or any anticoagulant medication\nHistory of recent trauma\nHistory of recent seizure\nHistory of recent surgery\nHistory of recent hemorrhage (e.g., GI bleed)\n\n________________________ Go To TOC\n\nCardiovascular Rev. March 2022\n\nSuspected Stroke/Transient Ischemic Attack 48\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### 4.", "start_char_idx": 98792, "end_char_idx": 102286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "daa465cc-2819-48f3-aa86-5d356cd5d569": {"__data__": {"id_": "daa465cc-2819-48f3-aa86-5d356cd5d569", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45c4adb3-6a9d-47c1-b73e-add0b14a913c", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "e9014d9630e96d53085c1e975bc8d70ffcb812b3e5ead169f5879f59c59ef785", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee99db64-dd02-4b8b-b523-3f332e1a9456", "node_type": "1", "metadata": {}, "hash": "9ab08444ada561967681aa8e21c8298d0bac7fa9d03ca635c979dcc867307257", "class_name": "RelatedNodeInfo"}}, "text": "Neurologic Status Assessment]\nPatient is taking warfarin or any anticoagulant medication\nHistory of recent trauma\nHistory of recent seizure\nHistory of recent surgery\nHistory of recent hemorrhage (e.g., GI bleed)\n\n________________________ Go To TOC\n\nCardiovascular Rev. March 2022\n\nSuspected Stroke/Transient Ischemic Attack 48\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### 4. Evaluate for the presence of stroke mimics including:\n\na. Hypoglycemia\nb. Seizure\nc. Sepsis\nd. Migraine\ne. Intoxication\n\n### Treatment and Interventions\n\nDetermine \u201clast known well\u201d time\nAdminister oxygen as appropriate with a target of achieving 94\u201398% saturation\nIf seizure activity present, treat per Seizures Guideline\nCheck blood glucose level (BGL)\n\nTreat only if glucose less than 60 mg/dL\n\nAcquire 12-lead EKG, if possible\nEarly hospital notification per local stroke plan that should include any suspected large vessel occlusion (LVO)\nstroke\n\n### Patient Safety Considerations\n\nPrevent aspiration \u2013 elevate head of stretcher 15\u201330 degrees if systolic BP greater than 100 mmHg\n\nMaintain head and neck in neutral alignment, without flexing the neck\n\nProtect paralyzed limbs from injury\nAvoid multiple IV attempts\n\n### Notes/Educational Pearls\n\n#### Key Considerations\n\nTransport and destination decisions should be based on local resources and stroke system of care\n\nDestination hospitals may include:\n\nStroke Ready\nPrimary Stroke Center\nThrombectomy-capable Stroke Center\nComprehensive Stroke Center\n\nTime of onset of stroke or last known well is critical data for patient treatment\n\nPositive stroke scale with time of onset or last known well less than 4\u00bd hours may be eligible for thrombolytic\nagents\nPositive stroke severity scale with time of onset or last known well less than 24 hours may be eligible for\nmechanical thrombectomy\n\nConsider transport to hospital capable of mechanical thrombectomy per local stroke plan\n\nDo not treat hypertension\nPlace on cardiac monitor\nPediatrics:\n\nTreatment principles remain the same\nAlthough rare, pediatric patients can have strokes\n\n________________________\n\nGo To TOC\n\n### Cardiovascular\n\nRev. March 2022\n\n### Suspected Stroke/Transient Ischemic Attack\n\n49\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914145 \u2013 Medical - Stroke/TIA\n\n#### Key Documentation Elements\n\n\u201cLast known well\u201d must be specific\n\nIf the patient was last known well prior to bedtime the night before, this is the time to be documented (not time the patient woke up with symptoms present)\n\nBlood glucose results\nSpecific validated stroke scale used and findings\nTime of notification to receiving hospital\n\n#### Performance Measures\n\nDocumentation of time \u201clast known well\u201d\nUse of validated stroke scale\nBlood glucose level obtained\nMinimize EMS scene time\nHospital stroke team pre-arrival alert or activation occurred as early as possible after positive stroke assessment finding\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nStroke\u201401: Suspected Stroke Receiving Prehospital Stroke Assessment\n\nNOTE: This measure can only be evaluated if EMS documentation can be combined with information provided by the receiving hospital\n\n#### References\n\nKleindorfer, D, Towfighi, A, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association, Stroke 2021;52:e364\u2013e467.\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nCardiovascular Rev.", "start_char_idx": 101872, "end_char_idx": 105594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee99db64-dd02-4b8b-b523-3f332e1a9456": {"__data__": {"id_": "ee99db64-dd02-4b8b-b523-3f332e1a9456", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "daa465cc-2819-48f3-aa86-5d356cd5d569", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8bdbf90ee2e1ace2afd82a9b1e760f17214658864f34e9900f4a1e70cec1bf76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59c7b1bd-6874-4dc4-a60b-d76951e40ca5", "node_type": "1", "metadata": {}, "hash": "d4822d35c253a797fb3e2715f3c6fb65e645c8df4c6085ba9d7809a76bf04bc5", "class_name": "RelatedNodeInfo"}}, "text": "2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association, Stroke 2021;52:e364\u2013e467.\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nCardiovascular Rev. March 2022 Suspected Stroke/Transient Ischemic Attack 50\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## General Medical - Abdominal Pain\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nImprove patient comfort\nIdentify life-threatening causes of abdominal pain\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nAbdominal pain or discomfort related to a non-traumatic cause\n\n#### Exclusion Criteria\n\nAbdominal pain due to trauma [See General Trauma Management Guideline]\nAbdominal pain due to or related to pregnancy [See OB/GYN Section]\n\n### Patient Management\n\n#### Assessment\n\nPerform airway assessment and management per the Airway Management Guideline\nObtain vital signs including pulse, blood pressure, respiratory rate, neurologic status assessment\nObtain blood glucose if hyperglycemia is suspected per Hyperglycemia Guideline\nProvide evaluation and management of pain per the Pain Management Guideline\nObtain vascular access as necessary to provide analgesia and/or fluid resuscitation\nAssess for life-threatening causes of abdominal pain, which may include:\n\nSigns and symptoms of ischemic, necrotic, or perforated bowel\n\nSevere tenderness\nAbdominal pain with motion or palpation of the abdomen\nFever\nBloody stool\nNausea and vomiting\nAbsence of passage of stool or gas\nAbdominal distention, with tympany to percussion\n\nSigns and symptoms of dissecting or ruptured abdominal aortic aneurysm (AAA)\n\nUnequal femoral or distal lower extremity pulses\n\u201cPulsatile\u201d abdominal mass\nAssociated back pain and/or chest pain\nKnown history of abdominal aortic aneurysm\n\nSigns and symptoms of ruptured ectopic pregnancy\n\nVaginal bleeding\nRecently diagnosed pregnancy\nRecent missed period/menstrual cycle in women of childbearing age\n\n________________________Go To TOC\n\nGeneral Medical - Abdominal Pain Rev. March 2022 Page 51\n---\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n#### Signs and symptoms of appendicitis\n\nFocal right lower quadrant tenderness, possibly with rebound and guarding\nRight lower quadrant tenderness noted during palpation of the left lower quadrant (positive Rovsing\u2019s sign)\nPeri-umbilical or diffuse abdominal tenderness with palpation of the abdomen/pelvis\nFever\nNausea, vomiting\nLack of appetite\n\n#### Signs and symptoms of acute cholecystitis\n\nRight upper quadrant or epigastric tenderness\nFever\nNausea and vomiting\nHistory of gallstones\n\n#### Signs and symptoms of pyelonephritis\n\nFever\nNausea, vomiting\nUrinary frequency/urgency\nDysuria\nHematuria\nBack/flank pain\nCostovertebral angle tenderness to percussion\n\n#### Assess for signs of shock\n\nIf shock is present, provide treatment per appropriate Shock Guideline\n\n#### Assess for other non-life-threatening causes of abdominal pain\n\nSigns and symptoms of kidney stone\n\nUnilateral flank pain\nNausea, vomiting\nHematuria\n\n### Treatment and Interventions\n\nMedication Administration:\n\nProvide analgesia per the Pain Management Guideline\nAdminister antiemetics per the Nausea-Vomiting Guideline\nProvide transport to an appropriate receiving facility. Consider specialty destination centers for conditions such as\nsuspected abdominal aortic aneurysm and aortic dissection\nReassess vital signs and response to therapeutic interventions throughout transport\n\n### Patient Safety Considerations\n\nAbdominal pain in older adults, patients with bleeding disorders, patients on anticoagulation medications, children less\nthan 2 years old and patients that are immunocompromised may be a harbinger for severe illness.\n\n________________________\n\nGo To TOC\n\nGeneral Medical\n\nRev.", "start_char_idx": 105306, "end_char_idx": 109170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59c7b1bd-6874-4dc4-a60b-d76951e40ca5": {"__data__": {"id_": "59c7b1bd-6874-4dc4-a60b-d76951e40ca5", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee99db64-dd02-4b8b-b523-3f332e1a9456", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "215eb69cdb443d69a1fcbbb33dcebd1bae3f9b1ba3d57c848876352e1ac7c170", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69ba04b1-ec0b-4f35-9c26-0dc6e2180114", "node_type": "1", "metadata": {}, "hash": "ebae0db0f4068a7a400a3a4f58c95b2f965a74878510d2c0bdb75c6955489b26", "class_name": "RelatedNodeInfo"}}, "text": "Consider specialty destination centers for conditions such as\nsuspected abdominal aortic aneurysm and aortic dissection\nReassess vital signs and response to therapeutic interventions throughout transport\n\n### Patient Safety Considerations\n\nAbdominal pain in older adults, patients with bleeding disorders, patients on anticoagulation medications, children less\nthan 2 years old and patients that are immunocompromised may be a harbinger for severe illness.\n\n________________________\n\nGo To TOC\n\nGeneral Medical\n\nRev. March 2022\n\nAbdominal Pain\n\n52\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Notes/Educational Pearls\n\nKey Considerations\n\nAssess for life-threatening causes of abdominal pain\nProvide appropriate treatment for pain, vomiting, and shock\nConsider transport to a specialty surgical center if aortic aneurysm or aortic dissection is suspected\n\nPertinent Assessment Findings\n\nRebound tenderness\nGuarding\nAbdominal distension\nAbdominal tympany to percussion\nTenderness focal to a specific abdominal quadrant\nPresence of \u201cpulsatile\u201d abdominal mass\nAbsence of or significant inequality of femoral or distal arterial pulses in lower extremities\nHyper or hypothermia\nRectal bleeding, hematemesis, vaginal bleeding\nJaundice\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914109 \u2013 Medical - Abdominal Pain\n\nKey Documentation Elements\n\nAssessment of abdomen to include findings on palpation/percussion including presence or absence of masses and presence and nature of tenderness/pain\nTreatment and response to treatment\n\nPerformance Measures\n\nAssessment for life-threatening etiology\nMitigation of pain per the Pain Management Guideline\n\n## References\n\nAttard AR, Corlett MJ, Kidner NJ, Leslie AP, Fraser IA. Safety of early pain relief for acute abdominal pain. BMJ. 1992;305(6853):554\u20136\nBrewster GS, Herbert ME, Hoffman JR. Medical myth: analgesia should not be given to patients with acute abdominal pain because it obscures the diagnosis. West J Med. 2000;172(3):209\u201310\nLoVecchio F, Oster N, Sturmann K, Nelson LS, Flashner S, Finger R. The use of analgesics in patients with acute abdominal pain. J Emerg Med 1997; 15:775\u20139\nManterola C, Astudillo P, Losada H, Pineda V, Sanhueza A, Vial M. Analgesia in patients with acute abdominal pain. Cochrane Database of Syst Rev. 2011;1:CD005660\nPace S, Burke TF. Intravenous morphine for early pain relief in patients with acute abdominal pain. Acad Emerg Med. 1996; 3:1086\u201392\nRanji SR, Goldman LE, Simel DL, Shojania KG. Do opiates affect the clinical evaluation of\n\nGeneral Medical\n\nAbdominal Pain\n\nRev. March 2022\n\n53\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\nRevision Date: March 11, 2022\n\nGeneral Medical\n\nAbdominal Pain\n\nRev. March 2022\n\n54\n\n## References\n\nGreen R. Acute abdominal pain. In: Tintinalli JE, Kelen GD, Stapczynski JS, Ma OJ, Cline DM, Cydulka RK, eds. Emergency Medicine: A Comprehensive Study Guide. 6th ed. New York, NY: McGraw-Hill; 2004: 470\u20134.\nWagner JM, McKinney WP, Carpenter JL. Does this patient have appendicitis? JAMA. 1996;276(19):1589\u201394.\nAndersson REB. Meta-analysis of the clinical and laboratory diagnosis of appendicitis. Br J Surg. 2004;91:28\u201337.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB.", "start_char_idx": 108654, "end_char_idx": 112451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69ba04b1-ec0b-4f35-9c26-0dc6e2180114": {"__data__": {"id_": "69ba04b1-ec0b-4f35-9c26-0dc6e2180114", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59c7b1bd-6874-4dc4-a60b-d76951e40ca5", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "928a6e2d556a6cad5e82ae62e828fd98a7a3b58b87b38ea91b4af203f119de0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e32cab25-cf9e-4ce9-bc0a-1763e97caf72", "node_type": "1", "metadata": {}, "hash": "e2623c1ced30127546033913332d9579d0ca55f1b797d6f36a15cf47784ed61e", "class_name": "RelatedNodeInfo"}}, "text": "Wagner JM, McKinney WP, Carpenter JL. Does this patient have appendicitis? JAMA. 1996;276(19):1589\u201394.\nAndersson REB. Meta-analysis of the clinical and laboratory diagnosis of appendicitis. Br J Surg. 2004;91:28\u201337.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.", "start_char_idx": 111701, "end_char_idx": 116076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e32cab25-cf9e-4ce9-bc0a-1763e97caf72": {"__data__": {"id_": "e32cab25-cf9e-4ce9-bc0a-1763e97caf72", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69ba04b1-ec0b-4f35-9c26-0dc6e2180114", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "15ea1fd873ac6d5f7bc55660ef4cb68d9c320697f9e2bd3d35e0ac11bffd1fac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24a37567-78f2-405e-ab36-09f0f98f53a7", "node_type": "1", "metadata": {}, "hash": "ec06a9c7894d486839d38089913df535d9fb68e155baf9e5cf5e722647051cc4", "class_name": "RelatedNodeInfo"}}, "text": "World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J Surg. 2007;31:86\u201392.\n\n## Additional Resources\n\nGreen R. Acute abdominal pain. In: Tintinalli JE, Kelen GD, Stapczynski JS, Ma OJ, Cline DM, Cydulka RK, eds. Emergency\nMedicine: A Comprehensive Study Guide. 6th ed. New York, NY: McGraw-Hill; 2004: 470\u20134.\nWagner JM, McKinney WP, Carpenter JL. Does this patient have appendicitis? JAMA. 1996;276(19):1589\u201394.\nAndersson REB. Meta-analysis of the clinical and laboratory diagnosis of appendicitis. Br J Surg. 2004;91:28\u201337.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and\npredominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J\nSurg. 2007;31:86\u201392.\nAndersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and\npredominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J\nSurg. 2007;31:86\u201392.\n\n## Related Articles\n\n|1.|Green R. Acute abdominal pain. In: Tintinalli JE, Kelen GD, Stapczynski JS, Ma OJ, Cline DM, Cydulka RK, eds. Emergency         Medicine: A Comprehensive Study Guide. 6th ed. New York, NY: McGraw-Hill; 2004: 470\u20134.|\n|---|---|\n|2.|Wagner JM, McKinney WP, Carpenter JL. Does this patient have appendicitis? JAMA. 1996;276(19):1589\u201394.|\n|3.|Andersson REB. Meta-analysis of the clinical and laboratory diagnosis of appendicitis. Br J Surg. 2004;91:28\u201337.|\n|4.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n\n## References (continued)\n\n|5.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n|---|---|\n|6.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n|7.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n|8.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n\n## References (continued)\n\n|9.|Andersson REB.", "start_char_idx": 115268, "end_char_idx": 119013, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24a37567-78f2-405e-ab36-09f0f98f53a7": {"__data__": {"id_": "24a37567-78f2-405e-ab36-09f0f98f53a7", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e32cab25-cf9e-4ce9-bc0a-1763e97caf72", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "02b4ba398885004d407eee6205706e6a607a6b53860d0c76dbba76861effb5e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49c0e777-a6c0-4529-974a-1d52c86e4cd8", "node_type": "1", "metadata": {}, "hash": "d23c182dfbb7f580a247baa20bc12f69f550d1cb489dc0260eed14027f1a2c87", "class_name": "RelatedNodeInfo"}}, "text": "The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n|7.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n|8.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n\n## References (continued)\n\n|9.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n|---|---|\n|10.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n\n## References (continued)\n\n|11.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n|---|---|\n|12.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n\n## References (continued)\n\n|13.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n|---|---|\n|14.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n\n## References (continued)\n\n|15.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n|---|---|\n|16.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n\n## References (continued)\n\n|17.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n|---|---|\n|18.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n\n## References (continued)\n\n|19.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n|---|---|\n|20.|Vermuelen B, Morabia A, Unger PF, et al. Acute appendicitis: influence of early pain relief on the accuracy of clinical         and US findings in the decision to operate \u2013 a randomized trial. Radiology.", "start_char_idx": 118143, "end_char_idx": 122504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49c0e777-a6c0-4529-974a-1d52c86e4cd8": {"__data__": {"id_": "49c0e777-a6c0-4529-974a-1d52c86e4cd8", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24a37567-78f2-405e-ab36-09f0f98f53a7", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "9ca005f8a421e9484460328f1d2427e67792bcc3b865f0abd5784c6f227f29c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40baa07a-bdda-403d-b422-81e5ef472ba7", "node_type": "1", "metadata": {}, "hash": "934217cfecddd663e7cb716ccfac663c9688f605ba6a63d0875537cc75dd4d6a", "class_name": "RelatedNodeInfo"}}, "text": "The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n\n## References (continued)\n\n|19.|Andersson REB. The natural history and traditional management of appendicitis revisited: spontaneous resolution and         predominance of prehospital perforations imply that a correct diagnosis is more important than an early diagnosis. World J         Surg. 2007;31:86\u201392.|\n|---|---|\n|20.|Vermuelen B, Morabia A, Unger PF, et al. Acute appendicitis: influence of early pain relief on the accuracy of clinical         and US findings in the decision to operate \u2013 a randomized trial. Radiology. 1999; 210:639\u201343|\n\n## Go To TOC\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Abuse and Maltreatment\n\n### Aliases\n\nMaltreatment of vulnerable populations, Non-accidental trauma\n\n### Definitions\n\nAbuse/Maltreatment: Any act or series of acts of commission or omission by a caregiver or person in a position of power over the patient that results in harm, potential for harm, or threat of harm to a patient of any age group. EMS clinicians should have a heightened awareness for vulnerable populations which include, but is not limited to, children, elderly, and adults with mental or physical disabilities\n\nChild Abuse/Maltreatment: Child maltreatment includes any act or series of acts of commission or omission by a parent or other caregiver that results in harm, potential for harm, or threat of harm to a child. An act of commission (child abuse) is the physical, sexual, or emotional maltreatment or neglect of a child or children. An act of omission (child neglect) includes, but is not limited to, failure to provide for the child\u2019s needs (e.g., physical, emotional, medical/dental, and educational neglect) and failure to supervise (e.g., inadequate supervision or safety precautions, lack of appropriate car seat use, and exposure to violent or dangerous environments)\n\nHuman Trafficking: when people are abducted or coerced into service (e.g., being forced into servitude without compensation and/or prostitution). Signs may include, but are not limited to, patient with branding/tattoos and environmental clues such as padlocks and/or doorknobs removed on interior doors and intact windows that are boarded up\n\n### Patient Care Goals\n\nRecognize any act or series of acts of commission or omission by a caregiver or person in a position of power over the patient that results in harm, potential for harm, or threat of harm to a patient\n\nTake appropriate steps to protect the safety of the responders as well as bystanders\n\nRemove the patient from immediate danger\n\nAssess any patient injuries that may be the result of acute or chronic events\n\nAttempt to preserve evidence whenever possible; however, the overriding concern should be providing appropriate emergency care to the patient\n\nComplete all mandatory reporting requirements per state guidelines\n\n### Patient Presentation\n\nClues to abuse or maltreatment can vary with age group of the patient and type of abuse\n\nNot all abuse or maltreatment is physical\n\nEMS role is to:\n\nDocument concerns\nAssess potentially serious injuries\nDisclose concerns to appropriate authorities\nInitiate help to get the patient and any other vulnerable individuals at the scene into a safe situation\nNot to investigate or intervene beyond the steps above\nLeave further intervention to law enforcement personnel\n\n________________________\n\nGo To TOC\n\n## General Medical\n\nRev. March 2022\n\n## Abuse and Maltreatment\n\n55\n---\n# NASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Inclusion/Exclusion Criteria\n\nAbsolute inclusion/exclusion criteria are not possible in this area.", "start_char_idx": 121714, "end_char_idx": 125557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40baa07a-bdda-403d-b422-81e5ef472ba7": {"__data__": {"id_": "40baa07a-bdda-403d-b422-81e5ef472ba7", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49c0e777-a6c0-4529-974a-1d52c86e4cd8", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "88347395bcc9af06f0e9ed699120a44b8e58e6751d850a7d021aaa79ab6580ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a587a50-e6bc-4dcb-90fa-2f15d08c055a", "node_type": "1", "metadata": {}, "hash": "83e69cf27c0fb5514de56319b8b0a29eaa1f9119a93bdeef95e08051907b188d", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n## Abuse and Maltreatment\n\n55\n---\n# NASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Inclusion/Exclusion Criteria\n\nAbsolute inclusion/exclusion criteria are not possible in this area. Rather, clues consistent with different types of abuse/maltreatment should be sought:\n\nPotential clues to abuse/maltreatment from caregivers or general environment:\n\nCaregiver apathy about patient\u2019s current situation\nCaregiver overreaction to questions about situation\nInconsistent histories from caregivers or bystanders regarding what happened\nInformation provided by caregivers or patient that is not consistent with injury patterns\nInjuries not appropriate for patient\u2019s age or physical abilities (e.g., infants with injuries usually associated with ambulatory children, elders who have limited mobility with injury mechanisms inconsistent with their capabilities)\nCaregiver not allowing adult patient to speak for themself, or who appears controlling \u2013 pay special attention to patients who cannot communicate due to young age or language and/or cultural barriers\nInadequate safety precautions or facilities where the patient lives and/or evidence of security measures that appear to confine the patient inappropriately\n\nPotential clues to abuse or maltreatment that can be obtained from the patient:\n\nMultiple bruises in various stages of healing\nAge-inappropriate behavior (e.g., adults who are submissive or fearful, children who act in a sexually inappropriate way)\nPattern burns, bruises, or scars suggestive of specific weaponry used\nEvidence of medical neglect for injuries or infections\nUnexplained trauma to genitourinary systems or frequent infections to this system\nEvidence of malnourishment and/or serious dental problems\n\nHave a high index of suspicion for abuse in children presenting with a Brief Resolved Unexplained Event (BRUE) [See Brief Resolved Unexplained Event (BRUE) & Acute Events in Infants Guideline]\n\n## Patient Management\n\n### Assessment\n\nPrimary survey and identify any potentially life-threatening issues\nDocument thorough secondary survey to identify clues of for potential abuse/maltreatment:\n\nMultiple bruises in various stages of healing. A complete skin exam can help identify suggestive findings that would otherwise be missed\nAge-inappropriate behavior (e.g., adults who are submissive or fearful, children who act in a sexually inappropriate way)\nPattern burns, bruises, or scars suggestive of specific weaponry used\nEvidence of medical neglect for injuries or infections\nUnexplained trauma to genitourinary systems or frequent infections to this system\nEvidence of malnourishment and/or serious dental problems\n\nAssess physical issues and avoid extensive investigation of the specifics of abuse or maltreatment, but document any statements made spontaneously by patient\n\nAvoid asking directed questions of a child\n\n________________________Go To TOC\n\nGeneral Medical Rev. March 2022 Abuse and Maltreatment 56\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Treatment and Interventions\n\nAddress life-threatening issues\nRemove the patient to a safe place even if no medical indication for transport\nReport concerns about potential abuse/maltreatment to law enforcement immediately, in accordance with state law,\nincluding:\n\nCaregivers impeding your ability to assess/transport patient\nCaregivers refusing care for the patient\n\nFor patients transported, report concerns to hospital and/or law enforcement personnel (including Child Protective\nServices agencies where appropriate) per mandatory reporting laws\n\n### Patient Safety Considerations\n\nIf no medical emergency exists, the next priority is safe patient disposition/removal from the potentially abusive\nsituation\nDo not confront suspected perpetrators of abuse/maltreatment. This can create an unsafe situation for EMS and for\nthe patient\nIn situations of parental or religious objections to life-saving medical care when EMS suspects abuse, law\nenforcement should be notified for assistance\n\n### Notes/Educational Pearls\n\n#### Key Considerations\n\nAll states have specific mandatory reporting laws that dictate which specific crimes such as suspected abuse or\nmaltreatment must be reported and to whom they must be reported. It is important to be familiar with the specific\nlaws in your state including specifically who must make disclosures, what the thresholds are for disclosures, and to\nwhom the disclosures must be made\nClues to abuse or maltreatment can vary depending on the age group of the patient and on the nature of the abuse.\nRemember that not all abuse or maltreatment involves physical harm. EMS clinicians are often unique in being the\nonly members of the medical team to observe the home environment or injury scene. It is important to realize that\nthe job of EMS is to document their concerns, assess the patient for potentially serious injuries, make sure that\ntheir concerns are disclosed to the appropriate legal authorities, and work towards getting the patient into a safe\nsituation.", "start_char_idx": 125345, "end_char_idx": 130389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a587a50-e6bc-4dcb-90fa-2f15d08c055a": {"__data__": {"id_": "4a587a50-e6bc-4dcb-90fa-2f15d08c055a", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40baa07a-bdda-403d-b422-81e5ef472ba7", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "e7950ccf235ca0f0baca04c917ed9fd17b12727843a32299ad8c37197128c50a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14d7c90d-0e4a-4de3-b1d1-6fd8b1bd90bb", "node_type": "1", "metadata": {}, "hash": "9e0b6fcd08bb925c3025415aa43234074343f47b826d07efc92c3b4f4091fc46", "class_name": "RelatedNodeInfo"}}, "text": "It is important to be familiar with the specific\nlaws in your state including specifically who must make disclosures, what the thresholds are for disclosures, and to\nwhom the disclosures must be made\nClues to abuse or maltreatment can vary depending on the age group of the patient and on the nature of the abuse.\nRemember that not all abuse or maltreatment involves physical harm. EMS clinicians are often unique in being the\nonly members of the medical team to observe the home environment or injury scene. It is important to realize that\nthe job of EMS is to document their concerns, assess the patient for potentially serious injuries, make sure that\ntheir concerns are disclosed to the appropriate legal authorities, and work towards getting the patient into a safe\nsituation. EMS personnel should not take it upon themselves to investigate, interview, or intervene above and beyond\nthose concepts and should leave further intervention to the appropriate law enforcement personnel\nAbuse and maltreatment can happen to patients of all ages\nPatients may be unwilling or unable to disclose abuse or maltreatment, so the responsibility falls on EMS personnel\nto assess the situation, document appropriately, and take appropriate action to secure a safe place for the patient\n\nDocument findings by describing what you see and not ascribing possible causes (e.g., \u201c0.5-inch round burn to back\u201d\nas opposed to \u201cburn consistent with cigarette burn\u201d)\n\n### Pertinent Assessment Findings\n\nAs noted above\n\n________________________\n\nGo To TOC\n\nGeneral Medical\n\nRev. March 2022\n\nAbuse and Maltreatment\n\n57\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914187 \u2013 General - Neglect or Abuse Suspected\n\n### Key Documentation Elements\n\nMeticulous documentation of any statements by the patient and any physical findings on the patient or the surroundings are critical in abuse or maltreatment cases\n\n### Performance Measures\n\nNone noted\n\n## References\n\nBlue Campaign. DHS.gov. https://www.dhs.gov/blue-campaign. Accessed March 11, 2022\nChild Abuse and Neglect Prevention. CDC.gov. https://www.cdc.gov/violenceprevention/childabuseandneglect/index.html. Accessed March 11, 2022\nChristian, Committee on Child Abuse and Neglect. The Evaluation of Suspected Child Physical Abuse. Pediatrics. 2015;135(5): e1337-e1354\nCOMMITTEE ON BIOETHICS. Conflicts between religious or spiritual beliefs and pediatric care: informed refusal, exemptions, and public funding. Pediatrics 2013; 132:962\nElder Abuse. CDC.gov. https://www.cdc.gov/violenceprevention/elderabuse/index.html. Accessed March 11, 2022\n\nRevision Date: March 11, 2022\n\n________________________ Go To TOC\n\nGeneral Medical Rev.", "start_char_idx": 129608, "end_char_idx": 132404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14d7c90d-0e4a-4de3-b1d1-6fd8b1bd90bb": {"__data__": {"id_": "14d7c90d-0e4a-4de3-b1d1-6fd8b1bd90bb", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a587a50-e6bc-4dcb-90fa-2f15d08c055a", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "5b389ff47ba24e99ae4503c0d0f3f077d3bce23369cbf4165f2fbb96e5d642bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71f7b1c0-17cc-4e46-ba75-d40b74faf6cf", "node_type": "1", "metadata": {}, "hash": "66a09ea0ca25c23805d38976ebbf1678ffbab9167decf907649b9391eb29c2ab", "class_name": "RelatedNodeInfo"}}, "text": "Accessed March 11, 2022\nChild Abuse and Neglect Prevention. CDC.gov. https://www.cdc.gov/violenceprevention/childabuseandneglect/index.html. Accessed March 11, 2022\nChristian, Committee on Child Abuse and Neglect. The Evaluation of Suspected Child Physical Abuse. Pediatrics. 2015;135(5): e1337-e1354\nCOMMITTEE ON BIOETHICS. Conflicts between religious or spiritual beliefs and pediatric care: informed refusal, exemptions, and public funding. Pediatrics 2013; 132:962\nElder Abuse. CDC.gov. https://www.cdc.gov/violenceprevention/elderabuse/index.html. Accessed March 11, 2022\n\nRevision Date: March 11, 2022\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022 Abuse and Maltreatment 58\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Agitated or Violent Patient/Behavioral Emergency\n\n#### Aliases\n\nAcute psychosis\n\nPatient restraint\n\n#### Patient Care Goals\n\nProvision of emergency medical care to the agitated, violent, or uncooperative patient\nMaximizing and maintaining safety for the patient, EMS personnel, and others\n\n#### Patient Presentation\n\n##### Inclusion Criteria\n\nPatients of all ages who are exhibiting agitated or violent behavior, are a danger to self or others and in the sole assessment of the EMS clinician require physical and/or pharmacologic restraint to mitigate injury to self or others\n\n##### Exclusion Criteria\n\nPatients exhibiting agitated or violent behavior due to medical conditions including, but not limited to:\n\nHead injury\nMetabolic disorders (e.g., hypoglycemia, hypoxia)\n\n#### Patient Management\n\n##### Assessment\n\nNote medications/substances on scene that may contribute to the agitation, or may be relevant to the treatment of a contributing medical condition\nMaintain and support airway\nNote respiratory rate and effort \u2013 If possible, monitor pulse oximetry and/or capnography\nAssess circulatory status:\n\nBlood pressure (if possible)\nPulse rate\nCapillary refill\n\nAssess mental status\n\nCheck blood glucose (if possible)\n\nObtain temperature (if possible)\nAssess for evidence of traumatic injuries\nUse a validated risk assessment tool such as RASS (Richmond Agitation Sedation Score), AMSS (Altered Mental Status Score), or BARS (Behavioral Activity Rating Scale) to risk stratify violent patients to help guide interventions\n\n##### Treatment and Interventions\n\nEstablish patient rapport\n\nAttempt verbal reassurance and calm patient prior to use of pharmacologic and/or physical management devices\nEngage family members/loved ones to encourage patient cooperation if their presence does not exacerbate the patient\u2019s agitation\n\nGo To TOC\n\n##### General Medical\n\nRev. March 2022\n\n##### Agitated or Violent Patient/Behavioral Emergency\n\n59\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nc. Continued verbal reassurance and calming of patient following use of chemical/physical management devices\n\n### Pharmacologic management\n\na. Notes:\n\ni. Selection of medications for pharmacologic management should be based upon the patient\u2019s clinical condition, current medications, and allergies in addition to EMS resources and medical direction\n\nii. The medications are annotated to indicate when they are preferred for patients that are particularly high-risk for violence as assessed by a validated scale \u2013 note that the dosing can be adjusted to achieve different levels of sedation\n\niii. The numbering of medications below is not intended to indicate a hierarchy/preference of administration\n\nb. Benzodiazepines\n\ni. Diazepam\n\n| |Adults| |\n|---|---|---|\n|1.|5 mg IV; 2\u20135 minute onset of action|OR|10 mg IM; 15\u201330 minute onset of action|\n| |Pediatrics| |\n|2.|0.05\u20130.1 mg/kg IV (maximum dose is 5 mg)|OR|0.1\u20130.2 mg/kg IM (maximum dose is 10 mg)|\n\nii. Lorazepam\n\n| |Adults| |\n|---|---|---|\n|1.|2 mg IV; 2\u20135 minute onset of action|OR|4 mg IM; 15\u201330 minute onset of action|\n| |Pediatrics| |\n|2.|0.05 mg/kg IV (maximum dose is 2 mg)|OR|0.05 mg/kg IM (maximum dose is 2 mg)|\n\niii.", "start_char_idx": 131739, "end_char_idx": 135727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71f7b1c0-17cc-4e46-ba75-d40b74faf6cf": {"__data__": {"id_": "71f7b1c0-17cc-4e46-ba75-d40b74faf6cf", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14d7c90d-0e4a-4de3-b1d1-6fd8b1bd90bb", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "74c0f0df0cc4dda4044a80f76236165f9a72b07f7d0495768c15714eaf947132", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f2369d1-2979-4dfa-97cc-197840df09bc", "node_type": "1", "metadata": {}, "hash": "1949933b8d23815ba1d107ca45de4014677ae4dbf358a5f87ded5559eb5fafbe", "class_name": "RelatedNodeInfo"}}, "text": "Lorazepam\n\n| |Adults| |\n|---|---|---|\n|1.|2 mg IV; 2\u20135 minute onset of action|OR|4 mg IM; 15\u201330 minute onset of action|\n| |Pediatrics| |\n|2.|0.05 mg/kg IV (maximum dose is 2 mg)|OR|0.05 mg/kg IM (maximum dose is 2 mg)|\n\niii. Midazolam\n\n| |Adults| |\n|---|---|---|\n|1.|5 mg IV; 3\u20135 minute onset of action|OR|5 mg IM; 10\u201315 minute onset of action|OR|5 mg IN; 3\u20135 minute onset of action|\n| |Pediatrics| |\n|2.|0.05\u20130.1 mg/kg IV (maximum dose 5 mg)|OR|0.1\u20130.15 mg/kg IM (maximum dose is 5 mg)|OR|0.3 mg/kg IN (maximum dose is 5 mg)|\n\nc. Antipsychotics\n\ni. Droperidol (option for high violence risk)\n\n| |Adults|\n|---|---|\n|1.|\n\nGeneral Medical\n\nAgitated or Violent Patient/Behavioral Emergency\n\nRev. March 2022\n\n60\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\na. 2.5 mg IV; 10-minute onset of action OR b. 5\u201310 mg IM; 20-minute onset of action\n\n2. Pediatrics: Not routinely recommended\n\nii. Haloperidol (Limited data available, optimal dose not established)\n\n1. Adults: a. 5 mg IV; 5\u201310 minute onset of action OR b. 5\u201310 mg IM; 10\u201320 minute onset of action\n\n2. Pediatrics: Age 6\u201312 years old: 1\u20133 mg IM (maximum dose 0.15 mg/kg)\n\niii. Olanzapine (Note: Concurrent use of IM/IV benzodiazepines and olanzapine IM is not recommended as fatalities\nhave been reported)\n\n1. Adults: a. 10 mg IM; 15\u201330 minute onset of action b. 10 mg ODT PO or SL\n\n2. Pediatrics: a. Age 6\u201311 years old: 5 mg IM (limited data available for pediatric use) b. Age 12\u201318 years old: 10\nmg IM c. Age 6\u201318 years old: 5 mg ODT PO or SL\n\niv. Ziprasidone\n\n1. Adults: 10 mg IM; 10-minute onset of action\n\n2. Pediatrics: a. Age 6\u201311 years old: 5 mg IM (limited data available for pediatric use) b. Age 12\u201318 years old: 10 mg\nIM\n\nd. Dissociative Agents (provide sedation and anesthesia)\n\ni. Ketamine (option for high violence risk)\n\n1. Adults: a. 2 mg/kg IV; 1 minute onset of action OR b. 4 mg/kg IM; 3\u20135 minute onset of action\n\n2. Pediatrics: a. 1 mg/kg IV OR b. 3 mg/kg IM\n\ne. Antihistamines\n\ni. Diphenhydramine\n\n1. Adults: 25\u201350 mg IM/IV/PO\n\n2. Pediatrics: 1 mg/kg IM/IV/PO (maximum dose of 25 mg)\n\n## 2. Physical Management Devices\n\na. Body\n\ni. Stretcher straps should be applied as the standard procedure for all patients during transport\n\nii. Physical management devices, including stretcher straps, should never restrict the patient\u2019s chest wall motion\n\niii. If necessary, sheets may be used as improvised supplemental stretcher straps. Other forms of improvised physical\nmanagement devices should be discouraged\n\n________________________ Go To TOC\n\nGeneral Medical Rev.", "start_char_idx": 135503, "end_char_idx": 138050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f2369d1-2979-4dfa-97cc-197840df09bc": {"__data__": {"id_": "6f2369d1-2979-4dfa-97cc-197840df09bc", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71f7b1c0-17cc-4e46-ba75-d40b74faf6cf", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "da05a5b4bfc66e386b990fc024d32e42cac0e1ca7777b5dff690122e9722a841", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bfa73c0-65f0-4b6b-bd9d-bb1d70cd71e6", "node_type": "1", "metadata": {}, "hash": "5a861fa9f9e357e6f8bc785fac00aa4412fdc9c935560647deee36e166aebea4", "class_name": "RelatedNodeInfo"}}, "text": "4 mg/kg IM; 3\u20135 minute onset of action\n\n2. Pediatrics: a. 1 mg/kg IV OR b. 3 mg/kg IM\n\ne. Antihistamines\n\ni. Diphenhydramine\n\n1. Adults: 25\u201350 mg IM/IV/PO\n\n2. Pediatrics: 1 mg/kg IM/IV/PO (maximum dose of 25 mg)\n\n## 2. Physical Management Devices\n\na. Body\n\ni. Stretcher straps should be applied as the standard procedure for all patients during transport\n\nii. Physical management devices, including stretcher straps, should never restrict the patient\u2019s chest wall motion\n\niii. If necessary, sheets may be used as improvised supplemental stretcher straps. Other forms of improvised physical\nmanagement devices should be discouraged\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022 Agitated or Violent Patient/Behavioral Emergency 61\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n#### Supplemental straps or sheets may be necessary to prevent flexion/extension of torso, hips, legs by being placed\naround the lower lumbar region, below the buttocks, and over the thighs, knees, and legs\n\nExtremities\n\nSoft or leather devices should not require a key to release them\nSecure all four extremities to maximize safety for patient, staff, and others\nSecure all extremities to the stationary frame of the stretcher\nMultiple knots should not be used to secure a device\n\n#### Patient Safety Considerations\n\nThe management of violent patients requires a constant reevaluation of the risk/benefit balance for the patient\nand bystanders to provide the safest care for all involved. These are complex and high-risk encounters. There is no\n\u201cone size fits all\u201d solution for addressing these patients\n\nDon PPE\nDo not attempt to enter or control a scene where physical violence or weapons are present\nDispatch law enforcement immediately to secure and maintain scene safety\nUrgent de-escalation of patient agitation is imperative in the interest of patient safety as well as for EMS\npersonnel and others on scene\nUncontrolled or poorly controlled patient agitation and physical violence can place the patient at risk for sudden\ncardiopulmonary arrest due to the following etiologies:\n\nDelirium with agitated behavior: A postmortem diagnosis of exclusion for sudden death thought to result from\nmetabolic acidosis (most likely from lactate) stemming from physical agitation or physical control measures and\npotentially exacerbated by stimulant drugs (e.g., cocaine) or alcohol withdrawal\nPositional asphyxia: Sudden death from restriction of chest wall movement and/or obstruction of the airway\nsecondary to restricted head or neck positioning resulting in hypercarbia and/or hypoxia\n\nApply a cardiac monitor as soon as possible, particularly when pharmacologic management medications have been\nadministered\nAll patients who have received pharmacologic management medications must be monitored closely for the development\nof hypoventilation and oversedation\n\nUtilize capnography if available\n\nPatients who have received antipsychotic medication for pharmacologic management must be monitored closely for the\npotential development of:\n\nDystonic reactions (this can easily be treated with diphenhydramine/benzodiazepines)\nMydriasis (dilated pupils)\nAtaxia\nCessation of perspiration\nDry mucous membranes\nCardiac arrhythmias (particularly QT prolongation)\n\nPatients who require physical management should also receive pharmacological treatment for agitation to prevent\nconsequences of delirium with agitated behavior\nPlacement of stretcher in sitting position prevents aspiration and reduces the patient\u2019s physical strength by\nplacing the abdominal muscles in the flexed position\nPatients who are more physically uncooperative should be physically secured with one arm above the head and the\nother arm below the waist, and both lower extremities individually secured\n\nGeneral Medical\n\nAgitated or Violent Patient/Behavioral Emergency\n\nRev. March 2022\n\n62\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n## 12. The following techniques should be expressly prohibited for use by EMS clinicians:\n\na. Secure or transport in a prone position with or without hands and feet behind the back (hobbling or \u201chog-tying\u201d)\n\nb. \"Sandwiching\u201d patients between backboards\n\nc. Techniques that constrict the neck or compromise the airway\n\n## 13. Concurrent use of IM/IV benzodiazepines and olanzapine IM is not recommended as fatalities have been reported\n\n### Notes/Educational Pearls\n\nKey considerations\n\n1.", "start_char_idx": 137362, "end_char_idx": 141803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bfa73c0-65f0-4b6b-bd9d-bb1d70cd71e6": {"__data__": {"id_": "0bfa73c0-65f0-4b6b-bd9d-bb1d70cd71e6", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f2369d1-2979-4dfa-97cc-197840df09bc", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "9af4bf1b2d6609fb24b342b2a1cec1ac6c5bd832fe3ad4c1b398c29e19eb5f33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b8c5c2b-d62f-4c3d-b88c-ff0b905bb01f", "node_type": "1", "metadata": {}, "hash": "c8f67f3d0dd214a66a07865ec60e8d51f31e9141e105c5f4ed56928cf5ed4c75", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n62\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n## 12. The following techniques should be expressly prohibited for use by EMS clinicians:\n\na. Secure or transport in a prone position with or without hands and feet behind the back (hobbling or \u201chog-tying\u201d)\n\nb. \"Sandwiching\u201d patients between backboards\n\nc. Techniques that constrict the neck or compromise the airway\n\n## 13. Concurrent use of IM/IV benzodiazepines and olanzapine IM is not recommended as fatalities have been reported\n\n### Notes/Educational Pearls\n\nKey considerations\n\n1. Direct medical direction should be contacted at any time for advice, especially when patient\u2019s level of agitation is such that transport may place all parties at risk\n\n2. Transport by air is not advised\n\n3. Stretchers with adequate foam padding, particularly around the head, facilitates patient\u2019s ability to self-position the head and neck to maintain airway patency\n\n4. For patients with key-locking devices, applied by another agency, consider the following options:\n\na. Remove device and replace it with a device that does not require a key\n\nb. Administer pharmacologic management medication then remove and replace device with another non-key-locking device after patient has become more cooperative\n\nc. Transport patient accompanied in patient compartment by person who has device key\n\nd. Transport patient in the vehicle of person who has the device key if medical condition of patient is deemed stable, direct medical direction so authorizes, and law allows\n\n### Pertinent Assessment Findings\n\n1. Continuous monitoring of:\n\na. Airway patency\n\nb. Respiratory status with pulse oximetry and/or capnography\n\nc. Circulatory status with frequent blood pressure measurements\n\nd. Mental status and trends in level of patient cooperation\n\ne. Cardiac status, especially if the patient has received pharmacologic management medication\n\nf. Extremity perfusion with capillary refill in patients in physical management device\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n\u2022 9914053 \u2013 General - Behavioral/Patient Restraint\n\nKey Documentation Elements\n\n\u2022 Etiology of agitated or violent behavior if known\n\n\u2022 Patient\u2019s medications, other medications or substances found on scene\n\n\u2022 Patient\u2019s medical history or other historic factors reported by patient, family, or bystanders\n\n\u2022 Physical evidence or history of trauma\n\n\u2022 Adequate oxygenation by pulse oximetry\n\n\u2022 Blood glucose measurement\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022\n\nAgitated or Violent Patient/Behavioral Emergency 63\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nMeasures taken to establish patient rapport\nDose, route, and number of doses of pharmacologic management medications administered\nClinical response to pharmacologic management medications\nNumber and physical sites of placement of physical management devices\nDuration of placement of physical management devices\nRepeated assessment of airway patency\nRepeated assessment of respiratory rate, effort, pulse oximetry/capnography\nRepeated assessment of circulatory status with blood pressure, capillary refill, cardiac monitoring\nRepeated assessment of mental status and trends in the level of patient cooperation\nRepeated assessment of capillary refill in patient with extremity securing devices\nCommunications with EMS medical direction\nInitiation and duration of engagement with law enforcement\n\nPerformance Measures\n\nIncidence of injuries to patient, EMS personnel, or others on scene\nIncidence of injuries to patient, EMS personnel, or others during transport\nMedical or physical complications (including sudden death) in patients\nAdvance informational communication of EMS protocols for the management of agitated and violent patients to\nothers within the emergency care system and law enforcement\nInitiation and engagement with EMS medical direction\nInitiation and duration of engagement with law enforcement\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\nPediatrics\u201403: Documentation of Estimated Weight in Kilograms\n\nReferences\n\nAdimando AJ, Poncin YB, Baum CR. Pharmacological management of the agitated pediatric patient. Pediatr Emerg\nCare. 2010;26(11):856\u201360\nCalver L, Drinkwater V, Gupta R, Page CB, Isbister GK. Droperidol v. haloperidol for sedation of aggressive\nbehaviour in acute mental health: randomized controlled trial. Br J Psychiatry. 2015;206(3):223-228.\nCalver L, Page CB, Downes MA, et al.", "start_char_idx": 141226, "end_char_idx": 145834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b8c5c2b-d62f-4c3d-b88c-ff0b905bb01f": {"__data__": {"id_": "8b8c5c2b-d62f-4c3d-b88c-ff0b905bb01f", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bfa73c0-65f0-4b6b-bd9d-bb1d70cd71e6", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "46c8baaba7d382fe8f0a394c0d0fe15e0f0597cb6fcb3da901c94861b5007118", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4d8731f-de36-422e-b47c-dde8f7d43c3a", "node_type": "1", "metadata": {}, "hash": "ffc6c9bea976f903790b914ebdb1407366cc3ff4572b1440b3512e4ff3c34eca", "class_name": "RelatedNodeInfo"}}, "text": "Pharmacological management of the agitated pediatric patient. Pediatr Emerg\nCare. 2010;26(11):856\u201360\nCalver L, Drinkwater V, Gupta R, Page CB, Isbister GK. Droperidol v. haloperidol for sedation of aggressive\nbehaviour in acute mental health: randomized controlled trial. Br J Psychiatry. 2015;206(3):223-228.\nCalver L, Page CB, Downes MA, et al. The Safety and Effectiveness of Droperidol for Sedation of Acute Behavioral\nDisturbance in the Emergency Department. Ann Emerg Med. 2015;66(3):230-238.e1.\nCalver L, Isbister GK. High dose droperidol and QT prolongation: analysis of continuous 12\u2010lead recordings.\nBritish Journal of Clinical Pharmacology. 2014;77(5):880-886\nDrayna PC, Estrada C, Wang W, Saville BR, Arnold DH. Ketamine sedation is not associated with clinically\nmeaningful elevation of intraocular pressure. Am J Emerg Med. 2012;30(7):1215\u20138.\nEly EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU patients: reliability and\nvalidity of the Richmond Agitation-Sedation Scale (RASS). JAMA. 2003;289(22):2983\u201391.\nGerson R, Malas N, Feuer V, Silver GH, Prasad R, Mroczkowski MM. Best Practices for Evaluation and Treatment of\nAgitated Children and Adolescents (BETA) in the Emergency Department: Consensus Statement of the American\nAssociation for Emergency Psychiatry [published correction appears in West J Emerg Med. 2019 May;20(3):537]\n[published correction appears in\n\nGo To TOC\n\nGeneral Medical\n\nAgitated or Violent Patient/Behavioral Emergency\n\nRev. March 2022\n\n64\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nWest J Emerg Med. 2019 Jul;20(4):688-689]. West J Emerg Med. 2019;20(2):409-418.\ndoi:10.5811/westjem.2019.1.41344\n\nHalstead SM, Deakyne SJ, Bajaj L, Enzenauer R, Roosevelt GE. The effect of ketamine on intraocular pressure in\npediatric patients during procedural sedation. Acad Emerg Med. 2012;19(10):1145\u201350.\nHo JD, Smith SW, Nystrom PC, et al. Successful management of excited delirium syndrome with prehospital ketamine:\ntwo case examples. Prehosp Emerg Care, 2013;17(2): 274\u20139.\nIsbister GK, Calver LA, Page CB, Stokes B, Bryant JL, Downes MA. Randomized controlled trial of intramuscular\ndroperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Ann Emerg Med.\n2010;56(4):392-401 e1.\nKupas DF, Wydro GC. Patient restraint in emergency medical services systems. Prehosp Emerg Care.\n2002;6(3):340\u20135.\nSonnier L, Barzman D. Pharmacologic management of acutely agitated pediatric patients. Paediatr Drugs.\n2011 1;13(1):1\u201310.\nSwift RH, Harrigan EP, Cappelleri JC, Kramer D, Chandler LP. Validation of the behavioural activity rating scale\n(BARS): a novel measure of activity in agitated patients. J Psychiatr Res. 2002;36(2):87\u201395.\nTsze DS, Steele DW, Machan JT, Akhlaghi F, Linakis JG. Intranasal ketamine for procedural sedation in pediatric\nlaceration repair: a preliminary report. Pediatr Emerg Care. 2012;28(8):767\u201370\nWhite Paper Report on Excited Delirium Syndrome. ACEP Excited Delirium Task Force, American College of Emergency\nPhysicians; September 10, 2009.\n\nRevision Date March 11, 2022\n\nGeneral Medical Agitated or Violent Patient/Behavioral Emergency 65\n\n## Go To TOC\n\nRev.", "start_char_idx": 145488, "end_char_idx": 148683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4d8731f-de36-422e-b47c-dde8f7d43c3a": {"__data__": {"id_": "f4d8731f-de36-422e-b47c-dde8f7d43c3a", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b8c5c2b-d62f-4c3d-b88c-ff0b905bb01f", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "1e188780ed6ea3008b683025f5787fc956bf03878396983a1816bd709c8b9614", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e54d1f30-7e17-4486-a9d6-9c317842cca2", "node_type": "1", "metadata": {}, "hash": "90caa102f1cd92afd6b4ceb3392ad47ff06c10112ada1659a7aa210a9db159d5", "class_name": "RelatedNodeInfo"}}, "text": "Swift RH, Harrigan EP, Cappelleri JC, Kramer D, Chandler LP. Validation of the behavioural activity rating scale\n(BARS): a novel measure of activity in agitated patients. J Psychiatr Res. 2002;36(2):87\u201395.\nTsze DS, Steele DW, Machan JT, Akhlaghi F, Linakis JG. Intranasal ketamine for procedural sedation in pediatric\nlaceration repair: a preliminary report. Pediatr Emerg Care. 2012;28(8):767\u201370\nWhite Paper Report on Excited Delirium Syndrome. ACEP Excited Delirium Task Force, American College of Emergency\nPhysicians; September 10, 2009.\n\nRevision Date March 11, 2022\n\nGeneral Medical Agitated or Violent Patient/Behavioral Emergency 65\n\n## Go To TOC\n\nRev. March 2022\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Anaphylaxis and Allergic Reaction\n\n(Adapted from an evidence-based guideline created using the National Prehospital Evidence-Based Prehospital Guideline Model Process)\n\n### Aliases\n\nAnaphylactic Shock\n\n### Patient Care Goals\n\nProvide timely therapy for potentially life-threatening reactions to known or suspected allergens to prevent cardiorespiratory collapse and shock\nProvide symptomatic relief for symptoms due to known or suspected allergens\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nPatients of all ages with suspected allergic reaction and/or anaphylaxis\n\n#### Exclusion Criteria\n\nNone noted\n\n### Patient Management\n\n#### Assessment\n\nEvaluate for patent airway and presence of oropharyngeal edema\nAuscultate for wheezing and assess level of respiratory effort\nAssess for adequacy of perfusion\nAssess for presence of signs and symptoms of anaphylaxis\n\nAnaphylaxis \u2013 More severe and is characterized by an acute onset involving:\n\nThe skin (urticaria) and/or mucosa with either respiratory compromise or decreased BP or signs of end-organ dysfunction\nHypotension for that patient after exposure to a known allergen\n\nAdults: Systolic BP less than 90\nPediatrics: See Appendix VIII. Abnormal Vital Signs\n\nTwo or more of the following occurring rapidly after exposure to a likely allergen:\n\nSkin and/or mucosal involvement (urticaria, itchy, swollen tongue/lips)\n\nSkin involvement may be ABSENT in up to 40% of cases of anaphylaxis\n\nRespiratory compromise (dyspnea, wheezing, stridor, hypoxemia)\nPersistent gastrointestinal symptoms (vomiting, abdominal pain, diarrhea)\nHypotension or associated symptoms (syncope, hypotonia, chest tightness, incontinence)\n\nNon-anaphylactic Allergic Reaction\n\nSigns involving only one organ system (e.g., localized angioedema that does not compromise the airway, or not associated with vomiting; hives alone)\n\n________________________\n\nGo To TOC\n\nGeneral Medical\n\nRev. March 2022\n\n## Anaphylaxis and Allergic Reaction\n\n66\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Treatment and Interventions\n\nIf signs of allergic reaction without signs of anaphylaxis, go to Step 8\nEpinephrine administration is the primary treatment for anaphylaxis.", "start_char_idx": 148023, "end_char_idx": 150996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e54d1f30-7e17-4486-a9d6-9c317842cca2": {"__data__": {"id_": "e54d1f30-7e17-4486-a9d6-9c317842cca2", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4d8731f-de36-422e-b47c-dde8f7d43c3a", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "88671cd5509a082b5c63f44b0c050f0c99eef949ec31e541500d2293d8259bef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00529685-51ce-451c-9738-58689422bda1", "node_type": "1", "metadata": {}, "hash": "c8b678e1e52ef8b0948756e73a6011a2fbf0886b96a5d208e28d5a1f81c454bd", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n## Anaphylaxis and Allergic Reaction\n\n66\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Treatment and Interventions\n\nIf signs of allergic reaction without signs of anaphylaxis, go to Step 8\nEpinephrine administration is the primary treatment for anaphylaxis. If signs of anaphylaxis, administer epinephrine\n1 mg/mL at the following dose and route:\n\nAdult (25 kg or more) 0.3 mg IM in the anterolateral thigh\nPediatric (less than 25 kg) 0.15 mg in the anterolateral thigh\nEpinephrine 1 mg/mL may be administered from a vial or via auto-injector, if available\n\nIf respiratory distress with wheezing is present, consider administering\n\nAlbuterol 2.5\u20135 mg nebulized\nEpinephrine 1 mg/mL, 5 mL nebulized\n\nIf stridor is present, consider administering epinephrine 1 mg/mL, 5 mL nebulized\nIf signs of anaphylaxis and hypoperfusion persist following the first dose of epinephrine, additional IM epinephrine\ncan be repeated q5\u201315 minutes at above noted doses\nFor signs of hypoperfusion, also administer 20 mL/kg isotonic fluid (normal saline or lactated Ringer\u2019s) rapidly\n(over 15 minutes) via IV or IO, and repeat as needed for ongoing hypoperfusion\nConsider an epinephrine IV drip (0.5 mcg/kg/minute) when cardiovascular collapse (hypotension with altered mental\nstatus, pallor, diaphoresis and/or delayed capillary refill) is present despite repeated IM doses of epinephrine in\nconjunction with at least 60 mL/kg isotonic fluid boluses\nFor urticaria or pruritus, administer a diphenhydramine 1 mg/kg, up to maximum dose of 50 mg IM, IV, or PO)\n\nThe IV route is preferred for the patient in severe symptoms\nAs a supplement to diphenhydramine given for urticaria, any H2-blocking antihistamine (e.g., famotidine,\ncimetidine) can be given IV or PO in conjunction with diphenhydramine\n\nTransport as soon as possible, and perform ongoing assessment as indicated. Cardiac monitoring is not required, but\nshould be considered for those with known heart problems or who received multiple doses of epinephrine\n\n## Patient Safety Considerations\n\nTime to epinephrine delivery\nConcentration of epinephrine in relation to route\nWeight-based dosing of medications\n\n## Notes/Educational Pearls\n\nKey Considerations\n\nWhen anaphylaxis is suspected, EMS personnel should always consider epinephrine as first-line treatment\nAllergic reactions and anaphylaxis are serious and potentially life-threatening medical emergencies. It is the\nbody\u2019s adverse reaction to a foreign protein (e.g., food, medicine, pollen, insect sting or any ingested, inhaled, or\ninjected substance). A localized allergic reaction (e.g., urticaria or angioedema that does not compromise the airway)\nmay be treated with antihistamine therapy. Cardiovascular collapse may occur abruptly, without the prior development\nof skin or respiratory symptoms. Constant monitoring of the patient\u2019s airway and breathing is essential\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022 Anaphylaxis and Allergic Reaction 67\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n3. Contrary to common belief that all cases of anaphylaxis present with cutaneous manifestations, such as urticaria\nor mucocutaneous swelling, a significant portion of anaphylactic episodes may not involve these signs and symptoms on\ninitial presentation. Moreover, most fatal reactions to food-induced anaphylaxis in children were not associated with\ncutaneous manifestations\n\n4. A thorough assessment and a high index of suspicion are required for all potential allergic reaction patients \u2013\nconsider:\n\na. History of Present Illness\n\ni. Onset and location\nii. Insect sting or bite\niii. Food allergy/exposure\niv. New clothing, soap, detergent\nv. Past history of reactions\nvi. Medication history\n\nb. Signs and Symptoms\n\ni. Itching or urticaria\nii. Coughing, wheezing, or respiratory distress\niii. Chest tightness or throat constriction\niv.", "start_char_idx": 150693, "end_char_idx": 154622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00529685-51ce-451c-9738-58689422bda1": {"__data__": {"id_": "00529685-51ce-451c-9738-58689422bda1", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e54d1f30-7e17-4486-a9d6-9c317842cca2", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "5b39f6168e0cc5323b14a39757893da6ecc9adc1f3182ceb0985acf2d9da4789", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb23ea85-cec7-47c9-b7ac-c1994897aa74", "node_type": "1", "metadata": {}, "hash": "1be03f7f073f8dcb95d3c45bae5b5c9e0dd8833c25dbe370ef7fe91c91cb7a74", "class_name": "RelatedNodeInfo"}}, "text": "Moreover, most fatal reactions to food-induced anaphylaxis in children were not associated with\ncutaneous manifestations\n\n4. A thorough assessment and a high index of suspicion are required for all potential allergic reaction patients \u2013\nconsider:\n\na. History of Present Illness\n\ni. Onset and location\nii. Insect sting or bite\niii. Food allergy/exposure\niv. New clothing, soap, detergent\nv. Past history of reactions\nvi. Medication history\n\nb. Signs and Symptoms\n\ni. Itching or urticaria\nii. Coughing, wheezing, or respiratory distress\niii. Chest tightness or throat constriction\niv. Hypotension or shock\nv. Persistent gastrointestinal symptoms (nausea, vomiting, and diarrhea)\nvi. Altered mental status (AMS)\n\nc. Other Considerations\n\ni. Angioedema (drug-induced)\nii. Aspiration/airway obstruction\niii. Vasovagal event\niv. Asthma or chronic obstructive pulmonary disease (COPD)\nv. Heart failure\n\n5. Gastrointestinal symptoms occur most commonly in food-induced anaphylaxis, but can occur with other causes\n\na. Oral pruritus is often the first symptom observed in patients experiencing food-induced anaphylaxis\nb. Abdominal cramping is also common, but nausea, vomiting, and diarrhea are frequently observed as well\n\n6. Patients with asthma are at high-risk for a severe allergic reaction\n\n7. There is no proven benefit to using steroids in the management of allergic reactions and/or anaphylaxis\n\n8. There is controversy among experts with very low-quality evidence to guide management for the use of empiric IM\nepinephrine after exposure to a known allergen in asymptomatic patients with a history of prior anaphylaxis\n\nPertinent Assessment Findings\n\n1. Presence or absence of angioedema\n2. Presence or absence of respiratory compromise\n3. Presence or absence of circulatory compromise\n4. Localized or generalized urticaria\n5. Response to therapy\n\nGeneral Medical\n\nRev. March 2022\n\nAnaphylaxis and Allergic Reaction\n\n68\n---\n# NASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914111 \u2013 Medical - Allergic Reaction/Anaphylaxis\n\n### Key Documentation Elements\n\nMedications given\nDose and concentration of epinephrine given\nRoute of epinephrine administration\nTime of epinephrine administration\nSigns and symptoms of the patient\n\n### Performance Measures\n\nPercentage of patients with anaphylaxis that receive epinephrine for anaphylaxis:\n\nVia the IM route (vs. other routes)\nVia the IM route in the anterolateral thigh (vs. other locations)\n\nPercentage of patients with anaphylaxis who receive:\n\nEpinephrine within 10 minutes of arrival\nThe appropriate weight-based dose of epinephrine\n\nPercentage of patients that require airway management in the prehospital setting (and/or the emergency department)\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nPediatrics\u201403: Documentation of Estimated Weight in Kilograms\n\n### References\n\nBanerji, A, Rudders SA, Corel B, Garth AP, Clark S, Camargo, CA Jr. Predictors of hospital admission for food-related allergic reactions that present to the emergency department. Ann Allergy Asthma Immunol. 2011;106(1):42\u20138\nBreuer C, Wachall B, Gerbeth K, Abdel-Tawab M, Fuhr U. Pharmacokinetics, and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler. Eur J Clin Pharmacol. 2013;69(6):303\u201310\nCapps JA, Sharma V, Arkwright, PD. Prevalence, outcome, and pre\u2013hospital management of anaphylaxis by first aiders and paramedical ambulance staff in Manchester, UK. Resuscitation. 2010;81(6):653\u20137\nDahlof C, Mellstrand T, Svedmyr N. Systemic absorption of adrenaline after aerosol, eye\u2013drop and subcutaneous administration to healthy volunteers. Allergy. 1987;42(3):215\u201321\nHauswald M. Can paramedics safely decide which patients do not need ambulance transport or emergency department care?", "start_char_idx": 154040, "end_char_idx": 157967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb23ea85-cec7-47c9-b7ac-c1994897aa74": {"__data__": {"id_": "eb23ea85-cec7-47c9-b7ac-c1994897aa74", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00529685-51ce-451c-9738-58689422bda1", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "30f507858ab58a63b86563e27d50cc89dd8233cf1ab74051d56dc911e89d82df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cb11c9f-ab42-4032-9247-42891281c397", "node_type": "1", "metadata": {}, "hash": "2b7b2aa762be57682d19ea6340e78be63200b1b7110dbb4afb3bd75790caca03", "class_name": "RelatedNodeInfo"}}, "text": "Eur J Clin Pharmacol. 2013;69(6):303\u201310\nCapps JA, Sharma V, Arkwright, PD. Prevalence, outcome, and pre\u2013hospital management of anaphylaxis by first aiders and paramedical ambulance staff in Manchester, UK. Resuscitation. 2010;81(6):653\u20137\nDahlof C, Mellstrand T, Svedmyr N. Systemic absorption of adrenaline after aerosol, eye\u2013drop and subcutaneous administration to healthy volunteers. Allergy. 1987;42(3):215\u201321\nHauswald M. Can paramedics safely decide which patients do not need ambulance transport or emergency department care? Prehosp Emerg Care. 2002;6(4):383\u20136\nHeilborn H, Hjemdahl P, Daleskog M, Adamsson U. Comparison of subcutaneous injection and high-dose inhalation of epinephrine \u2013 implications for self-treatment to prevent anaphylaxis. J Allergy Clin Immunol. 1986;78(6):1174\u20139\nHompes S, K\u00f6hli A, Nemat K, et al. Provoking allergens and treatment of anaphylaxis in children and adolescents \u2013 data from the anaphylaxis registry of German-speaking countries. Pediatr Allergy Immunol, 2011;22(6):568\u201374\nHuang F, Chawla K, Jarvinen KM, Nowak-Wegrzyn A. Anaphylaxis in a New York City pediatric emergency department: Triggers, treatments, and outcomes. J Allergy Clin Immunol. 2012;129(1):162\u2013168.e1\u20133\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022\n\nAnaphylaxis and Allergic Reaction 69\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n9. Iribarren C, Tolstykh IV, Miller MK, Eisner, MD. Asthma and the prospective risk of anaphylactic shock and other\nallergy diagnoses in a large integrated health care delivery system. Ann Allergy Asthma Immunol. 2010;104(5):371\u20137\n\n10. Kanwar M, Irvin CB, Frank JJ, Weber K, Rosman H. Confusion about epinephrine dosing leading to iatrogenic\noverdose: a life-threatening problem with a potential solution. Ann Emerg Med. 2010;55(4):341\u20134\n\n11. Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis-a practice parameter update 2015. Ann Allergy Asthma\nImmunol. 2015;115(5):341\u201384\n\n12. Pointer JE, Levitt MA, Young JC, Promes SB, Messana BJ, Ader ME. Can paramedics using guidelines accurately\ntriage patients? Ann Emerg Med. 2011;38(3):268\u201377\n\n13. Rea TD, Edwards C, Murray JA, Cloyd DJ, Eisenberg, MS. Epinephrine use by emergency medical technicians for\npresumed anaphylaxis. Prehosp Emerg Care. 2004;8(4):405\u201310\n\n14. Runge JW, Martinez JC, Caravati EM, Williamson SG, Hartsell, SC. Histamine antagonists in the treatment of acute\nallergic reactions. Ann Emerg Med. 1992;21(3):237\u201342\n\n15. Sampson HA. Anaphylaxis and emergency treatment. Pediatrics. 2003;111(6 Pt 3):1601\u20138\n\n16. Sampson HA, Munoz\u2013Furlong A, Campbell RL, et al. Second symposium on the definition and management of\nanaphylaxis: summary report \u2013 Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis\nNetwork Symposium. J Allergy Clin Immunol. 2004;117(2):391\u20137\n\n17. Sheikh A, Shehata YA, Brown SG, Simons FE. Adrenaline (epinephrine) for the treatment of anaphylaxis with and\nwithout shock. Cochrane Database Syst Rev. (4) 2008 CD006312\n\n18.", "start_char_idx": 157437, "end_char_idx": 160472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cb11c9f-ab42-4032-9247-42891281c397": {"__data__": {"id_": "9cb11c9f-ab42-4032-9247-42891281c397", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb23ea85-cec7-47c9-b7ac-c1994897aa74", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "87bdfd779102dfcca5fb4fb3156630440b8dfccb54327d12fa2012b2dd5994cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "937519ce-0dad-48f6-8445-232d1f32866e", "node_type": "1", "metadata": {}, "hash": "efbda95610daa81f52515af623b49cbd7161519b2a67158c1d4d22daab665cdf", "class_name": "RelatedNodeInfo"}}, "text": "1992;21(3):237\u201342\n\n15. Sampson HA. Anaphylaxis and emergency treatment. Pediatrics. 2003;111(6 Pt 3):1601\u20138\n\n16. Sampson HA, Munoz\u2013Furlong A, Campbell RL, et al. Second symposium on the definition and management of\nanaphylaxis: summary report \u2013 Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis\nNetwork Symposium. J Allergy Clin Immunol. 2004;117(2):391\u20137\n\n17. Sheikh A, Shehata YA, Brown SG, Simons FE. Adrenaline (epinephrine) for the treatment of anaphylaxis with and\nwithout shock. Cochrane Database Syst Rev. (4) 2008 CD006312\n\n18. Sheikh A, Simons FE, Barbour V, Worth A. Adrenaline auto-injectors for the treatment of anaphylaxis with and\nwithout cardiovascular collapse in the community. Cochrane Database Syst Rev. 2012 Aug 15;(8):CD008935\n\n19. Sheikh A, ten Broek V, Brown SG, Simons FE. H1-antihistamines for the treatment of anaphylaxis with and without\nshock. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006160\n\n20. Silvestri S, Rothrock SG, Kennedy D, Ladde J, Bryant M, Pagane J. Can paramedics accurately identify patients\nwho do not require emergency department care? Prehosp Emerg Care. 2002;6(4):387\u201390\n\n21. Simons FE, Chan ES, Gu X, Simons KJ. Epinephrine for the out-of-hospital (first aid) treatment of anaphylaxis in\ninfants: is the ampule/syringe/needle method practical? J Allergy Clin Immunol. 2001;108(6):1040\u20134\n\n22. Simons FE, Gu X, Johnston, LM, Simons KJ. Can epinephrine inhalations be substituted for epinephrine injection in\nchildren at risk for systemic anaphylaxis? Pediatrics. 2000;106(5):1040\u20134\n\n23. Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J\nAllergy Clin Immunol. 1998;101(1 Pt 1):33\u20137\n\n24. Taillac PP, Brown L, Lubogo N, Nichols J, Shah MI. An evidence-based guideline for pediatric prehospital allergic\nreaction management using GRADE methodology. Manuscript in preparation\n\n25. Watson NT, Weiss EL, Harter PM. Famotidine in the treatment of acute urticaria. Clin Exp Dermatol.\n2000;25(3):186\u20139\n\n26. Yavuz ST, Sahiner UM, Buyuktiryaki B, et al. Clinical features of children with venom allergy and risk factors for\nsevere systemic reactions. Int Arch Allergy Immunol. 2013;160(3):313\u201321\n\nRevision Date\n\nMarch 11, 2022\n\nGo To TOC\n\nGeneral Medical\n\nAnaphylaxis and Allergic Reaction\n\nRev.", "start_char_idx": 159897, "end_char_idx": 162229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "937519ce-0dad-48f6-8445-232d1f32866e": {"__data__": {"id_": "937519ce-0dad-48f6-8445-232d1f32866e", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cb11c9f-ab42-4032-9247-42891281c397", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "d5b416268f71bc6fb00facd4084e4ebd53bb1c5cc634630b50081db123ac0bde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61f7f586-3fbd-4224-9f4d-ee339ef1ba5a", "node_type": "1", "metadata": {}, "hash": "2b92f62e5e98c4f431e5f67dd913f7efc88aff3709769bf99e580a95b325a9b0", "class_name": "RelatedNodeInfo"}}, "text": "1998;101(1 Pt 1):33\u20137\n\n24. Taillac PP, Brown L, Lubogo N, Nichols J, Shah MI. An evidence-based guideline for pediatric prehospital allergic\nreaction management using GRADE methodology. Manuscript in preparation\n\n25. Watson NT, Weiss EL, Harter PM. Famotidine in the treatment of acute urticaria. Clin Exp Dermatol.\n2000;25(3):186\u20139\n\n26. Yavuz ST, Sahiner UM, Buyuktiryaki B, et al. Clinical features of children with venom allergy and risk factors for\nsevere systemic reactions. Int Arch Allergy Immunol. 2013;160(3):313\u201321\n\nRevision Date\n\nMarch 11, 2022\n\nGo To TOC\n\nGeneral Medical\n\nAnaphylaxis and Allergic Reaction\n\nRev. March 2022\n\n70\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# Altered Mental Status\n\n## Aliases\n\nAltered level of consciousness\n\nConfusion\n\n## Patient Care Goals\n\nIdentify treatable causes\nPerform appropriate assessment and diagnostics (e.g., oxygen saturation, glucose check, monitor)\nProtect patient from complications of altered mental status (e.g., respiratory failure, shock, cardiopulmonary arrest)\n\n## Patient Presentation\n\n### Inclusion Criteria\n\nImpaired decision-making capacity\n\n### Exclusion Criteria\n\nTraumatic brain injury\n\n## Patient Management\n\n### Assessment\n\nLook for treatable causes of altered mental status (AMS):\n\nAirway: Make sure airway remains patent; reposition patient as needed\nBreathing: Look for respiratory depression; check SPO2, EtCO2, and CO detector readings\nCirculation: Look for signs of poor perfusion\nGlasgow Coma Score and/or AVPU\nPupils\nHead and neck: Evaluate for signs of trauma\nNeck: Rigidity or pain with range of motion\nStroke assessment tool including focal neurologic findings\nBlood glucose level\nEKG or cardiac monitor: arrhythmia limiting perfusion\nBreath odor: Possible unusual odors include alcohol, acidosis, ammonia\nChest/Abdominal: Intra-thoracic hardware, assist devices, abdominal pain or distention, signs of trauma\nExtremities/skin: Track marks, hydration, edema, dialysis shunt, temperature to touch (or if able, use a thermometer),\nsigns of trauma\nSigns of infection: Fever, cough, skin changes, dysuria\nEnvironment: Survey for pills, paraphernalia, substance use, medication patches, medical devices, ambient temperature,\nsocial indicators of neglect, carbon monoxide exposures, multiple casualties with same complaint\n\n### Treatment and Interventions\n\nOxygen [Refer to Universal Care Guideline]\nGlucose [Refer to Hypoglycemia Guideline or Hyperglycemia Guideline]\n\nGo To TOC\n\n#### General Medical\n\nRev. March 2022\n\nAltered Mental Status\n\n71\n---\n## NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n### Altered Mental Status\n\n3. Naloxone [Refer to Opioid Poisoning/Overdose Guideline]\n\n4. Restraint: physical and chemical [See Agitated or Violent Patient/Behavioral Emergency Guideline]\n\n5. Anti-dysrhythmic medication [See Cardiovascular Section for specific dysrhythmia guidelines]\n\n6. Active cooling or warming [See Hypothermia/Cold Exposure Guideline or Hyperthermia/Heat Exposure Guideline]\n\n7. IV fluids [See fluid administration doses in Shock Guideline and Hypoglycemia Guideline or Hyperglycemia Guideline]\n\n8. Vasopressors [See Shock Guideline]\n\n#### Patient Safety Considerations\n\n1. With depressed mental status, initial focus is on airway protection, oxygenation, ventilation, and perfusion\n\n2. The violent patient may need pharmacologic and/or physical management to insure proper assessment and treatment\n\n3. Hypoglycemic and hypoxic patients can be irritable and violent [See Agitated or Violent Patient/Behavioral Emergency Guideline]\n\n#### Notes/Educational Pearls\n\nKey Considerations\n\n1. History from bystanders and caregivers\n\n2. Age of the patient\n\n3. Development age and baseline functional status\n\n4.", "start_char_idx": 161605, "end_char_idx": 165338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61f7f586-3fbd-4224-9f4d-ee339ef1ba5a": {"__data__": {"id_": "61f7f586-3fbd-4224-9f4d-ee339ef1ba5a", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "937519ce-0dad-48f6-8445-232d1f32866e", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "acd97c76c3c0e91cf650e94dcfe6bb54ab3622b9eba9fddaad38c64ad897bcde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68d17695-6053-4a48-af47-35705201d333", "node_type": "1", "metadata": {}, "hash": "84be115e72020930bc26cef1f9934e9505e3be56245474e7500713ffd626f846", "class_name": "RelatedNodeInfo"}}, "text": "Active cooling or warming [See Hypothermia/Cold Exposure Guideline or Hyperthermia/Heat Exposure Guideline]\n\n7. IV fluids [See fluid administration doses in Shock Guideline and Hypoglycemia Guideline or Hyperglycemia Guideline]\n\n8. Vasopressors [See Shock Guideline]\n\n#### Patient Safety Considerations\n\n1. With depressed mental status, initial focus is on airway protection, oxygenation, ventilation, and perfusion\n\n2. The violent patient may need pharmacologic and/or physical management to insure proper assessment and treatment\n\n3. Hypoglycemic and hypoxic patients can be irritable and violent [See Agitated or Violent Patient/Behavioral Emergency Guideline]\n\n#### Notes/Educational Pearls\n\nKey Considerations\n\n1. History from bystanders and caregivers\n\n2. Age of the patient\n\n3. Development age and baseline functional status\n\n4. Consider the following differential using the mnemonic AEIOU-TIPS:\n\n|A \u2013 Alcohol, Abuse, Atypical migraine|E \u2013 Epilepsy, Electrolytes|\n|---|---|\n|I \u2013 Insulin (hypoglycemia)|O \u2013 Oxygen, Overdose|\n|U \u2013 Uremia (kidney failure)|T \u2013 Trauma, Tumor|\n|I \u2013 Infection|P \u2013 Psych, Poisoning|\n|S \u2013 Seizure, Subarachnoid hemorrhage, Sepsis|\n\n5. Environment where patient found\n\n6. Recent complaints (e.g., headache, chest pain, difficulty breathing, vomiting, fever)\n\n7. Medical alert tags and accessory medical devices\n\n8. Evaluate for reduced PO intake and/or vomiting and/or diarrhea or dehydration as a cause of AMS in the pediatric and geriatric populations\n\n9. Evidence of ingestion or topical placement (e.g., pill bottles/medications, patches, detergent pods)\n\n10. Medications a child may have access to including but not limited to (includes patches, drops, pills, injectables):\n\na. Analgesics\n\nb. Antidepressants\n\nc. Antihypertensives/Cardiac medications\n\nd. Oral hypoglycemic\n\n________________________\n\nGo To TOC\n\nGeneral Medical\n\nRev. March 2022\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n## Pertinent Assessment Findings\n\nTrack marks\nBreath odor\nSkin temperature\nRash and/or petechiae\nEvidence of trauma\nFocal neurologic changes\nLocation\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914113 \u2013 Medical - Altered Mental Status\n\n### Key Documentation Elements\n\nGlasgow Coma Score (GCS) or AVPU description\nBaseline developmental status and change from baseline\nTemperature was taken when able\nPatient and medic safety were considered\nPupil and neck exam were done\nEvaluation of perfusion and skin exam were performed\nIV fluids given for poor perfusion\n\n### Performance Measure\n\nHypoglycemia considered and treated appropriately\n\nBlood glucose level obtained\n\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nHypoglycemia\u201401: Treatment Administered for Hypoglycemia\n\nSepsis considered as a possible cause of hypotension\nHypotension appropriately treated\nNaloxone is used as therapeutic intervention, not a diagnostic tool\nCO detector is used when available\n\n## References\n\nFrisch A, Miller T, Haag A, Martin-Gill C, Guyette FX, Suffoletto BP. Diagnostic accuracy of a rapid checklist to identify delirium in older patients transported by EMS. Prehosp Emerg Care, 2013 Apr-Jun; 17(2): 230\u20134\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022 Altered Mental Status 73\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n2. Kumar A, Roberts D et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med, 2006 Jun; 34(6): 1,589\u201396\n\n3. Leong LB, Jian KH, Vasu A, Seow E. Prospective study of patients with altered mental status: clinical features and outcome. Int J Emerg Med, 2008 Sep; 1(3): 179\u201382\n\n4.", "start_char_idx": 164503, "end_char_idx": 168346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68d17695-6053-4a48-af47-35705201d333": {"__data__": {"id_": "68d17695-6053-4a48-af47-35705201d333", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61f7f586-3fbd-4224-9f4d-ee339ef1ba5a", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "c8b79b0f066e4a07c584ec38d96a59178a4f25a5cad1c907cce6426e123819dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d3f64cc-bd9f-4fd3-a1b9-3a10ed44b518", "node_type": "1", "metadata": {}, "hash": "eab153dd9b29acdc4b568a8c4fc51102f048abf56175a3ab9b9075d616a9dffa", "class_name": "RelatedNodeInfo"}}, "text": "Prehosp Emerg Care, 2013 Apr-Jun; 17(2): 230\u20134\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022 Altered Mental Status 73\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n2. Kumar A, Roberts D et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med, 2006 Jun; 34(6): 1,589\u201396\n\n3. Leong LB, Jian KH, Vasu A, Seow E. Prospective study of patients with altered mental status: clinical features and outcome. Int J Emerg Med, 2008 Sep; 1(3): 179\u201382\n\n4. Sanello A, Gausche-Hill M, Mulkerin W, Sporer KA, Brown JF, Koenig KL, Rudnick EM, Salvucci AA, Gilbert GH. Altered mental status: Current evidenced-based guidelines for prehospital care. West J Emerg Med 2018;19(3):527\u2013541\n\n5. Thomas AA, Mazor S. Unintentional marijuana exposure presenting as altered mental status in the pediatric emergency department: A case series. J Emerg Med. 2017 Dec;53(6): e119\u2013e123. Pediatric Education for Prehospital Professionals, Fourth Edition; https://www.peppsite.com. Accessed March 11, 2022\n\nRevision Date\n\nMarch 11, 2022\n\n________________________\n\nGo To TOC\n\nGeneral Medical\n\nRev. March 2022\n\nAltered Mental Status\n\n74\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Back Pain\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nImprove patient discomfort\nIdentify life-threatening causes of back pain\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nBack pain or discomfort related to a non-traumatic cause\n\n#### Exclusion Criteria\n\nBack pain from spinal trauma [See Trauma Section]\nBack pain due to sickle cell pain crisis [See Sickle Cell Pain Crisis Guideline]\nBack pain from suspected labor [See OB/GYN Section]\n\n### Patient Management\n\n#### Assessment\n\nPerform airway assessment and management, per the Airway Management Guideline\nObtain vital signs including pulse, blood pressure, respiratory rate, neurologic status assessment, pulse oximetry,\ntemperature\nProvide evaluation and management of pain, per the Pain Management Guideline\nObtain vascular access as necessary to provide analgesia and/or fluid resuscitation\nAssess for life-threatening causes of back pain, which may include:\n\nSpinal cord compression (e.g., from spinal epidural abscess, malignancy, spinal epidural hematoma for patients\non anticoagulants)\n\nUrinary and/or bowel incontinence\nInability to walk due to weakness\nNew neurologic deficits in extremities\nLoss of sensation in saddle distribution\n\nAortic dissection or ruptured abdominal aortic aneurysm\n\nUnequal femoral or distal lower extremity pulses\n\u201cPulsatile\u201d abdominal mass\nAssociated abdominal pain and/or chest pain\nKnown history of abdominal aortic aneurysm or dissection\n\nPyelonephritis\n\nFever\nNausea, vomiting\nUrinary frequency/urgency\nDysuria\nHematuria\nAbdominal pain\nCostovertebral angle tenderness to percussion\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022\n\nBack Pain 75\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Assessment and Treatment\n\n6. Assess for signs of shock. If shock is present, provide treatment per appropriate Shock Guideline\n\n7. Assess for other non-life-threatening causes of back pain\n\na. Kidney stone\n\ni. Unilateral flank pain\nii. Nausea, vomiting\niii. Possible hematuria\niv. History of kidney stones\n\n### Treatment and Interventions\n\n1. Medication Administration\n\na. Provide analgesia, per Pain Management Guideline\nb. Administer antiemetics, per Nausea-Vomiting Guideline\nc. Provide transport to an appropriate receiving facility.", "start_char_idx": 167750, "end_char_idx": 171366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d3f64cc-bd9f-4fd3-a1b9-3a10ed44b518": {"__data__": {"id_": "0d3f64cc-bd9f-4fd3-a1b9-3a10ed44b518", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68d17695-6053-4a48-af47-35705201d333", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "94128a4ebe9608705183b4f278fdbffc55cd6416e22e357e4391bf7e92ba5844", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9be33f89-e3d7-44cc-a1dc-67347895e4c1", "node_type": "1", "metadata": {}, "hash": "4846574f06279fbe872bf1ae45c4ad82cdf3f9954cc258cdf5b58820585f6f3f", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nBack Pain 75\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Assessment and Treatment\n\n6. Assess for signs of shock. If shock is present, provide treatment per appropriate Shock Guideline\n\n7. Assess for other non-life-threatening causes of back pain\n\na. Kidney stone\n\ni. Unilateral flank pain\nii. Nausea, vomiting\niii. Possible hematuria\niv. History of kidney stones\n\n### Treatment and Interventions\n\n1. Medication Administration\n\na. Provide analgesia, per Pain Management Guideline\nb. Administer antiemetics, per Nausea-Vomiting Guideline\nc. Provide transport to an appropriate receiving facility. Consider specialty destination centers for conditions such as suspected aortic emergency\nd. Reassess vital signs and response to therapeutic interventions throughout transport\n\n### Patient Safety Considerations\n\nNone noted\n\n### Notes/Educational Pearls\n\nKey Considerations\n\nAssess for life-threatening causes of back pain\nProvide appropriate treatment for pain, vomiting, and shock\nConsider transport to appropriate specialty center if aortic emergency suspected\nBack and abdominal pain can often coexist with similar disease processes\nIdentify patients on anticoagulants since they are higher risk for spinal epidural hematoma or retroperitoneal hemorrhage which can present as back pain\nIdentify patients with intravenous drug abuse (IVDA) history and/or impaired immune system since they are higher risk for spinal epidural abscess\nIdentify patients with a history of cancer or with one suspicious for cancer \u2013 spinal metastases can cause spinal cord compression\nIdentify older adults or patients with prolonged use of corticosteroids at risk for vertebral body compression fracture\n\n### Pertinent Assessment Findings\n\nMidline back tenderness\nBack erythema or swelling\nMotor and/or sensory loss in arms or legs\nLoss of perianal sensation\nAbsence of or significant inequality of femoral or distal arterial pulses in lower extremities\nHyper or hypothermia\nRectal bleeding or hematemesis\n\n________________________\n\nGo To TOC\n\nGeneral Medical\n\nRev. March 2022\n\nBack Pain\n\n76\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914051 \u2013 General - Back Pain\n\n### Key Documentation Elements\n\nAssessment of back and abdomen to include findings on palpation/percussion including presence or absence of masses and presence and nature of tenderness/pain\nAssesses initial and changes in neurologic status\nAssesses initial and changes in perfusion/pulses\n\n### Performance Measures\n\nAssessment for life-threatening etiology\nMitigation of pain, per the Pain Management Guideline\n\n### References\n\nNone noted\n\n### Revision Date\n\nMarch 11, 2022\n\nGo To TOC\n\n## General Medical\n\nBack Pain\n\nRev. March 2022\n\n77\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### End-of-Life Care/Hospice Care\n\n#### Aliases\n\nNone noted\n\n#### Patient Care Goals\n\nWhen providing care for a patient near end-of-life:\n\nProvide relief from pain and other distressing symptoms\nAffirm dying as a normal process\nIntegrate psychological and spiritual aspects of patient care\nOffer a support system to help the family cope during the patient\u2019s illness and in their own bereavement\n\n#### Patient Presentation\n\n##### Inclusion Criteria\n\nPatients enrolled in hospice or end-of-life care, or who have advance care directives, experiencing complaints related to the illness for which the patient is receiving those services\n\n##### Exclusion Criteria\n\nComplaints unrelated to the illness for which the patient is receiving those services\n\n#### Patient Management\n\n##### Assessment, Treatment, and Interventions\n\nPerform general patient management\nEngage with the patient\u2019s hospice or end-of-life care team or their primary care physician if possible.", "start_char_idx": 170730, "end_char_idx": 174635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9be33f89-e3d7-44cc-a1dc-67347895e4c1": {"__data__": {"id_": "9be33f89-e3d7-44cc-a1dc-67347895e4c1", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d3f64cc-bd9f-4fd3-a1b9-3a10ed44b518", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "5ed4c2b582c2a4b5027a807c86e4bef0ba1a53b014ae91a4eaf57a43b2685c27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91d2c834-1bb8-459b-a791-c98887609019", "node_type": "1", "metadata": {}, "hash": "da7576b5914997feab249bbc2ec8f6d5a5cabe12f555a6f10f726fda135179e7", "class_name": "RelatedNodeInfo"}}, "text": "If not a viable option, contact medical direction\nIf the patient can communicate and has the capacity to make decisions regarding treatment and transport, consult directly with the patient before treatment and/or transport\nIf the patient lacks the capacity to make decisions regarding treatment and/or transport, identify any advanced care planning in place for information relating to advanced care planning and consent for treatment\n\nAdvance directives\nMedical/Physician Order for Life-Sustaining Treatment (MOLST/POLST) or similar directing forms\nGuardian, power of attorney, or other accepted healthcare proxy\n\nIf the patient requires pain relief See Pain Management Guideline\n\nOpioid medications are frequently the most appropriate choices for pain management\nMultimodal analgesia may be required for pain relief\nDo not withhold opioids for fear of respiratory depression as patient comfort is the primary goal for hospice and end-of-life care\n\nIf the patient is experiencing severe respiratory distress, consider:\n\nOxygen and bedside/handheld fan\nNoninvasive ventilation (BiPAP/CPAP) if aligned with patient care goals\nOpioids are the drug of choice for dyspnea for hospice and end-of-life care. Morphine 1\u20135\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022\n\nEnd-of-Life Care/Hospice Care 78\n---\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n### End-of-Life Care/Hospice Care\n\na. Analgesia for pain, consider morphine 2.5-5 mg IV, IM or SQ initially and repeat as needed. If symptoms are unrelieved, follow written hospice orders or contact medical direction for additional doses to administer\n\nb. Anxiolytic if needed for anxiety, lorazepam 1 mg SL (pediatric 0.1 mg/kg) If not avail, consider the administration of diazepam or midazolam.\n\n7. If the patient has nausea [See Nausea-Vomiting Guideline]\n\n8. If the patient has excessive secretions or aspiration, provide suctioning\n\n9. If the patient is anxious or has delirium, in addition to nonpharmacologic interventions such as creating a quiet environment, frequent reassurance, touch and verbal orientation, consider:\n\na. Benzodiazepines (diazepam, lorazepam, midazolam)\n\nb. Haloperidol 5 mg PO/IM/IV (pediatric: 0.5-1 mg)\n\nc. Ziprasidone 20 mg IM (pediatric 5 years old or older 0.2 mg/kg IM\n\n10. If the patient appears dehydrated\n\na. Encourage PO fluid intake if patient can swallow\n\nb. If available, offer ice chips and swabs soaked in ice water\n\nc. Consider administration of normal saline at 10\u201320 mL/kg IV\n\n11. In collaboration with hospice or end-of-life care clinician, coordinate with guardian, power of attorney, or other accepted healthcare proxy if non-transport is considered\n\n#### Patient Safety Considerations\n\n1. Careful and thorough assessments should be performed to identify complaints not related to the illness for which the patient is receiving hospice or end-of-life care\n\n2. Care should be delivered with the utmost patience and compassion\n\n#### Notes/Educational Pearls\n\nKey Considerations\n\n1. Social interactions with family may affect end-of-life care\n\n2. Scene safety should be considered when deciding on management\n\n#### Pertinent Assessment Findings\n\n1. Vital signs\n\n2. Pain score\n\n3. Neurologic exam\n\n4. Lung sounds\n\n#### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914169 \u2013 Cardiac Arrest - Do Not Resuscitate\n9914171 \u2013 Cardiac Arrest - Special Resuscitation Orders\n9914177 \u2013 General - Exception Protocol\n\nKey Documentation Elements\n\nInteraction with hospice or end-of-life care clinician\nConfirmation of advanced directive or other advanced care documentation\n\n________________________\n\nGo To TOC\n\nGeneral Medical\n\nEnd-of-Life Care/Hospice Care\n\nRev. March 2022\n\n79\n---\nNASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\nPain score if applicable\n\n## Performance Measures\n\nIf patient in pain, pain score change\nIf patient is nauseated, symptom relief\nIf patient is dehydrated, symptom relief or vital sign change\n\n## References\n\nCoyne PJ, Viswanathan R, Smith TJ. Nebulized fentanyl citrate improves patients' perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Manage.", "start_char_idx": 174636, "end_char_idx": 178861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91d2c834-1bb8-459b-a791-c98887609019": {"__data__": {"id_": "91d2c834-1bb8-459b-a791-c98887609019", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9be33f89-e3d7-44cc-a1dc-67347895e4c1", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "4f2d381e9243974f3819e6bb13cb4dde14e698fea85ffda1a3d252737bad3ea9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d16802c4-9be4-46da-9d90-7b95036ad451", "node_type": "1", "metadata": {}, "hash": "080afd79646645367c601b917af2706efb6645e914acb61e42a132e58d9725ba", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n79\n---\nNASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\nPain score if applicable\n\n## Performance Measures\n\nIf patient in pain, pain score change\nIf patient is nauseated, symptom relief\nIf patient is dehydrated, symptom relief or vital sign change\n\n## References\n\nCoyne PJ, Viswanathan R, Smith TJ. Nebulized fentanyl citrate improves patients' perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Manage. 2002;23(2):157\u201360\nFarahmand S, Shiralizadeh S, Talebian MT, et al. Nebulized fentanyl vs intravenous morphine for ED patients with acute limb pain: a randomized clinical trial. Am J Emerg Med. 2014;32(9):1011\u20135\nPortenoy RK, Mehta Z, Ahmed E. Cancer pain management with opioids: Optimizing analgesia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com/contents/cancer-pain-management-with-opioids-optimizing-analgesia. Accessed March 11, 2022\nPrehospital Evidence Based Practice Program (PEP) [Internet]. Halifax, Nova Scotia: Dalhousie University - Division of Emergency Medical Services https://emspep.cdha.nshealth.ca. Accessed March 11, 2022\nShirk MB, Donahue KR, Shirvai J. Unlabeled uses of nebulized medications. Am J Health Syst Pharm. 2006;63(18):1704\u201316\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022\n\nEnd-of-Life Care/Hospice Care 80\n---\n# NASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Hyperglycemia\n\n### Aliases\n\nDiabetes\n\nDiabetic ketoacidosis (DKA)\n\nHyperosmolar hyperglycemic state (HHS)\n\n### Patient Care Goals\n\nLimit morbidity from hyperglycemia by:\n\nAppropriate use of glucose monitoring\nAppropriate hydration for hyperglycemia\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nAdult or pediatric patient with altered level of consciousness [See Altered Mental Status Guideline]\nAdult or pediatric patient with stroke symptoms (e.g., hemiparesis, dysarthria) [See Suspected Stroke/Transient\nIschemic Attack Guideline]\nAdult or pediatric patient with seizure [See Seizures Guideline]\nAdult or pediatric patient with symptoms of hyperglycemia (e.g., polyuria, polydipsia, weakness, dizziness,\nabdominal pain, tachypnea)\nAdult or pediatric patient with history of diabetes and other medical symptoms\n\n#### Exclusion Criteria\n\nPatient in cardiac arrest\n\n### Patient Management\n\n#### Assessment\n\nMonitoring:\n\nCheck blood glucose level\n\nSecondary survey pertinent to altered blood glucose level:\n\nConstitutional: assess for tachycardia, hypotension, and tachypnea\nEyes: assess for sunken eyes from dehydration\nNose/mouth/ears: assess for dry mucous membranes or tongue bite from seizure\nAbdominal pain including nausea and vomiting especially in children\nNeurologic:\n\nAssess Glasgow Coma Score (GCS) and mental status\nAssess for focal neurologic deficit: motor and sensory\n\nEvaluate for possible concomitant sepsis and septic shock [See Shock Guideline]\nObtain 12-lead EKG to assess for findings consistent with hyperkalemia or acute coronary syndrome\n\n#### Treatment and Interventions\n\nIf altered level of consciousness, stroke, or sepsis/septic shock, treat per Altered Mental Status Guideline,\nSuspected Stroke/Transient Ischemic Attack Guideline, or Shock Guideline accordingly\nIf glucose greater than 250 mg/dL with symptoms of dehydration, vomiting, abdominal pain, or altered level of\nconsciousness:\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022\n\nHyperglycemia 81\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\na. Provide volume expansion with normal saline bolus\n\ni. Adult: Normal saline 20 mL/kg at rate of 1000 mL/hr; if symptoms of hypovolemic shock, follow Shock Guideline.\n\nii.", "start_char_idx": 178392, "end_char_idx": 182119, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d16802c4-9be4-46da-9d90-7b95036ad451": {"__data__": {"id_": "d16802c4-9be4-46da-9d90-7b95036ad451", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91d2c834-1bb8-459b-a791-c98887609019", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "61d46d44102569cb4b45e4d06e93adabce5ac7e81d5ca23a88d81d3e24a49323", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a0fd09c-bdda-4bd5-90a5-c829def51fda", "node_type": "1", "metadata": {}, "hash": "5e784e5a345391a435e1936d92daa4fb1a807a631b788288e548fc100301078c", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nHyperglycemia 81\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\na. Provide volume expansion with normal saline bolus\n\ni. Adult: Normal saline 20 mL/kg at rate of 1000 mL/hr; if symptoms of hypovolemic shock, follow Shock Guideline.\n\nii. Pediatric: Normal saline 10 mL/kg bolus IV, reassess, and repeat up to 40 mL/kg total; if symptoms of hypovolemic\nshock, follow Shock Guideline.\n\n3. If findings of hyperkalemia are present, administer IV fluids and consider administration of:\n\na. Calcium chloride: 1 gm IV/IO over 5 minutes, ensure IV patency and do not exceed 1 mL per minute\n\nOR\n\nb. Calcium gluconate: 2 gm IV/IO over 5 minutes, with constant cardiac monitoring\n\n4. If findings of hyperkalemia, consider administration of sodium bicarbonate 1 mEq/kg (max dose of 50 mEq) IV bolus\nover 5 minutes and consider albuterol 5 mg via nebulizer (can be repeated if no response is seen) to the two places\nin the document where the administration of albuterol is suggested for the treatment of hyperkalemia\n\n5. Reassess patient\n\na. Reassess vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment), mental status, and\nsigns of dehydration\n\nb. If mental status changes, reassess blood glucose level and provide appropriate treatment if hypoglycemia has\ndeveloped\n\n6. Disposition\n\na. Transport to closest appropriate receiving facility\n\nPatient Safety Considerations\n\n1. Overly aggressive administration of fluid in hyperglycemic patients may cause cerebral edema or dangerous\nhyponatremia. Cerebral edema is a leading cause of death in children with DKA but is very rare in adults\n\na. Closely monitor for signs of altered mental status, increased intracranial pressure, and immediately discontinue\nIV fluids and elevate head of bed if signs of increased ICP develop\n\nb. Reassess and manage airway as needed\n\n2. Asymptomatic hyperglycemia poses no risk to the patient while inappropriately aggressive interventions to manage\nblood sugar may harm patients\n\nNotes/Educational Pearls\n\nKey Considerations\n\n1. New onset DKA in pediatric patients commonly presents with nausea, vomiting, abdominal pain, and/or urinary\nfrequency\n\n2. Consider causes for hyperglycemia by thinking about the 3 I\u2019s:\n\na. Insulin: This refers to any medication changes for insulin or oral medications including poor compliance or\nmalfunctioning insulin pump\n\nb. Ischemia: This refers to hyperglycemia sometimes being an indication of physiologic stress in a patient and can\nbe a clue to myocardial ischemia in particular\n\nc. Infection: Underlying infection can cause derangements in glucose control\n\nPertinent Assessment Findings\n\n1. Concomitant trauma\n\n2. Abdominal pain, \u201cfruity breath,\u201d and rapid-deep respirations (Kussmaul respirations) may\n\n________________________\n\nGo To TOC\n\nGeneral Medical\n\nRev. March 2022\n\nHyperglycemia\n\n82\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Hyperglycemia\n\nQuality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914121 \u2013 Medical - Hyperglycemia\n\nKey Documentation Elements\n\nDocument reassessment of vital signs and mental status after administration of IV fluids\nDocument glucose level (if in scope of practice) when indicated\n\nPerformance Measures\n\nWhen in scope of practice, point of care blood glucose checked for all patients with symptoms of altered level of consciousness, seizure, stroke, or hyperglycemia\nWhen hyperglycemia documented, appropriate volume replacement given while avoiding overzealous repletion before insulin therapy at receiving center\n12-lead EKG obtained\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nPediatrics\u201403: Documentation of Estimated Weight in Kilograms\n\nReferences\n\nCorwell B, Knight B, Olivieri L, Willis GC. Current diagnosis and treatment of hyperglycemic emergencies. Emerg Med Clin North Am. 2014;32(2):437\u201352\nDesachy A, Vuagnat AC, Ghazali AD, et al.", "start_char_idx": 181837, "end_char_idx": 185860, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a0fd09c-bdda-4bd5-90a5-c829def51fda": {"__data__": {"id_": "1a0fd09c-bdda-4bd5-90a5-c829def51fda", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d16802c4-9be4-46da-9d90-7b95036ad451", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "2aec09ef2240a9417ca352aaad69e8856456395e4193461fe4f6adf1eca3b228", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "690b7103-f38e-46da-8511-f9e7835a084c", "node_type": "1", "metadata": {}, "hash": "4893b37d5f6bc4873393883fdbbd05ed854c8d1c8746eb8787afe09f0d6d0a0a", "class_name": "RelatedNodeInfo"}}, "text": "Current diagnosis and treatment of hyperglycemic emergencies. Emerg Med Clin North Am. 2014;32(2):437\u201352\nDesachy A, Vuagnat AC, Ghazali AD, et al. Accuracy of bedside glucometry in critically ill patients: influence of clinical characteristics and perfusion index. Mayo Clin Proc. 2008;83(4):400\u20135\nFunk DL, Chan L, Lutz N, Verdile VP. Comparison of capillary and venous glucose measurements in healthy volunteers. Prehosp Emerg Care. 2001;5(3):275\u20137\nHolstein A, Kuhne D, Elsing HG, et al. Practicality and accuracy of prehospital rapid venous blood glucose determination. Am J Emerg Med. 2000;18(6):690\u20134\nHolstein A, Plaschke A, Vogel MY, Egberts EH. Prehospital management of diabetic emergencies \u2013 a population\u2013based intervention study. Acta Anaesthesiol Scand. 2003;47(5):610\u20135\nJones JL, Ray VG, Gough JE, Garrison HG, Whitley TW. Determination of prehospital blood glucose: a prospective, controlled study. J Emerg Med. 1992;10(6):679\u201382\nKitabchi AE, Umpierrez GE, Miles JM, et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335\u201343\nKulkarni A, Saxena M, Price G., et al. Analysis of blood glucose measurements using capillary and arterial blood samples in intensive care patients. Intensive Care Med. 2005; 31:142\nKumar G, Sng BL, Kumar S. Correlation of capillary and venous glucometry with laboratory determination. Prehosp Emerg Care. 2004;8(4):378\u201383\nRoberts K, Smith A. Outcome of diabetic patients treated in the prehospital arena after a hypoglycemic episode, and an exploration of treat and release protocols: a review of the literature. Emerg J Med. 2003;20(3):274\u20136\n\nRevision Date\n\nMarch 11, 2022\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022\n---\n# NASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Hypoglycemia\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nLimit morbidity from hypoglycemia by:\n\nDescribing appropriate use of glucose monitoring\nTreating symptomatic hypoglycemia\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nPatients with blood glucose less than 60 mg/dL with symptoms of hypoglycemia\nPatients with altered level of consciousness [See Altered Mental Status Guideline]\nPatients with stroke symptoms (e.g., hemiparesis, dysarthria) [See Suspected Stroke/Transient Ischemic Attack\nGuideline]\nPatients with seizure [See Seizures Guideline]\nPatients with history of diabetes and other medical symptoms\nPatients with suspected alcohol ingestion\nPatients with metabolic disorders (glycogen storage disease, fatty oxidation or organic acid disorders, maple\nsyrup urine disease)\nPatients who appear to be intoxicated\n\n#### Exclusion Criteria\n\nPatient in cardiac arrest\n\nPatient with normal mental status in absence of inclusion criteria listed above\n\n### Patient Management\n\n#### Assessment\n\nMonitoring:\n\nCheck blood glucose level\n\nSecondary survey pertinent to altered blood glucose level:\n\nEvaluate for presence of an automated external insulin delivery device (insulin pump)\nConstitutional: assess for tachycardia and hypotension\nEyes: assess for sunken eyes from dehydration\nNose/mouth/ears: assess for dry mucous membranes or tongue bite from seizure\nNeurologic:\n\nAssess GCS and mental status\nAssess for focal neurologic deficit: motor and sensory\n\n#### Treatment and Interventions\n\nIf altered level of consciousness or stroke, treat per Altered Mental Status Guideline or Suspected Stroke/Transient\nIschemic Attack Guideline accordingly\nIf blood glucose is 60 mg/dL or less administer one of the following:\n\nConscious patient with a patent airway:\n\n________________________\n\nGo To TOC\n\nGeneral Medical\n\nRev. March 2022\n\nHypoglycemia\n\n84\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\ni. Glucose, oral (in form of glucose tablets, glucose gel, tube of cake icing, etc.)\n\n1.", "start_char_idx": 185714, "end_char_idx": 189536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "690b7103-f38e-46da-8511-f9e7835a084c": {"__data__": {"id_": "690b7103-f38e-46da-8511-f9e7835a084c", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a0fd09c-bdda-4bd5-90a5-c829def51fda", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "ddeadd2572bca6f0be83d400403480a925fe866f347a73efd5702d5e066d5752", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acb4dec0-79a4-454e-9289-7cdfd94ceb21", "node_type": "1", "metadata": {}, "hash": "1424a5c7c63374f12303db49214bd68faba5973c3d057e8161a3ae65db735f86", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nHypoglycemia\n\n84\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\ni. Glucose, oral (in form of glucose tablets, glucose gel, tube of cake icing, etc.)\n\n1. Adult Dosing: 25 g\n\n2. Pediatric Dosing: 0.5\u20131 g/kg\n\nb. Unconscious patient, or patients who are unable to protect their own airway:\n\ni. Dextrose IV \u2013 administer in incremental doses until mental status improves or maximum field dosing is reached (if available, D10% is preferred)\n\n1. Maximum field adult dosing: 25 g of 10\u201350% dextrose IV\n\na. 50 mL of 50% dextrose\n\nb. 100 mL of 25% dextrose\n\nc. 250 mL of 10% dextrose\n\n2. Maximum field pediatric dosing: 0.5\u20131 g/kg of 10\u201325% dextrose IV\n\na. 2\u20134 mL/kg of 25% dextrose for those greater than 8 years old\n\nb. 5\u201310 mL/kg of 10% dextrose (newborns 2 mL/kg)\n\nii. Glucagon IM/IN \u2013 an option for patients for whom IV access cannot be established\n\n1. Adult dosing: 1 mg IM/IN (or prefilled 3 mg dry powder IN or prefilled IM autoinjector)\n\n2. Pediatric dosing:\n\na. 1 mg IM/IN if \u2265 20 kg (or \u2265 5 years old (or prefilled 4 mg dry powder IN for patients greater than 4 years old or prefilled IM autoinjector)\n\nb. 0.5 mg IM/IN if less than 20 kg (or less than 5 years old)\n\niii. Remove or disable insulin pump if above treatments cannot be completed\n\na. For patients with an insulin pump who are hypoglycemic with associated altered mental status (GCS less than 15):\n\ni. Stop the pump, disconnect, or remove at insertion site if patient cannot ingest oral glucose or ALS is not available\n\nii. Leave the pump connected and running if able to ingest oral glucose or receive ALS interventions\n\n2. Reassess patient\n\na. Reassess vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment) and mental status\n\nb. Repeat check of blood glucose level if previous hypoglycemia and mental status has not returned to normal\n\ni. It is not necessary to repeat check of blood glucose level blood sugar if mental status has returned to normal\n\nc. If maximal field dosage of dextrose solution does not achieve euglycemia and normalization of mental status:\n\ni. Initiate transport to closest appropriate receiving facility for further treatment of refractory hypoglycemia\n\nii. Evaluate for alternative causes of altered mental status\n\niii. Continue treatment of hypoglycemia using dextrose solutions as noted above\n\n3. Disposition\n\na. If hypoglycemia with continued symptoms, transport to closest appropriate receiving facility\n\nb. Hypoglycemic patients who have had a seizure should be transported to the hospital regardless of their mental status and response to therapy\n\nc. If symptoms of hypoglycemia resolve after treatment, release without transport should only be considered if all the following are true:\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022\n\nHypoglycemia 85\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Criteria for Refusing Transport\n\nRepeat glucose is greater than 80 mg/dL\nPatient takes insulin or metformin to control diabetes and does not take long-acting oral sulphunylurea agents (e.g., glipizide, glyburide, or others)\nPatient returns to normal mental status, with no focal neurologic signs/symptoms after receiving glucose/dextrose\nPatient can promptly obtain and will eat a carbohydrate meal\nPatient or legal guardian refuses transport and EMS clinicians agree transport not indicated\nA reliable adult will be staying with the patient\nNo major co-morbid symptoms exist, like chest pain, shortness of breath, seizures, intoxication\nA clear cause of the hypoglycemia is identified (e.g., missed meal)\n\n### Patient Safety Considerations\n\nDextrose 10% can be safely used in all ages of patient.", "start_char_idx": 189338, "end_char_idx": 193063, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acb4dec0-79a4-454e-9289-7cdfd94ceb21": {"__data__": {"id_": "acb4dec0-79a4-454e-9289-7cdfd94ceb21", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "690b7103-f38e-46da-8511-f9e7835a084c", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "5821d285f56d82f2924ac6cd49f36abd78d79b8ed7aa2d0a157819dd9b4eff88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30f154ac-54d0-457c-af30-6373dace70ba", "node_type": "1", "metadata": {}, "hash": "8c66516a026949a20f4de512d65da93b1ae6fb3d4d90f81699fb178a7b2938bf", "class_name": "RelatedNodeInfo"}}, "text": "Dextrose 10% works as effectively and quickly as other concentrations\nDextrose 50% can cause local tissue damage if it extravasates from vein and may cause hyperglycemia. Dextrose 50% carries risk for little clinical gain. EMS systems may consider carrying no more than 25% concentration of dextrose for treating hypoglycemia in adults\nFor children less than 8 years old, dextrose concentration of no more than 25% should be used\nFor neonates and infants less than 1 month of age, dextrose concentration of no more than 10\u201312.5% should be used\nSulfonylureas (e.g., glyburide, glipizide) have long half-lives ranging from 12\u201360 hrs. Patients with corrected hypoglycemia who are taking these agents are at particular risk for recurrent symptoms and frequently require hospital admission\n\n### Notes/Educational Pearls\n\nA formula for calculating a 0.5 g/kg dose of IV dextrose:\n\n(____% concentration of glucose) x (_____mL/kg) = 50\n\nFor example:\n\n|Desired Dose|Fluid type|mL of fluid Dose|\n|---|---|---|\n|0.5 g/kg|25% dextrose|2mL/kg|\n| |10% dextrose|5mL/kg|\n|1 g/kg|25% dextrose|4mL/kg|\n| |10% dextrose|10mL/kg|\n\n### Key Considerations\n\nUsing 10% dextrose is as effective and safer than other stronger concentrations\nConsider contribution of oral diabetic medications to hypoglycemia\nIf possible, have family/patient turn off insulin pump\nConsider potential for intentional overdose of hypoglycemic agents\nAvoid overshoot hyperglycemia when correcting hypoglycemia. Administer dextrose-containing IV fluids in small doses until either mental status improves or a maximum field dose is achieved\n\n________________________\n\nGo To TOC\n\nGeneral Medical\n\nRev. March 2022\n\nHypoglycemia\n\n86\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n## Pertinent Assessment Findings\n\nConcomitant trauma\nDiaphoresis or hypothermia may be associated with hypoglycemia\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914125 \u2013 Medical - Hypoglycemia/Diabetic Emergency\n\n## Key Documentation Elements\n\nDocument reassessment of vital signs and mental status after administration of glucose/dextrose/glucagon\nDocument point of care glucose level (if in scope of practice) when indicated\n\n## Performance Measures\n\nWhen in scope of practice, blood glucose is checked for all patients with symptoms of altered level of consciousness, seizure, stroke, or hypoglycemia\nIf patient released at scene, criteria documented for safe release\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nHypoglycemia\u201401: Treatment Administered for Hypoglycemia\nPediatrics\u201403: Documentation of Estimated Weight in Kilograms\n\n## References\n\nA review of the efficiency of 10% dextrose as an alternative to high concentration glucose in the treatment of out-of-hospital hypoglycemia. J Emerg Prim Health Care. 2009;7(3):990341\nDesachy A, Vuagnat AC, Ghazali AD, et al. Accuracy of bedside glucometry in critically ill patients: influence of clinical characteristics and perfusion index. Mayo Clin Proc. 2008;83(4):400\u20135\nFunk DL, Chan L, Lutz N, Verdile VP. Comparison of capillary and venous glucose measurements in healthy volunteers. Prehosp Emerg Care. 2001;5(3):275\u20137\nHern HG, Kiefer M, Louie D, Barger J, Alter HJ. D10 in the treatment of prehospital hypoglycemia: a 24-month observational cohort study. Prehosp Emerg Care. 2017;21(1):63\u20137\nHolstein A, Kuhne D, Elsing HG, et al. Practicality and accuracy of prehospital rapid venous blood glucose determination. Am J Emerg Med. 2000;18(6):690\u20134\nHolstein A, Plaschke A, Vogel MY, Egberts EH.", "start_char_idx": 193064, "end_char_idx": 196714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30f154ac-54d0-457c-af30-6373dace70ba": {"__data__": {"id_": "30f154ac-54d0-457c-af30-6373dace70ba", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acb4dec0-79a4-454e-9289-7cdfd94ceb21", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "81f0c026b193f7f566c6c2a5c8ec9ea1b06d4308402c9ebcd74a7c6545b5437e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a4be7fb-c4e3-4b91-bf58-ffbb5cd7248d", "node_type": "1", "metadata": {}, "hash": "3b07a398340e220979f8f10500714ba651ce2dfc26d571d0423629691fa23e2f", "class_name": "RelatedNodeInfo"}}, "text": "2008;83(4):400\u20135\nFunk DL, Chan L, Lutz N, Verdile VP. Comparison of capillary and venous glucose measurements in healthy volunteers. Prehosp Emerg Care. 2001;5(3):275\u20137\nHern HG, Kiefer M, Louie D, Barger J, Alter HJ. D10 in the treatment of prehospital hypoglycemia: a 24-month observational cohort study. Prehosp Emerg Care. 2017;21(1):63\u20137\nHolstein A, Kuhne D, Elsing HG, et al. Practicality and accuracy of prehospital rapid venous blood glucose determination. Am J Emerg Med. 2000;18(6):690\u20134\nHolstein A, Plaschke A, Vogel MY, Egberts EH. Prehospital management of diabetic emergencies \u2013 a population-based intervention study. Acta Anaesthesiol Scand. 2003;47(5):610\u20135\nJones JL, Ray VG, Gough JE, Garrison HG, Whitley TW. Determination of prehospital blood glucose: a prospective, controlled study. J Emerg Med. 1992;10(6):679\u201382\nKulkarni A, Saxena M, Price G, O'Leary MJ, Jacques T, Myburgh JA. Analysis of blood glucose measurements using capillary and arterial blood samples in intensive care patients. Intensive Care Med. 2005;31(1):142\u20135\nKumar G, Sng BL, Kumar S. Correlation of capillary and venous glucometry with laboratory determination. Prehosp Emerg Care. 2004;8(4):378\u201383\nMoore C, Woollard M. Dextrose 10% or 50% in the treatment of hypoglycaemia out of hospital? a randomized controlled trial. Emerg Med J. 2005; 22:512\u20135\n\n________________________Go To TOC\n\nGeneral Medical Rev. March 2022\n\nHypoglycemia 87\n---\nNASEMSO\n\nNASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n11. Roberts K, Smith A. Outcome of diabetic patients treated in the prehospital arena after a hypoglycemic episode, and an exploration of treat and release protocols: a review of the literature. Emerg J Med. 2003;20(3):274\u20136\n\n12. Vilke GM, Castillo EM, Ray LU, Murrin PA, Chan TC. Evaluation of pediatric glucose monitoring and hypoglycemic therapy in the field. Pediatr Emerg Care. 2005;21(1):1\u20135\n\nRevision Date March 11, 2022\n\nGo To TOC\n\n## General Medical\n\nRev.", "start_char_idx": 196172, "end_char_idx": 198136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a4be7fb-c4e3-4b91-bf58-ffbb5cd7248d": {"__data__": {"id_": "6a4be7fb-c4e3-4b91-bf58-ffbb5cd7248d", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30f154ac-54d0-457c-af30-6373dace70ba", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "f99e81427a65994110beb99117e51a40a7f7a6d008973b9fbbc3b6f1a677ee51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "961e12af-4d2f-4f75-8018-8e3ababf2bd7", "node_type": "1", "metadata": {}, "hash": "80161bf65736a0a4f9f553448e48e75922a8c2af4a3190b477f24a199af98812", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nHypoglycemia 87\n---\nNASEMSO\n\nNASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n11. Roberts K, Smith A. Outcome of diabetic patients treated in the prehospital arena after a hypoglycemic episode, and an exploration of treat and release protocols: a review of the literature. Emerg J Med. 2003;20(3):274\u20136\n\n12. Vilke GM, Castillo EM, Ray LU, Murrin PA, Chan TC. Evaluation of pediatric glucose monitoring and hypoglycemic therapy in the field. Pediatr Emerg Care. 2005;21(1):1\u20135\n\nRevision Date March 11, 2022\n\nGo To TOC\n\n## General Medical\n\nRev. March 2022\n\n## Hypoglycemia\n\n88\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Nausea-Vomiting\n\n### Aliases\n\nEmesis\n\nGastroenteritis\n\n### Patient Care Goals\n\nIdentify hypoglycemia or hyperglycemia\nPrevent dehydration\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nCurrently nauseated and/or vomiting\n\n#### Exclusion Criteria\n\nNone noted\n\n### Patient Management\n\n#### Assessment\n\nRoutine patient care (e.g., vital signs)\nHistory and physical examination focused on potential causes of nausea and vomiting (e.g., gastrointestinal,\ncardiovascular, obstetric, gynecologic, hypoglycemia, hyperglycemia, neurologic, oncologic, psychogenic, or\ntoxidrome) as well as medications that may prolong the QT interval\nObtain glucose level\n\n#### Treatment and Interventions\n\nAntiemetic medication administration\n\nIsopropyl alcohol: Allow patient to inhale vapor from isopropyl alcohol wipe 3 times q (quaque, every) 15\nminutes as tolerated\nOndansetron (contraindicated for suspected or known diagnosis of prolonged QT syndrome)\n\nAdult:\n\n4 mg IV/PO/SL\n4 or 8 mg SL of the ODT formulation\n\nPediatric (6 months \u2013 14 years old):\n\n0.15 mg/kg IV/PO (maximum dose of 4 mg)\n2 mg SL for ages 1\u20135 years old; age 6 and older use 4 mg of the ODT formulation\n\nMetoclopramide\n\nAdult: 10 mg IV/IM\nPediatric (greater than 2 years old only and greater than 12 kg):\n\n0.1 mg/kg IM\n\nGeneral Medical\n\nRev. March 2022\n\nNausea-Vomiting\n\n89\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n2. 0.1 mg/kg IV (maximum 10 mg)\n\na. May repeat x 1 in 20\u201330 minutes if no relief\n\nd. Prochlorperazine\n\ni. Adult: 5 mg IV/IM\n\nii. Pediatric (over 2 years old only and greater than 12 kg):\n\n1. 0.1 mg/kg slow IV\n\nOR\n\n2. 0.1 mg/kg deep IM (maximum 10 mg)\n\ne. Droperidol\n\ni. Adult: 1.25 mg IV/IM (contraindicated for suspected or known diagnosis of prolonged QT syndrome)\n\nf. Diphenhydramine\n\ni. Adult: 12.5\u201325 mg IV/IM/PO\n\nii. Pediatric (over 2 years old only and greater than 12 kg): 0.1 mg/kg IV (maximum 25 mg)\n\n### Patient Safety Considerations\n\n1. Ondansetron should not be administered to patients who have a prolonged QT interval as it can cause torsades.\n\n2. For very young pediatric patients, ondansetron can be sedating\n\n3. Dystonic and extrapyramidal symptoms are possible side effects of antiemetics \u2013 If encountered, consider diphenhydramine:\n\na. Adult: 25\u201350 mg IV/IM/PO\n\nb. Pediatric: 1 mg/kg IV/IM/PO (maximum dose 50 mg)\n\n4. Medications that prolong the QT interval may alter treatment options.\n\n### Notes/Educational Pearls\n\nKey Considerations\n\n1. Ondansetron is preferred in children for the treatment of nausea and vomiting\n\n2. Metoclopramide has fewer adverse effects than prochlorperazine in children\n\n3.", "start_char_idx": 197568, "end_char_idx": 200884, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "961e12af-4d2f-4f75-8018-8e3ababf2bd7": {"__data__": {"id_": "961e12af-4d2f-4f75-8018-8e3ababf2bd7", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a4be7fb-c4e3-4b91-bf58-ffbb5cd7248d", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "90070b6f640477d03be155cf1b154343f55fc88c392536213fef7b1eab5a576f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9407dfbb-c851-4b9d-9004-7d81b463b5e3", "node_type": "1", "metadata": {}, "hash": "38abec09f57058cbb35ccd1b0e28562a350e7fd2080b8f71004aa8190129e9e4", "class_name": "RelatedNodeInfo"}}, "text": "Ondansetron should not be administered to patients who have a prolonged QT interval as it can cause torsades.\n\n2. For very young pediatric patients, ondansetron can be sedating\n\n3. Dystonic and extrapyramidal symptoms are possible side effects of antiemetics \u2013 If encountered, consider diphenhydramine:\n\na. Adult: 25\u201350 mg IV/IM/PO\n\nb. Pediatric: 1 mg/kg IV/IM/PO (maximum dose 50 mg)\n\n4. Medications that prolong the QT interval may alter treatment options.\n\n### Notes/Educational Pearls\n\nKey Considerations\n\n1. Ondansetron is preferred in children for the treatment of nausea and vomiting\n\n2. Metoclopramide has fewer adverse effects than prochlorperazine in children\n\n3. Prochlorperazine and metoclopramide (phenothiazines) have an increased risk of dystonic reactions\n\na. Some phenothiazines also have an increased risk of respiratory depression when used with other medications that cause respiratory depression, and some phenothiazines can cause neuroleptic malignant syndrome\n\nb. Prochlorperazine carries a black box warning for use in elderly patients with dementia-related psychosis.\n\n4. IV form of ondansetron may be given PO in same dose\n\n5. Nausea and vomiting are symptoms of illness \u2013 in addition to treating the patient\u2019s nausea and vomiting a thorough history and physical are key to identifying what may be a disease in need of emergent treatment (e.g., bowel obstruction, myocardial infarction, pregnancy)\n\n6. While ondansetron has not been adequately studied in pregnancy to determine safety, women should be counseled regarding the available data. In the first trimester of pregnancy, the administration of metoclopramide 5\u201310 mg IV with diphenhydramine 25 mg IV is recommended over the administration of ondansetron\n\n________________________\n\nGo To TOC\n\n#### General Medical\n\nRev. March 2022\n\n#### Nausea-Vomiting\n\n90\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Pertinent Assessment Findings\n\nVital signs (pulse, blood pressure, respiratory rate, neurologic status assessment)\nRisk factors for heart disease/EKG if applicable\nPregnancy status\nAbdominal exam\nBlood glucose levels\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914131 \u2013 Medical - Nausea/Vomiting\n\n### Key Documentation Elements\n\nPatient age\nPatient weight and/or length-based weight measure for pediatric patients\nMedications given, including time, clinician level, dose, dose units, route, response, and complications\nVital signs before and after medication administration\nHistory and physical regarding etiology of nausea/vomiting\nEKG performed and interpretation documented if cardiac risk factors are present\n\n### Performance Measures\n\nIn patients with nausea and vomiting, appropriate medication(s) was/were administered (including proper dosage) and the patient's response to treatment is documented\nAny event where complications occurred, such as a dystonic reaction, should have event and appropriate responsive interventions performed and documented\nEMS\u00ae NEMSQA Measure (for additional information, see www.nemsqa.org)\n\nPediatrics\u201403: Documentation of Estimated Weight in Kilograms\n\n### References\n\nACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy. Committee on Practice Bulletins-Obstetrics. Obstet Gynecol. 2018;131(1): e15\nBeadle KL, Helbling AR, Love SL, April MD, Hunter CJ. Isopropyl alcohol nasal inhalation for nausea in the emergency department: a randomized controlled trial. Ann Emerg Med. 2016;68(1):1\u20139\nColletti J. Brown KM, Sharieff GQ, Barata IA, Ishimine P; ACEP Pediatric Emergency Medicine Committee. The management of children with gastroenteritis and dehydration in the emergency department. J Emerg Med. 2010;38(5):686\u201398\nKenneday D. Ondansetron and pregnancy: understanding the data. Obstet Med. 2016;9(1):28\u201333\nNausea and Vomiting of Pregnancy. The American College of Obstetricians and Gynecologists; September 2015. Practice Bulletin Number 153\nNi\u00f1o-Serna LF, Acosta-Reyes J, Veroniki A, et al.", "start_char_idx": 200211, "end_char_idx": 204259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9407dfbb-c851-4b9d-9004-7d81b463b5e3": {"__data__": {"id_": "9407dfbb-c851-4b9d-9004-7d81b463b5e3", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "961e12af-4d2f-4f75-8018-8e3ababf2bd7", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "2eab85cda44b2c6f76231baa6e98d8e54a9680448e958197fbd0905e3c9a56bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c161b1ee-d189-455b-b78b-d089d9154a45", "node_type": "1", "metadata": {}, "hash": "cdf17e8eaf0bac217b2dbb648a1133d900b0f47636a33c7959ed3044e2fb2af5", "class_name": "RelatedNodeInfo"}}, "text": "Isopropyl alcohol nasal inhalation for nausea in the emergency department: a randomized controlled trial. Ann Emerg Med. 2016;68(1):1\u20139\nColletti J. Brown KM, Sharieff GQ, Barata IA, Ishimine P; ACEP Pediatric Emergency Medicine Committee. The management of children with gastroenteritis and dehydration in the emergency department. J Emerg Med. 2010;38(5):686\u201398\nKenneday D. Ondansetron and pregnancy: understanding the data. Obstet Med. 2016;9(1):28\u201333\nNausea and Vomiting of Pregnancy. The American College of Obstetricians and Gynecologists; September 2015. Practice Bulletin Number 153\nNi\u00f1o-Serna LF, Acosta-Reyes J, Veroniki A, et al. Antiemetics in Children with Acute Gastroenteritis: A Meta-analysis. Pediatrics. 2020;145(4): e20193260\nPatanwala A, Amini R, Hays DP, Rosen P. Antiemetic therapy for nausea and vomiting in the emergency department. J Emerg Med. 2010;39(3):330\u20136\nSalvucci AA, Squire B, Burdick M, Luoto M, Brazzel D, Vaezazizi R. Ondansetron is safe\n\nGo To TOC\n\n#### General Medical\n\nRev. March 2022\n\n#### Nausea-Vomiting\n\n91\n---\nNASEMSO\n\nNASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\neffective for prehospital treatment of nausea and vomiting by paramedics. Prehosp Emerg Care. 2011;15(1):34\u20138\n\n9. Warden CR, Moreno R, Daya M. Prospective evaluation of ondansetron for undifferentiated nausea and vomiting in the prehospital setting. Prehosp Emerg Care. 2008;12(1):87\u201391\n\nRevision Date\n\nMarch 11, 2022\n\nGo To TOC\n\n## General Medical\n\nRev. March 2022\n\n## Nausea-Vomiting\n\n92\n---\n# NASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Pain Management\n\n### Aliases\n\nAnalgesia\n\nPain control\n\n### Patient Care Goals\n\nCompassionately manage all patients with pain\nMinimize adverse events in the treatment of pain\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nPatients who are experiencing pain regardless of transport interval\n\n#### Exclusion Criteria\n\nPregnancy with active labor\n\n### Patient Management\n\n#### Assessment, Treatment, and Interventions\n\nChoice of medication class, route of administration, dosing and frequency are based on pain severity and the need for escalation from oral to parenteral routes\n\nThe dosing guidelines apply to patients of all ages except where noted\nDetermine patient\u2019s pain score assessment using standard pain scale\n\nLess than 4 years old or those with cognitive impairment unable to self-report:\n\nObservational Scales\n\nFaces, Legs, Arms, Cry, Consolability (FLACC)\nChildren\u2019s Hospital of Eastern Ontario Pain Scale (CHEOPS)\n\n4\u201312 years old:\n\nSelf-report scale\n\nWong Baker Faces\nFaces Pain Scale (FPS)\nFaces Pain Scale Revised (FPS-R)\n\nGreater than 12 years old:\n\nSelf-report scale\n\nNumeric Rating Scale (NRS)\n\nNon-pharmacologic pain management options include\n\nPlacement of the patient in a position of comfort\nApplication of ice packs and/or splints for pain secondary to trauma\nVerbal reassurance to control anxiety\n\nMinor pain or as an adjunct for moderate/severe pain consider the following non-opioid analgesic options:\n\nAcetaminophen 15 mg/kg PO or IV (maximum dose 1 g)\nNonsteroidal anti-inflammatories\n\nIbuprofen 10 mg/kg PO for patients greater than 6 months of age (maximum dose 800 mg) OR\n\n________________________\n\nGo To TOC\n\nGeneral Medical\n\nRev. March 2022\n\n## Pain Management\n\n93\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Pain Management\n\nii. Ketorolac\n\n|1. Adult:|30 mg IM or 15 mg IV|\n|---|---|\n|2. Pediatric age 2\u201316 years old:|0.5 mg/kg (maximum dose of 30 mg IM or 15 mg IV)|\n\n6. For Moderate to Severe pain, analgesics include:\n\na. Morphine sulfate:\n\ni.", "start_char_idx": 203620, "end_char_idx": 207218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c161b1ee-d189-455b-b78b-d089d9154a45": {"__data__": {"id_": "c161b1ee-d189-455b-b78b-d089d9154a45", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9407dfbb-c851-4b9d-9004-7d81b463b5e3", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "408f48667d8e9549165151f6d7a0ab32c380f4891301c68f7807a1f951623a32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b67ef33-19f3-4cb6-8fb3-d6d9259afe2f", "node_type": "1", "metadata": {}, "hash": "ffe1d89124269ebc0eb3b0641f43d90bbd8ff586b3382972f13e6d587acdf665", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n## Pain Management\n\n93\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Pain Management\n\nii. Ketorolac\n\n|1. Adult:|30 mg IM or 15 mg IV|\n|---|---|\n|2. Pediatric age 2\u201316 years old:|0.5 mg/kg (maximum dose of 30 mg IM or 15 mg IV)|\n\n6. For Moderate to Severe pain, analgesics include:\n\na. Morphine sulfate:\n\ni. 0.1 mg/kg IM, IV or IO (maximum initial dose is 10 mg)\n\nb. Fentanyl:\n\ni. 1 mcg/kg IN, IM, IV or IO (maximum initial dose of 100 mcg)\n\nc. Hydromorphone:\n\ni. 0.015 mg/kg IM, IV, or IO (maximum initial dose 2 mg; maximum cumulative dose of 4 mg)\n\nd. Ketamine:\n\ni. 0.25 mg/kg IM, IV or IO (maximum initial dose 25 mg; maximum cumulative dose 100 mg)\n\n7. Use of non-invasive capnography is an earlier predictor of hypoventilation than pulse oximetry if opioid medications are administered\n\n8. Consider administration of oral, sublingual, or IV antiemetics to prevent nausea [See Nausea/Vomiting Guideline]\n\n9. If indicated based on pain assessment, and vital signs allow, repeat pain medication administration (excluding acetaminophen and nonsteroidal anti-inflammatory medicines) after 5 minutes of the previous dose\n\n10. Transport in position of comfort and reassess as indicated\n\n#### Patient Safety Considerations\n\n1. All patients should have drug allergies identified prior to administration of pain medication\n\n2. Administer opioids with caution to patients with Glasgow Coma Score (GCS) less than 15, hypotension, identified medication allergy, hypoxia (SPO2 less than 90%) after maximal supplemental oxygen therapy, or signs of hypoventilation\n\n3. Opioids are contraindicated for patients who have taken monoamine oxidase inhibitors (MAOI) during the previous 14 days\n\n4. Avoid non-steroidal anti-inflammatory medications such as ibuprofen and ketorolac in patients with NSAID allergy, aspirin-sensitive asthma, renal insufficiency, pregnancy, or known peptic ulcer disease\n\n5. Ketorolac should not be used in patients with hypotension (due to renal toxicity)\n\n6. Use of splinting techniques and application of ice should be done to reduce the total amount of medication used to keep the patient comfortable\n\n#### Notes/Educational Pearls\n\nKey Considerations\n\n1. Intranasal routes of opioid analgesia are preferred as the initial dosing route in pediatrics where IV access may be problematic; consider in other patient populations when an IV in not otherwise indicated\n\n2. Onset of action is dependent on the pharmacokinetics of the drug class as well as route of administration; oral analgesics are effective for pain control but\n\n________________________\n\nGo To TOC\n\nGeneral Medical\n\nRev. March 2022\n\n94\n---\nNASEMSO National Model EMS Clinical Guidelines NASEMSO Version 3.0\n\n1. Pain medications should be titrated to effect\n\n2. Medications administered for pain management may have a slower onset of action so plan accordingly\n\n3. Pain severity scores should be recorded before and after analgesic medication administration and upon arrival at destination\n\n4. Patients with acute abdominal pain should receive analgesic interventions \u2013 Use of analgesics for acute abdominal pain does not mask clinical findings or delay diagnosis\n\n5. Opiates may cause a rise in intracranial pressure\n\nPertinent Assessment Findings\n\n1. Mental status (Glasgow Coma Score (GCS) and pain level)\n\n2. Respiratory system (tidal volume, chest rigidity)\n\n3.", "start_char_idx": 206872, "end_char_idx": 210257, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b67ef33-19f3-4cb6-8fb3-d6d9259afe2f": {"__data__": {"id_": "3b67ef33-19f3-4cb6-8fb3-d6d9259afe2f", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c161b1ee-d189-455b-b78b-d089d9154a45", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "60c6f882262f96df96192a3fffc718cb8705610a8b630f14d6788757130ec722", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a177ca05-4dea-44f4-970e-ee783b7bfc0a", "node_type": "1", "metadata": {}, "hash": "d372cac9102e4d4545fee46fc17f2ead2abaa8a7fa97e3def1c91ca69f540f41", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n94\n---\nNASEMSO National Model EMS Clinical Guidelines NASEMSO Version 3.0\n\n1. Pain medications should be titrated to effect\n\n2. Medications administered for pain management may have a slower onset of action so plan accordingly\n\n3. Pain severity scores should be recorded before and after analgesic medication administration and upon arrival at destination\n\n4. Patients with acute abdominal pain should receive analgesic interventions \u2013 Use of analgesics for acute abdominal pain does not mask clinical findings or delay diagnosis\n\n5. Opiates may cause a rise in intracranial pressure\n\nPertinent Assessment Findings\n\n1. Mental status (Glasgow Coma Score (GCS) and pain level)\n\n2. Respiratory system (tidal volume, chest rigidity)\n\n3. Gastrointestinal (assess for tenderness, rebound, guarding, and nausea)\n\nQuality Improvement Associated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914071 \u2013 General - Pain Control\n\nKey Documentation Elements\n\nDocumentation of patient vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment) with pulse oximetry\nAcquisition of patient\u2019s allergies prior to administration of medication\nDocumentation of initial patient pain scale assessment\nDocumentation of medication administration with correct dose\nDocumentation of patient reassessment with repeat vital signs and patient pain scale assessment\n\nPerformance Measures\n\nThe clinical efficacy of prehospital analgesia in terms of adequacy of dosing parameters\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\nPediatrics\u201403: Documentation of Estimated Weight in Kilograms\nTrauma\u201401: Pain Assessment of Injured Patients\n\nGo To TOC\n\nGeneral Medical Rev. March 2022 Pain Management 95\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n|Content|Page Number|\n|---|---|\n|General Medical Pain Management|96|\n\n### Table 1. Adult Nonverbal Pain Scale University of Rochester Medical Center\n\nAdult nonverbal pain scale University of Rochester Medical Center\n\n|Categories| |\n|---|---|\n|Face|No particular expression or smile;|\n|Activity (movement)|Lying quietly; normal position.|\n|Guarding|Lying quietly; no positioning of hands over areas of body;|\n|Physiology (vital signs)|Stable vital signs|\n|Respiratory|Baseline RR/SpO2 compliant with ventilator|\n\nAbbreviations: HR, heart rate; RR, respiratory rate; SBP, systolic blood pressure; SpO2, pulse oximetry;\n\nInstructions: Each of the 5 categories is scored from 0-2, which results in a total score between 0 and 10. Document\ntotal score by adding numbers from each of the 5 categories. Scores of 0-2 indicate no pain, 3-6 moderate pain, and\n7-10 severe pain. Document assessment every = hours on nursing flow sheet and complete assessment before and after\nintervention to maximize patient comfort. Sepsis, hypovolemia, hypoxia need to be excluded before interventions.\n\nStrong Memorial Hospital, University of Rochester Medical Center; 2004. Used with permission.\n\nSource: Odhner M, Wegman D, Freeland N, Ingersoll G. Evaluation of a newly developed non-verbal pain scale (NVPS)\nfor assessment of pain in sedated critically ill patients.\n\n________________________\n\nGo To TOC\n\nGeneral Medical Pain Management\n\nRev. March 2022\n---\n## Table 2.", "start_char_idx": 209513, "end_char_idx": 212837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a177ca05-4dea-44f4-970e-ee783b7bfc0a": {"__data__": {"id_": "a177ca05-4dea-44f4-970e-ee783b7bfc0a", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b67ef33-19f3-4cb6-8fb3-d6d9259afe2f", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "a404e890cd807faf3b8d582760aa1eb64d677e3e33db2deca3339119e992dbba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ffec63e-c37c-4c72-a712-3b7fccaef9d2", "node_type": "1", "metadata": {}, "hash": "992655c1efc46590425b650a89c0a0da5c6f96ec2a277df61a687cb13e4bd6fb", "class_name": "RelatedNodeInfo"}}, "text": "Document\ntotal score by adding numbers from each of the 5 categories. Scores of 0-2 indicate no pain, 3-6 moderate pain, and\n7-10 severe pain. Document assessment every = hours on nursing flow sheet and complete assessment before and after\nintervention to maximize patient comfort. Sepsis, hypovolemia, hypoxia need to be excluded before interventions.\n\nStrong Memorial Hospital, University of Rochester Medical Center; 2004. Used with permission.\n\nSource: Odhner M, Wegman D, Freeland N, Ingersoll G. Evaluation of a newly developed non-verbal pain scale (NVPS)\nfor assessment of pain in sedated critically ill patients.\n\n________________________\n\nGo To TOC\n\nGeneral Medical Pain Management\n\nRev. March 2022\n---\n## Table 2. Universal Pain Assessment Tool\n\n|Wong-Baker FACES\u00ae|Verbal Descriptor Scale|Verbal Descriptor Scale|Verbal Descriptor Scale|Verbal Descriptor Scale|Verbal Descriptor Scale|Verbal Descriptor Scale|Verbal Descriptor Scale|Verbal Descriptor Scale|Verbal Descriptor Scale|Verbal Descriptor Scale|\n|---|---|\n| |0|1|2|3|4|5|6|7|8|9|10|\n|No Pain|Mild Pain|Moderate Pain|Severe Pain|Very Severe Pain|Excruciating Pain|\n|Descriptive Scale|Alert|Humor|Pursed Lips|Furrowed Brow|Raised Upper Lip|Slow Blink|Wrinkled Nose|Eyes Closed|Moaning|Crying|\n|Activity Tolerance Scale|No Pain|Can be Ignored|Interferes with Tasks|Interferes with Concentration|Interferes with Basic Needs|Bed Rest Required|\n|Spanish|Nada de Dolor|Poquito de Dolor|Un Dolor Leve|Dolor Fuerte|Desmasiado Fuerte|Un Dolor Insoportable|\n\nSource: Hybrid of scales by authors. Wong-Baker FACES\u00ae Pain Scale Rating license grants this use. Reproduction of the Wong-Baker FACES\u00ae material requires licensing at www.wongbakerfaces.org.\n\nGeneral Medical Pain Management\n\nRev. March 2022\n\n97\n---\n## Pediatric-Appropriate Pain Assessment Tools\n\nTable 3. Faces, Legs, Activity, Cry, Consolability (FLACC) Behavioral Scale\n\nAppropriate age for use (per guideline): less than 4 years\n\n|Categories|Scoring|\n|---|---|\n|Face|No particular expression or smile|Occasional grimace or frown, withdrawn, disinterested|Frequent to constant frown, clenched jaw, quivering chin|\n|Legs|Normal position or relaxed|Uneasy, restless, tense or legs drawn up|Kicking,|\n|Activity|Lying quietly, normal position, moves easily|Squirming, shifting back and forth, tense|Arched, rigid, or jerking|\n|Cry|No cry (awake or asleep)|Moans or whimpers, occasional complaint|Crying steadily, screams or sobs, frequent complaints|\n|Consolability|Content, relaxed|Reassured by occasional touching, hugging, or being talked to, distractible|Difficult to console or comfort|\n\nEach of the five categories (F) Face; (L) Legs; (A) Activity; (C) Cry; (C) Consolability is scored from 0\u20132, which results in a total score between zero and ten.\n\nSource: \u00a9 2002, The Regents of the University of Michigan. All Rights Reserved.\n\n### Instructions:\n\nPatients who are awake: Observe for at least 1\u20132 minutes. Observe legs and body uncovered. Reposition patient or observe activity, assess body for tenseness and tone. Initiate consoling interventions if needed\nPatients who are asleep: Observe for at least 2 minutes or longer. Observe body and legs uncovered. If possible, reposition the patient. Touch the body and assess for tenseness and tone.", "start_char_idx": 212113, "end_char_idx": 215383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ffec63e-c37c-4c72-a712-3b7fccaef9d2": {"__data__": {"id_": "0ffec63e-c37c-4c72-a712-3b7fccaef9d2", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a177ca05-4dea-44f4-970e-ee783b7bfc0a", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "4c4d86d17e8635aa42b7e0131c5426fea001debe8199e2c0b3760140e896a738", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9692b485-7b15-4800-9659-f813ae362532", "node_type": "1", "metadata": {}, "hash": "e63c650aad0f395961d8eaecaea9c0fb2e5e32b2e7737171462f34ab7a084781", "class_name": "RelatedNodeInfo"}}, "text": "Source: \u00a9 2002, The Regents of the University of Michigan. All Rights Reserved.\n\n### Instructions:\n\nPatients who are awake: Observe for at least 1\u20132 minutes. Observe legs and body uncovered. Reposition patient or observe activity, assess body for tenseness and tone. Initiate consoling interventions if needed\nPatients who are asleep: Observe for at least 2 minutes or longer. Observe body and legs uncovered. If possible, reposition the patient. Touch the body and assess for tenseness and tone.\n\n### Face\n\nScore 0 point if patient has a relaxed face, eye contact and interest in surroundings\nScore 1 point if patient has a worried look to face, with eyebrows lowered, eyes partially closed, cheeks raised, mouth pursed\nScore 2 points if patient has deep furrows in the forehead, with closed eyes, open mouth and deep lines around nose/lips\n\n### Legs\n\nScore 0 points if patient has usual tone and motion to limbs (legs and arms)\nScore 1 point if patient has increase tone, rigidity, tense, intermittent flexion/extension of limbs\nScore 2 points if patient has hyper tonicity, legs pulled tight, exaggerated flexion/extension of limbs, tremors\n\n### Activity\n\nScore 0 points if patient moves easily and freely, normal activity/restrictions\nScore 1 point if patient shifts positions, hesitant to move, guarding, tense torso, pressure on body part\nScore 2 points if patient is in fixed position, rocking, side-to-side head movement, rubbing body part\n\n### Cry\n\nScore 0 points if patient has no cry (awake or asleep)\n\nScore 1 point if patient moans or whimpers, occasional complaint\n\nScore 2 points if patient is crying steadily, screams or sobs, frequent complaints\n\nGeneral Medical\n\nPain Management\n\nRev. March 2022\n\n98\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nScore 0 points if patient has no cry/moan awake or asleep\n\nScore 1 point if patient has occasional moans, cries, whimpers, sighs\n\nScore 2 points if patient has frequent/continuous moans, cries, grunts\n\nConsolability\n\nScore 0 points if patient is calm and does not require consoling\n\nScore 1 point if patient responds to comfort by touch or talk in \u00bd \u2013 1 minute\n\nScore 2 points if patient require constant consoling or is unconsoled after an extended time\n\nWhenever feasible, behavioral measurement of pain should be used in conjunction with self-report. When self-report is not possible, interpretation of pain behaviors and decision-making regarding treatment of pain requires careful consideration of the context in which the pain behaviors were observed.\n\nEach category is scored on a 0\u20132 scale, which results in a total score of 0\u201310\n\nAssessment of Behavioral Score:\n\n0 = Relaxed and comfortable\n\n1\u20133 = Mild discomfort\n\n4\u20136 = Moderate pain\n\n7\u201310 = Severe discomfort/pain\n\n\u00a9 2002, The Regents of the University of Michigan. All Rights Reserved.\n\nSource: The FLACC: A behavioral scale for scoring postoperative pain in young children, by S Merkel and others, 1997, Pediatr Nurse 23(3), p. 293\u2013297.\n\nGraphic 1. Faces Pain Scale \u2013 Revised (FPS-R)\n\n|2|3|2|8|2|6|\n|---|---|---|---|---|---|\n\nIn the following instructions, say \"hurt\" or \"pain\", whichever seems right for a particular child. \"These faces show how much something can hurt. This face [point to face on far left] shows no pain. The faces show more and more pain [point to each from left to right] up to this one [point to face on far right] \u2014 it shows very much pain. Point to the face that shows how much you hurt [right now].\"\n\nScore the chosen face 0, 2, 4, 6, 8, or 10, counting left to right, so \u201c0\u201d = \u201cno pain\u201d and \u201c10\u201d = \u201cvery much pain\u201d. Do not use words like \u201chappy\u201d or \u201csad.\u201d This scale is intended to measure how children feel inside, not how their face looks.\n\nSource: Permission for Use. Copyright of the FPS-R is held by the International Association for the Study of Pain (IASP) \u00a92001. This material may be photocopied for non-commercial clinical, educational and research use.", "start_char_idx": 214887, "end_char_idx": 218831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9692b485-7b15-4800-9659-f813ae362532": {"__data__": {"id_": "9692b485-7b15-4800-9659-f813ae362532", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ffec63e-c37c-4c72-a712-3b7fccaef9d2", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "44e5b4c76b7f05fa4d19de298411956bb7cafac13518fee80bc104b563ae639a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28ac60bc-bda8-4b08-9942-5edd029b9670", "node_type": "1", "metadata": {}, "hash": "2ab6a0a74effa2557683d6aa1bf90d829eaa321ced1682cd784e69934fd22f2f", "class_name": "RelatedNodeInfo"}}, "text": "This face [point to face on far left] shows no pain. The faces show more and more pain [point to each from left to right] up to this one [point to face on far right] \u2014 it shows very much pain. Point to the face that shows how much you hurt [right now].\"\n\nScore the chosen face 0, 2, 4, 6, 8, or 10, counting left to right, so \u201c0\u201d = \u201cno pain\u201d and \u201c10\u201d = \u201cvery much pain\u201d. Do not use words like \u201chappy\u201d or \u201csad.\u201d This scale is intended to measure how children feel inside, not how their face looks.\n\nSource: Permission for Use. Copyright of the FPS-R is held by the International Association for the Study of Pain (IASP) \u00a92001. This material may be photocopied for non-commercial clinical, educational and research use. For reproduction of the FPS-R in a journal, book or web page, or for any commercial use of the scale, request permission from IASP online at https://www.iasp-pain.org/publications/copyright-permissions/.\n\nReferences\n\nAttard AR, Corlett MJ, Kidner NJ, Leslie AP, Fraser IA. Safety of early pain relief for acute abdominal pain. BMJ. 1992;305(6853):554\u20136\nBieri D, Reeve R, Champion GD, Addico at L, Ziegler J. The Faces Pain Scale for the self-assessment of the severity of pain experienced by children: Development, initial validation\n\nGeneral Medical\n\nPain Management\n\nRev. March 2022\n\n99\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\nand preliminary investigation for ratio scale properties. Pain 1990;41:139\u2013150\n\nBrewster GS, Herbert ME. Hoffman JR. Medical myth: analgesia should not be given to patients with acute abdominal pain because it obscures the diagnosis. West J Med. 2000;172(3):209\u201310\nDe Nadal M, Munar F, Poca MA, Sahuquillo J, Garnacho A, Rossell\u00f3 J. Cerebral hemodynamic effects of morphine and fentanyl in patients with severe head injury: absence of correlation to cerebral autoregulation. Anesthesia. 2000; 92:1\u201311\nHicks CL, von Baeyer CL, Spafford P, van Korlaar I, Goodenough B. The Faces Pain Scale \u2013 Revised: Toward a common metric in pediatric pain measurement. Pain. 2001; 93:173\u201383\nJennings PA, Cameron P, Bernard S. Ketamine as an analgesic in the pre-hospital setting: a systematic review. Acta Anaesthsiol Scand. 2011;55(6):638\u201343\nLindbeck, George et al. (Evidence-Based Guidelines for Prehospital Pain Management: Literature and Methods (nasemso.org). Accessed March 11, 2022\nLoVecchio F, Oster N, Sturmann K, Nelson LS, Flashner S, Finger R. The use of analgesics in patients with acute abdominal pain. J Emerg Med. 1997;15(6):775\u20139\nManterola C, Astudillo P, Losada H, Pineda V, Sanhueza A, Vial M. Analgesia in patients with acute abdominal pain. Cochrane Database Syst Rev. 2007 Jul 18;(3) CD005660\nMerkel S, e al. The FLACC: A behavioral scale for scoring postoperative pain in young children., Pediatr Nurse. 1997;23(3):293\u20137\nPace S, Burke TF. Intravenous morphine for early pain relief in patients with acute abdominal pain. Acad Emerg Med. 1996;3(12):1086\u201392\nPrehospital use of Ketamine in Battlefield Analgesia 2012\u201313. Falls Church, VA: Defense Health Agency; March 8, 2012. Correspondence to Assistant Secretary of Defense (Health Affairs)\nPorter K. Ketamine in prehospital care. Emerg Med J 2004; 21:351\u20134\nPowell, Jonathan R., et al. Evidence-Based Guidelines for Prehospital Pain Management: Literature and Methods. Prehospital Emergency Care.\nRanji SR, Goldman LE, Simel DL, Shojania KG. Do opiates affect the clinical evaluation of patients with acute abdominal pain?", "start_char_idx": 218114, "end_char_idx": 221565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28ac60bc-bda8-4b08-9942-5edd029b9670": {"__data__": {"id_": "28ac60bc-bda8-4b08-9942-5edd029b9670", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9692b485-7b15-4800-9659-f813ae362532", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "94088a28b8d9ff71e25efaac6ee82f12dcf0f8d371dbbf6de4c92a5dbc565019", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcaeca5c-1ee8-430a-b687-58e0a3fbd310", "node_type": "1", "metadata": {}, "hash": "9fdf2a59a26d70dcf42e3bd61a8b73b2c04108cc57aac942c18515c02ce745f8", "class_name": "RelatedNodeInfo"}}, "text": "1997;23(3):293\u20137\nPace S, Burke TF. Intravenous morphine for early pain relief in patients with acute abdominal pain. Acad Emerg Med. 1996;3(12):1086\u201392\nPrehospital use of Ketamine in Battlefield Analgesia 2012\u201313. Falls Church, VA: Defense Health Agency; March 8, 2012. Correspondence to Assistant Secretary of Defense (Health Affairs)\nPorter K. Ketamine in prehospital care. Emerg Med J 2004; 21:351\u20134\nPowell, Jonathan R., et al. Evidence-Based Guidelines for Prehospital Pain Management: Literature and Methods. Prehospital Emergency Care.\nRanji SR, Goldman LE, Simel DL, Shojania KG. Do opiates affect the clinical evaluation of patients with acute abdominal pain? JAMA. 2006;296(14):1764\u201374\nSvenson JE, Abernathy MK. Ketamine for prehospital use: new look at an old drug. Am J Emerg Med. 2007; 25:977\u201380\nVermuelen B, Morabia A, Unger PF, et al. Acute appendicitis: influence of early pain relief on the accuracy of clinical and US findings in the decision to operate \u2013 a randomized trial. Radiology. 1999;210(3):639\u201343\nWiel E, Zitouni D, Assez N, et al. Continuous infusion of ketamine for out-of-hospital isolated orthopedic injuries secondary to trauma: a randomized controlled trial. Prehosp Emerg Care. 2015;19(1);10\u201316\nWood PR. Ketamine: prehospital and in-hospital use. Trauma. 2003;5(2):137\u201340\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022 Pain Management 100\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# Seizures\n\n(Adapted from an evidence-based guideline created using the National Prehospital Evidence-Based Guideline Model Process)\n\n## Aliases\n\nConvulsions, Eclampsia, Febrile seizure, Status epilepticus\n\n## Patient Care Goals\n\nPrompt cessation of seizures in the prehospital setting\nMinimizing adverse events in the treatment of seizures in the prehospital setting\nMinimizing seizure recurrence during transport\n\n## Patient Presentation\n\nSeizures due to trauma, pregnancy, hyperthermia, or toxic exposure should be managed according to those condition-specific guidelines\n\n### Inclusion Criteria\n\nSeizure activity upon arrival of prehospital personnel or new/recurrent seizure activity lasting greater than 5 minutes\n\n### Exclusion Criteria\n\nNone noted\n\n## Patient Management\n\n### Assessment\n\n#### History\n\nDuration of current seizure\nPrior history of seizures, diabetes, or hypoglycemia\nTypical appearance of seizures\nBaseline seizure frequency and duration\nFocality of onset, direction of eye deviation\nConcurrent symptoms of apnea, cyanosis, vomiting, bowel/bladder incontinence, or fever\nBystander administration of medications to stop the seizure\nCurrent medications, including anticonvulsants\nRecent dose changes or non-compliance with anticonvulsants\nHistory of trauma, pregnancy, heat exposure, or toxin exposure\n\n#### Exam\n\nAirway patency\nBreath sounds, respiratory rate, and effectiveness of ventilation\nSigns of perfusion (pulses, capillary refill, color)\nNeurologic status (GCS, nystagmus, pupil size, focal neurologic deficit, or signs of stroke)\n\nGo To TOC\n\nGeneral Medical\n\nRev. March 2022\n\nSeizures\n\n101\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Treatment and Interventions\n\nIf signs of airway obstruction are present and a chin-lift, jaw thrust, positioning, and/or suctioning does not alleviate it, place oropharyngeal airway (if gag reflex is absent) or nasopharyngeal airway\nPlace pulse oximeter and/or waveform capnography to monitor oxygenation/ventilation\nAdminister oxygen as appropriate with a target of achieving 94\u201398% saturation.", "start_char_idx": 220898, "end_char_idx": 224482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcaeca5c-1ee8-430a-b687-58e0a3fbd310": {"__data__": {"id_": "dcaeca5c-1ee8-430a-b687-58e0a3fbd310", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28ac60bc-bda8-4b08-9942-5edd029b9670", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "75fa30f2921751d08a0ca6d2da90e9a58021d850652ef8f27420b049d08b4747", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "288eccf3-d9f1-4b5f-b044-b3a3675208cd", "node_type": "1", "metadata": {}, "hash": "88272a16ecef0d2e5349f8409f49f0b04b7378b6cd9973b207bd86fa89acd23a", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nSeizures\n\n101\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Treatment and Interventions\n\nIf signs of airway obstruction are present and a chin-lift, jaw thrust, positioning, and/or suctioning does not alleviate it, place oropharyngeal airway (if gag reflex is absent) or nasopharyngeal airway\nPlace pulse oximeter and/or waveform capnography to monitor oxygenation/ventilation\nAdminister oxygen as appropriate with a target of achieving 94\u201398% saturation. Use bag-valve-mask (BVM) ventilation if oxygenation/ventilation are compromised\nAssess perfusion\nAssess neurologic status\nRoutes for treatment\n\nIN/IM routes are preferred over IV or IO routes (if not already established) and rectal (PR) route as an alternative\n\nIf no other route of delivery (IM/IV/IO/IN), diazepam 0.2 mg/kg PR (maximum dose 20 mg)\n\nIV placement is not necessary for treatment of seizures, but could be obtained if needed for other reasons\n\nAnticonvulsant Treatment\n\nIf vascular access is absent\n\nMidazolam 0.2 mg/kg (maximum dose 10 mg), IM preferred, or IN\n\nIf vascular access (IV or IO) is present:\n\nDiazepam 0.2 mg/kg IV or IO, maximum 10 mg\nLorazepam 0.1 mg/kg IV or IO, maximum 4 mg\nMidazolam 0.1 mg/kg IV or IO, maximum 4 mg\n\nGlucometry\n\nIf still actively seizing, check blood glucose level\nIf less than 60 mg/dL, treat per the Hypoglycemia Guideline\n\nAdminister magnesium sulfate in the presence of seizure in the third trimester of pregnancy or postpartum [See Eclampsia/Pre-eclampsia Guideline]\nFor febrile seizures, consider the following interventions after stopping the seizure. Please note that the administration of nonsteroidal anti-inflammatory medications is contraindicated in infants less than 6 months of age. The following interventions provide symptomatic relief for fevers, but do not stop the seizure:\n\nAcetaminophen 15 mg/kg, maximum dose 650 mg, PR/IV/IO (if unable to swallow) or PO (if able to swallow)\nKetorolac 1 mg/kg, maximum dose 15 mg, IV (if unable to swallow) OR Ibuprofen 10 mg/kg, maximum dose 600 mg, PO (if able to swallow)\nRemoving excessive layers of clothing\nApplying cool compresses to the body\n\nConsider acquiring a 12-lead EKG following cessation of seizure in patients without a history of seizure to determine possible cardiac cause\n\nGo To TOC\n\nGeneral Medical\n\nSeizures\n\nRev. March 2022\n\n102\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# Patient Safety Considerations\n\nTrained personnel should be able to give medication without contacting medical direction, however, more than two doses of benzodiazepines are associated with high-risk of airway compromise\n\nUse caution, weigh risks/benefits of deferring treatment until hospital, and/or consider consultation with medical direction if patient has received two doses of benzodiazepines by bystanders and/or prehospital clinicians\n\nHypoglycemic patients who are treated in the field for seizure should be transported to hospital, regardless of whether they return to baseline mental status after treatment\n\n## Notes/Educational Pearls\n\nKey Considerations\n\nMany airway/breathing issues in seizing patients can be managed without intubation or placement of an advanced airway.", "start_char_idx": 223977, "end_char_idx": 227189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "288eccf3-d9f1-4b5f-b044-b3a3675208cd": {"__data__": {"id_": "288eccf3-d9f1-4b5f-b044-b3a3675208cd", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcaeca5c-1ee8-430a-b687-58e0a3fbd310", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "a9f4b1860a333f2c63a8f9e8960ecf983beacb3273495b11fc2590e9415c8e8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b69d05c-f395-4901-91a4-5faccc2bc2fc", "node_type": "1", "metadata": {}, "hash": "bd4000d8f9e7b1af493264379b681aff9b365c56f1ad56ed62da0b58ed0eded2", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n102\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# Patient Safety Considerations\n\nTrained personnel should be able to give medication without contacting medical direction, however, more than two doses of benzodiazepines are associated with high-risk of airway compromise\n\nUse caution, weigh risks/benefits of deferring treatment until hospital, and/or consider consultation with medical direction if patient has received two doses of benzodiazepines by bystanders and/or prehospital clinicians\n\nHypoglycemic patients who are treated in the field for seizure should be transported to hospital, regardless of whether they return to baseline mental status after treatment\n\n## Notes/Educational Pearls\n\nKey Considerations\n\nMany airway/breathing issues in seizing patients can be managed without intubation or placement of an advanced airway. Reserve these measures for patients that fail less invasive maneuvers as noted above\n\nFor children with convulsive status epilepticus requiring medication management in the prehospital setting, trained EMS personnel should be allowed to administer medication without medical direction\n\nFor new onset seizures or seizures that are refractory to treatment, consider other potential causes including, but not limited to, trauma, stroke, electrolyte abnormality, toxic ingestion, pregnancy with eclampsia, hyperthermia\n\nA variety of safe and efficacious doses for benzodiazepines have been noted in the literature for seizures\n\nThe doses for anticonvulsant treatment noted above are those that are common to the forms and routes of benzodiazepines noted in this guideline\n\nOne dose, rather than a range, has been suggested to standardize a common dose in situations when an EMS agency may need to switch from one type of benzodiazepine to another due to cost or resource limitations\n\nRecent evidence supports the use of midazolam IM as an intervention that is at least as safe and effective as intravenous lorazepam for prehospital seizure cessation\n\n## Pertinent Assessment Findings\n\nThe presence of fever with seizure in children less than 6 months old and greater than 6 years old is not consistent with a simple febrile seizure, and should prompt evaluation for meningitis, encephalitis, or other cause\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914141 \u2013 Medical - Seizure\n\n## Key Documentation Elements\n\nActively seizing during transport and time of seizure onset/cessation\nOnset, focality, direction of eye deviation\nConcurrent symptoms of apnea, cyanosis, vomiting, bowel/bladder incontinence, or fever\nMedication amounts/routes given by bystanders or prehospital clinicians\n\nGo To TOC\n\nGeneral Medical\n\nSeizures\n\nRev. March 2022\n\n103\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nNeurologic status (GCS, nystagmus, pupil size, focal neurologic deficit, or signs of stroke)\nBlood glucose level\n\nPerformance Measures\n\nFrequency of performing glucometry\nTime to administration of anticonvulsant medication\nRate of respiratory failure\nRate of seizure recurrence\n\nReferences\n\nAlldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med. 2001;345(9):631\u20137\nAlldredge BK, Wall DB, Ferriero DM. Effect of prehospital treatment on the outcome of status epilepticus in children. Pediatr Neurol. 1995;12(3):213\u20136\nAppleton R, Sweeney A, Choonara I, Robson J, Molyneux E. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol. 1995;37(8):682\u20138\nArya R, Gulati S, Kabra M, Sahu JK, Kalra V. Intranasal versus intravenous lorazepam for control of acute seizures in children: a randomized open-label study. Epilepsia. 2011;52(4):788\u201393\nBhattacharyya M, Kalra V, Gulati S. Intranasal midazolam vs rectal diazepam in acute childhood seizures. Pediatr Neurol. 2006;34(5):355\u20139\nCain E, Ackroyd-Stolarz S, Alexiadis P, Murray D. Prehospital hypoglycemia: the safety of not transporting treated patients.", "start_char_idx": 226327, "end_char_idx": 230444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b69d05c-f395-4901-91a4-5faccc2bc2fc": {"__data__": {"id_": "6b69d05c-f395-4901-91a4-5faccc2bc2fc", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "288eccf3-d9f1-4b5f-b044-b3a3675208cd", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "13039942b75dbae7c4f65fd836b55843cd9ab42f9fe6e60f83c88f2697ff58d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56edb2ea-d832-48e1-a724-94a83e10b95d", "node_type": "1", "metadata": {}, "hash": "14c7c7642b9316bcfefc0d6d216d84a44fc13eb7cb0ad2fe9eabdd3ba33e4938", "class_name": "RelatedNodeInfo"}}, "text": "Dev Med Child Neurol. 1995;37(8):682\u20138\nArya R, Gulati S, Kabra M, Sahu JK, Kalra V. Intranasal versus intravenous lorazepam for control of acute seizures in children: a randomized open-label study. Epilepsia. 2011;52(4):788\u201393\nBhattacharyya M, Kalra V, Gulati S. Intranasal midazolam vs rectal diazepam in acute childhood seizures. Pediatr Neurol. 2006;34(5):355\u20139\nCain E, Ackroyd-Stolarz S, Alexiadis P, Murray D. Prehospital hypoglycemia: the safety of not transporting treated patients. Prehosp Emerg Care. 2003;7(4):458\u201365\nChamberlain JM, Altieri MA, Futterman C, Young GM, Ochsenschlager DW, Waisman Y. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Pediatr Emerg Care. 1997;13(2):92\u20134\nChin RF, Neville BG, Peckham C, Wade A, Bedford H, Scott RC. Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study. Lancet Neurol. 2008;7(8):696\u2013703\nFisgin T, Gurer Y, Tezic T, et al. Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: prospective randomized study. J Child Neurol. 2002;17(2):123\u20136\nFrascone RJ, Jensen J, Wewerka SS, Salzman JG. Use of the pediatric EZ-IO needle by emergency medical services providers. Pediatr Emerg Care. 2009;25(5):329\u201332\nGalustyan SG, Walsh-Kelly CM, Szewczuga D, Bergholte J, Hennes H. The short-term outcome of seizure management by prehospital personnel: a comparison of two protocols. Pediatr Emerg Care. 2003;19(4);221\u20135\nHolliman CJ, Wuerz RC, Vazquez-de Miguel G, Meador SA. Comparison of interventions in prehospital care by standing orders versus interventions ordered by direct (online) medical command. Prehosp Disaster Med. 1994;9(4):202\u20139\nHolsti M, Dudley N, Schunk J, et al. Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Pediatr Adolesc Med. 2010;164(8):747\u201353\nLahat E, Goldman M, Barr J, Bistritzer T, Berkovitch M. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomized study. Br Med J. 2000;321(7253):83\u20136\n\nGeneral Medical\n\nSeizures\n\nRev. March 2022\n\n104\n\nGo To TOC\n---\n15. Lamhaut L, Dagron C. Comparison of intravenous and intraosseous access by pre-hospital medical emergency personnel with and without CBRN protective equipment. Resuscitation. 2010;81(1):65\u20138\n\n16. Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav. 2004;5(2):253\u20135\n\n17. McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomized controlled trial. Lancet. 2005;366(9481):205\u201310\n\n18. McMullan J, Sasson C, Pancioli A, Silbergleit R. Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis. Acad Emerg Med. 2010;17(6):575\u201382\n\n19. Mittal P, Manohar R, Rawat AK.", "start_char_idx": 229955, "end_char_idx": 233009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56edb2ea-d832-48e1-a724-94a83e10b95d": {"__data__": {"id_": "56edb2ea-d832-48e1-a724-94a83e10b95d", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b69d05c-f395-4901-91a4-5faccc2bc2fc", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "24291050f282181e759a6c073546f82fa6a5c409d8740d0dd77cf6892f054fa4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "649ce2f9-13db-4093-815f-4d5af1186966", "node_type": "1", "metadata": {}, "hash": "3e776fd405e2baa4e4d52d76999359c194b460949f4b20261790051fddb3578c", "class_name": "RelatedNodeInfo"}}, "text": "Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav. 2004;5(2):253\u20135\n\n17. McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomized controlled trial. Lancet. 2005;366(9481):205\u201310\n\n18. McMullan J, Sasson C, Pancioli A, Silbergleit R. Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis. Acad Emerg Med. 2010;17(6):575\u201382\n\n19. Mittal P, Manohar R, Rawat AK. Comparative study of intranasal midazolam and intravenous diazepam sedation for procedures and seizures. Indian J Pediatr. 2006;73(11):975\u20138\n\n20. Mpimbaza A, Ndeezi G, Staedke S, Rosenthal PJ, Byarugaba J. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: a randomized clinical trial. Pediatrics. 2008;121(1):58\u201364\n\n21. Muchohi SN, Kokwaro GO, Ogutu BR, et al. Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. Br J Clin Pharmacol. 2008;66(4):529\u201338\n\n22. Muchohi SN, Obiero K, Newton CR, et al. Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions. Br J Clin Pharmacol. 2008;65(1):12\u201321\n\n23. Rainbow J, Browne GJ, Lam LT. Controlling seizures in the prehospital setting: diazepam or midazolam? J Paediatr Child Health. 2002;38(6):582\u20136\n\n24. Schwartz D, Amir L, Dichter R, et al. The use of a powered device for intraosseous drug and fluid administration in a national EMS: a 4-year experience. J Trauma. 2008;64(3):650\u20135\n\n25. Shah I, Deshmukh CT. Intramuscular midazolam vs. intravenous diazepam for acute seizures. Indian J Pediatr. 2005;72(8):667\u201370\n\n26. Shah MI, Macias CG, Dayan PS, et al. An evidence-based guideline for pediatric prehospital seizure management using GRADE methodology. Prehosp Emerg Care. 2014;18 Suppl 1:15\u201324\n\n27. Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366(7):591\u2013600\n\n28. Silbergleit R, Durkalski V, Lowenstein D, et al; NETT Investigators. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366(7):591\u2013600\n\n29. Silbergleit R et al. RAMPART (rapid anticonvulsant medication prior to arrival trial): a double-blind randomized clinical trial of the efficacy of IM midazolam versus IV lorazepam in the pre-hospital treatment of status epilepticus by paramedics. Epilepsia. 2011;52 Suppl 8:45\u20137\n\n30. Sporer KA, Johnson NJ. Detailed analysis of prehospital interventions in medical priority dispatch system determinants. West J Emerg Med. 2011;12(1):19\u201329\n\n31. Sreenath TG, Gupta P, Sharma KK, Krishnamurthy S. Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: a randomized controlled trial. Eur J Paediatr Neurol. 2010;14(2):162\u20138\n\n32.", "start_char_idx": 232419, "end_char_idx": 235439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "649ce2f9-13db-4093-815f-4d5af1186966": {"__data__": {"id_": "649ce2f9-13db-4093-815f-4d5af1186966", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56edb2ea-d832-48e1-a724-94a83e10b95d", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "defe78cc4ea3dd2b93a0c4637361b99b1ab081bcb0ae07b07373d9ab5c629886", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfdedacb-6f1d-4f5e-b6ee-75f18a47fa8c", "node_type": "1", "metadata": {}, "hash": "26cbbe9906b0dfab2a144aed599f9ae5462bb9a1fdcf85a27fa0d4112b9f9d63", "class_name": "RelatedNodeInfo"}}, "text": "RAMPART (rapid anticonvulsant medication prior to arrival trial): a double-blind randomized clinical trial of the efficacy of IM midazolam versus IV lorazepam in the pre-hospital treatment of status epilepticus by paramedics. Epilepsia. 2011;52 Suppl 8:45\u20137\n\n30. Sporer KA, Johnson NJ. Detailed analysis of prehospital interventions in medical priority dispatch system determinants. West J Emerg Med. 2011;12(1):19\u201329\n\n31. Sreenath TG, Gupta P, Sharma KK, Krishnamurthy S. Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: a randomized controlled trial. Eur J Paediatr Neurol. 2010;14(2):162\u20138\n\n32. Talukdar B, Chakrabarty B. Efficacy of buccal midazolam compared to intravenous diazepam in controlling convulsions in children: a randomized control trial. Brain Dev. 2009;31(10):744\u20139\n\n33. Vilke GM, Sharieff GQ, Marino A, Gerhart AE, Chan TC. Midazolam for the treatment of out-of-hospital pediatric seizures. Prehosp Emerg Care. 2002;6(2):215\u20137\n\n34. Wuerz RC, Swope GW, Holliman J, Vazquez-de Miguel G. Online medical direction: a prospective study. Prehosp Disaster Med. 1995;10(3):51\u20134\n\n________________________\n\nGo To TOC\n\nGeneral Medical\n\nSeizures\n\nRev. March 2022\n\n105\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## General Medical\n\n## Seizures\n\n35. Zarate L, Mandleco B, Wilshaw R, Ravert P. Peripheral intravenous catheters started in prehospital and emergency\ndepartment settings. J Trauma Nurs. 2008;15(2):47\u201352\n\nRevision Date: March 11, 2022\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n## Shock\n\n(Adapted from an evidence-based guideline created using the National Prehospital Evidence-Based Guideline Model Process)\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nInitiate early fluid resuscitation and vasopressors to maintain/restore adequate perfusion to vital organs\nDifferentiate between possible underlying causes of shock to promptly initiate additional therapy\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nSigns of poor perfusion (due to a medical cause) such as one or more of the following:\n\nAltered mental status\nDelayed capillary refill (> 3 seconds)\nFlash capillary refill (> 1 second) seen in early septic shock\nDecreased urine output\nRespiratory rate greater than 20 breaths per minute in adults or elevated in children (See normal vital signs table)\nHypotension for age (lowest acceptable systolic blood pressure in mmHg):\n\nLess than 1 years of age: 60\n1\u201310 years old: (age in years) (2) + 70\nGreater than 10 years old: 90\n\nTachycardia or bradycardia for age, out of proportion to temperature [See Appendix VIII. Abnormal Vital Signs]\nWeak, decreased or bounding pulses\nCool/mottled or flushed/ruddy skin\n\nPotential etiologies of shock:\n\nHypovolemic (hemorrhagic or non-hemorrhagic)\nDistributive (sepsis, anaphylaxis, neurogenic, overdose, endocrine)\nCardiogenic (cardiomyopathy, dysrhythmia, valve disorder)\nObstructive (pulmonary embolism (PE), tension pneumothorax, cardiac tamponade)\nCombined (one form causing another)\n\n#### Exclusion Criteria\n\nShock due to suspected trauma [See Trauma Section]\n\n### Patient Management\n\n#### Assessment\n\nHistory\n\nHistory of GI bleeding\n\n________________________ Go To TOC\n\nGeneral Medical Rev.", "start_char_idx": 234780, "end_char_idx": 238067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfdedacb-6f1d-4f5e-b6ee-75f18a47fa8c": {"__data__": {"id_": "bfdedacb-6f1d-4f5e-b6ee-75f18a47fa8c", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "649ce2f9-13db-4093-815f-4d5af1186966", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "28dedf3083c9d648d9a82e56baf82468b9c4fee44268b2854fb53fdd222ed6f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a3edce0-e362-4db2-92d1-94bbf0f25f97", "node_type": "1", "metadata": {}, "hash": "77f9c5a74b41ea93e1c3025f68b6e98722576d1aa78b874bf13efc83b1d3269a", "class_name": "RelatedNodeInfo"}}, "text": "Abnormal Vital Signs]\nWeak, decreased or bounding pulses\nCool/mottled or flushed/ruddy skin\n\nPotential etiologies of shock:\n\nHypovolemic (hemorrhagic or non-hemorrhagic)\nDistributive (sepsis, anaphylaxis, neurogenic, overdose, endocrine)\nCardiogenic (cardiomyopathy, dysrhythmia, valve disorder)\nObstructive (pulmonary embolism (PE), tension pneumothorax, cardiac tamponade)\nCombined (one form causing another)\n\n#### Exclusion Criteria\n\nShock due to suspected trauma [See Trauma Section]\n\n### Patient Management\n\n#### Assessment\n\nHistory\n\nHistory of GI bleeding\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022\n\nShock 107\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nb. Cardiac problems\n\nc. Stroke\n\nd. Fever\n\ne. Nausea/vomiting, diarrhea\n\nf. Frequent or no urination\n\ng. Syncopal episode\n\nh. Allergic reaction\n\ni. Immunocompromise (malignancy, transplant, asplenia)\n\nj. Adrenal insufficiency\n\nk. Presence of a central line or port\n\nl. Other risk of infection (spina bifida or other genitourinary anatomic abnormality)\n\nm. Overdose\n\n2. Exam\n\na. Airway/breathing (airway edema, rales, wheezing, pulse oximetry, respiratory rate)\n\nb. Circulation (heart rate, blood pressure, capillary refill)\n\nc. Abdomen (hepatomegaly)\n\nd. Mucous membrane hydration\n\ne. Skin (turgor, rash)\n\nf. Neurologic (GCS, sensorimotor deficits)\n\n3. Determination of type of shock\n\na. Cardiogenic\n\nb. Distributive (neurogenic, septic, anaphylactic)\n\nc. Hypovolemic\n\nd. Obstructive (e.g., pulmonary embolism, cardiac tamponade, tension pneumothorax)\n\nTreatment and Interventions\n\n1. Check vital signs\n\n2. Administer oxygen as appropriate with a target of achieving 94\u201398% saturation\n\n3. Cardiac monitor\n\n4. Pulse oximetry and EtCO2 (reading of less than 25 mmHg may be sign of poor perfusion)\n\n5. Check blood sugar, and correct if less than 60 mg/dL\n\n6. EKG\n\n7. Check lactate, if available (greater than 2 mmol/L is abnormal)\n\n8. Establish IV access. If unable to obtain within two attempts or less than 90 seconds, place an IO needle\n\n9. IV fluid volume goal attained by giving boluses that are pressure infused over less than 15 minutes each based on patient\u2019s condition and clinical impression. Fluid volume goal to achieve a mean arterial pressure (adults) or other targets (pediatrics). Mean Arterial Pressure is calculated: (MAP = [(2X diastolic) + (systolic]/3)\n\na. Adult\n\ni. Physiologic target: MAP goal 65 mmHg\n\nii. Fluid goal of up to 30 mL/kg of isotonic fluid by administering rapid, predetermined boluses (e.g., 500 mL) unless the MAP goal is achieved, or pulmonary edema develops.\n\niii. If available, the administration of packed red blood cells or whole blood may be indicated for hemorrhagic shock\n\nb. Pediatric\n\n________________________\n\nGo To TOC\n\nGeneral Medical\n\nRev. March 2022\n\nShock\n\n108\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# National Model EMS Clinical Guidelines Version 3.0\n\ni. Physiologic targets: Systolic blood pressure at least fifth percentile for age, strong distal pulses, warm skin perfusion,\ncapillary refill less than 2 seconds and improving mental status.\n\nii. Fluid goal of up to a total of 60 mL/kg or 1 liter of isotonic fluid by giving 20 mL/kg of isotonic fluid by administering\nrapid boluses (for cardiogenic shock give 10 mL/kg boluses)\n\niii. If available, the administration of packed red blood cells or whole blood may be indicated for hemorrhagic shock\n\n10.", "start_char_idx": 237448, "end_char_idx": 240891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a3edce0-e362-4db2-92d1-94bbf0f25f97": {"__data__": {"id_": "4a3edce0-e362-4db2-92d1-94bbf0f25f97", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfdedacb-6f1d-4f5e-b6ee-75f18a47fa8c", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "42b7fc4d3f702c1e78017ed89ae4b3b58a36f493790c28a29b5fb507b111947f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfd4b491-08f1-4d60-991a-3eda0c66750c", "node_type": "1", "metadata": {}, "hash": "358076b898e79643c77c5ef83a967a0311a6e270afb990354abbc4ca98591d2d", "class_name": "RelatedNodeInfo"}}, "text": "iii. If available, the administration of packed red blood cells or whole blood may be indicated for hemorrhagic shock\n\nb. Pediatric\n\n________________________\n\nGo To TOC\n\nGeneral Medical\n\nRev. March 2022\n\nShock\n\n108\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# National Model EMS Clinical Guidelines Version 3.0\n\ni. Physiologic targets: Systolic blood pressure at least fifth percentile for age, strong distal pulses, warm skin perfusion,\ncapillary refill less than 2 seconds and improving mental status.\n\nii. Fluid goal of up to a total of 60 mL/kg or 1 liter of isotonic fluid by giving 20 mL/kg of isotonic fluid by administering\nrapid boluses (for cardiogenic shock give 10 mL/kg boluses)\n\niii. If available, the administration of packed red blood cells or whole blood may be indicated for hemorrhagic shock\n\n10. If there is a history of adrenal insufficiency, long-term steroid dependence, or fluid-refractory shock requiring vasopressors\ngive:\n\na. Hydrocortisone succinate, 2 mg/kg (maximum 100 mg) IV/IM (preferred) OR\n\nb. Methylprednisolone 2 mg/kg IV (maximum 125 mg) OR\n\nc. Dexamethasone 0.6 mg/kg IV/IM (maximum dose of 16 mg)\n\n11. Vasopressors (shock unresponsive to IV fluids) titrated to physiologic targets\n\na. Cardiogenic, hypovolemic, obstructive shock and distributive shock:\n\ni. Norepinephrine 0.05\u20130.5 mcg/kg/minute\n\n1. Preference in both neurogenic and infectious (sepsis) causes of distributive shock\n\nii. Epinephrine, 0.05\u20130.3 mcg/kg/minute\n\n1. Alternative to a drip, push dose epinephrine may be administered:\n\na. Prepare 10 mcg/mL by diluting 1 mL of epinephrine 0.1 mg/mL (1:10,000) in 9 mL of normal saline\n\nb. Administer 0.01 mg/kg (0.1 mL/kg) up to a maximum single dose of 10 mcg (1 mL) q 3\u20135 minutes titrated to maintain\ngoal MAP. An example is shown below:\n\n\u2022 10 kg child receives 1 mL of the diluted epinephrine\n\n\u2022 20 kg child receives 2 mL of the diluted epinephrine\n\n\u2022 30 kg child receives 3 mL of the diluted epinephrine\n\niii. Dopamine, 2\u201320 mcg/kg/minute if norepinephrine or epinephrine is not available or for other specific causes of shock.\n\n12. For anaphylactic shock, treat per the Anaphylaxis and Allergic Reaction Guideline\n\n13. Provide advanced notification to the hospital\n\n14. Consider empiric antibiotics for suspected septic shock if transport time is anticipated to be prolonged, if blood cultures\ncan be obtained in advance, and/or EMS has coordinated with regional receiving hospitals about choice of antibiotic therapy\n\n15. Antipyretics for fever \u2013 nonsteroidal anti-inflammatory agents are contraindicated in infants less than 6 months of age\n\na. Acetaminophen (15 mg/kg; maximum dose of 1000 mg)\n\nb. Ibuprofen (10 mg/kg; maximum dose of 800 mg)\n\n## Patient Safety Considerations\n\nRecognition of cardiogenic shock - If the patient condition deteriorates after fluid administration, rales or hepatomegaly\ndevelop, then consider cardiogenic shock and withholding further fluid administration\n\nGeneral Medical\n\nShock\n\nRev. March 2022\n\n109\n\n|Content|Page Number|\n|---|---|\n|Go To TOC| |\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n## Notes/Educational Pearls\n\n### Key Considerations\n\nEarly, aggressive IV fluid administration is essential in the treatment of suspected septic shock\nPatients predisposed to shock:\n\nImmunocompromised (patients undergoing chemotherapy or with a primary or acquired immunodeficiency)\nAdrenal insufficiency (Addison's disease, congenital adrenal hyperplasia, chronic or recent steroid use)\nHistory of a solid organ or bone marrow transplant\nInfants\nElderly\n\nIn most adults, tachycardia is the first sign of compensated shock, and may persist for hours.", "start_char_idx": 240061, "end_char_idx": 243740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfd4b491-08f1-4d60-991a-3eda0c66750c": {"__data__": {"id_": "cfd4b491-08f1-4d60-991a-3eda0c66750c", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a3edce0-e362-4db2-92d1-94bbf0f25f97", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "393e31abb82b3191286a666c106619719350d7c922f27e1a53840c05de3268c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b71c35c2-6518-44ff-b2aa-949152b438ca", "node_type": "1", "metadata": {}, "hash": "3a405d079dd146fe4de702826fdb0b3dba7bd5ceb784ad31b1df763be2a2ddcb", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n109\n\n|Content|Page Number|\n|---|---|\n|Go To TOC| |\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n## Notes/Educational Pearls\n\n### Key Considerations\n\nEarly, aggressive IV fluid administration is essential in the treatment of suspected septic shock\nPatients predisposed to shock:\n\nImmunocompromised (patients undergoing chemotherapy or with a primary or acquired immunodeficiency)\nAdrenal insufficiency (Addison's disease, congenital adrenal hyperplasia, chronic or recent steroid use)\nHistory of a solid organ or bone marrow transplant\nInfants\nElderly\n\nIn most adults, tachycardia is the first sign of compensated shock, and may persist for hours. Tachycardia can be a late sign of shock in children and a tachycardic child may be close to cardiovascular collapse\nHypotension indicates uncompensated shock, which may progress to cardiopulmonary failure within minutes. Hypotension is a late and ominous sign in pediatric uncompensated shock\nHydrocortisone succinate, if available, is preferred over methylprednisolone and dexamethasone for the patient with adrenal insufficiency because of its dual glucocorticoid and mineralocorticoid effects\n\nPatients with no reported history of adrenal axis dysfunction may have adrenal suppression due to their acute illness, and hydrocortisone should be considered for any patient showing signs of treatment-resistant shock\nPatients with adrenal insufficiency may have an emergency dose of hydrocortisone available that can be administered IV or IM\n\n### Pertinent Assessment Findings\n\nDecreased perfusion manifested by altered mental status, or abnormalities in capillary refill or pulses, decreased urine output (1 mL/kg/hr):\n\nCardiogenic, hypovolemic, obstructive shock: capillary refill greater than 2 seconds, diminished peripheral pulses, mottled cool extremities\nDistributive shock: flash capillary refill, bounding peripheral pulses\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914127 \u2013 Medical - Hypotension/Shock (Non-Trauma)\n\n### Key Documentation Elements\n\nMedications administered\nFull vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment) with reassessment q 15 minutes or more frequently as appropriate\nLactate level (if available)\nNeurologic status assessment [See Appendix VII. Neurologic Status Assessment]\nAmount of fluids given\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022 Shock 110\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Performance Measures\n\nPercentage of patients who have full vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment),\ntemperature and O2 saturation) documented\nPresence of a decision support tool (laminated card, a protocol, or electronic alert) to identify patients in shock\nPercentage of patients with suspected shock for whom advanced notification to the hospital was provided\nMean time from abnormal vitals to initiation of a fluid bolus\nPercentage of patients who receive pressors for ongoing hypotension after receiving 30 mL/kg isotonic fluid in the setting\nof shock\n\n## References\n\nAnnane D, Bellissant E, Bollaert P, Briegel J, Keh, D, Kupfer Y. Corticosteroids for treating severe sepsis and septic\nshock. 2004. Cochrane Database Syst Rev. 2004;(1):CD002243\nBand, RA, Gaieski DF, Hylton JH, Shofer FS, Goyal M, Meisel ZF. Arriving by emergency medical services improves time\nto treatment endpoints for patients with severe sepsis or septic shock. Acad Emerg Med. 2011;18(9):934\u201340\nBernardin G, Pradier C, Tiger F, Deloffre P, Mattei M. Blood pressure and arterial lactate level are early indicators\nof short-term survival in human septic shock. Intensive Care Med. 1996;22(1):17\u201325\nBoluyt N, Bollen C, Bos A, Kok J, Offringa M. Fluid resuscitation in neonatal and pediatric hypovolemic shock: A Dutch\nPediatric Society evidence-based clinical practice guideline. Intensive Care Med. 2006;32(7):995\u20131003\nBrierley J, Carcillo JA, Choong K, et al.", "start_char_idx": 243049, "end_char_idx": 247130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b71c35c2-6518-44ff-b2aa-949152b438ca": {"__data__": {"id_": "b71c35c2-6518-44ff-b2aa-949152b438ca", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfd4b491-08f1-4d60-991a-3eda0c66750c", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "4e49708f25ec4e69c72b0af413d299940241554ac1afdc91c22f45d93bb88fab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5080571c-37c9-4a9c-b04b-c760b4384c72", "node_type": "1", "metadata": {}, "hash": "42be9d856d3d4d80fa7964439a7292f6964e3137004770c39f2bb9cb28711487", "class_name": "RelatedNodeInfo"}}, "text": "Arriving by emergency medical services improves time\nto treatment endpoints for patients with severe sepsis or septic shock. Acad Emerg Med. 2011;18(9):934\u201340\nBernardin G, Pradier C, Tiger F, Deloffre P, Mattei M. Blood pressure and arterial lactate level are early indicators\nof short-term survival in human septic shock. Intensive Care Med. 1996;22(1):17\u201325\nBoluyt N, Bollen C, Bos A, Kok J, Offringa M. Fluid resuscitation in neonatal and pediatric hypovolemic shock: A Dutch\nPediatric Society evidence-based clinical practice guideline. Intensive Care Med. 2006;32(7):995\u20131003\nBrierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal\npatients in septic shock. Crit Care Med. 2009;37(2):666\u20138\nCarcillo JA, Davis AL, Zaritsky A. Role of early fluid resuscitation in pediatric septic shock. JAMA. 1991;266(9):1242\u20135\nChoong K, Bohn D, Fraser DD, et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled\ntrial. Am J Respir Crit Care Med. 2009;180(7):632\u20139\nChopra A, Kumar V, Dutta A. Hypertonic versus normal saline as initial fluid bolus in pediatric septic shock. Indian J\nPediatr. 2011;78(7):833\u20137\nCronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the\nliterature. Crit Care Med. 1995;23(8):1430\u20139\nCruz AT, Perry AM, Williams EA, Graf JM, Wuestner ER, Patel B. Implementation of goal-directed therapy for children\nwith suspected sepsis in the emergency department. Pediatrics. 2011;127(3): e758\u201366\nDe Backer D, Aldecoa C, Njimi H, Vincent J. Dopamine versus norepinephrine in the treatment of septic shock: a\nmeta-analysis. Crit Care Med. 2011;13(6):1\u20136\nDe Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl\nJ Med. 2010;362(9):779\u201389\nGuyette F, Suffoletto B, Castillo JL, Quintero J, Callaway C, Puyana, JC. Prehospital serum lactate as a predictor of\noutcomes in trauma patients: a retrospective observational study. J Trauma. 2011;70(4):782\u20136\nGuyette FX, Gomez H, Suffoletto B, et al. Prehospital dynamic tissue oxygen saturation response predicts in-hospital\nlifesaving interventions in trauma patients. J Trauma Acute Care Surg. 2012;72(4):930\u20135\nHan YY, Carcillo JA, Dragotta MA, et al. Early reversal of pediatric-neonatal septic shock by\n\n## General Medical Shock\n\nRev. March 2022\n\n111\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\ncommunity physicians is associated with improved outcome. Pediatrics. 2013;112(4):793\u20139\n\n16. Hartholt KA, van Lieshout EM, Thies WC, Patka P, Schipper IB. Intraosseous devices: a randomized controlled\ntrial comparing three intraosseous devices. Prehosp Emerg Care. 2010;14(1):6\u201313\n\n17. Howell MD, David AM. Management of sepsis and septic shock. JAMA. 2017;317(8):847\u20138\n\n18. Hunter CL, Silvestri S, Dean M, Falk JL, Papa L. End-tidal carbon dioxide is associated with mortality and lactate\nin patients with suspected sepsis. Am J Emerg Med (2013) 31, 64\u201371\n\n19.", "start_char_idx": 246508, "end_char_idx": 249561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5080571c-37c9-4a9c-b04b-c760b4384c72": {"__data__": {"id_": "5080571c-37c9-4a9c-b04b-c760b4384c72", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b71c35c2-6518-44ff-b2aa-949152b438ca", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "e678605d05c0dfddb9f65625631a037f4d5d89e2797000912a99780888e3836d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e368f399-145d-4986-8c5e-ae5edf99d1d5", "node_type": "1", "metadata": {}, "hash": "9df380da03610e3730ee560463158f7b341cc87df6e27f894286b49f26d5a9fd", "class_name": "RelatedNodeInfo"}}, "text": "Pediatrics. 2013;112(4):793\u20139\n\n16. Hartholt KA, van Lieshout EM, Thies WC, Patka P, Schipper IB. Intraosseous devices: a randomized controlled\ntrial comparing three intraosseous devices. Prehosp Emerg Care. 2010;14(1):6\u201313\n\n17. Howell MD, David AM. Management of sepsis and septic shock. JAMA. 2017;317(8):847\u20138\n\n18. Hunter CL, Silvestri S, Dean M, Falk JL, Papa L. End-tidal carbon dioxide is associated with mortality and lactate\nin patients with suspected sepsis. Am J Emerg Med (2013) 31, 64\u201371\n\n19. Jansen TC, van Bommel J, Mulder PG, Rommes JH, Schieveld SJ, Bakker, J. The prognostic value of blood lactate\nlevels relative to that of vital signs in the pre-hospital setting: a pilot study. Crit Care. 2008;12(6): R160\n\n20. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy\nis the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589\u201396\n\n21. Lampard JG, Lang E. Vasopressors for hypotensive shock. Ann Emerg Med. 2013;31(3):351\u20132\n\n22. Larsen GY, Mecham N, Greenberg R. An emergency department septic shock protocol and care guideline for\nchildren initiated at triage. Pediatrics. 2011;127(6): e1585\u201392\n\n23. Levy B, Bastien O, Karim B, et al. Experts\u2019 recommendations for the management of adult patients with\ncardiogenic shock. Ann Intensive Care. 2015;5(1):17\n\n24. Lillis KA, Jaffe DM. Prehospital intravenous access in children. Ann Emerg Med. 1992;21(12):1430\u20134\n\n25. Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or dopamine for the treatment of hyperdynamic\nseptic shock? Chest. 1993;103(6):1826\u201331\n\n26. Martin C, Viviand X, Leone M, Thirion X. Effect of norepinephrine on the outcome of septic shock. Crit Care Med.\n2000;28(8):2758\u201365\n\n27. Mikkelsen ME, Miltiades AN, Gaieski DF, et al. Serum lactate is associated with mortality in severe sepsis\nindependent of organ failure and shock. Crit Care Med. 2009;37(5):1670\u20137\n\n28. Morimatsu H, Singh K, Uchino S, Bellomo R, Hart G. Early and exclusive use of norepinephrine in septic shock.\nResuscitation. 2004;62(2):249\u201354\n\n29. Nawrocki PS, Poremba M, Lawner BJ. Push dose epinephrine use in the management of hypotension during\ncritical care transport. Prehosp Emerg Care. 2020;24(2):188\u201395. //doi.org/10.1080/10903127.2019.1588443.\n\n30. Oliveira CF, Nogueira de S\u00e1 FR, Oliveira DS, et al. Time- and fluid-sensitive resuscitation for hemodynamic\nsupport of children in septic shock: barriers to the implementation of the American College of Critical Care\nMedicine/Pediatric Advanced Life Support Guidelines in a pediatric intensive care unit in a developing world.\nPediatr Emerg Care. 2008;24(12):810\u20135\n\n31. Patel GP, Grahe JS, Sperry M, et al. Efficacy and safety of dopamine versus norepinephrine in the management\nof septic shock. Shock. 2010;33(4):375\u201380\n\n32. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of\nsepsis and septic shock: 2016.", "start_char_idx": 249058, "end_char_idx": 252034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e368f399-145d-4986-8c5e-ae5edf99d1d5": {"__data__": {"id_": "e368f399-145d-4986-8c5e-ae5edf99d1d5", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5080571c-37c9-4a9c-b04b-c760b4384c72", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "f023ef604a84a9ca40f001d7abc117b8d7922a869840460a1fa7bf52700d9b6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba1ba382-5680-4b70-a172-f20f39d3bb6e", "node_type": "1", "metadata": {}, "hash": "9110e97bc7ed550ed912ac8eed2e00c9712eeda70681bf566c9c192de0d86571", "class_name": "RelatedNodeInfo"}}, "text": "30. Oliveira CF, Nogueira de S\u00e1 FR, Oliveira DS, et al. Time- and fluid-sensitive resuscitation for hemodynamic\nsupport of children in septic shock: barriers to the implementation of the American College of Critical Care\nMedicine/Pediatric Advanced Life Support Guidelines in a pediatric intensive care unit in a developing world.\nPediatr Emerg Care. 2008;24(12):810\u20135\n\n31. Patel GP, Grahe JS, Sperry M, et al. Efficacy and safety of dopamine versus norepinephrine in the management\nof septic shock. Shock. 2010;33(4):375\u201380\n\n32. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of\nsepsis and septic shock: 2016. Intensive Care Med. Epub 2017 Jan 18\n\n33. Santhanam I, Sangareddi S, Venkataraman S, Kissoon N, Thiruvengadamudayan V, Kasthuri RK. A prospective\nrandomized controlled study of two fluid regimens in the initial management of septic shock in the emergency\ndepartment. Pediatr Emerg Care. 2008;24(10):647\u201355\n\n34. Sebat F, Johnson D, Musthafa AA, et al. A multidisciplinary community hospital program for early and rapid\nresuscitation of shock in nontrauma patients. Chest. 2005;127(5):1729\u201343\n\n35. Seymour CW, Band RA, Cooke CR, et al. Out-of-hospital characteristics and care of patients with severe sepsis: a\ncohort study. J Crit Care. 2010;25(4):553\u201362\n\n________________________\n\nGo To TOC\n\nGeneral Medical\n\nShock\n\nRev. March 2022\n\n112\n---\n## NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n36. Shapiro NI, Howell MD, Talmor D, et al. Implementation and outcomes of the multiple urgent sepsis therapies\n(MUST) protocol. Crit Care Med. 2006;34(4):1025\u201332\n\n37. Sholl JM, Chung S, Prentiss S, Smith JM, Shah MI. An evidence-based guideline for pediatric prehospital shock\nmanagement using GRADE methodology. Manuscript in preparation\n\n38. Studnek JR, Artho MR, Garner CL Jr., Jones AE. The impact of emergency medical services on the ED care of severe\nsepsis. Am J Emerg Med. 2012;30(1):51\u20136\n\n39. Trzeciak S, Dellinger RP, Chansky ME, et al. Serum lactate as a predictor of mortality in patients with\ninfection. Intensive Care Med. 2007;33(6):970\u20137\n\n40. Up To Date. Evaluation of and Initial approach to the adult patient with undifferentiated hypotension and shock.\nAccessed May 27, 2021\n\n41. Up To Date. Initial management of shock in children. Accessed May 27, 2021\n\n42. Van Beest PA, Mulder PJ, Oetomo SB, van den Broek B, Kuiper MA, Spronk PE. Measurement of lactate in a\nprehospital setting is related to outcome. Eur J Emerg Med. 2009;16(6):318\u201322\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nGeneral Medical Shock Rev.", "start_char_idx": 251364, "end_char_idx": 253993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba1ba382-5680-4b70-a172-f20f39d3bb6e": {"__data__": {"id_": "ba1ba382-5680-4b70-a172-f20f39d3bb6e", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e368f399-145d-4986-8c5e-ae5edf99d1d5", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "c6d5961f077bd9378f2f965ef4e7c2112fc3067e2fd6495f9c76a92b8a64d445", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cb65691-478a-473a-a029-9031f6181067", "node_type": "1", "metadata": {}, "hash": "aea2e9d7882e60dd9ebb172dfda77b920aaafb2571e42505c6e93c88a1331828", "class_name": "RelatedNodeInfo"}}, "text": "Serum lactate as a predictor of mortality in patients with\ninfection. Intensive Care Med. 2007;33(6):970\u20137\n\n40. Up To Date. Evaluation of and Initial approach to the adult patient with undifferentiated hypotension and shock.\nAccessed May 27, 2021\n\n41. Up To Date. Initial management of shock in children. Accessed May 27, 2021\n\n42. Van Beest PA, Mulder PJ, Oetomo SB, van den Broek B, Kuiper MA, Spronk PE. Measurement of lactate in a\nprehospital setting is related to outcome. Eur J Emerg Med. 2009;16(6):318\u201322\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nGeneral Medical Shock Rev. March 2022 113\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Sickle Cell Pain Crisis\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nIdentify potentially life-threatening complications of a sickle cell disease\nImprove patient comfort\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nPatient with known sickle cell disease experiencing a pain crisis\n\n#### Exclusion Criteria\n\nPain due to acute traumatic injury [See Trauma Section]\nAbdominal pain due to or related to pregnancy [See OB/GYN Section]\nPatients with sickle cell trait\n\n### Patient Management\n\n#### Assessment\n\nPerform airway assessment and management per the Airway Management Guideline\nObtain vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment) and pulse oximetry\nProvide evaluation and management of altered mental status per the Altered Mental Status Guideline\nProvide evaluation and management of pain per the Pain Management Guideline\nObtain vascular access as necessary to provide analgesia and/or fluid resuscitation\nAssess for potentially serious complications other than pain crisis which may include:\n\nAcute chest syndrome\n\nHypoxia\nChest pain\nFever\n\nStroke [See Suspected Stroke/Transient Ischemic Attack Guideline]\n\nFocal neurologic deficits\n\nMeningitis\n\nHeadache\nAltered mental status\nFever\n\nSeptic arthritis\n\nSevere pain in a single joint\nFever\n\nSplenic sequestration crisis (usually young pediatric patients)\n\nAbdominal pain, LUQ\nSplenic enlargement (examine with care)\nHypotension, tachycardia\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022\n\nSickle Cell Pain Crisis 114\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## General Medical - Sickle Cell Pain Crisis\n\nf. Severe anemia\n\ni. Pallor\n\nii. Fatigue\n\niii. Dyspnea or dyspnea on exertion\n\niv. Shock\n\ng. Infections\n\ni. Pneumonia (cough, fever, sputum shortness of breath)\n\nh. Priapism\n\ni. Painful, prolonged erection in the absence of sexual activity\n\ni. Venous thromboembolism\n\ni. Calf pain, tenderness, swelling, chest/back pain especially with inspiration, shortness of breath\n\n### Assess for signs of shock \u2013 If shock is present, treat per Shock Guideline\n\n### Treatment and Interventions\n\n1. Medication Administration:\n\na. Provide analgesia per the Pain Management Guideline\n\nb. Start oxygen by nasal cannula if hypoxic\n\nc. Start an IV and provide saline 10 mL/kg normal saline bolus (up to 1 L)\n\nd. Provide transport to an appropriate receiving facility.\n\ne. Reassess vital signs and response to therapeutic interventions throughout transport\n\n2. Comfort measures:\n\na. Keep patient warm and dry\n\nb. Transport in a position of comfort unless clinical condition requires otherwise\n\n### Patient Safety Considerations\n\nNone noted\n\n### Notes/Educational Pearls\n\nKey Considerations\n\n1. Assess for life-threatening complications of sickle cell disease \u2013 these patients have significantly higher risk of numerous complications in addition to pain crises\n\n2. Provide appropriate treatment for pain, respiratory distress, and shock\n\n3. These patients may have a higher tolerance to narcotic pain medications if they are taking them on a regular basis\n\n4. These patients will tolerate acute blood loss poorly due to baseline anemia\n\n5. Patients with sickle cell trait can have acute pain crises in extreme conditions (e.g., heat exhaustion, dehydration) and several college athlete deaths have been linked to sickle cell trait\n\n### Pertinent Assessment Findings\n\n1.", "start_char_idx": 253387, "end_char_idx": 257499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cb65691-478a-473a-a029-9031f6181067": {"__data__": {"id_": "9cb65691-478a-473a-a029-9031f6181067", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba1ba382-5680-4b70-a172-f20f39d3bb6e", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "26231ae58ceb299a19f21cbfdf4f0686fba7c836e0d9944f45a8981036d1c4b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36601084-14f5-4891-8843-cf3da093f2e2", "node_type": "1", "metadata": {}, "hash": "6e8dfa5d2af08a3e9614bd8a2e8a73c73c79c8889a18c1aaa17d30826907b039", "class_name": "RelatedNodeInfo"}}, "text": "Comfort measures:\n\na. Keep patient warm and dry\n\nb. Transport in a position of comfort unless clinical condition requires otherwise\n\n### Patient Safety Considerations\n\nNone noted\n\n### Notes/Educational Pearls\n\nKey Considerations\n\n1. Assess for life-threatening complications of sickle cell disease \u2013 these patients have significantly higher risk of numerous complications in addition to pain crises\n\n2. Provide appropriate treatment for pain, respiratory distress, and shock\n\n3. These patients may have a higher tolerance to narcotic pain medications if they are taking them on a regular basis\n\n4. These patients will tolerate acute blood loss poorly due to baseline anemia\n\n5. Patients with sickle cell trait can have acute pain crises in extreme conditions (e.g., heat exhaustion, dehydration) and several college athlete deaths have been linked to sickle cell trait\n\n### Pertinent Assessment Findings\n\n1. Lung exam and assessment of respiratory distress\n\n2. Altered mental status\n\n3. Focal neurologic deficits\n\n4. Inability to move a joint\n\n________________________ Go To TOC\n\nGeneral Medical Rev. March 2022 Sickle Cell Pain Crisis 115\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914165 \u2013 Other\n\n### Key Documentation Elements\n\nDocumentation of normal respiratory and neuro status\nDocumentation of how this pain crisis compares with others in terms of location, severity, and triggers\nDocumentation of home pain medications used\n\n### Performance Measures\n\nAssessment for life-threatening etiology\nMitigation of pain per the Pain Management Guideline\n\n## Reference\n\nCintho Ozahata M, Page GP, Guo Y, et al. Clinical and Genetic Predictors of Priapism in Sickle Cell Disease: Results from the Recipient Epidemiology and Donor Evaluation Study III Brazil Cohort Study. J Sex Med 2019; 16:1988\nMitchell BL. Sickle cell trait and sudden death \u2013 bringing it home. J Natl Med Assoc. 2007;99(3):300\u20135\n\n### Revision Date\n\nMarch 11, 2022\n\n________________________ Go To TOC\n\n## General Medical\n\nRev. March 2022\n\n## Sickle Cell Pain Crisis\n\n116\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Resuscitation\n\n### Cardiac Arrest (VF/VT/Asystole/PEA)\n\n### Aliases\n\nArrest, Full arrest, Heart attack\n\n### Patient Care Goals\n\nReturn of spontaneous circulation (ROSC)\nPreservation of neurologic function\nHigh-quality chest compressions/CPR with minimal interruption from recognition of cardiac arrest until confirmation\nof ROSC or field termination of care\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nPatients with cardiac arrest\n\n#### Exclusion Criteria\n\nPatients suffering cardiac arrest due to severe hypothermia [See Hypothermia/Cold Exposure Guideline]\nPatients with identifiable Do Not Resuscitate (or equivalent such as POLST) order [See Do Not Resuscitate\nStatus/Advance Directive/Healthcare Power of Attorney (POA) Status Guideline]\nPatients in arrest due to traumatic etiology [See General Trauma Management Guideline]\n\n### Patient Management\n\n#### Assessment\n\nThe patient in cardiac arrest requires a prompt balance of treatment and assessment\nIn cases of cardiac arrest, assessments should be focused and limited to obtaining enough information to reveal\nthe patient is pulseless\nOnce pulselessness is discovered, treatment should be initiated immediately, and any further history must be\nobtained by bystanders while treatment is ongoing\n\n#### Treatment and Interventions\n\nThe most important therapies for patients suffering from cardiac arrest are prompt cardiac defibrillation for\nshockable rhythms and minimally interrupted effective chest compressions\n\nInitiate chest compressions in cases with no bystander chest compressions or take over compressions from\nbystanders while a second rescuer is setting up the AED or defibrillator\n\nIf adequate, uninterrupted bystander CPR has been performed or if the patient arrests in front of the EMS\nclinicians, immediately proceed with rhythm analysis and defibrillation, if appropriate\nIt is realistic for EMS clinicians to tailor the sequence of rescue actions to coincide the most likely cause\nof arrest\nThere is insufficient evidence to recommend for or against delaying defibrillation to provide a period of CPR\nfor patients in VF/pulseless VT out-of-hospital cardiac arrest\n\nGo To TOC\n\n## Resuscitation\n\nRev.", "start_char_idx": 256592, "end_char_idx": 261049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36601084-14f5-4891-8843-cf3da093f2e2": {"__data__": {"id_": "36601084-14f5-4891-8843-cf3da093f2e2", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cb65691-478a-473a-a029-9031f6181067", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "d31396d7dcb4d125280a124ebd9c1f7b84e882a48296832a3e987d83aa15db34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e08820ea-03f2-4a04-8f1e-5c0d71cfb10d", "node_type": "1", "metadata": {}, "hash": "fbf87f2d96e1e2f02a5be95a704807bface734b3f190a4d46309ed21ead3637d", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n### Cardiac Arrest (VF/VT/Asystole/PEA)\n\n117\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\nd. For adults and children with unwitnessed cardiac arrest or for whom an AED is not immediately available, it is reasonable that CPR be initiated while the defibrillator equipment is being retrieved and applied and that defibrillation, if indicated, be attempted as soon as the device is ready for use\n\nThe maximum setting on the defibrillator should be used for initial and subsequent defibrillation attempts. Defibrillation dosing should follow manufacturer\u2019s recommendation in the case of biphasic defibrillators. If the manufacturer\u2019s recommendation is unknown, use highest setting possible. In the case of monophasic devices, the setting should be 360J (joule) (or 4 J/kg for children)\nChest compressions should resume immediately after defibrillation attempts with no pauses for pulse checks for 2 minutes regardless of the rhythm displayed on the cardiac monitor\nAll attempts should be made to prevent avoidable interruptions in chest compressions, such as pre-charging the defibrillator and hovering over the chest, rather than stepping away during defibrillations\nIf feasible, IV or IO access should be obtained. Administer epinephrine during the first or second round of compressions. Prioritize early administration of epinephrine for non-shockable rhythms\nContinue the cycle of chest compressions for 2 minutes, followed by rhythm analysis and defibrillation of shockable rhythms; during this period, the proper strategy of airway management is currently not defined and many options for airway management exist. Regardless of the airway management and ventilation strategy, consider the following principles:\n\nThe airway management strategy should not interrupt compressions\nSuccessful resuscitation from cardiac arrest depends primarily on effective, minimally interrupted chest compressions and prompt defibrillation if the patient is in pulseless VT/VF. As opposed to children, an adult\u2019s airway management is of secondary importance and should not interfere with compressions and defibrillation. Options for airway management include:\n\nPassive ventilation:\n\nHigh flow oxygen is applied via a non-rebreather mask with an oropharyngeal airway\nSome oxygen will be entrained with each decompression of the chest\nThis may be applied for the first 3\u20134 compression cycles (6\u20138 minutes), after which one may consider BVM ventilation or placement of an advanced airway\n\nBVM ventilation at 10 breaths per minute (1 breath every 10 compressions), applied during the upstroke between compressions, without interrupting the compressions\nBVM ventilation with 30:2 ventilation to compression ratio: Each 30 compressions, the compressions are paused briefly to allow 2 BVM ventilations, then compressions immediately resumed\n\nPediatric Consideration: For multiple rescuer CPR in children, 15:2 is the recommended compression-to-ventilation ratio (30:2 for single rescuer)\nPediatric Consideration: For neonates, 3:1 is the recommended compression-to-ventilation ratio\n\nAdvanced airway placement:\n\nEither a supraglottic airway or an endotracheal tube may be placed without interruption of compressions\nVentilations are provided at 10 breaths/minute for adults\n\nResuscitation Rev. March 2022 Cardiac Arrest (VF/VT/Asystole/PEA) 118\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n3. Pediatric Consideration: for children, 1 breath every 3\u20135 seconds is recommended (12\u201320 breaths/minute)\n\n4. Pediatric Consideration: deliver volume needed to achieve chest rise\n\n7. Consider use of antiarrhythmic for recurrent VF/Pulseless VT\n\na. The principal objective of antiarrhythmic drug therapy in shock-refractory VF and pulseless VT is to facilitate the restoration and maintenance of a spontaneous perfusing rhythm in concert with the shock termination of VF/VT; some antiarrhythmic drugs have been associated with increased rates of ROSC and hospital admission, but none have yet been proven to increase long-term survival or survival with good neurologic outcome\n\ni. Amiodarone (5 mg/kg IV, max of 300 mg) may be considered for VF/pulseless VT that is unresponsive to CPR, defibrillation, and a vasopressor therapy\nii. Lidocaine (1 mg/kg IV) may be considered as an alternative to amiodarone for VF/pulseless VT that is unresponsive to CPR, defibrillation, and vasopressor therapy\niii.", "start_char_idx": 261050, "end_char_idx": 265453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e08820ea-03f2-4a04-8f1e-5c0d71cfb10d": {"__data__": {"id_": "e08820ea-03f2-4a04-8f1e-5c0d71cfb10d", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36601084-14f5-4891-8843-cf3da093f2e2", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "1c20c86093e4014d0004101c84f365208d867cd4d45996bccd8e03c1d0e0ec6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ced1544d-e977-49eb-8e8c-8e4cbe90fdec", "node_type": "1", "metadata": {}, "hash": "622bd7ce3b91ff6326aef6cd1de959a41fb2e9833c2608e84971c7b9b587835e", "class_name": "RelatedNodeInfo"}}, "text": "Consider use of antiarrhythmic for recurrent VF/Pulseless VT\n\na. The principal objective of antiarrhythmic drug therapy in shock-refractory VF and pulseless VT is to facilitate the restoration and maintenance of a spontaneous perfusing rhythm in concert with the shock termination of VF/VT; some antiarrhythmic drugs have been associated with increased rates of ROSC and hospital admission, but none have yet been proven to increase long-term survival or survival with good neurologic outcome\n\ni. Amiodarone (5 mg/kg IV, max of 300 mg) may be considered for VF/pulseless VT that is unresponsive to CPR, defibrillation, and a vasopressor therapy\nii. Lidocaine (1 mg/kg IV) may be considered as an alternative to amiodarone for VF/pulseless VT that is unresponsive to CPR, defibrillation, and vasopressor therapy\niii. The routine use of magnesium for VF/pulseless VT is not recommended in adult patients unless it is refractory, polymorphic VT, or Torsades de pointes.\n\nb. There is inadequate evidence to support the routine use of lidocaine and beta-blockers after cardiac arrest by EMS. There is insufficient evidence to recommend for or against the routine initiation or continuation of other antiarrhythmic medications after ROSC from cardiac arrest\nc. For torsades de pointes, give magnesium sulfate 2 g IV administered over 1\u20132 minutes (or 25\u201350 mg/kg for pediatrics). There is insufficient evidence to recommend for or against the routine administration during cardiac arrest\n\n8. Consider reversible causes of cardiac arrest which include the following:\n\na. Hypothermia \u2013 additions to care include attempts at active rewarming [See Hypothermia/Cold Exposure Guideline]\nb. The dialysis patient/known hyperkalemic patient \ufffd\ufffd Additions to care include the following:\n\ni. Calcium gluconate 10% 1 g IV bolus over 2 minutes (for pediatrics, the dose is 100 mg/kg which is 1 mL/kg), can repeat the dose if no response OR\nii. Calcium chloride 10% 1 g IV bolus over 2 minutes (for pediatrics, the dose is 20 mg/kg which is 0.2 mL/kg)\niii. Sodium bicarbonate 1 mEq/kg IV\n\nc. Tricyclic antidepressant overdose. Additions to care include sodium bicarbonate 1 mEq/kg IV\nd. Hypovolemia. Additions to care include normal saline 2 L IV (or 20 mL/kg, repeated up to 3 times for pediatrics)\ne. If the patient is intubated at the time of arrest, assess for tension pneumothorax and misplaced ETT\nf. If tension pneumothorax suspected, perform needle decompression. Assess ETT, if misplaced, replace ETT\n\n9. If at any time during this period of resuscitation the patient regains return of spontaneous circulation, treat per Adult Post-ROSC (Return of Spontaneous Circulation) Care Guideline\n\n10. If resuscitation remains ineffective, consider termination of resuscitation [See Termination of Resuscitative Efforts Guideline]\n\nResuscitation Rev. March 2022 Cardiac Arrest (VF/VT/Asystole/PEA) 119\n\nGo To TOC\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Patient Safety Considerations\n\n1. Performing manual chest compressions in a moving vehicle may pose a clinician safety concern\n\n2. In addition, manual chest compressions during patient movement are less effective in regard to hands on time, depth, recoil and rate\n\n3. Ideally, patients should be resuscitated as close to the scene as operationally possible\n\n4. Risks and benefits should be considered before patient movement in cardiac arrest situations\n\n## Notes/Educational Pearls\n\n### Key Considerations\n\n1. Effective chest compressions and defibrillation are the most important therapies to the patient in cardiac arrest. Effective chest compressions are defined as:\n\na. A rate of greater than 100 and less than 120 compressions/minute\nb. Depth of at least 2 inches (5 cm) and less than 2.4 inches (6 cm) for adults and children or 1.5 inches (4 cm) for infants; adolescents who have entered puberty should receive the same depth of chest compressions as an adult\nc. Allow for complete chest recoil (avoid leaning)\nd. Minimize interruptions in compressions\ne. Avoid rescuer fatigue by rotating rescuers at least every 2 minutes.", "start_char_idx": 264638, "end_char_idx": 268722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ced1544d-e977-49eb-8e8c-8e4cbe90fdec": {"__data__": {"id_": "ced1544d-e977-49eb-8e8c-8e4cbe90fdec", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e08820ea-03f2-4a04-8f1e-5c0d71cfb10d", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "bcfd998907aad009cd50e556c2fdb96299dbbd25929242cd94fe88ed3a36765b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a3b97b9-209d-46ef-a814-1918e1b13f3f", "node_type": "1", "metadata": {}, "hash": "dcd8483a7ff81ad477e25ce2456cce9335f1f87c3eda67d2c494ea667c03807a", "class_name": "RelatedNodeInfo"}}, "text": "Ideally, patients should be resuscitated as close to the scene as operationally possible\n\n4. Risks and benefits should be considered before patient movement in cardiac arrest situations\n\n## Notes/Educational Pearls\n\n### Key Considerations\n\n1. Effective chest compressions and defibrillation are the most important therapies to the patient in cardiac arrest. Effective chest compressions are defined as:\n\na. A rate of greater than 100 and less than 120 compressions/minute\nb. Depth of at least 2 inches (5 cm) and less than 2.4 inches (6 cm) for adults and children or 1.5 inches (4 cm) for infants; adolescents who have entered puberty should receive the same depth of chest compressions as an adult\nc. Allow for complete chest recoil (avoid leaning)\nd. Minimize interruptions in compressions\ne. Avoid rescuer fatigue by rotating rescuers at least every 2 minutes. Some EMS pit crew approaches use a clinician on either side of the chest, alternating compressions every minute or every 100 compressions to avoid fatigue\n\n2. Avoid excessive ventilation and consider delayed airway management \u2013 If no advanced airway, consider:\n\na. Passive ventilation using an NRB with 3\u20134 cycles of uninterrupted chest compressions (for arrests of suspected cardiac etiology). Consider BVM ventilation or advanced airway after 3\u20134 cycles\nb. BVM ventilation every 10\u201315 compressions with cycles of uninterrupted chest compressions. Upstroke ventilation between compressions. 30:2 ventilation to compression ratio for adults, and 15:2 for children when 2 rescuers are present\nc. If an advanced airway is placed, ventilations should not exceed 10 breaths/minute (1 breath every 6 seconds or 1 breath every 10 compressions) in adults. Pediatric Consideration: For children with an advanced airway, 1 breath every 3\u20135 seconds is recommended (equivalent to 12\u201320 breaths/minute)\n\n3. Quantitative end-tidal capnography (EtCO2) should be used to monitor effectiveness of chest compressions\n\na. If EtCO2 less than 10 mmHg during the initial phases of resuscitation, attempt to improve chest compression quality\nb. Consider additional monitoring with biometric feedback which may improve compliance with suggested Resuscitation Section\n\n4. Chest compressions are usually the most rapidly applied therapy for the patient in cardiac arrest and should be initiated as soon as the patient is noted to be pulseless. If the patient is being monitored with pads in place at the time of arrest, immediate defibrillation should take precedence over all other therapies. However, if there is any delay in defibrillation (e.g., in order to place pads), chest compressions should be initiated while the defibrillator is being applied. There is no guidance on how long these initial compressions should be applied; however, it is reasonable to either complete between 30 seconds and 2 minutes of chest\n\nResuscitation Rev. March 2022 Cardiac Arrest (VF/VT/Asystole/PEA) 120\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n5. There is insufficient evidence to recommend the routine use of extracorporeal CPR (ECPR) for patients with cardiac arrest. In settings where it can be rapidly implemented, ECPR may be considered for select cardiac arrest patients for whom the suspected etiology of the cardiac arrest is potentially reversible during a limited period of mechanical cardiorespiratory support\n\n6. Chest compressions should be reinitiated immediately after defibrillation as pulses, if present, are often difficult to detect and rhythm and pulse checks interrupt compressions\n\n7. Continue chest compressions between completion of AED analysis and AED charging\n\n8. The effectiveness of chest compressions decreases when moving patients\n\na. Patients should therefore be resuscitated as close to the point at which they are first encountered and should only be moved if the conditions on scene are unsafe or do not operationally allow for resuscitation\nb. Chest compressions are also less effective in a moving vehicle\nc. It is also dangerous to EMS clinicians, patients, pedestrians, and other motorists to perform chest compressions in a moving ambulance\nd. For these reasons and because in most cases the care provided by EMS clinicians is equivalent to that provided in emergency departments, resuscitation should occur on scene\n\n9. The maximum setting on the defibrillator should be used for initial and subsequent defibrillation attempts. Defibrillation dosing should follow manufacturer\u2019s recommendation in the case of biphasic defibrillators.", "start_char_idx": 267858, "end_char_idx": 272402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a3b97b9-209d-46ef-a814-1918e1b13f3f": {"__data__": {"id_": "1a3b97b9-209d-46ef-a814-1918e1b13f3f", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ced1544d-e977-49eb-8e8c-8e4cbe90fdec", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "f3e7e96c259c4d6a400f68263b9ff30fcadd4224c3aad427ebaa35ec5f3fafb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76f7a18e-9e55-4515-9a86-faabbfbcbd4e", "node_type": "1", "metadata": {}, "hash": "51559dc2c1fbe227ac412fd7246d3896d2f085315339403c0f8c8efa4a29bbbe", "class_name": "RelatedNodeInfo"}}, "text": "Continue chest compressions between completion of AED analysis and AED charging\n\n8. The effectiveness of chest compressions decreases when moving patients\n\na. Patients should therefore be resuscitated as close to the point at which they are first encountered and should only be moved if the conditions on scene are unsafe or do not operationally allow for resuscitation\nb. Chest compressions are also less effective in a moving vehicle\nc. It is also dangerous to EMS clinicians, patients, pedestrians, and other motorists to perform chest compressions in a moving ambulance\nd. For these reasons and because in most cases the care provided by EMS clinicians is equivalent to that provided in emergency departments, resuscitation should occur on scene\n\n9. The maximum setting on the defibrillator should be used for initial and subsequent defibrillation attempts. Defibrillation dosing should follow manufacturer\u2019s recommendation in the case of biphasic defibrillators. If the manufacturer\u2019s recommendation is unknown, use highest setting possible. In the case of monophasic devices, the setting should be 360 J (joule) (or 4 J/kg for children)\n\n10. IV or IO access without interrupting chest compressions\n\n11. Administer epinephrine (0.1 mg/kg, maximum dose 1 mg) IV/IO during the first or second round of compressions\n\n12. At present, the most effective mechanism of airway management is uncertain due to some systems managing the airway aggressively and others managing the airway with basic measures and both types of systems finding excellent outcomes. Regardless of the airway management style, consider the following principles:\n\na. Airway management should not interrupt chest compressions\nb. Carefully follow ventilation rate and prevent hyperventilation\nc. Consider limited tidal volumes\nd. There is uncertainty regarding the proper goals for oxygenation during resuscitation\n\ni. Current recommendations suggest using the highest flow rate possible through NRB or BVM\nii. This should not be continued into the post-resuscitation phase in which the goal should be an oxygen saturation (SpO2) of 94\u201398%\n\ne. Pediatric Considerations: Special attention should be applied to the pediatric population and airway management/respiratory support. Given that the most likely cause of cardiac arrest is respiratory, airway management may be considered early in the patient\u2019s care\n\ni. However, the order of Circulation-Airway-Breathing is still recommended as the order of priority by the American Heart Association for pediatric resuscitation to ensure timely initiation of chest compressions to maintain perfusion, regardless of the underlying cause of the arrest\n\n________________________ Go To TOC\n\nResuscitation Rev. March 2022\n\nCardiac Arrest (VF/VT/Asystole/PEA) 121\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## 13. Special Circumstances in Cardiac Arrest\n\na. Trauma, treat per the General Trauma Management Guideline\n\nb. Pregnancy\n\ni. The best hope for fetal survival is maternal survival\n\nii. Position the patient in the supine position with a second rescuer performing manual uterine displacement to the\nleft to displace the gravid uterus and increase venous return by avoiding aorto-caval compression\n\niii. If manual displacement is unsuccessful, the patient may be placed in the left lateral tilt position at 30\u00b0. This\nposition is less desirable than the manual uterine displacement as chest compressions are more difficult to perform\nin this position\n\niv. Chest compressions should be performed slightly higher on the sternum than in the non-pregnant patient to\naccount for elevation of the diaphragm and abdominal contents in the obviously gravid patient\n\nv. Defibrillation should be performed as in non-pregnant patients\n\nc. Arrests of respiratory etiology (including drowning). In addition to the above, consider early management of the\npatient\u2019s airway. Passive ventilation with a NRB is not indicated for these patients\n\n## 14. Application of the \u201cpit crew\u201d model of resuscitation\n\na. Ideally, clinicians in each EMS agency will use a \u201cpit crew\u201d approach when using this protocol to ensure the most\neffective and efficient cardiac arrest care. Training should include teamwork simulations integrating first responders,\nBLS, and ALS crewmembers who regularly work together. High-performance systems should practice teamwork using\n\u201cpit crew\u201d techniques with predefined roles and crew resource management principles.", "start_char_idx": 271435, "end_char_idx": 275886, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76f7a18e-9e55-4515-9a86-faabbfbcbd4e": {"__data__": {"id_": "76f7a18e-9e55-4515-9a86-faabbfbcbd4e", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a3b97b9-209d-46ef-a814-1918e1b13f3f", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "f1e98e6e89d8eb1359e312409a0683a466a5f7de5b85c56271a155ffc6d850ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75a48158-a4bc-4389-a621-57493449b494", "node_type": "1", "metadata": {}, "hash": "4cc2e2f24dffa2c1260f2b19cbcef320b855c0846aead238af80d38b9ca063a6", "class_name": "RelatedNodeInfo"}}, "text": "Chest compressions should be performed slightly higher on the sternum than in the non-pregnant patient to\naccount for elevation of the diaphragm and abdominal contents in the obviously gravid patient\n\nv. Defibrillation should be performed as in non-pregnant patients\n\nc. Arrests of respiratory etiology (including drowning). In addition to the above, consider early management of the\npatient\u2019s airway. Passive ventilation with a NRB is not indicated for these patients\n\n## 14. Application of the \u201cpit crew\u201d model of resuscitation\n\na. Ideally, clinicians in each EMS agency will use a \u201cpit crew\u201d approach when using this protocol to ensure the most\neffective and efficient cardiac arrest care. Training should include teamwork simulations integrating first responders,\nBLS, and ALS crewmembers who regularly work together. High-performance systems should practice teamwork using\n\u201cpit crew\u201d techniques with predefined roles and crew resource management principles. For example (the Pennsylvania\nState EMS Model for Pit Crew):\n\ni. Rescuer 1 and 2 set up on opposite sides of patient\u2019s chest and perform continuous chest compressions, alternating\nafter every 100 compressions to avoid fatigue\n\nii. Use a metronome or CPR feedback device to ensure that compression rate is 100\u2013120/minute\n\niii. Chest compressions are only interrupted during rhythm check (AED analysis or manual) and defibrillation shocks \u2013\nContinue compressions when AED/defibrillator is charging\n\niv. Additional rescuer obtains IO (or IV) access and gives epinephrine. For IO access:\n\n1. The proximal humerus is the preferred site for adults\n\n2. The tibial site is preferred for infants and children\n\nv. During the first four cycles of compressions/defibrillation (approximately 10 minutes) avoid advanced airway\nplacement\n\nvi. One responding clinician assumes code leader position overseeing the entire response\n\nvii. Use a CPR checklist to ensure that all best practices are followed during CPR\n\nb. For efficient \u201cpit crew\u201d style care, the EMS agency medical director should establish the options that will be used\nby clinicians functioning within the EMS agency. Options include\n\ni. The airway/ventilation management, if any, that will be used\n\nii. The initial route of vascular access\n\n## 15. The EMS agency must perform a Quality Improvement (QI) review of care and outcome, overseen by the agency\nmedical director, for every patient that receives CPR\n\n________________________ Go To TOC\n\nResuscitation Rev. March 2022\n\nCardiac Arrest (VF/VT/Asystole/PEA) 122\n---\n# Document\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\na. The QI should be coordinated with local receiving hospitals to include hospital admission, discharge, and condition information. This EMS agency QI can be accomplished by participation an organized cardiac arrest registry\n\nb. The QI should be coordinated with local PSAP/dispatch centers to review opportunities to assure optimal recognition of possible cardiac arrest cases and provision of dispatch-assisted CPR (including hands-only CPR when appropriate)\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914011 \u2013 Cardiac Arrest - Asystole\n9914013 \u2013 Cardiac Arrest - Hypothermia-Therapeutic\n9914015 \u2013 Cardiac Arrest - Pulseless Electrical Activity\n9914017 \u2013 Cardiac Arrest - Ventricular Fibrillation/Pulseless Ventricular Tachycardia\n9914055 \u2013 General - Cardiac Arrest\n9914087 \u2013 Injury - Cardiac Arrest\n\n### Key Documentation Elements\n\nShould be tailored to any locally utilized data registry but may include as a minimum the following elements:\n\nResuscitation attempted and all interventions performed\nArrest witnessed\nLocation of arrest\nFirst monitored rhythm\nCPR before EMS arrival\nOutcome\nAny ROSC\nPresumed etiology\n\nPresumed cardiac\nTrauma\nSubmersion\nRespiratory\nOther non-cardiac\nUnknown\n\n### Performance Measures\n\nTime to scene\nTime to patient\nTime to first CPR\nTime to first shock\nTime of ROSC\nReview of CPR quality\n\nCompression fraction\nAverage and longest peri-shock pause\nRate and depth of compressions\n\nGo To TOC\n\n## Resuscitation\n\nCardiac Arrest (VF/VT/Asystole/PEA)\n\nRev. March 2022\n\n123\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n## References\n\n|1.|Atkins DL, Berger S, Duff JP, et al.", "start_char_idx": 274924, "end_char_idx": 279240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75a48158-a4bc-4389-a621-57493449b494": {"__data__": {"id_": "75a48158-a4bc-4389-a621-57493449b494", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76f7a18e-9e55-4515-9a86-faabbfbcbd4e", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "179e73fd921cff0794cd16ee71ad24514858071e1d1be70caba473d28f765c62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7dca7282-c74c-4730-b0c3-c7facfe84305", "node_type": "1", "metadata": {}, "hash": "47d785dc0c021c8cecb800aedf30976d9b2a4effb74e1cd5943a4e4bc956b759", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n123\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n## References\n\n|1.|Atkins DL, Berger S, Duff JP, et al. Part 11: Pediatric Basic Life Support: 2015 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18 Suppl 2): S519\u201325|\n|---|---|\n|2.|Bobrow BJ, Clark LL, Ewy GA, et al. Minimally interrupted cardiac resuscitation by emergency medical services for out-of-hospital cardiac arrest. JAMA. 2008;299(10):1158\u201365|\n|3.|Brooks, Anderdon ML, Bruder E, et al. Part 6: alternative techniques and ancillary devices for cardiopulmonary resuscitation: 2015 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18 Suppl 2): S436\u201343|\n|4.|De Caen R, Berg MD, Chameides L, et al. Part 12: Pediatric Advanced Life Support: 2015 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18 Suppl 2) S526\u201342|\n|5.|Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002;346(12):884\u201390|\n|6.|Ewy GA. The cardiocerebral resuscitation protocol for treatment of out-of-hospital primary cardiac arrest. Scand J Trauma Resusc Emerg Med. 2012; 20:65|\n|7.|Garza AG, Gratton MC, Salomone JA, Lindholm D, McElroy J, Archer R. Improved patient survival using a modified resuscitation protocol for out-of-hospital cardiac arrest. Circulation. 2009;119(19):2597\u2013605|\n|8.|Grunau B, Kime N, Leroux B, et al. Association of Intra-arrest Transport vs Continued On-Scene Resuscitation With Survival to Hospital Discharge Among Patients With Out-of-Hospital Cardiac Arrest. JAMA. 2020;324(11):1058-1067|\n|9.|Grunau B, Kawano T, Rea TD, et al. Emergency medical services employing intra-arrest transport less frequently for out-of-hospital cardiac arrest have higher survival and favorable neurological outcomes. Resuscitation. Sep 9, 2021|\n|10.|Hinchey PR, Myers JB, Lewis R, et al. Improved out-of-hospital cardiac arrest survival after the sequential implementation of 2005 AHA guidelines for compressions, ventilations, and induced hypothermia: the Wake County experience. Ann Emerg Med. 2010;56(4):348\u2013357|\n|11.|Hopkins CL, Burk C, Moser S, Meersman J, Baldwin C, Youngquist ST. Implementation of pit crew approach and cardiopulmonary resuscitation metrics for out-of-hospital cardiac arrest improves patient survival and neurological outcome. J Am Hear Assoc. 2016,5|\n|12.|Hostler D, Everson-Stewart S, Rea TD, et al. Effect of real-time feedback during CPR. BMJ. 2011;342: d512|\n|13.|Huang CH, Yu PH, Tsai MS, et al. Acute hospital administration of amiodarone and/or lidocaine in shockable patients presenting with out-of-hospital cardiac arrest: a nationwide cohort study. Int J Cardiol. 2017; 227:292\u20138|\n|14.|Jacobs I, Hadkarni V, Bahr J, et al. Cardiac arrest and cardiopulmonary resuscitation outcome reports: update and simplification of the Utstein templates for resuscitation registries. Circulation. 2004;110(21):3385\u201397|\n|15.|Kleinman ME, Brennan EE, Goldberger ZD, et al. Part 5: Adult Basic Life Support: 2015 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation.", "start_char_idx": 279095, "end_char_idx": 282477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7dca7282-c74c-4730-b0c3-c7facfe84305": {"__data__": {"id_": "7dca7282-c74c-4730-b0c3-c7facfe84305", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75a48158-a4bc-4389-a621-57493449b494", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "63df019a4871e40d931190993324440721bed5cf6e11cd0ae4e2c6b142fb31c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a0a3d38-b758-4655-978a-349506737657", "node_type": "1", "metadata": {}, "hash": "854be6b92adf60df3faa7e54651dc4bf30516e07c9d7c7a2868434f8f91e335b", "class_name": "RelatedNodeInfo"}}, "text": "2011;342: d512|\n|13.|Huang CH, Yu PH, Tsai MS, et al. Acute hospital administration of amiodarone and/or lidocaine in shockable patients presenting with out-of-hospital cardiac arrest: a nationwide cohort study. Int J Cardiol. 2017; 227:292\u20138|\n|14.|Jacobs I, Hadkarni V, Bahr J, et al. Cardiac arrest and cardiopulmonary resuscitation outcome reports: update and simplification of the Utstein templates for resuscitation registries. Circulation. 2004;110(21):3385\u201397|\n|15.|Kleinman ME, Brennan EE, Goldberger ZD, et al. Part 5: Adult Basic Life Support: 2015 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;312(18 Suppl 2): S414\u201335|\n|16.|Kronick SL, Kurz MC, Lin S, et al. Part 4: systems of care and continuous quality improvement: 2015 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18 Suppl 2): S397\u2013413|\n\nResuscitation\n\nRev. March 2022\n\nCardiac Arrest (VF/VT/Asystole/PEA)\n\n124\n\nGo To TOC\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n17. Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016;374(18):1711\u20131722\n\n18. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999;341(12):871\u2013878\n\n19. Lavonas EJ, Drennan IR, Gabrielli A, et al. Part 10: cardiac arrest in special situations: 2015 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18 Suppl 2): S501\u201318\n\n20. Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: adult advanced cardiovascular life support: 2015 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18 Suppl 2): S444\u201364\n\n21. Neumar RW, Shuster M, Callaway CW, et al. Part 1: executive summary: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18 Suppl 2) S315\u201367\n\n22. Nichol G, Leroux B, Wang H, et al. Trial of continuous or interrupted chest compressions during CPR. N Engl J Med. 2015;373(23):2203\u201314\n\n23. Sporer K, Jacobs M, Derevin L, Duval S, Pointer J. Continuous quality improvement efforts increase survival with favorable neurologic outcome after out-of-hospital cardiac arrest. Prehospital Emerg Care. 2017;21(1):1\u20136\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nResuscitation Rev. March 2022\n\nCardiac Arrest (VF/VT/Asystole/PEA) 125\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Adult Post-ROSC (Return of Spontaneous Circulation) Care\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nThe immediate ROSC period is critical in stabilizing patients and preparing for transport.", "start_char_idx": 281799, "end_char_idx": 284769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a0a3d38-b758-4655-978a-349506737657": {"__data__": {"id_": "0a0a3d38-b758-4655-978a-349506737657", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7dca7282-c74c-4730-b0c3-c7facfe84305", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "202e333f45466c1aa344d1187486f4ff210b3a017233c90b1d7d1af1b815175c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddc8d27b-f612-4146-8ed4-87c59233eec7", "node_type": "1", "metadata": {}, "hash": "8dc8007a433fcfd412a120f4b978bf92d92b40a41a18ff22c1ff516dc1b40fc4", "class_name": "RelatedNodeInfo"}}, "text": "N Engl J Med. 2015;373(23):2203\u201314\n\n23. Sporer K, Jacobs M, Derevin L, Duval S, Pointer J. Continuous quality improvement efforts increase survival with favorable neurologic outcome after out-of-hospital cardiac arrest. Prehospital Emerg Care. 2017;21(1):1\u20136\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nResuscitation Rev. March 2022\n\nCardiac Arrest (VF/VT/Asystole/PEA) 125\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Adult Post-ROSC (Return of Spontaneous Circulation) Care\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nThe immediate ROSC period is critical in stabilizing patients and preparing for transport. The goal is therefore to maximize survival and optimize neurologic and cardiovascular function following a return of spontaneous circulation by the following steps:\n\nSecure airway\nObtain vascular access\nMaximize blood pressure\nIdentify ST-elevation myocardial infarction (STEMI) or reversible causes of arrest\nRecognize pending re-arrest\nConsider appropriate destination choice\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nPatient returned to spontaneous circulation following cardiac arrest resuscitation\n\n#### Exclusion Criteria\n\nNone noted\n\n### Patient Management\n\n#### Assessment, Treatment, and Interventions\n\nPerform general patient assessment attempting to identify cause of cardiac arrest.\nSupport life-threatening problems associated with airway, breathing, and circulation.\n\nFor example, most of the pediatric cardiac arrest occurs due to non-cardiac causes such as respiratory failure (hypoxemia) or shock (hypovolemia).\n\nMonitor closely for recurrence of cardiac arrest using clinical and adjunctive criteria such as cardiac monitoring, EtCO2 monitoring, and physical signs of perfusion\nAdminister oxygen as appropriate with a target of achieving 94\u201398% saturation. Do not hyperoxygenate.\nDo not hyperventilate. Maintain a ventilation rate of 8\u201310 breaths per minute, targeting an EtCO2 of 35\u201345 mmHg.\nFor hypotension (SBP less than 90 mmHg or MAP less than 65 in adults) see Shock Guideline\nPerform serial 12-lead EKGs to assess for evidence of reversible cause of arrest such as STEMI or electrolyte derangement (e.g., hyperkalemia)\nPost-cardiac arrest patients with evidence or interpretation consistent with ST elevation myocardial infarction (STEMI/acute MI) should be transported preferably to a facility capable of emergent cardiac catheterization or, as a secondary option, to a STEMI receiving facility based upon local resources and system of care\nCheck blood glucose\n\nIf hypoglycemic, treat per Hypoglycemia Guideline\nIf hyperglycemic, notify hospital on arrival\n\n________________________\n\nGo To TOC\n\nResuscitation\n\nRev. March 2022\n\nAdult Post-ROSC (Return of Spontaneous Circulation) Care\n\n126\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Resuscitation\n\n### Adult Post-ROSC (Return of Spontaneous Circulation) Care\n\n10. If patient seizes, treat per Seizures Guideline\n\n11. Consider transporting patients to an age-appropriate facility which offers specialized adult or pediatric\npost-resuscitation care\n\n### Patient Safety Considerations\n\n1. Avoid hyperthermia (temperature greater than 37.5\u00b0 C or 99.5\u00b0 F) by avoiding excessive environmental heat exposure,\nwarm blankets, etc.\n\na. Beyond interventions to prevent hyperthermia or fever, prehospital initiation of therapeutic hypothermia (targeted\ntemperature management) is not routinely recommended\n\n### Notes/Educational Pearls\n\n#### Key Considerations\n\n1. Hyperventilation is a significant cause of hypotension and recurrence of cardiac arrest in the post resuscitation\nphase and must be avoided. Similarly, hypoventilation (suggested by an EtCO2 greater than 40\u201345) contributes to\nworsening acidosis and may precipitate re-arrest\n\n2. Most patients are comatose immediately after resuscitation and will require airway management and ventilatory\nassistance\n\n3. Many patients experience \u201cstunning\u201d of the cardiac muscle after ROSC. Hypotension is common, and volume resuscitation\nor vasopressor support is often required. Refer to the [Shock Guideline] for further recommendations\n\n4.", "start_char_idx": 284091, "end_char_idx": 288260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddc8d27b-f612-4146-8ed4-87c59233eec7": {"__data__": {"id_": "ddc8d27b-f612-4146-8ed4-87c59233eec7", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a0a3d38-b758-4655-978a-349506737657", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "355ed9b33fd96405019ad3559bbc54c964a0c01659c3f47fcbb79989559b350f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28150757-f102-44c2-81a0-4a3d80492343", "node_type": "1", "metadata": {}, "hash": "6596a87fb83cdc60a12c1cc4efe865fd2bdc8a5f2519d33f282a842cc449ad4d", "class_name": "RelatedNodeInfo"}}, "text": "Hyperventilation is a significant cause of hypotension and recurrence of cardiac arrest in the post resuscitation\nphase and must be avoided. Similarly, hypoventilation (suggested by an EtCO2 greater than 40\u201345) contributes to\nworsening acidosis and may precipitate re-arrest\n\n2. Most patients are comatose immediately after resuscitation and will require airway management and ventilatory\nassistance\n\n3. Many patients experience \u201cstunning\u201d of the cardiac muscle after ROSC. Hypotension is common, and volume resuscitation\nor vasopressor support is often required. Refer to the [Shock Guideline] for further recommendations\n\n4. Common non-cardiac causes of post-resuscitation hypotension include hyperventilation, hypovolemia, and traumatic\npneumothorax from chest compressions\n\n5. The condition of post-resuscitation patients fluctuates rapidly and continuously requiring close monitoring. A\nsignificant percentage of post-ROSC patients will re-arrest\n\n6. Current research has demonstrated that care of patients with ROSC at specialized centers is associated with both\ndecreased mortality and improved neurologic outcomes\n\n7. Maintain mechanical CPR device in place in preparation for re-arrest\n\n8. A moderate number of adult post-ROSC patients may have transient ST-elevation on EKG. Consider performing serial\nEKGs. Post-ROSC patients should preferentially be transported to centers capable of managing STEMI, whenever\npossible\n\n### Pertinent Assessment Findings\n\nAssess post-ROSC rhythm, lung sounds, and for signs of hypoperfusion\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914019 \u2013 Cardiac Arrest - Post Resuscitation Care\n\n### Key Documentation Elements\n\nImmediate post-arrest rhythms, vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment) and\noxygen saturation\nPost-ROSC 12-lead EKG\n\n### Performance Measures\n\nPercent of ROSC patients transported to appropriate facility as defined by the EMS system\n\n________________________ Go To TOC\n\nResuscitation Rev. March 2022 Adult Post-ROSC (Return of Spontaneous Circulation) Care 127\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## References\n\n|1.|Aufderheide TP, Lurie KG. Death by hyperventilation: a common and life-threatening problem during         cardiopulmonary resuscitation. Crit Care Med. 2004;32(suppl): S345\u201351|\n|---|---|\n|2.|Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with         induced hypothermia. N Engl J Med. 2002; 346:557\u201363|\n|3.|Callaway CW, Donnino MW, Fink EL, et al. Part 8: Post cardiac arrest care: 2015 American Heart Association         guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18 Suppl         2): S465\u201382|\n|4.|De Backer D et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;         362:779\u201389|\n|5.|Garot P, Lefevre T, Eltchaninoff H, et al. Six-month outcome of emergency percutaneous coronary intervention in         resuscitated patients after cardiac arrest complicating ST-elevation myocardial infarction. Circulation.         2007;115(11):1354\u201362|\n|6.|Highlights of the 2020 American Heart Association's ... https://cpr.heart.org/-/media/cpr-files/cpr-guidelines-files/highlights/hghlghts_2020_ecc_guidelines_english.pdf.         Accessed March 11, 2022|\n|7.|Kim F, Nichol G, Maynard C, et al. Effect of prehospital induction of mild hypothermia on survival and neurological         status among adults with cardiac arrest. JAMA. 2014;311(1):45\u201352|\n|8.|Kim F, Nichol G, Maynard C, et al. Effect of prehospital induction of mild hypothermia on survival and neurological         status among adults with cardiac arrest: a randomized clinical trial. JAMA.", "start_char_idx": 287634, "end_char_idx": 291487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28150757-f102-44c2-81a0-4a3d80492343": {"__data__": {"id_": "28150757-f102-44c2-81a0-4a3d80492343", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddc8d27b-f612-4146-8ed4-87c59233eec7", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "6d909c841c230a4a09fa61a1c5f28e114d0d956d46b45a221d3cfe223f3e5187", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fd9ffa0-ff02-4dad-9d1a-43b06a4f2526", "node_type": "1", "metadata": {}, "hash": "fa928de9d65c6a2257c56dfd4b660feadc86d67e178d29c03ac13b977fc025f7", "class_name": "RelatedNodeInfo"}}, "text": "Circulation.         2007;115(11):1354\u201362|\n|6.|Highlights of the 2020 American Heart Association's ... https://cpr.heart.org/-/media/cpr-files/cpr-guidelines-files/highlights/hghlghts_2020_ecc_guidelines_english.pdf.         Accessed March 11, 2022|\n|7.|Kim F, Nichol G, Maynard C, et al. Effect of prehospital induction of mild hypothermia on survival and neurological         status among adults with cardiac arrest. JAMA. 2014;311(1):45\u201352|\n|8.|Kim F, Nichol G, Maynard C, et al. Effect of prehospital induction of mild hypothermia on survival and neurological         status among adults with cardiac arrest: a randomized clinical trial. JAMA. 2014;311(1):45\u201352|\n|9.|Kim F, Olsufka M, Longstreth WT Jr., et al. Pilot randomized clinical trial of prehospital induction of mild         hypothermia in out-of-hospital cardiac arrest patients with a rapid infusion of 4\u00b0C normal saline. Circulation.         2007;115(24):3064\u201370|\n|10.|Kliegel A, Janata A, Wandaller C, et al. Cold infusions alone are effective for induction of therapeutic hypothermia         but do not keep patients cool after cardiac arrest. Resuscitation. 2007;73(1):46\u201353|\n|11.|Nielsen N, Wetterslev J, Cronberg T, et al. Targeted temperature management at 33 degrees C versus 36 degrees C         after cardiac arrest. N Engl J Med. 2013;369(23):2197\u2013206|\n|12.|Nolan JP, Neumar RW, Adrie C, et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and         prognostication. A scientific statement from the International Liaison Committee on Resuscitation; the American         Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia;         the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; the Council         on Stroke. Circulation. 2008;79(3):350\u201379|\n|13.|Oddo M, Schaller MD, Feihl F, Ribordy V, Liaudet L. From evidence to clinical practice: effective implementation of         therapeutic hypothermia to improve patient outcome after cardiac arrest. Crit Care Med. 2006;34(7):1865\u201373|\n|14.|Quintero-Moran B, Moreno R, Villarreal S, et al. Percutaneous coronary intervention for cardiac arrest secondary to         ST-elevation acute myocardial infarction: influence of immediate paramedical/medical assistance on clinical outcome.         J Invasive Cardiol. 2006;18(6):269\u201372|\n|15.|Vega RM, Kaur H, Edemekong PF. Cardiopulmonary Arrest in Children. [Updated 2020 Jul 17]. In: StatPearls         [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan|\n|16.|Vereczki V, Martin E, Rosenthal RE, Hof PR, Hoffman GE, Fiskum G. Normoxic resuscitation after cardiac arrest         protects against hippocampal oxidative stress, metabolic dysfunction, and neuronal death. J Cereb Blood Flow Metab.         206;26(6):821\u201335|\n\n________________________\n\nGo To TOC\n\n## Resuscitation\n\nRev. March 2022\n\n## Adult Post-ROSC (Return of Spontaneous Circulation) Care\n\n128\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n17. Virkkunen I, Yli-Hankala A, Silfvast T. Induction of therapeutic hypothermia after cardiac arrest in prehospital\npatients using ice-cold Ringer\u2019s solution: a pilot study. Resuscitation. 2004;62(3):299\u2013302\n\nRevision Date March 11, 2022\n\nGo To TOC\n\nResuscitation Rev.", "start_char_idx": 290840, "end_char_idx": 294162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fd9ffa0-ff02-4dad-9d1a-43b06a4f2526": {"__data__": {"id_": "9fd9ffa0-ff02-4dad-9d1a-43b06a4f2526", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28150757-f102-44c2-81a0-4a3d80492343", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "40602464137268987933d87b1ccec7a7dc1fc50bc2d31bb73bb7a2b244d74e05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42409b83-d018-4272-8c0e-0b419cae7e82", "node_type": "1", "metadata": {}, "hash": "c76b28351b3118bf9f6465c3ddefe6e83387b3dca1ce78cb3b669994302c093f", "class_name": "RelatedNodeInfo"}}, "text": "J Cereb Blood Flow Metab.         206;26(6):821\u201335|\n\n________________________\n\nGo To TOC\n\n## Resuscitation\n\nRev. March 2022\n\n## Adult Post-ROSC (Return of Spontaneous Circulation) Care\n\n128\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n17. Virkkunen I, Yli-Hankala A, Silfvast T. Induction of therapeutic hypothermia after cardiac arrest in prehospital\npatients using ice-cold Ringer\u2019s solution: a pilot study. Resuscitation. 2004;62(3):299\u2013302\n\nRevision Date March 11, 2022\n\nGo To TOC\n\nResuscitation Rev. March 2022\n\nAdult Post-ROSC (Return of Spontaneous Circulation) Care 129\n---\n# NASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Determination of Death/Withholding Resuscitative Efforts\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nAll clinically dead patients will receive all available resuscitative efforts including cardiopulmonary\nresuscitation (CPR) unless contraindicated by one of the exceptions defined below\n\n### Patient Presentation\n\nA clinically dead patient is defined as any unresponsive patient found without respirations and without a palpable\ncarotid pulse\n\n### Inclusion/Exclusion Criteria:\n\n1. Resuscitation should be started on all patients who are found apneic and pulseless unless the following conditions\nexist (does not apply to victims of lightning strikes, drowning, or hypothermia):\n\na. Medical cause or traumatic injury or body condition clearly indicating biological death (irreversible brain death),\nlimited to:\n\ni. Decapitation: the complete severing of the head from the remainder of the patient\u2019s body\nii. Decomposition or putrefaction: the skin is bloated or ruptured, with or without soft tissue sloughed off. The\npresence of at least one of these signs indicated death occurred at least 24 hours previously\niii. Transection of the torso: the body is completely cut across below the shoulders and above the hips through all\nmajor organs and vessels. The spinal column may or may not be severed\niv. Incineration: 90% of body surface area with full thickness burns as exhibited by ash rather than clothing and\ncomplete absence of body hair with charred skin\nv. Injuries incompatible with life (such as massive crush injury, complete exsanguination, severe displacement of\nbrain matter)\nvi. Futile and inhumane attempts as determined by agency policy/protocol related to \u201ccompelling reasons\u201d for\nwithholding resuscitation\nvii. In blunt and penetrating trauma, if the patient is apneic, pulseless, and without other signs of life upon EMS\narrival including, but not limited to spontaneous movement, EKG activity, or pupillary response\nviii. Nontraumatic arrest with obvious signs of death including dependent lividity or rigor mortis\n\nOR\n\nb. A valid DNR order (form, card, bracelet) or other actionable medical order (e.g., Physician Orders for\nLife-Sustaining Treatment (POLST)/Medical Orders for Life-Sustaining Treatment (MOLST) form) is present, and it:\n\ni. Conforms to the state specifications for color and construction\nii. Is intact: it has not been cut, broken, or shows signs of being repaired\niii. Displays the patient\u2019s name and, if required by state law or regulation, the physician\u2019s name\n\n________________________\n\nGo To TOC\n\n### Resuscitation\n\nRev. March 2022\n\n### Determination of Death/Withholding Resuscitative Efforts\n\n130\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Patient Management\n\n### Assessment\n\nAssess for dependent lividity with rigor mortis and/or other inclusion criteria\n\n### Treatment and Interventions\n\nIf all the components above are confirmed, no CPR is required\nIf CPR has been initiated but all the components above have been subsequently confirmed, CPR should be discontinued,\nand medical direction contacted as needed\nIf any of the findings are different than those described above, clinical death is not confirmed, and resuscitative\nmeasures should be immediately initiated or continued.", "start_char_idx": 293629, "end_char_idx": 297566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42409b83-d018-4272-8c0e-0b419cae7e82": {"__data__": {"id_": "42409b83-d018-4272-8c0e-0b419cae7e82", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fd9ffa0-ff02-4dad-9d1a-43b06a4f2526", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "3a877ad097c905db2fdd74bb2a0e4223b314d085ee49b2a4da53c1fceada8dee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6e4c1ed-008e-43c0-9157-6a944babce8f", "node_type": "1", "metadata": {}, "hash": "3cc4c0a7ed31b8ef61d9953496025c0f1365929b75dee65ea15b3f5b1a427425", "class_name": "RelatedNodeInfo"}}, "text": "Is intact: it has not been cut, broken, or shows signs of being repaired\niii. Displays the patient\u2019s name and, if required by state law or regulation, the physician\u2019s name\n\n________________________\n\nGo To TOC\n\n### Resuscitation\n\nRev. March 2022\n\n### Determination of Death/Withholding Resuscitative Efforts\n\n130\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Patient Management\n\n### Assessment\n\nAssess for dependent lividity with rigor mortis and/or other inclusion criteria\n\n### Treatment and Interventions\n\nIf all the components above are confirmed, no CPR is required\nIf CPR has been initiated but all the components above have been subsequently confirmed, CPR should be discontinued,\nand medical direction contacted as needed\nIf any of the findings are different than those described above, clinical death is not confirmed, and resuscitative\nmeasures should be immediately initiated or continued. The Termination of Resuscitative Efforts Guideline should then\nbe implemented\nDo Not Resuscitate (DNR) order (DNR/MOLST/POLST) with signs of life:\n\nIf there is a DNR bracelet or DNR transfer form and there are signs of life (pulse and respirations), provide\nstandard appropriate treatment under existing protocols matching the patient\u2019s condition\nTo request permission to withhold treatment under these conditions for any reason contact medical direction\nIf there is documentation of a Do Not Intubate (DNI/MOLST/POLST) advanced directive, the patient should receive\nfull treatment per protocols except for any intervention specifically prohibited in the patient\u2019s advanced\ndirective\nIf for any reason an intervention that is prohibited by an advanced directive is being considered, contact\nmedical direction\n\n### Patient Safety Considerations\n\nIn cases where the patient's status is unclear and the appropriateness of withholding resuscitation efforts is\nquestioned, EMS personnel should initiate CPR immediately and then contact medical direction\n\n## Notes/Educational Pearls\n\n### Key Considerations\n\nFor scene safety and/or family wishes, clinician may decide to implement CPR even if all the criteria for death are\nmet\nAt a likely crime scene, disturb as little potential evidence as possible\n\n### Pertinent Assessment Findings\n\nNone noted\n\n## Quality improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914169 \u2013 Cardiac Arrest - Do Not Resuscitate\n9914201 \u2013 Cardiac Arrest - Determination of Death/Withholding Resuscitative Efforts\n\n### Key Documentation Elements\n\nClinical/situational details that may be available from bystanders/caregivers\n\n________________________ Go To TOC\n\nResuscitation Rev. March 2022 Determination of Death/Withholding Resuscitative Efforts 131\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\nDocumentation of details surrounding decision to determine death\n\nTime of contact with medical direction\nTime of death determination\n\nNames/contact information for significant bystanders\n\n## Performance Measures\n\nNone noted\n\n## References\n\n'Do Not Attempt Resuscitation' in the Out-of-Hospital Setting. American College of Emergency Physicians; October\n2003. ACEP Policy Statement\nMillin MG, Galvagno SM, Khandker SR, Malki A, Bulger EM. Withholding and termination of resuscitation of adult\ncardiopulmonary arrest secondary to trauma: resource document to the joint NAEMSP-ACSCOT position statements. J\nTrauma Acute Care Surg. 2013;75(3):459\u201367\nNational Guidelines for Statewide Implementation of EMS \"Do Not Resuscitate\" (DNR) Programs National Association\nof Emergency Medical Services Directors and the National Association of Emergency Medical Services Physicians.\nPrehosp Disaster Med. 1994;9(2):197\u20139\nNational Association of EMS Physicians, American College of Surgeons Committee on Trauma. Termination of\nresuscitation for adult traumatic cardiopulmonary arrest. Prehosp Emerg Care. 2012;16(4):571\nNational Association of EMS Physicians, et al. Withholding of resuscitation for adult traumatic cardiopulmonary\narrest. Prehosp Emerg Care. 2013;17(2):291\n\n## Revision Date\n\nMarch 11, 2022\n\n________________________ Go To TOC\n\nResuscitation Rev.", "start_char_idx": 296644, "end_char_idx": 300829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6e4c1ed-008e-43c0-9157-6a944babce8f": {"__data__": {"id_": "e6e4c1ed-008e-43c0-9157-6a944babce8f", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42409b83-d018-4272-8c0e-0b419cae7e82", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "0db263e433180deed40e2b91eb4fe28668d39276f925474d43ca7ac906dedbca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fafb8693-ecdb-4afc-b535-4ed2d173d0a5", "node_type": "1", "metadata": {}, "hash": "b812415c362883c10f39311bc1117b7684ffd2206ad671ccaffa9b3fe4c762a9", "class_name": "RelatedNodeInfo"}}, "text": "J\nTrauma Acute Care Surg. 2013;75(3):459\u201367\nNational Guidelines for Statewide Implementation of EMS \"Do Not Resuscitate\" (DNR) Programs National Association\nof Emergency Medical Services Directors and the National Association of Emergency Medical Services Physicians.\nPrehosp Disaster Med. 1994;9(2):197\u20139\nNational Association of EMS Physicians, American College of Surgeons Committee on Trauma. Termination of\nresuscitation for adult traumatic cardiopulmonary arrest. Prehosp Emerg Care. 2012;16(4):571\nNational Association of EMS Physicians, et al. Withholding of resuscitation for adult traumatic cardiopulmonary\narrest. Prehosp Emerg Care. 2013;17(2):291\n\n## Revision Date\n\nMarch 11, 2022\n\n________________________ Go To TOC\n\nResuscitation Rev. March 2022 Determination of Death/Withholding Resuscitative Efforts 132\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Do Not Resuscitate Status/Advance Directives/Healthcare Power of Attorney (POA) Status\n\n### Aliases\n\nComfort care\n\nDo Not Resuscitate (DNR)\n\n### Patient Care Goals\n\nTo acknowledge and maintain the variety of ways that patients can express their wishes about cardiopulmonary\nresuscitation or end-of-life decision making\n\n### Patient Presentation\n\n#### Inclusion/Exclusion Criteria\n\nPatients must have one of the following documents or a valid alternative (such as identification bracelet indicating\nwishes) immediately available. Note that some specifics can vary widely from state to state:\n\nPhysician Orders for Life Sustaining Treatment (POLST) or Medical Orders for Life Sustaining Treatment (MOLST) \u2013\nexplicitly describes acceptable interventions for the patient in the form of medical orders, must be signed by a\nphysician or other empowered medical clinician to be valid\n\nDo Not Resuscitate (DNR) order \u2013 identifies that CPR and intubation are not to be initiated if the patient is in\narrest or peri-arrest. The interventions covered by this order and the details around when to implement them can\nvary widely\n\nAdvance directives \u2013 document that describes acceptable treatments under a variable number of clinical situations\nincluding some or all the following: what to do for cardiac arrest, whether artificial nutrition is acceptable, organ\ndonation wishes, dialysis, and other parameters. The directives frequently do not apply to emergent or potentially\ntransient medical conditions\n\nAs specified from state to state, in the absence of formal written directions (MOLST, POLST, DNR, advanced directives),\nand in the presence of a person with power of attorney for healthcare or healthcare proxy, that person may prescribe\nlimits of treatment\n\nOne of the documents above is valid when it meets all the following criteria:\n\nConforms to the state specifications for color and construction\nIs intact: it has not been cut, broken or shows signs of being repaired\nDisplays the patient\u2019s name and, if required by state law or regulation, the physician\u2019s name\n\nIf there is question about the validity of the form/instrument, the best course of action is to proceed with the\nresuscitation until additional information can be obtained to clarify the best course of action\n\nIf a patient has a valid version of one of the above documents, it will be referred to as a \u201cvalid exclusion to\nresuscitation\u201d for the purposes of this protocol\n\n### Patient Management\n\n#### Assessment\n\nIf the patient has a valid exclusion to resuscitation, then no CPR or airway management should be attempted, however\nthis does not exclude comfort measures including medications for\n\nResuscitation\n\nRev.", "start_char_idx": 300081, "end_char_idx": 303717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fafb8693-ecdb-4afc-b535-4ed2d173d0a5": {"__data__": {"id_": "fafb8693-ecdb-4afc-b535-4ed2d173d0a5", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6e4c1ed-008e-43c0-9157-6a944babce8f", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "928f696dcf8d4203c564a1a0bf35de074ea68312ed93fa3147a5858f295c1fe4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "936e113b-929f-4223-8c9b-818105a8cc6b", "node_type": "1", "metadata": {}, "hash": "3ee8032426290f31260dffa45c56a32153eee14dc97dee9c5d182f5fa5107950", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nDo Not Resuscitate Status/Advance Directives/Healthcare Power of Attorney (POA) Status\n\n133\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Resuscitation\n\nDo Not Resuscitate Status/Advance Directives/Healthcare Power of Attorney (POA) Status\n\nPage: 134\n\n### Treatment and Interventions\n\nIf there is a valid exclusion to resuscitation and there are signs of life (pulse and respirations), EMS clinicians should provide standard appropriate treatment under existing protocols according to the patient\u2019s condition\n\nIf the patient has a MOLST or POLST, it may provide specific guidance on how to proceed in this situation\nDirectives should be followed as closely as possible and medical direction contacted as needed\n\nThe patient should receive full treatment per protocols with the exception of any intervention specifically prohibited in the patient\u2019s valid exclusion to resuscitation\nIf for any reason an intervention that is prohibited by an advanced directive is being considered, medical direction should be contacted\n\n### Patient Safety Considerations\n\nIn cases where the patient's status is unclear and the appropriateness of withholding resuscitation efforts is questioned, EMS personnel should initiate CPR immediately and contact medical direction\n\n### Notes/Educational Pearls\n\nKey Considerations\n\nIf there is a personal physician present at the scene who has an ongoing relationship with the patient, that physician may decide if resuscitation is to be initiated\nIf there is a registered nurse from a home healthcare or hospice agency present at the scene who has an ongoing relationship with the patient and who is operating under orders from the patient\u2019s private physician, that nurse (authorized nurse) may decide if resuscitation is to be initiated\nIf the physician or nurse decides resuscitation is to be initiated, usual medical direction procedures will be followed\nSpecial Consideration: For scene safety and/or family wishes, the EMS clinician may decide to implement CPR even if all the criteria for death are met\n\n### Pertinent Assessment Findings\n\nNone noted\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914201 \u2013 Cardiac Arrest - Determination of Death/Withholding Resuscitative Efforts\n9914169 \u2013 Cardiac Arrest - Do Not Resuscitate\n9914171 \u2013 Cardiac Arrest - Special Resuscitation Orders\n\n________________________ Go To TOC\n\nResuscitation Rev. March 2022\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Key Documentation Elements\n\nDetailed description of the valid exclusion to resuscitation documentation used to guide resuscitation including a copy of the document if possible\nNames/contact information for significant bystanders\n\n## Performance Measures\n\nNone noted\n\n## References\n\n'Do Not Attempt Resuscitation' in the Out-of-Hospital Setting. American College of Emergency Physicians; October 2003. ACEP Policy Statement\nNational Guidelines for Statewide Implementation of EMS \"Do Not Resuscitate\" (DNR) Programs National Association of Emergency Medical Services Directors and the National Association of Emergency Medical Services Physicians. Prehos Disaster Med. 1994;9(2):197\u20139\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nResuscitation Rev. March 2022\n\nDo Not Resuscitate Status/Advance Directives/Healthcare Power of Attorney (POA) Status 135\n---\n## Termination of Resuscitative Efforts\n\n### Aliases\n\nCall the code\n\n### Patient Care Goals\n\nWhen there is no response to prehospital cardiac arrest treatment, it is acceptable and often preferable to cease futile resuscitation efforts in the field\nIn patients with cardiac arrest, prehospital resuscitation is initiated with the goal of returning spontaneous circulation before permanent neurologic damage occurs. In most situations, ALS clinicians are capable of performing an initial resuscitation that is equivalent to an in-hospital resuscitation attempt, and there is usually no additional benefit to emergency department resuscitation in most cases\nCPR that is performed during patient packaging and transport is much less effective than CPR done at the scene. Additionally, EMS clinicians risk physical injury while attempting to perform CPR in a moving ambulance while unrestrained. In addition, continuing resuscitation in futile cases places other motorists and pedestrians at risk, increases the time that EMS crews are not available for another call, impedes emergency department care of other patients, and incurs unnecessary hospital charges. Lastly, return of spontaneous circulation is dependent on a focused, timely resuscitation.", "start_char_idx": 303718, "end_char_idx": 308413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "936e113b-929f-4223-8c9b-818105a8cc6b": {"__data__": {"id_": "936e113b-929f-4223-8c9b-818105a8cc6b", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fafb8693-ecdb-4afc-b535-4ed2d173d0a5", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "92ec58bb9ddbe0405d3c68e99d065e26b9b226f4e12f4f4c3d96ffa5aa0f2e28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b241987-b338-4b9d-8276-91acd4d8a4e4", "node_type": "1", "metadata": {}, "hash": "973c222d5dc9b7b024c846b6fd066a4c45e6e75eefdaa65e4a23f933fbd6260c", "class_name": "RelatedNodeInfo"}}, "text": "In most situations, ALS clinicians are capable of performing an initial resuscitation that is equivalent to an in-hospital resuscitation attempt, and there is usually no additional benefit to emergency department resuscitation in most cases\nCPR that is performed during patient packaging and transport is much less effective than CPR done at the scene. Additionally, EMS clinicians risk physical injury while attempting to perform CPR in a moving ambulance while unrestrained. In addition, continuing resuscitation in futile cases places other motorists and pedestrians at risk, increases the time that EMS crews are not available for another call, impedes emergency department care of other patients, and incurs unnecessary hospital charges. Lastly, return of spontaneous circulation is dependent on a focused, timely resuscitation. The patient in arrest should be treated as expeditiously as possible, including quality, uninterrupted CPR and timely defibrillation as indicated\nWhen cardiac arrest resuscitation becomes futile, the patient\u2019s family should become the focus of the EMS clinicians. Families need to be informed of what is being done and that transporting all cardiac arrest patients to the hospital is not supported by evidence. This practice also inconveniences the family by requiring a trip to the hospital where they must begin grieving in an unfamiliar setting. Most families understand the futility of the situation and are accepting of ceasing resuscitation efforts in the field\nConsider potential for organ donation if feasible\n\n### Patient Presentation\n\nPatient in cardiac arrest\n\n### Inclusion Criteria\n\nAny cardiac arrest patient that has received resuscitation in the field but has not responded to treatment\nWhen resuscitation has begun and it is found that the patient has a DNR order or other actionable medical order (e.g., POLST/MOLST form)\n\n### Exclusion Criteria\n\nConsider continuing resuscitation for patients in cardiac arrest associated with medical conditions that may have a better outcome despite prolonged resuscitation, including hypothermia (although under certain circumstances, medical direction may order termination of resuscitation in these conditions)\n\n### Patient Management\n\nResuscitation may be terminated under the following circumstances:\n\n________________________\n\nGo To TOC\n\nResuscitation\n\nRev. March 2022\n\nTermination of Resuscitative Efforts\n\n136\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### 1. Non-traumatic arrest\n\na. Patient is at least 18 years of age\n\nb. Patient is in cardiac arrest at the time of arrival of advanced life support (ALS)\n\ni. No pulse\nii. No respirations\niii. No evidence of meaningful cardiac activity (e.g., asystole or wide complex PEA less than 60 BPM, no heart\nsounds)\n\nc. ALS resuscitation is administered appropriate to the presenting and persistent cardiac rhythm.\n\ni. Resuscitation may be terminated in asystole and slow wide complex PEA if there is\n\n1. No return of spontaneous circulation after 20 minutes in the absence of hypothermia AND\n2. The EtCO2 is less than 20 mmHg\n\nii. Narrow complex PEA with a rate above 40 or refractory and recurrent ventricular fibrillation/ventricular\ntachycardia:\n\n1. Consider resuscitation for up to 60 minutes from the time of dispatch.\n2. Termination efforts may be ceased before 60 minutes based on factors including, but not limited to, EtCO2\nless than 20 mmHg, age, co-morbidities, distance from, and resources available at the closest hospital.\nTermination before this timeframe should be done in consultation with online medical direction\n\nd. There is no return of spontaneous pulse and no evidence of neurological function (non-reactive pupils, no response\nto pain, no spontaneous movement)\n\ne. No evidence or suspicion of hypothermia\n\nf. All EMS clinicians involved in the patient\u2019s care agree that discontinuation of the resuscitation is appropriate\n\ng. Consider contacting medical direction before termination of resuscitative efforts\n\n### 2. Traumatic arrest\n\na. Patient is at least 18 years of age\n\nb. Resuscitation efforts may be terminated in any blunt trauma patient who, based on thorough primary assessment, is\nfound apneic, pulseless, and asystolic on an EKG or cardiac monitor upon arrival of emergency medical services at the\nscene\n\nc. Victims of penetrating trauma found apneic and pulseless by EMS should be rapidly assessed for the presence of\nother signs of life, such as pupillary reflexes, spontaneous movement, response to pain, and electrical activity on\nEKG\n\ni. Resuscitation may be terminated by contacting medical direction oversight if these signs of life are absent\nii.", "start_char_idx": 307580, "end_char_idx": 312248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b241987-b338-4b9d-8276-91acd4d8a4e4": {"__data__": {"id_": "1b241987-b338-4b9d-8276-91acd4d8a4e4", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "936e113b-929f-4223-8c9b-818105a8cc6b", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "aeb2f57184f25756692275945544ccbf56233588017443fdea30f72a039a65f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47f9d7a3-2e00-4c5c-a277-57af3f134ee2", "node_type": "1", "metadata": {}, "hash": "b0d1d4b86b45bf16c73bc6e53452a26ea740416d9f59c8c2c1ccc54b64bea74b", "class_name": "RelatedNodeInfo"}}, "text": "Traumatic arrest\n\na. Patient is at least 18 years of age\n\nb. Resuscitation efforts may be terminated in any blunt trauma patient who, based on thorough primary assessment, is\nfound apneic, pulseless, and asystolic on an EKG or cardiac monitor upon arrival of emergency medical services at the\nscene\n\nc. Victims of penetrating trauma found apneic and pulseless by EMS should be rapidly assessed for the presence of\nother signs of life, such as pupillary reflexes, spontaneous movement, response to pain, and electrical activity on\nEKG\n\ni. Resuscitation may be terminated by contacting medical direction oversight if these signs of life are absent\nii. If resuscitation is not terminated, transport is indicated\n\nd. Cardiopulmonary arrest patients in whom mechanism of injury does not correlate with clinical condition, suggesting a\nnon-traumatic cause of arrest, should have standard ALS resuscitation initiated\n\ne. All EMS personnel involved in the patient\u2019s care agree that discontinuation of the resuscitation is appropriate\n\nf. Consider contacting medical direction before termination of resuscitative efforts\n\n### Assessment\n\n1. Pulse\n\n________________________ Go To TOC\n\nResuscitation Rev. March 2022 Termination of Resuscitative Efforts 137\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Respirations\n\n## Neurologic status assessment [See Appendix VII. Neurologic Status Assessment; purposeful movement, pupillary\nresponse]\n\n## Cardiac activity (cardiac auscultation, cardiac monitoring, and/or, if available, ultrasonography)\n\n## Quantitative capnography\n\n## Treatment and Interventions\n\nFocus on continuous, quality CPR that is initiated as soon as possible\nFocus attention on the family and/or bystanders. Explain the rationale for termination\nConsider support for family members such as other family, friends, clergy, faith leaders, or chaplains\nFor patients that are less than 18 years of age, consultation with medical direction is recommended\n\n## Patient Safety Considerations\n\nAll patients who are found in ventricular fibrillation or whose rhythm changes to ventricular fibrillation should in\ngeneral have full resuscitation continued on scene\n\n## Notes/Educational Pearls\n\n### Key Considerations and Pertinent Assessment Findings\n\nRecent evidence has shown that, to capture over 99% of potential survivors from medical cardiac arrest (especially\nVF and pulseless VT arrests), resuscitation should be continued for approximately 40 minutes. This does not imply,\nhowever, that all resuscitations should continue this long (e.g., asystolic rhythms)\nIn remote or wilderness situations, EMS clinicians should make every effort to contact medical direction, but\nresuscitation may be terminated in the field without contacting medical direction when the following have occurred:\n\nThere has been no return of pulse despite greater than 30 minutes of CPR (this does not apply in the case of\nhypothermia)\nTransport to an emergency department will take greater than 30 minutes (this does not apply in the case of\nhypothermia)\nEMS clinicians are exhausted, and it is physically impossible to continue the resuscitation\n\nLogistical factors should be considered, such as collapse in a public place, family wishes, and safety of the crew\nand public\nSurvival and functional neurologic outcomes are unlikely if ROSC is not obtained by EMS. It is dangerous to crew,\npedestrians, and other motorists to attempt to resuscitate a patient during ambulance transport\nQuantitative EtCO2 measurements of less than 10 mmHg or falling greater than 25% despite resuscitation indicates a\npoor prognosis and provide additional support for termination\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (for additional information, go to www.nemsis.org)\n\n9914055 \u2013 General - Cardiac Arrest\n9914087 \u2013 Injury - Cardiac Arrest\n9914169 \u2013 Cardiac Arrest - Do Not Resuscitate\n\n________________________ Go To TOC\n\nResuscitation Rev. March 2022 Termination of Resuscitative Efforts 138\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n9914171 \u2013 Cardiac Arrest - Special Resuscitation Orders\n9914201 \u2013 Cardiac Arrest - Determination of Death/Withholding Resuscitative Efforts\n\n### Key Documentation Elements\n\nAll items (a\u2013f in Non-traumatic or Traumatic arrest) listed under patient management must be clearly documented\nin the EMS patient care report in addition to the assessment findings supporting this medical decision making. If\nresuscitation is continued for special circumstance or despite satisfying the criteria in this guideline, the rationale\nfor such decision making must be documented.", "start_char_idx": 311599, "end_char_idx": 316223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47f9d7a3-2e00-4c5c-a277-57af3f134ee2": {"__data__": {"id_": "47f9d7a3-2e00-4c5c-a277-57af3f134ee2", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b241987-b338-4b9d-8276-91acd4d8a4e4", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "d6b9ea077fc6a63f9d9adc9f2d0651e478fc4bc94a6aa53ee7aab28bda82789c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43d54893-d8e8-4be2-845a-935680a75dc3", "node_type": "1", "metadata": {}, "hash": "569ff8890bf3f0b427dfca10f5f830a5ee7d0f57268556d6badbd39fc091da15", "class_name": "RelatedNodeInfo"}}, "text": "March 2022 Termination of Resuscitative Efforts 138\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n9914171 \u2013 Cardiac Arrest - Special Resuscitation Orders\n9914201 \u2013 Cardiac Arrest - Determination of Death/Withholding Resuscitative Efforts\n\n### Key Documentation Elements\n\nAll items (a\u2013f in Non-traumatic or Traumatic arrest) listed under patient management must be clearly documented\nin the EMS patient care report in addition to the assessment findings supporting this medical decision making. If\nresuscitation is continued for special circumstance or despite satisfying the criteria in this guideline, the rationale\nfor such decision making must be documented.\n\n### Performance Measures\n\nTime to CPR\nTime to AED application if applicable\nReview of CPR quality\nDuration of resuscitative efforts\nReview of biometric data/CPR quality if available\nAppropriateness of termination\nReview of every patient transport from scene with patient in arrest\n\n### References\n\n|1.|American College of Emergency Physicians. Discontinuing resuscitation in the out-of-hospital setting. Ann         Emerg Med. 2008;52(5):592|\n|---|---|\n|2.|Cha WC, Lee EJ, Hwang SS. The duration of cardiopulmonary resuscitation in emergency departments after         out-of-hospital cardiac arrest is associated with the outcome: A nationwide observational study. Resuscitation.         2015; 96:323\u20137|\n|3.|Eckstein M, Hatch L, Malleck J, McClung C, Henderson SO. End-tidal CO2 as a predictor of survival in         out-of-hospital cardiac arrest. Prehosp Disaster Med. 2011;26(3):148\u201350|\n|4.|Fallat ME, American College of Surgeons Committee on Trauma, American College of Emergency Physicians,         National Association of EMS Physicians, American Academy of Pediatrics. Withholding or termination of         resuscitation in pediatric out-of-hospital traumatic cardiopulmonary arrest. Pediatrics, 2014 Apr; 133(4):         e1104\u201316|\n|5.|Goldberger ZD, Chan PS, Berg RA, et al. Duration of resuscitation efforts and survival after in-hospital         cardiac arrest: an observational study. Lancet. 2012;380(9852):1473\u201381|\n|6.|Goto Y, Funada A, Goto Y. Duration of prehospital cardiopulmonary resuscitation and favorable neurological         outcomes for pediatric out-of-hospital cardiac arrests: a nationwide, population-based cohort study. Circulation.         2016;(1):1\u201310|\n|7.|Hung SC, Mou CY, Hung HC, Lin IH, Lai SW, Huang JY. Chest compression fraction in ambulance while         transporting patients with out-of-hospital cardiac arrest to the hospital in rural Taiwan. Emerg Med J. 2016;         0:1\u20134|\n|8.|Kim F, Nichol G, Maynard C, et al. Effect of prehospital induction of mild hypothermia on survival and         neurological status among adults with cardiac arrest. JAMA. 2014;311(1):45\u201352|\n|9.|Matsuyama T, Kitamura T, Kiyohara K, et al. Impact of cardiopulmonary resuscitation duration on neurologically         favourable outcome after out-of-hospital cardiac arrest: a population-based study in japan. Resuscitation.         2017; 113:1\u20137|\n|10.|Millin MG, Khandker SR, Malki A. Termination of resuscitation of nontraumatic cardiopulmonary arrest:         resource document for the National Association of EMS Physicians|\n\n________________________\n\nGo To TOC\n\n### Resuscitation\n\nRev. March 2022\n\n### Termination of Resuscitative Efforts\n\n139\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\nposition statement. Prehosp Emerg Care. 2011;15(4):547\u201354\n\n11. Morrison LJ, Verbeek PR, Zhan C, Kiss A, Allan KS. Validation of a universal prehospital termination of resuscitation clinical prediction rule for advanced and basic life support providers. Resuscitation. 2009;80(3):324\u20138\n\n12. Ponce A, Swor R, Quest TE, Macy M, Meurer W, Sasson C. Death notification training for prehospital providers: a pilot study.", "start_char_idx": 315527, "end_char_idx": 319384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43d54893-d8e8-4be2-845a-935680a75dc3": {"__data__": {"id_": "43d54893-d8e8-4be2-845a-935680a75dc3", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47f9d7a3-2e00-4c5c-a277-57af3f134ee2", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "1da8e6d812087386c016e71afa2ad2fe2a208ca6685c91ef17ac8958f0cdb795", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f6ef761-f940-4459-a9e9-aa0324c39d73", "node_type": "1", "metadata": {}, "hash": "c32dbe414d7fd4badb0451cf19668e0f95c2f947e75d87aa41ae67591e0916d3", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n### Termination of Resuscitative Efforts\n\n139\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\nposition statement. Prehosp Emerg Care. 2011;15(4):547\u201354\n\n11. Morrison LJ, Verbeek PR, Zhan C, Kiss A, Allan KS. Validation of a universal prehospital termination of resuscitation clinical prediction rule for advanced and basic life support providers. Resuscitation. 2009;80(3):324\u20138\n\n12. Ponce A, Swor R, Quest TE, Macy M, Meurer W, Sasson C. Death notification training for prehospital providers: a pilot study. Prehosp Emerg Care. 2010;14(4):537\u201342\n\n13. Reynolds JC, Grunau BE, Rittenberger JC, Sawyer KN, Kurz MC, Callaway CW. The association between duration of resuscitation and favorable outcome after out-of-hospital cardiac arrest: implications for prolonging or terminating resuscitation. Circulation. 2016;134(25):2084\u201394\n\n## Revision Date\n\nMarch 11, 2022\n\n________________________\n\nGo To TOC\n\n## Resuscitation\n\nRev. March 2022\n\n## Termination of Resuscitative Efforts\n\n140\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Resuscitation in Traumatic Cardiac Arrest\n\n### Aliases\n\nTraumatic Cardiac Arrest (TCA)\n\n### Patient Care Goals\n\nReturn of spontaneous circulation\nTreatment and resolution of the underlying pathophysiology leading to the traumatic cardiac arrest\nWhen appropriate, transport to the closest and most capable hospital within the defined trauma system\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nPatients suffering blunt or penetrating trauma with cardiac arrest after arrival of EMS clinicians or while under the care of EMS clinicians (witnessed arrest or recent arrest with continued signs of life)\n\n#### Exclusion Criteria\n\nWhen the mechanism of injury does not correlate with the clinical condition, suggesting a nontraumatic cause of cardiac arrest, standard resuscitative measures should be followed. In such cases, refer to the Resuscitation Section\nIn victims of blunt or penetrating trauma with pulses or other signs of life on EMS clinician assessment refer to the General Trauma Management Guideline\nIn victims of blunt or penetrating trauma with rigor mortis, lividity, or evidence of injuries incompatible with life (including decapitation, hemicorporectomy). In such cases, refer to Determination of Death/Withholding Resuscitative Efforts Guideline\nResuscitation efforts may be withheld in any blunt trauma patient who, based on thorough primary assessment, is found apneic, pulseless, and asystolic on an EKG or cardiac monitor upon arrival of emergency medical services at the scene. In such cases, refer to the Determination of Death/Withholding Resuscitative Efforts Guideline\nResuscitation efforts may be withheld in victims of penetrating trauma found apneic, pulseless, and without other signs of life including pupillary reflexes, respiratory effort, spontaneous movement, response to pain, and electrical activity on EKG. In such cases, refer to the Determination of Death/Withholding Resuscitative Efforts Guideline\n\n### Patient Management\n\n#### Assessment\n\nManagement of traumatic cardiac arrest requires a balance of rapid, focused evaluation followed by prompt treatment of reversible life threats, including management of massive hemorrhage, airway management, decompression of tension pneumothorax, and resuscitation\nAssess for signs of life, including pulses, respiratory effort, and evaluation of other signs of life\nAssess for evidence of massive hemorrhage\n\nIncluding evidence of massive external hemorrhage\n\n________________________ Go To TOC\n\nResuscitation Rev. March 2022 Resuscitation in Traumatic Cardiac Arrest 141\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Resuscitation in Traumatic Cardiac Arrest\n\nb. Evidence of pelvic injury (such as instability)\n\n4. Assess the patient\u2019s airway\n\n5. Assess the patient\u2019s respiratory effort, if present, or for evidence of tension pneumothorax\n\n6. Assess vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment)\n\n### Treatment and Interventions\n\nManage massive hemorrhage.", "start_char_idx": 318835, "end_char_idx": 322923, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f6ef761-f940-4459-a9e9-aa0324c39d73": {"__data__": {"id_": "2f6ef761-f940-4459-a9e9-aa0324c39d73", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43d54893-d8e8-4be2-845a-935680a75dc3", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "f02ab1ddfc415e25380f410e125aaf63665a138a99ac5691b640f9449c21a2a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbd14bdd-47db-47d3-8db0-9cf973e24878", "node_type": "1", "metadata": {}, "hash": "7faacacc5139fd8855b9554c2dfb424d16db534806ec92d9c069a127a165604a", "class_name": "RelatedNodeInfo"}}, "text": "March 2022 Resuscitation in Traumatic Cardiac Arrest 141\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Resuscitation in Traumatic Cardiac Arrest\n\nb. Evidence of pelvic injury (such as instability)\n\n4. Assess the patient\u2019s airway\n\n5. Assess the patient\u2019s respiratory effort, if present, or for evidence of tension pneumothorax\n\n6. Assess vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment)\n\n### Treatment and Interventions\n\nManage massive hemorrhage. Refer to General Trauma Management Guideline for complete list of therapies for the treatment of massive hemorrhage, including the following:\n\nPlace tourniquets for wounds amenable to tourniquet placement\nUse a combination of wound packing and direct pressure for junctional wounds or junctional tourniquets if available\nPlace a pelvic binder on all patients with blunt or blast trauma suffering traumatic arrest\n\nManage the patient\u2019s airway. Refer to the Airway Management Guideline\nPerform bilateral, rapid chest decompression\nEstablish intravenous access\nInitiate volume resuscitation and adjunctive hemorrhage control measures (such as tranexamic acid (TXA)) en route to the hospital\n\n### Patient Safety Considerations\n\nNone noted\n\n### Notes/Educational Pearls\n\nKey Considerations\n\nSurvival from traumatic cardiac arrest requires careful coordination between rapid prehospital assessment, EMS clinician treatment of reversible causes of traumatic cardiac arrest and transport that is rapid, but also allows maintenance of necessary therapies in a manner that is effective for patients as well as safe for EMS clinicians\nEvidence for the benefit of CPR in traumatic cardiac arrest is limited. Treatment priorities should initially focus on control of massive hemorrhage (including management of pelvis fractures), airway management, and consideration of bilateral needle thoracostomy. If CPR is performed at all, it should be performed en route to the hospital but only if it can be performed in a safe and effective manner by EMS clinicians\nUnless there is an immediate and correctable cause, patients suffering traumatic cardiac arrest have the best chance for survival when arrival time to a hospital is within minutes\nIf transport is initiated, consider the ACS-COT\u2019s Once the above treatments and interventions have been performed, patients should be transported to the closest appropriate hospital within the defined trauma system\nIn an effort to reduce on-scene time, consider IV/IO access and initiation of resuscitation during transport\nOptimal choices for resuscitation are (in descending order as available) as follows: whole blood, balanced blood products (red blood cells (RBC), plasma), packed red blood cells alone, liquid, or freeze-dried plasma alone, no fluid resuscitation. Excessive crystalloid and colloid have little to no value and may in fact be harmful in hemorrhagic shock\nConsider the duration of resuscitation and transport, contact online medical direction if available to discuss. If termination of resuscitation is advised, refer to the Termination of Resuscitation Efforts Guideline\n\nGo To TOC\n\nResuscitation\n\nRev. March 2022\n\nResuscitation in Traumatic Cardiac Arrest\n\n142\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Pertinent Assessment Findings\n\nEvidence of injuries incompatible with life\nEvidence of signs of life\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\nNone noted\n\n## Key Documentation Elements\n\nMechanism of injury\nPrimary survey findings\nSecondary survey findings\nScene time\nProcedures performed and patient response\n\n## Performance Measures\n\nScene time\nAppropriateness of procedures, including airway management, hemorrhage control, needle thoracostomy, intravenous access and resuscitation\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nPediatrics\u201403: Documentation of Estimated Weight in Kilograms\n\nWeight value in kilograms or length-based weight entered for patients less than 15 years old when Type of Service Requested = 2205001\u2014911 Response (Scene)\n\n## References\n\nEvans C, Quinlan D, Engels P, Sherbino J. Reanimating patients after traumatic cardiac arrest: a practical approach informed by best evidence. Emerg Med Clin N Am. 36 (2018) 19\u201340\nMillin MG, Galvagno SM, Khandker SR, Malki A, Bulger EM. Withholding and termination of resuscitation of adult cardiopulmonary arrest secondary to trauma: resource document to the joint NAEMSP-ACSCOT position statements. J Trauma Acute Care Surg.", "start_char_idx": 322419, "end_char_idx": 327051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbd14bdd-47db-47d3-8db0-9cf973e24878": {"__data__": {"id_": "cbd14bdd-47db-47d3-8db0-9cf973e24878", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f6ef761-f940-4459-a9e9-aa0324c39d73", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "fb6655c6fecd1881166b4775917173390c4634b2a8d24c3e2401ed7a8dfbd6e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4117d508-400d-456d-b3f1-52d90a14a586", "node_type": "1", "metadata": {}, "hash": "13837da7105cbb64ac69f46bf4e4d3b7fc33c79acd55c6894e5634f9170c7a21", "class_name": "RelatedNodeInfo"}}, "text": "Emerg Med Clin N Am. 36 (2018) 19\u201340\nMillin MG, Galvagno SM, Khandker SR, Malki A, Bulger EM. Withholding and termination of resuscitation of adult cardiopulmonary arrest secondary to trauma: resource document to the joint NAEMSP-ACSCOT position statements. J Trauma Acute Care Surg. 2013;75(3):459\u2013467. doi: 10.1097/TA.0b013e31829cfaea\nThe Royal College of Emergency Medicine. Traumatic cardiac arrest in adults best practice guideline. Sept 2019. From the website: https://rcem.ac.uk/wp-content/uploads/2021/10/RCEM_Traumatic_Cardiac_Arrest_Sept2019_FINAL.pdf. Accessed March 11, 2022\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nResuscitation Rev. March 2022\n\n## Resuscitation in Traumatic Cardiac Arrest 143\n---\n# National Model EMS Clinical Guidelines\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Pediatric-Specific Guidelines\n\n### Brief Resolved Unexplained Event (BRUE) & Acute Events in Infants\n\n#### Aliases\n\nApparent Life-Threatening Event (ALTE)\n\n#### Patient Care Goals\n\nRecognize patient characteristics and symptoms consistent with a BRUE\nPromptly identify and intervene for patients who require escalation of care\nChoose proper destination for patient transport\n\n#### Patient Presentation\n\n##### Inclusion Criteria\n\nSuspected BRUE: An event in an infant less than 1 year old reported by a bystander as sudden, brief (less than 1 minute), unexplained, and completely resolved upon EMS arrival that includes one or more of the following:\n\nBreathing change (absent, decreased, or irregular)\nColor change (central cyanosis or pallor)\nMarked change in muscle tone (hyper- or hypotonia)\nAltered level of responsiveness (increased, irritability, or decreased)\n\n##### Exclusion Criteria\n\nAny signs or symptoms suggestive of underlying or acute illness or injury present upon EMS evaluation, such as:\n\nAbnormal vital signs for age (including fever)\nVomiting\nSigns of trauma\nNoisy or labored breathing\n\nIdentifiable cause for the event, such as:\n\nGastric reflux (spitting up)\nSwallowing dysfunction\nNasal congestion or excessive secretions from the nose and/or mouth\nPeriodic breathing of the newborn\nBreath-holding spell\nChange in tone associated with choking, gagging, crying, feeding\nSeizure (e.g., eye deviation, nystagmus, tonic-clonic activity)\nHypoglycemia\nSignificant past medical history (e.g., congenital heart disease, pulmonary disease, VP shunt, or seizure disorder)\nNeed for IV medication administration\n\nHistory or exam concerning for child abuse or neglect\nColor change that involved only redness (e.g., in the face) or isolated hands/feet cyanosis\n\n________________________Go To TOC\n\n## Pediatric-Specific Guidelines\n\nRev. March 2022\n\nBrief Resolved Unexplained Event (BRUE) & Acute Events in Infants\n\n144\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Patient Management\n\n### Assessment\n\n1. History\n\na. History of circumstances and symptoms before, during, and after the event, including duration, interventions done, as well as patient color, tone, breathing, feeding, position, location, activity, and level of consciousness\nb. Other concurrent symptoms (e.g., fever, congestion, cough, rhinorrhea, vomiting, diarrhea, rash, labored breathing, fussy, less active, poor sleep, poor feeding)\nc. Prior history of BRUE (ever, including past 24 hours)\nd. Past medical history (e.g., prematurity, prenatal/birth complications, gastric reflux, congenital heart disease, developmental delay, airway abnormalities, breathing problems, prior hospitalizations, surgeries, or injuries)\ne. Family history of sudden unexplained death or cardiac arrhythmia in other children or young adults\nf. Social history: those living at home, recent household stressors, exposures to toxins/drugs, sick contacts\ng. Considerations for possible child abuse (i.e., multiple/changing versions of the story or reported mechanism of injury does not seem plausible, especially for child\u2019s developmental stage) [See Abuse and Maltreatment Guideline]\n\n2.", "start_char_idx": 326768, "end_char_idx": 330769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4117d508-400d-456d-b3f1-52d90a14a586": {"__data__": {"id_": "4117d508-400d-456d-b3f1-52d90a14a586", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbd14bdd-47db-47d3-8db0-9cf973e24878", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "b286f83045868ec78a35383d7dfb69e249a06f40f664357cb99b2be15ba39e0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39ecc645-2496-4cab-97f7-339e1dff17bb", "node_type": "1", "metadata": {}, "hash": "d31fd50bf04f278d2da88af3886d204f65f771c2749902046bcfe5d4247c8765", "class_name": "RelatedNodeInfo"}}, "text": "Exam\n\na. Full set of vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment)\nb. General assessment:\n\ni. Signs of respiratory distress or increased work of breathing (e.g., tachypnea, grunting or other abnormal breath sounds, nasal flaring, retracting, or head bobbing)\nii. Color, both central and peripheral (pallor, cyanosis, redness, or normal), capillary refill\niii. Mental status (alert, tired, lethargic, unresponsive, or irritable)\n\nc. Head to toe exam, including:\n\ni. Physical exam for signs of trauma or neglect\nii. Pupillary response and anterior fontanelle\n\n### Treatment and Interventions\n\n1. Monitoring (all patients with possible BRUE)\n\na. Continuous cardiac monitor\nb. Continuous pulse oximetry\nc. Serial observations during transport for change in condition\nd. Check point-of-care (POC) blood glucose and treat symptomatic hypoglycemia [See Hypoglycemia Guideline]\n\n2. Airway\n\na. Give supplemental oxygen for signs of respiratory distress or hypoxemia \u2014 escalate from a nasal cannula to a simple face mask to a non-rebreather mask as needed [See Airway Management Guideline]\nb. Suction excessive secretions from the nose and/or mouth (using bulb syringe or suction catheter) [See Pediatric Respiratory Distress (Bronchiolitis) Guideline]\n\n3. Utility of IV placement and fluids\n\na. Routine IVs should not be placed on all suspected BRUE patients\nb. IVs should be placed only for clinical concerns of shock or to administer IV medications\n\n________________________\n\nGo To TOC\n\n## Pediatric-Specific Guidelines\n\nRev. March 2022\n\nBrief Resolved Unexplained Event (BRUE) & Acute Events in Infants\n\n145\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Transport the patient to the appropriate facility even if they appear well or have returned to their baseline\n\nPatient Safety Considerations\n\nRegardless of the patient\u2019s well appearance, all infants with a history of signs or symptoms suggestive of BRUE should be transported for further evaluation\n\nBy definition, infants who are not completely well-appearing at EMS evaluation do not meet the definition of possible BRUE and should be treated and transported according to local guidelines\n\nDestination considerations\n\nAll patients should be transported to facilities with at least baseline pediatric readiness, i.e., appropriate equipment, resources, and trained staff capable of providing initial emergency care and stabilization to pediatric patients prior to hospital admission or interfacility transfer, if feasible\nConsider transport to a facility with pediatric critical care capability for patients with any high-risk criteria:\n\nLess than 2 months of age\nHistory of prematurity (less than or equal to 32 weeks gestation)\nMore than one BRUE, now or in the past\nEvent duration greater than 1 minute\nCPR or resuscitation by caregivers or trained rescuers\n\nNotes/Educational Pearls\n\nKey Considerations\n\nBRUE is a group of symptoms, not a disease process\nIf the infant is not completely well upon EMS arrival, this excludes possible BRUE event:\n\nTreat and transport according to local guidelines\n\nAvoid using \u201cBRUE\u201d, \u201cALTE\u201d, \u201cSIDS\u201d (sudden infant death syndrome), or \u201cnear-miss SIDS\u201d terminology with parent/guardian\nEMS clinicians play a unique and important role in obtaining an accurate history soon after the event and in observing, documenting, and reporting environmental, scene and social indicators that may point to an alternate diagnosis\nHigh-risk patients with a possible BRUE have worse outcomes and may require emergency department (ED) or inpatient testing, intervention, and/or follow-up\nThe determination of a BRUE is made only after hospital evaluation, not in the field:\n\nA few of these infants will die even after hospital evaluation and treatment\n\nAll patients should be transported to an ED\nContact medical direction if parent/guardian is refusing medical care and/or transport, especially if any high-risk criteria are present\n\nQuality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914197 \u2013 Medical - Apparent Life-Threatening Event (ALTE)\n\nGo To TOC\n\nPediatric-Specific Guidelines Rev. March 2022 Brief Resolved Unexplained Event (BRUE) & Acute Events in Infants 146\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Key Documentation Elements\n\nDocument key aspect of history\n\nThe event:\n\nBreathing (apnea or respiratory distress)\nColor change (central and/or peripheral)\nChange in muscle tone\nLevel of responsiveness\nEvent duration\nWitnessed?", "start_char_idx": 330770, "end_char_idx": 335325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39ecc645-2496-4cab-97f7-339e1dff17bb": {"__data__": {"id_": "39ecc645-2496-4cab-97f7-339e1dff17bb", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4117d508-400d-456d-b3f1-52d90a14a586", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "d6b3065ab7488e71c46df8e865ea3126db019a79ae004d654825244cd7a3e84d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ca16fd9-8388-4140-b3c5-d260c925b00b", "node_type": "1", "metadata": {}, "hash": "d3e18944c03cb090cadb346cc7514f8fb218efc0ea32551cbb27857f2e80917a", "class_name": "RelatedNodeInfo"}}, "text": "March 2022 Brief Resolved Unexplained Event (BRUE) & Acute Events in Infants 146\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Key Documentation Elements\n\nDocument key aspect of history\n\nThe event:\n\nBreathing (apnea or respiratory distress)\nColor change (central and/or peripheral)\nChange in muscle tone\nLevel of responsiveness\nEvent duration\nWitnessed?\n\nPre-event circumstances and history\n\nEvent associated with feeding or other activity\nHistory of prematurity\nPrior BRUE events (ever or in past 24 hours)\nPast medical history, especially cardiac, respiratory, gastrointestinal, neurologic\n\nCaregiver resuscitation efforts\nPost-event symptoms and circumstances\n\nDocument key aspects of the exam and assess for changes after each intervention:\n\nFull set of vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment), temperature,\nand O2 saturation\nRespiratory effort\nMental status including pupillary reaction and pediatric Glasgow Coma Score (GCS) or AVPU\nColor (central and peripheral) and capillary refill\nPresence of signs of abuse, trauma, or neglect\n\nDocument environmental and scene/social clues, especially those suggesting abuse, neglect, non-accidental trauma,\nor unsafe sleeping practices\n\n## Performance Measures\n\nComplete set of vital signs recorded\nAppropriate transport destination relative to risk criteria\n\n## References\n\n### Key Reference\n\nTieder JS, Bonkowsky JL, Etzel RA, et al. Brief resolved unexplained events (formerly apparent life-threatening\nevents) and evaluation of lower-risk infants: a systematic review. Pediatrics. 2016;137(5): e20165090\n\n### Supplemental References\n\nAlhaboob AA. Clinical Characteristics and Outcomes of Patients Admitted with Brief Resolved Unexplained Events to\na Tertiary Care Pediatric Intensive Care Unit. Cureus. 2020;12(6): e8664\nAl-Kindy H, Gelinas J, Hatzakis G, Cote A. Risk factors for extreme events in infant hospitalized for apparent\nlife-threatening events. J Pediatr. 2009;154(3):332\u20137\nArane K, Claudius I, Goldman RD. Brief resolved unexplained event: new diagnosis in infants. Can Fam Phys. Jan\n2017; 63:39\u201341\nBastin JP. Brief Resolved Unexplained Events in Infants. JAAPA. 2019;32(7):38\u201340\nBenham-Terneus M, Clemente M. SIDS, BRUE, and Safe Sleep Guidelines. Pediatr in Rev.\n\n________________________ Go To TOC\n\nPediatric-Specific Guidelines Rev. March 2022\n\nBrief Resolved Unexplained Event (BRUE) & Acute Events in Infants 147\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n2019;40(9):443\u2013455\n\n|6.|Brand DA, Fazzari MJ. Risk of Death in Infants Who Have Experienced a Brief Resolved Unexplained Event: A         Meta-Analysis. J Pediatr. 2018; 197:63\u201367|\n|---|---|\n|7.|Bonkowsky J. Guenther E, Filloux F, Srivastatva R. Death, child abuse, and adverse neurologic outcome of infants         after an apparent life-threatening event. Pediatrics. 2008;122(1):125\u201331|\n|8.|Colombo M, Katz ES, Bosco A, Melzi mL, Nosetti L. Brief resolved unexplained events: Retrospective validation of         diagnostic criteria and risk stratification. Pediatric Pulmonology. 2019; 54:61\u201365|\n|9.|Delaroche AM, Mittal MK. But What Was \u201cIt\u201d? Talking to Parents About BRUE. Hosp Pediatr. July 2019;9(7):566\u2013568|\n|10.|Delaroche AM, Haddad R, Farooqi A, Sapi\u00e9n RE, Tieder JS. Outcome Prediction of Higher-Risk Brief Resolved         Unexplained Events. Hosp Pediatr. April 2020;10(4):303\u2013310|\n|11.|Gausche-Hill M, Eckstein M, Horeczko T, McGrath N, Kurobe A, et al. Paramedics Accurately Apply the Pediatric         Assessment Triangle to Drive Management. Prehosp Emerg Care.", "start_char_idx": 334957, "end_char_idx": 338557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ca16fd9-8388-4140-b3c5-d260c925b00b": {"__data__": {"id_": "8ca16fd9-8388-4140-b3c5-d260c925b00b", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39ecc645-2496-4cab-97f7-339e1dff17bb", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "653e09c257f9f6d8e43c001ff62a6cfdec071e79b75d1010aa4d36e5b9ade2ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f395d788-fb73-4df3-b4d7-a9b7e7295919", "node_type": "1", "metadata": {}, "hash": "ecd927c53261e689df4c6285f53a1fb56cbefbe3e1caa58d725815141f1d1a29", "class_name": "RelatedNodeInfo"}}, "text": "Pediatric Pulmonology. 2019; 54:61\u201365|\n|9.|Delaroche AM, Mittal MK. But What Was \u201cIt\u201d? Talking to Parents About BRUE. Hosp Pediatr. July 2019;9(7):566\u2013568|\n|10.|Delaroche AM, Haddad R, Farooqi A, Sapi\u00e9n RE, Tieder JS. Outcome Prediction of Higher-Risk Brief Resolved         Unexplained Events. Hosp Pediatr. April 2020;10(4):303\u2013310|\n|11.|Gausche-Hill M, Eckstein M, Horeczko T, McGrath N, Kurobe A, et al. Paramedics Accurately Apply the Pediatric         Assessment Triangle to Drive Management. Prehosp Emerg Care. 2014;18(4):52\u2013530.|\n|12.|Gausche-Hill M, Schmitz C, Lewis RL. Pediatric Preparedness of US Emergency Departments: A 2003 Survey.         Pediatrics. Dec 2007;120(6):1229\u201337|\n|13.|Gerber NL, Fawcett KJ, Weber EG, Patel R, Glick AF et al. Brief Resolved Unexplained Event: Not Just a New Name for         Apparent Life-Threatening Event. Pediatr Emerg Care. 2020; May 28. doi: 10.1097/PEC.0000000000002069. Epub ahead of         print. PMID: 32472924|\n|14.|Guenther E, Powers A, Srivastava R, Bonkowsky JL. Abusive head trauma in children presenting with an apparent         life-threatening event. J Pediatr. 2010;157(5):821\u20135|\n|15.|Haddad R, Parker S, Farooqi A, Delaroche AM. Diagnostic Evaluation Low Yield for Patients with a Lower-Risk Brief         Resolved Unexplained Event. Global Pediatr Health. February 2021; 8:1\u20137|\n|16.|Kaji A, Claudius I, Santillanes G, et al. Apparent life-threatening event: multicenter prospective cohort study to         develop a clinical decision rule for admission to the hospital. Ann Emerg Med. 2013;61(4):379\u201387|\n|17.|Kaji A, Claudius I, Santillanes G, et al. Do infants less than 12 months of age with an apparent life-threatening         event need transport to a pediatric critical care center? Prehosp Emerg Care. 2013; Vol 17(3):304\u201311|\n|18.|Meyer JS, Stensland EG, Murzycki J, Gulen CR, Evindar A, Cardoso MZ. Retrospective Application of BRUE Criteria to         Patients Presenting with ALTE. Hosp Pediatr. 2018;8(12):740\u2013745|\n|19.|Middleton KR, Burt CW. Availability of pediatric services and equipment in emergency departments: United States,         2002\u201303. Adv Data. 2006; 367:1\u201316|\n|20.|Mittal M, Sun G, Baren JM. A clinical decision rule to identify infants with apparent life-threatening event who can         be discharged from the emergency department. Pediatric Emerg Care. 2012; 28:599\u2013605|\n|21.|Oglesbee SJ, Roberts MH, Sapi\u00e9n RE. Implementing lower-risk brief resolved unexplained events guidelines reduces         admissions in a modelled population. J Eval Clin Pract. 2020; 26:343\u2013356|\n|22.|Parker K, Pitetti R. Mortality and child abuse in children presenting with apparent life-threatening events. Ped Emerg         Care. 2011;27(7):591\u20135|\n|23.|Prezioso G, Perrone S, Biasucci G, Pisi G, Fainardi V, et al. Management of Infants with Brief Resolved Unexplained         Events (BRUE) and Apparent Life-Threatening Events (ALTE): A RAND/UCLA Appropriateness Approach. MDPI Life.         2021;11(171):|\n\n________________________\n\nGo To TOC\n\n## Pediatric-Specific Guidelines\n\nRev.", "start_char_idx": 338039, "end_char_idx": 341101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f395d788-fb73-4df3-b4d7-a9b7e7295919": {"__data__": {"id_": "f395d788-fb73-4df3-b4d7-a9b7e7295919", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ca16fd9-8388-4140-b3c5-d260c925b00b", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "1e38538b7e3bb4659f4f9f01dc71ab0895f1be71d2ffd4557dbaa943675cae25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d0f803e-a067-4c27-8108-2d5ee25030e8", "node_type": "1", "metadata": {}, "hash": "293d319c64b87ba80a9daa7adf61a9dcc1edcac89a76b194a2bad0be3d72bbe0", "class_name": "RelatedNodeInfo"}}, "text": "Implementing lower-risk brief resolved unexplained events guidelines reduces         admissions in a modelled population. J Eval Clin Pract. 2020; 26:343\u2013356|\n|22.|Parker K, Pitetti R. Mortality and child abuse in children presenting with apparent life-threatening events. Ped Emerg         Care. 2011;27(7):591\u20135|\n|23.|Prezioso G, Perrone S, Biasucci G, Pisi G, Fainardi V, et al. Management of Infants with Brief Resolved Unexplained         Events (BRUE) and Apparent Life-Threatening Events (ALTE): A RAND/UCLA Appropriateness Approach. MDPI Life.         2021;11(171):|\n\n________________________\n\nGo To TOC\n\n## Pediatric-Specific Guidelines\n\nRev. March 2022\n\nBrief Resolved Unexplained Event (BRUE) & Acute Events in Infants\n\n148\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nhttps://doi.org/10.3390/life11020171\n\n24. Ramgopal S, Noorbakhsh KA, Callaway CW, Wilson PM, Pitetti RD. Changes in the Management of Children with\nBrief Resolved Unexplained Events (BRUEs). Pediatr. October 2019;144(4): e20190375\n\n25. Ramgopal S, Soung J, Pitetti RD. Brief Resolved Unexplained Events: An Analysis of an Apparent Life Threatening\nEvent Database. Acad Pediatr. November-December 2019;19(8):963\u2013968\n\n26. Remick K, Gausche-Hill M, Joseph MM, Brown K, Snow SK et al. Pediatric Readiness in the Emergency Department.\nPediatrics. November 2018;142(5): e20182459.\n\n27. Stiell IG, Spaite DW, Field B, Nesbitt LP, Munkley D, Maloney J, et al. Advanced life support for out-of-hospital\nrespiratory distress. N Engl J Med. 2007;356(21):2156\u201364\n\n28. Stratton S, Taves A, Lewis R, Clements H, Henderson D, McCollough M. Apparent life-threatening events in\ninfants: high-risk in the out-of-hospital environment. Ann Emerg Med. 2004; 43:711\u20137\n\n29. Tieder JS, Altman RL, Bonkowsky JL, et al. Management of apparent life\u2013threatening events in infants: a\nsystematic review. J Pediatr. 2013; 163:94\u20139\n\n30. Tieder JS. Weird Baby Things or Brief Resolved Unexplained Events? Hosp Pediatr. 2018;8(12):799\u2013800\n\nRevision Date March 11, 2022\n\nGo To TOC\n\n## Pediatric-Specific Guidelines\n\nRev.", "start_char_idx": 340450, "end_char_idx": 342548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d0f803e-a067-4c27-8108-2d5ee25030e8": {"__data__": {"id_": "2d0f803e-a067-4c27-8108-2d5ee25030e8", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f395d788-fb73-4df3-b4d7-a9b7e7295919", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "6e40b9a71628c68199d55953be9179126aa76fbb8809bb460f1eaa8cd5b2fbf9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85d49957-ae50-466a-8c85-6d029bf7295f", "node_type": "1", "metadata": {}, "hash": "ebff1a0c6f6a1b2f96c79b86df9d51b306f960846d1b3accfe4718eb9e285de1", "class_name": "RelatedNodeInfo"}}, "text": "N Engl J Med. 2007;356(21):2156\u201364\n\n28. Stratton S, Taves A, Lewis R, Clements H, Henderson D, McCollough M. Apparent life-threatening events in\ninfants: high-risk in the out-of-hospital environment. Ann Emerg Med. 2004; 43:711\u20137\n\n29. Tieder JS, Altman RL, Bonkowsky JL, et al. Management of apparent life\u2013threatening events in infants: a\nsystematic review. J Pediatr. 2013; 163:94\u20139\n\n30. Tieder JS. Weird Baby Things or Brief Resolved Unexplained Events? Hosp Pediatr. 2018;8(12):799\u2013800\n\nRevision Date March 11, 2022\n\nGo To TOC\n\n## Pediatric-Specific Guidelines\n\nRev. March 2022\n\n## Brief Resolved Unexplained Event (BRUE) & Acute Events in Infants\n\n149\n---\n# National Model EMS Clinical Guidelines\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Pediatric Respiratory Distress (Bronchiolitis)\n\n(Adapted from an evidence-based guideline created using the National Prehospital Evidence-Based Guideline Model\nProcess)\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nAlleviate respiratory distress\nPromptly identify respiratory distress, failure, and/or arrest, and intervene for patients who require\nescalation of therapy\nDeliver appropriate therapy by differentiating other causes of pediatric respiratory distress\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nChild less than 2 years of age typically with diffuse rhonchi and/or wheezing with a viral or other undifferentiated\nillness characterized by rhinorrhea, cough, fever, tachypnea, and/or respiratory distress\n\n#### Exclusion Criteria\n\nAnaphylaxis\nCroup\nEpiglottitis\nForeign body aspiration\nSubmersion/drowning\nAsthma\n\n### Patient Management\n\n#### Assessment\n\n##### History\n\nOnset of symptoms\nConcurrent symptoms (e.g., fever, cough, rhinorrhea, tongue/lip swelling, rash, labored breathing, foreign\nbody aspiration)\nSick contacts\nHistory of wheezing\nRespiratory and other treatments given\nNumber of emergency department visits in the past year\nNumber of admissions in the past year\nNumber of intensive care unit (ICU) admissions ever (including pediatric ICU (PICU) and neonatal ICU\n(NICU))\nHistory of prematurity\nFamily history of asthma, eczema, or allergies\nChange in feeding patterns and/or number of wet diapers\n\n##### Exam\n\n________________________ Go To TOC\n\nPediatric-Specific Guidelines Rev. March 2022\n\nPediatric Respiratory Distress (Bronchiolitis) 150\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Pediatric Respiratory Distress (Bronchiolitis)\n\na. Full set of vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment) temperature, and O2\nsaturation\n\nb. Air entry (normal vs. diminished)\n\nc. Breath sounds (wheezes, crackles, rales, rhonchi, diminished, clear)\n\nd. Signs of distress (grunting, nasal flaring, retracting, accessory muscle use)\n\ne. Weak cry or inability to speak full sentences (sign of shortness of breath)\n\nf. Color (pallor, cyanosis, normal)\n\ng. Mental status (alert, tired, lethargic, unresponsive)\n\nh. Hydration status (+/- sunken eyes, delayed capillary refill, mucous membranes (moist vs. tacky), fontanel (flat\nvs. sunken))\n\n### Treatment and Interventions\n\n1. Pulse oximetry and end-tidal capnography (EtCO2) should be routinely used as an adjunct to other forms of\nrespiratory monitoring\n\n2. Perform EKG only if there are no signs of clinical improvement after treating respiratory distress\n\n3. Airway\n\na. Give supplemental oxygen \u2013 escalate from a nasal cannula to a simple face mask to a non-breather mask as needed,\nto maintain normal oxygenation (goal SpO2 94\u201398%)\n\nb. Suction the nose and/or mouth (via bulb or suction catheter) particularly if excessive secretions are present\n\n4.", "start_char_idx": 341979, "end_char_idx": 345629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85d49957-ae50-466a-8c85-6d029bf7295f": {"__data__": {"id_": "85d49957-ae50-466a-8c85-6d029bf7295f", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d0f803e-a067-4c27-8108-2d5ee25030e8", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "4b8f7c683c10d98ce7b61f5aabded2b2c6b1104ef6600c08ade33664b30a25a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "685897a8-6be3-45c8-9972-c7e3dee7c261", "node_type": "1", "metadata": {}, "hash": "da134c1a6857a8b7ffbbf2aa8d29e9b5a925a9f3f7cda10eb545466829387ada", "class_name": "RelatedNodeInfo"}}, "text": "tacky), fontanel (flat\nvs. sunken))\n\n### Treatment and Interventions\n\n1. Pulse oximetry and end-tidal capnography (EtCO2) should be routinely used as an adjunct to other forms of\nrespiratory monitoring\n\n2. Perform EKG only if there are no signs of clinical improvement after treating respiratory distress\n\n3. Airway\n\na. Give supplemental oxygen \u2013 escalate from a nasal cannula to a simple face mask to a non-breather mask as needed,\nto maintain normal oxygenation (goal SpO2 94\u201398%)\n\nb. Suction the nose and/or mouth (via bulb or suction catheter) particularly if excessive secretions are present\n\n4. Inhaled medications \u2013 nebulized epinephrine 5 mg (5 mL of 1 mg/mL solution) should be administered to children\nin severe respiratory distress with bronchiolitis in the prehospital setting if other treatments (e.g., suctioning,\noxygen) fail to result in clinical improvement; if immediate reassessment after treatment does not demonstrate clinical\nimprovement, airway management should be escalated as necessary (see below and refer to Airway Management Guideline)\n\n5. Utility of IV placement and fluids. IVs should only be placed in children with respiratory distress for clinical\nconcerns of dehydration, or when administering IV medications. Otherwise, IV access is not routinely needed in\nbronchiolitis.\n\n6. Steroids are not efficacious and should not be given\n\n7. Improvement of oxygenation and/or respiratory distress with non-invasive airway adjuncts\n\na. High flow nasal cannula (HFNC) or continuous positive airway pressure (CPAP) can be administered, when available,\nfor severe respiratory distress\n\nb. Bag-valve-mask ventilation should be utilized in children with respiratory failure or impending respiratory failure\n\n8. Supraglottic devices and intubation\n\na. Supraglottic devices and intubation should be utilized only if bag-valve-mask (BVM) ventilation fails\n\nb. The airway should be managed in the least invasive way possible\n\n### Patient Safety Considerations\n\nRoutine use of lights and sirens is not recommended during transport\n\n________________________ Go To TOC\n\nPediatric-Specific Guidelines Rev. March 2022\n\n151\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Notes/Educational Pearls\n\nKey Considerations\n\nSuctioning can be a very effective intervention to alleviate distress since infants are obligate nose breathers\nHeliox should not be routinely administered to children with respiratory distress\nInsufficient data exist to recommend the use of inhaled steam or nebulized saline\nAlthough albuterol and steroids have previously been a consideration, the most recent evidence does not demonstrate a benefit in routine use of albuterol or steroids for bronchiolitis\nIpratropium and other anticholinergic agents should not be given to children with bronchiolitis in the prehospital setting\nAlthough nebulized hypertonic saline has been shown to decrease hospital length of stay when used for bronchiolitis, it does not provide immediate relief of distress and should not be administered to children in respiratory distress in the prehospital setting\n\n## Pertinent Assessment Findings\n\nFrequent reassessment is necessary to determine if interventions have alleviated signs of respiratory distress.\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914221 \u2013 Medical - Respiratory Distress-Bronchiolitis\n\nProtocol Age Category: 3602005 - Pediatric Only\n\n## Key Documentation Elements\n\nDocument key aspects of the exam to assess for a change after each intervention:\n\nRespiratory rate\nOxygen saturation\nUse of accessory muscles\nBreath sounds\nAir entry\nMental status\nColor\n\n## Performance Measures\n\nSupplemental oxygen, high flow oxygen by nasal cannula (HFNC), time to administration of specified interventions in the protocol\nRate of administration of accepted therapy (whether certain medications/interventions were given)\nChange in vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment) temperature, O2 saturation and capnography values)\nTime to administration of specified interventions in the protocol\nNumber of advanced airway attempts\nMortality\n\n________________________ Go To TOC\n\nPediatric-Specific Guidelines Rev.", "start_char_idx": 345029, "end_char_idx": 349293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "685897a8-6be3-45c8-9972-c7e3dee7c261": {"__data__": {"id_": "685897a8-6be3-45c8-9972-c7e3dee7c261", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85d49957-ae50-466a-8c85-6d029bf7295f", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "03dbedd3788103530d968ac027c55f1a94ef51f43443002aa2c3ff593764cf2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e919736f-026a-497d-a57a-d9e914102879", "node_type": "1", "metadata": {}, "hash": "a375e5c756f0c6b60fa422f0c10e124c24117e31e7d0d553285ec07952db941c", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nPediatric Respiratory Distress (Bronchiolitis) 152\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## References\n\n|1.|Abramo TJ, Wiebe RA, Scott SM, Primm PA, McIntyre D, Mydlyer T. Noninvasive capnometry in a pediatric population         with respiratory emergencies. Pediatr Emerg Care. 1996;12(4):252\u20134|\n|---|---|\n|2.|Al-Ansari K, Sakran M, Davidson BL, El Sayyed R, Mahjoub H, Ibrahim K. Nebulized 5% or 3% hypertonic or 0.9%         saline for treating acute bronchiolitis in infants. J Pediatr. 2010;157(4): 630\u20134|\n|3.|Cambonie G, Mil\u00e9si C, Jaber S, et al. Nasal continuous positive airway pressure decreases respiratory muscles         overload in young infants with severe acute viral bronchiolitis. Intensive Care Med. 2008;34(10):1865\u201372|\n|4.|Chavasse R, Seddon P, Bara A, McKean M. Short acting beta2-agonists for recurrent wheeze in children under two         years old. Cochrane Database Syst Rev. 2002;(3):CD002873|\n|5.|Chowdhury MM, McKenzie SA, Pearson CC, et al. Heliox therapy in bronchiolitis: phase III multicenter double-blind         randomized controlled trial. Pediatrics. 2013;131(4):661\u20139|\n|6.|Corneli HM, Zorc JJ, Mahajan P, et al. A multicenter, randomized, controlled trial of dexamethasone for         bronchiolitis. N Engl J Med. 2007;357(4):331\u20139|\n|7.|Denver Metro Airway Study Group. A prospective multicenter evaluation of prehospital airway management performance         in a large metropolitan region. Prehosp Emerg Care. 2009;13(3):304\u201310|\n|8.|Ehrlich PF, Seidman PS, Atallah O, Haque A, Helmkamp J. Endotracheal intubations in rural pediatric trauma         patients. J Pediatr Surg. 2004;39(9):1376\u201380|\n|9.|Everard ML, Bara A, Kurian M, Elliot TM, Ducharme F. Anticholinergic drugs for wheeze in children under the age         of two years. Cochrane Database Syst Rev. 2002;(1):CD001279|\n|10.|Freedman SB, Haladyn JK, Floh A, Kirsh JA, Taylor G, Thull-Freedman J. Pediatric myocarditis: emergency         department clinical findings and diagnostic evaluation. Pediatrics. 2007;120(6):1278\u201385|\n|11.|Gausche-Hill M, Lewis RJ, Stratton SJ, Haynes BE, Gunter CS, Goodrich SM, et al. Effect of out-of-hospital         pediatric endotracheal intubation on survival and neurological outcome. JAMA. 2000;283(6):783\u201390|\n|12.|Grewal S, Ali S, McConnell DW, Vandermeer B, Klassen TP. A randomized trial of nebulized 3% hypertonic saline         with epinephrine in the treatment of acute bronchiolitis in the emergency department. Arch Pediatr Adolesc Med.         2009;163(11):1007\u201312|\n|13.|Hartling L, Russell KF, Patel H, Klassen TP, Liang Y. Epinephrine for bronchiolitis. Cochrane Database Syst Rev.         2004;(1):CD003123|\n|14.|Ho J, Casey B. Time saved with use of emergency warning lights and sirens during response to requests for         emergency medical aid in an urban environment. Ann Emerg Med. 1998;32(5):585\u20138|\n|15.|Ho J, Lindquist M. Time saved with the use of emergency warning lights and siren while responding to requests for         emergency medical aid in a rural environment. Prehosp Emerg Care.", "start_char_idx": 349294, "end_char_idx": 352392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e919736f-026a-497d-a57a-d9e914102879": {"__data__": {"id_": "e919736f-026a-497d-a57a-d9e914102879", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "685897a8-6be3-45c8-9972-c7e3dee7c261", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "7f60f7f75b1fec8d195166c5b2781e207724f11aa56f7d6b0fcdabc44baf1ffa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62fbd0d4-0d75-4298-8ab6-3d8b39d03334", "node_type": "1", "metadata": {}, "hash": "126e1ce631e1ae97d029d03d5ae8b171c1c0f87d0f0fa7d2d5501696ba424554", "class_name": "RelatedNodeInfo"}}, "text": "Arch Pediatr Adolesc Med.         2009;163(11):1007\u201312|\n|13.|Hartling L, Russell KF, Patel H, Klassen TP, Liang Y. Epinephrine for bronchiolitis. Cochrane Database Syst Rev.         2004;(1):CD003123|\n|14.|Ho J, Casey B. Time saved with use of emergency warning lights and sirens during response to requests for         emergency medical aid in an urban environment. Ann Emerg Med. 1998;32(5):585\u20138|\n|15.|Ho J, Lindquist M. Time saved with the use of emergency warning lights and siren while responding to requests for         emergency medical aid in a rural environment. Prehosp Emerg Care. 2001;5(2):159\u201362|\n|16.|Hunt RC, Brown LH, Cabinum ES, Whitley TW, Prasad NH, Owens JCF, et al. Is ambulance transport time with lights         and siren faster than that without? Ann Emerg Med. 1995;25(4):507\u201311|\n|17.|Javouhey E, Barats A, Richard N, Stamm D, Floret D. Non-invasive ventilation as primary ventilatory support for         infants with severe bronchiolitis. Intensive Care Med. 2008;34(9):1608\u201314|\n|18.|Kuzma K, Sporer KA, Michael GE, Youngblood GM. When are prehospital intravenous catheters used for treatment? J         Emerg Med. 2009;36(4):357\u201362|\n\n________________________\n\nGo To TOC\n\n## Pediatric-Specific Guidelines\n\nRev. March 2022\n\n### Pediatric Respiratory Distress (Bronchiolitis)\n\n153\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n19. Lacher ME, Bausher JC. Lights and siren in pediatric 911 ambulance transports: are they being misused? Ann\nEmerg Med. 1997;29(2):223\u20137\n\n20. Lashkeri T, Howell JM, Place R. Capnometry as a predictor of admission in bronchiolitis. Pediatr Emerg Care.\n2012;28(9):895\u20137\n\n21. Liet JM, Ducruet T, Gupta V, Cambonie G. Heliox. Inhalation therapy for bronchiolitis in infants. Cochrane\nDatabase Syst Rev. 2010;(4):CD006915\n\n22. Martinon-Torres F, Rodriguez-Nunez A, Martinon-Sanchez JM. Heliox therapy in infants with acute bronchiolitis.\nPediatrics. 2002;109(1):68\u201373\n\n23. Moses JM, Alexander JL, Agus MS. The correlation and level of agreement between end-tidal and blood gas PCO2 in\nchildren with respiratory distress: a retrospective analysis. BMC Pediatr. 2009; 9:20\n\n24. Mussman GM, Parker MW, Statile A, Sucharew H, Brady PW. Suctioning and length of stay in infants hospitalized\nwith bronchiolitis. JAMA Pediatr. 2013;167(5):414\u201321\n\n25. Ralston RL, Lieberthal H, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and\nprevention of bronchiolitis. Pediatrics. 2014;134: e1474\u2013502\n\n26. Skjerven HO, Hunderi JO, Br\u00fcgmann-Pieper SK, et al. Racemic adrenaline and inhalation strategies in acute\nbronchiolitis. N Engl J Med. 2013;368(24):2286\u201393\n\n27. Spaite DW, Valenzuela TD, Criss EA, Meislin HW, Hinsberg P. A prospective in-field comparison of intravenous\nline placement by urban and nonurban emergency medical services personnel. Ann Emerg Med. 1994;24(2):209\u201314\n\n28. Stiell IG, Spaite DW, Field B, et al. Advanced life support for out-of-hospital respiratory distress. N Engl J\nMed. 2007;356(21):2156\u201364\n\n29.", "start_char_idx": 351800, "end_char_idx": 354824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62fbd0d4-0d75-4298-8ab6-3d8b39d03334": {"__data__": {"id_": "62fbd0d4-0d75-4298-8ab6-3d8b39d03334", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e919736f-026a-497d-a57a-d9e914102879", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "7fac413f310f4e563fab8114ce18a93aa1acb55ce608e2e4e110321a4b24f4d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e62b029-8891-4b2b-b0bb-d9c998a907dc", "node_type": "1", "metadata": {}, "hash": "1e494bd4ffcf98143e363132c6b76022556e62608a60c6e0f59b684912768369", "class_name": "RelatedNodeInfo"}}, "text": "Pediatrics. 2014;134: e1474\u2013502\n\n26. Skjerven HO, Hunderi JO, Br\u00fcgmann-Pieper SK, et al. Racemic adrenaline and inhalation strategies in acute\nbronchiolitis. N Engl J Med. 2013;368(24):2286\u201393\n\n27. Spaite DW, Valenzuela TD, Criss EA, Meislin HW, Hinsberg P. A prospective in-field comparison of intravenous\nline placement by urban and nonurban emergency medical services personnel. Ann Emerg Med. 1994;24(2):209\u201314\n\n28. Stiell IG, Spaite DW, Field B, et al. Advanced life support for out-of-hospital respiratory distress. N Engl J\nMed. 2007;356(21):2156\u201364\n\n29. Thia LP, McKenzie SA, Blyth TP, Minasian CC, Kozlowska WJ, Carr SB. Randomized controlled trial of nasal\ncontinuous positive airways pressure (CPAP) in bronchiolitis. Arch Dis Child. 2008;93(1):45\u20137\n\n30. Umoren R, Odey F, Meremikwu MM. Steam inhalation or humidified oxygen for acute bronchiolitis in children up to\nthree years old. Cochrane Database Syst Rev. 2011;(1):CD006435\n\n31. Wang HE, Mann NC, Mears G, Jacobson K, Yealy DM. Out-of-hospital airway management in the United States.\nResuscitation. 2011;82(4):378\u201385\n\n32. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulized hypertonic saline solution for acute bronchiolitis\nin infants. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD006458\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nPediatric-Specific Guidelines Rev. March 2022\n\nPediatric Respiratory Distress (Bronchiolitis) 154\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Pediatric Respiratory Distress (Croup)\n\n(Adapted from an evidence-based guideline created using the National Prehospital Evidence-Based Guideline Model Process)\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nAlleviate respiratory distress\nPromptly identify respiratory distress, respiratory failure, respiratory arrest, and intervene for patients who require escalation of therapy\nDeliver appropriate therapy by differentiating other causes of pediatric respiratory distress\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nSuspected croup (history of stridor or history of barky cough)\n\n#### Exclusion Criteria\n\nPresumed underlying cause that includes one of the following:\n\nAnaphylaxis\nAsthma\nBronchiolitis (wheezing in a patient less than 2 years of age)\nForeign body aspiration\nSubmersion/drowning\nEpiglottitis\n\n### Patient Management\n\n#### Assessment\n\nHistory\n\nOnset of symptoms (history of choking)\nConcurrent symptoms (fever, cough, rhinorrhea, tongue/lip swelling, rash, labored breathing, foreign body aspiration)\nSick contacts\nTreatments given\nPersonal history of asthma, wheezing, or croup in the past\n\nExam\n\nFull set of vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment) temperature, and O2 saturation\nPresence of stridor at rest or when agitated\nDescription of cough\nOther signs of distress (grunting, nasal flaring, retracting, use of accessory muscles)\nColor (pallor, cyanosis, normal)\nMental status (alert, tired, lethargic, unresponsive)\n\n#### Treatment and Interventions\n\nMonitoring\n\n________________________\n\nGo To TOC\n\n### Pediatric-Specific Guidelines\n\nRev. March 2022\n\n## Pediatric Respiratory Distress (Croup)\n\n155\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Pediatric Respiratory Distress (Croup)\n\na. Pulse oximetry and EtCO2 should be routinely used as an adjunct to other forms of respiratory monitoring\n\n2. Airway\n\na. Give supplemental oxygen. Escalate from a nasal cannula to a simple face mask to a non-breather mask to SPO2 94-98%\n\nb. Suction the nose and/or mouth (via bulb or suction catheter) if excessive secretions are present\n\n3.", "start_char_idx": 354263, "end_char_idx": 357885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e62b029-8891-4b2b-b0bb-d9c998a907dc": {"__data__": {"id_": "5e62b029-8891-4b2b-b0bb-d9c998a907dc", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62fbd0d4-0d75-4298-8ab6-3d8b39d03334", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "03d3d593439d8ec401e22db1cffeadc377577dd0f40903f32ddbd838d30de62c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8dadadf-2830-4e78-a001-1bdfab2bf5fb", "node_type": "1", "metadata": {}, "hash": "b2a3be88f68e7731b237c1d7f15896a988003ceb32c87d33dfc7d635fb4a7b95", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n## Pediatric Respiratory Distress (Croup)\n\n155\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Pediatric Respiratory Distress (Croup)\n\na. Pulse oximetry and EtCO2 should be routinely used as an adjunct to other forms of respiratory monitoring\n\n2. Airway\n\na. Give supplemental oxygen. Escalate from a nasal cannula to a simple face mask to a non-breather mask to SPO2 94-98%\n\nb. Suction the nose and/or mouth (via bulb or suction catheter) if excessive secretions are present\n\n3. Inhaled medications should be administered to all children with croup in respiratory distress with signs of stridor at rest\u2014these medications should be repeated at this dose with unlimited frequency for ongoing respiratory distress\n\na. Epinephrine 5 mg (5 mL of 1 mg/mL solution) nebulized (may repeat in 20 minutes as needed), or\n\nb. Racemic epinephrine 0.5 mL of 2.25% solution mixed in 2.5 mL NS (may repeat in 20 minutes as needed)\n\nc. Humidified oxygen or mist therapy is not indicated\n\n4. Dexamethasone 0.6 mg/kg oral, IV, or IM to maximum dose of 16 mg should be administered to patients with suspected croup\n\n5. Utility of IV placement and fluids. IVs should only be placed in children with respiratory distress for clinical concerns of dehydration or when administering IV medications\n\n6. Improvement of oxygenation and/or respiratory distress with non-invasive airway adjuncts\n\na. Heliox for the treatment of croup can be considered for severe distress not responsive to more than 2 doses of epinephrine\n\nb. Continuous positive airway pressure (CPAP) should be administered for severe respiratory distress\n\nc. BVM ventilation should be utilized in children with respiratory failure\n\n7. Supraglottic devices and intubation \u2014 should be utilized only if BVM ventilation fails. The airway should be managed in the least invasive way possible\n\n### Patient Safety Considerations\n\n1. Routine use of lights and sirens is not recommended during transport\n\n2. Patients who receive inhaled epinephrine should be transported to definitive care\n\n### Notes/Educational Pearls\n\nKey Considerations\n\n1. Upper airway obstruction can have inspiratory, expiratory, or biphasic stridor\n\n2. Foreign bodies can mimic croup, it is important to ask about a possible choking event\n\n3. Impending respiratory failure is indicated by:\n\na. Change in mental status such as fatigue and listlessness\n\nb. Pallor\n\nc. Dusky appearance\n\nd. Decreased retractions\n\ne. Decreased breath sounds with decreasing stridor\n\n4. Without stridor at rest or other evidence of respiratory distress, inhaled medications may not be necessary\n\n### Pertinent Assessment Findings\n\n1. Respiratory distress (retractions, wheezing, stridor, accessory muscle use)\n\n________________________\n\nGo To TOC\n\nPediatric-Specific Guidelines\n\nRev. March 2022\n\nPediatric Respiratory Distress (Croup)\n\n156\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914223 \u2013 Medical - Respiratory Distress-Croup\n\nProtocol Age Category: 3602005 - Pediatric Only\n\n## Key Documentation Elements\n\nDocument key aspects of the exam to assess for a change after each intervention:\n\nRespiratory rate\nOxygen saturation\nUse of accessory muscles or tracheal tugging\nBreath sounds\nAir entry\nMental status\nColor\n\n## Performance Measures\n\nTime to administration of specified interventions in the protocol\nFrequency of administration of specified interventions in the protocol\n\n## References\n\nAbramo TJ, Wiebe RA, Scott SM, Primm PA, McIntyre D, Mydlyer T. Noninvasive capnometry in a pediatric\npopulation with respiratory emergencies. Pediatr Emerg Care. 1996;12(4):252\u20134\nAusejo M, Saenz A, Pham B, et al. The effectiveness of glucocorticoids in treating croup: meta-analysis. West J\nMed. 1999;171(4):227\u201332\nBjornson CL, Klassen TP, Williamson J, et al. A randomized trial of a single dose of oral dexamethasone for mild\ncroup.", "start_char_idx": 357374, "end_char_idx": 361376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8dadadf-2830-4e78-a001-1bdfab2bf5fb": {"__data__": {"id_": "f8dadadf-2830-4e78-a001-1bdfab2bf5fb", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e62b029-8891-4b2b-b0bb-d9c998a907dc", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "f3196554bb8e9860fbf15e25afab3a8b22960a61f315d11e326ab7bf4d2fcda5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4066d87e-0092-45ec-b530-31e17778ef3e", "node_type": "1", "metadata": {}, "hash": "7d37cd3827d6d221e427b2344fc4471c19c4f62beaf3847f9a676ff7bd8595a0", "class_name": "RelatedNodeInfo"}}, "text": "Pediatr Emerg Care. 1996;12(4):252\u20134\nAusejo M, Saenz A, Pham B, et al. The effectiveness of glucocorticoids in treating croup: meta-analysis. West J\nMed. 1999;171(4):227\u201332\nBjornson CL, Klassen TP, Williamson J, et al. A randomized trial of a single dose of oral dexamethasone for mild\ncroup. Pediatric Emergency Research Canada Network. N Engl J Med. 2004;351(13):1306\u201313\nBjornson C, Russell KF, Vandermeer B, Durec T, Klassen TP, Johnson DW. Nebulized epinephrine for croup in\nchildren. Cochrane Database Syst Rev. 2011;(2):CD006619\nDenver Metro Airway Study Group. A prospective multicenter evaluation of prehospital airway management\nperformance in a large metropolitan region. Prehosp Emerg Care. 2009;13(3):304\u201310\nEhrlich PF, Seidman PS, Atallah O, Haque A, Helmkamp J. Endotracheal intubations in rural pediatric trauma\npatients. J Pediatr Surg. 2004;39(9):1376\u201380\nFreedman SB, Haladyn JK, Floh A, Kirsh JA, Taylor G, Thull-Freedman J. Pediatric myocarditis: Emergency\ndepartment clinical findings and diagnostic evaluation. Pediatrics. 2007;120(6):1278\u201385\nGausche M, Lewis RJ, Stratton SJ, et al. Effect of out-of-hospital pediatric endotracheal intubation on survival\nand neurological outcome. JAMA. 2000;283(6):783\u201390\nGrosz AH, Jacobs IN, Cho C, Schears GJ. Use of helium-oxygen mixture to relieve upper airway obstruction in a\npediatric population. Laryngoscope. 2001;111(9):1512\u20134\n\n________________________ Go To TOC\n\nPediatric-Specific Guidelines Rev. March 2022\n\nPediatric Respiratory Distress (Croup) 157\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n10. Guideline for the Diagnosis and Management of Croup. Alberta, ON, Canada: Alberta Medical Association; 2015.\nhttps://actt.albertadoctors.org/CPGs/Lists/CPGDocumentList/croup-guideline.pdf\nAccessed March 11, 2022\n\n11. Ho J, Casey B. Time saved with use of emergency warning lights and sirens during response to requests for emergency\nmedical aid in an urban environment. Ann Emerg Med. 1998;32(5):585\u20138\n\n12. Hunt RC, Brown LH, Cabinum ES, et al. Is ambulance transport time with lights and siren faster than that without?\nAnn Emerg Med. 1995;25(4):507\u201311\n\n13. Keahey L, Bulloch B, Becker AB, Pollack CV, Clark S, Camargo CA. Initial oxygen saturation as a predictor of\nadmission in children presenting to the emergency department with acute asthma. Ann Emerg Med. 2002;40(3):300\u20137\n\n14. Kline-Krammes S, Reed C, Giuliano JS Jr., et al. Heliox in children with croup: a strategy to hasten improvement.\nAir Med J. 2012;31(3):131\u20137\n\n15. Kunkel NC, Baker MD. Use of racemic epinephrine, dexamethasone, and mist in the outpatient management of croup.\nPediatr Emerg Care. 1996;12(3):156\u20139\n\n16. Kuzma K, Sporer KA, Michael GE, Youngblood GM. When are prehospital intravenous catheters used for treatment?\nJ Emerg Med. 2009;36(4):357\u201362\n\n17. Lacher ME, Bausher JC. Lights and siren in pediatric 911 ambulance transports: are they being misused? Ann Emerg\nMed. 1997;29(2):223\u20137\n\n18. Moses JM, Alexander JL, Agus MSD.", "start_char_idx": 361084, "end_char_idx": 364094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4066d87e-0092-45ec-b530-31e17778ef3e": {"__data__": {"id_": "4066d87e-0092-45ec-b530-31e17778ef3e", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8dadadf-2830-4e78-a001-1bdfab2bf5fb", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "52df1b3b0032aec63f638e685e28441b41bb327e255771ae079ad8e411032d4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3888ea3-4c0d-491a-bc9d-4df171f4602a", "node_type": "1", "metadata": {}, "hash": "0270dd68a8d89ea395ea788b7ad80c579f5d3b7a09998f2e3585da3534c675bf", "class_name": "RelatedNodeInfo"}}, "text": "Heliox in children with croup: a strategy to hasten improvement.\nAir Med J. 2012;31(3):131\u20137\n\n15. Kunkel NC, Baker MD. Use of racemic epinephrine, dexamethasone, and mist in the outpatient management of croup.\nPediatr Emerg Care. 1996;12(3):156\u20139\n\n16. Kuzma K, Sporer KA, Michael GE, Youngblood GM. When are prehospital intravenous catheters used for treatment?\nJ Emerg Med. 2009;36(4):357\u201362\n\n17. Lacher ME, Bausher JC. Lights and siren in pediatric 911 ambulance transports: are they being misused? Ann Emerg\nMed. 1997;29(2):223\u20137\n\n18. Moses JM, Alexander JL, Agus MSD. The correlation and level of agreement between end-tidal and blood gas pCO2 in\nchildren with respiratory distress: A retrospective analysis. BMC Pediatr. 2009; 9:20\n\n19. Neto GM, Kentab O, Klassen TP, Osmond MH. A randomized controlled trial of mist in the acute treatment of\nmoderate croup. Acad Emerg Med. 2002;9(9):873\u20139\n\n20. Russell KF, Liang Y, O'Gorman K, Johnson DW, Klassen TP. Glucocorticoids for croup. Cochrane Database Syst Rev.,\n2011 Jan 19;(1):CD001955.\n\n21. Scolnik D, Coates AL, Stephens D, Da Silva Z, Lavine E, Schuh S. Controlled delivery of high vs low humidity vs\nmist therapy for croup in emergency departments: a randomized controlled trial. JAMA. 2006;295(11):1274\u201380\n\n22. Spaite DW, Valenzuela TD, Criss EA, Meislin HW, Hinsberg PA. prospective in-field comparison of intravenous line\nplacement by urban and nonurban emergency medical services personnel. Ann Emerg Med. 1994;24(2):209\u201314\n\n23. Stiell IG, Spaite DW, Field B, et al. Advanced life support for out-of-hospital respiratory distress. N Engl J Med.\n2007;356(21):2156\u201364\n\n24. Stoney PJ, Chakrabarti MK. Experience of pulse oximetry in children with croup. J Laryngol Otol. 1991;105(4):295\u20138\n\n25. Vorwerk C, Coats T. Heliox for croup in children. Cochrane Database Syst Rev. 2012;(10):CD006822\n\n26. Warner GS. Evaluation of the effect of prehospital application of continuous positive airway pressure therapy in\nacute respiratory distress. Prehosp Disast Med. 2010;25(1):87\u201391\n\n27. Westley CR, Cotton EK, Brooks JG. Nebulized racemic epinephrine by IPPB for the treatment of croup: a double-blind\nstudy. Am J Dis Child. 1978;132(5):484\u20137\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nPediatric-Specific Guidelines Rev. March 2022\n\nPediatric Respiratory Distress (Croup) 158\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Neonatal Resuscitation\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nPlan for resources based on number of anticipated patients (e.g., mother and newborn or multiple births)\nProvide routine care to the newly born infant\nPerform a neonatal assessment\nRapidly identify newly born infants requiring resuscitative efforts\nProvide appropriate interventions to minimize distress in the newly born infant\nRecognize the need for additional resources based on patient condition and/or environmental factors\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nNewly born infants\n\n#### Exclusion Criteria\n\nDocumented gestational age less than 20 weeks (usually calculated by date of last menstrual period).", "start_char_idx": 363523, "end_char_idx": 366633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3888ea3-4c0d-491a-bc9d-4df171f4602a": {"__data__": {"id_": "f3888ea3-4c0d-491a-bc9d-4df171f4602a", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4066d87e-0092-45ec-b530-31e17778ef3e", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8874a8cfe7477d19a01aaab346db802438b18dee0ade74617d16a49f85d486d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4e1aa3d-c9b9-4dfb-b74e-941e7d91ce55", "node_type": "1", "metadata": {}, "hash": "5a70c5723eaccd1bc49be51e47d7d243e305114784a0d909a4030177b62d6b4a", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nPediatric Respiratory Distress (Croup) 158\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Neonatal Resuscitation\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nPlan for resources based on number of anticipated patients (e.g., mother and newborn or multiple births)\nProvide routine care to the newly born infant\nPerform a neonatal assessment\nRapidly identify newly born infants requiring resuscitative efforts\nProvide appropriate interventions to minimize distress in the newly born infant\nRecognize the need for additional resources based on patient condition and/or environmental factors\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nNewly born infants\n\n#### Exclusion Criteria\n\nDocumented gestational age less than 20 weeks (usually calculated by date of last menstrual period). If any doubt about accuracy of gestational age, initiate resuscitation\n\n### Patient Management\n\n#### Assessment\n\n##### History\n\nDate and time of birth\nOnset of symptoms\nPrenatal history (prenatal care, substance abuse, multiple gestation, maternal illness)\nBirth history (maternal fever, presence of meconium, maternal bleeding, difficult delivery (e.g., shoulder dystocia, prolapsed or nuchal cord, breech))\nEstimated gestational age (may be based on last menstrual period)\n\n##### Exam\n\nRespiratory rate and effort (strong, weak, or absent; regular or irregular)\nSigns of respiratory distress (grunting, nasal flaring, retractions, gasping, apnea)\nHeart rate (fast, slow, or absent)\n\nPrecordium, umbilical stump, or brachial pulse may be used (auscultation of chest is preferred since palpation of umbilical stump is less accurate)\n\nMuscle tone (poor or strong)\nColor/Appearance (central cyanosis, acrocyanosis, pallor, normal)\nAPGAR score (Appearance, Pulse, Grimace, Activity, Respiratory effort) \u2014 may be calculated for documentation, but not necessary to guide resuscitative efforts\nEstimated gestational age (term, late preterm, premature)\nPulse oximetry should be considered if resuscitative efforts are initiated or if supplemental oxygen is administered\n\n________________________\n\nGo To TOC\n\n### Pediatric-Specific Guidelines\n\nRev. March 2022\n\n## Neonatal Resuscitation\n\n159\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Treatment and Interventions\n\nIf immediate resuscitation is required and the newborn is still attached to the mother, clamp the cord in two places and cut between the clamps. If no resuscitation is required, warm/dry/stimulate the newborn, and then cut/clamp the cord after 60 seconds or the cord stops pulsating\n\nDry, warm, and stimulate\n\na. Wrap infant in dry towel or thermal blanket to keep infant as warm as possible during resuscitation; keep head covered if possible\nb. If strong cry, regular respiratory effort, good tone, and term gestation, infant should be placed skin-to-skin with mother and covered with dry linen\n\nIf weak cry, signs of respiratory distress, poor tone, or preterm gestation then position airway (sniffing position) and clear airway as needed. If signs of respiratory distress with airway obstruction, suction mouth then nose; routine suctioning is not recommended\n\nApply cardiac monitor, if available\n\nIf heart rate greater than 100 BPM\n\na. Monitor for central cyanosis \u2014 provide blow-by oxygen as needed\nb. Monitor for signs of respiratory distress. If apneic or in significant respiratory distress:\n\ni. Ventilate: BVM ventilation with room air at 40\u201360 breaths per minute\n\n1. Positive pressure ventilation (PPV) with bag-mask device may be initiated with room air (21% oxygen) in term and late preterm babies; otherwise use 100% oxygen\n2. Goal: SPO2 at 10 minutes is 85\u201395%\n\nii. Consider endotracheal intubation per local guidelines\n\nEvaluate: If heart rate less than 100 BPM\n\na. Initiate BVM ventilation with room air at 40\u201360 breaths per minute for 90 seconds with room air\n\ni. Primary indicator of effective ventilation is improvement in heart rate\nii. Evaluate heart rate every 30 seconds\niii.", "start_char_idx": 365818, "end_char_idx": 369815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4e1aa3d-c9b9-4dfb-b74e-941e7d91ce55": {"__data__": {"id_": "e4e1aa3d-c9b9-4dfb-b74e-941e7d91ce55", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3888ea3-4c0d-491a-bc9d-4df171f4602a", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "1be8049daf03cef9e6512884179f862e9042241640d74e459a20eff3a7a3bcbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "972c0f03-1969-4128-96a5-cc324384f60c", "node_type": "1", "metadata": {}, "hash": "2c7f65464615794754bd6de9416a4de3ad314899a965e072cce00977d5e18e9f", "class_name": "RelatedNodeInfo"}}, "text": "If apneic or in significant respiratory distress:\n\ni. Ventilate: BVM ventilation with room air at 40\u201360 breaths per minute\n\n1. Positive pressure ventilation (PPV) with bag-mask device may be initiated with room air (21% oxygen) in term and late preterm babies; otherwise use 100% oxygen\n2. Goal: SPO2 at 10 minutes is 85\u201395%\n\nii. Consider endotracheal intubation per local guidelines\n\nEvaluate: If heart rate less than 100 BPM\n\na. Initiate BVM ventilation with room air at 40\u201360 breaths per minute for 90 seconds with room air\n\ni. Primary indicator of effective ventilation is improvement in heart rate\nii. Evaluate heart rate every 30 seconds\niii. Rates and volumes of ventilation required can be variable, only use the minimum necessary rate and volume to achieve chest rise and a change in heart rate; can control rate and volume by saying \u201csqueeze, release\u201d \u2013 squeeze the bag just until chest rise is indicated then release to allow for exhalation\n\nb. If no improvement after 90 seconds, change oxygen delivery to 30% FiO2 (fraction of inspired oxygen) if blender available, otherwise 100% FiO2 until heart rate normalizes\nc. Consider endotracheal intubation or supraglottic airway per local guidelines if BVM ventilation is ineffective\n\nResuscitate: If heart rate less than 60 BPM:\n\na. Ensure effective ventilations with supplementary oxygen and adequate chest rise\nb. If no improvement after 30 seconds, initiate chest compressions \u2014 two-thumb-encircling-hands technique is preferred\nc. Coordinate chest compressions with positive pressure ventilation (3:1 ratio, 90 compressions and 30 breaths per minute)\nd. Consider endotracheal intubation or supraglottic airway per local guidelines\ne. Administer epinephrine (0.1 mg/mL) 0.01 mg/kg IV/IO (preferable if access obtained) or 0.1 mg/kg via the ETT (if unable to obtain access) q 3\u20135 min if heart rate remains less than 60 BPM\n\n________________________\n\nGo To TOC\n\nPediatric-Specific Guidelines\n\nRev. March 2022\n\nNeonatal Resuscitation\n\n160\n---\nNASEMSO National Model EMS Clinical Guidelines NASEMSO Version 3.0\n\n8. Consider checking a blood glucose for ongoing resuscitation, maternal history of diabetes, ill appearing or unable to feed\n\n9. Administer 20 mL/kg normal saline IV/IO for signs of shock or post-resuscitative care\n\n## Patient Safety Considerations\n\n1. Hypothermia is common in newborns and worsens outcomes of nearly all post-natal complications\n\na. Ensure heat retention by drying the infant thoroughly, covering the head, and wrapping the baby in dry cloth\nb. When it does not encumber necessary assessment or required interventions, \u201ckangaroo care\u201d (i.e., placing the infant skin-to-skin directly against mother\u2019s chest and wrapping them together) is an effective warming technique\nc. Newborn infants are prone to hypothermia which may lead to hypoglycemia, hypoxia, and lethargy. Aggressive warming techniques should be initiated including drying, swaddling, and warm blankets covering body and head. When available, radiant warmers or other warming adjuncts are suggested for babies who require resuscitation, especially for preterm babies. Check blood glucose and follow Hypoglycemia Guideline as appropriate\n\n2. During transport, neonate should be appropriately secured (e.g., secured to mother with approved neonatal restraint system, car seat or isolette) and mother should be appropriately secured\n\n## Notes/Educational Pearls\n\nKey Considerations\n\n1. Approximately 10% of newly born infants require some assistance to begin breathing at birth and 1% require resuscitation to support perfusion\n\n2. Most newborns require only drying, warming, and stimulating to help them transition from fetal respiration to newborn respiration. The resuscitation sequence can be remembered as Dry, Warm, and Stimulate \u2013 Ventilate \u2013 Evaluate \u2013 and Resuscitate\n\n**Table 1.", "start_char_idx": 369167, "end_char_idx": 373001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "972c0f03-1969-4128-96a5-cc324384f60c": {"__data__": {"id_": "972c0f03-1969-4128-96a5-cc324384f60c", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4e1aa3d-c9b9-4dfb-b74e-941e7d91ce55", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "611b27f0216111f13110e16064056ba1e70a105664c527b357a8c361e0d4998e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57edc9ec-0116-4bc5-aece-44adab3723a4", "node_type": "1", "metadata": {}, "hash": "bdb1e8ba904595f88c304904bf28f2ddacc9269e3ddaf99341f047323168ea75", "class_name": "RelatedNodeInfo"}}, "text": "When available, radiant warmers or other warming adjuncts are suggested for babies who require resuscitation, especially for preterm babies. Check blood glucose and follow Hypoglycemia Guideline as appropriate\n\n2. During transport, neonate should be appropriately secured (e.g., secured to mother with approved neonatal restraint system, car seat or isolette) and mother should be appropriately secured\n\n## Notes/Educational Pearls\n\nKey Considerations\n\n1. Approximately 10% of newly born infants require some assistance to begin breathing at birth and 1% require resuscitation to support perfusion\n\n2. Most newborns require only drying, warming, and stimulating to help them transition from fetal respiration to newborn respiration. The resuscitation sequence can be remembered as Dry, Warm, and Stimulate \u2013 Ventilate \u2013 Evaluate \u2013 and Resuscitate\n\n**Table 1. Assessments that are used to initiate BMV and chest compressions**\n|INTERVENTION INDICATED|Blow-by Oxygen|Bag-Mask-Ventilation (BVM)|BVM and Chest compressions|\n|---|---|---|---|\n|Heart Rate (BPM)|> 100|60\u2013100|< 60|\n|Respiratory Distress/Apnea|No|Yes| |\n|Central Cyanosis Present|Yes|Yes/No| |\n\n3. Deliveries complicated by maternal bleeding (placenta previa, vas previa, or placental abruption) place the infant at risk for hypovolemia secondary to blood loss\n\n4. Low birth weight infants are at high-risk for hypothermia due to heat loss\n\n________________________ Go To TOC\n\nPediatric-Specific Guidelines Rev. March 2022 Neonatal Resuscitation 161\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n5. Measuring the pulse oximetry on the right hand provides the most accurate oxygen saturation (SpO2) in infants that are transitioning from fetal to normal circulation. At 60 seconds, 60% is the target with an increase of 5% every minute until 5 minutes of life when pulse oximetry is 80\u201385%\n\n**Table 2. Projected Pulse Oximetry in Infants Over Time**\n|Time Since Birth|Projected Increase in Pulse Oximeter Over Time|\n|---|---|\n|1 minute|60\u201365%|\n|2 minutes|65\u201370%|\n|3 minutes|70\u201375%|\n|4 minutes|75\u201380%|\n|5 minutes|80\u201385%|\n|10 minutes|85\u201390%|\n\n6. Both hypoxia and excess oxygen administration can result in harm to the infant. If prolonged oxygen use is required, titrate to maintain an SPO2 of 85\u201395%\n\n7. While not ideal, a larger facemask than indicated for patient size may be used to provide BVM ventilation if an appropriately sized mask is not available. Avoid pressure over the eyes as this may result in bradycardia\n\n8. Increase in heart rate is the most reliable indicator of effective resuscitative efforts\n\n9. A multiple gestation delivery may require additional resources and/or clinicians\n\n10. There is no evidence to support the routine practice of administering sodium bicarbonate for the resuscitation of newborns\n\n11. APGAR scoring is not critical during the resuscitation, although it may be prognostic after 20 minutes if the APGAR Score remains \u201c0\u201d despite resuscitation\n\n**Table 3. APGAR Score**\n|Sign|0|1|2|\n|---|---|---|---|\n|Appearance:|Blue, Pale|Body pink, Extremities blue|Completely pink|\n|Pulse:|Absent|Slow (less than 100)|\u2265 100|\n|Grimace:|No response|Grimace|Cough or Sneeze|\n|Activity:|Limp|Some flexion|Active motion of extremities|\n|Respirations:|Absent|Slow, Irregular|Good, Crying|\n\nPertinent Assessment Findings\n\n1. It is difficult to determine gestational age in the field \u2013 if there is any doubt as to viability, resuscitation efforts should be initiated\n\n2. Acrocyanosis, a blue discoloration of the distal extremities, is a common finding in the newly born infant transitioning to extrauterine life \u2013 this must be differentiated from central cyanosis\n\nSource: The Apgar Score. www.acog.org\n\n________________________\n\nGo To TOC\n\nPediatric-Specific Guidelines Rev.", "start_char_idx": 372143, "end_char_idx": 375913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57edc9ec-0116-4bc5-aece-44adab3723a4": {"__data__": {"id_": "57edc9ec-0116-4bc5-aece-44adab3723a4", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "972c0f03-1969-4128-96a5-cc324384f60c", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "de7558df69e518850d1baeae5674876e3774232bcebe5cced44fbc513e570799", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5aaa0ab-09ee-4a4b-ac0f-3afee52f7b6b", "node_type": "1", "metadata": {}, "hash": "c697f899f0a82e069187380050e06b8695a2f149b1674f358b43d85e3cb46a53", "class_name": "RelatedNodeInfo"}}, "text": "It is difficult to determine gestational age in the field \u2013 if there is any doubt as to viability, resuscitation efforts should be initiated\n\n2. Acrocyanosis, a blue discoloration of the distal extremities, is a common finding in the newly born infant transitioning to extrauterine life \u2013 this must be differentiated from central cyanosis\n\nSource: The Apgar Score. www.acog.org\n\n________________________\n\nGo To TOC\n\nPediatric-Specific Guidelines Rev. March 2022 Neonatal Resuscitation 162\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914133 \u2013 Medical - Newborn/Neonatal Resuscitation\n\n### Key Documentation Elements\n\nHistorical elements\n\nPrenatal complications\nDelivery complications\nDate and time of birth\nEstimated gestational age\n\nPhysical exam findings\n\nHeart rate\nRespiratory rate\nRespiratory effort\nAppearance\nAPGAR score at 1 minute and 5 minutes\n\n### Performance Measures\n\nPrehospital on-scene time\nCall time for additional resources\nArrival time of additional unit\nTime to initiation of interventions\nUse of oxygen during resuscitation\nPresence of advanced life support (ALS) versus basic life support (BLS) clinicians\nHypothermia on arrival in the emergency department\nHypoglycemia evaluated and treated\nROSC (return of spontaneous circulation) and/or normalization of heart rate\nLength of stay in neonatal intensive care unit\nLength of stay in newborn nursery\nLength of stay in hospital\nKnowledge retention of prehospital clinicians\nNumber of advanced airway attempts\nMortality\n\n### References\n\nAGOG Recommends Delayed Umbilical Cord Clamping for All Healthy Infants. Agog.org. https://www.acog.org/About-ACOG/News-Room/News-Releases/2016/Delayed-Umbilical-Cord-Clamping-for-All-Healthy-Infants.\nPublished December 21, 2006. Accessed August 27, 2017\nAziz K, Lee HC, Escobedo, MB et al. Part 5: Neonatal Resuscitation: 2020 American Heart Association Guidelines\nfor Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2020; 142; S524\u2013S550\nVali P, Chandrasekharian P, Rawat M, et al. Evaluation of timing and route of epinephrine administration in a\nneonatal model of asphyxia arrest. J Am Heart Assoc 2017;6: e004402\nWeiner GM, Zaichkin J. Textbook of neonatal resuscitation (NRP), 7th Ed. Elk Grove Village, IL:\n\nGo To TOC\n\n## Pediatric-Specific Guidelines\n\nRev. March 2022\n\n## Neonatal Resuscitation\n\n163\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\nAmerican Academy of Pediatrics; 2016\n\n5. Welsford M, Nichiyama C, Shortt C, et al. Room air for initiating term newborn resuscitation: A systematic review and meta-analysis. Pediatrics 2019; 143\n\nRevision Date March 11, 2022\n\nGo To TOC\n\n## Pediatric-Specific Guidelines\n\nRev.", "start_char_idx": 375463, "end_char_idx": 378315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5aaa0ab-09ee-4a4b-ac0f-3afee52f7b6b": {"__data__": {"id_": "f5aaa0ab-09ee-4a4b-ac0f-3afee52f7b6b", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57edc9ec-0116-4bc5-aece-44adab3723a4", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "5d673afd7f40112de34aa0ab2948505642d45bf56b0ddb1c4ada5cb6f06766fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a769a85-a4a1-4035-a56e-651cbbb29a3a", "node_type": "1", "metadata": {}, "hash": "2bd4e882ecebdd9465dcd340778fa7f0ffc5d46b3a48bf196bafe4c3038b54f8", "class_name": "RelatedNodeInfo"}}, "text": "J Am Heart Assoc 2017;6: e004402\nWeiner GM, Zaichkin J. Textbook of neonatal resuscitation (NRP), 7th Ed. Elk Grove Village, IL:\n\nGo To TOC\n\n## Pediatric-Specific Guidelines\n\nRev. March 2022\n\n## Neonatal Resuscitation\n\n163\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\nAmerican Academy of Pediatrics; 2016\n\n5. Welsford M, Nichiyama C, Shortt C, et al. Room air for initiating term newborn resuscitation: A systematic review and meta-analysis. Pediatrics 2019; 143\n\nRevision Date March 11, 2022\n\nGo To TOC\n\n## Pediatric-Specific Guidelines\n\nRev. March 2022\n\n### Neonatal Resuscitation 164\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## OB/GYN - Childbirth\n\n### Aliases\n\nBirth, Delivery, Labor\n\n### Patient Care Goals\n\nObtain necessary history to plan for birth and resuscitation of the newborn\nRecognize imminent birth\nPlan for resources based on number of anticipated patients (e.g., mother and child or multiple births)\nAssist with uncomplicated delivery of term newborn\nRecognize complicated delivery situations (e.g., nuchal or prolapsed umbilical cord, breech delivery, shoulder\ndystocia) and plan for management and appropriate transport destination\nApply appropriate techniques when an obstetric complication exists\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nImminent delivery with crowning\n\n#### Exclusion Criteria\n\nVaginal bleeding in any stage of pregnancy [See Obstetrical/Gynecological Conditions Guideline]\nEmergencies in first or second trimester of pregnancy [See Obstetrical/Gynecological Conditions Guideline]\nSeizure from eclampsia [See Obstetrical/Gynecological Conditions Guideline and Eclampsia/Pre-Eclampsia Guideline]\n\n### Patient Management\n\n#### Assessment:\n\nSigns of imminent delivery:\n\nCrowning or other presentation in vaginal opening\nUrge to push\nUrge to move bowels\nMother\u2019s sense of imminent delivery\n\nSigns of active labor\n\nContractions\nMembrane rupture\nBloody show\n\n#### Treatment and Interventions\n\nIf patient in labor but no signs of imminent delivery, transport to appropriate receiving facility\nDelivery should be controlled to allow a slow controlled delivery of infant \u2013 This will prevent injury to mother\n\nGo To TOC\n\n### OB/GYN\n\nRev. March 2022\n\n### Childbirth\n\n165\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n3. Check for nuchal cord (i.e., around the baby\u2019s neck)\n\na. If present, slip it over the head\n\nb. If unable to free the cord from the neck, double clamp the cord and cut between the clamps\n\n4. Do not routinely suction the infant\u2019s airway (even with a bulb syringe) during delivery\n\n5. Grasping the head with hand over the ears, gently guide head down to allow delivery of the anterior shoulder\n\n6. Gently guide the head up to allow delivery of the posterior shoulder\n\n7. Slowly deliver the remainder of the infant\n\n8. After 1 minute, clamp cord about 5\u20136 inches from the abdomen with two clamps; cut the cord between the clamps\n\na. If resuscitation is needed, the baby can still benefit from a 1-minute delay in cord clamping. Start resuscitation immediately after birth and then clamp and cut the cord at 1 minute\n\nb. While cord is attached, take care to ensure the baby is not significantly higher positioned than the mother to prevent blood from flowing backwards from baby to placenta\n\n9. Dry, warm, and stimulate infant, wrap in towel and place on maternal chest unless resuscitation needed\n\n10. Resuscitation takes priority over recording APGAR scores. Record APGAR scores at 1 and 5 minutes once neonate is stabilized\n\n11. After delivery of infant, suctioning (including suctioning with a bulb syringe) should be reserved for infants who have obvious obstruction to the airway or require positive pressure ventilation (follow Neonatal Resuscitation Guideline for further care of the infant) The placenta will deliver spontaneously, often within 5\u201315 minutes after the infant is delivered\n\na. Do not force the placenta to deliver; do not pull on the umbilical cord\n\nb. Contain all tissue in plastic bag and transport\n\n12.", "start_char_idx": 377740, "end_char_idx": 381792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a769a85-a4a1-4035-a56e-651cbbb29a3a": {"__data__": {"id_": "2a769a85-a4a1-4035-a56e-651cbbb29a3a", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5aaa0ab-09ee-4a4b-ac0f-3afee52f7b6b", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "a6a0dea97cee158f3252b098b59a2d44246e45aee90fef4044d0c2ecf3c53ddd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ca669ab-3103-419f-954a-6a9bed6946f1", "node_type": "1", "metadata": {}, "hash": "670cef6dfd98270b869480a09ca5a42c7b40a3d86c7cb28ee423bd91ef308c41", "class_name": "RelatedNodeInfo"}}, "text": "Dry, warm, and stimulate infant, wrap in towel and place on maternal chest unless resuscitation needed\n\n10. Resuscitation takes priority over recording APGAR scores. Record APGAR scores at 1 and 5 minutes once neonate is stabilized\n\n11. After delivery of infant, suctioning (including suctioning with a bulb syringe) should be reserved for infants who have obvious obstruction to the airway or require positive pressure ventilation (follow Neonatal Resuscitation Guideline for further care of the infant) The placenta will deliver spontaneously, often within 5\u201315 minutes after the infant is delivered\n\na. Do not force the placenta to deliver; do not pull on the umbilical cord\n\nb. Contain all tissue in plastic bag and transport\n\n12. After delivery, massaging the uterus (should be located at about the umbilicus) and allowing the infant to nurse will promote uterine contraction and help control bleeding\n\na. Estimate maternal blood loss\n\nb. Treat mother for hypovolemia as needed\n\n13. Transport infant secured to mother with approved neonatal restraint system, in car seat or isolette unless resuscitation is needed\n\n14. Keep infant warm during transport\n\n15. Most deliveries proceed without complications \u2013 If complications of delivery occur, apply high flow oxygen to mother and expedite transport to the appropriate receiving facility. Maternal resuscitation is critical for best fetal outcome. Contact medical direction and/or closest appropriate receiving facility for direct medical oversight and to prepare the receiving team. The following are recommendations for specific complications:\n\na. Shoulder dystocia \u2013 if delivery fails to progress after head delivers, quickly attempt the following\n\ni. Hyperflex mother\u2019s hips to severe supine knee-chest position (i.e., McRoberts\u2019 maneuver)\n\nii. Apply firm suprapubic pressure to attempt to dislodge shoulder. This often requires two EMS clinicians to perform and allows for delivery in up to 75% of cases\n\niii. Attempt to angle baby\u2019s head as posteriorly as possible but NEVER pull\n\n________________________ Go To TOC\n\nOB/GYN Rev. March 2022 Childbirth 166\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\niv. Continue with delivery as normal once the anterior shoulder is delivered\n\n## Prolapsed umbilical cord\n\ni. Placed gloved hand into vagina and gently lift head/body off the cord\n\n1. Assess for pulsations in cord, if no pulses are felt, lift the presenting part off the cord\n\n2. Wrap the prolapsed cord in moist sterile gauze\n\n3. Maintain until relieved by hospital staff\n\nii. If previous techniques are not successful, mother should be placed in prone knee-chest position or extreme\nTrendelenburg with hips elevated\n\n## Breech birth\n\ni. Place mother supine, allow the buttocks, feet, and trunk to deliver spontaneously, then support the body while the\nhead is delivered\n\nii. If needed, put the mother in a kneeling position which may assist in the delivery of the newborn\n\niii. Assess for presence of prolapsed cord and treat as above\n\niv. If head fails to deliver, place gloved hand into vagina with fingers between infant\u2019s face and uterine wall to\ncreate an open airway. Place your index and ring fingers on the baby\u2019s cheeks forming a \u201cV\u201d taking care not to block\nthe mouth and allowing the chin to be tilted toward the chest flexing the neck\n\nv. When delivering breech, you may need to rotate the baby\u2019s trunk clockwise; or sweep the legs from the vagina\n\nvi. Once the legs are delivered support the body to avoid hyperextension of the head; keep the fetus elevated off the\numbilical cord\n\nvii. NEVER pull on the body, especially a preterm or previable baby \u2013 just support the baby\u2019s body while mother pushes\nwhen she feels the urge to\n\n## The presentation of an arm or leg through the vagina is an indication for immediate transport to hospital\n\n## Nuchal cord\n\ni. After the head has been delivered, palpate the neck for a nuchal cord, if present, slip over the head\n\nii. If the loop is too tight to slip over the head, attempt to slip the cord over the shoulders and deliver the body\nthrough the loop\n\niii. The cord can be doubly clamped and cut between the clamps; the newborn should be delivered promptly\n\n## Excessive bleeding during active labor may occur with placenta previa or placental abruption\n\ni. Obtain history from patient \u2013 known previa, recent pre-eclampsia symptoms, hypertension history, recent trauma, drug\nuse especially cocaine\n\nii.", "start_char_idx": 381058, "end_char_idx": 385491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ca669ab-3103-419f-954a-6a9bed6946f1": {"__data__": {"id_": "1ca669ab-3103-419f-954a-6a9bed6946f1", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a769a85-a4a1-4035-a56e-651cbbb29a3a", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "f86379c02b4eed94c06887d640dfb685cb31613d087ab7c1a7a837b45d0d2f35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed28d78a-bfe1-4e4d-aeb6-f735250f7d43", "node_type": "1", "metadata": {}, "hash": "17ca248475140d16615c7ce142831ffae9613c80bc40f15d4ef7a6ea6e81c732", "class_name": "RelatedNodeInfo"}}, "text": "NEVER pull on the body, especially a preterm or previable baby \u2013 just support the baby\u2019s body while mother pushes\nwhen she feels the urge to\n\n## The presentation of an arm or leg through the vagina is an indication for immediate transport to hospital\n\n## Nuchal cord\n\ni. After the head has been delivered, palpate the neck for a nuchal cord, if present, slip over the head\n\nii. If the loop is too tight to slip over the head, attempt to slip the cord over the shoulders and deliver the body\nthrough the loop\n\niii. The cord can be doubly clamped and cut between the clamps; the newborn should be delivered promptly\n\n## Excessive bleeding during active labor may occur with placenta previa or placental abruption\n\ni. Obtain history from patient \u2013 known previa, recent pre-eclampsia symptoms, hypertension history, recent trauma, drug\nuse especially cocaine\n\nii. Placenta previa most likely will prevent delivery of infant vaginally\n\niii. Place large bore IV and administer IV fluids as indicated\n\niv. If available, transfusion or the administration of whole blood as indicated\n\nv. C-Section most likely needed \u2013 transport emergently\n\n## Postpartum hemorrhage\n\ni. Obtain history from patient \u2013 history of prenatal or delivery complications, recent trauma, prescription\nanticoagulants, drug use especially cocaine\n\nii. Perform fundal massage\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Maternal Care\n\n### IV Fluid Resuscitation and Blood Transfusion\n\nInitiate IV fluid resuscitation and, if approved by medical direction, transfuse blood products.\n\n### Tranexamic Acid (TXA)\n\nConsider administration of tranexamic acid (TXA).\n\n### Postpartum Hemorrhage\n\nAlthough recommended following all deliveries, if postpartum hemorrhage occurs following delivery, consider administration of oxytocin.\n\n## Maternal Cardiac Arrest\n\nApply manual pressure to displace uterus from midline.\n\nTreat per the Cardiac Arrest Guideline (VF/VT/Asystole/PEA) for resuscitation care (defibrillation and medications should be given for same indications and doses as if non-pregnant patient).\n\nTransport as soon as possible if infant is estimated to be over 24 weeks gestation (perimortem Cesarean section (also known as resuscitative hysterotomy) at receiving facility is most successful if started within 5 minutes of maternal cardiac arrest).\n\n## Patient Safety Considerations\n\nSupine Hypotension Syndrome:\n\nIf mother has hypotension before delivery, place patient in left lateral recumbent position or manually displace gravid uterus to the left in supine position.\nKnee-chest position may create safety issues during rapid ambulance transport.\n\nDo not routinely suction the infant\u2019s airway (even with a bulb syringe) during delivery.\nNewborns are very slippery, take care not to drop the infant.\nDry, warm and stimulate all newborns to facilitate respirations and prevent hypothermia.\nDo not pull on the umbilical cord while the placenta is delivering.\nIf possible, transport between deliveries if mother is expecting twins.\n\n## Notes/Educational Pearls\n\nOB assessment:\n\nLength of pregnancy\nNumber of pregnancies\nNumber of viable births\nNumber of non-viable births\nDue date (calculate gestational age in weeks)\n\nIf unknown gestational age, rough estimated gestational age with palpation of the uterine fundus at the umbilicus is 20 weeks\n\nLast menstrual period\n\nOnly ask for estimated last menstrual period (first day of last period) if patient has not had prenatal care/ultrasound and does not know their due date.\n\nPrenatal care\nNumber of expected babies (multiple gestations)\nDrug use and maternal medication use\nAny known pregnancy complications \u2013 hypertension, gestational diabetes, placenta previa, premature labor, history of fetal demise, fetal anomalies/birth defects, etc.\nSigns of imminent delivery (e.g., crowning, urge to push, urge to move bowels, mother feels delivery is imminent)\nLocation where patient receives care (considered a preferred destination if time delay is not an issue and based on local protocols)\n\nNotify medical direction/receiving facility if:\n\nOB/GYN Rev. March 2022 Childbirth 168\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## OB/GYN Childbirth\n\n1. Antepartum hemorrhage\n\n2. Postpartum hemorrhage\n\n3. Breech presentation\n\n4. Limb presentation\n\n5. Complicated nuchal cord (around neck) \u2013 unable/difficult to reduce\n\n6. Prolapsed umbilical cord\n\n7. Shoulder dystocia\n\n8.", "start_char_idx": 384632, "end_char_idx": 389051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed28d78a-bfe1-4e4d-aeb6-f735250f7d43": {"__data__": {"id_": "ed28d78a-bfe1-4e4d-aeb6-f735250f7d43", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ca669ab-3103-419f-954a-6a9bed6946f1", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "580298b30fa452f325b4d26b2564a12ca144ef2cd15fe331dc04ad59235a6773", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d9bc5ff-f858-4ca5-a1a7-02609294c7a2", "node_type": "1", "metadata": {}, "hash": "417fb2d5d955bc18f88934b130dd40e58753935057d9ff3f2e47686740f91145", "class_name": "RelatedNodeInfo"}}, "text": "Signs of imminent delivery (e.g., crowning, urge to push, urge to move bowels, mother feels delivery is imminent)\nLocation where patient receives care (considered a preferred destination if time delay is not an issue and based on local protocols)\n\nNotify medical direction/receiving facility if:\n\nOB/GYN Rev. March 2022 Childbirth 168\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## OB/GYN Childbirth\n\n1. Antepartum hemorrhage\n\n2. Postpartum hemorrhage\n\n3. Breech presentation\n\n4. Limb presentation\n\n5. Complicated nuchal cord (around neck) \u2013 unable/difficult to reduce\n\n6. Prolapsed umbilical cord\n\n7. Shoulder dystocia\n\n8. Maternal cardiac arrest\n\n9. If anticipated transport time is greater than 30 minutes\n\nSome light bleeding/bloody show (blood-tinged mucus/fluid) is normal with any childbirth. Large quantities of blood/clots or profuse bleeding are abnormal.\n\n### Table 1. APGAR Score\n\n|Sign|0|1|2|\n|---|---|---|---|\n|Appearance:|Blue, Pale|Body pink, Extremities blue|Completely pink|\n|Pulse:|Absent|Slow (less than 100)|>= 100|\n|Grimace:|No response|Grimace|Cough or Sneeze|\n|Activity:|Limp|Some flexion|Active motion of extremities|\n|Respirations:|Absent|Slow, Irregular|Good, Crying|\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (for additional information, go to www.nemsis.org)\n\n9914133 \u2013 Medical - Neonatal/Newborn Resuscitation\n9914155 \u2013 OB/GYN - Childbirth/Labor/Delivery\n9914161 \u2013 OB/GYN - Pregnancy Related Disorders\n9914163 \u2013 OB/GYN - Postpartum Hemorrhage\n\n### Key Documentation Elements\n\nDocument all times (delivery, contraction frequency and length)\n\n### Performance Measures\n\nRecognition of complications\nDocumentation of APGAR scores\nMaternal reassessment\n\n### References\n\nBeaird DT, Ladd M, Kahwaii CI. EMS Prehospital Deliveries. Stat Pearls. 12-27-2020\nFlanagan B, Lord B, Barnes M. Is unplanned out-of-hospital birth managed by paramedics 'infrequent', 'normal' and\n'uncomplicated'? BMC Pregnancy Childbirth. 2017 Dec 22;17(1):436\n\n________________________ Go To TOC\n\nRev. March 2022\n\n169\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n3. Piaggio G, Carvalho JF, Althabe F. Prevention of postpartum haemorrhage: a distributional approach for analysis.\nReprod Health. 2018 Jun 22;15(Suppl 1):97\n\n4. Sheldon WR, Blum J, Vogel JP, Souza JP, G\u00fclmezoglu AM, Winikoff B., WHO Multicountry Survey on Maternal and\nNewborn Health Research Network. Postpartum haemorrhage management, risks, and maternal outcomes: findings from\nthe World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG. 2014 Mar;121 Suppl 1:5\u201313\n\n5. Stallard T, Burns B. Emergency delivery and perimortem C-section. Emerg Med Clin N Am. 2003; 21:679\u201393\n\n6. WHO, United Nations Population Fund, UNICEF. Pregnancy, Childbirth, Postpartum and Newborn Care: A guide for\nessential practice (3rd edition). Geneva, Switzerland: WHO Press; 2015\n\nRevision Date March 11, 2022\n\nGo To TOC\n\nOB/GYN\n\nRev.", "start_char_idx": 388414, "end_char_idx": 391372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d9bc5ff-f858-4ca5-a1a7-02609294c7a2": {"__data__": {"id_": "7d9bc5ff-f858-4ca5-a1a7-02609294c7a2", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed28d78a-bfe1-4e4d-aeb6-f735250f7d43", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "1892ebfb1b0f4337873a9ae997cdfed086c9a7740e6ccd7d55f48fc5abb82393", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94507c4d-a376-4aee-940c-f069bda93e75", "node_type": "1", "metadata": {}, "hash": "ac4a0b665c02dfb027344161e8d2b5d65ef837cf792aa5ab36ca3c1201578f21", "class_name": "RelatedNodeInfo"}}, "text": "Postpartum haemorrhage management, risks, and maternal outcomes: findings from\nthe World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG. 2014 Mar;121 Suppl 1:5\u201313\n\n5. Stallard T, Burns B. Emergency delivery and perimortem C-section. Emerg Med Clin N Am. 2003; 21:679\u201393\n\n6. WHO, United Nations Population Fund, UNICEF. Pregnancy, Childbirth, Postpartum and Newborn Care: A guide for\nessential practice (3rd edition). Geneva, Switzerland: WHO Press; 2015\n\nRevision Date March 11, 2022\n\nGo To TOC\n\nOB/GYN\n\nRev. March 2022\n\nChildbirth\n\n170\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Eclampsia/Pre-Eclampsia\n\n### Aliases\n\nPregnancy induced hypertension, Pregnant seizures, Toxemia of pregnancy\n\n### Patient Care Goals\n\nRecognize serious conditions associated with pregnancy and hypertension\nPrevention of eclampsia-related seizures\nProvide adequate treatment for eclampsia-related seizures\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nFemale patient, more than 20-weeks\u2019 gestation, presenting with hypertension and evidence of end organ dysfunction\nincluding renal insufficiency, liver involvement, neurological, or hematological involvement\nMay occur up to 6 weeks postpartum but is rare after 48 hours post-delivery\n\nOften the presenting symptom of postpartum pre-eclampsia is headache or SOB\n\nSevere features of pre-eclampsia include:\n\nSevere hypertension (SBP greater than 160, DBP greater than 110)\nHeadache\nConfusion/altered mental status\nVision changes including blurred vision, spots/floaters, loss of vision (these symptoms are often a precursor to\nseizure)\nRight upper quadrant or epigastric pain\nShortness of breath/Pulmonary edema\nEcchymosis suggestive of low platelets (bruising, petechiae)\nVaginal bleeding suggestive of placental abruption\nFocal neurologic deficits suggesting hemorrhagic or thromboembolic stroke\n\nEclampsia\n\nAny pregnant patient who is seizing should be assumed to have eclampsia and treated as such until arrival at the\nhospital\nSeizure in any late term pregnancy or postpartum patient\n\nEclampsia/pre-eclampsia can be associated with abruptio placenta and fetal loss\n\n#### Exclusion Criteria\n\nNone noted\n\n### Patient Management\n\n#### Assessment\n\nObtain history\n\nGestational age in weeks or recent post-partum\nSymptoms suggestive of end organ involvement such as headache, confusion, visual disturbances, seizure, epigastric\npain, right upper quadrant pain, nausea/vomiting, stroke symptoms, shortness of breath\n\n________________________ Go To TOC\n\nOB/GYN Rev. March 2022\n\nEclampsia/Pre-Eclampsia 171\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nc. Previous history of hypertension or known pre-eclampsia\n\n2. Monitoring\n\na. Vital signs including repeat blood pressures every 10 min\n\n3. Secondary survey pertinent to obstetric issues:\n\na. Constitutional: vital signs, skin color\n\nb. Abdomen: distension, tenderness, uterine rigidity\n\nc. Genitourinary: visible bleeding\n\nd. Neurologic: mental status, focal deficits\n\nTreatment and Interventions\n\n1. Severe hypertension (SBP greater than 160 or DBP greater than 110) lasting more than 15 min with associated preeclampsia symptoms\n\na. Severely elevated blood pressures must be treated to reduce the risk of maternal stroke\n\nb. However, goal blood pressure should be roughly 140/90 to maintain uterine perfusion and to keep fetus well-oxygenated\n\nc. Goal BP is approximately 140/90 to reduce stroke risk but maintain uterine perfusion\n\ni. Labetalol 20 mg IV over 2 minutes\n\n1. May repeat every 10 minutes X 2 doses for persistent severe hypertension with preeclampsia symptoms\n\n2. Goal is to reduce MAP by 20\u201325% initially\n\n3. Ensure that HR is greater than 60 BPM prior to administration\n\nOR\n\nii. Hydralazine 5 mg IV\n\n1. May repeat 10 mg after 20 minutes for persistent severe hypertension with preeclampsia symptoms\n\n2.", "start_char_idx": 390834, "end_char_idx": 394728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94507c4d-a376-4aee-940c-f069bda93e75": {"__data__": {"id_": "94507c4d-a376-4aee-940c-f069bda93e75", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d9bc5ff-f858-4ca5-a1a7-02609294c7a2", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "322e07c1983a3b3fa2e9e2724145a488d0579ff86e4df021fb76d7d0b638006a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbed5a8c-886c-4f8e-a434-3e8635945b52", "node_type": "1", "metadata": {}, "hash": "e7d43a7e5e8f211d4614a8f308463a66b2c6e989d2175c514d97bc4e9c8b273b", "class_name": "RelatedNodeInfo"}}, "text": "May repeat every 10 minutes X 2 doses for persistent severe hypertension with preeclampsia symptoms\n\n2. Goal is to reduce MAP by 20\u201325% initially\n\n3. Ensure that HR is greater than 60 BPM prior to administration\n\nOR\n\nii. Hydralazine 5 mg IV\n\n1. May repeat 10 mg after 20 minutes for persistent severe hypertension with preeclampsia symptoms\n\n2. Goal is to reduce MAP by 20\u201325% initially\n\nOR\n\niii. Nifedipine 10 mg immediate release PO\n\n1. May repeat 10\u201320 mg by mouth every 20 minutes X 2 doses for persistent severe hypertension with pre-eclampsia symptoms\n\n2. Goal is to reduce MAP by 20\u201325% initially\n\nd. Magnesium sulfate: 4 g IV over 5\u201310 min, followed by 2 g/hr\n\ne. Reassess vital signs every 10 minutes during transport\n\n2. Seizure prophylaxis and seizure management, associated with pregnancy greater than 20-weeks gestation\n\na. Magnesium sulfate\n\ni. Seizure prophylaxis: 4 g IV over 20\u201330 minutes, followed by 2 g/hr IV if available\n\nii. Seizure Management: 6 g IV over 5\u201310 minutes or 8 g IM (4 grams in each buttock) to prevent seizure\n\nb. Benzodiazepine, per Seizures Guideline, for active seizure not responding to magnesium. Caution: respiratory depression\n\n3. IV fluids:\n\na. NS or LR \u2013 keep continuous infusion with maximum rate of fluids to 80 mL/hr\n\n4. Administer high flow oxygen as indicated\n\n5. Disposition\n\na. Transport emergently to closest appropriate receiving facility \u2013 notify en route if possible so the receiving team can prepare\n\n________________________ Go To TOC\n\nOB/GYN Rev. March 2022\n\nEclampsia/Pre-Eclampsia 172\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nb. Patients in second or third trimester of pregnancy should be transported on left side or with uterus manually\ndisplaced to left to ensure adequate uterine perfusion\n\n### Patient Safety Considerations\n\nMagnesium toxicity (progression)\n\nHypotension followed by\nLoss of deep tendon reflexes followed by\nSomnolence, slurred speech followed by\nRespiratory paralysis followed by\nCardiac arrest\n\nTreatment of magnesium toxicity\n\nStop magnesium drip\nGive calcium gluconate 3 g IV or calcium chloride 1 g IV in cases of pending respiratory arrest\nSupport respiratory effort\n\n### Notes/Educational Pearls\n\nKey Considerations\n\nDelivery of the placenta is the only definitive management for pre-eclampsia and eclampsia\nEarly treatment of severe pre-eclampsia with magnesium for seizure prophylaxis and anti-hypertensive significantly\nreduces the rate of eclampsia. Use of magnesium encouraged if signs of severe pre-eclampsia present to prevent\nseizure\nPatients with a history of chronic hypertension may have superimposed pre-eclampsia\nAlthough less frequent, eclampsia, including eclampsia-related seizures, can occur in postpartum patients\n\n### Pertinent Assessment Findings\n\nVital signs assessment with repeat blood pressure monitoring before and after treatment\nAssessment of deep tendon reflexes after magnesium therapy\nExamination for end organ involvement\nEvaluate fundal height\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914157 \u2013 OB/GYN - Eclampsia\n9914159 \u2013 OB/GYN - Gynecological Emergencies\n9914161 \u2013 OB/GYN - Pregnancy Related Disorders\n\n### Key Documentation Elements\n\nDocument full vital signs and physical exam findings\n\n### Performance Measures\n\nPatients with signs of hypertension and greater than 20-week gestation or recent postpartum should be assessed for\nsigns of pre-eclampsia\nRecognition and appropriate treatment of eclampsia\n\n|________________________|Go To TOC|\n|---|---|\n\nOB/GYN\n\nRev. March 2022\n\nEclampsia/Pre-Eclampsia\n\n173\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# References\n\nAmerican College of Obstetricians and Gynecologists Committee on Obstetric Practice Emergent Therapy for\nAcute-onset, Severe Hypertension During Pregnancy and the Postpartum Period. Committee opinion no 767: Obstet\nGynecol.", "start_char_idx": 394384, "end_char_idx": 398334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbed5a8c-886c-4f8e-a434-3e8635945b52": {"__data__": {"id_": "bbed5a8c-886c-4f8e-a434-3e8635945b52", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94507c4d-a376-4aee-940c-f069bda93e75", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "17a3eb134aba9db1e9a22609e1e9400ee24bf9a7a0871b64b2ed1bccf9286d0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc81e3a0-aa8a-4556-9b03-c0a093c91302", "node_type": "1", "metadata": {}, "hash": "316f482ea6ecaadae82adfda2cbee003656659373ca299842e49d3ac2e1b0282", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nEclampsia/Pre-Eclampsia\n\n173\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# References\n\nAmerican College of Obstetricians and Gynecologists Committee on Obstetric Practice Emergent Therapy for\nAcute-onset, Severe Hypertension During Pregnancy and the Postpartum Period. Committee opinion no 767: Obstet\nGynecol. 2019;133(2): 174\u2013180\nAmerican College of Obstetricians and Gynecologists Committee on Obstetric Practice Magnesium sulfate use in\nobstetrics. Committee opinion no 652: Obstet Gynecol. 2016;127(1): e52\u20133\nAmerican College of Obstetrics and Gynecologists Task Force on Hypertension in Pregnancy. Report of the American\nCollege of Obstetricians and Gynecologists\u2019 task force on hypertension in pregnancy. Obstet Gynecol.\n2013;122(5):1122\u201331\nCuero M, Varelas P. Neurologic complications in pregnancy. Crit Care Clin. 2016;32(1):43\u201359\nEmergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. ACOG Committee\nOpinion No. 767. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;133: e174\u201380\nGestational Hypertension and Preeclampsia. ACOG Committee Opinion No. 222. American College of Obstetricians and\nGynecologists. Obstet Gynecol 2020; 135: e237\u201360\nMol BW, Roberts CT, Thangaratinam S, Magee LA, de Groot CJ, Hofmeyr GJ. Pre-eclampsia. Lancet.\n2016;387(10022):999\u20131011\nOlson-Chen C, Seligman N. Hypertensive Emergencies in Pregnancy. Crit Care Clin. 2016;32(1):29\u201341\n\nRevision Date: March 11, 2022\n\nOB/GYN Eclampsia/Pre-Eclampsia\n\nRev. March 2022\n\n174\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Obstetrical and Gynecological Conditions\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nRecognize serious conditions associated with hemorrhage during pregnancy even when hemorrhage or pregnancy is not apparent (e.g., ectopic pregnancy, abruptio placenta, placenta previa)\nProvide adequate resuscitation for hypovolemia\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nFemale patient with vaginal bleeding in any trimester\nFemale patient with pelvic pain or possible ectopic pregnancy\nConsider pregnancy in any female between the ages of 10\u201360 years of age\n\n#### Exclusion Criteria\n\nChildbirth and active labor [See Childbirth Guideline]\nPostpartum hemorrhage [See Childbirth Guideline]\n\n#### Differential Diagnosis\n\nAbruptio placenta:\n\nMost frequently occurs in third trimester of pregnancy; placenta prematurely separates from the uterus causing intrauterine bleeding\nLower abdominal pain, uterine rigidity (often not present until abruption is advanced)\nVaginal bleeding \u2013 this symptom may not occur in cases of concealed abruption\nClinical index of suspicion for abruption (history of trauma, maternal hypertension, maternal drug use especially cocaine)\nShock, with minimal or no vaginal bleeding\n\nPlacenta previa:\n\nPlacenta covers part or all of the cervical opening\nGenerally, late second or third trimester\nPainless vaginal bleeding, unless in active labor\nFor management during active labor [See Childbirth Guideline]\n\nEctopic pregnancy\n\nFirst trimester\nAbdominal/pelvic pain with or without minimal bleeding\nShock is possible even with minimal or no vaginal bleeding\n\nSpontaneous abortion (miscarriage)\n\nGenerally, first trimester\nIntermittent pelvic pain (uterine contractions) with vaginal bleeding/passage of clots or tissue\n\n### Patient Management\n\n#### Assessment\n\nObtain history\n\n________________________\n\nGo To TOC\n\n### OB/GYN\n\nRev.", "start_char_idx": 397998, "end_char_idx": 401483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc81e3a0-aa8a-4556-9b03-c0a093c91302": {"__data__": {"id_": "cc81e3a0-aa8a-4556-9b03-c0a093c91302", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbed5a8c-886c-4f8e-a434-3e8635945b52", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "1a3465e1cb5b853b10aecfd45825e93b7c947e663983d6b95e21cf1bb96ebd3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9355efb-ad67-44eb-b4ca-72994217a088", "node_type": "1", "metadata": {}, "hash": "7f4166157efb86312bcdf90dd09b099ce2cb94c7454295d6d22b8c8f0eb21190", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n### Obstetrical and Gynecological Conditions\n\n175\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### History and Assessment\n\na. Obstetrical history [See Childbirth Guideline]\n\nb. Abdominal pain \u2013 onset, duration, quality, radiation, provoking or relieving factors\n\nc. Vaginal bleeding \u2013 onset, duration, quantity (pads saturated)\n\nd. Syncope/lightheadedness\n\ne. Nausea/vomiting\n\nf. Fever or history of recent fever\n\n### Monitoring\n\na. Monitor EKG if history of syncope or lightheadedness\n\nb. Monitor pulse oximetry if signs of hypotension or respiratory symptoms\n\n### Secondary survey pertinent to obstetric issues\n\na. Constitutional: vital signs, skin color\n\nb. Abdomen: distension, tenderness, peritoneal signs\n\nc. Genitourinary: visible vaginal bleeding\n\nd. Neurologic: mental status\n\n### Treatment and Interventions\n\n1. If signs of shock or orthostasis:\n\na. Position patient supine or in the left lateral recumbent position if third trimester and keep patient warm\n\nb. Place large bore IV\n\nc. Volume resuscitation: crystalloid 1\u20132 liters IV wide open\n\nd. Reassess vital signs and response to fluid resuscitation\n\ne. Save all possible tissue so that the receiving team can assess\n\n2. Disposition \u2013 transport emergently to closest appropriate receiving facility \u2013 notify en route if possible so the\nreceiving team may prepare\n\n### Patient Safety Considerations\n\n1. Patients in third trimester of pregnancy should be transported on left side or with uterus manually displaced to\nleft if hypotensive\n\n2. Do not place hand/fingers into vagina of bleeding patient except in cases of prolapsed cord or breech birth that\nis not progressing\n\n### Notes/Educational Pearls\n\nKey Considerations\n\nSyncope can be a presenting symptom of intraabdominal hemorrhage from ectopic pregnancy or antepartum hemorrhage\nfrom spontaneous abortion, placental abruption, or placenta previa\n\nPertinent Assessment Findings\n\n1. Vital signs to assess for signs of shock (e.g., tachycardia, hypotension)\n\n2. Abdominal exam (e.g., distension, rigidity, guarding)\n\n3. If pregnant, evaluate fundal height\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914159 \u2013 OB/GYN - Gynecological Emergencies\n9914161 \u2013 OB/GYN - Pregnancy Related Disorders\n\n|________________________|Go To TOC|\n|---|---|\n\nOB/GYN\n\nRev. March 2022\n\nObstetrical and Gynecological Conditions\n\n176\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Key Documentation Elements\n\nDocument full vital signs and physical exam findings\n\n### Performance Measures\n\nPatients with signs of hypoperfusion or shock should not be ambulated to stretcher\nIf available, IV should be initiated on patients with signs of hypoperfusion or shock\nRecognition and appropriate treatment of shock\n\n### References\n\nCoppola PT, Coppola M. Vaginal bleeding in the first 20 weeks of pregnancy. Emerg Med Clin N Am. 2003;21(3):667\u201377\nDella-Giustina D, Denny M. Ectopic Pregnancy. Emerg Med Clin N Am. 2003;21(3):565\u201384\nWHO, United Nations Population Fund, UNICEF. Pregnancy, Childbirth, Postpartum and Newborn Care: A guide for essential practice (3rd edition). Geneva, Switzerland: WHO Press; 2015\n\n### Revision Date\n\nMarch 11, 2022\n\n________________________\n\nGo To TOC\n\nOB/GYN\n\nRev. March 2022\n\nObstetrical and Gynecological Conditions\n\n177\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Respiratory Airway Management\n\n### Patient Care Goals\n\n1. Maintain a patent airway\n2. Provide effective oxygenation and adequate ventilation using the least invasive possible method to achieve\nthose goals paired with pulse oximetry and end-tidal capnography (EtCO2) data\n3. Anticipate, recognize, and alleviate respiratory distress\n4. Provide necessary interventions quickly and safely to patients with the need for respiratory support\n5.", "start_char_idx": 401484, "end_char_idx": 405388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9355efb-ad67-44eb-b4ca-72994217a088": {"__data__": {"id_": "a9355efb-ad67-44eb-b4ca-72994217a088", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc81e3a0-aa8a-4556-9b03-c0a093c91302", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "5ef8634b0e4aa9ffacaac0f700448a123e05ac91c67c3bd1abd17698429f75a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b2fe97e-e211-426c-abf6-a9ff248071ab", "node_type": "1", "metadata": {}, "hash": "dd97daa146bcf352793c00d686aa46d8a69d7314e226d5bdfd96627512a74445", "class_name": "RelatedNodeInfo"}}, "text": "Pregnancy, Childbirth, Postpartum and Newborn Care: A guide for essential practice (3rd edition). Geneva, Switzerland: WHO Press; 2015\n\n### Revision Date\n\nMarch 11, 2022\n\n________________________\n\nGo To TOC\n\nOB/GYN\n\nRev. March 2022\n\nObstetrical and Gynecological Conditions\n\n177\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Respiratory Airway Management\n\n### Patient Care Goals\n\n1. Maintain a patent airway\n2. Provide effective oxygenation and adequate ventilation using the least invasive possible method to achieve\nthose goals paired with pulse oximetry and end-tidal capnography (EtCO2) data\n3. Anticipate, recognize, and alleviate respiratory distress\n4. Provide necessary interventions quickly and safely to patients with the need for respiratory support\n5. Anticipate, identify, and plan for a potentially difficult airway\n6. Optimize the patient for any advanced airway attempts\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\n1. Patients with signs of severe respiratory distress/respiratory failure\n2. Patients with evidence of hypoxemia or hypoventilation with medical or traumatic etiology\n3. Patients with tracheostomies (See Tracheostomy Management Guideline)\n4. Patients with acute foreign body airway obstruction\n\n#### Exclusion Criteria\n\n1. Chronically ventilated patients\n2. Newborn patients\n\n### Patient Management\n\nImplement emergent interventions and monitoring [Refer to Universal Care Guideline]\n\n#### Assessment\n\nHistory \u2013 Assess for:\n\na. Time of onset of symptoms\nb. Associated symptoms and triggers for dyspnea (e.g., exertion, exercise, lying flat)\nc. History of asthma or other breathing disorders\nd. Choking or other evidence of upper airway obstruction\ne. History of trauma\nf. Prior similar episodes (e.g., prior intubation, prior ICU stay, prior airway surgery including tracheostomy,\nanaphylaxis, angioedema). If prior episodes, what has helped in the past (meds, interventions) Home\ninterventions for symptoms (e.g., increased home oxygen, nebulizer)\ng. Severity of shortness of breath, sensation of dyspnea\n\nPhysical Examination \u2013 Assess for:\n\na. Abnormal respiratory pattern, rate and/or effort\nb. Use of accessory muscles\nc. Ability to speak words/sentences\nd. Quality of air exchange, including depth of respiration and equality of breath sounds\ne. Abnormal breath sounds (e.g., wheezing, rhonchi, rales, or stridor)\n\n________________________ Go To TOC\n\nRespiratory Rev. March 2022 Airway Management 178\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n### Respiratory Airway Management\n\nf. Cough\n\ng. Skin color (cyanosis or pallor), presence of diaphoresis\n\nh. Mental status, including anxiety\n\ni. Airway obstruction with foreign body or swelling (e.g., angioedema, posterior pharyngeal and laryngeal infections)\n\nj. Signs of a difficult airway (short jaw or limited jaw thrust or mobility, small thyromental space, upper airway obstruction, large tongue, obesity, large tonsils, large neck, craniofacial abnormalities, excessive facial hair, tracheostomy scar or evidence of other neck/facial surgery, trismus)\n\nk. Signs of fluid overload (e.g., ascites, peripheral edema)\n\nl. Traumatic injuries impairing upper and lower airway anatomy and physiology:\n\ni. Facial injuries\nii. High spine injury (affecting phrenic nerve/intercostals)\niii. Neck injury (expanding hematoma, tracheal injury)\niv. Chest wall injury (bruising), including rib and sternal fracture, paradoxical chest motion, subcutaneous air, sucking chest wound\n\n#### Monitoring\n\nPatients with significant respiratory distress should have continuous pulse oximetry and waveform capnography monitoring for both assessment and for guiding therapy\nPulse oximetry is indicated to assess oxygenation\nQuantitative waveform capnography:\n\nIs indicated:\n\nFor assessment and monitoring of ventilatory status in patients with significant respiratory distress, with or without airway adjuncts\nTo assist in decision-making for patients with respiratory difficulty of unclear cause (e.g., bronchospasm vs. pulmonary edema) and to help direct therapy\nTo evaluate acid-base status in critically ill patients\n\nIs not indicated for every patient with shortness of breath.", "start_char_idx": 404610, "end_char_idx": 408807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b2fe97e-e211-426c-abf6-a9ff248071ab": {"__data__": {"id_": "9b2fe97e-e211-426c-abf6-a9ff248071ab", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9355efb-ad67-44eb-b4ca-72994217a088", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "3859f9b607d183ba4e30914d437c0f221f995960be07cfaff689687a7e79d091", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0fee0bb-948b-41b4-a18f-204cb0140cb3", "node_type": "1", "metadata": {}, "hash": "67ac3a4d283aac34a8d514f7bc54dc58a487489705ed56c8de3d9c1abc1b9fa2", "class_name": "RelatedNodeInfo"}}, "text": "High spine injury (affecting phrenic nerve/intercostals)\niii. Neck injury (expanding hematoma, tracheal injury)\niv. Chest wall injury (bruising), including rib and sternal fracture, paradoxical chest motion, subcutaneous air, sucking chest wound\n\n#### Monitoring\n\nPatients with significant respiratory distress should have continuous pulse oximetry and waveform capnography monitoring for both assessment and for guiding therapy\nPulse oximetry is indicated to assess oxygenation\nQuantitative waveform capnography:\n\nIs indicated:\n\nFor assessment and monitoring of ventilatory status in patients with significant respiratory distress, with or without airway adjuncts\nTo assist in decision-making for patients with respiratory difficulty of unclear cause (e.g., bronchospasm vs. pulmonary edema) and to help direct therapy\nTo evaluate acid-base status in critically ill patients\n\nIs not indicated for every patient with shortness of breath. Rather, it is a monitoring and decision-making tool for patients with significant respiratory distress where interpretation of the capnography waveform and EtCO2 values assist in determining the appropriate course of treatment for the patient as well as the patient\u2019s response\n\n#### Treatment and Interventions\n\nGenerally, the approach is to implement the interventions below in an escalating fashion to meet the patient care goals above\nAdminister oxygen if needed for air hunger or respiratory distress and titrate to a target SPO2 of 94\u201398%. Depending on patient presentation, this may be accomplished with nasal cannula, nonrebreather, BVM, NIV\n\nEven in apneic patients, starting passive oxygenation while escalating interventions are implemented may be useful\nDuring CPR, maximal oxygen supplementation should be provided\nConsider humidified oxygen for patients with tracheostomy (See Tracheostomy Management Guideline)\n\nOpen and maintain patent airway. If needed,\n\nProvide head tilt/chin lift, or jaw thrust if concern for potential spinal injury\n\nGo To TOC\n\nRespiratory\n\nRev. March 2022\n\nAirway Management\n\n179\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nb. Suction airway: for significantly contaminated airways, consider utilizing a suction assisted laryngeal airway\ndecontamination (SALAD) technique\n\nc. Oropharyngeal airways (OPA) or nasopharyngeal airways (NPA) can be placed if needed to maintain a patent airway\nand make BVM ventilation more effective\n\ni. OPA are used for patients without gag reflex\n\nii. NPA are used for patients with gag reflex\n\nd. Patient positioning can significantly impact respiratory mechanics. Patients with severe bronchospasm should be\nleft in the position of comfort (perhaps tripod) whenever possible. Elevating the head or padding (shoulders,\nocciput) can assist with opening airway and respiratory mechanics. This can both improve the ability to ventilate and\nlimit aspiration\n\ne. For patients with tracheostomy in respiratory distress, see Tracheostomy Management Guideline\n\n4. Use bag-valve-mask (BVM) ventilation in the setting of respiratory failure or arrest. Whenever possible, the\npatient\u2019s head should be elevated up to 30 degrees\n\na. Two-person, two-thumbs-up BVM ventilation is preferred\n\nb. PEEP should be used with BVM\n\ni. 5 cmH20 is generally an appropriate initial PEEP setting\n\nii. Increase PEEP in stepwise fashion (2\u20133 cmH20 at a time) as necessary, allowing time for the patient to\nequilibrate with each change before further adjustments are made. The goal is to reach the lowest PEEP needed to\nadequately ventilate the patient. Higher PEEP results in greater negative hemodynamic impact. Generally, physician\nconsultation should be considered for higher PEEP levels (greater than 10\u201315 cmH20)\n\nc. Continuous wave-form capnography monitoring should be placed in line\n\ni. In patients without primary pulmonary pathology (i.e., acute respiratory distress syndrome (ARDS), COPD),\nmaintain EtCO2 of no less than 35 and up to 40 mmHg. Patients with specific disease processes such as acute\nacid-base disorders (i.e., DKA, lactic acidosis due to severe sepsis or trauma), acute respiratory failure due to\nprimary pulmonary pathology, or post-cardiac arrest will have different EtCO2 parameters due to their underlying\ndisease\n\nii.", "start_char_idx": 407870, "end_char_idx": 412133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0fee0bb-948b-41b4-a18f-204cb0140cb3": {"__data__": {"id_": "b0fee0bb-948b-41b4-a18f-204cb0140cb3", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b2fe97e-e211-426c-abf6-a9ff248071ab", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "1c96213f0baf6797a98b8ca0a9a63d6cc96a2d228a70b6bcd1a3ac98817b1e5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6630ff4-f3ef-4204-9883-711d7685995a", "node_type": "1", "metadata": {}, "hash": "75aec56ce0659127cf88fdc66458024ed33ceaa2bbae524aa8b88cd39b9657c1", "class_name": "RelatedNodeInfo"}}, "text": "The goal is to reach the lowest PEEP needed to\nadequately ventilate the patient. Higher PEEP results in greater negative hemodynamic impact. Generally, physician\nconsultation should be considered for higher PEEP levels (greater than 10\u201315 cmH20)\n\nc. Continuous wave-form capnography monitoring should be placed in line\n\ni. In patients without primary pulmonary pathology (i.e., acute respiratory distress syndrome (ARDS), COPD),\nmaintain EtCO2 of no less than 35 and up to 40 mmHg. Patients with specific disease processes such as acute\nacid-base disorders (i.e., DKA, lactic acidosis due to severe sepsis or trauma), acute respiratory failure due to\nprimary pulmonary pathology, or post-cardiac arrest will have different EtCO2 parameters due to their underlying\ndisease\n\nii. In patients with severe head injury with signs of herniation (unilateral dilated pupil or decerebrate\nposturing), modest hyperventilation to EtCO2 no less than 30 mmHg may be considered for a brief time\n\nd. Tidal volume:\n\ni. Ventilate with just enough volume to see chest rise, approximately 6\u20138 mL/kg ideal body weight\n\nii. Over-inflation (e.g., excessive tidal volume) and overventilation (e.g., excessive minute ventilation) are both\nundesirable and potentially harmful\n\ne. Rate\n\ni. Adult: 10\u201312 breaths/minute\n\nii. Child: 20\u201330 breaths/minute\n\niii. Infant: 20\u201330 breaths/minute\n\nf. Continuously monitor EtCO2 to guide tidal volume and minute ventilation\n\n5. Non-invasive ventilation (NIV) should be considered early for severe respiratory distress or impending respiratory\nfailure\n\nRespiratory\n\nAirway Management\n\nRev. March 2022\n\n180\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# Respiratory Airway Management\n\na. NIV options include continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), bilevel nasal CPAP, and high flow oxygen by nasal cannula (HFNC)\n\nb. NIV can also be used to improve oxygenation pre-intubation in some patients with respiratory failure\n\n6. Supraglottic airways (SGA): Consider the use of an appropriately sized SGA if BVM (with OPA/NPA) alone is not effective in maintaining oxygenation and/or ventilation. This is especially important in children as prehospital endotracheal intubation is an infrequently performed skill in this age group and has not been shown to improve outcomes over prehospital BVM or SGA\n\n7. Endotracheal intubation\n\na. When less-invasive methods (two-person BVM, SGA placement) are ineffective or inappropriate, consider endotracheal intubation to maintain oxygenation and/or ventilation. Other indications may include potential airway obstruction, severe inhalation burns, multiple traumatic injuries, altered mental status with loss of normal protective airway reflexes\n\nb. Optimize patient for first-pass success with pre-procedure resuscitation, preoxygenation, positioning, sedatives and paralytics as indicated by patient presentation\n\ni. A bougie may be a helpful adjunct to successful airway placement, especially when video laryngoscopy is unavailable and the glottic opening is difficult to visualize with direct laryngoscopy\n\nii. For experienced EMS clinicians, video laryngoscopy may enhance intubation success rates and should be used when available\n\nc. Monitor clinical signs, pulse oximetry, cardiac rhythm, blood pressure, and waveform capnography for the intubated patient\n\nd. For adults, the largest tube size possible should be placed in the patient to limit difficulty with mechanical ventilation and high airway pressures. Absent significant airway swelling or underlying anatomic abnormalities, initial tube size (internal diameter in millimeters) for adult females should be 7.5, adult males 8.0. For pediatrics, cuffed tubes are now recommended\n\n8. Post-intubation management\n\na. Inflate endotracheal tube cuff with minimum air to seal airway. An ETT cuff manometer can be used to measure and adjust the ETT cuff pressure to the recommended 20 cmH20 pressure\n\nb. Confirm placement of advanced airway (endotracheal tube, SGA) with waveform capnography (most reliable), absent gastric sounds, and bilateral breath sounds\n\nc. Secure tube manually.", "start_char_idx": 411357, "end_char_idx": 415499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6630ff4-f3ef-4204-9883-711d7685995a": {"__data__": {"id_": "c6630ff4-f3ef-4204-9883-711d7685995a", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0fee0bb-948b-41b4-a18f-204cb0140cb3", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "c773639ceb370cf73b69196d47c2cd2aed75b531967a49fac132c49a0b7da8e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00a56089-0956-4078-8a0a-02b888f08c2c", "node_type": "1", "metadata": {}, "hash": "7035b633f38baba4b4cbb56234fab72505f16a2b7d803c0a31167b3d8b95bc7e", "class_name": "RelatedNodeInfo"}}, "text": "Absent significant airway swelling or underlying anatomic abnormalities, initial tube size (internal diameter in millimeters) for adult females should be 7.5, adult males 8.0. For pediatrics, cuffed tubes are now recommended\n\n8. Post-intubation management\n\na. Inflate endotracheal tube cuff with minimum air to seal airway. An ETT cuff manometer can be used to measure and adjust the ETT cuff pressure to the recommended 20 cmH20 pressure\n\nb. Confirm placement of advanced airway (endotracheal tube, SGA) with waveform capnography (most reliable), absent gastric sounds, and bilateral breath sounds\n\nc. Secure tube manually. Once proper position is confirmed, secure the tube with tape, twill, or commercial device\n\ni. Note measurement of tube at incisors or gum line and assess frequently for tube movement/displacement using continuous waveform capnography and visual inspection\n\nii. Cervical collar and/or cervical immobilization device may help reduce neck movement and risk of tube displacement\n\nd. Continuously monitor correct airway placement with waveform capnography during treatment and transport, paying particular attention to reassessing after each patient movement\n\ne. Manual ventilation (see above for rate and tidal volume guidance)\n\nf. Mechanical ventilation should be considered following advanced airway placement\n\nGo To TOC\n\nRev. March 2022\n\n181\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\nRespiratory Airway Management\n\n1. Mechanical ventilation should be considered for patients with respiratory failure.\n\n2. Non-invasive ventilation (NIV) should be considered for patients with respiratory distress.\n\n3. Intubation should be performed by trained personnel when necessary.\n\n4. Gastric decompression can improve oxygenation and ventilation for patients with advanced airway and positive pressure ventilation.\n\n5. Surgical airway management is an option when conventional airway approaches are impossible.\n\n6. Patients with respiratory failure should be transported to the closest appropriate hospital for airway stabilization.\n\nPatient Safety Considerations\n\n1. Suctioning should be prioritized to limit aspiration.\n\n2. Avoid excessive pressures or tidal volumes during BVM ventilation to prevent barotrauma and overventilation.\n\n3. Routine use of sedation is not recommended for treatment of anxiety in patients on NIV.\n\n4. Endotracheal intubation should only be used if less invasive methods do not meet patient care goals.\n\n5. Securing of endotracheal tubes is important to prevent obstruction or displacement.\n\n6. Attention should be paid to avoiding hypoxia and hypotension during intubation attempts.\n\n7. Waveform capnography should be used to confirm placement prior to the first breath through an invasive airway.\n\n8. Drug Assisted Airway Management (DAAM) should be reserved for specialized clinicians within a comprehensive program.\n\n9. CPAP/BiPAP should not be discontinued until patient is on the emergency department stretcher and hospital CPAP/BiPAP is immediately available.\n\n10. If patient deteriorates on CPAP/BiPAP, remove and escalate airway management options.\n\n11. If an endotracheal tube becomes dislodged, SGA should be strongly considered.\n\n________________________\n\nGo To TOC\n\nRev. March 2022\n\nPage: 182\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n12. Pediatric airway management requires appropriately sized tools and adjuncts based on patient size/age. A method for determining appropriate sizing should be available to all EMS clinicians.\n\na. Skill in BVM ventilation and NIV application should be emphasized in pediatrics.\n\nb. SGA are reasonable primary and secondary adjuncts if needed.\n\nc. Pediatric endotracheal intubation has unclear benefit in the prehospital setting.\n\nd. Pediatric endotracheal tube placement and maintenance requires significant training to achieve and maintain competency.\n\n### Notes/Educational Pearls\n\n### Key Considerations\n\nOxygen is a drug with an appropriate dose range and undesirable effects from both too much and too little supplementation. Effective oxygenation meets the oxygen saturation (SpO2) target set for that specific patient in the context of their acute and chronic medical condition(s). Permissive hypoxia (SPO2 \u2265 90%) may be appropriate in patients with COPD or other complex respiratory pathology\nAdequate ventilation provides sufficient minute ventilation to meet the patient\u2019s acute respiratory and metabolic needs and is generally titrated to an EtCO2 goal\nParamedics are less likely to attempt endotracheal intubation in children than adults with cardiac arrest and are more likely to be unsuccessful when intubating children.", "start_char_idx": 414875, "end_char_idx": 419563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00a56089-0956-4078-8a0a-02b888f08c2c": {"__data__": {"id_": "00a56089-0956-4078-8a0a-02b888f08c2c", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6630ff4-f3ef-4204-9883-711d7685995a", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "a1bef85118dad385bdd99d06f80c0b50bee4504c9d24a96424633d95e7a58a39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11e0291a-7412-4c7b-906f-27ad7188631e", "node_type": "1", "metadata": {}, "hash": "baa16f7b4e3e47b0e89c6a0542948a85b2dd1ad0f438ab26e04482c1a55b22c8", "class_name": "RelatedNodeInfo"}}, "text": "c. Pediatric endotracheal intubation has unclear benefit in the prehospital setting.\n\nd. Pediatric endotracheal tube placement and maintenance requires significant training to achieve and maintain competency.\n\n### Notes/Educational Pearls\n\n### Key Considerations\n\nOxygen is a drug with an appropriate dose range and undesirable effects from both too much and too little supplementation. Effective oxygenation meets the oxygen saturation (SpO2) target set for that specific patient in the context of their acute and chronic medical condition(s). Permissive hypoxia (SPO2 \u2265 90%) may be appropriate in patients with COPD or other complex respiratory pathology\nAdequate ventilation provides sufficient minute ventilation to meet the patient\u2019s acute respiratory and metabolic needs and is generally titrated to an EtCO2 goal\nParamedics are less likely to attempt endotracheal intubation in children than adults with cardiac arrest and are more likely to be unsuccessful when intubating children. Complications such as malposition of the ET tube or aspiration can be nearly three times as common in children as compared to adults\nContinuous waveform capnography is an important adjunct in the monitoring of patients with respiratory distress, respiratory failure, and those treated with positive pressure ventilation. It should be used as the standard to confirm placement of all advanced airways. It can also be helpful in the respiratory distress patient without an invasive airway to assess for causes of respiratory distress, adequacy of ventilation, progression toward respiratory failure, monitoring of BVM ventilation, as well as numerous other applications that provide insight into acute metabolic and infectious disease processes. Continuous waveform capnography:\n\nShould be used for patients with invasive airways for\n\ninitial verification of correct airway placement\ncontinuous evidence of correct tube placement\nto adjust ventilatory rate\n\nto maintain EtCO2 35\u201345 in most patients\nto appropriately but not excessively hyperventilate patients with signs of herniation only to maintain EtCO2 30\u201335 (no lower than 30)\nto gradually decrease EtCO2 in chronically and acutely severely hypercarbic patients including post-arrest\n\nIs strongly encouraged in patients in cardiac arrest\n\nto monitor quality of CPR\nas an early indicator of ROSC (rapid increase of 10\u201315 in EtCO2)\nto assist in evaluating prognosis for survival\n\nShould be used in spontaneously breathing patients who are:\n\non NIV\nin severe respiratory distress (e.g., receiving epinephrine, magnesium therapy)\n\nIn spontaneously breathing patients, waveform capnography can help with assessment of critically ill patients, for example:\n\n________________________\n\nGo To TOC\n\n### Respiratory Airway Management\n\nRev. March 2022\n\n183\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\ni. assessment of adequacy of ventilation and change in ventilatory status in response to treatment\n\nii. differentiating between severe bronchospasm (shark fin waveform) and other causes of respiratory distress (normal\nwaveform, pulmonary edema)\n\niii. hypotension due to sepsis or unclear cause (metabolic acidosis with/without compensatory respiratory alkalosis)\n\niv. status epilepticus to evaluate ventilatory and acid/base status\n\nv. evaluation for acidosis in patients with altered mental status and potential diabetic ketoacidosis (metabolic\nacidosis)\n\n5. Bag-valve-mask (BVM) ventilation (for cardiac arrest patients see Cardiac Arrest Guideline):\n\na. Appropriately sized masks should completely cover the nose and mouth and maintain an effective seal around the\ncheeks and chin\n\nb. Ventilations should be delivered with only sufficient volume to achieve chest rise. Overventilation is undesirable\n\ni. In children, ventilating breaths should be delivered over one second, with a two second pause between breaths\n\nc. Ventilation rate:\n\ni. Adult\n\n1. Support spontaneous respirations if the patient is hypoventilating\n\n2. For apnea, provide one breath every 6 seconds adjusting based on pulse oximetry and digital capnometry or\ncapnography (with the goal of 35\u201345 mmHg)\n\nii. Pediatric \u2013 infant/child\n\n1. Support spontaneous respirations if the patient is hypoventilating\n\n2. For apnea, provide 1 breath every 2\u20133 seconds adjusting based on pulse oximetry and digital capnometry or\ncapnography (with the goal of 35\u201345 mmHg)\n\n6.", "start_char_idx": 418573, "end_char_idx": 422965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11e0291a-7412-4c7b-906f-27ad7188631e": {"__data__": {"id_": "11e0291a-7412-4c7b-906f-27ad7188631e", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00a56089-0956-4078-8a0a-02b888f08c2c", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "39c8db7382581f75f8b7a25a20f0d6c1f6d21f8e4e30da81b5bbb54d4285e0f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfaa5827-9140-45c1-a536-639ea9fdf92e", "node_type": "1", "metadata": {}, "hash": "eae35fb4533aedcfacc148d5ab3b454840264275b3c27c0780edecdc90c0532f", "class_name": "RelatedNodeInfo"}}, "text": "Overventilation is undesirable\n\ni. In children, ventilating breaths should be delivered over one second, with a two second pause between breaths\n\nc. Ventilation rate:\n\ni. Adult\n\n1. Support spontaneous respirations if the patient is hypoventilating\n\n2. For apnea, provide one breath every 6 seconds adjusting based on pulse oximetry and digital capnometry or\ncapnography (with the goal of 35\u201345 mmHg)\n\nii. Pediatric \u2013 infant/child\n\n1. Support spontaneous respirations if the patient is hypoventilating\n\n2. For apnea, provide 1 breath every 2\u20133 seconds adjusting based on pulse oximetry and digital capnometry or\ncapnography (with the goal of 35\u201345 mmHg)\n\n6. PEEP improves oxygenation or decreases risk of developing hypoxemia, by increasing functional residual capacity\n(FRC), and tidal ventilation and may assist in meeting airway goals by decreasing intrapulmonary shunting of blood and\nbetter matching perfused lung to ventilated lung tissue, thus improving arterial oxygenation. It does not open fully\ncollapsed alveoli but re-expands partially collapsed ones. It does not decrease extravascular lung water but\nredistributes it\n\na. Higher levels of PEEP are particularly useful in patients with acute respiratory distress syndrome (ARDS)\n\nb. PEEP should be increased slowly by 2\u20133 cmH20 from 5 cmH20 to a max of 15 cmH20 closely monitoring response and\nvital sign changes\n\nc. Excessive PEEP over distends alveoli, increases dead space and work of breathing, reduces lung compliance, and\ncompresses alveolar capillaries, reducing oxygenation and risking pulmonary barotrauma\n\nd. Increased intrathoracic pressure can progressively decrease cardiac output and is most notable when PEEP is greater\nthan 15 cmH20. The higher the level of PEEP (over 5 cmH20), the more likely the patient will experience a variety of\nadverse consequences, both ventilatory and hemodynamic\n\n7. Noninvasive ventilation (NIV) (e.g., CPAP or BiPAP):\n\na. NIV goals of therapy will vary based on patient presentation and history. More support than is needed to relieve\nsymptoms or \u201cnormal\u201d is not necessarily better in these patients. Goals of care may include:\n\ni. Decreased air hunger\n\n________________________ Go To TOC\n\nRespiratory Rev. March 2022\n\nAirway Management 184\n---\n## National Model EMS Clinical Guidelines Version 3.0\n\nii. SPO2 of \u2265 94%. Chronic COPD patients tolerate hypoxia better, and an SPO2 of 90% may relieve their symptoms and be adequate\n\niii. Normalization of respiratory rate (decreased tachypnea)\n\niv. Normalization of EtCO2. This means a downward trend in a patient with increased EtCO2. Patients who have end stage COPD may have chronically elevated EtCO2 as high as 50s\u201360s, and thus tolerate elevated EtCO2 better so normalization may not be a good target\n\nb. The key to successful use of NIV in a patient who has not used it before is coaching and explanation of the process and reassurance of the patient\n\nc. For any patient on NIV, focus on maintaining a continuous mask seal is essential to maximizing the positive impact of PEEP, particularly at higher levels. Breaking the circuit or removing the mask should be meticulously avoided, as the significant atelectasis will occur which will take time to reverse\n\nd. Nebulized medications may be administered through a CPAP or BiPAP mask. A specialized T-connector with a spring valve assembly is required to allow maintenance of positive airway pressure\n\n8. Orotracheal/Endotracheal intubation (ETI)\n\na. Checklist use and use of protocolized interventions to optimize the patient physically and physiologically have been shown to both improve success rates of orotracheal intubation as well as decrease peri-intubation complications. Preparation should also include a promptly available plan for alternate airway placement if ETI unsuccessful.", "start_char_idx": 422309, "end_char_idx": 426109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfaa5827-9140-45c1-a536-639ea9fdf92e": {"__data__": {"id_": "cfaa5827-9140-45c1-a536-639ea9fdf92e", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11e0291a-7412-4c7b-906f-27ad7188631e", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "be52983be28fa37470462655b2c4ffcf7b4496c7cccc8f66355de9476fd76fa4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1053b498-b6b2-4e1d-a0ba-d0ad8da908ae", "node_type": "1", "metadata": {}, "hash": "dc0731f1d668a64cc44953d5091782f40b5ad32d1aaeecbafb64a72f3ae8adb8", "class_name": "RelatedNodeInfo"}}, "text": "Breaking the circuit or removing the mask should be meticulously avoided, as the significant atelectasis will occur which will take time to reverse\n\nd. Nebulized medications may be administered through a CPAP or BiPAP mask. A specialized T-connector with a spring valve assembly is required to allow maintenance of positive airway pressure\n\n8. Orotracheal/Endotracheal intubation (ETI)\n\na. Checklist use and use of protocolized interventions to optimize the patient physically and physiologically have been shown to both improve success rates of orotracheal intubation as well as decrease peri-intubation complications. Preparation should also include a promptly available plan for alternate airway placement if ETI unsuccessful.\n\nb. Endotracheal tube sizes (cuffed tubes preferred in pediatrics)\n\n|Age|Size (mm) Uncuffed|Size (mm) Cuffed|\n|---|---|---|\n|Premature|2.5| |\n|Term to 3 months|3.0| |\n|3\u20137 months|3.5|3.0|\n|7\u201315 months|4.0|3.5|\n|15\u201324 months|4.5|3.5|\n|2\u201315 years|[age(yrs.)/4]+4|[age(yrs.)/4]+3.5|\n|>15 years| |7.5 female 8.0 male|\n\nc. Approximate depth of insertion = (3) x (endotracheal tube size)\n\nd. In addition to preoxygenation, apneic oxygenation (high-flow oxygen by nasal cannula) may prolong the period before hypoxia during an intubation attempt\n\ne. Positive pressure ventilation after intubation can decrease preload and subsequently lead to hypotension\n\nf. Significant attention should be paid to adequate preoxygenation to avoid peri-intubation hypoxia and hypoxic cardiac arrest\n\ng. Routine use of cricoid pressure is not recommended in pediatric or adult intubation\n\nh. Prompt suctioning of soiled airways before intubation attempt may improve first pass success and limit morbidity and mortality\n\ni. Confirm successful placement with waveform capnography. Less optimal methods of confirmation include bilateral chest rise, bilateral breath sounds, and maintenance of\n\nRespiratory\n\nAirway Management\n\nRev. March 2022\n\n185\n---\nNASEMSO\n\nNASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nadequate oxygenation. Color change on EtCO2 is less accurate than clinical assessment, and wave-form capnography is superior. Misting observed in the tube is not a reliable method of confirmation. Re-visualization with video laryngoscopy, when available, may assist in confirming placement when unclear due to capnography failure or conflicting information\n\nj. Video laryngoscopy may be a useful tool for endotracheal intubation in the hands of a practiced clinician\n\n6. Manual vs. Mechanical ventilation: If mechanical ventilation is available, it is preferred to manual ventilation due to the increased consistency of tidal volume and ventilatory rate, and its ability to limit risk of overventilation. [See Mechanical Ventilation (Invasive) Guideline]\n\n7. For patients being transferred from a hospital ventilator to a transport ventilator, the patient\u2019s current ventilator settings are generally a reasonable starting point if the patient is being adequately oxygenated and ventilated based on pulse oximetry and capnography\n\n8. Currently, there is limited experience with high-flow nasal cannula in the EMS environment, so evidence-informed recommendations are not included in this guideline\n\n9. Anxiety should be presumed due to hypoxia or inadequate minute ventilation and treated primarily with ventilatory support. Routine use of sedation is not recommended for treatment of anxiety in patients on NIV\n\n### Pertinent Assessment Findings\n\n1. Ongoing assessment is critical when an airway device is in place.\n\n2.", "start_char_idx": 425380, "end_char_idx": 428926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1053b498-b6b2-4e1d-a0ba-d0ad8da908ae": {"__data__": {"id_": "1053b498-b6b2-4e1d-a0ba-d0ad8da908ae", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfaa5827-9140-45c1-a536-639ea9fdf92e", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "3bc3636bd3be5ae916432bed996213dad89bb56de472374a0f1382c34a8d065e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60c0aaa9-5f40-4fbc-bdd8-6fe51181f6a2", "node_type": "1", "metadata": {}, "hash": "8a7a0ab40e2462c6c4cf4c412dbe70738fd06d1e84d92365d0ddcf1b3afa8fab", "class_name": "RelatedNodeInfo"}}, "text": "[See Mechanical Ventilation (Invasive) Guideline]\n\n7. For patients being transferred from a hospital ventilator to a transport ventilator, the patient\u2019s current ventilator settings are generally a reasonable starting point if the patient is being adequately oxygenated and ventilated based on pulse oximetry and capnography\n\n8. Currently, there is limited experience with high-flow nasal cannula in the EMS environment, so evidence-informed recommendations are not included in this guideline\n\n9. Anxiety should be presumed due to hypoxia or inadequate minute ventilation and treated primarily with ventilatory support. Routine use of sedation is not recommended for treatment of anxiety in patients on NIV\n\n### Pertinent Assessment Findings\n\n1. Ongoing assessment is critical when an airway device is in place.\n\n2. Acute worsening of respiratory status or evidence of hypoxemia can be secondary to displacement or obstruction of the airway device, pneumothorax, or equipment failure\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914001 \u2013 Airway\n9914133 \u2013 Medical - Newborn/Neonatal Resuscitation\n\n### Key Documentation Elements\n\nInitial vital signs and physical exam\nInterventions attempted including the method of airway intervention, the size of equipment used, and the number of attempts to achieve a successful result\nIndications for advanced airway management\nSubsequent vital signs and physical exam to assess for change after the interventions\nOccurrence of peri-intubation hypoxia (less than 90% SPO2), bradycardia (per age), hypotension (SBP less than 90mmHg or lowest age-appropriate SBP) or cardiac arrest. The peri-intubation period encompasses the time from sedative administration to up to 10 minutes post any invasive airway attempt\nPost-intubation with advanced airway, EtCO2 value and capnograph should be documented immediately after airway placement, with each patient movement (e.g., into and out of ambulance), and at the time of patient transfer in the ED\nRecordings of video laryngoscopy may be useful for quality improvement purposes\n\n________________________ Go To TOC\n\nRespiratory Rev. March 2022 Airway Management 186\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Performance Measures\n\nPercentage of clinicians that have received hands-on airway training (simulation or non-simulation-based) for basic and advanced airway adjuncts and skills within the past year\nPercentage of patients with initial hypoxia who improve to target saturation of 94\u201398% by arrival at hospital\nPercentage of patients with respiratory chief complaints for whom both oxygen saturation (SpO2) and respiratory rate are measured and documented\nRate of NIV use in respiratory distress (COPD, congestive heart failure (CHF)) patients with GCS 15\nDocumentation of PEEP use with assisted ventilation\nPercentage of patients with advanced airway placement with capnographic verification of correct placement within 1 minute\nPercentage of patients with advanced airway placement who have documentation of waveform capnography for both initial confirmation and repeated verification of placement during transport and at hospital arrival\nPercentage of intubated patients with endotracheal tube verified in proper position upon turnover to receiving facility\nRate of advanced airway (ETT or SGA) success without hypoxia or hypotension\nFirst pass success rate and number of intubation attempts\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nRespiratory\u201401: Respiratory Assessment\n\n## References\n\nCabrini L, Landoni G, Baiardo Redaelli M, Saleh O, Votta CD, Fominskiy E, et al. Tracheal intubation in critically ill patients: a comprehensive systematic review of randomized trials. Crit Care. 2018;22(1):6\nCarney N, Cheney T, Totten AM, Jungbauer R, Neth MR, Weeks C, et al. AHRQ Comparative Effectiveness Reviews. Prehospital Airway Management: A Systematic Review. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021\nDriver BE, Prekker ME, Klein LR, Reardon RF, Miner JR, Fagerstrom ET, et al. Effect of Use of a Bougie vs Endotracheal Tube and Stylet on First-Attempt Intubation Success Among Patients With Difficult Airways Undergoing Emergency Intubation: A Randomized Clinical Trial. JAMA.", "start_char_idx": 428112, "end_char_idx": 432478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60c0aaa9-5f40-4fbc-bdd8-6fe51181f6a2": {"__data__": {"id_": "60c0aaa9-5f40-4fbc-bdd8-6fe51181f6a2", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1053b498-b6b2-4e1d-a0ba-d0ad8da908ae", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "5ebd90b1054915dca1ddd6273fff52ee8d082ac1876216a69a782d6a11843c72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d415fc58-0e1d-4d0a-bcbc-f61170701876", "node_type": "1", "metadata": {}, "hash": "6379d8e2ef9ea14bcea0899eda1c048ffdd31d75fa9147723621bdfa387e4f9f", "class_name": "RelatedNodeInfo"}}, "text": "Tracheal intubation in critically ill patients: a comprehensive systematic review of randomized trials. Crit Care. 2018;22(1):6\nCarney N, Cheney T, Totten AM, Jungbauer R, Neth MR, Weeks C, et al. AHRQ Comparative Effectiveness Reviews. Prehospital Airway Management: A Systematic Review. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021\nDriver BE, Prekker ME, Klein LR, Reardon RF, Miner JR, Fagerstrom ET, et al. Effect of Use of a Bougie vs Endotracheal Tube and Stylet on First-Attempt Intubation Success Among Patients With Difficult Airways Undergoing Emergency Intubation: A Randomized Clinical Trial. JAMA. 2018;319(21):2179\u201389\n\u201cThe Epic Project: Impact of Implementing the EMS Traumatic Brain Injury Treatment Guidelines - Full Text View.\u201d The EPIC Project: Impact of Implementing the EMS Traumatic Brain Injury Treatment Guidelines - Full Text View - ClinicalTrials.gov. Link. Accessed March 11 2022.\nFan E, Del Sorbo L, Goligher EC, Hodgson CL, Munshi L, Walkey AJ, et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2017;195(9):1253\u201363\nFan E, Brodie D, Slutsky AS. Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment. JAMA. 2018;319(7):698\u2013710\nFawcett VJ, Warner KJ, Cuschieri J, Copass M, Grabinsky A, Kwok H, et al. Pre-hospital aspiration is associated with increased pulmonary complications. Surg Infect (Larchmt). 2015;16(2):159\u201364\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n8. Fouche P, Stein C, Simpson P, Carlson J, Md MS, Doi S. Nonphysician Out-of-Hospital Rapid Sequence Intubation\nSuccess and Adverse Events: A Systematic Review and Meta-Analysis. Ann Emerg Med. 2017;70(4):449\u201359e20\n\n9. George BP, Vakkalanka JP, Harland KK, Faine B, Rewitzer S, Zepeski A, et al. Sedation Depth is Associated with\nIncreased Hospital Length of Stay in Mechanically Ventilated Air Medical Transport Patients: A Cohort Study. Prehosp\nEmerg Care. 2020;24(6):783\u201392\n\n10. Gerber L, Botha M, Laher AE. Modified Two-Rescuer CPR With a Two-Handed Mask-Face Seal Technique Is Superior\nTo Conventional Two-Rescuer CPR With a One-Handed Mask-Face Seal Technique. J Emerg Med. 2021\n\n11. Gok PG, Ozakin E, Acar N, Karakilic E, Kaya FB, Tekin N, et al. Comparison of Endotracheal Intubation Skills With\nVideo Laryngoscopy and Direct Laryngoscopy in Providing Airway Patency in a Moving Ambulance. J Emerg Med.\n2021;60(6):752\u20139\n\n12. Hope Kilgannon J, Hunter BR, Puskarich MA, Shea L, Fuller BM, Jones C, et al. Partial pressure of arterial carbon\ndioxide after resuscitation from cardiac arrest and neurological outcome: A prospective multi-center protocol-directed\ncohort study. Resuscitation. 2019;135:212\u201320\n\n13. Ilia S, van Schelven PD, Koopman AA, Blokpoel RGT, de Jager P, Burgerhof JGM, et al. Effect of Endotracheal Tube\nSize, Respiratory System Mechanics, and Ventilator Settings on Driving Pressure. Pediatr Crit Care Med.\n2020;21(1):e47\u2013e51\n\n14. Jarvis JL, Gonzales J, Johns D, Sager L. Implementation of a Clinical Bundle to Reduce Out-of-Hospital Peri-intubation\nHypoxia. Ann Emerg Med. 2018\n\n15.", "start_char_idx": 431843, "end_char_idx": 435136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d415fc58-0e1d-4d0a-bcbc-f61170701876": {"__data__": {"id_": "d415fc58-0e1d-4d0a-bcbc-f61170701876", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60c0aaa9-5f40-4fbc-bdd8-6fe51181f6a2", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "3b3a7ca8d4334848214045fd1f7dc5df65bca7113c4a09d08532ed4a325b3653", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2adb8e6f-9152-4417-8ddd-4748f3ab3d6e", "node_type": "1", "metadata": {}, "hash": "fc13e27ccee5613fa5585853340770be401e5586d54d466334187baadbafb733", "class_name": "RelatedNodeInfo"}}, "text": "Partial pressure of arterial carbon\ndioxide after resuscitation from cardiac arrest and neurological outcome: A prospective multi-center protocol-directed\ncohort study. Resuscitation. 2019;135:212\u201320\n\n13. Ilia S, van Schelven PD, Koopman AA, Blokpoel RGT, de Jager P, Burgerhof JGM, et al. Effect of Endotracheal Tube\nSize, Respiratory System Mechanics, and Ventilator Settings on Driving Pressure. Pediatr Crit Care Med.\n2020;21(1):e47\u2013e51\n\n14. Jarvis JL, Gonzales J, Johns D, Sager L. Implementation of a Clinical Bundle to Reduce Out-of-Hospital Peri-intubation\nHypoxia. Ann Emerg Med. 2018\n\n15. Kopsaftis Z, Carson\u2010Chahhoud KV, Austin MA, Wood\u2010Baker R. Oxygen therapy in the pre\u2010hospital setting for acute\nexacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2020(1)\n\n16. Kornas RL, Owyang CG, Sakles JC, Foley LJ, Mosier JM. Evaluation and Management of the Physiologically Difficult\nAirway: Consensus Recommendations From Society for Airway Management. Anesth Analg. 2021;132(2):395\u2013405\n\n17. Krisciunas GP, Langmore SE, Gomez-Taborda S, Fink D, Levitt JE, McKeehan J, et al. The Association Between\nEndotracheal Tube Size and Aspiration (During Flexible Endoscopic Evaluation of Swallowing) in Acute Respiratory\nFailure Survivors. Crit Care Med. 2020;48(11):1604\u201311\n\n18. Kupas DF, Kauffman KF, Wang HE. Effect of airway-securing method on prehospital endotracheal tube dislodgment.\nPrehosp Emerg Care. 2010;14(1):26\u201330\n\n19. Losek JD, Bonadio WA, Walsh-Kelly C, Hennes H, Smith DS, Glaeser PW. Prehospital pediatric endotracheal intubation\nperformance review. Pediatr Emerg Care. 1989;5(1):1\u20134\n\n20. Le Conte P, Terzi N, Mortamet G, Abroug F, Carteaux G, Charasse C, et al. Management of severe asthma exacerbation:\nguidelines from the Societe Francaise de Medecine d'Urgence, the Societe de Reanimation de Langue Francaise and the\nFrench Group for Pediatric Intensive Care and Emergencies. Ann Intensive Care. 2019;9(1):115\n\n21. Levy M. NAEMSP Airway Compendium Project. 2021\n\n22. Marjanovic N, Flacher A, Drouet L, Gouhinec AL, Said H, Vigneau JF, et al. High-Flow Nasal Cannula in Early Emergency\nDepartment Management of Acute Hypercapnic Respiratory Failure Due to Cardiogenic Pulmonary Edema. Respir Care.\n2020;65(9):1241\u20139\n\n23. Panchal AR, Bartos JA, Caba\u00f1as JG, Donnino MW, Drennan IR, Hirsch KG, et al. Part 3: Adult Basic and Advanced Life\nSupport: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular\nCare. Circulation. 2020;142(16_suppl_2):S366\u2013s468\n\n________________________ Go To TOC\n\nRespiratory Rev. March 2022 Airway Management 188\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n24. Powell EK, Hinckley WR, Stolz U, Golden AJ, Ventura A, McMullan JT. Predictors of Definitive Airway Sans\nHypoxia/Hypotension on First Attempt (DASH-1A) Success in Traumatically Injured Patients Undergoing Prehospital\nIntubation. Prehospital Emergency Care. 2020;24(4):470\u20137\n\n25. Schober P, Biesheuvel T, de Leeuw MA, Loer SA, Schwarte LA.", "start_char_idx": 434538, "end_char_idx": 437607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2adb8e6f-9152-4417-8ddd-4748f3ab3d6e": {"__data__": {"id_": "2adb8e6f-9152-4417-8ddd-4748f3ab3d6e", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d415fc58-0e1d-4d0a-bcbc-f61170701876", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "b42efdded02520a939dacdde4f8441e631ad253ed06a4a1d90632638e5c747fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd78f9cd-07c6-4f4c-92ba-3ce65df77e9b", "node_type": "1", "metadata": {}, "hash": "7f541b82fbbee59d29d9fb9aa523364a08dcaea7450fd0cfa6b85410ab0cd290", "class_name": "RelatedNodeInfo"}}, "text": "Circulation. 2020;142(16_suppl_2):S366\u2013s468\n\n________________________ Go To TOC\n\nRespiratory Rev. March 2022 Airway Management 188\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n24. Powell EK, Hinckley WR, Stolz U, Golden AJ, Ventura A, McMullan JT. Predictors of Definitive Airway Sans\nHypoxia/Hypotension on First Attempt (DASH-1A) Success in Traumatically Injured Patients Undergoing Prehospital\nIntubation. Prehospital Emergency Care. 2020;24(4):470\u20137\n\n25. Schober P, Biesheuvel T, de Leeuw MA, Loer SA, Schwarte LA. Prehospital cricothyrotomies in a helicopter\nemergency medical service: analysis of 19,382 dispatches. BMC Emerg Med. 2019;19(1):12\n\n26. Topjian AA, Raymond TT, Atkins D, Chan M, Duff JP, Joyner BL, Jr., et al. Part 4: Pediatric Basic and Advanced\nLife Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency\nCardiovascular Care. Circulation. 2020;142(16_suppl_2):S469\u2013s523\n\n27. Vissers G, Soar J, Monsieurs KG. Ventilation rate in adults with a tracheal tube during cardiopulmonary\nresuscitation: A systematic review. Resuscitation. 2017;119:5\u201312\n\n28. Wang HE, Schmicker RH, Daya MR, et al. Effect of a strategy of initial laryngeal tube insertion vs endotracheal\nintubation on 72-hour survival in adults with out-of-hospital cardiac arrest: A randomized clinical trial. JAMA.\n2018;320(8):769\u201378\n\n29. Wetsch WA, Schneider A, Schier R, Spelten O, Hellmich M, Hinkelbein J. In a difficult access scenario, supraglottic\nairway devices improve success and time to ventilation. Eur J Emerg Med. 2015;22(5):374\u20136\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nRespiratory Rev. March 2022 Airway Management 189\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Respiratory Distress (includes Bronchospasm, Pulmonary Edema)\n\n#### Patient Care Goals\n\nAssure adequate oxygenation and ventilation\nRecognize impending respiratory failure\nPromptly identify and intervene for patients who require escalation of therapy\nDeliver appropriate therapy by differentiating likely cause of respiratory distress\nAlleviate respiratory distress\n\n#### Patient Presentation\n\n##### Inclusion Criteria\n\nPatients aged 2 and older with respiratory distress due to disease processes including:\n\nAsthma exacerbation\nChronic obstructive pulmonary disease (COPD) exacerbation\nWheezing/bronchospasm from suspected pulmonary infection (e.g., pneumonia, acute bronchitis)\nPulmonary edema of cardiac (i.e., heart failure) or non-cardiac etiology\n\n##### Exclusion Criteria\n\nRespiratory distress related to acute trauma\nRespiratory distress due to a presumed underlying cause that includes one of the following:\n\nAnaphylaxis\nBronchiolitis (wheezing in patients less than 2 years of age)\nCroup\nEpiglottitis\nForeign body aspiration\nSubmersion/drowning\nLower airway obstruction from malignancy (very rare)\n\n#### Patient Management\n\n##### Assessment\n\nHistory\n\nOnset of symptoms\nConcurrent symptoms (e.g., fever, cough, rhinorrhea, tongue/lip swelling, rash, labored breathing, foreign body\naspiration)\nUsual triggers of symptoms (e.g., cigarette smoke, change in weather, upper respiratory infections, exercise)\nSick contacts\nTreatments prior to EMS: Oxygen, inhaler, nebulizer, other treatments, chronic or recent steroids\nHospitalizations: Number of emergency department visits in the past year, number of hospital admissions in the past\nyear, number of ICU admissions (ever), previously intubated (ever)\nFamily history of asthma, eczema, or allergies\n\nExam\n\n________________________Go To TOC\n\nRespiratory\n\nRev.", "start_char_idx": 437057, "end_char_idx": 440730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd78f9cd-07c6-4f4c-92ba-3ce65df77e9b": {"__data__": {"id_": "dd78f9cd-07c6-4f4c-92ba-3ce65df77e9b", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2adb8e6f-9152-4417-8ddd-4748f3ab3d6e", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "c2e5700836b464b1154635a57b9ce16c81fa4f2b5547b8389dc939d63ef32129", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37306512-b166-48ce-8ec1-6d617a833ac9", "node_type": "1", "metadata": {}, "hash": "b7cd13d66f86c94861cedc38612ca5f8e79379ea946b68dcd84afda98a9c63cd", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nRespiratory Distress (includes Bronchospasm, Pulmonary Edema)\n\n190\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Respiratory Distress (includes Bronchospasm, Pulmonary Edema)\n\na. Full set of vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment), temperature, and O2\nsaturation. Consider temperature and waveform capnography\n\nb. Air entry (normal vs. diminished, prolonged expiratory phase)\n\nc. Breath sounds (wheezes, crackles, rales, rhonchi, diminished, clear)\n\nd. Skin color (pallor, cyanosis, mottling, normal) and temperature (febrile, diaphoretic)\n\ne. Mental status (alert, tired, lethargic, unresponsive)\n\nf. Signs of distress include:\n\ni. Apprehension, anxiety, combativeness\nii. Hypoxia (less than 90% oxygen saturation)\niii. Intercostal/subcostal/supraclavicular retractions, accessory muscle use\niv. Grunting, stridor, inability to speak full sentences\nv. Nasal flaring\nvi. Cyanosis\n\n## Treatment and Interventions\n\n1. Airway: See Airway Management Guideline for additional specifics\n\na. Give supplemental oxygen for dyspnea to a target of 94\u201398% saturation. Escalate from a nasal cannula as needed to\nreach this goal\n\nb. BVM ventilation should be utilized in children with respiratory failure\n\nc. Non-invasive ventilation (NIV) should be administered for severe respiratory distress via BVM, continuous positive\nairway pressure (CPAP) or bi-level positive airway pressure (BiPAP)\n\nd. If indicated, bronchodilators should be administered in line with NIV\n\n2. Monitoring\n\na. Pulse oximetry and EtCO2 should be routinely used as adjuncts to other forms of monitoring in patients with\nrespiratory complaints\n\nb. Continuous cardiac monitoring may be indicated in patients with respiratory distress associated with suspected acute\nor decompensated congestive heart failure (CHF) or dysrhythmia\n\nc. 12-lead EKG may be indicated to assess for dysrhythmia or ischemia, particularly in patients with risk factors for\ncoronary artery disease and/or presentation consistent with CHF\n\n3. IV Access and Fluids \u2013 IV access should be placed when IV medication administration is indicated, or when there are\nclinical concerns of dehydration so that IV fluids can be administered\n\n4. Suspected bronchospasm, asthma, COPD:\n\na. Inhaled Medications\n\ni. While albuterol 2.5 mg nebulized is usually sufficient for mild wheezing without clinical distress, albuterol 5 mg\nnebulized (or 6 puffs metered dose inhaler) should be administered to all patients in respiratory distress with signs\nof bronchospasm (e.g., known asthmatics, quiet wheezers). Repeat at this dose with unlimited frequency for ongoing\nrespiratory distress\nii. Ipratropium 0.5 mg nebulized should be given up to 3 doses in conjunction with albuterol\n\nb. Steroids should be administered in the prehospital setting\n\ni. PO steroid options for patients not critical enough to require IV placement include:\n\n________________________\n\nGo To TOC\n\nRespiratory\n\nRev. March 2022\n\n191\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n1. Dexamethasone (0.6 mg/kg, maximum dose of 16 mg) PO solution or IV solution given PO, or\n\n2. Prednisolone/prednisone (1 mg/kg, maximum dose 60 mg) PO\n\nii. IV steroid options for critically ill patients include:\n\n1. Dexamethasone (0.6 mg/kg, maximum dose of 16 mg) IV/IM, or\n\n2. Methylprednisolone (2 mg/kg, maximum dose 125 mg) IV/IM\n\niii. Other steroids at equivalent doses may be given as alternatives\n\nc. Magnesium sulfate (40 mg/kg IV, maximum dose of 2 g) over 10\u201315 minutes should be administered for severe\nbronchoconstriction and concern for impending respiratory failure.", "start_char_idx": 440731, "end_char_idx": 444367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37306512-b166-48ce-8ec1-6d617a833ac9": {"__data__": {"id_": "37306512-b166-48ce-8ec1-6d617a833ac9", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd78f9cd-07c6-4f4c-92ba-3ce65df77e9b", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "ddf0f5ec892ef61f2f88add847e213d69a67bd261a65a070409783424543dac7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c29c57a-b9c0-4f36-ac8d-2ec9a1f2b020", "node_type": "1", "metadata": {}, "hash": "b9207f57c86eaabd5313071146212ae551d59f06b31322b3b1bad4a896c68374", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n191\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n1. Dexamethasone (0.6 mg/kg, maximum dose of 16 mg) PO solution or IV solution given PO, or\n\n2. Prednisolone/prednisone (1 mg/kg, maximum dose 60 mg) PO\n\nii. IV steroid options for critically ill patients include:\n\n1. Dexamethasone (0.6 mg/kg, maximum dose of 16 mg) IV/IM, or\n\n2. Methylprednisolone (2 mg/kg, maximum dose 125 mg) IV/IM\n\niii. Other steroids at equivalent doses may be given as alternatives\n\nc. Magnesium sulfate (40 mg/kg IV, maximum dose of 2 g) over 10\u201315 minutes should be administered for severe\nbronchoconstriction and concern for impending respiratory failure. Consider decreased dose of 1 g IV for geriatric\npatients\n\nd. Epinephrine (0.01 mg/kg of 1 mg/mL solution IM, maximum dose of 0.3 mg) should only be administered for impending\nrespiratory failure as adjunctive therapy when there are no clinical signs of improvement with the above treatments\n\n5. Adults with suspected pulmonary edema due to acute heart failure or fluid overload (such as dialysis noncompliance):\n\na. Restoration of adequate oxygenation and ventilation should precede or be accomplished simultaneously with other\nmedication therapies below\n\ni. CPAP/BiPAP: See Airway Management Guideline for goals of care and escalation of interventions\n\nb. SBP less than 100 mmHg\n\ni. IV fluid bolus 250\u2013500 mL\n\nii. Consider vasopressor: Norepinephrine 0.02\u20132 mcg/kg/min\n\nc. SBP less than 160 mmHg\n\ni. Nitroglycerin\n\n1. 0.4 mg SL, can repeat every 5 minutes for SBP greater than 100 mmHg\n\nd. SBP >= 160 mmHg or MAP greater than 120\n\ni. Nitroglycerin\n\n1. 0.8 mg SL, can repeat every 5 minutes for SBP greater than 100 mmHg\n\n2. Consider IV nitroglycerin infusion titrated to blood pressure\n\n6. Suspected pulmonary edema due to other noncardiogenic causes (such as irritant inhalation, abrupt opioid withdrawal).\nProvide supportive care to promote adequate oxygenation.\n\na. Inhaled Medications\n\ni. While albuterol 2.5 mg nebulized is usually sufficient for mild wheezing without clinical distress, albuterol 5 mg\nnebulized (or 6 puffs metered dose inhaler) should be administered to patients in respiratory distress with signs of\nbronchospasm (e.g., known asthmatics, quiet wheezers). Repeat at this dose with unlimited frequency for ongoing\nrespiratory distress\n\nii. Ipratropium 0.5 mg nebulized should be given up to 3 doses in conjunction with albuterol\n\nPatient Safety Considerations\n\n1. Normal EtCO2 (35\u201345 mmHg) with tachypnea and respiratory distress is an indicator of impending respiratory failure\n\n2. The use of nitrates should be avoided in any patient who has used a phosphodiesterase inhibitor within the past 48\nhours. Examples are sildenafil, vardenafil and tadalafil, which are used for erectile dysfunction and pulmonary\nhypertension. Also avoid use in patients receiving intravenous epoprostenol or treprostenil which are used for pulmonary\nhypertension\n\n________________________ Go To TOC\n\nRespiratory Rev. March 2022\n\nRespiratory Distress (includes Bronchospasm, Pulmonary Edema) 192\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Respiratory Distress (includes Bronchospasm, Pulmonary Edema)\n\n3. Invasive airways do not improve bronchospasm. The airway should be managed in the least invasive way possible.\nSupraglottic devices and endotracheal intubation should be considered only if BVM ventilation fails\n\n4. Positive pressure ventilation in the setting of bronchoconstriction, either via a supraglottic airway or intubation,\nincreases the risk of air trapping which can lead to pneumothorax and cardiovascular collapse. These interventions\nshould be reserved for situations of respiratory failure\n\n5.", "start_char_idx": 443702, "end_char_idx": 447402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c29c57a-b9c0-4f36-ac8d-2ec9a1f2b020": {"__data__": {"id_": "3c29c57a-b9c0-4f36-ac8d-2ec9a1f2b020", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37306512-b166-48ce-8ec1-6d617a833ac9", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "02ffc33be26c35bb25bd64168714473fc5f589a44d769700016436a0888eea75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c8fe47b-c642-4052-8f16-d2c8d2ce9458", "node_type": "1", "metadata": {}, "hash": "99f1d9b6c6dc8e474733519e1ef15a0075d7ffe35fb84c2bed2f9425e1817746", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nRespiratory Distress (includes Bronchospasm, Pulmonary Edema) 192\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Respiratory Distress (includes Bronchospasm, Pulmonary Edema)\n\n3. Invasive airways do not improve bronchospasm. The airway should be managed in the least invasive way possible.\nSupraglottic devices and endotracheal intubation should be considered only if BVM ventilation fails\n\n4. Positive pressure ventilation in the setting of bronchoconstriction, either via a supraglottic airway or intubation,\nincreases the risk of air trapping which can lead to pneumothorax and cardiovascular collapse. These interventions\nshould be reserved for situations of respiratory failure\n\n5. The following medications should not be administered to manage bronchospasm as there is no evidence of patient\nbenefit:\n\nInhaled magnesium sulfate\nHeliox\n\n### Notes/Educational Pearls\n\n1. The combination of ipratropium with albuterol may decrease the need for hospital admission in certain patients\n\n2. Magnesium sulfate may cause hypotension that will usually respond to a fluid bolus\n\n3. Patient with acute heart failure and hypotension have high mortality\n\n4. When assessing for cause of respiratory distress, CHF tends to be associated with lower levels of EtCO2 compared to\nCOPD. EtCO2 values that are extremely low and high are markers of poor outcomes and need for intubation or ICU\nadmission\n\n### Key Considerations\n\n1. Nebulizer droplets can carry viral particles and other airborne pathogens, so additional PPE should be considered,\nincluding placement of a surgical mask over the nebulizer (if feasible) to limit droplet spread\n\n2. Factors that have been shown to be associated with increased mortality from asthma include:\n\nSevere asthma as evidenced by at least one of the following:\n\nPrior near-fatal asthma (e.g., ICU admission or intubation/mechanical ventilation)\nPrior admissions for asthma or repeated ED visits, particularly if in the last year\nHeavy use of beta-agonist medications, or requiring three or more classes of asthma medication\n\nTogether with one or more behavioral or psychosocial contributors:\n\nMedication noncompliance\nAlcohol or drug abuse\nObesity\nPsychosis, depression, other psychiatric illness, or major tranquilizer use\nEmployment or income difficulties\nSevere domestic, marital, or legal stressors\n\n3. Single dose dexamethasone has been found equally effective as several days dosing of other steroids, so dexamethasone\nis preferred over other po steroids\n\n4. Acute heart failure is a common cause of pulmonary edema \u2013 other causes include:\n\nOpioid overdose\nHigh altitude exposure\nKidney failure or dialysis noncompliance\nLung damage caused by gases or severe infection\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n5. Nitroglycerin reduces left ventricular filling pressure primarily via venous dilation. At higher doses the drug\nvariably lowers systemic afterload and increases stroke volume and cardiac output\n\n6. Pulmonary edema is more commonly a problem of volume distribution than total body fluid overload, so\nadministration of diuretics such as furosemide provide no immediate benefit for most patients and can cause\nsignificant harm. Inducement of inappropriate diuresis can lead to increased morbidity and mortality in patients\nwith other disease processes such as pneumonia and sepsis\n\n7. Nitrates provide both subjective and objective improvement, and might decrease intubation rates, incidence of\nMIs, and mortality. High-dose nitrates can reduce both preload and afterload and potentially increase cardiac\noutput and blood pressure\n\n8. If available and trained, ultrasound is useful to distinguish pulmonary edema from other causes of respiratory\ndistress (including pneumothorax)\n\n9. Pulmonary edema due to irritant gas inhalation (i.e., chlorine) generally is best managed by supportive care\nand escalation of airway interventions as above once the patient is appropriately decontaminated. Early poison\ncenter consultation should be strongly considered for guidance\n\n10. Pulmonary edema due to high altitude should be managed as described in Altitude Illness Guideline\n\n## Pertinent Assessment Findings\n\n1. Severe respiratory distress may manifest with hypoxia, altered mentation, diaphoresis, or inability to speak more\nthan 2\u20133 words\n\n2. In the setting of severe bronchoconstriction, wheezing may not be heard.", "start_char_idx": 446690, "end_char_idx": 451093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c8fe47b-c642-4052-8f16-d2c8d2ce9458": {"__data__": {"id_": "8c8fe47b-c642-4052-8f16-d2c8d2ce9458", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c29c57a-b9c0-4f36-ac8d-2ec9a1f2b020", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "f3e2cbe6f3ce622b875c77db80230a6b986d4ce208fa5500fb474947763619db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fbcd7b5-6e4b-4a84-8f71-02ce8ce7173b", "node_type": "1", "metadata": {}, "hash": "5dd0b44ddfca2c9570c9f7a64b48c34fe703fb04ce97310921f428abc0b03150", "class_name": "RelatedNodeInfo"}}, "text": "If available and trained, ultrasound is useful to distinguish pulmonary edema from other causes of respiratory\ndistress (including pneumothorax)\n\n9. Pulmonary edema due to irritant gas inhalation (i.e., chlorine) generally is best managed by supportive care\nand escalation of airway interventions as above once the patient is appropriately decontaminated. Early poison\ncenter consultation should be strongly considered for guidance\n\n10. Pulmonary edema due to high altitude should be managed as described in Altitude Illness Guideline\n\n## Pertinent Assessment Findings\n\n1. Severe respiratory distress may manifest with hypoxia, altered mentation, diaphoresis, or inability to speak more\nthan 2\u20133 words\n\n2. In the setting of severe bronchoconstriction, wheezing may not be heard. Patients with known asthma with severe\ndyspnea should be empirically treated, even if wheezing is absent\n\n3. A \u201cshark fin\u201d on waveform capnography suggests significant bronchospasm and obstructive physiology\n\n4. Etiology of respiratory distress:\n\na. Bronchospastic etiology (e.g., asthma, COPD) is suggested by:\n\ni. Wheezing on auscultation\n\nii. \u201cShark fin\u201d waveform capnograph or prolonged expiratory phase\n\niii. History of asthma/COPD\n\nb. Fluid overload etiology (e.g., CHF, pulmonary edema) is suggested by:\n\ni. Jugular venous distention\n\nii. Rales on auscultation\n\niii. Peripheral edema\n\niv. History of CHF, diuretic therapy, dialysis noncompliance, hypertension\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914137 \u2013 Pulmonary Edema/CHF\n9914139 \u2013 Respiratory Distress/Asthma/COPD/Croup/Reactive Airway\n\n## Key Documentation Elements\n\nDocument key aspects of the exam at baseline and after each intervention:\n\nRespiratory rate\n\nGo To TOC\n\nRespiratory\n\nRev. March 2022\n\nRespiratory Distress (includes Bronchospasm, Pulmonary Edema)\n\n194\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Assessment of Respiratory Distress\n\nOxygen saturation\nEtCO2/waveform shape\nUse of accessory muscles\nBreath sounds and quality\nMental status\nResponse to interventions\n\n## Performance Measures\n\nUse of pulse oximetry and capnography for patients with moderate-severe respiratory distress (RR greater than\nage-appropriate normal, SPO2 less than 90%)\nPercentage of patients with abnormal pulse oximetry, respiratory rate, EtCO2 value with normalization on final\nset of vital signs\nTime to administration of oxygen in hypoxic patients\nTime to bronchodilator administration in patients with wheezing\nPercentage of asthma/COPD patients receiving steroids and bronchodilators\nTime to improved SPO2 and/or decreased respiratory rate\nNormalizing change in vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment),\ntemperature, O2 saturation, and capnography values with treatment\nTime to initiation of non-invasive positive pressure ventilation\nNumber of CPAP/BiPAP patients who require intubation\nDocumentation of blood pressure reassessment in patients receiving nitrates\n\n## References\n\n|1.|Albertson TE, Sutter ME, Chan AL. The acute management of asthma. Clin Rev Allergy Immunol. 2015;48(1):114\u201325|\n|---|---|\n|2.|Amnuaypattanapon K, Limjindaporn C, Srivilaithon W, Dasanadeba I. Characteristics and outcomes of treatment in         status asthmaticus patients at emergency department. Asian Pac J Allergy Immunol. 2019;37(2):87\u201393|\n|3.|Brzezi\u0144ska-Paw\u0142owska OE, Rydzewska AD, \u0141uczy\u0144ska M, Majkowska-Wojciechowska B, Kowalski ML, Makowska JS.         Environmental factors affecting seasonality of ambulance emergency service visits for exacerbations of asthma and         COPD. J Asthma. 2016;53(2):139\u201345|\n|4.|Clemency BM, Thompson JJ, Tundo GN, Lindstrom HA. Prehospital high-dose sublingual nitroglycerin rarely causes         hypotension. Prehospital and disaster medicine.", "start_char_idx": 450315, "end_char_idx": 454189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fbcd7b5-6e4b-4a84-8f71-02ce8ce7173b": {"__data__": {"id_": "0fbcd7b5-6e4b-4a84-8f71-02ce8ce7173b", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c8fe47b-c642-4052-8f16-d2c8d2ce9458", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "0b6a453ed2d3884646faf143447d35d934ea7a0ecee7e0fc09003a912e90c504", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c84f13da-ce73-47e9-aadd-31d13db6533e", "node_type": "1", "metadata": {}, "hash": "bddad9fafa21b8d1baa69ef094014da079388fbed405a45416e221438f1103b0", "class_name": "RelatedNodeInfo"}}, "text": "Asian Pac J Allergy Immunol. 2019;37(2):87\u201393|\n|3.|Brzezi\u0144ska-Paw\u0142owska OE, Rydzewska AD, \u0141uczy\u0144ska M, Majkowska-Wojciechowska B, Kowalski ML, Makowska JS.         Environmental factors affecting seasonality of ambulance emergency service visits for exacerbations of asthma and         COPD. J Asthma. 2016;53(2):139\u201345|\n|4.|Clemency BM, Thompson JJ, Tundo GN, Lindstrom HA. Prehospital high-dose sublingual nitroglycerin rarely causes         hypotension. Prehospital and disaster medicine. 2013;28(5):477\u201381|\n|5.|Cronin JJ, McCoy S, Kennedy U, An Fhail\u00ed SN, Wakai A, Hayden J, et al. A Randomized Trial of Single-Dose Oral         Dexamethasone Versus Multidose Prednisolone for Acute Exacerbations of Asthma in Children Who Attend the         Emergency Department. Ann Emerg Med. 2016;67(5):593\u2013601.e3|\n|6.|D'Amato G, Vitale C, Lanza M, Sanduzzi A, Molino A, Mormile M, et al. Near fatal asthma: treatment and         prevention. Eur Ann Allergy Clin Immunol. 2016;48(4):116\u201322|\n|7.|Fenwick R. Management of acute heart failure in the emergency department. Emerg Nurse. 2015;23(8):26\u201335|\n|8.|Gartner BA, Fehlmann C, Suppan L, Niquille M, Rutschmann OT, Sarasin F. Effect of noninvasive ventilation on         intubation risk in prehospital patients with acute cardiogenic pulmonary edema: a retrospective study. European         journal of emergency medicine: Official Journal of the European Society for Emergency Medicine.         2020;27(1):54\u20138|\n\n________________________ Go To TOC\n\nRespiratory Rev. March 2022 Respiratory Distress (includes Bronchospasm, Pulmonary Edema) 195\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nGovier P, Coulson JM. Civilian exposure to chlorine gas: A systematic review. Toxicol Lett. 2018;293:249\u201352\nHensel M, Strunden MS, Tank S, Gagelmann N, Wirtz S, Kerner T. Prehospital non-invasive ventilation in acute\nrespiratory failure is justified even if the distance to hospital is short. The American journal of emergency\nmedicine. 2019;37(4):651\u20136\nHsu J, Chen J, Mirabelli MC. Asthma Morbidity, Comorbidities, and Modifiable Factors Among Older Adults. J Allergy\nClin Immunol Pract. 2018;6(1):236\u201343.e7\nHunter CL, Silvestri S, Ralls G, Papa L. Prehospital end-tidal carbon dioxide differentiates between cardiac and\nobstructive causes of dyspnoea. Emergency medicine journal : EMJ. 2015;32(6):453\u20136\nHyun Cho W, Ju Yeo H, Hoon Yoon S, Lee S, SooJeon D, Seong Kim Y, et al. High-Flow Nasal Cannula Therapy for Acute\nHypoxemic Respiratory Failure in Adults: A Retrospective Analysis. Intern Med. 2015;54(18):2307\u201313\nJones BP, Paul A. Management of acute asthma in the pediatric patient: an evidence-based review. Pediatric emergency\nmedicine practice. 2013;10(5):1\u201323; quiz -4\nKenyon N, Zeki AA, Albertson TE, Louie S. Definition of critical asthma syndromes. Clin Rev Allergy Immunol.\n2015;48(1):1\u20136\nLaursen CB, H\u00e4nselmann A, Posth S, Mikkelsen S, Videb\u00e6k L, Berg H. Prehospital lung ultrasound for the diagnosis of\ncardiogenic pulmonary oedema: a pilot study. Scand J Trauma Resusc Emerg Med.", "start_char_idx": 453698, "end_char_idx": 456753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c84f13da-ce73-47e9-aadd-31d13db6533e": {"__data__": {"id_": "c84f13da-ce73-47e9-aadd-31d13db6533e", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fbcd7b5-6e4b-4a84-8f71-02ce8ce7173b", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "89096889f66fef0db49697403e2f9d92ecedfe61a4c19cf53995916a7766bc66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54fe4d0d-8f14-439d-adab-cafb9c57d862", "node_type": "1", "metadata": {}, "hash": "83b265e880a9e533ffeb11ddb80e73e51f0c0c694f01bc2898bdaf42133e4e87", "class_name": "RelatedNodeInfo"}}, "text": "High-Flow Nasal Cannula Therapy for Acute\nHypoxemic Respiratory Failure in Adults: A Retrospective Analysis. Intern Med. 2015;54(18):2307\u201313\nJones BP, Paul A. Management of acute asthma in the pediatric patient: an evidence-based review. Pediatric emergency\nmedicine practice. 2013;10(5):1\u201323; quiz -4\nKenyon N, Zeki AA, Albertson TE, Louie S. Definition of critical asthma syndromes. Clin Rev Allergy Immunol.\n2015;48(1):1\u20136\nLaursen CB, H\u00e4nselmann A, Posth S, Mikkelsen S, Videb\u00e6k L, Berg H. Prehospital lung ultrasound for the diagnosis of\ncardiogenic pulmonary oedema: a pilot study. Scand J Trauma Resusc Emerg Med. 2016;24:96\nLuiz T, Kumpch M, Gr\u00fcttner J, Madler C, Viergutz T. Prehospital CPAP Therapy by Emergency Physicians in Patients\nwith Acute Respiratory Failure due to Acute Cardiogenic Pulmonary Edema or Acutely Exacerbated COPD. In vivo (Athens,\nGreece). 2016;30(2):133\u20139\nMac Donncha C, Cummins N, Hennelly D, Hannigan A, Ryan D. An observational study of the utility of continuous\npositive airway pressure ventilation for appropriate candidates in prehospital care in the Midwest region. Irish\njournal of medical science. 2017;186(2):489\u201394\nNagurka R, Bechmann S, Gluckman W, Scott SR, Compton S, Lamba S. Utility of initial prehospital end-tidal carbon\ndioxide measurements to predict poor outcomes in adult asthmatic patients. Prehospital emergency care: official\njournal of the National Association of EMS Physicians and the National Association of State EMS Directors.\n2014;18(2):180\u20134\nNassif A, Ostermayer DG, Hoang KB, Claiborne MK, Camp EA, Shah MI. Implementation of a Prehospital Protocol Change\nFor Asthmatic Children. Prehospital emergency care: official journal of the National Association of EMS Physicians\nand the National Association of State EMS Directors. 2018;22(4):457\u201365\nPatrick C, Ward B, Anderson J, Rogers Keene K, Adams E, Cash RE, et al. Feasibility, Effectiveness and Safety of\nPrehospital Intravenous Bolus Dose Nitroglycerin in Patients with Acute Pulmonary Edema. Prehospital emergency care:\nofficial journal of the National Association of EMS Physicians and the National Association of State EMS Directors.\n2020;24(6):844\u201350\nPollock M, Sinha IP, Hartling L, Rowe BH, Schreiber S, Fernandes RM. Inhaled short-acting bronchodilators for\nmanaging emergency childhood asthma: an overview of reviews. Allergy. 2017;72(2):183\u2013200\nRamgopal S, Mazzarini A, Martin-Gill C, Owusu-Ansah S. Prehospital management of pediatric asthma patients in a\nlarge emergency medical services system. Pediatr Pulmonol. 2020;55(1):83\u20139\n\n________________________\n\nGo To TOC\n\nRespiratory\n\nRev. March 2022\n\nRespiratory Distress (includes Bronchospasm, Pulmonary Edema)\n\n196\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n24. Raun LH, Ensor KB, Campos LA, Persse D. Factors affecting ambulance utilization for asthma attack treatment:\nunderstanding where to target interventions. Public Health. 2015;129(5):501\u20138\n\n25. Society BT. British guideline on the management of asthma: A national clinical guideline. London, England:\nScottish Intercollegiate Guidelines Network; 2019\n\n26. Strnad M, Prosen G, Borovnik Lesjak V. Bedside lung ultrasound for monitoring the effectiveness of prehospital\ntreatment with continuous positive airway pressure in acute decompensated heart failure. European journal of\nemergency medicine: official journal of the European Society for Emergency Medicine. 2016;23(1):50\u20135\n\n27. Turker S, Dogru M, Yildiz F, Yilmaz SB. The effect of nebulised magnesium sulphate in the management of\nchildhood moderate asthma exacerbations as adjuvant treatment.", "start_char_idx": 456134, "end_char_idx": 459743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54fe4d0d-8f14-439d-adab-cafb9c57d862": {"__data__": {"id_": "54fe4d0d-8f14-439d-adab-cafb9c57d862", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c84f13da-ce73-47e9-aadd-31d13db6533e", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "1728cf2aacd4f577bfc384570e1ec6cb03d3d3fa6d257609adedd542fdf53719", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0f20e7a-9885-4a78-b9f5-d6c7b02b1dfb", "node_type": "1", "metadata": {}, "hash": "a4c4fd2dfe471169f614824571be6ad5c41cb4b2fa2ffdaf11b94b88427000b2", "class_name": "RelatedNodeInfo"}}, "text": "Public Health. 2015;129(5):501\u20138\n\n25. Society BT. British guideline on the management of asthma: A national clinical guideline. London, England:\nScottish Intercollegiate Guidelines Network; 2019\n\n26. Strnad M, Prosen G, Borovnik Lesjak V. Bedside lung ultrasound for monitoring the effectiveness of prehospital\ntreatment with continuous positive airway pressure in acute decompensated heart failure. European journal of\nemergency medicine: official journal of the European Society for Emergency Medicine. 2016;23(1):50\u20135\n\n27. Turker S, Dogru M, Yildiz F, Yilmaz SB. The effect of nebulised magnesium sulphate in the management of\nchildhood moderate asthma exacerbations as adjuvant treatment. Allergol Immunopathol (Madr). 2017;45(2):115\u201320\n\n28. Williams TA, Finn J, Fatovich D, Perkins GD, Summers Q, Jacobs I. Paramedic Differentiation of Asthma and COPD\nin the Prehospital Setting Is Difficult. Prehospital emergency care: official journal of the National Association of\nEMS Physicians and the National Association of State EMS Directors. 2015;19(4):535\u201343\n\n29. Wilson SS, Kwiatkowski GM, Millis SR, Purakal JD, Mahajan AP, Levy PD. Use of nitroglycerin by bolus prevents\nintensive care unit admission in patients with acute hypertensive heart failure. The American journal of emergency\nmedicine. 2017;35(1):126\u201331\n\n30. Zellner T, Eyer F. Choking agents and chlorine gas\u2014History, pathophysiology, clinical effects and treatment.\nToxicol Lett. 2020;320:73\u20139\n\nRevision Date March 11, 2022\n\nRespiratory Distress (includes Bronchospasm, Pulmonary Edema) 197\n\n________________________ Go To TOC\n\nRespiratory Rev. March 2022\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Mechanical Ventilation (Invasive)\n\n#### Patient Care Goals\n\nMaintain adequate oxygenation\nMaintain adequate minute ventilation and capnography targets based on patient pathophysiology\nPrevent or limit risk of short- and long-term invasive airway and ventilator-associated complications including\nbarotrauma, pneumothorax, aspiration, over-ventilation\n\n#### Patient Presentation\n\n##### Inclusion Criteria\n\nAdult patients with invasive airway requiring mechanical ventilation\n\n##### Exclusion Criteria\n\nInterfacility transfer patients with established vent settings\nPatients with suspected untreated pneumothorax or large airway injury\nPatients in cardiac arrest\n\n#### Patient Management\n\n##### Assessment\n\nConfirm airway placement with ventilation and auscultation over epigastrium and assess for symmetric bilateral lung\nsounds\nVerify that airway (ETT, SGA) is securely held in place (by holder or other method)\nAssess oxygen delivery and confirm that FiO2 meets patients' needs and maintains desired oxygen saturation (SpO2)\n\nIf oxygen will be needed during transport calculate the duration of supply needed (O2 tank time (min) = tank\npressure (psi) x tank conversion factor/flow rate (L/min)\n\nAssess blood pressure to assure SBP greater than 90 mmHg or resuscitate to SBP >=90 mmHg or MAP >=60 mmHg\nAssess mental status, level of consciousness, Richmond Agitation Sedation Scale (RASS) or similar sedation score\n\n##### Treatment and Interventions\n\nSet up ventilator and circuit, program initial ventilator settings as below. Suggested general guidelines for adults\nwith EMS initiation of mechanical ventilation:\n\nConsider and modify based on any underlying acute or chronic lung pathology (COPD, asthma, CHF)\nVolume mode is generally preferred initially in adults\nSelect an appropriate ventilator mode: Assist Control (AC) is acceptable for most patients\n\nGo To TOC\n\nRespiratory\n\nRev.", "start_char_idx": 459051, "end_char_idx": 462644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0f20e7a-9885-4a78-b9f5-d6c7b02b1dfb": {"__data__": {"id_": "e0f20e7a-9885-4a78-b9f5-d6c7b02b1dfb", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54fe4d0d-8f14-439d-adab-cafb9c57d862", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "508d02864bdde1672094bd8ef5e0d7f0334c535d3c1db31fa59aee1b36487ee6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3eb08217-0b56-40e7-b585-d9cd98dd376b", "node_type": "1", "metadata": {}, "hash": "287ec091eb16f8be117827c5f107747073ea4691d482532190a87edb5fb55c0f", "class_name": "RelatedNodeInfo"}}, "text": "Suggested general guidelines for adults\nwith EMS initiation of mechanical ventilation:\n\nConsider and modify based on any underlying acute or chronic lung pathology (COPD, asthma, CHF)\nVolume mode is generally preferred initially in adults\nSelect an appropriate ventilator mode: Assist Control (AC) is acceptable for most patients\n\nGo To TOC\n\nRespiratory\n\nRev. March 2022\n\nRespiratory Distress (includes Bronchospasm, Pulmonary Edema)\n\n198\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines\n\n## Version 3.0\n\n### Initial settings:\n\n|Tidal volume|6\u20138 mL/kg ideal body weight|\n|---|---|\n|Respiratory rate|12\u201314 (or 8\u201312) breaths/min|\n|Inspiratory time|1 second|\n|PEEP|5 cmH20|\n|FiO2|60%|\n|Sensitivity|-2 cmH20|\n\nSet the heat moisture exchange (HME) at circuit Y.\n\nPlateau pressure (PPlat) goal is less than 30 cmH20\n\n### Patient Safety Considerations\n\nVentilators have different capabilities and features. Users must be familiar with the device they use and must be properly educated on its use and application in the specific population being treated\n\nEnsure that all vent alarms are set appropriately, and patient is continually monitored with pulse oximetry and waveform capnography\n\nSet all alarms that involve high pressure, low pressure, minute volume, and apnea\nPlateau pressure (PPlat) goal is less than 30 cmH20\nSet high pressure alarm 10 cmH2O above resting PIP\nSet low pressure alarm 5 cmH2O below resting PIP\nSet low minute volume alarm 25% below resting minute volume\n\nDuring transport of a critically ill patient only necessary adjustments should be made to the ventilator. Focus on maintaining adequate oxygenation, minute volume and patient comfort.\n\nAn increase in the respiratory rate shortens the expiratory time. If changing rate, also check the I:E ratio (the proportions of each breath cycle devoted to the inspiratory and expiratory phases) and adjust the inspiratory time if necessary\n\nThe inspiratory time can be adjusted slightly to ensure greater patient comfort, however any change in inspiratory time will affect the I:E ratio. Rarely should an inspiratory time be less than 0.7 for an adult\n\nAssure proper sedation level for patient to tolerate ventilator\nAssure patient does not have auto-PEEP\n\nAsthmatics and patients with severe bronchoconstriction require different initial settings: for example, PEEP of 0, FiO2 100%, tidal volume 5 mL/kg, rate 10, I:E of 1:4 \u2013 1:6 to allow full exhalation and limit breath stacking/auto-PEEP. Hemodynamic instability may indicate increased intrathoracic pressure and require either manual chest wall compression to promote full exhalation or possibly needle chest decompression for pneumothorax\n\nGo To TOC\n\nRespiratory\n\nRespiratory Distress (includes Bronchospasm, Pulmonary Edema)\n\nRev. March 2022\n\n199\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Notes/Educational Pearls\n\nKey Considerations\n\nIt is important to understand the patient's underlying pulmonary status to choose the appropriate type of ventilation (volume or pressure) and mode (AC or SIMV most common)\n\nVolume control ventilation is generally preferred initially in adults with compliant lungs (PPlat less than 30) because of better control of minute ventilation\nPressure control ventilation can be used in patients with non-compliant lungs and elevated PPlat\nAssist Control (AC) mode is acceptable for most patients and provides best control of minute ventilation. Synchronized Intermittent Mandatory Ventilation (SIMV) is an alternative option\n\nPertinent Assessment Findings\n\nPerform a pre-ventilator use inspection including a circuit check on the ventilator prior to placing it on a patient\nAssess values during transport, including:\n\nPeak inspiratory pressure (PIP) Compare against baseline value to monitor for compliance changes or obstruction in the circuit\nRespiratory rate. Compare with baseline value, rapid increases could indicate leaks. Overbreathing may require vent setting adjustment\nExhaled tidal volume. Compare against baseline, if extreme fluctuations, check for leaks in circuit and in ET tube\nMonitor the I:E ratio.", "start_char_idx": 462285, "end_char_idx": 466396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3eb08217-0b56-40e7-b585-d9cd98dd376b": {"__data__": {"id_": "3eb08217-0b56-40e7-b585-d9cd98dd376b", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0f20e7a-9885-4a78-b9f5-d6c7b02b1dfb", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "aa710fa1fb396d0836ab7ed6a6f7fb3c3c78e19d6472de9d369012c6bfe426b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fccb0447-15d5-462d-b4fa-fb371fe7192d", "node_type": "1", "metadata": {}, "hash": "28eaef7c873a5fe755cdbef490555161fc94bc4857bc19e2242ac86381f48ea6", "class_name": "RelatedNodeInfo"}}, "text": "Synchronized Intermittent Mandatory Ventilation (SIMV) is an alternative option\n\nPertinent Assessment Findings\n\nPerform a pre-ventilator use inspection including a circuit check on the ventilator prior to placing it on a patient\nAssess values during transport, including:\n\nPeak inspiratory pressure (PIP) Compare against baseline value to monitor for compliance changes or obstruction in the circuit\nRespiratory rate. Compare with baseline value, rapid increases could indicate leaks. Overbreathing may require vent setting adjustment\nExhaled tidal volume. Compare against baseline, if extreme fluctuations, check for leaks in circuit and in ET tube\nMonitor the I:E ratio. 1:2 or 1:3 for normal lungs, longer E times may be needed for patients with obstructive or restrictive lung disease\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\nNone noted\n\nKey Documentation Elements\n\nDocumentation of ventilator settings and monitored values should include:\n\nVentilator Settings: Volume or pressure breaths; mode; respiratory rate; inspiratory time; tidal volume or pressure, PEEP, FiO2; sensitivity\nPatient Values (baseline and repeated): Peak inspiratory pressure (PIP); exhaled tidal volume; respiratory rate; I:E ratio; minute volume; EtCO2; SPO2\n\nPerformance Measures\n\nNone noted\n\nGo To TOC\n\nRespiratory Rev.", "start_char_idx": 465724, "end_char_idx": 467104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fccb0447-15d5-462d-b4fa-fb371fe7192d": {"__data__": {"id_": "fccb0447-15d5-462d-b4fa-fb371fe7192d", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3eb08217-0b56-40e7-b585-d9cd98dd376b", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "f48f4569b3b2ee3b94b7d346b223d23dad2c95bfbbbec32c986403cf07469ad7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0e57b5b-06e8-4917-88de-19c754283d0b", "node_type": "1", "metadata": {}, "hash": "97b2a8456b4bf343e83e1db475ae7d5c55e51a27666a9ffaff5f3c862730fc45", "class_name": "RelatedNodeInfo"}}, "text": "Compare against baseline, if extreme fluctuations, check for leaks in circuit and in ET tube\nMonitor the I:E ratio. 1:2 or 1:3 for normal lungs, longer E times may be needed for patients with obstructive or restrictive lung disease\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\nNone noted\n\nKey Documentation Elements\n\nDocumentation of ventilator settings and monitored values should include:\n\nVentilator Settings: Volume or pressure breaths; mode; respiratory rate; inspiratory time; tidal volume or pressure, PEEP, FiO2; sensitivity\nPatient Values (baseline and repeated): Peak inspiratory pressure (PIP); exhaled tidal volume; respiratory rate; I:E ratio; minute volume; EtCO2; SPO2\n\nPerformance Measures\n\nNone noted\n\nGo To TOC\n\nRespiratory Rev. March 2022\n\nRespiratory Distress (includes Bronchospasm, Pulmonary Edema) 200\n---\n|Content|Page number|\n|---|---|\n|Respiratory Distress (includes Bronchospasm, Pulmonary Edema)|201|\n\n## Adult Male Patients\n\n|Height|IBW kg|Vt|Initial f|Vt|Initial f|Vt|Initial f|\n|---|---|---|---|---|---|---|---|\n|5'0\"|50|300|12|500|12|400|20|\n|5'1\"|52|314|12|523|12|418|20|\n|5'2\"|55|328|12|546|12|437|20|\n|5'3\"|57|341|12|569|12|455|20|\n|5'4\"|59|355|12|592|12|474|20|\n|5'5\"|62|369|12|615|12|492|20|\n|5'6\"|64|383|12|638|12|510|20|\n|5'7\"|66|397|12|661|12|529|20|\n|5'8\"|68|410|12|684|12|547|20|\n|5'9\"|71|424|12|707|12|566|20|\n|5'10\"|73|438|12|730|12|584|20|\n|5'11\"|75|452|12|753|12|602|20|\n|6'0\"|78|466|12|776|12|621|20|\n|6'1\"|80|479|12|799|12|639|20|\n|6'2\"|82|493|12|822|12|658|20|\n|6'3\"|85|507|12|845|12|676|20|\n|6'4\"|87|521|12|868|12|694|20|\n|6'5\"|89|535|12|891|12|713|20|\n|6'6\"|91|548|12|914|12|731|20|\n\nSource: NIH-NHLBI ARDS Network\n\n## Adult Female Patients\n\n|Height|IBW kg|Vt|Initial f|Vt|Initial f|Vt|Initial f|\n|---|---|---|---|---|---|---|---|\n|5'0\"|46|273|12|455|12|364|20|\n|5'1\"|48|287|12|478|12|382|20|\n|5'2\"|50|301|12|501|12|401|20|\n|5'3\"|52|314|12|524|12|419|20|\n|5'4\"|55|328|12|547|12|438|20|\n|5'5\"|57|342|12|570|12|456|20|\n|5'6\"|59|356|12|593|12|474|20|\n|5'7\"|62|370|12|616|12|493|20|\n|5'8\"|64|383|12|639|12|511|20|\n|5'9\"|66|397|12|662|12|530|20|\n|5'10\"|69|411|12|685|12|548|20|\n|5'11\"|71|425|12|708|12|566|20|\n|6'0\"|73|439|12|731|12|585|20|\n|6'1\"|75|452|12|754|12|603|20|\n|6'2\"|78|466|12|777|12|622|20|\n|6'3\"|80|480|12|800|12|640|20|\n|6'4\"|82|494|12|823|12|658|20|\n|6'5\"|85|508|12|846|12|677|20|\n|6'6\"|87|521|12|869|12|695|20|\n\nSource: NIH-NHLBI ARDS Network\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## References\n\n|1.|NIH-NHLBI ARDS Network.", "start_char_idx": 466281, "end_char_idx": 468886, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0e57b5b-06e8-4917-88de-19c754283d0b": {"__data__": {"id_": "d0e57b5b-06e8-4917-88de-19c754283d0b", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fccb0447-15d5-462d-b4fa-fb371fe7192d", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "496d1982498f79cd062421cdaefc935eeeefb3d8a6f27782ffe1b2a109c7994f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39c76bfa-1c0d-459d-b92b-aafeb82c530f", "node_type": "1", "metadata": {}, "hash": "6ca835e2d8aedc95ada41b9e23241c3619cfb0a85027a3b9160856bc2a88827c", "class_name": "RelatedNodeInfo"}}, "text": "Predicted Body Weight and Tidal Volume Charts. 2014.|\n|---|---|\n|2.|Schauf, M. Respiratory emergencies, Airway Management and Ventilation. In: Pollak AN (Ed): Critical Care Transport         Second Edition. Jones &Bartlett Learning, Burlington, MA 2018.|\n\nRevision Date\n\nMarch 11, 2022\n\nGo To TOC\n\n### Respiratory\n\nRev. March 2022\n\n### Respiratory Distress (includes Bronchospasm, Pulmonary Edema)\n\n202\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Tracheostomy Management\n\n### Aliases\n\nNone\n\n### Patient Care Goals\n\nMeet airway management goals in a patient with a tracheostomy\n\nAssure patent airway, understand how to troubleshoot tracheostomy in a patient with respiratory distress\n\nAssure adequate oxygenation and ventilation\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nAny adult or pediatric patient with an existing tracheostomy greater than 7 days post placement and a mature stoma tract\n\n#### Exclusion Criteria\n\nAdult or pediatric patient with tracheostomy less than 7 days post placement (i.e., no mature stoma tract)\n\n### Patient Management\n\n#### Assessment\n\nEvaluate patient respiratory status as per Airway Management Guideline\nIn a patient with respiratory distress, evaluate for DOPE:\n\nDislodgement or misplaced tracheostomy (e.g., decannulation)\n\nAssess for subcutaneous air in the neck which may indicate the tracheostomy is not in the trachea\nDirectly visualize the tracheostomy and the stoma (i.e., remove anything obstructing direct view of stoma including clothing/bandages/sponges etc.) to assure it remains properly seated in the stoma\n\nObstruction or secretions in tracheostomy\n\nAssure tracheostomy is patent. Especially in pediatric tracheostomy patients with significant respiratory distress, plugging or dislodgement/decannulation of the tracheostomy is the problem until proven otherwise\nAuscultate breath sounds, consider potential for plugging of large airways in patients with significant respiratory distress\n\nPneumothorax\nEquipment connection problems\n\nAs with any patient with respiratory distress, appropriate monitoring with pulse oximetry and waveform capnography should be provided as per Airway Management Guideline\n\n#### Treatment and Troubleshooting Interventions\n\nIn patient with mild respiratory distress and adequate oxygenation:\n\nSuctioning/clearing obstruction:\n\n________________________\n\nGo To TOC\n\n## Respiratory\n\nRev. March 2022\n\n## Tracheostomy Management\n\n203\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\ni. If the patient is not on a ventilator, remove any cap, filter, or speaking valve that may be connected to the tracheostomy\n\nii. Provide passive oxygenation with high flow oxygen over nose/mouth and stoma to avoid hypoxia during procedure\n\niii. Remove inner cannula if present\n\niv. If needed, use 1\u20133 mL sterile saline directly into the tracheostomy to loosen secretions and help clear obstruction\n\nv. Pass appropriately sized suction catheter through tracheostomy\n\nvi. Once obstruction is cleared, assist ventilations as needed with BVM to tracheostomy tube, provide passive oxygenation or return patient to ventilator if patient on chronic ventilator via tracheostomy\n\n2. In patient with significant/severe respiratory distress and/or inadequate oxygenation:\n\na. If patient on ventilator, remove from vent and attempt BVM ventilation\n\nb. Suctioning/clearing obstruction:\n\ni. If the patient is not on a ventilator, remove any cap, filter, or speaking valve that may be connected to the tracheostomy\n\nii. Provide passive oxygenation with high flow oxygen over nose/mouth and stoma to avoid hypoxia during procedure\n\niii. Remove inner cannula if present\n\niv. Attempt to pass appropriately sized suction catheter through tracheostomy\n\nv. If needed, use 1\u20133 mL sterile saline directly into the tracheostomy to loosen secretions and help clear obstruction\n\nvi. If suction catheter will not pass, the tracheostomy needs to be changed emergently due to obstruction. (See below)\n\nvii.", "start_char_idx": 468887, "end_char_idx": 472904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39c76bfa-1c0d-459d-b92b-aafeb82c530f": {"__data__": {"id_": "39c76bfa-1c0d-459d-b92b-aafeb82c530f", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0e57b5b-06e8-4917-88de-19c754283d0b", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "c047a65d1d7567d437850708c20337f40352571d4c93a4bff67a61a27d520771", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b59ee300-57d8-4a28-94aa-1c9a3d7f93ad", "node_type": "1", "metadata": {}, "hash": "160400ddc4143645bf6fc47c38bab99e4f07af62d4e1d6d4bc26f1744c81f1ed", "class_name": "RelatedNodeInfo"}}, "text": "In patient with significant/severe respiratory distress and/or inadequate oxygenation:\n\na. If patient on ventilator, remove from vent and attempt BVM ventilation\n\nb. Suctioning/clearing obstruction:\n\ni. If the patient is not on a ventilator, remove any cap, filter, or speaking valve that may be connected to the tracheostomy\n\nii. Provide passive oxygenation with high flow oxygen over nose/mouth and stoma to avoid hypoxia during procedure\n\niii. Remove inner cannula if present\n\niv. Attempt to pass appropriately sized suction catheter through tracheostomy\n\nv. If needed, use 1\u20133 mL sterile saline directly into the tracheostomy to loosen secretions and help clear obstruction\n\nvi. If suction catheter will not pass, the tracheostomy needs to be changed emergently due to obstruction. (See below)\n\nvii. Once obstruction is cleared, assist ventilations as needed with BVM to tracheostomy tube, provide passive oxygenation or return patient to ventilator if patient on chronic ventilator via tracheostomy tube\n\nc. Emergent tracheostomy change: determine size of tracheostomy needed from imprint on existing tracheostomy flange/collar. If no replacement tracheostomy is available, an endotracheal tube of the same size or smaller may be used\n\ni. Ventilate or provide passive oxygenation during procedure. Attempt to ventilate from the upper airway or direct high flow O2 to stoma during attempts.\n\nii. Deflate cuff (if present)\n\niii. Remove ties and obstructed tracheostomy\n\niv. Immediately replace with new (lubricated) tracheostomy, remove obturator, and begin BVM ventilation. Never use force. For difficult replacement, the following strategies can be attempted:\n\na. Reposition patient with neck extended\n\nb. Ensure proper lubrication and re-attempt approach at a 90-degree angle from long axis of neck (i.e., from the side) to enter the stoma and then rotate back along the long axis to complete insertion\n\nc. Attempt reinsertion with a smaller sized tracheostomy or endotracheal tube\n\nv. Confirm correct placement with waveform capnography, breath sounds, oxygen saturation, chest rise\n\nvi. Secure tracheostomy with tracheostomy ties or tube with appropriate holder\n\n3. Consider use of humidified air or oxygen in any patient with a tracheostomy\n\nRespiratory\n\nTracheostomy Management\n\nRev. March 2022\n\n204\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n4. Cuff may need to be inflated to provide adequate oxygenation and ventilation when positive pressure ventilation is required. However, cuff should never be inflated if positive pressure ventilation is not being performed, or in patients with a Passy-Muir (teal colored) speaking valve in place\n\nPatient Safety Considerations\n\nEspecially in pediatric tracheostomy patients with significant respiratory distress, plugging or dislodgement of the tracheostomy is the problem until proven otherwise. Signs and symptoms of respiratory distress, cyanosis, ventilator alarms sounding, decreased level of consciousness, decreased SpO2 or cardiac arrest in patients with a tracheostomy, as well as bradycardia in pediatric tracheostomy patients should be presumed due to a tracheostomy obstruction\nLaryngectomy patients and some patients with congenital or surgical airway abnormalities cannot be orally intubated. Patients with tracheostomy alone (e.g., for mechanical ventilation) and no airway abnormalities should be able to be orally intubated\nFor recent tracheostomy patients who present with bleeding from the tracheostomy in the early (up to 3 weeks) postoperative period, a tracheoinnominate arterial bleed is an uncommon and life-threatening complication (0.7% incidence and a 90% mortality rate)\n\n50% of these patients present initially with a smaller sentinel bleed/hemoptysis which appears to have stopped\nInflation of the tracheostomy balloon to the maximum is a potential temporizing measure until definitive care can be provided, even overinflation may be needed. If the tracheostomy is uncuffed, it can be replaced with a cuffed endotracheal tube and the balloon maximally inflated\nAny patient in the early postoperative period (within a month of surgery) with hemoptysis or bleeding from a tracheostomy should be transported for evaluation, even if bleeding has stopped\n\nPrompt tracheostomy replacement is important.", "start_char_idx": 472101, "end_char_idx": 476418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b59ee300-57d8-4a28-94aa-1c9a3d7f93ad": {"__data__": {"id_": "b59ee300-57d8-4a28-94aa-1c9a3d7f93ad", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39c76bfa-1c0d-459d-b92b-aafeb82c530f", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "4facd241b142b959330d4c6f757676663e9096ff72e75e1856cb7c455fa52989", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32e8a32f-4e2d-4dea-9c55-f16df2df9a98", "node_type": "1", "metadata": {}, "hash": "86e79ab1cc7ccf08d886c4f72b55496bec82f2fb14afdf673bc2c8f6f5b0a27a", "class_name": "RelatedNodeInfo"}}, "text": "If the tracheostomy is uncuffed, it can be replaced with a cuffed endotracheal tube and the balloon maximally inflated\nAny patient in the early postoperative period (within a month of surgery) with hemoptysis or bleeding from a tracheostomy should be transported for evaluation, even if bleeding has stopped\n\nPrompt tracheostomy replacement is important. Delays allow for narrowing of the stoma and can make recannulation more difficult\n\nNotes/Educational Pearls\n\nKey Considerations\n\nTracheostomy tube components\n\nOuter cannula: the tracheostomy size is stamped on the collar\nInner cannula: not found in all tracheostomies\n\nNot commonly used in pediatric patients\nRemoved by gently twisting a quarter turn to the left and pulling out\n\nBalloon cuff: protects lower airway from secretions/blood from above, allows for better mechanical ventilation\nCollar: includes imprint of tube size and attachment for umbilical tape/tracheostomy ties\nObturator: stiffens and provides shape to tracheostomy tube to facilitate insertion. Must be removed for ventilation\n\nTo determine the appropriate size suction catheter, double the size of the tracheostomy (number on collar of tracheostomy tube)\nA bougie may aid in the placement of an endotracheal tube into a mature stoma\nAn inner cannula may be required to ventilate through the tracheostomy tube\n\n________________________Go To TOC\n\nRespiratory\n\nTracheostomy Management\n\nRev. March 2022\n\n205\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n5. Uncuffed and fenestrated cuffed tracheostomy tubes may not protect the patient from aspiration\n\n6. If transporting a patient with a tracheostomy either in an emergency or routine transport, the patients home\ntracheostomy equipment (e.g., \u201cGo bag\u201d) should accompany them. The equipment that needs to be at the bedside to\nensure safety includes appropriately sized French suction catheters, operating suction system, and spare tracheostomy\ntubes. Sterile saline, sterile gloves and water-soluble medical lubrication packets should also be available. Most\ntracheostomy patients will maintain a kit with these supplies to travel with\n\n7. Inadvertent tracheostomy decannulation incidence is the second most frequent life-threatening pediatric tracheostomy\ncomplication, occurring at rates of 0.35\u201315%, with the vast majority occurring more than 7 days postoperatively\n\n8. Tracheostomy obstruction can occur for several reasons, including mucus plugging, abnormal/excess granulation\ntissue, tracheomalacia causing collapse of the tracheal wall around the tube\n\n9. Do not replace a heat moisture exchange (HME) filter cap if soiled or wet as it can impede airflow\n\n### Pertinent Assessment Findings\n\n1. Adequate oxygenation without respiratory distress suggests that the tracheostomy is patent and functioning correctly\n\n2. Inadequate oxygenation and ventilation, respiratory distress, air hunger in a patient with a tracheostomy should first\nbe presumed to be due to tracheostomy obstruction\n\n3. Neck or chest crepitus on palpation suggests tracheostomy misplacement outside the trachea\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914001 \u2013 Airway\n9914003 \u2013 Airway - Failed\n9914005 \u2013 Airway - Obstruction/Foreign Body\n\n### Key Documentation Elements\n\nFor any tracheostomy patient with respiratory distress, visual verification of correct location of tracheostomy in the\nstoma and auscultation of breath sounds\nContinuous pulse oximetry and preferably continuous waveform capnography (or if unavailable, repeated capnometry\nmeasurements) should be documented for every patient. [eAirway.03: 4003015]\n\n### Performance Measures\n\nNone noted\n\n### References\n\nBontempo LJ, Manning SL. Tracheostomy Emergencies. Emergency medicine clinics of North America. 2019;37(1):109\u201319\nDawson, D. (2014). Essential principles: tracheostomy care in the adult patient. Nurs Crit Care, 19(2), 63\u201372.\ndoi:10.1111/nicc.12076\n\n________________________ Go To TOC\n\nRespiratory Rev.", "start_char_idx": 476064, "end_char_idx": 480107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32e8a32f-4e2d-4dea-9c55-f16df2df9a98": {"__data__": {"id_": "32e8a32f-4e2d-4dea-9c55-f16df2df9a98", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b59ee300-57d8-4a28-94aa-1c9a3d7f93ad", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "4d991d02a9947d37d7d9529b9e2099213b196f4f6a149817038ed162ae11d481", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27feed5c-1a29-4060-9413-32a8e1c84ccd", "node_type": "1", "metadata": {}, "hash": "fac9c0af3c2023d5af165b06426b6f0951b988357b1a646dc5c5c5145fc49c19", "class_name": "RelatedNodeInfo"}}, "text": "[eAirway.03: 4003015]\n\n### Performance Measures\n\nNone noted\n\n### References\n\nBontempo LJ, Manning SL. Tracheostomy Emergencies. Emergency medicine clinics of North America. 2019;37(1):109\u201319\nDawson, D. (2014). Essential principles: tracheostomy care in the adult patient. Nurs Crit Care, 19(2), 63\u201372.\ndoi:10.1111/nicc.12076\n\n________________________ Go To TOC\n\nRespiratory Rev. March 2022 Tracheostomy Management 206\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n3. Doherty, C., Neal, R., English, C., Cooke, J., Atkinson, D., Bates, L., . . . McGrath, B. A. (2018). Multidisciplinary\nguidelines for the management of paediatric tracheostomy emergencies. Anaesthesia, 73(11), 1400\u20131417.\ndoi:10.1111/anae.14307\n\n4. Fernandez-Bussy S, Mahajan B, Folch E, Caviedes I, Guerrero J, Majid A. Tracheostomy Tube Placement: Early and\nLate Complications. J Bronchology Interv Pulmonol. 2015;22(4):357\u201364\n\n5. Fuller C, Wineland AM, Richter GT. Update on Pediatric Tracheostomy: Indications, Technique, Education, and\nDecannulation. Curr Otorhinolaryngol Rep. 2021:1\u201312\n\n6. Hess DR, Altobelli NP. Tracheostomy tubes. Respiratory care. 2014;59(6):956\u201371; discussion 71\u20133\n\n7. Kligerman MP, Saraswathula A, Sethi RK, Divi V. Tracheostomy Complications in the Emergency Department: A\nNational Analysis of 38,271 Cases. ORL J Otorhinolaryngol Relat Spec. 2020;82(2):106\u201314\n\n8. Kohn, J., McKeon, M., Munhall, D., Blanchette, S., Wells, S., & Watters, K. (2019). Standardization of pediatric\ntracheostomy care with \"Go-bags\". Int J Pediatr Otorhinolaryngol, 121, 154\u2013156. doi:10.1016/j.ijporl.2019.03.022\n\n9. Mehta, K., Schwartz, M., Falcone, T. E., & Kavanagh, K. R. (2019). Tracheostomy Care Education for the\nNonsurgical First Responder: A Needs-Based Assessment and Quality Improvement Initiative. OTO Open, 3(2),\n2473974x19844993. doi:10.1177/2473974x19844993\n\n10. Muller RG, Mamidala MP, Smith SH, Smith A, Sheyn A. Incidence, Epidemiology, and Outcomes of Pediatric\nTracheostomy in the United States from 2000 to 2012. Otolaryngol Head Neck Surg. 2019;160(2):332\u20138\n\n11. Prickett, K., Deshpande, A., Paschal, H., Simon, D., & Hebbar, K. B. (2019). Simulation-based education to\nimprove emergency management skills in caregivers of tracheostomy patients. Int J Pediatr Otorhinolaryngol, 120,\n157\u2013161. doi:10.1016/j.ijporl.2019.01.020\n\n12. Sandler ML, Ayele N, Ncogoza I, Blanchette S, Munhall DS, Marques B, et al. Improving Tracheostomy Care in\nResource-Limited Settings. Ann Otol Rhinol Laryngol. 2020;129(2):181\u201390\n\n13. Sterni LM, Collaco JM, Baker CD, Carroll JL, Sharma GD, Brozek JL, et al. An Official American Thoracic Society\nClinical Practice Guideline: Pediatric Chronic Home Invasive Ventilation. American journal of respiratory and\ncritical care medicine. 2016;193(8):e16\u2013e35\n\n14.", "start_char_idx": 479729, "end_char_idx": 482529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27feed5c-1a29-4060-9413-32a8e1c84ccd": {"__data__": {"id_": "27feed5c-1a29-4060-9413-32a8e1c84ccd", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32e8a32f-4e2d-4dea-9c55-f16df2df9a98", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "999042b47a3279720941d531193758918ca90c41a2f24520459b3bda68c193df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9887439d-a408-4ca3-8fcb-1c8234128c66", "node_type": "1", "metadata": {}, "hash": "3143f848604c4adb7e8737308b2705fe35264095ed765851d3c269174eac6cf7", "class_name": "RelatedNodeInfo"}}, "text": "Int J Pediatr Otorhinolaryngol, 120,\n157\u2013161. doi:10.1016/j.ijporl.2019.01.020\n\n12. Sandler ML, Ayele N, Ncogoza I, Blanchette S, Munhall DS, Marques B, et al. Improving Tracheostomy Care in\nResource-Limited Settings. Ann Otol Rhinol Laryngol. 2020;129(2):181\u201390\n\n13. Sterni LM, Collaco JM, Baker CD, Carroll JL, Sharma GD, Brozek JL, et al. An Official American Thoracic Society\nClinical Practice Guideline: Pediatric Chronic Home Invasive Ventilation. American journal of respiratory and\ncritical care medicine. 2016;193(8):e16\u2013e35\n\n14. Volsko TA, Parker SW, Deakins K, Walsh BK, Fedor KL, Valika T, et al. AARC Clinical Practice Guideline:\nManagement of Pediatric Patients With Tracheostomy in the Acute Care Setting. Respiratory care. 2021;66(1):144\u201355\n\n15. Walsh BK, Crotwell DN, Restrepo RD. Capnography/Capnometry During Mechanical Ventilation: 2011. Respiratory\ncare. 2011;56(4):503\u20139\n\n16. Watters KF. Tracheostomy in Infants and Children. Respiratory care. 2017;62(6):799\u2013825\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC Respiratory Rev. March 2022 Tracheostomy Management 207\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Trauma\n\n### General Trauma Management\n\nAliases: None noted\n\n### Patient Care Goals\n\nRapid assessment and management of life-threatening injuries\nRecognition of when to rapidly transport\nTransport to the appropriate level of trauma care\nSafe movement of patient to prevent worsening injury severity\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nPatients of all ages who have sustained an injury due to mechanical trauma, including:\n\nBlunt injury\nPenetrating injury\nBlast\nBurns\n\n#### Exclusion Criteria\n\nNot an acute traumatic injury\n\n### Patient Management\n\n#### Initial Assessment\n\nPrimary survey (Use \u201cMARCH\u201d algorithm)\n\nMassive Hemorrhage\n\nInitial visual and body sweep to assess for penetrating wounds and severe life-threatening hemorrhage [See Extremity Trauma/External Hemorrhage Management Guideline]\n\nAirway\n\nAssess airway patency by asking the patient basic questions to assess for stridor and ease of air movement\nLook for injuries that may lead to airway obstruction including unstable facial fractures, expanding neck hematoma, blood or vomitus in the airway, facial burns/inhalation injury\nEvaluate mental status for ability to protect airway (patients with a Glasgow Coma Score (GCS) less than or equal to \u201c8\u201d are more likely to require airway protection)\n\nRespiratory/Breathing\n\nAssess respiratory rate and pattern\nAssess for tracheal deviation\nAssess symmetry of chest wall movement\nListen bilaterally on lateral chest wall for breath sounds\n\nCirculation\n\nAssess blood pressure and heart rate\n\n________________________ Go To TOC\n\nTrauma Rev. March 2022 General Trauma Management 208\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Immediate Treatment and Interventions\n\n|1. Massive or exsanguinating hemorrhage control|a. First stop severe external and extremity hemorrhage with extremity tourniquets or appropriate wound packing with hemostatic gauze. Be sure to roll patient and examine the back as well. [See Extremity Trauma/External Hemorrhage Management Guideline]|\n|---|---|\n| |b. Utilize junctional tourniquets if needed for junctional area hemorrhage|\n|2. Airway|a. If impending airway obstruction or altered mental status resulting in inability to maintain airway patency, immediately ensure patent airway. [See Airway Management Guideline and Spinal Care Guideline]|\n| |b. Consider airway adjuncts as appropriate avoiding nasal airway adjuncts in patents with oral or other facial injuries. [See Airway Management Guideline]|\n|3. Respiratory/Breathing|a.", "start_char_idx": 481991, "end_char_idx": 485683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9887439d-a408-4ca3-8fcb-1c8234128c66": {"__data__": {"id_": "9887439d-a408-4ca3-8fcb-1c8234128c66", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27feed5c-1a29-4060-9413-32a8e1c84ccd", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "0c4985b51644ac785fc01a7ff7d50aa00e349066ee18cd513792e3abecb13b2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04a9b834-4bf4-4a4f-a360-4514a947785b", "node_type": "1", "metadata": {}, "hash": "c3acf546723a82e20188df4004c3d9a4cceb944c6fc3b3a8d6df912b8595d42e", "class_name": "RelatedNodeInfo"}}, "text": "First stop severe external and extremity hemorrhage with extremity tourniquets or appropriate wound packing with hemostatic gauze. Be sure to roll patient and examine the back as well. [See Extremity Trauma/External Hemorrhage Management Guideline]|\n|---|---|\n| |b. Utilize junctional tourniquets if needed for junctional area hemorrhage|\n|2. Airway|a. If impending airway obstruction or altered mental status resulting in inability to maintain airway patency, immediately ensure patent airway. [See Airway Management Guideline and Spinal Care Guideline]|\n| |b. Consider airway adjuncts as appropriate avoiding nasal airway adjuncts in patents with oral or other facial injuries. [See Airway Management Guideline]|\n|3. Respiratory/Breathing|a. If absent or diminished breath sounds in a hypotensive trauma patient, especially those with chest trauma and/or tracheal deviation, consider tension pneumothorax and perform needle decompression of side without breath sounds or side opposite tracheal deviation; may need second or third needle decompression on same side if there is a rush of air but patient again has symptoms|\n| |b. For open chest wound, place semi-occlusive dressing|\n| |c. Monitor oxygen saturation (SpO2) and, if indicated, provide supplemental oxygen to maintain SPO2 greater than 94% and respiratory support if needed. [See Respiratory Section]|\n|4. Circulation|a. If pelvis is unstable, place pelvic binder or sheet to stabilize pelvis|\n| |b. Establish IV access if needed (large bore preferred)|\n| |c. Fluid resuscitation|\n| |i. Adults|\n| |1. If SBP greater than 90 mmHg and heart rate less than 120 BPM, no IV fluids required|\n| |2. If SBP less than 90 mmHg or HR greater than 120 BPM, initiate resuscitation:|\n| |a. Blood products are recommended if available|\n| |b. If blood products not available, consider 500 mL bolus of IV fluid, repeat as needed for persistent signs and symptoms of shock|\n| |i. If signs and symptoms of shock persist after a total of 2 L crystalloid bolus, contact online medical direction|\n\n________________________\n\nGo To TOC\n\nTrauma\n\nRev. March 2022\n\nGeneral Trauma Management\n\n209\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## General Trauma Management\n\nc. Trauma resuscitation target SBP 90 mmHg (palpable radial pulse or alert mental status)\n\nd. Reassess SBP after bolus given\n\nHead injury: target SBP greater than 110 mmHg. Hypotension should be avoided to maintain cerebral perfusion\n\n### Pediatrics\n\nIf patient demonstrates tachycardia for age with signs of poor perfusion (low BP, greater than 2-second capillary refill, altered mental status, hypoxia, weak pulses, pallor, or mottled/cool skin), give 20 mL/kg crystalloid bolus and reassess. Repeat as needed for persistent signs and symptoms of shock\n\nIf signs and symptoms of shock persist after a total of 60 mL/kg crystalloid bolus, contact online medical direction\n\nTarget normal BP for age [See Appendix VIII. Abnormal Vital Signs]\n\nBlood product administration may be considered based on local availability and protocols\n\nTranexamic acid (TXA) administration may be considered within three hours of injury and signs of hemorrhagic shock\n\n### Disability/Head/Hypothermia\n\nIf clinical signs of traumatic brain injury [See Head Injury Guideline]\n\nAvoid/treat hypothermia\n\nRemove wet clothing\n\nCover patient to warm and/or prevent further heat loss\n\nNOTE: Patients with major hemorrhage, hemodynamic instability, penetrating torso trauma, or signs of traumatic brain injury often require rapid surgical intervention.", "start_char_idx": 484940, "end_char_idx": 488490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04a9b834-4bf4-4a4f-a360-4514a947785b": {"__data__": {"id_": "04a9b834-4bf4-4a4f-a360-4514a947785b", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9887439d-a408-4ca3-8fcb-1c8234128c66", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "efad0274219a90704bb2529c038c9e42ed42bda15599fc4b11d9992b4264aaaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3bb362e-b548-4a6b-b0ee-36cca203cbce", "node_type": "1", "metadata": {}, "hash": "a2c71b5de207eceb2174686b897489fc51657ff1a03ed856f574a0ae02cc7e6e", "class_name": "RelatedNodeInfo"}}, "text": "Repeat as needed for persistent signs and symptoms of shock\n\nIf signs and symptoms of shock persist after a total of 60 mL/kg crystalloid bolus, contact online medical direction\n\nTarget normal BP for age [See Appendix VIII. Abnormal Vital Signs]\n\nBlood product administration may be considered based on local availability and protocols\n\nTranexamic acid (TXA) administration may be considered within three hours of injury and signs of hemorrhagic shock\n\n### Disability/Head/Hypothermia\n\nIf clinical signs of traumatic brain injury [See Head Injury Guideline]\n\nAvoid/treat hypothermia\n\nRemove wet clothing\n\nCover patient to warm and/or prevent further heat loss\n\nNOTE: Patients with major hemorrhage, hemodynamic instability, penetrating torso trauma, or signs of traumatic brain injury often require rapid surgical intervention. Minimize scene time (goal is under 10 minutes) and initiate rapid transport to the highest level of care within the trauma system\n\nRepeat primary assessment or secondary assessment should be conducted en route to the trauma center\n\nDecisions regarding transport destination should be based on the ACS-COT 2022 National Guideline for the Field Triage of Injured Patients\n\n## Secondary Assessment, Treatment, and Interventions\n\nAssessment\n\nObtain medical history from patient or family including:\n\nAllergies\n\nMedications\n\nPast medical and surgical history\n\nLast meal\n\nEvents leading up to the injury\n\nSecondary survey: Head to toe physical exam including re-assessment of interventions from primary survey\n\n### Head/Face\n\nPalpate head and scalp and face and evaluate for soft tissue injury or bony crepitus indicating injury to skull or facial bones\n\nAssess for globe injury and subjective change in vision\n\nSee Facial/Dental Trauma Guideline\n\n### Neck\n\nCheck for:\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\na. Contusions\n\nb. Abrasions\n\nc. Hematomas\n\nd. Jugular vein distention (JVD)\n\ne. Tracheal deviation\n\n2. Palpate for crepitus\n\n3. Spinal assessment per Spinal Care Guideline\n\nii. Chest \u2013 See Initial Treatment\n\n1. Palpate for instability/crepitus\n\n2. Listen to breath sounds\n\n3. Inspect for penetrating or soft tissue injuries\n\niii. Abdomen\n\n1. Palpate for tenderness\n\n2. Inspect for penetrating or soft tissue injuries\n\n3. Cover eviscerated abdominal contents with moist dressings\n\niv. Pelvis\n\n1. Inspect for penetrating or soft tissue injuries\n\n2. Palpate once for instability by applying medial pressure on the iliac crests bilaterally\n\nv. Back\n\n1. Maintain spinal alignment. Refer to Spinal Care Guideline\n\n2. Inspect for penetrating or soft tissue injuries\n\nvi. Neurologic status assessment [See Appendix VII. Neurologic Status Assessment]\n\n1. Serial assessment of mental status\n\n2. Gross exam of motor strength and sensation in all four extremities\n\nvii. Extremities\n\n1. Assess for fracture/deformity \u2013 See Extremity Trauma/External Hemorrhage Management Guideline\n\n2. Assess peripheral pulses/capillary refill\n\nc. Additional treatment considerations\n\ni. Maintain spine precautions per the Spinal Care Guideline\n\nii. Splint obvious extremity fractures per the Extremity Trauma/External Hemorrhage Management Guideline\n\niii. Provide pain medication per the Pain Management Guideline\n\n## Patient Safety Considerations\n\n1. Life-threatening injuries identified on primary survey should be mitigated immediately with rapid transport to a\ntrauma center\n\n2. Monitor patient for deterioration over time with serial vital signs (pulse, blood pressure, respiratory rate,\nneurologic status assessment) and repeat neurologic status assessment [See Appendix VII. Neurologic Status\nAssessment]\n\na. Patients with compensated shock may not manifest hypotension until severe blood loss has occurred\n\nb. Patients with traumatic brain injury may deteriorate as intracranial swelling and hemorrhage increase. [See Head\nInjury Guideline]\n\n3. Anticipate potential for progressive airway compromise in patients with trauma to head and neck\n\nGo To TOC\n\n### Trauma Rev.", "start_char_idx": 487663, "end_char_idx": 491667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3bb362e-b548-4a6b-b0ee-36cca203cbce": {"__data__": {"id_": "f3bb362e-b548-4a6b-b0ee-36cca203cbce", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04a9b834-4bf4-4a4f-a360-4514a947785b", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "834f59813af23765b44d02a070d348e07749d5bedb2af235e750dbf62da4ba6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50e1fbc6-ce92-4407-b3ee-1236bf051cb6", "node_type": "1", "metadata": {}, "hash": "6246ed398be11235fc7b0c56fc9c2cdebdb496fd4435bb68e9af742136fabe1f", "class_name": "RelatedNodeInfo"}}, "text": "Splint obvious extremity fractures per the Extremity Trauma/External Hemorrhage Management Guideline\n\niii. Provide pain medication per the Pain Management Guideline\n\n## Patient Safety Considerations\n\n1. Life-threatening injuries identified on primary survey should be mitigated immediately with rapid transport to a\ntrauma center\n\n2. Monitor patient for deterioration over time with serial vital signs (pulse, blood pressure, respiratory rate,\nneurologic status assessment) and repeat neurologic status assessment [See Appendix VII. Neurologic Status\nAssessment]\n\na. Patients with compensated shock may not manifest hypotension until severe blood loss has occurred\n\nb. Patients with traumatic brain injury may deteriorate as intracranial swelling and hemorrhage increase. [See Head\nInjury Guideline]\n\n3. Anticipate potential for progressive airway compromise in patients with trauma to head and neck\n\nGo To TOC\n\n### Trauma Rev. March 2022 General Trauma Management 211\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Notes/Educational Pearls\n\nKey Considerations\n\nOptimal trauma care requires a structured approach to the patient emphasizing first control of massive hemorrhage using MARCH (Massive hemorrhage, Airway, Respiratory/Breathing, Circulation, Head injury/Hypothermia)\nTarget scene time less than 10 minutes for unstable patients or those likely to need surgical intervention\nClinician training should include the ACS-COT 2022 National Guideline for the Field Triage of Injured Patients\nFrequent reassessment of the patient is important\n\nIf patient develops difficulty with ventilation, reassess breath sounds for development of tension pneumothorax\nIf extremity hemorrhage is controlled with pressure dressing or tourniquet, reassess for evidence of continued hemorrhage\nIf mental status declines, reassess ABCs (Airway, Breathing, Circulation) and repeat neurologic status assessment [See Appendix VII. Neurologic Status Assessment]\n\nUse structured communication tool for patient handoff to higher level care such as AT-MIST\n\nAge\nTime of incident or onset of symptoms\nMechanism\nInjuries noted\nSymptoms/Signs\nTreatments provided\n\n## Traumatic Arrest: Withholding and Termination of Resuscitative Efforts\n\nResuscitative efforts should be withheld for trauma patients with the following:\n\nDecapitation\nHemicorpectomy\nSigns of rigor mortis or dependent lividity\nBlunt trauma: apneic, pulseless, no organized cardiac activity on monitor\n\nNote \u2013 Adult and Pediatric: Resuscitative efforts may be terminated in patients with traumatic arrest who have no return of spontaneous circulation after 15\u201330 minutes of resuscitative efforts, including airway management, evaluation/treatment for possible tension pneumothorax, fluid bolus, and minimally interrupted CPR\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914207 \u2013 Injury - General Trauma Management\n\n## Key Documentation Elements\n\nMechanism of injury\nPrimary and secondary survey\nSerial vital signs including neurologic status assessments\nScene time\nProcedures performed and patient response\n\n________________________Go To TOC\n\n## Trauma\n\nRev. March 2022\n\n## General Trauma Management\n\n212\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Performance Measures\n\nMonitor scene time for unstable patients\nMonitor appropriateness of procedures\nMonitor appropriate airway management\n\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nPediatrics\u201403: Documentation of Estimated Weight in Kilograms\nTrauma\u201401: Pain Assessment of Injured Patients\n\n## References\n\nAmerican College of Surgeons Committee on Trauma; American College of Emergency Physicians Pediatric Emergency\nMedicine Committee; National Association of EMS Physicians; American Academy of Pediatrics Committee on Pediatric\nEmergency Medicine, Fallat ME. Withholding, or termination of resuscitation in pediatric out-of-hospital traumatic\ncardiopulmonary arrest. Pediatrics. 2014;133(4): e1104.\nBickell WH, Wall MJ Jr., Pepe PE, et al. Immediate versus delayed fluid resuscitation for hypotensive patients\nwith penetrating torso injuries. N Engl J Med. 1994; 331:1105\u20139\nCullinane DC, Schiller HJ, Zielinski MD, et al. Eastern Association for the Surgery of Trauma practice management\nguidelines for hemorrhage in pelvic fracture \u2013 update and systematic review. J Trauma.", "start_char_idx": 490740, "end_char_idx": 495216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50e1fbc6-ce92-4407-b3ee-1236bf051cb6": {"__data__": {"id_": "50e1fbc6-ce92-4407-b3ee-1236bf051cb6", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3bb362e-b548-4a6b-b0ee-36cca203cbce", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "65beea76856b542a0742d7924c251a0c912ba1682b29584f58c570fc756d2fc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "713c32b8-2196-49a5-9a53-ca53a0676fde", "node_type": "1", "metadata": {}, "hash": "2a7535b8b99e2f3333a38c94efd0af7ecce45d780cdba8b96ea21bf35be5296a", "class_name": "RelatedNodeInfo"}}, "text": "Withholding, or termination of resuscitation in pediatric out-of-hospital traumatic\ncardiopulmonary arrest. Pediatrics. 2014;133(4): e1104.\nBickell WH, Wall MJ Jr., Pepe PE, et al. Immediate versus delayed fluid resuscitation for hypotensive patients\nwith penetrating torso injuries. N Engl J Med. 1994; 331:1105\u20139\nCullinane DC, Schiller HJ, Zielinski MD, et al. Eastern Association for the Surgery of Trauma practice management\nguidelines for hemorrhage in pelvic fracture \u2013 update and systematic review. J Trauma. 2011;71(6):1850\u201368\nDeakin CD et al. Accuracy of the Advanced Trauma Life Support Guidelines for Predicting Systolic Blood Pressure\nUsing Carotid, Femoral, and radial Pulses: Observational Study. BMJ 2000. PMID: 10987771\nGuidelines for the Field Triage of Injured Patients: Recommendations of the National Expert Panel on Field Triage,\n2011. Washington, DC: Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report;\n2012;61(RR01):1\u201320\nGuidelines for the Management of Severe Traumatic Brain Injury, 4th Edition. Brain Trauma Foundation, September\n2016. Available at https://braintrauma.org/guidelines/guidelines-for-the-management-of-severe-tbi-4th-ed#.\nAccessed March 11, 2022\nJason F Naylor, SP, Andrew D Fisher, SP, Michael D April, MC, Steven G Schauer, MC, An analysis of radial pulse\nstrength to recorded blood pressure in the Department of Defense Trauma Registry, Military Medicine,\n2020:185(11-12):e1903\u2013e1907, https://doi.org/10.1093/milmed/usaa197\nMillin M, Galvagno SM, Khandker SR, et al. Withholding and termination of resuscitation of adult cardiopulmonary\narrest secondary to trauma: Resource document to the joint NAEMSP-ACS (COT) position statements. J Trauma Acute\nCare Surg. 2013;75(3):459\u201367\nMorrison C, Carrick M, Norman M, et al. Hypotensive resuscitation strategy reduces transfusion requirements and\nsever postoperative coagulopathy in trauma patients with hemorrhagic shock: preliminary results of a randomized\ncontrolled trial. J Trauma. 2011;70(3):652\u201363\nPrehospital Trauma Life Support, 9th Edition. Burlington, MA: Jones & Bartlett; 2020\nPoulton TJ et al. ATLS Paradigm Fails. Ann Emerg Med 1988. PMID: 3337405\nSpaite DW, Bobrow BJ, Keim SM, et al. Association of Statewide Implementation of the Prehospital Traumatic Brain\nInjury Treatment Guidelines With Patient Survival Following Traumatic Brain Injury. The Excellence in Prehospital\nInjury Care (EPIC) Study. JAMA Surg. 2019;154(7): e191152\n\n________________________ Go To TOC\n\n### Trauma Rev. March 2022 General Trauma Management 213\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n13. Tactical Combat Casualty Care (TCCC) Guidelines for Medical Personnel, 05 November 2020. Available at\nhttps://deployedmedicine.com/content/40. Accessed March 11, 2022\n\n14. Tactical Emergency Casualty Care (TECC) Guidelines for BLS/ALS Medical Providers. Current as of March 2019.\nAvailable at https://www.c-tecc.org/images/4-2019_TECC_ALS_BLS_Guidelines_.pdf.\nAccessed March 11, 2022\n\n15. The CRASH-2 Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion\nin trauma patients with significant hemorrhage (CRASH-2): a randomized, placebo-controlled trial. Lancet. 2010;\n376:23\u201332\n\n16. Topijian et al. Part 4: Pediatric Basic and Advanced Life Support: 2020 American Heart Association Guidelines for\nCardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation.", "start_char_idx": 494701, "end_char_idx": 498162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "713c32b8-2196-49a5-9a53-ca53a0676fde": {"__data__": {"id_": "713c32b8-2196-49a5-9a53-ca53a0676fde", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50e1fbc6-ce92-4407-b3ee-1236bf051cb6", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "b3e902e9d81e889e7f552a8d9ddc95d8a7286abd7102c5b9f73c07ad462ea299", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "255105fb-6aef-4034-b7c8-19428baa2b26", "node_type": "1", "metadata": {}, "hash": "e48923c2e8334c2e004dafc40e4ccfad9be108111dfd3018e0e312b5c9ea72a9", "class_name": "RelatedNodeInfo"}}, "text": "Accessed March 11, 2022\n\n14. Tactical Emergency Casualty Care (TECC) Guidelines for BLS/ALS Medical Providers. Current as of March 2019.\nAvailable at https://www.c-tecc.org/images/4-2019_TECC_ALS_BLS_Guidelines_.pdf.\nAccessed March 11, 2022\n\n15. The CRASH-2 Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion\nin trauma patients with significant hemorrhage (CRASH-2): a randomized, placebo-controlled trial. Lancet. 2010;\n376:23\u201332\n\n16. Topijian et al. Part 4: Pediatric Basic and Advanced Life Support: 2020 American Heart Association Guidelines for\nCardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020;142: S469\u2013S523\n\n17. Truhlar A, Deakin C, Soar J, et al. European resuscitation council guidelines for resuscitation 2015: section 4.\nCardiac arrest in special circumstances. Resuscitation. 2015; 95:148\u2013201\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\n## Trauma\n\n### General Trauma Management\n\n214\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Blast Injuries\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nMaintain patient and clinician safety by identifying ongoing threats at the scene of an explosion\n\nIdentify multi-system injuries which may result from a blast, including possible toxic contamination\n\nPrioritize treatment of multi-system injuries to minimize patient morbidity\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nPatients exposed to explosive force. Injuries may include any or all the following:\n\nBlunt trauma\nPenetrating trauma\nBurns\nPressure-related injuries (barotrauma)\nToxic chemical contamination\nChemical, biological, radiological, nuclear, and explosive devices, or agents\n\n#### Exclusion Criteria\n\nNone noted\n\n### Patient Management\n\n#### Assessment\n\nHemorrhage Control\n\nAssess for and stop severe hemorrhage [See Extremity Trauma/External Hemorrhage Management Guideline]\n\nAirway\n\nAssess airway patency\nConsider possible thermal or chemical burns to the airway\n\nBreathing\n\nEvaluate the adequacy of respiratory effort, oxygenation, quality of lung sounds, and chest wall integrity\nConsider possible pneumothorax or tension pneumothorax (because of penetrating/blunt trauma or barotrauma)\nContinually reassess for blast lung injury\n\nCirculation\n\nLook for evidence of hemorrhage\nAssess BP, pulse, skin color/character, and distal capillary refill for signs of shock\n\nDisability\n\nAssess patient responsiveness (e.g., AVPU) and level of consciousness (e.g., GCS) [See Appendix VII: Neurologic Status Assessment]\nAssess pupils\nAssess gross motor movement of extremities\n\n________________________\n\nGo To TOC\n\n### Trauma\n\nRev. March 2022\n\n### Blast Injuries\n\n215\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Exposure\n\nRapid evaluation of entire skin surface, including back (log roll), to identify blunt or penetrating injuries\n\n## Treatment and Interventions\n\n### Hemorrhage control:\n\nControl any severe external hemorrhage [See Extremity Trauma/External Hemorrhage Management Guideline]\n\n### Airway:\n\na. If thermal or chemical burn to the airway is suspected, early airway management is vital\n\nb. Secure airway, utilizing airway maneuvers, airway adjuncts, supraglottic device, or endotracheal tube [See Airway\nManagement Guideline]\n\n### Breathing:\n\na. Administer oxygen as appropriate with a target of achieving 94\u201398% saturation.\n\nb. Assist respirations as needed\n\nc. Cover any open chest wounds with a semi-occlusive dressing\n\nd. If the patient has evidence of tension pneumothorax, perform needle decompression\n\n### Circulation:\n\na. Establish IV access with two large bore IVs or IOs\n\ni. Administer resuscitative fluids, per the General Trauma Management Guideline\n\nii.", "start_char_idx": 497485, "end_char_idx": 501231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "255105fb-6aef-4034-b7c8-19428baa2b26": {"__data__": {"id_": "255105fb-6aef-4034-b7c8-19428baa2b26", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "713c32b8-2196-49a5-9a53-ca53a0676fde", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "dec1ff1a94090337e6d254aca165fc04deff02efbdabeb0910d5bed423e6afcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ef969b0-03f1-469f-8653-e2cbc4668112", "node_type": "1", "metadata": {}, "hash": "40661296d973e6a583215cba437d5171740213ae7515783b39a20287d0c7456c", "class_name": "RelatedNodeInfo"}}, "text": "b. Assist respirations as needed\n\nc. Cover any open chest wounds with a semi-occlusive dressing\n\nd. If the patient has evidence of tension pneumothorax, perform needle decompression\n\n### Circulation:\n\na. Establish IV access with two large bore IVs or IOs\n\ni. Administer resuscitative fluids, per the General Trauma Management Guideline\n\nii. If the patient is burned, administer normal saline (NS) or lactated Ringer\u2019s (LR) per the Burns Guideline\n\n### Disability:\n\na. If evidence of head injury, treat per the Head Injury Guideline\n\nb. Apply spinal precautions, per the Spinal Care Guideline\n\nc. Monitor GCS during transport to assess for changes\n\n### Exposure:\n\na. Keep patient warm to prevent hypothermia\n\n## Patient Safety Considerations\n\n### Ensuring scene safety is especially important at the scene of an explosion\n\na. Always consider the possibility of subsequent explosions\n\nb. Structural safety, possible toxic chemical contamination, the presence of poisonous gasses, and other hazards\nmight cause a delay in patient extraction\n\n### Remove patient from the scene as soon as is practical and safe\n\n### If the patient has sustained burns (thermal, chemical, or airway), consider transport to a specialized burn\ncenter\n\n## Notes/Educational Pearls\n\n### Key Considerations\n\nScene safety is of paramount importance when responding to an explosion or blast injury\nPatients sustaining blast injury may sustain complex, multi-system injuries, including blunt and penetrating trauma,\nshrapnel, barotrauma, burns, and toxic chemical exposure\nConsideration of airway injury, particularly airway burns, should prompt early and aggressive airway management\nMinimize IV fluid resuscitation in patients without signs of shock. Consider injuries due to barotrauma\n\n________________________ Go To TOC\n\nTrauma Rev. March 2022 Blast Injuries 216\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\na. Tension pneumothorax\n\ni. Hypotension or other signs of shock associated with decreased or absent breath sounds, jugular venous distension, and/or tracheal deviation\n\nb. Tympanic membrane perforation resulting in deafness which may complicate the evaluation of their mental status and their ability to follow commands\n\n5. Primary transport to a trauma or burn center is preferable, whenever possible\n\n## Pertinent Assessment Findings\n\n1. Evidence of multi-system trauma, especially:\n\na. Airway injury/burn\n\nb. Barotrauma to lungs\n\nc. Toxic chemical contamination\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n\u2022 9914045 \u2013 Exposure - Explosive/Blast Injury\n\nKey Documentation Elements\n\n\u2022 Airway status and intervention\n\n\u2022 Breathing status:\n\no Quality of breath sounds (equal bilaterally)\n\no Adequacy of respiratory effort\n\no Oxygenation\n\n\u2022 Documentation of burns, including Total Burn Surface Area (TBSA) [See Burns Guideline]\n\n\u2022 Documentation of possible toxic chemical contamination\n\n## Performance Measures\n\n\u2022 Airway assessment and early and aggressive management\n\n\u2022 Appropriate IV fluid management\n\n\u2022 Transport to trauma or burn center\n\n\u2022 National EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\no Pediatrics\u201403: Documentation of Estimated Weight in Kilograms\n\no Trauma\u201401: Pain Assessment of Injured Patients\n\n## References\n\n1. Explosions and Blast Injuries; A Primer for Clinicians. CDC.gov.\n\nwww.cdc.gov/masstrauma/preparedness/primer.pdf. Accessed March 11, 2022\n\n2. Mathews ZR, Koyfman A. Blast Injuries. J Emerg Med. 2015 Oct;49(4):573\u201387. doi: 10.1016/j.jemermed.2015.03.013. Epub 2015 Jun 10. PMID: 26072319.\n\n3. Plurad DS. Blast injury. Mil Med. 2011 Mar;176(3):276\u201382. doi: 10.7205/milmed-d-10-00147. PMID: 21456353.\n\nRevision Date\n\nMarch 11, 2022\n\n________________________ Go To TOC\n\nTrauma Rev.", "start_char_idx": 500891, "end_char_idx": 504733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ef969b0-03f1-469f-8653-e2cbc4668112": {"__data__": {"id_": "4ef969b0-03f1-469f-8653-e2cbc4668112", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "255105fb-6aef-4034-b7c8-19428baa2b26", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "57e0197d84c32527f47a6914c80864b85f562da4dfa74378ff728508f3f318fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a4812e1-28d6-468f-86ac-8ce53cebd625", "node_type": "1", "metadata": {}, "hash": "53cc7cccd301a8f1e7bc5fac5a007d63cc77b58e0747f32c12a1db168e44549d", "class_name": "RelatedNodeInfo"}}, "text": "Explosions and Blast Injuries; A Primer for Clinicians. CDC.gov.\n\nwww.cdc.gov/masstrauma/preparedness/primer.pdf. Accessed March 11, 2022\n\n2. Mathews ZR, Koyfman A. Blast Injuries. J Emerg Med. 2015 Oct;49(4):573\u201387. doi: 10.1016/j.jemermed.2015.03.013. Epub 2015 Jun 10. PMID: 26072319.\n\n3. Plurad DS. Blast injury. Mil Med. 2011 Mar;176(3):276\u201382. doi: 10.7205/milmed-d-10-00147. PMID: 21456353.\n\nRevision Date\n\nMarch 11, 2022\n\n________________________ Go To TOC\n\nTrauma Rev. March 2022 Blast Injuries 217\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Burns\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nMinimize tissue damage and patient morbidity from burns\n\n### Patient Presentation\n\nPatient may present with:\n\na. Airway \u2013 stridor, hoarse voice\nb. Mouth and nares \u2013 redness, blisters, soot, singed hairs\nc. Breathing \u2013 rapid, shallow, wheezes, rales\nd. Skin \u2013 Estimate Total Burn Surface Area (TBSA) and depth (partial vs. full thickness)\ne. Associated trauma \u2013 blast, fall, assault\n\n### Inclusion Criteria\n\nPatients sustaining thermal burns\n\n### Exclusion Criteria\n\nElectrical, chemical, and radiation burns [See Toxins and Environmental Section]\n\n### Special Transport Considerations\n\nTransport to most appropriate trauma center when there is airway or respiratory involvement, or when significant\ntrauma or blast injury is suspected\nConsider air ambulance transportation for long transport times or airway management needs beyond the scope of the\nresponding ground medic\nConsider transport directly to burn center if partial or full thickness burns (TBSA) greater than 10% and/or\ninvolvement of hands/feet, genitalia, face, and/or circumferential burns\n\n### Scene Management\n\nAssure crew safety:\n\na. Power off\nb. Electrical lines secure\nc. Gas off\nd. No secondary devices\ne. Hazmat determinations made\nf. Proper protective attire including breathing apparatus may be required\n\n### Patient Management\n\n#### Assessment\n\nCircumstances of event \u2013 Consider:\n\na. Related trauma in addition to the burns\nb. Inhalation exposures such as carbon monoxide (CO) and cyanide (CN)\nc. Pediatric or elder abuse\n\n________________________\n\nGo To TOC\n\n## Trauma\n\nRev. March 2022\n\n## Burns\n\n218\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Trauma\n\n### Burns\n\nRev. March 2022\n\n219\n\n## Treatments and Interventions\n\nStop the burning\n\nRemove wet clothing (if not stuck to the patient)\nRemove jewelry\nLeave blisters intact\n\nMinimize burn wound contamination\n\nCover burns with dry dressing or clean sheet\nDo not apply gels or ointments\n\nMonitor SPO2, EtCO2 and cardiac monitor\nHigh flow supplemental oxygen for all burn patients rescued from an enclosed space\nEstablish IV access, avoid placement through burned skin\nEvaluate respiratory status in patients with circumferential thoracic burns due to the risk for ventilatory\ncompromise and potential need for escharotomy\nEvaluate distal circulation in circumferentially burned extremities due to increased risk of circulatory compromise\nand potential need for escharotomy\nConsider early management of pain and nausea/vomiting\nInitiate fluid resuscitation \u2013 Use lactated Ringer\u2019s or normal saline\n\nIf patient in shock:\n\nConsider other cause, such as trauma or cyanide toxicity\nAdminister IV fluid per the Shock Guideline\n\nIf patient not in shock:\n\nBegin fluids based on estimated TBSA [See Appendix VI.", "start_char_idx": 504256, "end_char_idx": 507672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a4812e1-28d6-468f-86ac-8ce53cebd625": {"__data__": {"id_": "1a4812e1-28d6-468f-86ac-8ce53cebd625", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ef969b0-03f1-469f-8653-e2cbc4668112", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "190873e9177d97ebee39f7a5d064b6a9049496b6d001a1edbed5824a1b7e4ab9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14b7a12a-641e-4648-9dca-60a535a97025", "node_type": "1", "metadata": {}, "hash": "d111b5229f705587ede9fa5150bcd34593f3809e9fcb61ab36d087f1a0dece3a", "class_name": "RelatedNodeInfo"}}, "text": "Burn and Burn Fluid Charts as appropriate to patient\nweight]\nPediatric patients weighing less than 40 kg, use length-based tape for weight estimate and follow\nFor persons over 40 kg, the initial fluid rate can also be calculated using the \u201cRule of 10\u201d:\n\nCalculate the TBSA (round to nearest 10%)\nMultiply TBSA x 10 = initial fluid rate (mL/hr) {for persons between 40\u201380 kg}\nAdd 100 mL/hr for every 10 kg of body weight over 80 kg\n\nPrevent systemic heat loss and keep the patient warm\n\n## Special Treatment Considerations\n\nIf blast mechanism, treat per the Blast Injury Guideline\nAirway burns can rapidly lead to upper airway obstruction and respiratory failure. After performing the appropriate\nairway management measures, the administration of nebulized epinephrine, bronchodilators, nebulized n-acetylcystine,\nand nebulized heparin, if available, can be considered to reduce edema of the laryngeal and pulmonary tissues and\nairway occlusion from secretions and blood.\n\n________________________\n\nGo To TOC\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n3. Have a high index of suspicion for cyanide poisoning in a patient with depressed GCS, respiratory difficulty, and cardiovascular collapse in the setting of an enclosed-space fire. Give the antidote (hydroxocobalamin), if available, in this circumstance\n\n4. Particularly in enclosed-space fires, carbon monoxide toxicity is a consideration and pulse oximetry may not be accurate [See Carbon Monoxide/Smoke Inhalation Guideline]\n\n5. For specific chemical exposures (cyanide, hydrofluoric acid, other acids, and alkali) [See Topical Chemical Burn Guideline]\n\n6. Consider decontamination and notification of receiving facility of potentially contaminated patient (e.g., methamphetamine (meth) lab incident)\n\n7. Burns that involve significant sloughing or loss of skin can result in uncontrolled heat loss. These patients should be monitored closely for the development of hypothermia and appropriate preventative measures should be taken\n\n## Notes/Educational Pearls\n\n1. Onset of stridor and change in voice are sentinel signs of potentially significant airway burns, which may rapidly lead to airway obstruction or respiratory failure.\n\n2. If the patient is in shock within one hour of burn, it is not from the burn. Evaluate the patient carefully for associated trauma or cyanide toxicity.\n\n3. If the patient is not in shock, the fluid rates recommended above will adequately maintain patient\u2019s fluid volume.\n\n4. Pain management is critical in acute burns.\n\n5. End-tidal capnography (EtCO2) monitoring may be particularly useful to monitor respiratory status in patients receiving significant doses of narcotic pain medication.\n\n6. Cardiac monitor is important in electrical burns and chemical inhalations.\n\n7. TBSA is calculated only based on percent of second- and third-degree burns \u2013 First degree/superficial burns are not included in this calculation\n\n## Quality Improvement\n\nBurn trauma is relatively uncommon. Clinicians should receive regular training on burn assessment and management.\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914085 \u2013 Injury - Burns-Thermal\n\n## Key Documentation Elements\n\nInitial airway status\nTotal volume of fluid administered\nBody surface area of second- and third-degree burns (TBSA)\nPulse and capillary refill exam distally on any circumferentially burned extremity\nPain scale documentation and pain management\n\n## Performance Measures\n\nPatient transported to most appropriate hospital, preferably a burn center\nPain scale documented and pain appropriately managed\nAirway assessment and management appropriately documented\n\n________________________ Go To TOC\n\nTrauma Rev. March 2022\n\nBurns 220\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nPediatrics\u201403: Documentation of Estimated Weight in Kilograms\nTrauma\u201401: Pain Assessment of Injured Patients\n\nReferences\n\nAmerican Burn Association. Advanced Burn Life Support (ABLS) Handbook; 2011\nChung K, Salinas J, Renz E, et al. Simple derivation of the initial fluid rate for the resuscitation of severely\nburned adult combat casualties: in Silico validation of the rule of ten. J Trauma. 2010;69 Suppl 1: S49\u201354\nDries DJ, Endorf FW.", "start_char_idx": 507673, "end_char_idx": 512055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14b7a12a-641e-4648-9dca-60a535a97025": {"__data__": {"id_": "14b7a12a-641e-4648-9dca-60a535a97025", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a4812e1-28d6-468f-86ac-8ce53cebd625", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "70adaabd78ef478af8bb56ac3f71c5e1d654973f48c3e9f38a0b2288582e3a12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3d574ea-c88e-4e89-a6d1-e85ac3587dfb", "node_type": "1", "metadata": {}, "hash": "1816fd85ac5ec7eea90ef8bb8002644308545e1f66b650ae74eb8cf5a6d71a72", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nBurns 220\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nPediatrics\u201403: Documentation of Estimated Weight in Kilograms\nTrauma\u201401: Pain Assessment of Injured Patients\n\nReferences\n\nAmerican Burn Association. Advanced Burn Life Support (ABLS) Handbook; 2011\nChung K, Salinas J, Renz E, et al. Simple derivation of the initial fluid rate for the resuscitation of severely\nburned adult combat casualties: in Silico validation of the rule of ten. J Trauma. 2010;69 Suppl 1: S49\u201354\nDries DJ, Endorf FW. Inhalation injury: epidemiology, pathology, treatment strategies. Scand J Trauma Resusc\nEmerg Med. 2013; 21:31\nEndorf FW, Gamelli RL. Inhalation injury, pulmonary perturbations, and fluid resuscitation. J Burn Care Res.\n2007; 28(1):80-83\nFluid Rate charts (based on Parkland formula) and TBSA diagrams courtesy of the University of Utah Burn Center;\n2014. As presented in Appendix VI. Burn and Burn Fluid Charts\nHettiaratchy S, Papini R. Initial management of a major burn: II\u2014 assessment and resuscitation. BMJ.\n2004;329(7457):101\u2013103. doi:10.1136/bmj.329.7457.101\nMcIntire AM, Harris SA, Whitten JA, et al. Outcomes Following the Use of Nebulized Heparin for Inhalation\nInjury (HIHI Study). J Burn Care Res 2017; 38:45-52\nMiller AC. Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke\ninhalation injury. J Burn Care Res. 2009; 30:249\u2013256\n\nRevision Date\n\nMarch 11, 2022\n\nGo To TOC\n\nTrauma\n\nRev. March 2022\n\nBurns\n\n221\n---\n# Crush Injury/Crush Syndrome\n\n## Aliases\n\nCompartment syndrome, Crush\n\n## Patient Care Goals\n\nRecognizing traumatic crush injury mechanism\nMinimize systemic effects such as rhabdomyolysis, hyperkalemia, acute kidney injury\n\n## Patient Presentation\n\n### Inclusion criteria\n\nTraumatic crush mechanism of injury\n\nNon-traumatic injuries that may cause compartment syndrome include prolonged immobilization, prolonged compression\nof the torso/limbs, electrical injury, or burns\n\n### Exclusion criteria\n\nNone noted\n\n## Patient Management\n\n### Assessment\n\nIdentify any severe hemorrhage\nAssess airway, breathing, and circulation\nEvaluate for possible concomitant injury (e.g., fractures, solid organ damage, or spinal injury)\nMonitor for development of compartment syndrome (pain out of proportion to clinical exam, tense swelling, pain\nwith passive stretch, muscle weakness, absent pulses, parasthesias)\n\n### Treatment and Interventions\n\nThe treatment of crushed casualties should begin as soon as they are discovered\nIf severe hemorrhage is present, see Extremity Trauma/External Hemorrhage Management Guideline\nEstablish IV access. IV fluids should be administered prior to releasing the crushed body part. Administer 1000 mL\nnormal saline (NS) bolus. Avoid lactated Ringer\u2019s solution as it contains potassium. Crush injury without adequate\nfluid resuscitation develops into crush syndrome\nFor significant crush injuries or prolonged entrapment of an extremity, consider sodium bicarbonate 1 mEq/kg\n(maximum dose of 50 mEq) IV bolus over 5 minutes\nAttach cardiac monitor. Obtain/interpret 12-lead EKG, if available. Carefully monitor for dysrhythmias or signs of\nhyperkalemia before and immediately after release of pressure and during transport (e.g., peaked T waves, wide QRS,\nlengthening QT interval, loss of P wave)\nFor pain control, consider analgesics [See Pain Management Guideline]\nConsider the following post extrication\n\nContinued resuscitation with normal saline (500\u20131000 mL/hr for adults, 10 mL/kg/hr for children)\nIf EKG suggestive of hyperkalemia or if findings of hyperkalemia, administer IV fluids and consider\nadministration of:\n\n________________________\n\nGo To TOC\n\n## Trauma\n\nRev.", "start_char_idx": 511411, "end_char_idx": 515224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3d574ea-c88e-4e89-a6d1-e85ac3587dfb": {"__data__": {"id_": "b3d574ea-c88e-4e89-a6d1-e85ac3587dfb", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14b7a12a-641e-4648-9dca-60a535a97025", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "d18500b488e388c289547e182010f48dbda5562b512b11858a5261fcfffabea4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7dd20e2-c7fa-46fe-9ab0-ef6f2e374f23", "node_type": "1", "metadata": {}, "hash": "b92a91871b72f55f0d68afdcdc7918d67cf6f6360881fc633476a46959000c3f", "class_name": "RelatedNodeInfo"}}, "text": "Obtain/interpret 12-lead EKG, if available. Carefully monitor for dysrhythmias or signs of\nhyperkalemia before and immediately after release of pressure and during transport (e.g., peaked T waves, wide QRS,\nlengthening QT interval, loss of P wave)\nFor pain control, consider analgesics [See Pain Management Guideline]\nConsider the following post extrication\n\nContinued resuscitation with normal saline (500\u20131000 mL/hr for adults, 10 mL/kg/hr for children)\nIf EKG suggestive of hyperkalemia or if findings of hyperkalemia, administer IV fluids and consider\nadministration of:\n\n________________________\n\nGo To TOC\n\n## Trauma\n\nRev. March 2022\n\n## Crush Injury/Crush Syndrome\n\n222\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\ni. Calcium chloride \u2013 1 gm IV/IO over 5 minutes, ensure IV patency and do not exceed 1 mL per minute (Pediatric: 10%\n20 mg/kg, max 1 g, IV.IO over 5 minutes. OR\n\nii. Calcium gluconate \u2013 3 gm IV/IO over 5 minutes with constant cardiac monitoring (Pediatric: 10% 50 mg/kg (0.5 mL/kg),\nmax 2 gram, IV over 5 minutes\n\nc. If not already administered, for significant crush injuries with EKG suggestive of hyperkalemia, administer sodium\nbicarbonate 1 mEq/kg (max dose of 50 mEq) IV bolus over 5 minutes\n\nd. If EKG suggestive of hyperkalemia, consider albuterol 5 mg via small volume nebulizer (can be repeated if no response\nis seen)\n\n### Patient Safety Considerations\n\nScene safety for both rescuers and patients are of paramount importance.\n\n### Notes/Educational Pearls\n\nCauses of mortality in untreated crush syndrome:\n\nImmediate\n\nSevere head injury\nTraumatic asphyxia\nTorso injury with damage to intrathoracic or intra-abdominal organs\n\nEarly\n\nSudden release of a crushed extremity may result in reperfusion syndrome (acute hypovolemia, electrolyte abnormalities,\nand subsequent lethal arrhythmia)\nHyperkalemia (potassium is released from injured muscle cells)\nHypovolemia/shock\n\nLate\n\nAcute kidney injury (from release of toxins from injured muscle cells)\nCoagulopathy and hemorrhage\nSepsis\n\n### Key Considerations\n\nRapid extrication and evacuation to a definitive care facility (trauma center preferred)\nA patient with a crush injury may initially present with very few signs and symptoms. Maintain a high index of suspicion\nfor any patient with a compressive mechanism of injury\nA fatal medical complication of crush syndrome is hyperkalemia. Suspect hyperkalemia if T-waves become peaked, QRS\nbecomes prolonged (greater than 0.12 seconds), absent P wave, prolonged QTc, or sine wave. Continue fluid resuscitation\nthrough extrication and transfer to hospital\n\n### Pertinent Assessment Findings\n\nMental status/Glasgow Coma Scale (GCS)\nEvaluation for fractures and potential compartment syndrome development (neurovascular status of injured extremity)\nExamination of spine\nEvidence of additional trauma, potentially masked by with other painful injuries\n\nGo To TOC\n\nTrauma Rev. March 2022\n\nCrush Injury/Crush Syndrome 223\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914089 \u2013 Injury - Crush Syndrome\n\n### Key Documentation Elements\n\nTime of tourniquet application, if applied\nNeurovascular status of any crushed extremity\nEKG findings consistent with hyperkalemia\nAmount of IV fluid administered\n\n### Performance Measures\n\nInitiation of fluid resuscitation prior to extrication\nEKG/monitor to monitor for dysrhythmias or changes related to hyperkalemia\nTreatment of hyperkalemia if evidence is noted on EKG\n\n### References\n\nBetter OS. The crush syndrome revisited (1940\u20131990). Nephron. 1990; 55:97\u2013103\nJagodzinski N, Weerasinghe C, Porter K. Crush injuries and crush syndrome \u2013 a review. Trauma. 2010; 12:69\u201388\nSever MS, Vanholder R, Lameire N. Management of crush-related injuries after disasters. N Engl J Med.", "start_char_idx": 514596, "end_char_idx": 518522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7dd20e2-c7fa-46fe-9ab0-ef6f2e374f23": {"__data__": {"id_": "b7dd20e2-c7fa-46fe-9ab0-ef6f2e374f23", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3d574ea-c88e-4e89-a6d1-e85ac3587dfb", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "455d07a42961c458db29633677eed40b4a6ad78aef7c279e295c8303b73fcb0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee974b0e-438c-4280-b3e6-ec22c700d4dc", "node_type": "1", "metadata": {}, "hash": "286e0bd7665ce1193cd0e1db4da5389bada31bfab946f1cd23ce9784afdf6dc2", "class_name": "RelatedNodeInfo"}}, "text": "The crush syndrome revisited (1940\u20131990). Nephron. 1990; 55:97\u2013103\nJagodzinski N, Weerasinghe C, Porter K. Crush injuries and crush syndrome \u2013 a review. Trauma. 2010; 12:69\u201388\nSever MS, Vanholder R, Lameire N. Management of crush-related injuries after disasters. N Engl J Med. 2006;354(10):1052\u201363\nSmith J, Greaves I. Crush injury and crush syndrome: a review. J Trauma. 2003;54(5): S226\u201330\n\nRevision Date: March 11, 2022\n\n________________________ Go To TOC\n\nTrauma Rev. March 2022\n\nCrush Injury/Crush Syndrome 224\n---\n# Extremity Trauma/External Hemorrhage Management\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Extremity Trauma/External Hemorrhage Management\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nMinimize blood loss from extremity hemorrhage\nAvoid hemorrhagic shock due to extremity hemorrhage\nMinimize pain and further injury due to fractures, dislocations, or soft-tissue injuries\n\n### Patient Presentation\n\n#### Inclusion Criteria [Refer to Crush Injury and Crush Syndrome Guideline]\n\nTraumatic extremity hemorrhage (external hemorrhage) due to blunt or penetrating injury\nKnown or suspected extremity fractures or dislocations\n\n#### Exclusion Criteria\n\nNone noted\n\n### Patient Management\n\n#### Assessment\n\nAssess degree of extremity/external bleeding/blood loss\nVascular status of extremity:\n\nPallor\nPulse\nCapillary refill and skin temperature\n\nEvaluate for obvious deformity, shortening, rotation, or instability\nNeurologic status of extremity:\n\nSensation to light touch\nDistal movement of extremity\n\n#### Treatments and Interventions\n\nManage bleeding:\n\nExpose the wound and apply direct pressure to bleeding site, followed by a pressure dressing\nIf direct pressure/pressure dressing is ineffective or impractical:\n\nIf the bleeding site is amenable to tourniquet placement, apply a commercial tourniquet to extremity:\n\nTourniquet should be placed 2\u20133 inches proximal to wound, not over a joint, and tightened until bleeding stops\nand distal pulse is eliminated\nIf bleeding continues, place a second tourniquet proximal to the first\nFor thigh wounds, consider placement of two tourniquets, side-by-side, and tighten sequentially\n\nWound packing:\n\nIndications: Groin/axillary (\u201cjunctional\u201d) injury or any limb wound with persistent bleeding despite direct pressure\nand/or application of commercial tourniquet(s)\n\n________________________ Go To TOC\n\nTrauma Rev. March 2022\n\nExtremity Trauma/External Hemorrhage Management 225\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nii. Materials: hemostatic gauze, regular gauze, or any available material\n\niii. Procedure: pack tightly and fully to the depth of the wound until bleeding stops (may require significant packing\nfor deep, large wounds), then apply direct pressure and/or pressure dressing; do not remove packing to assess bleeding\n\n1. Pack around (do not remove) bone fragments or foreign objects\n\nd. Junctional tourniquets may be considered for groin or axillary wounds, if available\n\ne. Consider tranexamic acid (TXA) for injury associated with hemorrhagic shock if within three hours of injury\n\n2. Manage pain [See Pain Management Guideline]\n\na. Pain management should be strongly considered for patients with tourniquets and suspected fractures\n\nb. Do not loosen tourniquet to relieve pain\n\n3. Stabilize suspected fractures/dislocations:\n\na. Strongly consider pain management before attempting to move a suspected fracture\n\nb. If distal vascular function is compromised, gently attempt to restore normal anatomic position, and reassess perfusion\nstatus\n\nc. Use splints as appropriate to limit movement of suspected fracture\n\nd. Elevate extremity fractures above heart level whenever possible to limit swelling\n\ne. Apply ice/cool packs to limit swelling in suspected fractures or soft tissue injury, but do not apply ice directly to\nbare skin\n\nf. Reassess distal neurovascular status after any manipulation or splinting of fractures/dislocations\n\ng. Dress open wounds associated with fractures with saline-moistened gauze\n\n4. Remove wet or blood-soaked clothing and use measures to prevent heat loss\n\n5. Remove jewelry and potentially constricting clothing from the injured limb\n\n6.", "start_char_idx": 518245, "end_char_idx": 522451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee974b0e-438c-4280-b3e6-ec22c700d4dc": {"__data__": {"id_": "ee974b0e-438c-4280-b3e6-ec22c700d4dc", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7dd20e2-c7fa-46fe-9ab0-ef6f2e374f23", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "c6bff8b28e2df28a5bed38c5e991a1140b71f982fc68f5e2dc9e2ead2436201d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "653f14f5-48db-4fa7-b2ca-754d8a7f4497", "node_type": "1", "metadata": {}, "hash": "e59999073dae5fa4400e8371744f51e59f8854c6a7117abd37c1872c3547dc96", "class_name": "RelatedNodeInfo"}}, "text": "Stabilize suspected fractures/dislocations:\n\na. Strongly consider pain management before attempting to move a suspected fracture\n\nb. If distal vascular function is compromised, gently attempt to restore normal anatomic position, and reassess perfusion\nstatus\n\nc. Use splints as appropriate to limit movement of suspected fracture\n\nd. Elevate extremity fractures above heart level whenever possible to limit swelling\n\ne. Apply ice/cool packs to limit swelling in suspected fractures or soft tissue injury, but do not apply ice directly to\nbare skin\n\nf. Reassess distal neurovascular status after any manipulation or splinting of fractures/dislocations\n\ng. Dress open wounds associated with fractures with saline-moistened gauze\n\n4. Remove wet or blood-soaked clothing and use measures to prevent heat loss\n\n5. Remove jewelry and potentially constricting clothing from the injured limb\n\n6. Do not remove impaled foreign bodies\n\nPatient Safety Considerations\n\n1. If improvised tourniquet has been placed by bystander, reassess, and consider placing commercial tourniquet proximal\nto it\n\n2. If tourniquet is placed:\n\na. Ensure that the tourniquet is sufficiently tight to occlude the distal pulse\n\nb. Ensure that the tourniquet is well marked and visible, and that all subsequent clinicians are aware of the presence\nof the tourniquet\n\nc. Do not cover the tourniquet with clothing or dressings\n\n3. Mark the time of tourniquet placement prominently on the patient and in the patient care report\n\n4. Without removing the tourniquet or dressing, reassess frequently for signs of ongoing or renewed bleeding, such as:\n\na. Blood soaking through dressing\n\nb. Bleeding distal to tourniquet\n\nNotes/Educational Pearls\n\nKey Considerations\n\n1. Tourniquets should be applied to bare skin, 2\u20133 inches proximal to the wound\n\n2. Tourniquet should be reassessed at every stage of patient movement to ensure ongoing hemorrhage control.\n\n________________________ Go To TOC\n\nTrauma Rev. March 2022\n\nExtremity Trauma/External Hemorrhage Management 226\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Survival is markedly improved when a tourniquet is placed before shock develops\n\nProperly-applied tourniquets in conscious patients are painful \u2013 treat pain with analgesics, but do not loosen a tourniquet to relieve discomfort\n\nArterial pressure points may not be effective in controlling hemorrhage; however, may help slow bleeding while tourniquet is applied\n\nAmputated body parts should be transported with patient for possible re-implantation\n\nIt should remain cool but dry\nPlace the amputated part in a plastic bag\nPlace the bag with the amputated part on ice in a second bag\nDo not let the amputated part come into direct contact with the ice\n\n## Pediatric considerations:\n\nExternal hemorrhage control to prevent shock is critical in infants and young children, due to their relatively small blood volume\n\nMost commercial tourniquets can be used effectively on children over 2 years of age\n\nStretch-wrap-tuck elastic-type tourniquets can be used on any age patient\n\nDirect pressure and wound packing may be more suitable for infants and young children\n\nConsult with local online medical direction regarding use of traction splints for femur fractures in young children, to avoid risk of possible nerve damage\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (for additional information, go to www.nemsis.org)\n\n9914083 \u2013 Injury - Bleeding/Hemorrhage Control\n9914097 \u2013 Injury - Extremity\n\n### Key Documentation Elements\n\nVital signs and vascular status of extremity after placement of tourniquet, pressure dressing, packing, and/or splint\nTime of tourniquet placement\nDocumentation of signs/symptoms of possible compartment syndrome\n\n### Performance Measures\n\nProper placement of tourniquet (location, cessation of bleeding)\nProper marking and timing of tourniquet placement and notification of tourniquet placement to subsequent EMS clinicians and ED personnel\nAppropriate splinting and padding of fractures\n\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nPediatrics\u201403: Documentation of Estimated Weight in Kilograms\nTrauma\u201401: Pain Assessment of Injured Patients\n\nGo To TOC\n\n#### Trauma Rev.", "start_char_idx": 521564, "end_char_idx": 525828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "653f14f5-48db-4fa7-b2ca-754d8a7f4497": {"__data__": {"id_": "653f14f5-48db-4fa7-b2ca-754d8a7f4497", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee974b0e-438c-4280-b3e6-ec22c700d4dc", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "ba19d36014aec07d00c27a4f63037600cc44b5fe81ef677545618c7ca56ea789", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d71dba8-8788-40f7-b748-b1efe293bfc2", "node_type": "1", "metadata": {}, "hash": "ffa2dd379dcd3058a5bbeb1bb82284a6a21c5f0a7457ce1de3b715930ddaa713", "class_name": "RelatedNodeInfo"}}, "text": "March 2022 Extremity Trauma/External Hemorrhage Management 227\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nGraphic 1. Prehospital External Hemorrhage Control Protocol\n\n|Direct pressure effective|Apply direct pressure/pressure dressing to injury|\n|---|---|\n|Direct pressure ineffective or [hemorrhage controlled)|Wound amenable to tourniquet placement|Wound not amenable to tourniquet placement|\n| |Apply a tourniquet*|Apply a topical hemostatic agent with direct pressurel|\n\n* Use of tourniquet for extremity hemorrhage is strongly recommended if sustained direct pressure is ineffective or impractical; Use a commercially produced, windlass, pneumatic, or ratcheting device, which has been demonstrated to occlude arterial flow and avoid narrow, elastic, or bungee-type devices; Utilize improvised tourniquets only if no commercial device is available; Do not release a properly applied tourniquet until the patient reaches definitive care\n\n# Apply a topical hemostatic agent, in combination with direct pressure, for wounds in anatomic areas where tourniquets cannot be applied and sustained direct pressure alone is ineffective or impractical; Only apply topical hemostatic agents in a gauze format that support wound packing; Only utilize topical hemostatic agents which have been determined to be effective and safe in a standardized laboratory injury model\n\nSource: Bulger et al. 2014\n\n### References\n\nBedri H, Ayoub H, Engelbart J, Lilienthal M, Galet C, Skeete D. Tourniquet application for bleeding control in a rural trauma system: outcomes and implications for prehospital providers. Prehos Emerg Care. 2021; DOI: 10.1080/10903127.2020.1868635\nBulger E et al. An evidence-based prehospital guideline for external hemorrhage control: American College of Surgeons Committee on Trauma. Prehosp Emerg Care. 2014;18(2):163\u201373\nCharlton NP, et al. Pediatric Tourniquet Types: First Aid New TF SR. CoSTR.ILCOR.org [Internet]. Available from: https://costr.ilcor.org/document/pediatric-tourniquet-types-first-aid-new-tf-sr. Accessed March 11, 2022\nCornelissen M, Brandwijk A, Schoonmade L, Giannakopoulos G, van Oostendorp S, Geeraedts L. The safety and efficacy of improvised tourniquet in life-threatening hemorrhage: A systematic review. European Journal of Trauma and Emergency Surgery. 2020; 46:531\u2013538\nCunningham A, Auerbach M, Cicero M, Jafri M. Tourniquet usage in prehospital care and resuscitation of pediatric trauma patients \u2013 Pediatric Trauma Society position statement. J Trauma Acute Care Surg. 2018;85(4):665\u2013667\nDoyle G, Taillac P. Tourniquets: a review of current use with proposals for expanded prehospital use. Prehosp Emerg Care. 2008;12(2):241\u201356\nKelly JR, Levy MJ, Reyes J, Anders J. Effectiveness of the combat application tourniquet for Trauma\n\nGo To TOC\n\nRev. March 2022\n\nExtremity Trauma/External Hemorrhage Management\n\n228\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\nRevision Date: March 11, 2022\n\n## Trauma\n\n### Extremity Trauma/External Hemorrhage Management\n\n1. Bulger EM, Snyder D, Schoelles K, et al. An evidence-based prehospital guideline for external hemorrhage control: American College of Surgeons. J Trauma Acute Care Surg. 2018;84(6):818\u2013826\n\n2. Butler FK, Holcomb JB, Shackelford S, et al. Advanced Resuscitative Care in Tactical Combat Casualty Care: TCCC Guidelines Change 18-01. J Spec Oper Med. 2018;18(1):1\u201348\n\n3. Eastridge BJ, Mabry RL, Seguin P, et al. Death on the battlefield (2001\u20132011): implications for the future of combat casualty care. J Trauma Acute Care Surg. 2012;73(6 Suppl 5):S431\u2013S437\n\n4.", "start_char_idx": 525829, "end_char_idx": 529440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d71dba8-8788-40f7-b748-b1efe293bfc2": {"__data__": {"id_": "3d71dba8-8788-40f7-b748-b1efe293bfc2", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "653f14f5-48db-4fa7-b2ca-754d8a7f4497", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "fca4408eb243c2a9e6049b712dba5fdbaadc849f16367a2a2810c4c2f09910be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40a9ed84-8fbc-464a-b243-576444978912", "node_type": "1", "metadata": {}, "hash": "a3069ffc4d231d153887f61cdbb9cea21ae9f486b80630a48a26b8ac8ab4143f", "class_name": "RelatedNodeInfo"}}, "text": "Bulger EM, Snyder D, Schoelles K, et al. An evidence-based prehospital guideline for external hemorrhage control: American College of Surgeons. J Trauma Acute Care Surg. 2018;84(6):818\u2013826\n\n2. Butler FK, Holcomb JB, Shackelford S, et al. Advanced Resuscitative Care in Tactical Combat Casualty Care: TCCC Guidelines Change 18-01. J Spec Oper Med. 2018;18(1):1\u201348\n\n3. Eastridge BJ, Mabry RL, Seguin P, et al. Death on the battlefield (2001\u20132011): implications for the future of combat casualty care. J Trauma Acute Care Surg. 2012;73(6 Suppl 5):S431\u2013S437\n\n4. Kheirabadi BS, Terrazas IB, Miranda N, et al. Long-term effects of combat-relevant battlefield smoke inhalation injury. J Trauma Acute Care Surg. 2012;73(6 Suppl 5):S470\u2013S475\n\n5. Kragh JF, Murphy C, Dubick M, et al. New tourniquet device concepts for battlefield hemorrhage control. US Army Med Dep J. 2011:4\u201311\n\n6. Kragh JF, Walters TJ, Baer DG, et al. Practical use of emergency tourniquets to stop bleeding in major limb trauma. J Trauma. 2008;64(2 Suppl):S38\u2013S49\n\n7. Kragh JF, Littrel ML, Jones JA, et al. Battle casualty survival with emergency tourniquet use to stop limb bleeding. J Emerg Med. 2011;41(6):590\u20137\n\n8. Leonard J, Aietlow J, Morris D, et al. A multi-institutional study of hemostatic gauze and tourniquets in rural civilian trauma. J Trauma Acute Care Surg. 2016;81(3):441\u20134\n\n9. Mawhinney A and Kirk S. A systematic review of the use of tourniquets and topical haemostatic agents in conflicts in Afghanistan and Iraq. J R Nav Med Serv. 2015;101(2):147\u201354\n\n10. Meusnier J, Dewar C, Mavrovi E, et al. Evaluation of two junctional tourniquets used on the battlefield: Combat Ready Clamp\u00ae versus SAM\u00ae Junctional Tourniquet. J Spec Oper Med. 2016;16:41\u20136\n\n11. Peng H. Hemostatic agents for prehospital hemorrhage control: a narrative review. Military Med Res. 2020; 7:13. DOI: 10.1186/x40779-020-00241\n\n12. Prehospital Trauma Life Support, 9th Edition. Burlington, MA: Jones & Bartlett; 2021\n\n13. Snyder CL. Bleeding Children. Pediatrics. May 2019;143(5):1\u20132\n\n14. Snyder D, Schoelles K. Efficacy of prehospital application of tourniquets and hemostatic dressings to control traumatic external hemorrhage [Internet]. National Highway Traffic Safety Administration. Retrieved from: https://www.ems.gov/pdf/research/Studies-and-Reports/Prehospital_Applications_Of_Tourniquest_And_Hemostatic_Dressings.pdf. Accessed March 11, 2022\n\n15. Van Oostendorp S, Tan E, Geeraedts L. Prehospital control of life-threatening truncal and junctional haemorrhage is the ultimate challenge in optimizing trauma care: a review of treatment options and their applicability in the civilian trauma setting. Scand J Trauma Resusc Emerg Med. 2016;24(1):110\n\n16. Watters J, Van P, Hamilton G, et al. Advanced hemostatic dressings are not superior to gauze for care under fire scenarios. J Trauma.", "start_char_idx": 528883, "end_char_idx": 531725, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40a9ed84-8fbc-464a-b243-576444978912": {"__data__": {"id_": "40a9ed84-8fbc-464a-b243-576444978912", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d71dba8-8788-40f7-b748-b1efe293bfc2", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "51bcb4b28da220b9eb549078cde3cd36b68cb53ff448771860b606345acc2541", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4820a60d-7c6e-422c-8fb4-d65d67aaad21", "node_type": "1", "metadata": {}, "hash": "81c012b0d30113a9d61c5a2bebde1c0e9e1aa1f1b0ebcc11c7f26e6a6d0dcc52", "class_name": "RelatedNodeInfo"}}, "text": "National Highway Traffic Safety Administration. Retrieved from: https://www.ems.gov/pdf/research/Studies-and-Reports/Prehospital_Applications_Of_Tourniquest_And_Hemostatic_Dressings.pdf. Accessed March 11, 2022\n\n15. Van Oostendorp S, Tan E, Geeraedts L. Prehospital control of life-threatening truncal and junctional haemorrhage is the ultimate challenge in optimizing trauma care: a review of treatment options and their applicability in the civilian trauma setting. Scand J Trauma Resusc Emerg Med. 2016;24(1):110\n\n16. Watters J, Van P, Hamilton G, et al. Advanced hemostatic dressings are not superior to gauze for care under fire scenarios. J Trauma. 2011;70(6):1413\u20139\n\nGo To TOC\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Facial/Dental Trauma\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nPreservation of a patent airway\nPreservation of vision\nPreservation of dentition\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nIsolated facial injury, including trauma to the eyes, nose, ears, midface, mandible, dentition\n\n#### Exclusion Criteria\n\nGeneral Trauma [See General Trauma Management Guideline]\nBurn trauma [See Burns Guideline]\n\n### Patient Management\n\n#### Assessment\n\nOverall trauma assessment\nABCs (Airway, Breathing, Circulation) with particular focus on ability to keep airway patent\n\nStable midface\nStable mandible\nStable dentition (poorly anchored teeth require vigilance for possible aspiration)\n\nBleeding (which may be severe \u2013 epistaxis, oral trauma, facial lacerations)\nPatient medications with focus on blood thinners/anti-platelet agents\nCervical spine pain or tenderness [See Spinal Care Guideline]\nMental status assessment for possible traumatic brain injury [See Head Injury Guideline]\nGross vision assessment\nDental avulsions\nAny tissue or teeth avulsed should be collected, if possible\nSpecific re-examination geared toward airway and ability to ventilate adequately\n\n#### Treatment and Interventions\n\nAdminister oxygen as appropriate with a target of achieving 94\u201398% saturation. Use EtCO2 to help monitor for\nhypoventilation and apnea\nIV access, as needed, for fluid or medication administration\nPain medication per the Pain Management Guideline\nAvulsed tooth:\n\nAvoid touching the root of the avulsed tooth. Do not wipe off tooth\nPick up at crown end. If dirty, rinse off under cold water for 10 seconds\nPlace in milk or saline as the storage medium. Alternatively, an alert and cooperative patient can hold tooth\nin mouth using own saliva as storage medium\n\nEye trauma:\n\n________________________ Go To TOC\n\nRev. March 2022\n\nFacial/Dental Trauma\n\n230\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Facial/Dental Trauma\n\na. Place eye shield for any significant eye trauma\n\nb. If globe is avulsed or enucleated, do not put back into socket. Cover eye socket with moist saline dressings and\nthen place eye shield over it\n\n6. Mandible unstable:\n\na. Expect patient cannot spit/swallow effectively and have suction readily available\n\nb. Preferentially transport sitting up with emesis basin/suction available (in the absence of a suspected spinal\ninjury.) [See Spinal Care Guideline]\n\n7. Epistaxis: squeeze nose (or have patient do so) for 10\u201315 minutes continuously\n\n8. Nose/ear avulsion:\n\na. Recover tissue, if possible\n\nb. Transport with tissue wrapped in dry sterile gauze in a plastic bag placed on ice\n\nc. Severe ear and nose lacerations can be addressed with a protective moist sterile dressing\n\n### Patient Safety Considerations\n\n1. Frequent reassessment of airway\n\n2. Maintenance of a patent airway is the highest priority; therefore, conduct cervical spine assessment for field\nclearance (per Spinal Care Guideline) to enable transport sitting up for difficulty with bleeding, swallowing, or\nhandling secretions\n\n### Notes/Educational Pearls\n\nKey Considerations\n\n1. Airway may be compromised because of fractures or bleeding\n\n2. Lost teeth not recovered on scene may be in the airway\n\n3. After nasal fractures, epistaxis may be posterior and may not respond to direct pressure over the nares with\nbleeding running down posterior pharynx, potentially compromising airway\n\n4.", "start_char_idx": 531071, "end_char_idx": 535215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4820a60d-7c6e-422c-8fb4-d65d67aaad21": {"__data__": {"id_": "4820a60d-7c6e-422c-8fb4-d65d67aaad21", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40a9ed84-8fbc-464a-b243-576444978912", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "3e12ab2c5d55455ea0ba372a47c4f70089a2b3288c39d61332eae9b613b7fc15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8f545c2-4b4d-499d-be28-520d710af962", "node_type": "1", "metadata": {}, "hash": "abfccaea183c81629186c6ccf9164c6f6d3ee49975be0e9841269661a15b6b0d", "class_name": "RelatedNodeInfo"}}, "text": "Frequent reassessment of airway\n\n2. Maintenance of a patent airway is the highest priority; therefore, conduct cervical spine assessment for field\nclearance (per Spinal Care Guideline) to enable transport sitting up for difficulty with bleeding, swallowing, or\nhandling secretions\n\n### Notes/Educational Pearls\n\nKey Considerations\n\n1. Airway may be compromised because of fractures or bleeding\n\n2. Lost teeth not recovered on scene may be in the airway\n\n3. After nasal fractures, epistaxis may be posterior and may not respond to direct pressure over the nares with\nbleeding running down posterior pharynx, potentially compromising airway\n\n4. Protect avulsed tissue and teeth\n\na. Avulsed teeth may be successfully re-implanted if done so in a very short period after injury\n\nb. Use moist sterile dressing for ear and nose cartilage\n\n5. For penetrating eye injuries, do not remove foreign bodies. Splint in place. Cover uninjured eye or ask patient to\nclose eye to prevent conjugate movement of injured eye\n\n6. Consider administration of antiemetics to prevent increases in intraocular pressure due to nausea and vomiting in\npenetrating and blunt trauma to the eye [See Nausea - Vomiting Guideline]\n\n### Pertinent Assessment Findings\n\n1. Unstable facial fractures that can abruptly compromise airway\n\n2. Loose teeth and retro-pharynx bleeding\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914057 \u2013 Injury - Facial Trauma\n9914099 \u2013 Injury - Eye\n9914205 \u2013 General - Dental Problems\n\n________________________ Go To TOC\n\nTrauma Rev. March 2022 Facial/Dental Trauma 231\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Key Documentation Elements\n\nAirway patency and reassessment\nDegree and location of hemorrhage\nMental status (GCS or AVPU)\nTechnique used to transport tissue or teeth\nEye exam documented, when applicable\nAssessment and management of cervical spine\nPatient use of anticoagulant medications\n\n## Performance Measures\n\nAppropriate airway management and satisfactory oxygenation\nEye shield applied to eye trauma\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nPediatrics\u201403: Documentation of Estimated Weight in Kilograms\nTrauma\u201401: Pain Assessment of Injured Patients\n\n## References\n\nBord S, Linden J. Trauma to the globe and orbit. Emerg Med Clin N Am. 2008;26(1):97\u2013123\nMordini L, Lee P, Lazaro R, Biagi R, Gianetti L. Sport and dental traumatology: Surgical solutions and prevention. Dent J (Basel) 2021;9(3):33\nPatel P, Stanton D, Granquist E. Common dental and orofacial trauma: evaluation and management. Med Clin N Am. 2014;98(6):1261\u201379\n\nRevision Date: March 11, 2022\n\n________________________ Go To TOC\n\n### Trauma\n\nRev. March 2022\n\n### Facial/Dental Trauma\n\n232\n---\n# Head Injury\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Head Injury\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nLimit disability and mortality from head injury by limiting secondary brain injury through\n\nPromoting adequate oxygenation and preoxygenating to protect against unanticipated deterioration\nPromoting good cerebral perfusion and avoid hypotension\nPreventing hypocapnia (by avoiding hyperventilation and overventilation)\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nAdult or pediatric patient with blunt or penetrating head injury \u2013 loss of consciousness or amnesia not required\n\n#### Exclusion Criteria\n\nNone noted\n\n### Patient Management\n\n#### Assessment\n\nMaintain cervical stabilization [See Spinal Care Guideline]\nPrimary survey per the General Trauma Management Guideline\nMonitoring:\n\nContinuous pulse oximetry\nFrequent systolic and diastolic blood pressure measurement\nInitial neurologic status assessment [See Appendix VII.", "start_char_idx": 534573, "end_char_idx": 538385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8f545c2-4b4d-499d-be28-520d710af962": {"__data__": {"id_": "d8f545c2-4b4d-499d-be28-520d710af962", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4820a60d-7c6e-422c-8fb4-d65d67aaad21", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "44383faa85d5779a77112f921126c065bfe0ae8f24bb4fa89553e24288a965f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7a52c70-826c-44e8-abef-54480625ddfb", "node_type": "1", "metadata": {}, "hash": "144345d989f077dce63cf5d3825249a44da0eeb46d34e1e912da3ad5d15ea3a1", "class_name": "RelatedNodeInfo"}}, "text": "Neurologic Status Assessment] and reassessment with any change in mentation\nModerate/severe head injury: apply continuous waveform EtCO2, if available\n\nSecondary survey pertinent to isolated head injury:\n\nHead: Gently palpate skull to evaluate for depressed or open skull fracture\nEyes:\n\nEvaluate pupil size and reaction to light to establish baseline\nReassess pupils if decrease in mentation\n\nNose/mouth/ears: evaluate for blood/fluid drainage\nFace: evaluate for bony stability\nNeck: palpate for cervical spine tenderness or deformity\nNeurologic:\n\nPerform neurologic status assessment (GCS or AVPU)\nEvaluate for focal neurologic deficit: motor and sensory\n\n#### Treatment and Interventions\n\nNOTE: These are not necessarily the order they are to be done, but are grouped by conceptual areas\n\nAirway:\n\n________________________\n\nGo To TOC\n\nTrauma\n\nRev. March 2022\n\nHead Injury\n\n233\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Trauma\n\n### Head Injury\n\nRev. March 2022\n\nPage: 234\n\n## 1. Airway:\n\na. Administer high-flow oxygen via NRB (non-rebreather) as a precaution against unanticipated deterioration\n\nb. If patient unable to maintain airway, consider oral airway (nasal airway should not be used with significant facial\ninjury or possible basilar skull fracture)\n\nc. BVM (bag-valve-mask) ventilation if high flow oxygen (HFO)/non-rebreather (NRB) inadequate to maintain good airway\nand/or oxygenation\n\nd. Place supraglottic airway or perform endotracheal intubation or if BVM ventilation ineffective in maintaining\noxygenation or if airway is continually compromised. Endotracheal intubation (ETI)/supraglottic airway (SGA) should only\nbe used in systems that have continuous EtCO2 monitoring\n\n## 2. Breathing:\n\na. For patients who cannot maintain adequate oxygenation with HFO/NRB, BVM ventilation (15 years old or older: 10\nbreaths per minute; 2\u201314 years old: 20 breaths per minute; less than 2 years old: 25 breaths per minute) with gentle\nmanual bagging. Consider flow-controlled bags and ventilation rate timers to help prevent hyper-/overventilation\n\nb. SGA placement or ETI should only be performed if BVM ventilation fails to maintain adequate oxygenation. With\nadvanced airways, manage with a target EtCO2 of 40 (normal range 35\u201345 mmHg)\n\nc. Do not induce hypocapnia through hyper-/overventilation\n\n## 3. Circulation:\n\na. Wound care\n\ni. Control bleeding with direct pressure if no suspected open skull injury\n\nii. Moist sterile dressing to any potential open skull wound\n\niii. Cover an injured eye with moist saline dressing and place cup over it\n\nb. Moderate/severe closed head injury\n\ni. Blood pressure: avoid hypotension\n\n1. Adult (age greater than 10 years): maintain SBP greater than or equal to 110 mmHg\n\n2. Pediatric: maintain SBP:\n\na. Age less than 1 month: greater than 60 mmHg\n\nb. Age 1\u201312 months: greater than 70 mmHg\n\nc. Age 1\u201310 years: greater than 70 + 2x age in years\n\nc. Closed head injury\n\ni. Administer normal saline (NS)/lactated Ringer\u2019s (LR) fluid boluses to maintain SBP above threshold. Do not wait until\nafter the patient is already hypotensive\u2014prevent hypotension\n\nd. Do not delay transport to initiate IV access\n\n## 4. Disability:\n\na. Evaluate for other causes of altered mental status \u2014 check blood glucose during transport\n\nb. Spinal assessment and management, per Spinal Care Guideline\n\nc. Perform and trend neurologic status assessment (GCS or AVPU scale)\n\ni. Early signs of deterioration:\n\n1. Confusion\n\n2. Agitation\n\n3. Drowsiness\n\n4. Vomiting\n\n5. Severe headache\n\nGo To TOC\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Head Injury\n\nd. Severe head injury \u2013 Elevate head of bed 30 degrees\n\n5.", "start_char_idx": 538386, "end_char_idx": 542094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7a52c70-826c-44e8-abef-54480625ddfb": {"__data__": {"id_": "e7a52c70-826c-44e8-abef-54480625ddfb", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8f545c2-4b4d-499d-be28-520d710af962", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "c8080664e926872c8c40b16e7cda793ce981f73aa46fe6889e8f1b5f3124bd02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e224655b-9379-4af3-99b0-5d50cb96489f", "node_type": "1", "metadata": {}, "hash": "bb362c0bc0d6b746eb557072525fa1cde3e2f5af6aa40274ec7d1419f7ecd769", "class_name": "RelatedNodeInfo"}}, "text": "Do not wait until\nafter the patient is already hypotensive\u2014prevent hypotension\n\nd. Do not delay transport to initiate IV access\n\n## 4. Disability:\n\na. Evaluate for other causes of altered mental status \u2014 check blood glucose during transport\n\nb. Spinal assessment and management, per Spinal Care Guideline\n\nc. Perform and trend neurologic status assessment (GCS or AVPU scale)\n\ni. Early signs of deterioration:\n\n1. Confusion\n\n2. Agitation\n\n3. Drowsiness\n\n4. Vomiting\n\n5. Severe headache\n\nGo To TOC\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Head Injury\n\nd. Severe head injury \u2013 Elevate head of bed 30 degrees\n\n5. Transport destination specific to head trauma\n\na. Preferential transport to highest level of care within trauma system:\n\ni. GCS 3\u201313, P (pain) or U (unresponsive) on AVPU scale\n\nii. Penetrating head trauma\n\niii. Open or depressed skull fracture\n\n### Patient Safety Considerations\n\n1. Do not hyperventilate patients: Maintain all patients in EtCO2 range of 35\u201345 mmHg\n\n2. Assume concomitant cervical spine injury in patients with moderate/severe head injury\n\n3. Geriatric Consideration: Elderly patients with ankylosing spondylitis or severe kyphosis should be padded and\nimmobilized in a position of comfort and may not tolerate a cervical collar\n\n4. Pediatric Consideration: Children have disproportionately larger heads. When securing pediatric patients to a\nspine board, the board should have a recess for the head, or the body should be elevated approximately 1\u20132 cm to\naccommodate the larger head size and avoid neck flexion when immobilized\n\n### Notes/Educational Pearls\n\nKey Considerations\n\n1. Head injury severity guideline:\n\na. Mild: GCS 14\u201315/AVPU = (A)\n\nb. Moderate: GCS 9\u201313/AVPU = (V)\n\nc. Severe: GCS 3\u20138/AVPU = (P) or (U)\n\n2. Important that clinicians be specifically trained in accurate neurologic status assessment [See Appendix VII.\nNeurologic Status Assessment]\n\n3. If endotracheal intubation or invasive airways are used, continuous waveform capnography is required to document\nproper tube placement and assure proper ventilation rate and minute volume (preventing both hyperventilation [too\nfast] and overventilation [too much])\n\n4. Herniation is difficult to diagnose in the prehospital setting. Hyperventilation results in vasoconstriction which\nfurther decreases blood flow to the brain and worsens the secondary brain injury.\n\n### Pertinent Assessment Findings\n\n1. Neurologic status assessment findings\n\n2. Pupils\n\n3. Trauma findings on physical exam\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n\u2022 9914101 \u2013 Injury - Head\n\nKey Documentation Elements\n\n\u2022 High-flow oxygen with non-rebreather (NRB) mask\n\n\u2022 Airway status and management\n\n\u2022 EtCO2 monitored and documented for all traumatic brain injury (TBI) patients with advanced airway and strict\navoidance of hyperventilation, overventilation, and hypocapnia)\n\n________________________ Go To TOC\n\nTrauma Rev. March 2022 Head Injury 235\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nNeurological status with vitals: AVPU, GCS\nExams: Neurological and Mental Status Assessment pre- and post-treatment\n\nPerformance Measures\n\nNo oxygen desaturation less than 90%\nNo hypotension:\n\nAdults: less than 110 mmHg\nPediatrics:\n\nAge less than 1 month: less than 60 mmHg\nAge 1\u201312 months: less than 70 mmHg\nAge 1\u201310 years: less than 70 + 2x age in years\n\nAssess the patient\u2019s blood pressure prior to the administration of any medication that may cause hypotension.\nEtCO2 target 40 mmHg (range 35\u201345 mmHg).", "start_char_idx": 541446, "end_char_idx": 545063, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e224655b-9379-4af3-99b0-5d50cb96489f": {"__data__": {"id_": "e224655b-9379-4af3-99b0-5d50cb96489f", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7a52c70-826c-44e8-abef-54480625ddfb", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "2d36d88ac79ad505e230242212135623815b4ffbf3567f007a621e00306b2895", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "532068e0-122a-408d-9acc-6be26d94d2a6", "node_type": "1", "metadata": {}, "hash": "4febba59aca03fecce11ed26f0e977f932d81d56b78dc69c2109afe7b6e3a055", "class_name": "RelatedNodeInfo"}}, "text": "March 2022 Head Injury 235\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nNeurological status with vitals: AVPU, GCS\nExams: Neurological and Mental Status Assessment pre- and post-treatment\n\nPerformance Measures\n\nNo oxygen desaturation less than 90%\nNo hypotension:\n\nAdults: less than 110 mmHg\nPediatrics:\n\nAge less than 1 month: less than 60 mmHg\nAge 1\u201312 months: less than 70 mmHg\nAge 1\u201310 years: less than 70 + 2x age in years\n\nAssess the patient\u2019s blood pressure prior to the administration of any medication that may cause hypotension.\nEtCO2 target 40 mmHg (range 35\u201345 mmHg). Meticulous prevention of hypocapnia in all patients\nTriage to the appropriate level hospital within the local trauma system\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nPediatrics\u201403: Documentation of Estimated Weight in Kilograms\nTrauma\u201401: Pain Assessment of Injured Patients\n\nReferences\n\nAmbrosi PB, Valen\u00e7a MM, Azevedo-Filho H. Prognostic factors in civilian gunshot wounds to the head: a series of 110\nsurgical patients and brief literature review. Neurosurg Rev. 2012;35(3):429\u201335; discussion 435\u20136\nBadjatia N, Carney N, Crocco TJ, et al; Brain Trauma Foundation; BTF Center for Guidelines Management. Guidelines\nfor prehospital management of traumatic brain injury 2nd edition. Prehosp Emerg Care. 2008;12 Suppl 1: S1\u201352\nBerlot G, La Fata C, Bacer B, et al. Influence of prehospital treatment on the outcome of patients with severe blunt\ntraumatic brain injury: a single-centre study. Eur J Emerg Med. 2009;16(6):312\u201317\nDavis DP, Koprowicz KM, Newgard CD, et al. The relationship between out-of-hospital airway management and outcome\namong trauma patients with Glasgow Coma Scale scores of 8 or less. Prehosp Emerg Care. 2011;15(2):184\u201392\nDumont TM, Visioni AJ, Rughani AI, Tranmer BI, Crookes B. Inappropriate prehospital ventilation in severe traumatic\nbrain injury increases in-hospital mortality. J Neurotrauma. 2010 Jul;27(7):233\u201341\nFranschman G, Peerdeman SM, Andriessen TM, et al; Amsterdam Lifeliner: Analysis of Results and Methods--Traumatic\nBrain Injury (ALARM-TBI) Investigators. Effect of secondary prehospital risk factors on outcome in severe traumatic\nbrain injury in the context of fast access to trauma care. J Trauma. 2011;71(4):826\u201332\nGaither JB, Spaite DW, Bobrow BJ, et al: Impact of Implementing the Prehospital Traumatic Brain Injury Treatment\nGuidelines: The Excellence In Prehospital Injury Care for Children (EPIC4Kids) Study. Ann Emerg Med. 2021:77(2):139\u2013153.\nDOI: 10.1016/j.annemergmed.2020.09.435. NIH Manuscript System ID: NIHMSID:1654418; PubMed PMID:33187749\n\nGo To TOC\n\nTrauma\n\nRev. March 2022\n\nHead Injury\n\n236\n---\n## National Model EMS Clinical Guidelines Version 3.0\n\n8. Haut ER, Kalish BT, Cotton BA, et al. Prehospital intravenous fluid administration is associated with higher\nmortality in trauma patients: a National Trauma Data Bank analysis. Ann Surg. 2011;253(2):371\u20137\n\n9. Jagoda AS, Bazarian JJ, Bruns JJ Jr, et al; American College of Emergency Physicians; Centers for Disease\nControl and Prevention. Clinical policy: neuroimaging and decision making in adult mild traumatic brain injury in\nthe acute setting. Ann Emerg Med. 2008;52(6):714\u201348\n\n10. Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart\nAssociation guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation.", "start_char_idx": 544455, "end_char_idx": 547946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "532068e0-122a-408d-9acc-6be26d94d2a6": {"__data__": {"id_": "532068e0-122a-408d-9acc-6be26d94d2a6", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e224655b-9379-4af3-99b0-5d50cb96489f", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "9b4ef9559991dd02ec0ca6e51d8113fcee34bf8bde016c7ec45bfd4d7eff6056", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cd6511e-bc6a-4254-baec-f7b36239c34e", "node_type": "1", "metadata": {}, "hash": "4daf263416dc703747d4ad15bd51e223d3b5b5fda5be66d18d4a8f69fe9853d5", "class_name": "RelatedNodeInfo"}}, "text": "Haut ER, Kalish BT, Cotton BA, et al. Prehospital intravenous fluid administration is associated with higher\nmortality in trauma patients: a National Trauma Data Bank analysis. Ann Surg. 2011;253(2):371\u20137\n\n9. Jagoda AS, Bazarian JJ, Bruns JJ Jr, et al; American College of Emergency Physicians; Centers for Disease\nControl and Prevention. Clinical policy: neuroimaging and decision making in adult mild traumatic brain injury in\nthe acute setting. Ann Emerg Med. 2008;52(6):714\u201348\n\n10. Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart\nAssociation guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122:\nS876\u2013908\n\n11. Reed D. Adult Trauma Clinical Practice Guidelines: Initial Management of Closed Head Injury in Adults: 2nd\nEdition. New South Wales Institute of Trauma and Injury Management; 2011\n\n12. Roberts I, Schierhout G. Hyperventilation therapy for acute traumatic brain injury. Cochrane Database Syst\nRev. 1997;(4):CD000566\n\n13. Spaite DW, Bobrow BJ, Keim SM, et al: Association of Statewide Implementation of the Prehospital Traumatic\nBrain Injury Treatment Guidelines With Patient Survival Following Traumatic Brain Injury: The Excellence In\nPrehospital Injury Care (EPIC) Study. JAMA Surg. 2019;154(7): e191152. doi:10.1001/jamasurg.2019.1152. NIH\nManuscript System ID: NIHMSID: 1663161; PubMed PMID: 31066879; PMCID: PMC6506902\n\n14. Stocchetti N, Maas AIR, Chieregato A, van der Plas AA. Hyperventilation in head injury a review. Chest.\n2005;127(5):1812\u201327\n\n15. Zebrack M, Dandoy C, Hansen K, Scaife E, Mann NC, Bratton SL. Early resuscitation of children with\nmoderate-to-severe traumatic brain injury. Pediatrics. 2009;124(1):56\u201364\n\nRevision Date March 11, 2022\n\n________________________\n\nGo To TOC\n\n### Trauma\n\nRev. March 2022\n\n### Head Injury\n\n237\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## High Threat Considerations/Active Shooter Scenario\n\n### Aliases\n\nNone noted\n\n### Definitions\n\nHot Zone/Direct Threat Zone: an area within the inner perimeter where active threat and active hazards exist.\nWarm Zone/Indirect Threat Zone: an area within the inner perimeter where security and safety measures are in place. This zone may have potential hazards, but no active hazards exist.\n\n### Patient Care Goals\n\nAssess scene\nMitigating further harm\nAccomplish mission with minimal additional injuries\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nHigh threat environment \u2013 when greater than normal conditions exist that could cause threat to clinician or patient\n\n#### Exclusion Criteria\n\nNo significant threat exists to clinician or patient allowing for the performance of routine care\n\n### Patient Management\n\n#### Assessment, Treatment, and Interventions\n\nHot Zone/Direct Threat care considerations:\n\nMitigate threat as able to minimize risk to patients and clinicians, move to a safer position and recognize that threats are dynamic and may be ongoing, requiring continuous assessment of threat\nDefer in depth medical interventions if engaged in ongoing direct threat (e.g., active shooter, unstable building collapse, improvised explosive device, hazardous material threat)\nTriage should be deferred to when no longer in a hot zone/direct threat care zone\nPrioritization for extraction is based on resources available and the situation encountered\nEncourage patients to provide self-first aid or instruct uninjured bystanders to provide aid\nConsider hemorrhage control:\n\nTourniquet application is the primary \u201cmedical\u201d intervention to be considered in Hot Zone/Direct Threat Zone. Tourniquet choice should be guided by expected ability to perform in the desired patient population (pediatrics)\nConsider instructing patient to apply direct pressure to the wound if no tourniquet available (or application is not feasible)\nConsider quickly placing or directing patient to be placed in position to protect airway, if not immediately moving patient\n\n________________________ Go To TOC\n\nTrauma Rev.", "start_char_idx": 547245, "end_char_idx": 551291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cd6511e-bc6a-4254-baec-f7b36239c34e": {"__data__": {"id_": "7cd6511e-bc6a-4254-baec-f7b36239c34e", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "532068e0-122a-408d-9acc-6be26d94d2a6", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "2d18d7ffed530a9b65b7588c0f355d4442703c0772a98cb88953239b81972f3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "848dd453-5336-4ef9-b445-4508dcbb0ad4", "node_type": "1", "metadata": {}, "hash": "5b7f0175f8ac37c8a2e9861e0844e62a6f0b6b162b70a639573d42effe5a008e", "class_name": "RelatedNodeInfo"}}, "text": "Tourniquet choice should be guided by expected ability to perform in the desired patient population (pediatrics)\nConsider instructing patient to apply direct pressure to the wound if no tourniquet available (or application is not feasible)\nConsider quickly placing or directing patient to be placed in position to protect airway, if not immediately moving patient\n\n________________________ Go To TOC\n\nTrauma Rev. March 2022\n\nHigh Threat Considerations/Active Shooter Scenario 238\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## 2. Warm Zone/Indirect Threat care considerations:\n\na. Maintain situational awareness\n\nb. Ensure safety of both responders and patients by rendering equipment and environment safe (firearms, vehicle\nignition)\n\nc. Conduct primary survey, per the General Trauma Management Guideline, and initiate appropriate life-saving\ninterventions\n\ni. Hemorrhage control\n\n|1. Tourniquet|\n|---|\n|2. Wound packing if feasible|\n\nii. Maintain airway and support ventilation [See Airway Management Guideline]\n\nd. Maintain body temperature and prevent hypothermia\n\ne. Do not delay patient extraction and evacuation for non-life-saving interventions\n\nf. Consider establishing a casualty collection point if multiple patients are encountered\n\ng. Unless in a fixed casualty collection point, triage in this phase of care should be limited to the following\ncategories:\n\ni. Uninjured and/or capable of self-extraction\nii. Deceased/expectant\niii. All others\n\n## Patient Safety Considerations\n\n1. Anticipate unique threats based on situation\n\n2. During high threat situations, clinician safety should be considered in balancing the risks and benefits of patient\ntreatment\n\n## Notes/Educational Pearls\n\nKey Considerations\n\n1. In high threat situations clinician and patient safety will need to be simultaneously considered\n\n2. During high threat situations, an integrated response with other public safety entities may be warranted\n\n3. Risks taken and threats to responder safety must be weighed in relations to the expected benefit to patient safety\nand outcome\n\n4. During these situations, maintaining communications and incident management concepts may be crucial to maximizing\nefficiency and mitigating dangers\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\nNone noted\n\nKey Documentation Elements\n\nTraditional documentation may not be appropriate during Hot Zone/Direct Threat and Warm Zone/Indirect Threat care\n\nDocumentation of key intervention should be relayed:\n\nTime of tourniquet application\nGCS for patients with suspected head injury\n\nGo To TOC\n\nTrauma\n\nRev. March 2022\n\nHigh Threat Considerations/Active Shooter Scenario\n\n239\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## References\n\n|1.|Callaway DW, Smith ER, Cain J, et al. The Committee for Tactical Emergency Casualty Care (C-TECC): evolution and application of TCCC guidelines to civilian high threat medicine. J Spec Oper Med. 2011;11(3):104\u2013122|\n|---|---|\n|2.|Hartford Consensus. Facs.org. https://www.facs.org/about-acs/hartford-consensus. Accessed March 11, 2022|\n|3.|Kelly JR, Levy MJ, Reyes J, Anders J. Effectiveness of the combat application tourniquet for arterial occlusion in young children. J Trauma Acute Care Surg. 2020 May;88(5):644\u2013647|\n|4.|TCCC-MP Guidelines and Curriculum. NAEMT.org http://www.naemt.org/education/TCCC/guidelines_curriculum. Accessed March 11, 2022|\n|5.|TECC Guidelines. C-TECC.org. https://www.c-tecc.org/images/content/TECC_Guidelines_-_JUNE_2015_update.pdf. Committee for Tactical Emergency Casualty Care. Accessed March 11, 2022|\n\n## Revision Date\n\nMarch 11, 2022\n\n________________________\n\nGo To TOC\n\n## Trauma\n\nRev.", "start_char_idx": 550879, "end_char_idx": 554636, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "848dd453-5336-4ef9-b445-4508dcbb0ad4": {"__data__": {"id_": "848dd453-5336-4ef9-b445-4508dcbb0ad4", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cd6511e-bc6a-4254-baec-f7b36239c34e", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "69ece462d167e9f912290d29c58af0912740ed15268382b14a040475050488ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "990c7852-628c-49d8-b18f-141e7e0d4417", "node_type": "1", "metadata": {}, "hash": "0c8502143758f6871a1f3a4fb0e406ad6ecb2e7c345ef316850e808ae424bb2d", "class_name": "RelatedNodeInfo"}}, "text": "Accessed March 11, 2022|\n|3.|Kelly JR, Levy MJ, Reyes J, Anders J. Effectiveness of the combat application tourniquet for arterial occlusion in young children. J Trauma Acute Care Surg. 2020 May;88(5):644\u2013647|\n|4.|TCCC-MP Guidelines and Curriculum. NAEMT.org http://www.naemt.org/education/TCCC/guidelines_curriculum. Accessed March 11, 2022|\n|5.|TECC Guidelines. C-TECC.org. https://www.c-tecc.org/images/content/TECC_Guidelines_-_JUNE_2015_update.pdf. Committee for Tactical Emergency Casualty Care. Accessed March 11, 2022|\n\n## Revision Date\n\nMarch 11, 2022\n\n________________________\n\nGo To TOC\n\n## Trauma\n\nRev. March 2022\n\n### High Threat Considerations/Active Shooter Scenario\n\n240\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Spinal Care\n\n(Adapted from an evidence-based guideline created using the National Prehospital Evidence-Based Guideline Model Process)\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nSelect patients for whom spinal motion restriction (SMR) is indicated\nMinimize secondary injury to spine in patients who have, or may have, an unstable spinal injury\nMinimize patient morbidity from the unnecessary use of immobilization devices\n\n### Patient Presentation\n\n#### Inclusion criteria\n\nTraumatic mechanism of injury\n\n#### Exclusion criteria\n\nNone noted\n\n### Patient Management\n\n#### Assessment\n\nAssess the scene to determine the mechanism of injury\n\nMechanism alone should not determine if a patient requires spinal motion restriction \u2013 however, mechanisms that have been associated with a higher risk of injury are:\n\nMotor vehicle crashes (including automobiles, all-terrain vehicles, and snowmobiles)\nAxial loading injuries to the spine\nFalls greater than 10 feet\n\nAssess the patient in the position found for findings associated with spine injury:\n\nMental status\nNeurologic deficits\nSpinal pain or tenderness\nAny evidence of intoxication\nOther severe injuries, particularly associated torso injuries\n\n#### Treatment and Interventions\n\nPlace patient in cervical collar and initiate spinal motion restriction in adults if there are any of the following:\n\nPatient complains of midline neck or spine pain\nAny midline neck or spinal tenderness with palpation\nAny abnormal mental status (including extreme agitation)\nFocal or neurologic deficit\nAny evidence of alcohol or drug intoxication\nAnother severe or painful distracting injury\nTorticollis in children\n\nGo To TOC\n\n### Trauma\n\nRev. March 2022\n\n### Spinal Care\n\n241\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Spinal Care\n\n1. Patients with suspected spinal injury should be managed using spinal precautions until spinal injury is ruled out.\n\na. Spinal precautions include use of a cervical collar, maintaining spinal immobilization, and minimizing movement of the patient.\n\nb. A communication barrier that prevents accurate assessment\n\nc. If none of the above apply, patient may be managed without a cervical collar\n\n2. Patients with penetrating injury to the neck should not be placed in a cervical collar or other spinal precautions regardless of whether they are exhibiting neurologic symptoms or not. Doing so can lead to delayed identification of injury or airway compromise and has been associated with increased mortality\n\n3. If extrication is required:\n\na. From a vehicle: After placing a cervical collar, if indicated, children in a booster seat and adults should be allowed to self-extricate. For infants and toddlers already strapped in a car seat with a built-in harness, extricate the child while strapped in his/her car seat\n\nb. Other situations requiring extrication: A, preferably padded, long board may be used for extrication, using the lift and slide (rather than a logroll) technique\n\n4. Helmet removal\n\na. If a football helmet needs to be removed, it is recommended to remove the face mask followed by manual removal (rather than the use of automated devices) of the helmet while keeping the neck manually immobilized \u2014 occipital and shoulder padding should be applied, as needed, with the patient in a supine position to maintain neutral cervical spine positioning\n\nb. Evidence is lacking to provide guidance about other types of helmet removal\n\n5. Do not transport patients on rigid long boards unless the clinical situation warrants long board use. An example of this may be facilitation of immobilization of multiple extremity injuries or an unstable patient where removal of a board will delay transport and/or other treatment priorities.", "start_char_idx": 554022, "end_char_idx": 558505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "990c7852-628c-49d8-b18f-141e7e0d4417": {"__data__": {"id_": "990c7852-628c-49d8-b18f-141e7e0d4417", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "848dd453-5336-4ef9-b445-4508dcbb0ad4", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "98e1b4b84616a28c839e4d00f6fb0874ae4736761b1c66181c0a7bea497d321a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65d74546-e665-421f-a2d2-f6ae5d2544de", "node_type": "1", "metadata": {}, "hash": "e10b096ee45252c19135004c2ecc71fe087c7cdfaa0678b5135d3be6cddb5af8", "class_name": "RelatedNodeInfo"}}, "text": "Helmet removal\n\na. If a football helmet needs to be removed, it is recommended to remove the face mask followed by manual removal (rather than the use of automated devices) of the helmet while keeping the neck manually immobilized \u2014 occipital and shoulder padding should be applied, as needed, with the patient in a supine position to maintain neutral cervical spine positioning\n\nb. Evidence is lacking to provide guidance about other types of helmet removal\n\n5. Do not transport patients on rigid long boards unless the clinical situation warrants long board use. An example of this may be facilitation of immobilization of multiple extremity injuries or an unstable patient where removal of a board will delay transport and/or other treatment priorities. In these situations, long boards should ideally be padded or have a vacuum mattress applied to minimize secondary injury to the patient\n\n6. Patients should be transported to the nearest appropriate facility, in accordance with the American College of Surgeons Committee on Trauma (ACS COT) 2022 National Guideline for the Field Triage of Injured Patients\n\n7. Patients with severe kyphosis or ankylosing spondylitis may not tolerate a cervical collar. These patients should be immobilized in a position of comfort using towel rolls or sandbags\n\n### Patient Safety Considerations\n\n1. Be aware of potential airway compromise or aspiration in immobilized patient with nausea/vomiting or with facial/oral bleeding\n\n2. Excessively tight immobilization straps can limit chest excursion and cause hypoventilation\n\n3. Prolonged immobilization on spine board can lead to ischemic pressure injuries to skin\n\n4. Prolonged immobilization on spine board can be very uncomfortable for patient\n\n5. Children are abdominal breathers therefore immobilization straps should go across chest and pelvis and not across the abdomen\n\n6. Children have disproportionately larger heads. When securing pediatric patients to a spine board, the board should have a recess for the head or the body should be elevated approximately 1\u20132 cm to accommodate the larger head size and avoid neck flexion when immobilized\n\n7. In an uncooperative patient, avoid interventions that may promote increased spinal movement\n\n8. The preferred position for all patients with spine management is flat and supine. There are three circumstances under which raising the head of the bed to 30 degrees may be considered:\n\n________________________\n\nGo To TOC\n\nTrauma\n\nRev. March 2022\n\n242\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Notes/Educational Pearls\n\nKey Considerations\n\nEvidence is lacking to support or to refute the use of manual stabilization prior to spinal assessment in the setting\nof a possible traumatic injury when the patient is alert with spontaneous head/neck movement. Clinicians should not\nmanually stabilize these alerts and spontaneously moving patients since patients with pain will self-limit movement and\nforcing immobilization in this scenario may unnecessarily increase discomfort and anxiety\nCertain populations with musculoskeletal instability may be predisposed to cervical spine injury. However, evidence\ndoes not support or refute that these patients should be treated differently than those who do not have these\nconditions. These patients should be treated according to the Spinal Care Guideline like other patients without these\nconditions\nPediatric considerations:\n\nAge alone should not be a factor in decision-making for prehospital spine care, yet the patient\u2019s ability to\nreliably be assessed at the extremes of age should be considered. Communication barriers with infants/toddlers or\nelderly patients with dementia may prevent the clinician from accurately assessing the patient\nThere is no evidence that children experience non-contiguous multilevel injuries. The existing evidence suggests\nthat the rate of contiguous multilevel injuries is exceedingly low at 1%\nBecause of variation in head size to body ratio, consider additional padding under the shoulders to avoid\nexcessive cervical spine flexion\n\nSpinal precautions should be considered a treatment or preventive therapy\nPatients who are likely to benefit from immobilization should undergo this treatment\nPatients who are not likely to benefit from immobilization, who have a low likelihood of spinal injury, should not\nbe immobilized\nAmbulatory patients may be safely immobilized on gurney with cervical collar and straps and will not generally\nrequire a spine board. The role for standing take downs is extremely limited, e.g., extrication of a patient with a\nhigh likelihood of a spinal cord injury from a large body of water. Ambulatory patients may have a collar applied and\nwalked to the EMS gurney\nReserve long spine board use for the movement of patients whose injuries limit ambulation and who meet criteria for\nthe use of spinal precautions.", "start_char_idx": 557749, "end_char_idx": 562630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65d74546-e665-421f-a2d2-f6ae5d2544de": {"__data__": {"id_": "65d74546-e665-421f-a2d2-f6ae5d2544de", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "990c7852-628c-49d8-b18f-141e7e0d4417", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "68c20f653946f12e48600846125bc4ce7f2fe6cd3f01402bb6853a229ba4d117", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "019ef2a0-55d9-4563-8be3-bcb58b6810ea", "node_type": "1", "metadata": {}, "hash": "b7fd27226fe16eba0f2eccfd2f81dd9c7b61782cdc869e2cd03eb342db3e67be", "class_name": "RelatedNodeInfo"}}, "text": "The role for standing take downs is extremely limited, e.g., extrication of a patient with a\nhigh likelihood of a spinal cord injury from a large body of water. Ambulatory patients may have a collar applied and\nwalked to the EMS gurney\nReserve long spine board use for the movement of patients whose injuries limit ambulation and who meet criteria for\nthe use of spinal precautions. Remove from the long board as soon as is practical\n\n## Pertinent Assessment Findings\n\nMental status\nNormal neurologic examination\nEvidence of intoxication\nEvidence of multiple traumas with other severe injuries\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914073 \u2013 General - Spinal Precautions/Clearance\n\n________________________ Go To TOC\n\nTrauma Rev. March 2022\n\nSpinal Care 243\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## 9914107 \u2013 Injury - Spinal Cord\n\n### Key Documentation Elements\n\nPatient complaint of neck or spine pain\nSpinal tenderness\nMental status/GCS\nNeurologic examination\nEvidence of intoxication\nDocumentation of multiple trauma\nDocumentation of mechanism of injury\nDocument patient capacity with:\n\nAll barriers to patient care in the NEMSIS element \u201cBarriers to Patient Care\u201d (eHistory.01\u2014required of all software systems)\nExam fields for Mental Status and Neurological Assessment\nVitals for Level of Responsiveness and Glasgow Coma Scale\nAlcohol and drug use indicators\n\nPatient age\nPatient who is underage and not emancipated: legal guardian name, contact, and relationship\n\n### Performance Measures\n\nPercentage of patients with high-risk mechanisms of injury and/or signs or symptoms of cervical spine injury who are placed in a cervical collar\nPercentage of patients without known trauma who have a cervical immobilization device placed (higher percentage creates a negative aspect of care)\nPercentage of trauma patients who are transported on a long backboard (target is a low percentage)\nPercentage of patients with a cervical spinal cord injury or unstable cervical fracture who did not receive cervical collar\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nPediatrics\u201403: Documentation of Estimated Weight in Kilograms\nTrauma\u201401: Pain Assessment of Injured Patients\n\n### References\n\nAnders JF, Adelgais K, Hoyle JD Jr., Olsen C, Jaffe DM, Leonard JC. Comparison of outcomes for children with cervical spine injury based on destination hospital from scene of injury. Acad Emerg Med. 2014;21(1):55\u201364\nArmstrong BP, Simpson HK, Crouch R, Deakin CD. Prehospital clearance of the cervical spine: does it need to be a pain in the neck? Emerg Med J. 2007;24(7):501\u20133\nBarkana Y, Stein M, Scope A, Maor R, Abramovich Y, Friedman Z, Knoller N. Prehospital stabilization of the cervical spine for penetrating injuries of the neck\u2014is it necessary? Injury. 2007;31(5):305\u20139\nBen-Galim P, Dreiangel N, Mattox KL, Reitman CA, Kalantar SB, Hipp JA. Extrication collars can result in abnormal separation between vertebrae in the presence of a dissociative injury. J Trauma. 2010;69(2):447\u201350\nBenner JP, Brauning G, Green M, Caldwell W, Borloz MP, Brady WJ. Disagreement between\n\nGo To TOC\n\nRev. March 2022\n\nSpinal Care\n\n244\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\ntransport team and ED staff regarding the prehospital assessment of air medically evacuated scene patients. Air Med J. 2006;25(4):165\u20139\n\n6. Brown JB, Bankey PE, Sangosanya AT, Cheng JD, Stassen NA, Gestring ML. Prehospital spinal immobilization does not appear to be beneficial and may complicate care following gunshot injury to the torso. J Trauma. 2009;67(4):774\u20138\n\n7. Bureau of Emergency Medical Services. State of New Hampshire Patient Care Protocols. Concord, NH: New Hampshire Department of Safety; 2013\n\n8. Burton JH, Dunn MG, Harmon NR, Hermanson TA, Bradshaw JR. A statewide, prehospital emergency medical service selective patient spine immobilization protocol.", "start_char_idx": 562248, "end_char_idx": 566328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "019ef2a0-55d9-4563-8be3-bcb58b6810ea": {"__data__": {"id_": "019ef2a0-55d9-4563-8be3-bcb58b6810ea", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65d74546-e665-421f-a2d2-f6ae5d2544de", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "398aea3397b7680bcf467434d442b4e8caff9c246c04c111f13a806b89cb1b8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "980db64e-92c2-47c0-8d6c-f1d967bd5535", "node_type": "1", "metadata": {}, "hash": "c3223ced9e5c244bc5dc50f6c1fd0f38fd756d1f940e6e258a452e7ad8e21394", "class_name": "RelatedNodeInfo"}}, "text": "Air Med J. 2006;25(4):165\u20139\n\n6. Brown JB, Bankey PE, Sangosanya AT, Cheng JD, Stassen NA, Gestring ML. Prehospital spinal immobilization does not appear to be beneficial and may complicate care following gunshot injury to the torso. J Trauma. 2009;67(4):774\u20138\n\n7. Bureau of Emergency Medical Services. State of New Hampshire Patient Care Protocols. Concord, NH: New Hampshire Department of Safety; 2013\n\n8. Burton JH, Dunn MG, Harmon NR, Hermanson TA, Bradshaw JR. A statewide, prehospital emergency medical service selective patient spine immobilization protocol. J Trauma. 2006;61(1):161\u20137\n\n9. Burton JH, Harmon NR, Dunn MG, Bradshaw JR. EMS provider findings and interventions with a statewide EMS spine-assessment protocol. Prehosp Emerg Care. 2005;9(3):303\u20139\n\n10. Chan D, Goldberg R, Tascone A, Harmon S, Chan L. The effect of spinal immobilization on healthy volunteers. Ann Emerg Med. 1994;23(1):48\u201351\n\n11. Chong CL, Ware DN, Harris JH Jr. Is cervical spine imaging indicated in gunshot wounds to the cranium? J Trauma. 1998;44(3):501\u20132\n\n12. Cirak B, Ziegfeld S, Knight VM, Chang D, Avellino AM, Paidas, CN. Spinal injuries in children. J Pediatr Surg. 2004;39(4):607\u201312\n\n13. Cordell WH, Hollingsworth JC, Olinger ML, Stroman SJ, Nelson DR. Pain and tissue-interface pressures during spine-board immobilization. Ann Emerg Med. 1995;26(1):31\u20136\n\n14. Davies G, Deakin C, Wilson A. The effect of a rigid collar on intracranial pressure. Injury. 1996;27(9):647\u20139\n\n15. Decoster LC, Burns MF, Swartz EE, et al. Maintaining neutral sagittal cervical alignment after football helmet removal during emergency spine injury management. Spine (Phila Pa 1976). 2012;37(8):654\u20139\n\n16. Del Rossi G, Heffernan TP, Horodyski M, Rechtine GR. The effectiveness of extrication collars tested during the execution of spine-board transfer techniques. Spine J. 2004;4(6):619\u201323\n\n17. Del Rossi G, Horodyski MH, Conrad BP, Di Paola CP, Di Paola MJ, Rechtine GR. The 6-plus-person lift transfer technique compared with other methods of spine boarding. J Athl Train. 2008;43(1):6\u201313\n\n18. Del Rossi G, Horodyski M, Conrad BP, Dipaola CP, Dipaola MJ, Rechtine GR. Transferring patients with thoracolumbar spinal instability: Are there alternatives to the log roll maneuver? Spine (Phila Pa 1976). 2008;33(14):1611\u20135\n\n19. Del Rossi G, Rechtine GR, Conrad BP, Horodyski M. Are scoop stretchers suitable for use on spine-injured patients? Am J Emerg Med, 2010 28(7), 751\u2013756\n\n20. Dixon, M, O'Halloran J, Cummins NM. Biomechanical analysis of spinal immobilisation during prehospital extrication: a proof of concept study. Emerg Med J. 2014;31(9):745\u20139\n\n21. Domeier RM, Frederiksen SM, Welch K. Prospective performance assessment of an out-of-hospital protocol for selective spine immobilization using clinical spine clearance criteria. Ann Emerg Med. 2005;46(2):123\u201331\n\n22. Domeier RM, Swor RA, Evans RW, et al. Multicenter prospective validation of prehospital clinical spinal clearance criteria. J Trauma. 2002;53(4):744\u201350\n\n23. Edlich RF, Mason SS, Vissers RJ, et al. Revolutionary advances in enhancing patient comfort on patients transported on a backboard. Am J Emerg Med.", "start_char_idx": 565764, "end_char_idx": 568915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "980db64e-92c2-47c0-8d6c-f1d967bd5535": {"__data__": {"id_": "980db64e-92c2-47c0-8d6c-f1d967bd5535", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "019ef2a0-55d9-4563-8be3-bcb58b6810ea", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "2bb534c9949f85e1ad79f3061c3a0e10e5a84ec60055608dd1ee3cc762285935", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d1e1223-80da-4d4e-92c9-7c998f55e656", "node_type": "1", "metadata": {}, "hash": "9d7883e695254f5113e302467535c0675911e8883ad3c2c49642a49e8d29046e", "class_name": "RelatedNodeInfo"}}, "text": "Biomechanical analysis of spinal immobilisation during prehospital extrication: a proof of concept study. Emerg Med J. 2014;31(9):745\u20139\n\n21. Domeier RM, Frederiksen SM, Welch K. Prospective performance assessment of an out-of-hospital protocol for selective spine immobilization using clinical spine clearance criteria. Ann Emerg Med. 2005;46(2):123\u201331\n\n22. Domeier RM, Swor RA, Evans RW, et al. Multicenter prospective validation of prehospital clinical spinal clearance criteria. J Trauma. 2002;53(4):744\u201350\n\n23. Edlich RF, Mason SS, Vissers RJ, et al. Revolutionary advances in enhancing patient comfort on patients transported on a backboard. Am J Emerg Med. 2011;29(2):181\u20136\n\n24. Engsberg JR, Standeven JW, Shurtleff TL, Eggars JL, Shafer JS, Naunheim RS. Cervical spine motion during extrication. J Emerg Med. 2013;44(1):122\u20137\n\n## Go To TOC\n\n### Trauma\n\nRev. March 2022\n\n### Spinal Care\n\n245\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n25.   Hale DF, Fitzpatrick CM, Doski JJ, et al. Absence of clinical findings reliably excludes unstable cervical spine injuries in children 5 years or younger. J Trauma Acute Care Surg. 2015; 78:943\u2013948\n\n26.   Hasler RM, Kehl C, Exadaktylos AK, et al. Accuracy of prehospital diagnosis and triage of a Swiss helicopter emergency medical service. J Trauma Acute Care Surg. 2012;73(3):709\u201315\n\n27.   Hauswald M, Hsu M, Stockoff C. Maximizing comfort and minimizing ischemia: a comparison of four methods of spinal immobilization. Prehosp Emerg Care. 2000;4(3):250\u20132\n\n28.   Hauswald M, Ong G, Tandberg D, Omar Z. Out-of-hospital spinal immobilization: its effect on neurologic injury. Acad Emerg Med. 1998;5(3):214\u20139\n\n29.   Haut ER, Kalish BT, Efron DT, et al. Spine immobilization in penetrating trauma: More harm than good? J Trauma. 2010;68(1):115\u201320; discussion 120\u20131\n\n30.   Hemmes B, Poeze M, Brink PR. Reduced tissue-interface pressure and increased comfort on a newly developed soft-layered long spineboard. J Trauma. 2010;68(3):593\u20138\n\n31.   Hoffman JR, Mower WR, Wolfson AB, Todd KH, Zucker MI. Validity of a set of clinical criteria to rule out injury to the cervical spine in patients with blunt trauma. National Emergency X-Radiography Utilization Study Group. N Engl J Med. 2000;343(2):94\u20139\n\n32.   Hostler D, Colburn D, Seitz SR. A comparison of three cervical immobilization devices. Prehosp Emerg Care. 2009;13(2):256\u201360\n\n33.   Huerta C, Griffith R, Joyce SM. Cervical spine stabilization in pediatric patients: evaluation of current techniques. Ann Emerg Med. 1987;16(10):1121\u20136\n\n34.   Kim EG, Brown KM, Leonard JC, Jaffe DM, Olsen CS, Kuppermann N. Variability of prehospital spinal immobilization in children at risk for cervical spine injury. Pediatr Emerg Care. 2013;29(4):413\u20138\n\n35.   Kolb JC, Summers RL, Galli RL. Cervical collar-induced changes in intracranial pressure. Am J Emerg Med. 1999;17(2):135\u20137\n\n36.   Kwan I, Bunn F. Effects of prehospital spinal immobilization: a systematic review of randomized trials on healthy subjects. Prehosp Disaster Med. 2005;20(1):47\u201353\n\n37.   Leonard JC, Mao J, Jaffe DM. Potential adverse effects of spinal immobilization in children. Prehosp Emerg Care.", "start_char_idx": 568253, "end_char_idx": 571444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d1e1223-80da-4d4e-92c9-7c998f55e656": {"__data__": {"id_": "4d1e1223-80da-4d4e-92c9-7c998f55e656", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "980db64e-92c2-47c0-8d6c-f1d967bd5535", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "ed02e9829b106e654a5e5aa9a39039009fe841293b1a58c21767009da14603a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9937b0e1-4130-432e-8d55-cc1aea6411f9", "node_type": "1", "metadata": {}, "hash": "2af9567c2457d26f33b0cf9f721ad913cc4a77b916bd9e8616d7740083583964", "class_name": "RelatedNodeInfo"}}, "text": "Kim EG, Brown KM, Leonard JC, Jaffe DM, Olsen CS, Kuppermann N. Variability of prehospital spinal immobilization in children at risk for cervical spine injury. Pediatr Emerg Care. 2013;29(4):413\u20138\n\n35.   Kolb JC, Summers RL, Galli RL. Cervical collar-induced changes in intracranial pressure. Am J Emerg Med. 1999;17(2):135\u20137\n\n36.   Kwan I, Bunn F. Effects of prehospital spinal immobilization: a systematic review of randomized trials on healthy subjects. Prehosp Disaster Med. 2005;20(1):47\u201353\n\n37.   Leonard JC, Mao J, Jaffe DM. Potential adverse effects of spinal immobilization in children. Prehosp Emerg Care. 2012;16(4):513\u20138\n\n38.   Leonard JC, Kuppermann N, Olsen C, et al. Factors associated with cervical spine injury in children after blunt trauma. Ann Emerg Med. 2011;58(2):145\u201355\n\n39.   Leonard JC, Kuppermann N, Olsen C, Babcock-Cimpello L, Brown K, Mahajan P, et al. Factors associated with cervical spine in children after blunt trauma. Ann Emerg Med. 2011;58(2):145\u2013155\n\n40.   Leonard JC, Jaffe DM, Olsen CS, Kuppermann N. Age- related differences in factors associated with cervical spine injuries in children. Acad Emerg Med. 2015; 22:1\u20136\n\n41.   Leonard JR, Jaffe DM, Kuppermann N, Olsen C, Leonard JC. Cervical spine injury patterns in children. Pediatrics. 2014:133(5): e1179\u2013e1188\n\n42.   Lin HL, Lee WC, Chen CW, et al. Neck collar used in treatment of victims of urban motorcycle accidents: Over- or underprotection? Am J Emerg Med. 2011;29(9):1028\u201333\n\n43.   Lovell ME, Evans JH. A comparison of the spinal board and the vacuum stretcher, spinal stability and interface pressure. Injury. 1994;25(3):179\u201380\n\n44.   Luscombe MD, Williams, JL. Comparison of a long spinal board and vacuum mattress for spinal immobilisation. Emerg Med J. 2003;20(5):476\u20138\n\n45.   March JA, Ausband SC, Brown, LH. Changes in physical examination caused by use of spinal immobilization. Prehosp Emerg Care. 2002;6(4):421\u20134\n\n46.   McGuire RA, Degnan G, Amundson GM. Evaluation of current extrication orthoses in\n\n## Go To TOC\n\n## Trauma\n\n## Rev. March 2022\n\n## Spinal Care\n\n246\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n47. Mohseni S, Talving P, Branco BC, et al. Effect of age on cervical spine injury in pediatric population: a National\nTrauma Data Bank review. J Pediatr Surg. 2011;46(9):1771\u20136\n\n48. National Association of EMS Physicians/American College of Surgeons Committee on Trauma. Position statement: EMS\nspinal precautions and the use of the long backboard. Prehosp Emerg Care. 2013; 17:392\u20133\n\n49. Nypaver M, Treloar D. Neutral cervical spine positioning in children. Ann Emerg Med. 1994;23(2):208\u201311\n\n50. Office of Emergency Medical Services. Spinal Motion Restriction Guideline. Hartford, Connecticut. Department of\nPublic Health; 2013\n\n51. Parent S, Mac-Thiong JM, Roy-Beaudry M, Sosa JF, Labelle H. Spinal cord injury in the pediatric population: a\nsystematic review of the literature. J Neurotrauma. 2011;28(8):1515\u201324\n\n52. Peery CA, Brice J, White WD. Prehospital spinal immobilization and the backboard quality assessment study. Prehosp\nEmerg Care. 2007;11(3):293\u20137\n\n53.", "start_char_idx": 570829, "end_char_idx": 573955, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9937b0e1-4130-432e-8d55-cc1aea6411f9": {"__data__": {"id_": "9937b0e1-4130-432e-8d55-cc1aea6411f9", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d1e1223-80da-4d4e-92c9-7c998f55e656", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "dcda10cf82b7485db6440fbff87457d065c6d7d98cb0534b20ffed9d62ad078e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53916f59-fff6-497f-82c6-4b7831eed5c1", "node_type": "1", "metadata": {}, "hash": "233099b49337508898d52e6607b11c78ae2b832f55b178e941d50e145a61ac90", "class_name": "RelatedNodeInfo"}}, "text": "Nypaver M, Treloar D. Neutral cervical spine positioning in children. Ann Emerg Med. 1994;23(2):208\u201311\n\n50. Office of Emergency Medical Services. Spinal Motion Restriction Guideline. Hartford, Connecticut. Department of\nPublic Health; 2013\n\n51. Parent S, Mac-Thiong JM, Roy-Beaudry M, Sosa JF, Labelle H. Spinal cord injury in the pediatric population: a\nsystematic review of the literature. J Neurotrauma. 2011;28(8):1515\u201324\n\n52. Peery CA, Brice J, White WD. Prehospital spinal immobilization and the backboard quality assessment study. Prehosp\nEmerg Care. 2007;11(3):293\u20137\n\n53. Pieretti-Vanmarcke R, Velmahos GC, Nance ML, et al. Clinical clearance of the cervical spine in blunt trauma\npatients younger than 3 years: a multi-center study of the American Association for the Surgery of Trauma. J Trauma.\n2009;67(3):543\u201349; discussion 549\u201350\n\n54. Podolsky S, Baraff LJ, Simon RR, Hoffman JR, Larmon B, Ablon W. Efficacy of cervical spine immobilization\nmethods. J Trauma. 1983;23(6):461\u20135\n\n55. Prasarn ML, Zhou H, Dubose D, et al. Total motion generated in the unstable thoracolumbar spine during management\nof the typical trauma patient: A comparison of methods in a cadaver model. J Neurosurg Spine. 2012;16(5):504\u20138\n\n56. Ramasamy A, Midwinter M, Mahoney P, Clasper J. Learning the lessons from conflict: Pre-hospital cervical spine\nstabilization following ballistic neck trauma. Injury. 2009;40(12):1342\u20135\n\n57. Rhee P, Kuncir EJ, Johnson L, et al. Cervical spine injury is highly dependent on the mechanism of injury\nfollowing blunt and penetrating assault. J Trauma. 2006;61(5):1166\u201370\n\n58. Schafermeyer RW, Ribbeck BM, Gaskins J, Thomason S, Harlan M, Attkisson A. Respiratory effects of spinal\nimmobilization in children. Ann Emerg Med. 1991;20(9):1017\u20139\n\n59. Shafer JS, Naunheim RS. Cervical spine motion during extrication: A pilot study. West J Emerg Med. 2009;10(2):74\u20138\n\n60. Shah MI, Kamin R, Freire J, Jaeger E, Lobo C, Sholl JM. An evidence-based guideline for pediatric prehospital\nspinal care using GRADE methodology. Manuscript in preparation\n\n61. Sochor M, Althoff S, Bose D, Maio R, Deflorio P. Glass intact assures safe cervical spine protocol. J Emerg Med.\n2013;44(3):631\u20136. e1\n\n62. Spinal motion restriction in penetrating trauma: A Practice Management Guideline from the Eastern Association for\nthe Surgery of Trauma (EAST). J Trauma Acute Care Surg. 2018;84(5):736\u2013744\n\n63. Stroh G, Braude D. Can an out-of-hospital cervical spine clearance protocol identify all patients with injuries? An\nargument for selective immobilization. Ann Emerg Med. 2001;37(6):609\u201315\n\n64. Swartz EE, Hernandez AE, Decoster LC, Mihalik JP, Burns MF, Reynolds, C. Prehospital emergency removal of\nfootball helmets using two techniques. Prehosp Emerg Care. 2011;15(2):166\u201374\n\n65. Theodore N, Hadley MN, Aarabi B, et al. Prehospital cervical spinal immobilization after trauma. Neurosurgery.\n2013;72 Suppl 2:22\u201334\n\n66. Vaillancourt C, Stiell IG, Beaudoin T, et al. The out-of-hospital validation of the Canadian C-Spine Rule by\nparamedics. Ann Emerg Med. 2009;54(5):663-71. e1\n\n67.", "start_char_idx": 573376, "end_char_idx": 576455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53916f59-fff6-497f-82c6-4b7831eed5c1": {"__data__": {"id_": "53916f59-fff6-497f-82c6-4b7831eed5c1", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9937b0e1-4130-432e-8d55-cc1aea6411f9", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8bf82984906b4ac3649d75bfdffe58fed0ba5fc348d84e7e39138bfeec99993c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43c217ae-86ed-4b41-aa49-efe0219b8ef4", "node_type": "1", "metadata": {}, "hash": "84df8f73756521824f988bf457d52f4a4d6087639665c762128215c09f0d24b7", "class_name": "RelatedNodeInfo"}}, "text": "An\nargument for selective immobilization. Ann Emerg Med. 2001;37(6):609\u201315\n\n64. Swartz EE, Hernandez AE, Decoster LC, Mihalik JP, Burns MF, Reynolds, C. Prehospital emergency removal of\nfootball helmets using two techniques. Prehosp Emerg Care. 2011;15(2):166\u201374\n\n65. Theodore N, Hadley MN, Aarabi B, et al. Prehospital cervical spinal immobilization after trauma. Neurosurgery.\n2013;72 Suppl 2:22\u201334\n\n66. Vaillancourt C, Stiell IG, Beaudoin T, et al. The out-of-hospital validation of the Canadian C-Spine Rule by\nparamedics. Ann Emerg Med. 2009;54(5):663-71. e1\n\n67. Vanderlan WB, Tew BE, McSwain NE Jr. Increased risk of death with cervical spine Trauma\n\n________________________\n\nGo To TOC\n\n## Rev. March 2022\n\nSpinal Care\n\n247\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n68. Vanderlan WB, Tew BE, Seguin CY, et al. Neurologic sequelae of penetrating cervical trauma. Spine (Phila Pa\n1976). 2009;34(24):2646\u201353\n\n69. Velopulos, C. G., Shihab, H. M., Lottenberg, L., Feinman, M., Raja, A., Salomone, J., & Haut, E. R. Prehospital\nspine immobilization/spinal motion restriction in penetrating trauma: A practice management guideline from the\nEastern Association for the Surgery of Trauma (EAST). Journal of Trauma and Acute Care Surgery, 2018, 84(5),\n736-744.\n\n70. Viccellio P, Simon H, Pressman BD, Shah MN, Mower WR, Hoffman JR. A prospective multicenter study of cervical\nspine injury in children. Pediatrics. 2001;108(2): e20\n\n71. Werman HA, White LJ, Herron H, et al. Clinical clearance of spinal immobilization in the air medical\nenvironment: a feasibility study. J Trauma. 2008;64(6):1539\u201342\n\n72. White CC IV, Domeier RM, Millin MG. EMS spinal precautions and the use of the long backboard \u2013 resource\ndocument to the position statement of the National Association of EMS Physicians and the American College of\nSurgeons Committee on Trauma. Prehosp Emerg Care. 2013; 17:392\u20133\n\n73. White CC, Domeier RM, Millin MG. EMS spinal precautions and the use of the long backboard\u2014resource document to\nthe position statement of the National Association of EMS Physicians and the American College of Surgeons Committee\non Trauma. Prehosp Emerg Care. 2014;18(2):306\u2013314\n\n### Revision Date\n\nMarch 11, 2022\n\nGo To TOC\n\n## Trauma\n\n### Rev. March 2022\n\n## Spinal Care\n\n248\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Trauma Mass Casualty Incident\n\n### Aliases\n\nDisaster\n\nMass casualty incident (MCI)\n\nTrauma triage for multiple casualties overwhelming EMS resources\n\n### Patient Care Goals\n\nSave life and limb for greatest number given resources available\nTriage and transport most critical requiring immediate in-hospital care first\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nTrauma MCI overwhelming immediately available resources\n\n#### Exclusion Criteria\n\nRoutine EMS response for non-MCI for trauma\n\n### Patient Management\n\nSpecial circumstances may occur in any incident in which the resources of the emergency medical services are overwhelmed by the number and severity of casualties.\n\n#### Triage and Treat\n\nEnsure scene safety for EMS clinicians\nSenior EMS clinician rapidly assesses scene and assigns roles and responsibilities to EMS personnel\nSort patients using a locally agreed upon MCI triage process such as SALT (Sort, Assess, Lifesaving Interventions, Treatment/Transport), START/JUMP-START (Simple Triage and Rapid Transport), MUCC (Model Uniform Core Criteria), etc.", "start_char_idx": 575887, "end_char_idx": 579323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43c217ae-86ed-4b41-aa49-efe0219b8ef4": {"__data__": {"id_": "43c217ae-86ed-4b41-aa49-efe0219b8ef4", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53916f59-fff6-497f-82c6-4b7831eed5c1", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "96259949b80c425929d92dc7a7faed7e57ce3ce1a6bb9f9fe362756c1c75abd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ad3447d-121a-4927-b435-36ded6bdc526", "node_type": "1", "metadata": {}, "hash": "8ddf0d00373195e4d66442f8977f00f1a808fbab2fb143d702be1264aaa44583", "class_name": "RelatedNodeInfo"}}, "text": "#### Triage and Treat\n\nEnsure scene safety for EMS clinicians\nSenior EMS clinician rapidly assesses scene and assigns roles and responsibilities to EMS personnel\nSort patients using a locally agreed upon MCI triage process such as SALT (Sort, Assess, Lifesaving Interventions, Treatment/Transport), START/JUMP-START (Simple Triage and Rapid Transport), MUCC (Model Uniform Core Criteria), etc.\nIdentify those in need of immediate life-saving intervention\nTriage categories are recommended and should be guided by local protocols: immediate, delayed, minimal, expectant, dead\nTriage new patients as identified\nRe-triage frequently for duration of MCI\nImmediate life-saving interventions for immediate patients\n\nTreat hemorrhage with tourniquets, direct pressure with assistance from other patients or other devices\nEnsure patent airway by opening airway and using rapid adjuncts\nDecompress tension pneumothorax\nUse autoinjector antidotes if needed\n\n#### Transport\n\nFirst transport immediate patients\n\nThose requiring immediate in-hospital care for life and limb, particularly surgical care (suspected torso hemorrhage, uncontrollable junctional or extremity hemorrhage)\n\n________________________\n\nGo To TOC\n\nTrauma\n\nRev. March 2022\n\nTrauma Mass Casualty Incident\n\n249\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Triage and Transport Decision Making\n\n1. First, immediate transport patients\n\na. Those with injuries requiring immediate transport (e.g., airway intervention, decompressed tension pneumothorax,\neffective tourniquets for extremity hemorrhage or amputations)\n\n2. Second, transport delayed patients\n\na. Continue to re-triage continuously\n\nb. Continue life-saving interventions\n\nc. Initiate urgent required therapy\n\n3. Assess minimal patients for appropriate transport decision\n\n## Patient Safety Considerations\n\n1. Ensure patients remain in safe area\n\n2. Re-assess scene safety as incident progresses as needed\n\n## Notes/Educational Pearls\n\nKey Considerations\n\n1. The most experienced EMS clinician should perform triage.\n\n2. Another experienced EMS clinician should be assigned to immediate patient area and perform life-saving\ninterventions as well as continuous triage.\n\n3. Prioritize patients within immediate group for transport.\n\n4. If available, another EMS clinician should be assigned to delayed area and perform urgent interventions if\npatient condition changes. Continuously triage and prioritize within the delayed patient group for transport.\n\n5. Patient triage category may change with subsequent triage. If need for up-triage occurs, perform life-saving\ninterventions, and move patient to appropriate triage area (delayed or immediate).\n\n6. EMS system leaders within a defined area should work collaboratively to agree upon a common triage tool.\n\n7. Evidence is limited on the highest performing triage tool. Available evidence suggests that the SALT triage tool\nwas most likely to correctly triage adult emergency department patients, but all tested triage tools demonstrated\nrelatively high rates of under triage.\n\n## Pertinent Assessment Findings\n\nNone noted\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (for additional information, go to www.nemsis.org)\n\nNone noted\n\n## Key Documentation Elements\n\nDocument pertinent patient information per local EMS protocol when able and before transport\n\n## Performance Measures\n\nRapidly triage, treat and transport immediate life-threatening injuries\nMaintain scene safety for EMS clinicians and patients\n\n________________________ Go To TOC\n\nTrauma Rev. March 2022\n\nTrauma Mass Casualty Incident 250\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\nContinue triage and treat for all patients until relieved, until all patients transported or dispositioned, and until incident completion\n\n## References\n\nCourtney H. McKee, Robert W. Heffernan, Brian D. Willenbring, Richard B. Schwartz, J. Marc Liu, M. Riccardo Colella & E. Brooke Lerner (2020) Comparing the Accuracy of Mass Casualty Triage Systems When Used in an Adult Population, Prehospital Emergency Care 2019, 24:4, 515\u2013524, DOI: 10.1080/10903127.2019.1641579\nModel Uniform Core Criteria for Mass Casualty Triage, Disaster Med Public Health Prep. 2011 Jun;5(2):125\u20138\nSALT Mass Casualty Triage Concept Endorsed by the American College of Emergency Physicians, American College of Surgeons Committee on Trauma, American Trauma Society, National Association of EMS Physicians, National Disaster Life Support Education Consortium, and State and Territorial Injury Prevention Directors Association. Disaster Medicine and Public Health Preparedness.", "start_char_idx": 578930, "end_char_idx": 583547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ad3447d-121a-4927-b435-36ded6bdc526": {"__data__": {"id_": "3ad3447d-121a-4927-b435-36ded6bdc526", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43c217ae-86ed-4b41-aa49-efe0219b8ef4", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "0251e6ed8cc728e3c189634649344926144aa1af772669f951048077a41e4997", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18e5cd46-9c56-48b3-a643-27847ea52e77", "node_type": "1", "metadata": {}, "hash": "370b5d56634263e856c808d3b1f47a8ed7f9e202357309667e8242799f964560", "class_name": "RelatedNodeInfo"}}, "text": "2011 Jun;5(2):125\u20138\nSALT Mass Casualty Triage Concept Endorsed by the American College of Emergency Physicians, American College of Surgeons Committee on Trauma, American Trauma Society, National Association of EMS Physicians, National Disaster Life Support Education Consortium, and State and Territorial Injury Prevention Directors Association. Disaster Medicine and Public Health Preparedness. 2008; Vol2(4): 245\u20136\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nTrauma Rev. March 2022\n\n### Trauma Mass Casualty Incident 251\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Toxins and Environmental Poisoning/Overdose Universal Care\n\n### Aliases\n\nExposure, Overdose, Poison, Toxin\n\n### Patient Care Goals\n\nRemove patient from hazardous environment. Decontaminate to remove continued sources of absorption, ingestion, inhalation, or injection\nIdentify intoxicating agent by toxidrome or appropriate environmental testing\nAssess risk for organ impairments (heart, brain, kidney)\nIdentify antidote or mitigating agent\nTreat signs and symptoms in effort to stabilize patient\n\n### Patient Presentation\n\nInclusion (suspect exposure) Criteria Presentation may vary depending on the concentration and duration of exposure. Signs and symptoms vary, and may include, but are not limited to, the following:\nAbsorption:\n\nNausea\nVomiting\nDiarrhea\nAltered mental status\nAbdominal pain\nRapid heart rate\nDyspnea\nWheezing\nSeizures\nArrhythmias\nRespiratory depression\nSweating\nTearing\nDefecation\nConstricted/dilated pupils\nRash\nBurns to the skin\n\nIngestion:\n\nNausea\nVomiting\nDiarrhea\nAltered mental status\nAbdominal pain\nRapid or slow heart rate\nDyspnea\nSeizures\n\n________________________\n\nGo To TOC\n\nToxins and Environmental Poisoning/Overdose Universal Care\n\nRev. March 2022\n\n252\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## 2. Toxidromes (constellations of signs and symptoms that aid in the identification of certain classes of medications and their toxic manifestations). These toxidrome constellations may be masked or obscured in polypharmacy events due to counteracting effects of the toxins\n\n### a. Anticholinergic\n\ni. Red as a beet (flushed skin)\n\nii. Dry as a bone (dry skin)\n\niii. Mad as a hatter (altered mental status)\n\niv. Blind as a bat (mydriasis)\n\n## 1. Toxins and Environmental Poisoning/Overdose Universal Care\n\nRev. March 2022\n\nPage: 253\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\nv. Hot as a pistol (hyperthermia)\n\nvi. Full as a flask (urinary retention)\n\nvii. \"Tacky\" like a pink flamingo (tachycardia and hypertension)\n\n## Cholinergic (DUMBELS)\n\nDUMBELS is a mnemonic used to describe the signs and symptoms of acetylcholinesterase inhibitor agent poisoning. All patient age groups are included where the signs and symptoms exhibited are consistent with the toxidrome of DUMBELS\n\ni. Diarrhea\n\nii. Urination\n\niii. Miosis/Muscle weakness\n\niv. Bronchospasm/Bronchorrhea/Bradycardia (the killer Bs)\n\nv. Emesis\n\nvi. Lacrimation\n\nvii. Salivation/Sweating\n\n## Opioids\n\ni. Respiratory depression\n\nii. Miosis (pinpoint pupils)\n\niii. Altered mental status\n\niv. Decreased bowel sounds\n\n## Sedative Hypnotic\n\ni. Central nervous system depression\n\nii. Ataxia (unstable gait or balance)\n\niii. Slurred speech\n\niv. Normal or depressed vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment)\n\n## Stimulants (Sympathomimetic)\n\ni. Tachycardia, tachydysrhythmias\n\nii. Hypertension\n\niii. Diaphoresis\n\niv. Delusions/paranoia\n\nv. Seizures\n\nvi. Hyperthermia\n\nvii. Mydriasis (dilated pupils)\n\n## Serotonin Syndrome (presentation with at least three of the following)\n\ni. Agitation\n\nii.", "start_char_idx": 583151, "end_char_idx": 586828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18e5cd46-9c56-48b3-a643-27847ea52e77": {"__data__": {"id_": "18e5cd46-9c56-48b3-a643-27847ea52e77", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ad3447d-121a-4927-b435-36ded6bdc526", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "0f49c165580a2a5ae8093e212aa97c6dc828851ad4780f5c9df530b33c5b253c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d00b99f9-6510-463a-90b9-1f8e3745dc11", "node_type": "1", "metadata": {}, "hash": "6e1c6536c9226f174ab03e5ac503d14204a4e3b511f6d95d44abb98c336d36af", "class_name": "RelatedNodeInfo"}}, "text": "Salivation/Sweating\n\n## Opioids\n\ni. Respiratory depression\n\nii. Miosis (pinpoint pupils)\n\niii. Altered mental status\n\niv. Decreased bowel sounds\n\n## Sedative Hypnotic\n\ni. Central nervous system depression\n\nii. Ataxia (unstable gait or balance)\n\niii. Slurred speech\n\niv. Normal or depressed vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment)\n\n## Stimulants (Sympathomimetic)\n\ni. Tachycardia, tachydysrhythmias\n\nii. Hypertension\n\niii. Diaphoresis\n\niv. Delusions/paranoia\n\nv. Seizures\n\nvi. Hyperthermia\n\nvii. Mydriasis (dilated pupils)\n\n## Serotonin Syndrome (presentation with at least three of the following)\n\ni. Agitation\n\nii. Ataxia\n\niii. Diaphoresis\n\niv. Diarrhea\n\nv. Hyperreflexia\n\nvi. Mental status changes\n\nvii. Myoclonus\n\nviii. Shivering\n\nix. Tremor\n\nx. Hyperthermia\n\nxi. Tachycardia\n\n________________________ Go To TOC\n\nToxins and Environmental Poisoning/Overdose Universal Care Rev. March 2022 254\n---\n## Exclusion Criteria\n\nNone noted\n\n## Patient Management\n\n### Assessment\n\nMake sure the scene is safe. Use environmental Carbon Monoxide (CO) detector on \"first in\" bag if possible\nConsider body substance isolation (BSI) or appropriate PPE\nAssess ABCD and, if indicated, expose patient for assessment and then re-cover to assure retention of body heat\nVital signs (pulse, blood pressure, respiratory rate, neurologic status assessment) temperature, and O2 saturation including temperature\nAttach cardiac monitor and examine rhythm strip for arrhythmias (consider 12-lead EKG)\nCheck blood glucose level\nMonitor pulse oximetry and end-tidal capnography (EtCO2) for respiratory decompensation\nPerform carboxyhemoglobin device assessment, if available\nWhen indicated, identify specific medication taken (including immediate release vs sustained release), time of ingestion, dose, and quantity. When appropriate, bring all medications (prescribed and not prescribed) found in the environment\nObtain an accurate ingestion history (as patient may become unconscious before arrival at the emergency department (ED)):\n\nTime of ingestion or exposure\nRoute of exposure\nQuantity of medication or toxin taken (safely collect all possible medications or agents)\nAlcohol or other intoxicant taken\n\nIf bringing in exposure agent, consider the threat to yourself and the destination facility\nObtain pertinent cardiovascular history and other prescribed medications\nCheck for needle marks, paraphernalia, bites, bottles, or evidence of agent involved in exposure, self-inflicted injury, or trauma\nLaw enforcement should have checked for weapons and drugs, but you may need to re-check\nObtain any other pertinent patient history\nPerform remainder of physical examination\n\n### Treatment and Interventions\n\nAssure a patent airway\nAdminister oxygen as appropriate with a target of achieving 94\u201398% saturation, and if there is hypoventilation noted, support breathing\nInitiate IV access for infusion of treatment medication and/or lactated Ringer's or normal saline if indicated, and obtain blood samples if EMS management might change based upon the value (e.g., glucose, lactate, cyanide)\nConsider fluid bolus (20 mL/kg) if evidence of hypoperfusion\nAdministration of appropriate antidote or mitigating medication (refer to specific agent guideline if not listed below)\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n### a. Acetaminophen overdose:\n\ni. Consider activated charcoal without sorbitol (1 g/kg) PO only if within the first hour of ingestion and prolonged\ntransport to definitive care\n\nii. Based on suspected quantity and timing, consider acetylcysteine (pediatric and adult), if available\n\n1. Loading dose is acetylcysteine 150 mg/kg IV; mix in 200 mL of dextrose 5% in water (D5W) and infuse over 1 hr\n\n2. After loading dose, give acetylcysteine 50 mg/kg IV in 500 mL D5W over 4 hrs.\n\n3. If IV is not available, acetylcysteine 140 mg/kg PO\n\niii.", "start_char_idx": 586169, "end_char_idx": 590075, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d00b99f9-6510-463a-90b9-1f8e3745dc11": {"__data__": {"id_": "d00b99f9-6510-463a-90b9-1f8e3745dc11", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18e5cd46-9c56-48b3-a643-27847ea52e77", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "ae7c4f8f2b54f7f1890c36dcc72577cb54257ce69a7dd41938988eddff01aafb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43e6c42e-71b3-4523-a906-d599c04a21fd", "node_type": "1", "metadata": {}, "hash": "3a51c2ba0db1586649e4a71de45d9ce73af24ad1077141ee775405874ff4b190", "class_name": "RelatedNodeInfo"}}, "text": "Based on suspected quantity and timing, consider acetylcysteine (pediatric and adult), if available\n\n1. Loading dose is acetylcysteine 150 mg/kg IV; mix in 200 mL of dextrose 5% in water (D5W) and infuse over 1 hr\n\n2. After loading dose, give acetylcysteine 50 mg/kg IV in 500 mL D5W over 4 hrs.\n\n3. If IV is not available, acetylcysteine 140 mg/kg PO\n\niii. If risk of rapidly decreasing mental status, do not administer oral agents\n\n### b. Aspirin overdose:\n\ni. Consider activated charcoal without sorbitol (1 gm/kg) PO only if within the first hour of ingestion\n\n1. As ASA is erratically absorbed, charcoal is highly recommended to be administered early\n\n2. If altered mental status or risk of rapid decreasing mental status from polypharmacy, do not administer oral\nagents including activated charcoal\n\nii. In salicylate poisonings, let the patient breathe on their own, even if tachypneic, until there is evidence of\ndecompensation or dropping oxygen saturation. Acid/base disturbances and outcomes worsen when the patient is\nmanually ventilated\n\n### c. Benzodiazepine overdose:\n\ni. Respiratory support\n\nii. Consider fluid challenge (20 mL/kg) for hypotension\n\niii. Consider vasopressors after adequate fluid resuscitation (1\u20132 liters of crystalloid in adult) for the hypotensive\npatient\n\n### d. Caustic substances ingestion (i.e., acids and alkali):\n\ni. Evaluate for airway compromise secondary to spasm or direct injury associated with oropharyngeal burns\n\n### e. Dystonia (symptomatic), extrapyramidal signs or symptoms, or mild allergic reactions\n\ni. Consider administration of diphenhydramine\n\n1. Adult: diphenhydramine 25\u201350 mg IV or IM\n\n2. Pediatric: diphenhydramine 1\u20131.25 mg/kg IVP/IO or IM (maximum single dose of 25 mg)\n\n### f. Monoamine oxidase inhibitor overdose (symptomatic, e.g., MAOI; isocarboxazid, phenelzine, selegiline,\ntranylcypromine)\n\ni. Consider administration of midazolam for temperature control\n\nii. Adult and Pediatric: Midazolam 0.1 mg/kg in 2 mg increments slow IV push over one to two minutes per increment\nwith maximum single dose 5 mg \u2014 reduce by 50% for patients 69 years old or older\n\n### g. Opiate overdose, treat per the Opioid Poisoning/Overdose Guideline\n\n### h. Oral ingestion unknown poisoning:\n\ni. If there is a risk of rapidly decreasing mental status or for petroleum-based ingestions, do not administer oral\nagents\n\nii. Consider administration of activated charcoal without sorbitol (1 g/kg)\n\n________________________ Go To TOC\n\nToxins and Environmental Poisoning/Overdose Universal Care Rev. March 2022 256\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nPO particularly if it is within the first 1 hour after ingestion (including acetaminophen) and there will be prolonged\ntransport to definitive care.", "start_char_idx": 589718, "end_char_idx": 592505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43e6c42e-71b3-4523-a906-d599c04a21fd": {"__data__": {"id_": "43e6c42e-71b3-4523-a906-d599c04a21fd", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d00b99f9-6510-463a-90b9-1f8e3745dc11", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "b12b301d6df51155452821c27cca03c1da78cfdb920103906cd1e3d8527d2061", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57481040-2e71-4a0b-b48b-7be0a81156f8", "node_type": "1", "metadata": {}, "hash": "ebcd1f03ce8b7146790a7d73e7e0101d17ba9cdb1178228855165a4294a8cfa4", "class_name": "RelatedNodeInfo"}}, "text": "Consider administration of activated charcoal without sorbitol (1 g/kg)\n\n________________________ Go To TOC\n\nToxins and Environmental Poisoning/Overdose Universal Care Rev. March 2022 256\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nPO particularly if it is within the first 1 hour after ingestion (including acetaminophen) and there will be prolonged\ntransport to definitive care.\n\n### Selective serotonin reuptake inhibitors (SSRIs)\n\nConsider early airway management\n\nTreat arrhythmias following Advanced Cardiac Life Support (ACLS) guidelines\n\nAggressively control hyperthermia with cooling measures\n\nConsider fluid challenge (20 mL/kg) for hypotension\n\nConsider vasopressors after adequate fluid resuscitation (1\u20132 liters of crystalloid in adult) for the hypotensive\npatient [See Shock Guideline]\n\nFor agitation, consider midazolam\n\nAdult: midazolam 0.1 mg/kg in 2 mg increments slow IV push over one to two minutes per increment with maximum\nsingle dose 5 mg\n\nReduce by 50% for patients 69 years or older\n\nPediatric: midazolam 0.1 mg/kg in 2 mg increments slow IV push over one to two minutes per increment with maximum\nsingle dose 4 mg or midazolam 0.2 mg/kg IN to maximum single dose of 10 mg\n\nFor seizures, treat per Seizures Guideline\n\n### Tricyclic Antidepressant (TCA)/Sodium Channel Blocker Overdose\n\nConsider early airway management\n\nIf widened QRS (100 msec or greater), consider sodium bicarbonate 1\u20132 mEq/kg IV, this can be repeated as needed to\nnarrow QRS and improve blood pressure\n\nConsider fluid challenge (20 mL/kg) for hypotension\n\nConsider vasopressors after adequate fluid resuscitation (1\u20132 liters of crystalloid) for the hypotensive patient [See\nShock Guideline]\n\nFor agitation, consider midazolam\n\nAdult: midazolam 0.1 mg/kg in 2 mg increments slow IV push over one to two minutes per increment with maximum\nsingle dose 5 mg\n\nReduce by 50% for patients 69 years or older\n\nPediatric: midazolam 0.1 mg/kg in 2 mg increments slow IV push over one to two minutes per increment with maximum\nsingle dose 4 mg or midazolam 0.2 mg/kg IN to maximum single dose of 10 mg\n\nFor seizure, treat per Seizures Guideline\n\n## Patient Safety Considerations\n\nScene/environmental safety for patient and clinician\n\nConsider environmental carbon monoxide monitor use\n\nMonitor patient airway, breathing, pulse oximetry, EtCO2 for adequate ventilation as they may change over time\nRepeat vital signs often\nMonitor level of consciousness\nMonitor EKG with special attention to rate, rhythm, QRS and QT duration\nMaintain or normalize patient temperature\n\nGo To TOC\n\nToxins and Environmental\n\nPoisoning/Overdose Universal Care\n\nRev. March 2022\n\n257\n---\nNASEMSO\n\nNASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n7. The regional poison center should be engaged as early as reasonably possible to aid in appropriate therapy and to track patient outcomes to improve knowledge of toxic effects. The national 24-hour toll-free telephone number to poison control centers is (800) 222- 1222, and it is a resource for free, confidential expert advice from anywhere in the United States\n\n### Notes/Educational Pearls\n\nKey Considerations\n\nEach toxin or overdose has unique characteristics which must be considered in individual protocols\nActivated charcoal (which does not bind to all medications or agents) is still a useful adjunct in the serious-agent, enterohepatic, or extended-release agent poisoning if the patient does not have the potential for rapid alteration of mental status or airway/aspiration risk.", "start_char_idx": 592088, "end_char_idx": 595640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57481040-2e71-4a0b-b48b-7be0a81156f8": {"__data__": {"id_": "57481040-2e71-4a0b-b48b-7be0a81156f8", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43e6c42e-71b3-4523-a906-d599c04a21fd", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "ce035e84517153199906569aaf2f63e32043fb6eca417f504260758e192d2fab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "501aa4df-f3f5-409d-adbd-ea2532add26f", "node_type": "1", "metadata": {}, "hash": "cf5b8923f99858a5d90a65cc33d51177886132b4f760c06a4d2d2feb6aea204a", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n257\n---\nNASEMSO\n\nNASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n7. The regional poison center should be engaged as early as reasonably possible to aid in appropriate therapy and to track patient outcomes to improve knowledge of toxic effects. The national 24-hour toll-free telephone number to poison control centers is (800) 222- 1222, and it is a resource for free, confidential expert advice from anywhere in the United States\n\n### Notes/Educational Pearls\n\nKey Considerations\n\nEach toxin or overdose has unique characteristics which must be considered in individual protocols\nActivated charcoal (which does not bind to all medications or agents) is still a useful adjunct in the serious-agent, enterohepatic, or extended-release agent poisoning if the patient does not have the potential for rapid alteration of mental status or airway/aspiration risk. Precautions should be taken to avoid or reduce the risk of aspiration\nIpecac is not recommended for any poisoning or toxic ingestion \u2014 the manufacturer has stopped production of this medication\nFlumazenil is not indicated in a suspected benzodiazepine overdose as it can precipitate refractory/intractable seizures if the patient is a benzodiazepine dependent patient\n\n### Pertinent Assessment Findings\n\nFrequent reassessment is essential as patient deterioration can be rapid and catastrophic\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914135\u2014General - Overdose/Poisoning/Toxic Ingestion\n\n### Key Documentation Elements\n\nRepeat evaluation and documentation of signs and symptoms as patient clinical conditions may deteriorate rapidly\nIdentification of possible etiology of poisoning\nInitiating measures on scene to prevent exposure of bystanders when appropriate/indicated\nTime of symptoms onset and time of initiation of exposure-specific treatments\n\n### Performance Measures\n\nEarly airway management in the rapidly deteriorating patient\nAccurate exposure history\n\nTime of ingestion/exposure\nRoute of exposure\nQuantity of medication or toxin taken (safely collect all possible mediations or agents)\nAlcohol or other intoxicant taken\n\nAppropriate protocol selection and management\nMultiple frequent documented reassessments\n\n### References\n\nBoyer EW, Shannon MS. The serotonin syndrome. N Engl J M ed. 2005; 352:1112\u201320\nBruccoleri RE, Burns MM. A Literature Review of the Use of Sodium Bicarbonate for the Toxins and Environmental Poisoning/Overdose Universal Care\n\n________________________ Go To TOC\n\nToxins and Environmental Poisoning/Overdose Universal Care\n\nRev. March 2022\n\n258\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\nTreatment of QRS Widening. J Med Toxicol. 2016 Mar;12(1):121-9. doi: 10.1007/s13181-015-0483-y. PMID: 26159649;\nPMCID: PMC4781799\n\n3. Cushing TA. Selective Serotonin Reuptake Inhibitor Toxicity https://emedicine.medscape.com/article/821737-overview.\nUpdated April 24, 2018. Accessed March 11, 2022\n\n4. Gresham C. Benzodiazepine toxicity treatment and management. http://emedicine.medscape.com/article/813255-treatment#d10.\nUpdated January 23, 2020. Accessed March 11, 2022\n\n5. Hoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR. Goldfrank's Toxicologic Emergencies, 10th Edition.\nChina: McGraw -Hill Education; 2015. http://accessemergencymedicine.mhmedical.com/book.aspx?bookID=1163\nAccessed March 11, 2022\n\n6. Lemyze M, Masse J, Queva C, Huchette D. Cardiac effect of sodium bicarbonate in sodium-channel blocker poisoning.\nIntensive Care Med. 2016 Apr;42(4):588-590. doi: 10.1007/s00134-015-4122-5\n\n7. Spiller H. A prospective evaluation of the effect of activated charcoal before N-Acetyl cysteine in acetaminophen\noverdose. Ann of Emerg Med. 1994;23(3):519 -23\n\n8. Tsai V. Tricyclic Antidepressant Toxicity. http://emedicine.medscape.com/article/819204-overview.", "start_char_idx": 594755, "end_char_idx": 598646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "501aa4df-f3f5-409d-adbd-ea2532add26f": {"__data__": {"id_": "501aa4df-f3f5-409d-adbd-ea2532add26f", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57481040-2e71-4a0b-b48b-7be0a81156f8", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "af2ee902b28cb54d2996756e6c3de0921964dc78ed6cdd9796465a63997bfc03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fcb2b47-0b13-4d84-893a-961eee50260d", "node_type": "1", "metadata": {}, "hash": "096a1e55b2674ccce3c8984a0c95a5177cd9c67382ff97778406919f7e4c87eb", "class_name": "RelatedNodeInfo"}}, "text": "Lemyze M, Masse J, Queva C, Huchette D. Cardiac effect of sodium bicarbonate in sodium-channel blocker poisoning.\nIntensive Care Med. 2016 Apr;42(4):588-590. doi: 10.1007/s00134-015-4122-5\n\n7. Spiller H. A prospective evaluation of the effect of activated charcoal before N-Acetyl cysteine in acetaminophen\noverdose. Ann of Emerg Med. 1994;23(3):519 -23\n\n8. Tsai V. Tricyclic Antidepressant Toxicity. http://emedicine.medscape.com/article/819204-overview.\nUpdated May 19, 2020. Accessed March 11, 2022\n\n9. Wolf S. Clinical policy: critical issues in the management of patients presenting to the emergency department with\nacetaminophen overdose. Ann of Emerg Med. 2007;50(3):292\u2013 313\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nToxins and Environmental Poisoning/Overdose Universal Care Rev. March 2022 259\n---\n# National Model EMS Clinical Guidelines - Version 3.0\n\n# National Model EMS Clinical Guidelines - Version 3.0\n\n## Acetylcholinesterase Inhibitors (Carbamates, Nerve Agents, Organophosphates) Exposure\n\nAliases: Acetylcholinesterase inhibitor, Carbamate, Insecticide, Nerve agent, Organophosphate, Pesticide, Weapons of mass destruction (WMD)\n\n### Patient Care Goals\n\nRapid recognition of the signs and symptoms of confirmed or suspected acetylcholinesterase inhibitor (AChEI) agents such as carbamates, nerve agents, or organophosphates exposure followed by expeditious and repeated administration of atropine, the primary antidote\nCarbamates and organophosphates are commonly active agents in commercial insecticides\nAccidental carbamate exposure rarely requires treatment\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nDUMBELS is a mnemonic used to describe the signs and symptoms of acetylcholinesterase inhibitor agent poisoning. All patient age groups are included where the signs and symptoms exhibited are consistent with the toxidrome of DUMBELS\n\nDiarrhea\nUrination\nMiosis/Muscle weakness\nBronchospasm/Bronchorrhea/Bradycardia (the killer Bs)\nEmesis\nLacrimation\nSalivation/Sweating\n\n#### Exclusion Criteria\n\nNone noted\n\n### Patient Management\n\nDon the appropriate PPE\nRemove the patient's clothing and wash the skin with soap and warm water\n\nAcetylcholinesterase inhibitor agents can be absorbed through the skin\nContaminated clothing can provide a source of continued exposure to the toxin\n\nRapidly assess the patient's respiratory status, mental status, and pupillary status\nAdminister the antidote atropine immediately for confirmed or suspected acetylcholinesterase inhibitor agent exposure\nAdminister oxygen as appropriate with a target of achieving 94\u201398% saturation and provide airway management\nEstablish intravenous access (if possible)\nApply a cardiac monitor (if available)\n\nThe heart rate may be normal, bradycardic, or tachycardic\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nAcetylcholinesterase Inhibitors (Carbamates, Nerve Agents, Organophosphates) Exposure\n\n260\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Toxins and Environmental - Acetylcholinesterase Inhibitors (Carbamates, Nerve Agents, Organophosphates) Exposure\n\n9. Clinical improvement should be based upon the drying of secretions and easing of respiratory effort rather than heart\nrate or pupillary response\n\n10.", "start_char_idx": 598191, "end_char_idx": 601454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fcb2b47-0b13-4d84-893a-961eee50260d": {"__data__": {"id_": "0fcb2b47-0b13-4d84-893a-961eee50260d", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "501aa4df-f3f5-409d-adbd-ea2532add26f", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "e0a600204aca6d5991b98ffe197bdb92ad580f1e441b1eb0c63ce63312fea8df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b8517c0-5e2c-4ff2-8847-77ebe7162328", "node_type": "1", "metadata": {}, "hash": "e0a4b4e66a49887a7b6a172541e423e8545ff200fde43f8af2c01edb5cdc3c0e", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nAcetylcholinesterase Inhibitors (Carbamates, Nerve Agents, Organophosphates) Exposure\n\n260\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Toxins and Environmental - Acetylcholinesterase Inhibitors (Carbamates, Nerve Agents, Organophosphates) Exposure\n\n9. Clinical improvement should be based upon the drying of secretions and easing of respiratory effort rather than heart\nrate or pupillary response\n\n10. Continuous and ongoing patient reassessment is critical\n\n### Assessment\n\nAcetylcholinesterase inhibitor agents are highly toxic chemical agents and can rapidly be fatal\nPatients with low-dose chronic exposures may have a more delayed presentation of symptoms\nAntidotes (atropine and pralidoxime) are effective if administered before circulation fails\nThe patient may develop:\n\nMiosis (pinpoint pupils)\nBronchospasm\nBradycardia\nVomiting\nExcessive secretions in the form of:\n\nTearing\nSalivation\nRhinorrhea\nDiarrhea\nUrination\nBronchorrhea\n\nPenetration of an acetylcholinesterase inhibitor agent into the central nervous system (CNS) will cause:\n\nHeadache\nConfusion\nGeneralized muscle weakness\nSeizures\nLethargy or unresponsiveness\n\nEstimated level of exposure based upon signs and symptoms\n\nMild\n\nMiosis alone (while this is a primary sign in vapor exposure, it may not be present is all exposures)\nMiosis and severe rhinorrhea\n\nMild to moderate (in addition to symptoms of mild exposure)\n\nLocalized swelling\nMuscle fasciculations\nNausea and vomiting\nWeakness\nShortness of breath\n\nSevere (in addition to symptoms of mild to moderate exposure)\n\nUnconsciousness\nConvulsions\nApnea or severe respiratory distress requiring assisted ventilation\nFlaccid paralysis\n\nOnset of symptoms can be immediate with an exposure to a large amount of the acetylcholinesterase inhibitor\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\na. There is usually an asymptomatic interval of minutes after liquid exposure before these symptoms occur\n\nb. Effects from vapor exposure occur almost immediately\n\n8. Signs and symptoms with large acetylcholinesterase inhibitor agent exposures (regardless of route)\n\na. Sudden loss of consciousness\n\nb. Seizures\n\nc. Copious secretions\n\nd. Apnea\n\ne. Death\n\n9. Obtain an accurate exposure history (as patient may become unconscious before arrival at the ED:\n\na. Time of ingestion or exposure\n\nb. Route of exposure\n\nc. Quantity of medication or toxin taken (safely collect all possible medications or agents)\n\nd. Alcohol or other intoxicant taken\n\ne. Pertinent cardiovascular history or other prescribed medications for underlying disease\n\n10. The patient can manifest any of the signs and symptoms of the toxidrome based on the route of exposure, agent involved, and concentration of the agent:\n\na. Vapor exposures will have a direct effect on the eyes and pupils causing miosis\n\nb. Patients with isolated skin exposures will have normally reactive pupils\n\nc. Certain acetylcholinesterase inhibitor agents can place the patient at risk for both a vapor and skin exposure\n\nTreatment and Interventions (See dosing tables)\n\n1. Medications:\n\na. Atropine\n\ni. Atropine is the primary antidote for organophosphate, carbamate, or nerve agent exposures, and repeated doses should be administered liberally to patients who exhibit signs and symptoms of exposure or toxicity\n\nii. Atropine may be provided in multi-dose vials, pre-filled syringes, or auto-injectors\n\nb. Pralidoxime chloride (2-PAM)\n\ni. Pralidoxime chloride is a secondary treatment and should be given concurrently to reactivate acetylcholinesterase\n\nii. Pralidoxime chloride may be provided in a single dose vial, pre-filled syringes, or auto-injectors\n\niii. Auto-injectors typically contain 600 mg of pralidoxime chloride\n\niv. To be beneficial to the victim, a dose of pralidoxime chloride should be administered shortly after the nerve agent or organophosphate poisoning as it has minimal clinical effect if administration is delayed\n\nc. Benzodiazepines\n\ni. Benzodiazepines are administered as an anticonvulsant for those patients who exhibit seizure activity [See Seizures Guideline for doses and routes of administration]\n\nii.", "start_char_idx": 601024, "end_char_idx": 605184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b8517c0-5e2c-4ff2-8847-77ebe7162328": {"__data__": {"id_": "3b8517c0-5e2c-4ff2-8847-77ebe7162328", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fcb2b47-0b13-4d84-893a-961eee50260d", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "d0870a2ecf5d34b94a00923583291281196b38c0a516d336e8d70e02b4a0d536", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1dce9361-c062-49ba-809a-3183a280c0c8", "node_type": "1", "metadata": {}, "hash": "cdd4de8c349065d9b623f8dd8540162e467532d3d341b8c41ae5580afdf4215d", "class_name": "RelatedNodeInfo"}}, "text": "Pralidoxime chloride may be provided in a single dose vial, pre-filled syringes, or auto-injectors\n\niii. Auto-injectors typically contain 600 mg of pralidoxime chloride\n\niv. To be beneficial to the victim, a dose of pralidoxime chloride should be administered shortly after the nerve agent or organophosphate poisoning as it has minimal clinical effect if administration is delayed\n\nc. Benzodiazepines\n\ni. Benzodiazepines are administered as an anticonvulsant for those patients who exhibit seizure activity [See Seizures Guideline for doses and routes of administration]\n\nii. Lorazepam, diazepam, and midazolam are the most frequently used benzodiazepines in the prehospital setting; midazolam may have the fastest\n\nGo To TOC\n\nToxins and Environmental\n\nAcetylcholinesterase Inhibitors (Carbamates, Nerve Agents, Organophosphates) Exposure\n\nRev. March 2022\n\n262\n---\nNASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\nonset of action\n\nBenzodiazepines may be provided in multi-dose or single-dose vials, pre-filled syringes, or auto-injectors\nCANA\u00ae (Convulsive Antidote Nerve Agent) is a commercially available auto-injector that contains 10 mg of diazepam\n\nDuodote\u00ae\n\nA commercially available auto-injector of nerve agent/organophosphate antidote\nDuodote\u00ae is one auto-injector that contains 2.1 mg of atropine and 600 mg of pralidoxime chloride\n\nATNAA\u00ae (Antidote Treatment Nerve Agent Auto-injector)\n\nAn auto-injector of nerve agent/organophosphate antidote that is typically in military supplies\nATNAA\u00ae is one auto-injector that contains 2.1 mg of atropine and 600 mg of pralidoxime chloride\nATNAA\u00ae may be seen in civilian supplies assets when Duodote\u00ae is unavailable or in short supply\n\nCHEMPACK\n\nFederal cache of nerve agent antidotes that is managed by the Centers for Disease Control and Prevention (CDC) and offered to states that voluntarily agree to maintain custody and security of CHEMPACK assets\nThese are forward-deployed at sites determined by states that are part of the program such as hospitals and EMS centers\nDeployment of CHEMPACKs is reserved for events where the nerve agent/organophosphate exposure will deplete the local or regional supply of antidotes\nThere are two types of CHEMPACK containers:\n\nEMS Containers: CHEMPACK assets for EMS contain a large portion of auto-injectors for rapid administration of antidotes by EMS clinicians of all levels of licensure/certification. They contain enough antidote to treat roughly 454 patients\nHospital Containers: CHEMPACK assets contain a large portion of multidose vials and powders for reconstitution \u2014 they contain enough antidote to treat roughly 1,000 patients\n\nMedication Administration:\n\nAtropine, in large and potentially multiple doses, is the antidote for an acetylcholinesterase inhibitor agent poisoning\nAtropine should be administered immediately followed by repeated doses until the patient's secretions resolve\nPralidoxime chloride (2-PAM) is a secondary treatment and, when possible, should be administered concurrently with atropine\nThe stock of atropine and pralidoxime chloride available to EMS clinicians is usually not sufficient to fully treat the victim of an acetylcholinesterase inhibitor agent exposure; however, EMS clinicians should initiate the administration of atropine and, if available, pralidoxime chloride\nSeizures should be treated with benzodiazepines. There is some emerging evidence that, for midazolam, the intranasal route of administration may be\n\n________________________\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nAcetylcholinesterase Inhibitors (Carbamates, Nerve Agents, Organophosphates) Exposure\n\n263\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n3. Recommended Doses (See dosing tables)\n\nThe medication dosing tables that are provided below are based upon the severity of the clinical signs and symptoms exhibited by the patient. There are several imperative factors to note:\n\na. For organophosphate or severe acetylcholinesterase inhibitor agent exposure, the required dose of atropine necessary to dry secretions and improve the respiratory status may exceed 20 mg.", "start_char_idx": 604608, "end_char_idx": 608742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1dce9361-c062-49ba-809a-3183a280c0c8": {"__data__": {"id_": "1dce9361-c062-49ba-809a-3183a280c0c8", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b8517c0-5e2c-4ff2-8847-77ebe7162328", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "41447ed38422a503367badeb6364c62812c71cb1c35548872b2cb99ffc45a1a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffb16ab1-8580-4243-a4c9-7d31c12a621b", "node_type": "1", "metadata": {}, "hash": "07f9155d1c63e54d75738f492d500e255b2e270da7b41fc548fcc349d2033c25", "class_name": "RelatedNodeInfo"}}, "text": "There is some emerging evidence that, for midazolam, the intranasal route of administration may be\n\n________________________\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nAcetylcholinesterase Inhibitors (Carbamates, Nerve Agents, Organophosphates) Exposure\n\n263\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n3. Recommended Doses (See dosing tables)\n\nThe medication dosing tables that are provided below are based upon the severity of the clinical signs and symptoms exhibited by the patient. There are several imperative factors to note:\n\na. For organophosphate or severe acetylcholinesterase inhibitor agent exposure, the required dose of atropine necessary to dry secretions and improve the respiratory status may exceed 20 mg. Atropine should be administered rapidly and repeatedly until the patient's clinical symptoms diminish. Atropine must be given until the acetylcholinesterase inhibitor agent has been metabolized.\n\nb. Because Duodote\u00ae auto-injectors contain pralidoxime chloride, they should not be used for additional dosing of atropine beyond the recommended administered dose of pralidoxime chloride\n\nc. All the medications below can be administered intravenously in the same doses cited for the intramuscular route. However, due to the rapidity of onset of signs, symptoms, and potential death from acetylcholinesterase inhibitor agents, intramuscular administration is highly recommended to eliminate the inherent delay associated with establishing intravenous access\n\nd. The antidotes can be administered via the intraosseous route. However, due to the rapidity of onset of signs, symptoms, and potential death from acetylcholinesterase inhibitor agents, intramuscular administration remains the preferable due to the inherent delay associated with establishing intraosseous access and the limited use of this route of administration for other medications\n\nGo To TOC\n\nToxins and Environmental\n\nAcetylcholinesterase Inhibitors (Carbamates, Nerve Agents, Organophosphates) Exposure\n\nRev. March 2022\n\n264\n---\n# NASEMSO National Model EMS Clinical Guidelines\n\n## Version 3.0\n\n### Table 1. Mild Acetylcholinesterase Inhibitor Agent Exposure\n\n|Patient|Atropine Dose (Weight) IM or via Auto-injector|\n|---|---|\n|Infant: 0\u20132 years of age|0.05 mg/kg IM or via auto-injector (i.e., 0.25 and/or 0.5 mg auto-injector(s))|\n|Child: 3\u20137 years of age (13\u201325 kg)|1 mg IM or via auto-injector (i.e., one 1 mg or two 0.5 mg auto-injectors)|\n|Child: 8\u201314 years of age (26\u201350 kg)|2 mg IM or via auto-injector (i.e., one 2 mg or two 1 mg auto-injectors)|\n|Adolescent/Adult|2 mg IM or via auto-injector|\n|Pregnant Women|2 mg IM or via auto-injector|\n|Geriatric/Frail|1 mg IM or via auto-injector|\n\nAdapted from: U.S. Department of Health and Human Services, ASPR, National Library of Medicine, Chemical Hazards\nEmergency Medical Management: Nerve Agents\u2014 Prehospital Management,\nSource\n\n### Table 2.", "start_char_idx": 607976, "end_char_idx": 610906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffb16ab1-8580-4243-a4c9-7d31c12a621b": {"__data__": {"id_": "ffb16ab1-8580-4243-a4c9-7d31c12a621b", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1dce9361-c062-49ba-809a-3183a280c0c8", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "cbaae55dfb07d4c27df05e21bf2cd4a006de17760394335c4263d38c92d4f217", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73637211-3e06-4849-a900-ba6c48bf8e5e", "node_type": "1", "metadata": {}, "hash": "60c9214213d8eb5c3efd3c89947277c708202c7c78223f96737707aaab12e97e", "class_name": "RelatedNodeInfo"}}, "text": "Department of Health and Human Services, ASPR, National Library of Medicine, Chemical Hazards\nEmergency Medical Management: Nerve Agents\u2014 Prehospital Management,\nSource\n\n### Table 2. Mild to Moderate Acetylcholinesterase Inhibitor Agent Exposure\n\n|Patient (Weight)|Atropine Dose IM or via Auto-injector|Pralidoxime Chloride Dose IM or via 600 mg Auto-injector|\n|---|---|---|\n|Infant: 0\u20132 years of age|0.05 mg/kg IM or via auto-injector (i.e., 0.25 mg and/or 0.5 mg auto-injector)|15 mg/kg IM|\n|Child: 3\u20137 years of age (13\u201325 kg)|1 mg IM or via auto-injector (i.e., one 1 mg auto-injector or two 0.5 mg auto-injectors)|15 mg/kg IM OR One auto-injector (600 mg)|\n|Child: 8\u201314 years of age (26\u201350 kg)|2 mg IM or via auto-injector (i.e., one 2 mg auto-injector or two 1 mg auto-injectors)|15 mg/kg IM OR One auto-injector (600 mg)|\n|Adolescent/Adult|2\u20134 mg IM or via auto-injector|15 mg/kg IM OR One auto-injector (600 mg)|\n|Pregnant Women|2\u20134 mg IM or via auto-injector|10 mg/kg IM OR One auto-injector (600 mg)|\n|Geriatric/Frail|2 mg IM or via auto-injector|15 mg/kg IM OR One auto-injector (600 mg)|\n\nAdapted from: U.S. Department of Health and Human Services, ASPR, National Library of Medicine, Chemical Hazards\nEmergency Medical Management: Nerve Agents\u2014 Prehospital Management,\nSource\n\n________________________Go To TOC\n\nToxins and Environmental Acetylcholinesterase Inhibitors (Carbamates, Nerve Agents, Organophosphates) Exposure\n\nRev. March 2022\n\n265\n---\n## Table 3. Severe Acetylcholinesterase Inhibitor Agent Exposure\n\n|Patient (Weight)|Atropine Dose (IM or via 600 mg Auto-injector)|Pralidoxime Chloride Dose (IM or via Auto-injector)|\n|---|---|---|\n|Infant:   0\u20132 years of age|0.1 mg/kg IM or via auto-injector   (i.e., 0.25 mg and/or 0.5 mg auto-injector)|45 mg/kg IM|\n|Child:   3\u20137 years of age   (13\u201325 kg)|0.1 mg/kg IM OR   2 mg via auto-injector   (i.e., one 2 mg auto-injector or four 0.5 mg auto-injectors)|45 mg/kg IM OR   One auto-injector (600 mg)|\n|Child:   8\u201314 years of age   (26\u201350 kg)|4 mg IM or via auto-injector   (i.e., two 2 mg auto-injectors or four 1 mg auto-injectors)|45 mg/kg IM OR   Two auto-injectors (1200 mg)|\n|Adolescent:   14 years of age or older|6 mg IM or via auto-injector   (i.e., three 2 mg auto-injectors)|Three auto-injectors (1800 mg)|\n|Adult|6 mg IM or via auto-injector   (i.e., three 2 mg auto-injectors)|Three auto-injectors (1800 mg)|\n|Pregnant Women|6 mg IM or via auto-injector   (i.e., three 2 mg auto-injectors)|Three auto-injectors (1800 mg)|\n|Geriatric/Frail|2\u20134 mg IM or via auto-injector   (i.e., one to two 2 mg auto-injectors)|25 mg/kg IM OR   two to three auto-injectors (1200 mg\u20131800 mg)|\n\nAdapted from: U.S.", "start_char_idx": 610724, "end_char_idx": 613398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73637211-3e06-4849-a900-ba6c48bf8e5e": {"__data__": {"id_": "73637211-3e06-4849-a900-ba6c48bf8e5e", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffb16ab1-8580-4243-a4c9-7d31c12a621b", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "7956c4d38e5efe28c48747c55a2807fb443dd514167d1db8826a32e83fc5d89d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99c04a38-ede0-4d32-97d5-7dadfd17ace1", "node_type": "1", "metadata": {}, "hash": "5cfedb7b2e8b799e418c302b54ee1297c1e28ebaffd2fa9ada07d342b0d9c060", "class_name": "RelatedNodeInfo"}}, "text": "Department of Health and Human Services, ASPR, National Library of Medicine, Chemical Hazards\nEmergency Medical Management: Nerve Agents\u2014 Prehospital Management,\nLink\n---\n# National Model EMS Clinical Guidelines NASEMSO Version 3.0\n\n|Patient|Diazepam|Midazolam|\n|---|---|---|\n|Infant (0\u20132 y/o)|0.2\u20130.5 mg/kg IM Repeat q 2\u20135 minutes 0.2\u20130.5 mg/kg IV q 15\u201330 minutes May repeat twice as needed Total maximum dose: 5 mg|0.2 mg/kg IM Repeat prn in 10 minutes May repeat dose once Total maximum dose: 0.4 mg/kg|\n|Child (3\u201313 y/o)|0.2\u20130.5 mg/kg IM Repeat q 2\u20135 minutes 0.2\u20130.5 mg/kg IV q 15\u201330 minutes May repeat dose twice if needed Total maximum dose: 5 mg if less than 5 years Total maximum dose: 10 mg if age 5 years or older 1 CANA\u00ae auto-injector|0.2 mg/kg IM Not to exceed 10 mg May repeat dose once Total maximum dose: 0.4 mg/kg Not to exceed 20 mg 0.2 mg/kg IM Total maximum dose of 10 mg Repeat prn in 10 minutes|\n|Adolescent: 14 y/o or older|5\u201310 mg IV q 15 minutes Total maximum dose: 30 mg 2\u20133 CANA\u00ae auto-injectors|10 mg IM May repeat dose once Total maximum dose: 20 mg 10 mg IM Repeat prn in 10 minutes|\n|Adult|5\u201310 mg IV q 15 minutes Total maximum dose: 30 mg 2\u20133 CANA\u00ae auto-injectors|10 mg IM May repeat dose once Total maximum dose: 20 mg 10 mg IM|\n|Pregnant Women|5\u201310 mg IV q 15 minutes Total maximum dose: 30 mg 2\u20133 CANA\u00ae auto-injectors|10 mg IM May repeat dose once Total maximum dose: 20 mg 10 mg IM Repeat prn in 10 minutes|\n|Geriatric|5\u201310 mg IV q 15 minutes Total maximum dose: 30 mg|10 mg IM May repeat dose once Total maximum dose: 20 mg|\n\nAdapted from: U.S. Department of Health and Human Services, ASPR, National Library of Medicine, Chemical Hazards Emergency Medical Management: Nerve Agents \u2014 Prehospital Management, Source\n\n## Patient Safety Considerations\n\nContinuous and ongoing patient reassessment is critical\nClinical response to treatment is demonstrated by the drying of secretion and the easing of respiratory effort\nInitiation of and ongoing treatment should not be based upon heart rate or\n\n________________________Go To TOC\n\nToxins and Environmental Acetylcholinesterase Inhibitors (Carbamates, Nerve Agents, Organophosphates) Exposure\n\nRev. March 2022\n\n267\n---\n## National Model EMS Clinical Guidelines Version 3.0\n\npupillary response\n\nPrecautions for pralidoxime chloride administration:\n\nAlthough Duodote\u00ae and ATNAA\u00ae contains atropine, the primary antidote for an acetylcholinesterase inhibitor agent poisoning, the inclusion of pralidoxime chloride in the auto-injector can present challenges if additional doses of atropine are warranted by the patient condition and other formulations of atropine are unavailable:\n\nPediatrics: an overdose of pralidoxime chloride may cause profound neuromuscular weakness and subsequent respiratory depression\nAdults: Especially for the geriatric victim, excessive doses of pralidoxime chloride may cause severe systolic and diastolic hypertension, neuromuscular weakness, headache, tachycardia, and visual impairment\nGeriatrics: victim who may have underlying medical conditions, particularly impaired kidney function or hypertension, the EMS clinician should consider administering the lower recommended adult dose of intravenous pralidoxime chloride\n\nConsiderations during the use of auto-injectors\n\nIf an auto-injector is administered, a dose calculation prior to administration is not necessary\nFor atropine, additional auto-injectors should be administered until secretions diminish.", "start_char_idx": 613399, "end_char_idx": 616865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99c04a38-ede0-4d32-97d5-7dadfd17ace1": {"__data__": {"id_": "99c04a38-ede0-4d32-97d5-7dadfd17ace1", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73637211-3e06-4849-a900-ba6c48bf8e5e", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "744305a2259c0c6c226379f4fea738e63a9bf41b12dcf92b53efcbc4483cf53d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a0c2f99-1b79-412c-9dcf-007eba999855", "node_type": "1", "metadata": {}, "hash": "d9753a31e70717d1949e2c45650dc54982004ed6ae43ba382411f932282d64fa", "class_name": "RelatedNodeInfo"}}, "text": "Mark 1 kits, Duodote\u00ae and ATNAA\u00ae have not been approved for pediatric use by the Food and Drug Administration (FDA), but they can be considered for the initial treatment for children of any age with severe symptoms of an acetylcholinesterase inhibitor agent poisoning especially if other formulations of atropine are unavailable\nPediatric Atro-Pen\u00ae auto-injectors are commercially available in a 0.25 mg auto-injector (yellow) and a 0.5 mg auto-injector (red). Atro-Pen\u00ae auto-injectors are commercially available in a 1 mg auto-injector (blue) and a 2 mg auto-injector (green)\nA pralidoxime chloride 600 mg auto-injector may be administered to an infant that weighs greater than 12 kg\n\nNotes/Educational Pearls\n\nKey Considerations\n\nClinical effects of acetylcholinesterase inhibitor agents\n\nThe clinical effects are caused by the inhibition of the enzyme acetylcholinesterase which allows excess acetylcholine to accumulate in the nervous system\nThe excess accumulated acetylcholine causes hyperactivity in muscles, glands, and nerves\n\nOrganophosphates Insecticides\n\nCan be legally purchased by the general public\nOrganophosphate pesticides penetrate tissues and bind to the patient's body fat producing a prolonged period of illness and ongoing toxicity even during aggressive treatment\n\nNerve agents\n\nTraditionally classified as weapons of mass destruction (WMD)\nNot readily accessible to the general public\nExtremely toxic and rapidly fatal with any route of exposure\nGA (tabun), GB (sarin), GD (soman), GF, and VX are types of nerve agents and are WMDs\n\n________________________\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nAcetylcholinesterase Inhibitors (Carbamates, Nerve Agents, Organophosphates) Exposure\n\n268\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Pertinent Assessment Findings\n\nThe signs and symptoms exhibited with the toxidrome of DUMBELS [See Patient Presentation\u2014Inclusion Criteria]\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914047\u2014Exposure - Nerve Agents\n\n## Key Documentation Elements\n\nTime to recognize initial signs and symptoms\nNumber of repeated doses of atropine required for the secretions diminish and respirations to improve\nPatient reassessments\nPatient responses to therapeutic interventions\nMeasures taken to decontaminate the patient\nMeasures taken to protect clean environments from contamination\n\n## Performance Measures\n\nAbility of the EMS system to rapidly locate additional and adequate antidote assets\nAbility of the EMS system to rapidly deploy additional and adequate antidote assets\nSurvival rates of victims\nComplication rates from the toxin\nComplication rates from the antidotes\nLong-term clinical sequelae of the victims\n\n## References\n\nBarkin RM, Rosen P, Seidel JS, Caputo GL, Jaffe DM. Pediatric Emergency Medicine: Concepts and Clinical Practice. St Louis, MO: Mosby; 1992:490\u20131\nBurillo-Putze G, Nogue Xarau SN. In Tintinalli JE, ed. Tintinalli's Emergency Medicine, 8th Edition. McGraw-Hill Education; 2016:1318\u201321\nEddelston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus poisoning. Lancet. 2008;371(9612):597\u2013607\nHoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR. Goldfrank's Toxicologic Emergencies, 10th Edition. China: McGraw -Hill Education; 2015\nHorowitz BZ, Hendrickson RG. Chemical disasters. In Tintinalli JE, ed. Tintinalli's Emergency Medicine, 8th Edition. McGraw-Hill Education; 2016:44\u20135\nMarx JA et al. Rosen's Emergency Medicine: Concepts and Clinical Practice. 2014:825-6,2057-60,2476-7\nNelson LS. Goldfrank\u2019s Toxicologic Emergencies, 10th Edition. China: McGraw -Hill Education; 2015:1450\u201376\nNerve Agents\u2014Prehospital Management. Chemm.nlm.nih.gov.\n\n________________________ Go To TOC\n\nToxins and Environmental Rev.", "start_char_idx": 616866, "end_char_idx": 620707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a0c2f99-1b79-412c-9dcf-007eba999855": {"__data__": {"id_": "2a0c2f99-1b79-412c-9dcf-007eba999855", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99c04a38-ede0-4d32-97d5-7dadfd17ace1", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "80d06caf8e3a53aa725f5749ebe3f50e39dfb1060a3348ba23aa56c7e322bd48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae640b64-0210-4262-936c-6ca16f261f76", "node_type": "1", "metadata": {}, "hash": "130a7f1ffbb28effc8bb6220951e52cd7e727b6e06ac227de8878adb12829c15", "class_name": "RelatedNodeInfo"}}, "text": "Goldfrank's Toxicologic Emergencies, 10th Edition. China: McGraw -Hill Education; 2015\nHorowitz BZ, Hendrickson RG. Chemical disasters. In Tintinalli JE, ed. Tintinalli's Emergency Medicine, 8th Edition. McGraw-Hill Education; 2016:44\u20135\nMarx JA et al. Rosen's Emergency Medicine: Concepts and Clinical Practice. 2014:825-6,2057-60,2476-7\nNelson LS. Goldfrank\u2019s Toxicologic Emergencies, 10th Edition. China: McGraw -Hill Education; 2015:1450\u201376\nNerve Agents\u2014Prehospital Management. Chemm.nlm.nih.gov.\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Acetylcholinesterase Inhibitors (Carbamates, Nerve Agents, Organophosphates) Exposure 269\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\nhttps://wwwn.cdc.gov/TSP/MMG/MMGDetails.aspx?mmgid=523&toxid=93 Updated April 28, 2017. Accessed August 27, 2017\n\nSilbergleit R, Lowenstein D, Durkalski V, Conwit R; Neurological Emergency Treatment Trials (NETT) Investigators. RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics. Epilepsia. 2011 Oct;52(8):45\u20137. doi: 10.1111/j.1528\u20131167.2011. 03235.x. PMID: 21967361\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\n## Toxins and Environmental Acetylcholinesterase Inhibitors (Carbamates, Nerve Agents, Organophosphates) Exposure 270\n\nRev. March 2022\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Radiation Exposure\n\n### Aliases\n\nNone noted\n\n### Patient Care Goals\n\nPrioritize identification and treatment of immediately life-threatening medical conditions and traumatic injuries above any radiation-associated injury\n\nIdentify and appropriately treat acute radiation injury\n\nReduce risk for contamination of personnel while caring for patients potentially or known to be contaminated with radioactive material\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nPatients who have been acutely exposed to ionizing radiation from accidental environmental release of a radioactive source\n\nPatients who have been acutely exposed to ionizing radiation from a non-accidental environmental release of a radioactive source\n\nPatients who have been contaminated with material emitting ionizing radiation\n\n#### Exclusion Criteria\n\nPatients exposed to normal doses of ionizing radiation from medical imaging studies\n\nPatients exposed to normal doses of ionizing radiation from therapeutic medical procedures\n\n### Patient Management\n\n#### Assessment\n\nDon standard PPE capable of preventing skin exposure to liquids and solids (gown and gloves), mucous membrane exposure to liquids and particles (face mask and eye protection), and inhalational exposure to particles (N95 face mask or respirator)\n\nIdentification and treatment of life-threatening injuries and medical problems takes priority over decontamination\n\nDo not eat or drink any food or beverages while caring for patients with radiation injuries until screening completed for contamination and appropriate decontamination if needed\n\nUse caution to avoid dispersing contaminated materials\n\nProvide appropriate condition-specific care for any immediately life-threatening injuries or medical problems\n\n#### Treatment and Interventions\n\nIf patient experiences nausea, vomiting, and/or diarrhea:\n\nProvide care, per Nausea-Vomiting Guideline\n\nDocument the time gastrointestinal symptoms started\n\nIf seizure occurs:\n\nConsider a primary medical cause or exposure to possible chemical agents unless indicators for a large whole-body radiation dose (greater than 20 Gy (Gray)), such as rapid onset of vomiting, are present\n\nGo To TOC\n\n### Toxins and Environmental Radiation Exposure\n\nRev.", "start_char_idx": 620141, "end_char_idx": 623957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae640b64-0210-4262-936c-6ca16f261f76": {"__data__": {"id_": "ae640b64-0210-4262-936c-6ca16f261f76", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a0c2f99-1b79-412c-9dcf-007eba999855", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8a06753355c3922ae780ec13f4c1711a90d1a4f656c452ad18647571f5890d38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a5edce9-d52a-4176-91b9-8b64198a61fc", "node_type": "1", "metadata": {}, "hash": "f9203184ec7fe88eeacc1e59075f0c26c15845b68b9ad6a18ea84c8b30379cb7", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n271\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nb. Treat per Seizures Guideline\n\n### Patient Safety Considerations\n\nTreat life-threatening medical problems and traumatic injuries prior to assessing for and treating radiation injuries or performing decontamination\n\n### Notes/Educational Pearls\n\nKey Considerations\n\nIrradiated patients pose no threat to medical clinicians\nContaminated patients pose very little threat to medical clinicians who use appropriate PPE including N95 masks or respirators, gloves, gowns, and face and eye protection\nSources of radiation\n\nLegal\n\nIndustrial plants\nHealthcare facilities that provide radiologic services\nNuclear power plants\nMobile engineering sources (i.e., construction sites that are installing cement)\n\nIllegal\n\nWeapons of mass destruction\n\"Dirty bomb\" design to contaminate widespread areas\n\nPhysiology of radiation poisoning\n\nContamination: Poisoning from direct exposure to a radioactive source, contaminated debris, liquids, or clothing where radiation continues to be emitted from particles on surface\nExposure: Poisoning from radioactivity, in the form of ionizing rays, penetrating through the bodily tissues of the patient\n\nCommon types of radioactivity that cause poisoning\n\nGamma rays\n\nHighest frequency of ionizing rays\nPenetrates the skin deeply\nCauses the most severe radiation toxicity\n\nBeta rays: can penetrate up to 1 cm of the skin's thickness\nAlpha rays\n\nLowest frequency of ionizing rays\nShort range of absorption\nDangerous only if ingested or inhaled\n\nRadioactive daughters\n\nProducts of decay of the original radioactive substance\nCan produce gamma and beta rays (i.e., uranium decays into a series of radon daughters)\n\nIn general, trauma patients who have been exposed to or contaminated by radiation should be triaged and treated based on the severity of their conventional injuries\nA patient who is contaminated with radioactive material (i.e., flecks of radioactive material embedded in their clothing and skin) generally poses a minimal exposure risk to medical personnel, although should not be placed in a contained space before decontamination\nEMS clinicians may be asked to assist public health agencies in the distribution and\n\n________________________ Go To TOC\n\nToxins and Environmental Radiation Exposure\n\nRev. March 2022\n\n272\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nAdministration of potassium iodide in a mass casualty incident involving radiation release or exposure\n\n### Stages of Radiation Sickness\n\ni. Prodromal: nausea, vomiting, diarrhea, fatigue, fever, agitation, starting hours up to 4 days after initial exposure\n\nj. Latent: May last up to four weeks (this is the maximum period for immunocompromise due to radiation exposure); however, time span may be less as dose of radiation exposure increases. Symptoms include anorexia, fever, weakness, bleeding, diarrhea, potentially altered mental status after two to three weeks\n\nk. Recovery: may take weeks to months\n\n### Pertinent Assessment Findings\n\n1. Treatment of life-threatening injuries or medical conditions takes priority over assessment for contamination or initiation of decontamination\n\n2. Time to nausea and vomiting is a reliable indicator of the received dose of ionizing radiation. The more rapid the onset of vomiting, the higher the whole-body dose of radiation\n\n3. Tissue burns are a late finding (weeks following exposure) of ionizing radiation injury. If burns are present acutely, they are from a thermal or chemical mechanism\n\n4. Seizures may suggest acute radiation syndrome if accompanied by early vomiting. If other clinical indicators do not suggest a whole-body dose of greater than 20 Gy, consider other causes of seizure\n\n5. Delayed symptoms (days to weeks after exposure or contamination)\n\na. Skin burns with direct contact with radioactive source\n\nb. Skin burns or erythema from ionizing rays\n\nc. Fever\n\nd. Bone marrow suppression presenting as:\n\ni. Immunosuppression\n\nii. Petechiae\n\ne. Spontaneous internal and external bleeding\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914049\u2014Exposure - Radiologic Agents\n\n### Key Documentation Elements\n\nDuration of exposure to the radioactive source or environment\nDistance (if able to be determined) from the radioactive source (if known)\nTime of onset of vomiting\n\n### Performance Measures\n\nUse of appropriate PPE\nUse of dosimetry by EMS clinician\nScene measurements of radioactivity\n\n### References\n\nCenter for Disease Control and Prevention, Emergency Preparedness and Response, Toxins and Environmental Radiation Exposure\n\n________________________ Go To TOC\n\nRev.", "start_char_idx": 623958, "end_char_idx": 628704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a5edce9-d52a-4176-91b9-8b64198a61fc": {"__data__": {"id_": "0a5edce9-d52a-4176-91b9-8b64198a61fc", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae640b64-0210-4262-936c-6ca16f261f76", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "1e8ead4972b00f36cd8e8938130fb81509970fafa1b325512dae8197761d7466", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bedabdb3-df05-4d9f-a051-cef8ffa5f871", "node_type": "1", "metadata": {}, "hash": "94968d9243f86f254f6ca638b0360aab87b2a74610ab9f983421e770ca363d49", "class_name": "RelatedNodeInfo"}}, "text": "Petechiae\n\ne. Spontaneous internal and external bleeding\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914049\u2014Exposure - Radiologic Agents\n\n### Key Documentation Elements\n\nDuration of exposure to the radioactive source or environment\nDistance (if able to be determined) from the radioactive source (if known)\nTime of onset of vomiting\n\n### Performance Measures\n\nUse of appropriate PPE\nUse of dosimetry by EMS clinician\nScene measurements of radioactivity\n\n### References\n\nCenter for Disease Control and Prevention, Emergency Preparedness and Response, Toxins and Environmental Radiation Exposure\n\n________________________ Go To TOC\n\nRev. March 2022\n\n273\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nSpecific Hazards: Radiation, 2013\n\nCone DC, Koenig KL. Mass casualty triage in the chemical, biological, radiological, or nuclear environment. Eur J\nEmerg Med;12(6): 287\u2013 302\nMarx JA et al. Rosen's Emergency Medicine: Concepts and Clinical Practice, 2010 1937\u20131939\nRadiation Emergency Assistance Center/Training Site (REAC/TS) Training Site. Orise.orau.gov.\nhttps://orise.orau.gov/reacts/. Accessed August 28, 2017\nThe Medical Aspects of Radiation Incidents\nhttps://orise.orau.gov/reacts/documents/medical-aspects-of-radiation-incidents.pdf.\nRevised January 2017. Accessed August 28, 2017\n\nRevision Date: March 11, 2022\n\nGo To TOC\n\n### Toxins and Environmental Radiation Exposure\n\nRev. March 2022\n\n274\n---\n# NASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Topical Chemical Burn\n\n### Aliases\n\nChemical Burn\n\n### Patient Care Goals\n\nRapid recognition of a topical chemical burn\nInitiation of emergent and appropriate intervention and patient transport\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nPatients of all ages who have sustained exposure to a chemical that can cause a topical chemical burn may develop immediate or in some cases a delayed clinical presentation\nAgents that are known to cause chemical burns include alkalis, acids, mustard agent, and lewisite\n\n#### Exclusion criteria\n\nNone noted\n\n### Patient Management\n\nDon the appropriate PPE\nRemove the patient's clothing, if necessary\nContaminated clothing should preferably be placed in double bags\nIf deemed necessary and manpower resources permit, the patient should be transported by EMS clinicians who did not participate in the decontamination process, and in an emergency response vehicle that has not been exposed to the chemical\nInformation regarding the chemical should be gathered while on scene including materials safety data sheet if available\nCommunicate all data regarding the chemical to the receiving facility\n\n#### Assessment\n\nClinical effects and severity of a topical chemical burn is dependent upon:\n\nClass of agent (alkali injury or acid injury)\nConcentration of the chemical the (higher the concentration, the greater the risk of injury)\npH of the chemical\n\nAlkali-increased risk with pH greater than or equal to 11\nAcid-increased risk with pH less than or equal to 3\n\nOnset of burn\n\nImmediate\nDelayed (e.g., hydrofluoric acid)\n\nCalculate the estimated total body surface area that is involved\nPrevent further contamination\nSpecial attention to assessment of ocular or oropharyngeal exposure \u2014 evaluate for airway compromise secondary to spasm or direct injury associated with oropharyngeal\n\n________________________\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nTopical Chemical Burn\n\n275\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Topical Chemical Burn\n\n5.", "start_char_idx": 627989, "end_char_idx": 631586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bedabdb3-df05-4d9f-a051-cef8ffa5f871": {"__data__": {"id_": "bedabdb3-df05-4d9f-a051-cef8ffa5f871", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a5edce9-d52a-4176-91b9-8b64198a61fc", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "04b23feebe3702217805f36d6916c06bae9bdb5c42b9eaf00d118ec2d3a31e52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5aae2931-fc70-4fe0-a893-ad7f219dae57", "node_type": "1", "metadata": {}, "hash": "000c27e0057d2946eafa5fa1bc6bd98afceb979e30f619968b780d267de75ab9", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nTopical Chemical Burn\n\n275\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Topical Chemical Burn\n\n5. Some acid and alkali agents may manifest systemic effects\n\n### Treatment and Interventions\n\nIf dry chemical contamination, carefully brush off solid chemical prior to flushing the site as the irrigating\nsolution may activate a chemical reaction\nIf wet chemical contamination, flush the patient's skin (and eyes, if involved) with copious amounts of water or\nnormal saline\nProvide adequate analgesia per the Pain Management Guideline\nConsider the use of topical anesthetic eye drops (e.g., tetracaine) for chemical burns of the eye\nFor eye exposure, administer continuous flushing of irrigation fluid to eye \u2014 Morgan lens may facilitate\nadministration\nEarly airway intervention for airway compromise or bronchospasm associated with oropharyngeal burns\nTake measures to minimize hypothermia\nInitiate intravenous fluid resuscitation if necessary to obtain hemodynamic stability\n\n### Hydrofluoric Acid\n\nHydrofluoric acid (HF) is a highly corrosive substance that is primarily used for automotive cleaning products, rust\nremoval, porcelain cleaners, etching glass, cleaning cement or brick, or as a pickling agent to remove impurities\nfrom various forms of steel. Hydrofluoric acid readily penetrates intact skin and there may be underlying tissue\ninjury. It is unlikely that low concentration HF will cause an immediate acid-like burn however there may be delayed\nonset of pain to the exposed area. Higher concentration HF may cause immediate pain as well as more of a burn\nappearance that can range from mild erythema to an obvious burn. An oral or large dermal exposure can result in\nsignificant systemic hypocalcemia with possible QT prolongation and cardiovascular collapse\n\nFor all patients in whom a hydrofluoric acid exposure is confirmed or suspected:\n\nVigorously irrigate all affected areas with water or normal saline for a minimum of 15 minutes\nApply a cardiac monitor for oral or large dermal exposures significant HF exposures\nApply calcium preparation:\n\nCalcium prevents tissue damage from hydrofluoric acid\nTopical calcium preparations:\n\nCommercially manufactured calcium gluconate gel\nIf commercially manufactured calcium gluconate gel is not available, a topical calcium gluconate gel\npreparation can be made by combining 150 mL (5 ounces) of a sterile water-soluble gel (e.g., Surgilube\u00ae\nor KY\u00ae jelly) with one of the following:\n\n35 mL of calcium gluconate 10% solution\n10 g of calcium gluconate tablets (e.g., Tums\u00ae)\n3.5 g calcium gluconate powder or\n\nIf calcium gluconate is not available, 10 mL of calcium chloride 10% solution in 150 mL in sterile\nwater-soluble gel (e.g., Surgilube\u00ae or KY\u00ae jelly)\nApply generous amounts of the calcium gluconate gel to the exposed skin sites to neutralize the pain of\nthe hydrofluoric acid\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022\n\n276\n---\nNASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n5. Hydrofluoric acid exposure is very painful. Calcium gel is the foundation of pain control. While intravenous pain medications may be less effective, they should be added to calcium gel to assist with pain control. Hydrofluoric acid exposure typically causes pain out of proportion to the visible dermal effects. Minimal skin changes may exist with substantial exposures\n\n6. If fingers are involved, apply the calcium gel to the hand, squirt additional calcium gel into a surgical glove, and then insert the affected hand into the glove\n\n7. For patients who have ingested hydrofluoric acid or who have a large dermal exposure consider intravenous calcium gluconate, 1\u20132 grams of 10% solution, as symptomatic hypocalcemia can precipitate rapidly as manifest by muscle spasms, seizures, hypotension ventricular arrhythmias, and QT prolongation\n\n## Patient Safety Considerations\n\n1. Don PPE\n\n2. Take measures to prevent the patient from further contamination through decontamination\n\n3. Take measures to protect the EMS clinician and others from contamination\n\n4. Do not attempt to neutralize an acid with an alkali or an alkali with an acid as an exothermic reaction will occur and cause serious thermal injury to the patient\n\n5.", "start_char_idx": 631461, "end_char_idx": 635708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5aae2931-fc70-4fe0-a893-ad7f219dae57": {"__data__": {"id_": "5aae2931-fc70-4fe0-a893-ad7f219dae57", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bedabdb3-df05-4d9f-a051-cef8ffa5f871", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "3d4504baa9d268b2b3146c69f09fe42346a765c4d36322b9df3a4a84a0d8c9dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dba4efe-88d4-4301-87fc-e0cefea78bd6", "node_type": "1", "metadata": {}, "hash": "125e93b346158d3bca446d0fd00b82914dd281f1de04047c4d43ea1adcc5ee7e", "class_name": "RelatedNodeInfo"}}, "text": "If fingers are involved, apply the calcium gel to the hand, squirt additional calcium gel into a surgical glove, and then insert the affected hand into the glove\n\n7. For patients who have ingested hydrofluoric acid or who have a large dermal exposure consider intravenous calcium gluconate, 1\u20132 grams of 10% solution, as symptomatic hypocalcemia can precipitate rapidly as manifest by muscle spasms, seizures, hypotension ventricular arrhythmias, and QT prolongation\n\n## Patient Safety Considerations\n\n1. Don PPE\n\n2. Take measures to prevent the patient from further contamination through decontamination\n\n3. Take measures to protect the EMS clinician and others from contamination\n\n4. Do not attempt to neutralize an acid with an alkali or an alkali with an acid as an exothermic reaction will occur and cause serious thermal injury to the patient\n\n5. Expeditious transport or transfer to a designated burn center should be considered for burns that involve a significant percentage of total body surface area or burns that involve the eyes, face, hands, feet, or genitals\n\n## Notes/Educational Pearls\n\nKey Considerations\n\n1. IV fluid resuscitation should be guided by patient age, percentage of body surface area involved in burn, body habitus and calculated by the Parkland Formula [See Appendix VI. Burn and Burn Fluid Charts]\n\n2. Since the severity of topical chemical burns is largely dependent upon the type, concentration, and pH of the chemical involved as well as the body site and surface area involved, it is imperative to obtain as much information as possible while on scene about the chemical substance by which the patient was exposed. The information gathering process will often include:\n\na. Transport of the sealed container of the chemical to the receiving facility\n\nb. Transport of the original or a copy of the Material Safety Data Sheet (MSDS) of the substance to the receiving facility\n\nc. Contacting the reference agency to identify the chemical agent and assist in management (e.g., CHEMTREC\u00ae)\n\n3. Inhalation of HF should be considered in any dermal exposure involving the face and neck or if clothing is soaked in the product\n\n4. Decontamination is critical for both acid and alkali agents to reduce injury \u2014 removal of chemicals with a low pH (acids) is more easily accomplished than chemicals with a high pH (alkalis) because alkalis tend to penetrate and bind to deeper tissues\n\n5. Some chemicals will also manifest local and systemic signs, symptoms, and bodily damage\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Topical Chemical Burn 277\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Pertinent Assessment Findings\n\nAn estimate of the total body surface area that is involved\nPatient response to therapeutic interventions\nPatient response to fluid resuscitation\nPatient response to analgesia\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914213\u2014Injury - Topical Chemical Burn\n\n## Key Documentation Elements\n\nBurn site\nBody surface area involved\nIdentification of the chemical\nReported or measured pH of the chemical\nAcquisition and transfer of MSDS, chemical container, or other pertinent substance information to the receiving\nfacility\n\n## Performance Measures\n\nAccurate (overtriage/undertriage) triage of patients to designated burn centers\nEarly recognition of a topical chemical burn with appropriate treatment\nEarly recognition of hydrofluoric acid burns followed by expeditious initiation of treatment with calcium\ngluconate and/or calcium chloride and appropriate analgesia\nMeasures taken to prevent further contamination\n\n## References\n\nAmerican Heart Association. Advanced Pediatric Life Support. Jones & Bartlett Learning LLC; 2013\nFerng M, Gupta R, Bryant SM. Hazardous Brick Cleaning. J Emergency Medicine. 2009;37(3):305\u20137\nHoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR. Goldfrank\u2019s Toxicologic Emergencies, 10th Edition.\nChina: McGraw-Hill Education; 2015\nMarx JA et al. Rosen's Emergency Medicine: Concepts and Clinical Practice, 2010 769\u2013770\nO'Sullivan SB, Schmitz TJ. Physical Rehabilitation, 5th Edition. F.A. Davis; 2007: 1098\nRecommended Medical Treatment for hydrofluoric Acid Exposure. Morristown, NJ: Honeywell Performance Materials and\nTechnologies; October 2012\nTintinalli JE, ed.", "start_char_idx": 634856, "end_char_idx": 639229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dba4efe-88d4-4301-87fc-e0cefea78bd6": {"__data__": {"id_": "9dba4efe-88d4-4301-87fc-e0cefea78bd6", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5aae2931-fc70-4fe0-a893-ad7f219dae57", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "97a718259963c55ee46009c16b366aba704a3b5934453c683f90bf0c2af41778", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d50917b1-8db6-496f-abb6-272260bb0986", "node_type": "1", "metadata": {}, "hash": "c3c6a86497129468589d5f4538446285148694f5b95ae4e3428fa33b211c5af0", "class_name": "RelatedNodeInfo"}}, "text": "Jones & Bartlett Learning LLC; 2013\nFerng M, Gupta R, Bryant SM. Hazardous Brick Cleaning. J Emergency Medicine. 2009;37(3):305\u20137\nHoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR. Goldfrank\u2019s Toxicologic Emergencies, 10th Edition.\nChina: McGraw-Hill Education; 2015\nMarx JA et al. Rosen's Emergency Medicine: Concepts and Clinical Practice, 2010 769\u2013770\nO'Sullivan SB, Schmitz TJ. Physical Rehabilitation, 5th Edition. F.A. Davis; 2007: 1098\nRecommended Medical Treatment for hydrofluoric Acid Exposure. Morristown, NJ: Honeywell Performance Materials and\nTechnologies; October 2012\nTintinalli JE, ed. Tintinalli's Emergency Medicine, 9th Edition. McGraw-Hill Education; 2021:35\u201340, 1391\u201396\n\nRevision Date: March 11, 2022\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Topical Chemical Burn 278\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Stimulant Poisoning/Overdose\n\n### Aliases\n\nAmphetamines, Bath Salts, Cocaine, Ice, Methamphetamine, Phencyclidine (PCP), Stimulant\n\n### Patient Care Goals\n\nIdentify intoxicating agent\nProtect organs at risk for injury such as heart, brain, liver, kidney\nDetermine if there is an antidote\nTreat the symptoms, which may include severe tachycardia and hypertension, agitation, hallucinations, chest pain,\nseizure, and arrhythmia\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nTachycardia/tachydysrhythmias\nHypertension\nDiaphoresis\nDelusions/paranoia\nSeizures\nHyperthermia\nMydriasis (dilated pupils)\nStimulant/hallucinogenic (with stimulant properties) agents:\n\nCocaine\nAmphetamine/methamphetamine\nPhencyclidine (PCP) (hallucinogen)\nBupropion\nSynthetic stimulant drugs of abuse (some having mixed properties)\nEcstasy\nMethamphetamine\nKhat or Synthetic cathinones (\u201cbath salts\u201d)\n\u201cSpice\u201d\n\u201cK2\u201d\nSynthetic THC\n\n#### Exclusion Criteria\n\nNone noted\n\n### Patient Management\n\n#### Assessment\n\nBegin with the ABCDs:\n\nAirway is patent\nBreathing is oxygenating\nCirculation is perfusing\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022\n\nStimulant Poisoning/Overdose 279\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Assessment\n\n1. Assess airway, breathing, and circulation (ABCs) and disability/neuro/mental status\n\na. Airway, breathing, and circulation (ABCs)\n\nb. Disability/neuro/mental status\n\nc. Treat any compromise of these parameters\n\nd. Ask about chest pain and difficulty breathing\n\n2. Vital signs including temperature for hyperthermia\n\n3. Apply a cardiac monitor and examine rhythm strip for arrhythmias\n\n4. Check blood glucose level\n\n5. Monitor EtCO2 for respiratory decompensation\n\n6. Check a 12-lead EKG when possible\n\n7. Check for trauma, self-inflicted injury\n\n8. Law enforcement should have checked for weapons and drugs, but you may need to repeat the inspection\n\n## Treatment and Interventions\n\n1. IV access for any fluids and meds\n\n2. Give fluids for poor perfusion; cool fluids for hyperthermia [See Shock Guideline and Hyperthermia/Heat\nExposure Guideline]\n\n3. Treat chest pain as acute coronary syndrome (ACS) and follow ST-Elevation Myocardial Infarction (STEMI)\nGuideline if there is EKG is consistent with STEMI\n\n4. Consider treating shortness of breath as atypical ACS\n\na. Administer oxygen as appropriate with a target of achieving 94\u201398% saturation\n\n5. Consider soft physical management devices especially if law enforcement has been involved in getting patient to\ncooperate [See Agitated or Violent Patient/Behavioral Emergency Guideline]\n\n6.", "start_char_idx": 638619, "end_char_idx": 642160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d50917b1-8db6-496f-abb6-272260bb0986": {"__data__": {"id_": "d50917b1-8db6-496f-abb6-272260bb0986", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dba4efe-88d4-4301-87fc-e0cefea78bd6", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "a8ff69b64ce5524256d0ae490795fa657eb701bd3ef0327a6c3f866719113ab6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "447c65af-0137-497f-946d-b395640da62b", "node_type": "1", "metadata": {}, "hash": "72b252c4778d6f79d4ef00d35861a209943ff55bcc5c86481f5bc5bb69152ad7", "class_name": "RelatedNodeInfo"}}, "text": "Check for trauma, self-inflicted injury\n\n8. Law enforcement should have checked for weapons and drugs, but you may need to repeat the inspection\n\n## Treatment and Interventions\n\n1. IV access for any fluids and meds\n\n2. Give fluids for poor perfusion; cool fluids for hyperthermia [See Shock Guideline and Hyperthermia/Heat\nExposure Guideline]\n\n3. Treat chest pain as acute coronary syndrome (ACS) and follow ST-Elevation Myocardial Infarction (STEMI)\nGuideline if there is EKG is consistent with STEMI\n\n4. Consider treating shortness of breath as atypical ACS\n\na. Administer oxygen as appropriate with a target of achieving 94\u201398% saturation\n\n5. Consider soft physical management devices especially if law enforcement has been involved in getting patient to\ncooperate [See Agitated or Violent Patient/Behavioral Emergency Guideline]\n\n6. Consider medications to reduce agitation and other significant sympathomimetic findings, preferably\nbenzodiazepines, for the safety of the patients and clinicians. The administration of ketamine should be considered\nfor delirium with agitated behavior. This may improve behavior and compliance [See Agitated or Violent\nPatient/Behavioral Emergency Guideline]\n\na. If haloperidol or droperidol is used, maintain cardiac monitoring (or obtain 12-lead EKGs) for QT-interval\nprolongation if feasible\n\n7. Consider prophylactic use of antiemetic:\n\na. Adult: administer ondansetron 4\u20138 mg SLOW IV over 2\u20135 minutes or 4\u20138 mg IM or 8 mg orally disintegrating\ntablet\n\nb. Pediatric: Administer ondansetron 0.15 mg/kg SLOW IV over 2\u20135 minutes\n\nc. Do not use promethazine if haloperidol or droperidol are to be or have been given. They all increase QT\nprolongation, but ondansetron has less seizure risk\n\n8. If hyperthermia suspected, begin external cooling (e.g., cold or ice packs to axilla/groin)\n\n## Patient Safety Considerations\n\n1. Apply the least amount of physical management devices that are necessary to protect the patient and the\nclinicians [See Agitated or Violent Patient/Behavioral Emergency Guideline]\n\n2. Assessment for potential weapons or additional drugs is very important since these items can pose a threat not\njust to the patient but also to the EMS crew\n\n|Content|Page number|\n|---|---|\n|Toxins and Environmental Stimulant Poisoning/Overdose|280|\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Notes/Educational Pearls\n\nKey Considerations\n\nRecognition and treatment of hyperthermia (including sedatives to decrease heat production from muscular activity) is essential as many deaths are attributable to hyperthermia\n\nIf law enforcement has placed the patient in handcuffs, this patient needs ongoing physical security for safe transport. Have law enforcement in back of ambulance for the handcuffed patient or make sure proper non-handcuff physical management devices are in place before law enforcement leaves and ambulance departs from scene\n\nIf patient has signs and symptoms of ACS, consider giving nitroglycerin sublingual (SL) q (quaque, every) 3\u20135 minutes if SBP greater than 100 mmHg and until pain resolves (if range not desired, use q 3 minutes)\n\nVasospasm is often the problem in this case as opposed to a fixed coronary artery lesion\n\nConsider administration of benzodiazepines as if to treat anxiety\n\nMaintaining IV access, cardiac monitor, and SPO2/EtCO2 monitors are key to being able to catch and intervene decompensations in a timely manner\n\nIf agitated, consider restraining the patient to facilitate patient assessment and lessen likelihood of vascular access or monitor displacements\n\nCocaine has sodium channel blocking effects and can cause significant cardiac conduction abnormalities with a widened QRS. Treatment is with sodium bicarbonate similar to a tricyclic antidepressant. Check a 12-lead EKG to assess for these complications\n\nPertinent Assessment Findings\n\nHistory is as important as the physical examination.\n\nIf the patient is on psychiatric medication, but has failed to be compliant, this fact alone puts the patient at higher risk for the adverse outcome of delirium with agitated behavior\n\nIf the patient is found naked, this may elevate the suspicion for stimulant use or abuse. These substances increase the risk for sudden death secondary to delirium with agitated behavior.", "start_char_idx": 641324, "end_char_idx": 645620, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "447c65af-0137-497f-946d-b395640da62b": {"__data__": {"id_": "447c65af-0137-497f-946d-b395640da62b", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d50917b1-8db6-496f-abb6-272260bb0986", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "a3cfaf1c9fc69e4495f6e5273e44d3367c1d689dfabc6a24941d3d01033875ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fca67361-d74c-4b9b-b58b-894379487234", "node_type": "1", "metadata": {}, "hash": "0ed809890ce163a4e60f2ca8c59124a8cf6861fc9b8ee7247b2288f05d3d2f43", "class_name": "RelatedNodeInfo"}}, "text": "Treatment is with sodium bicarbonate similar to a tricyclic antidepressant. Check a 12-lead EKG to assess for these complications\n\nPertinent Assessment Findings\n\nHistory is as important as the physical examination.\n\nIf the patient is on psychiatric medication, but has failed to be compliant, this fact alone puts the patient at higher risk for the adverse outcome of delirium with agitated behavior\n\nIf the patient is found naked, this may elevate the suspicion for stimulant use or abuse. These substances increase the risk for sudden death secondary to delirium with agitated behavior. Neuroleptic malignant syndrome or serotonin syndrome can present with similar signs and symptoms\n\nIf polypharmacy is suspected, hypertension and tachycardia are expected hemodynamic findings secondary to increased dopamine release. Stimulus reduction from benzodiazepines, anti-psychotics, and ketamine will improve patient's vital signs and behavior\n\nBe prepared for the potential of cardiovascular collapse as well as respiratory arrest\n\nIf a vasopressor is needed, epinephrine or norepinephrine is recommended over dopamine\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914225\u2014Medical - Stimulant Poisoning/Overdose\n\n## Key Documentation Elements\n\nReason for psychologic and physical management procedures used and neurologic/circulatory exams with device use\nReason for medications selected\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Stimulant Poisoning/Overdose 281\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\nDocumentation of QT interval when antiemetic medications, haloperidol, or droperidol is used and result conveyed to ED staff\n\n## Performance Measures\n\nRecognition and treatment of hyperthermia\nRecognition of need for monitoring cardiovascular and respiratory status of patient with stimulant toxicity\nACS evaluation and treatment considered for chest pain and shortness of breath\nRespiratory compromise quickly recognized and treated\nCardiovascular compromise quickly recognized and treated\nPatient and medics did not suffer any harm\nAccess and monitoring were not lost during transport\n\n## References\n\nKupas, D, Wydro, G, Tan, D, Kamin, R, Harrell, A, Wang, A, NASEMSO Position Paper 2020 Clinical Care and Restraint\nof Agitated or Combative Patients by Emergency Medical Services Practitioners Link.\nAccessed March 11, 2022\nWarrcik BJ, Hill M, Hekman K, et al. A 9-state analysis of designer stimulant, \"bath salt, \" hospital visits reported\nto poison control centers. Ann Emerg Med. 2013;62(3):244\u201351\nWhite Paper Report on Excited Delirium Syndrome. ACEP Excited Delirium Task Force, American College of Emergency\nPhysicians; September 10, 2009\n\nRevision Date: March 11, 2022\n\n________________________ Go To TOC\n\nToxins and Environmental Stimulant Poisoning/Overdose Rev. March 2022 282\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Cyanide Exposure\n\n### Aliases\n\nBlood agent, Cyanide, Hydrogen cyanide\n\n### Patient Care Goals\n\nRemove patient from toxic environment\nAssure adequate ventilation, oxygenation, and correction of hypoperfusion\n\n### Patient Presentation\n\nCyanide is a colorless gas or white crystal which binds to the ferric ion in cells, blocking the enzyme cytochrome oxidase, thus preventing the use of oxygen by the cell's mitochondria, leading to cellular hypoxia. While it has a characteristic \"bitter almond smell\u201d, genetically only 40% of the population can smell it\n\n#### Inclusion Criteria\n\nDepending on its form, cyanide can enter the body through inhalation, ingestion, or absorption through the skin. Cyanide should be suspected in occupational or other smoke exposures (e.g., firefighting), industrial accidents, natural catastrophes, suicide and murder attempts, chemical warfare, and terrorism (whenever there are multiple casualties of an unclear etiology).", "start_char_idx": 645032, "end_char_idx": 648997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fca67361-d74c-4b9b-b58b-894379487234": {"__data__": {"id_": "fca67361-d74c-4b9b-b58b-894379487234", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "447c65af-0137-497f-946d-b395640da62b", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "d46dfeef61202c05c4d0bef7d5bce70b96e82536483a6120ab9a5e424d0ebd82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b36e6fd-cb6b-4055-a0bb-44e3be63eb43", "node_type": "1", "metadata": {}, "hash": "74af77e7499060c8bd21a6d52ee2b4f94b0c550a6234762ab2278160cf2db1a0", "class_name": "RelatedNodeInfo"}}, "text": "While it has a characteristic \"bitter almond smell\u201d, genetically only 40% of the population can smell it\n\n#### Inclusion Criteria\n\nDepending on its form, cyanide can enter the body through inhalation, ingestion, or absorption through the skin. Cyanide should be suspected in occupational or other smoke exposures (e.g., firefighting), industrial accidents, natural catastrophes, suicide and murder attempts, chemical warfare, and terrorism (whenever there are multiple casualties of an unclear etiology). Non-specific and early signs of cyanide exposure (inhalation, ingestion, or absorption) include the following signs and symptoms: anxiety, vertigo, weakness, headache, tachypnea, nausea, dyspnea, vomiting, and tachycardia\n\nHigh concentrations of cyanide will produce:\n\nMarkedly altered level of consciousness, including rapid collapse\nSeizures\nRespiratory depression or respiratory arrest\nCardiac dysrhythmias (other than sinus tachycardia)\n\nThe rapidity of onset is related to the severity of exposure (inhalation or ingestion) and may be dramatic with immediate effects that include early hypertension with subsequent hypotension, sudden cardiovascular collapse or seizure/coma, and rapid death\n\n#### Exclusion Criteria\n\nNone noted\n\n### Patient Management\n\n#### Assessment\n\nRemove patient from toxic environment\nAssess ABCDs and, if indicated, expose the patient, and then re-cover the patient to assure retention of body heat\nAssess vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment) including temperature and pulse oximetry (which may not correlate with tissue oxygenation in cyanide/smoke exposure)\nAttach a cardiac monitor and examine rhythm strip for arrhythmias\n\nPerform a 12-lead EKG\n\nCheck blood glucose level\n\n________________________Go To TOC\n\nToxins and Environmental\n\nCyanide Exposure\n\nRev. March 2022\n\n283\n---\n## National Model EMS Clinical Guidelines Version 3.0\n\n6. Monitor pulse oximetry and EtCO2\n\n7. Monitor patient for signs of hypoxia (pulse oximetry less than 94%) and respiratory decompensation regardless of pulse oximetry reading\n\n8. Identify the specific agent of exposure, time of ingestion/inhalation, and quantity/timing of exposure\n\n9. Obtain patient history including cardiovascular history and prescribed medication\n\n10. Obtain other pertinent patient history\n\n11. Perform physical exam\n\n### Treatment and Interventions\n\nThere is no widely available, rapid, confirmatory cyanide blood test. Many hospitals will not be able to rapidly assess cyanide levels. Therefore, treatment decisions must be made on the basis of clinical history and signs and symptoms of cyanide intoxication. For the patient with an appropriate history and manifesting one or more significant cyanide exposure signs or symptoms, treat with:\n\n1. 100% oxygen via non-rebreather mask, CPAP, or bag valve mask\n\n2. Collect a pre-treatment blood sample in the appropriate tube for lactate and cyanide levels, if feasible\n\n3. Administer one of the following medication regimes\n\na. Hydroxocobalamin (the preferred agent)\n\ni. Adult: Administer hydroxocobalamin\n\n1. Initial dose is 5 g administered over 15 minutes slow IV\n\n2. Each 5 g vial of hydroxocobalamin for injection is to be reconstituted with 200 mL of LR, NS, or D5W (25 mg/mL) and administered at 10\u201315 mL/minute\n\n3. An additional 5 g dose may be administered with medical consultation.\n\nii. Pediatric: Administer hydroxocobalamin 70 mg/kg (reconstitute concentration is 25 mg/mL)\n\n1. Each 5 g vial of hydroxocobalamin for injection is to be reconstituted with 200 mL of LR, NS, or DSW (25 mg/mL) and administered at 10\u201315 mL/minute\n\n2. Maximum single dose is 5 g\n\nOR\n\nb. Sodium thiosulfate\n\ni. Adult: Sodium thiosulfate 12.5 g IVF (50 mL of 25% solution)\n\nii. Pediatric: Sodium thiosulfate 0.5 g/kg IV (2 mL/kg of 25% solution)\n\n4. If seizure, treat per Seizures Guideline\n\n### Patient Safety Considerations\n\n1. In the event of multiple casualties, be sure to wear appropriate PPE during rescue evacuation from the toxic environment\n\n2. If the patient ingests cyanide, it will react with the acids in the stomach generating hydrogen cyanide gas.", "start_char_idx": 648493, "end_char_idx": 652635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b36e6fd-cb6b-4055-a0bb-44e3be63eb43": {"__data__": {"id_": "8b36e6fd-cb6b-4055-a0bb-44e3be63eb43", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fca67361-d74c-4b9b-b58b-894379487234", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "1031906aa0fbeb3dec01c0f5309f98b9615617f530539372b8bcea59fdb94f37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "629a39b7-a00e-4058-b941-a8dfa0f516f3", "node_type": "1", "metadata": {}, "hash": "3ae2bb1d55611afc2b37bde77b86691d2270b25b5674985ae5dc346af3ba3f9b", "class_name": "RelatedNodeInfo"}}, "text": "Each 5 g vial of hydroxocobalamin for injection is to be reconstituted with 200 mL of LR, NS, or DSW (25 mg/mL) and administered at 10\u201315 mL/minute\n\n2. Maximum single dose is 5 g\n\nOR\n\nb. Sodium thiosulfate\n\ni. Adult: Sodium thiosulfate 12.5 g IVF (50 mL of 25% solution)\n\nii. Pediatric: Sodium thiosulfate 0.5 g/kg IV (2 mL/kg of 25% solution)\n\n4. If seizure, treat per Seizures Guideline\n\n### Patient Safety Considerations\n\n1. In the event of multiple casualties, be sure to wear appropriate PPE during rescue evacuation from the toxic environment\n\n2. If the patient ingests cyanide, it will react with the acids in the stomach generating hydrogen cyanide gas. Be sure to maximize air circulation in closed spaces (ambulance) as the patient's gastric contents may contain hydrogen cyanide gases when released with vomiting or belching\n\n3. Do not use nitrites in conjunction with suspected carbon monoxide poisoning as it worsens the hemoglobin oxygen carrying capacity even more than carbon monoxide (CO)\n\n4. Hydroxocobalamin is only agent safe for treatment of cyanide poisoning in pregnant patients\n\n________________________\n\nGo To TOC\n\n|Toxins and Environmental|Rev. March 2022|\n|---|---|\n|Cyanide Exposure|284|\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Notes/Educational Pearls\n\nKey Considerations\n\nPulse oximetry accurately reflects serum levels of oxygen but does not accurately reflect tissue oxygen levels therefore should not be relied upon in possible cyanide and/or carbon monoxide toxicity\n\nAfter hydroxocobalamin has been administered, pulse oximetry levels are no longer accurate and skin, tears, and urine will all turn red. This flushing should not be interpreted as an allergic reaction\n\nIf the patient ingests cyanide, it will react with the acids in the stomach generating hydrogen cyanide gas. Be sure to maximize air circulation in closed spaces (ambulance) as the patient's gastric contents may contain hydrogen cyanide gases when released with vomiting or belching\n\nAmyl nitrite and sodium nitrite are no longer being used and no longer available in commercial kits\n\n## Pertinent Assessment Findings\n\nEarly and repeated assessment is essential\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914043\u2014Exposure - Cyanide\n\n## Key Documentation Elements\n\nRepeat evaluation and documentation of signs and symptoms as the patient's clinical condition may deteriorate rapidly\nIdentification of possible etiology of poisoning\nTime of symptom onset and time of initiation of exposure-specific treatments\nTherapy and response to therapy\n\n## Performance Measure\n\nEarly airway management in the rapidly deteriorating patient\nAccurate exposure history\n\nTime of ingestion/exposure\nRoute of exposure\nQuantity of medication or toxin taken (safely collect all possible medications or agents)\nAlcohol or other intoxicant taken\n\nAppropriate protocol selection and management\nMultiple frequent documented reassessments\n\n## References\n\nAmyl Nitrite\u2014Medical Countermeasures Database. Chemm.nlm.nih.gov. https://wwwn.cdc.gov/TSP/MMG/MMGDetails.aspx?mmgid=523&toxid=93. Accessed March 11, 2022\n\nBebarta VS, Tanen DA, Lairet J, Dixon PS, Valtier S, Bush A. Hydroxocobalamin and\n\nToxins and Environmental Rev. March 2022 Cyanide Exposure 285\n\nGo To TOC\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nsodium thiosulfate versus sodium nitrite and sodium thiosulfate in the treatment of acute cyanide toxicity in a swine\n(Sus scrota) model. Ann Emerg Med. 2010; 55(4):345\u201351\n\n3. Cyanide Poisoning. UpToDate.com. https://www.uptodate.com/contents/cyanide-poisoning?source=search_result&search=cyanide%20and%20pulse%20oximetry&selectedTitle=3~150.\nUpdated September 28, 2016. March 11, 2022\n\n4. Hoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR. Goldfrank's Toxicologic Emergencies, 10th Edition.", "start_char_idx": 651974, "end_char_idx": 655906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "629a39b7-a00e-4058-b941-a8dfa0f516f3": {"__data__": {"id_": "629a39b7-a00e-4058-b941-a8dfa0f516f3", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b36e6fd-cb6b-4055-a0bb-44e3be63eb43", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "f26395f5e4b0edf5cb702dafe78aae8843ca634d28fd6f2a4e7f829947f37e83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "040a1177-7e5f-4891-9d1b-fe7d3b12463d", "node_type": "1", "metadata": {}, "hash": "587dfb5a7fc97106cc130d1874937d683fa40953d7d1e885d23e44de2ce23fe6", "class_name": "RelatedNodeInfo"}}, "text": "Ann Emerg Med. 2010; 55(4):345\u201351\n\n3. Cyanide Poisoning. UpToDate.com. https://www.uptodate.com/contents/cyanide-poisoning?source=search_result&search=cyanide%20and%20pulse%20oximetry&selectedTitle=3~150.\nUpdated September 28, 2016. March 11, 2022\n\n4. Hoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR. Goldfrank's Toxicologic Emergencies, 10th Edition.\nChina: McGraw-Hill Education; 2015\n\n5. Marraffa JM, Cohen V, Howland MA. Antidotes for toxicological emergencies: a practical review. Am J Health Syst\nPharm. 2012;69(3):199\u2013212\n\n6. Meridian Cyanokit (package insert). Semoy, France: Merck Sante. https://www.meridianmeds.com/sites/default/files/pi/CYANOKIT_PI.pdf.\nAccessed March 11, 2022\n\n7. Roderique EJ, Gebre-Giorgis AA, Stewart DH, Feldman MJ, Pozez AL. Smoke inhalation injury in a pregnant patient: a\nliterature review of the evidence and current best practices in the setting of a classic case. J Burn Care Res.\n2012; Sep-Oct;33(5):624\u201333\n\n8. Shepherd G, Velez LI. Role of hydroxocobalamin in acute cyanide poisoning. Ann Pharmacotherapy.\n2008;42(5):661\u20139\n\n9. Thompson JP, Marrs TC. Hydroxocobalamin in cyanide poisoning. Clin Toxicol (Phila). 2012;50(10):875\u201385\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Cyanide Exposure 286\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Beta Blocker Poisoning/Overdose\n\n### Aliases\n\nAnti-hypertensive\n\n### Patient Care Goals\n\nReduce GI absorption of oral agents with some form of binding agent (activated charcoal) especially for extended release\nEarly airway protection is required as patients may have rapid mental status deterioration\nAssure adequate ventilation, oxygenation, and correction of hypoperfusion\n\n### Patient Presentation\n\nBeta blocker or beta-adrenergic antagonist medication to reduce the effects of epinephrine/adrenaline\n\n#### Inclusion Criteria\n\nPatients may present with:\n\nBradycardia\nHypotension\nAltered mental status\nWeakness\nShortness of breath\nPossible seizures\nHypoglycemia\n\nBeta blocker agent examples:\n\nAcebutolol hydrochloride (Sectral\u00ae)\nAtenolol (Tenormin\u00ae)\nBetaxolol hydrochloride (Kerlone\u00ae)\nBisoprolol fumarate (Zebeta\u00ae)\nCarteolol hydrochloride (Cartrol\u00ae)\nEsmolol hydrochloride (Brevibloc\u00ae)\nMetoprolol (Lopressor\u00ae, Toprol XL\u00ae)\nNadolol (Corgard\u00ae)\nNebivolol (Bystolic\u00ae)\nPenbutolol sulfate (Levatol\u00ae)\nPindolol (Visken\u00ae)\nPropranolol (lnderal\u00ae, lnno Pran\u00ae)\nTimolol maleate (Blocadren\u00ae)\nSotalol hydrochloride (Betapace\u00ae)\n\nAlpha/beta-adrenergic blocking agents\u2019 examples:\n\nCarvedilol (Coreg\u00ae)\nLabetalol hydrochloride (Trandate\u00ae, Normodyne\u00ae)\n\n#### Exclusion Criteria\n\nNone noted\n\n________________________\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nBeta Blocker Poisoning/Overdose\n\n287\n---\n# NASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Patient Management\n\n### Assessment\n\nAssess ABCDs and if indicated expose and then cover to assure retention of body heat\nVital signs which include temperature\nApply a cardiac monitor, examine rhythm strip for arrhythmias, and consider obtaining a 12-lead EKG\nCheck blood glucose level\nMonitor pulse oximetry and EtCO2 for respiratory decompensation\nIdentify specific medication taken (noting immediate release vs.", "start_char_idx": 655545, "end_char_idx": 658810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "040a1177-7e5f-4891-9d1b-fe7d3b12463d": {"__data__": {"id_": "040a1177-7e5f-4891-9d1b-fe7d3b12463d", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "629a39b7-a00e-4058-b941-a8dfa0f516f3", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "54db8b29837ddfe4bc58db2f05f6001d752e2bb925f46e09944d90c87661f0fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b59f1c00-1560-4736-9c6a-13ff264e444f", "node_type": "1", "metadata": {}, "hash": "dfdd1b5b89a4aa0ab0eac684fe65f49ab6a8f8c8c29b00e18e4ca0591ec18f9a", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nBeta Blocker Poisoning/Overdose\n\n287\n---\n# NASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Patient Management\n\n### Assessment\n\nAssess ABCDs and if indicated expose and then cover to assure retention of body heat\nVital signs which include temperature\nApply a cardiac monitor, examine rhythm strip for arrhythmias, and consider obtaining a 12-lead EKG\nCheck blood glucose level\nMonitor pulse oximetry and EtCO2 for respiratory decompensation\nIdentify specific medication taken (noting immediate release vs. sustained release formulations), time of ingestion,\nand quantity\nPertinent cardiovascular history or other prescribed medications for underlying disease\nPatient pertinent history\nPatient physical\n\n### Treatment and Interventions\n\nConsider activated charcoal without sorbitol (1 g/kg) PO only if within the first hour of ingestion, if indicated\nper the time of ingestion. If risk of rapid decreasing mental status, do not administer oral agent without adequately\nprotecting the airway\n\nIf risk of rapid decreasing mental status, do not administer oral agent without adequately protecting the\nairway\n\nCheck blood glucose level on all patients but especially on pediatric patients as beta-blockers can cause\nhypoglycemia in pediatric population\nConsider atropine sulfate for symptomatic bradycardia\n\nAdult: Atropine 1 mg IV q 5 minutes to maximum of 3 mg\nPediatric: Atropine 0.02 mg/kg (0.5 mg maximum) q 5 minutes, maximum total dose 1 mg\n\nConsider fluid challenge (20 mL/kg) for hypotension with associated bradycardia\nFor symptomatic patients with cardiac effects (e.g., hypotension, bradycardia) consider:\n\nAdult: Glucagon initial dose 5 mg IVP \u2014 this can be repeated in 5\u201310 minutes for a total of 10 mg\nPediatric:\n\nGlucagon 1 mg IVP (25\u201340 kg) every 5 minutes as necessary\nGlucagon 0.5 mg IVP (less than 25 kg) q 5 minutes as necessary\n\nConsider vasopressors after adequate fluid resuscitation (1\u20132 liters of crystalloid) for the hypotensive patient [See\nShock Guideline for pediatric vs. adult dosing]\nConsider transcutaneous pacing if refractory to initial pharmacologic interventions\nIf seizure, treat per Seizures Guideline\nIf widened QRS (100 msec or greater), consider sodium bicarbonate 1\u20132 mEq/kg IV. This can be repeated as needed to\nnarrow QRS\n\n## Patient Safety Considerations\n\nTranscutaneous pacing may not always capture nor correct hypotension when capture is successful\nAspiration of activated charcoal can cause airway management to be nearly impossible. Do not administer activated\ncharcoal to any patients that may have a worsening mental status\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nBeta Blocker Poisoning/Overdose\n\n288\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Notes/Educational Pearls\n\nKey Considerations\n\nPediatric Considerations\n\nPediatric patient may develop hypoglycemia from beta blocker overdose therefore it is important to perform\nglucose evaluation\n\nA single pill can kill a toddler.", "start_char_idx": 658276, "end_char_idx": 661271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b59f1c00-1560-4736-9c6a-13ff264e444f": {"__data__": {"id_": "b59f1c00-1560-4736-9c6a-13ff264e444f", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "040a1177-7e5f-4891-9d1b-fe7d3b12463d", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "bd45ae71e633152000f234812ec88ca37217a7287ffa871095b739374a45570a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48959635-c9a5-4b2e-b695-55d12cc9b70c", "node_type": "1", "metadata": {}, "hash": "3be4abc7f20cb0e672bc30b31f5836e026bd01034f3bda15f0856400aef20061", "class_name": "RelatedNodeInfo"}}, "text": "This can be repeated as needed to\nnarrow QRS\n\n## Patient Safety Considerations\n\nTranscutaneous pacing may not always capture nor correct hypotension when capture is successful\nAspiration of activated charcoal can cause airway management to be nearly impossible. Do not administer activated\ncharcoal to any patients that may have a worsening mental status\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nBeta Blocker Poisoning/Overdose\n\n288\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Notes/Educational Pearls\n\nKey Considerations\n\nPediatric Considerations\n\nPediatric patient may develop hypoglycemia from beta blocker overdose therefore it is important to perform\nglucose evaluation\n\nA single pill can kill a toddler. It is very important that a careful assessment of medications the toddler could\nhave access to is done by EMS and all suspect medications should be brought into the ED\n\nGlucagon has a side effect of increased vomiting at these doses and ondansetron prophylaxis may be considered\n\nAtropine may have little or no effect (likely to be more helpful in mild overdoses) \u2014 the hypotension and bradycardia\nmay be mutually exclusive, and the blood pressure may not respond to correction of bradycardia\n\nPropranolol crosses the blood brain barrier and can cause altered mental status, seizure, and widened QRS similar to\nTCA toxicity\n\n## Pertinent Assessment Findings\n\nCertain beta-blockers, such as acebutolol and propranolol, may increase QRS duration\n\nCertain beta-blockers, such as acebutolol and pindolol, may produce tachycardia and hypertension\n\nSotalol can produce increase in QTc interval and ventricular dysrhythmias\n\nFrequent reassessment is essential as patient deterioration can be rapid and catastrophic\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914215\u2014Medical - Beta Blocker Poisoning/Overdose\n\nKey Documentation Elements\n\nRepeat evaluation and documentation of signs and symptoms and vital signs as patient clinical conditions may\ndeteriorate rapidly\nIdentification of possible etiology of poisoning\nTime of symptoms onset and time of initiation of exposure-specific treatment\nTherapy and response to therapy\n\nPerformance Measures\n\nEarly airway management in the rapidly deteriorating patient\nAccurate exposure history\n\nTime of ingestion/exposure\nRoute of exposure\nQuantity of medication or toxin taken (safely collect all possible mediations or agents)\nAlcohol or other intoxicant taken\n\nAppropriate protocol selection and management\nMultiple frequent documented re-assessments\nBlood glucose checks (serial if long transport, especially in children)\nGood evaluation of the EKG and the segment intervals\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Beta Blocker Poisoning/Overdose 289\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# References\n\nBoyd R, Ghosh A. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. Glucagon for the treatment of symptomatic beta blocker overdose. Emerg Med J. 2003;20 (3): 266\u20137\nHepherd G. Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers. Am J Health Syst Pharm. 2006;63(19):1828\u201335\nHoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR. Goldfrank\u2019s Toxicologic Emergencies, 10th Edition. China: McGraw -Hill Education; 2015\nKerns W 2nd Management of beta-adrenergic blocker and calcium channel antagonist toxicity. Emerg Med Clin N Am. 2007 ;25(2):309\u2013 31\nMarraffa JM, Cohen V, Howland MA. Antidotes for Toxicological Emergencies. Am J Health Syst Pharm. 2012 ;69(3):19 9\u2013212\nReview. Erratum in. Am J Health Syst Pharm. 2008;65(17):1592\nWax PM. b-Blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clinical Toxicology. 2005; 43:131\u201346\n\nRevision Date: March 11, 2022\n\nToxins and Environmental\n\nBeta Blocker Poisoning/Overdose\n\nRev.", "start_char_idx": 660523, "end_char_idx": 664477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48959635-c9a5-4b2e-b695-55d12cc9b70c": {"__data__": {"id_": "48959635-c9a5-4b2e-b695-55d12cc9b70c", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b59f1c00-1560-4736-9c6a-13ff264e444f", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "7c536a6cd895d994f48e209d94c9a29af034e693b93612bca47f33d27c1c4178", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df8c28d5-68b9-4a2b-bac6-f889ef058960", "node_type": "1", "metadata": {}, "hash": "7cde600dfc18c7841e552a05092200e2b6e26f3c33bd00d39478f4c062eacbd5", "class_name": "RelatedNodeInfo"}}, "text": "China: McGraw -Hill Education; 2015\nKerns W 2nd Management of beta-adrenergic blocker and calcium channel antagonist toxicity. Emerg Med Clin N Am. 2007 ;25(2):309\u2013 31\nMarraffa JM, Cohen V, Howland MA. Antidotes for Toxicological Emergencies. Am J Health Syst Pharm. 2012 ;69(3):19 9\u2013212\nReview. Erratum in. Am J Health Syst Pharm. 2008;65(17):1592\nWax PM. b-Blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clinical Toxicology. 2005; 43:131\u201346\n\nRevision Date: March 11, 2022\n\nToxins and Environmental\n\nBeta Blocker Poisoning/Overdose\n\nRev. March 2022\n\n290\n\nGo To TOC\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# Bites and Envenomation\n\n## Aliases\n\nStings\n\n## Patient Care Goals\n\nBites, stings, and envenomations can come from a variety of insects, marine, and terrestrial animals. Assure adequate ventilation, oxygenation, and correction of hypoperfusion. Provide pain control which also may include external interventions to reduce pain.\n\n## Patient Presentation\n\n### Inclusion Criteria\n\nBites, stings, and envenomations can come from a variety of marine and terrestrial animals and insects causing local or systemic effects\nPatients may present with toxin specific reactions which may include:\n\nSite pain\nSwelling\nMuscle pain (hallmark of black widow spider bites)\nErythema\nDiscoloration\nBleeding\nNausea\nAbdominal pain\nHypotension\nTachycardia\nTachypnea\nMuscle incoordination\nConfusion\nAnaphylaxis/allergic reactions\n\nThere is a spectrum of toxins or envenomations and limited EMS interventions that will have any mitigating effect on the patient in the field\n\nThe critical intervention is to get the patient to a hospital that has access to the antivenin if applicable\n\n### Exclusion Criteria\n\nNone noted\n\n## Patient Management\n\n### Assessment\n\nAssess ABCDs and if indicated expose and then cover to assure retention of body heat\nVital signs (pulse, blood pressure, respiratory rate, neurologic status assessment) which include temperature\nApply a cardiac monitor, examine rhythm strip for arrhythmias, and consider obtaining a 12-lead EKG\nCheck blood glucose Level\nMonitor pulse oximetry and EtCO2 for respiratory decompensation\n\nToxins and Environmental\n\nRev. March 2022\n\nBites and Envenomation\n\n291\n\nGo To TOC\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Treatment and Interventions\n\nConsider an IV fluid bolus (normal saline or lactated Ringer's) 20 mL/kg up to 2 liters\nConsider vasopressors after adequate fluid resuscitation for the hypotensive patient\n\n[for adult vs. pediatric dosing, see Shock Guideline]\nIf seizure, treat per Seizures Guideline\nSpecific therapy for select bites, stings, or envenomation\n\nEnvenomations that are known to antivenom readily available in the USA include black widow spider, bark\nscorpions, crotalid snakes (rattlesnake, copperhead) and coral snakes\n\nFor these envenomations, consider transport to a hospital that has access to antivenom, if feasible\n\nJellyfish\n\nAs there is a significant variety and diversity of jellyfish, it is important to be familiar with the species\nand the appropriate treatment for your local aquatic creatures\nGenerally, scrape off any remaining tentacles or nematocysts, then immerse affected body part in hot water\n(113\u00b0F/45\u00b0C). Vinegar may be used to reduce pain due to deactivation of the nematocysts remaining in the skin\nexcept for stings from certain species of jellyfish (i.e., Physalia, a species found in Australian waters) which\nmay have nematocysts activated by vinegar (acetic acid).", "start_char_idx": 663897, "end_char_idx": 667457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df8c28d5-68b9-4a2b-bac6-f889ef058960": {"__data__": {"id_": "df8c28d5-68b9-4a2b-bac6-f889ef058960", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48959635-c9a5-4b2e-b695-55d12cc9b70c", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "dbf25d8f79aaf2076ce139d255a40590665a57218a044b27ac4b2d65af9a2231", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72b7497b-2899-4c2a-95f5-245037f81c02", "node_type": "1", "metadata": {}, "hash": "52cdb65092cb136df1c3582b820c7d52ead9974214ec26677e49cb52857ec8e8", "class_name": "RelatedNodeInfo"}}, "text": "Vinegar may be used to reduce pain due to deactivation of the nematocysts remaining in the skin\nexcept for stings from certain species of jellyfish (i.e., Physalia, a species found in Australian waters) which\nmay have nematocysts activated by vinegar (acetic acid). Vinegar may also activate the nematocysts of sea nettles\nand is not recommended after this type of jellyfish exposure\n\nLionfish, scorpionfish, stingray:\n\nImmerse affected body part in hot water to reduce the pain associated with the toxin\n\nProvide adequate analgesia per the Pain Management Guideline\n\n### Patient Safety Considerations\n\nDo NOT:\n\nApply tourniquets, tight Ace\u00ae/crepe bandage, or constricting bands above or below the site of the envenomation\nIncise and/or suction wound to remove toxin\nApply cold packs or immerse the effect extremity in ice water (cryotherapy)\n\nEMS clinicians should not try to capture the marine or terrestrial animal or insect\nIf the organism has been killed, beware that many dead insect, marine, or fanged animals can continue to bite or\nsting with venom and should be safely placed in a hard sided and closed container for future identification\nPatient may still have an imbedded stinger, tooth, nematocyst, or barb which may continue to deliver toxin if left\nimbedded. Consider safe removal without squeezing the toxin delivery apparatus\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Notes/Educational Pearls\n\nKey Considerations\n\nVinegar has potential to increase pain associated with jellyfish sting as it can increase nematocyst discharge in certain species. Clinicians must be familiar with endemic species and how to best address exposure\n\nPertinent Assessment Findings\n\nAssess for signs and symptoms of local and systematic impact of the suspected toxin\nPatient may still have an imbedded stinger, tooth, nematocysts, or barb which may continue to deliver toxin if left imbedded\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914079\u2014Injury - Bites and Envenomations-Land\n9914081\u2014Injury - Bites and Envenomations-Marine\n\n### Key Documentation Elements\n\nIt is helpful to accurately describe the suspect bite or sting source without risking patient or EMS clinician\nOnly transport source animal or insect if can be done safely in a hard-sided container\nRepeat evaluation and documentation of signs and symptoms as patient clinical conditions may deteriorate rapidly\nTime of symptoms onset and time of initiation of exposure-specific treatments\nTherapy and response to therapy\n\n### Performance Measures\n\nOffending organism was managed appropriately without secondary exposure\nAppropriate and timely definitive treatment was provided\nAppropriate pain management\n\n## References\n\nAacharya RP, Gastmans C, Denier Y. Emergency department tri age: an ethical analysis. BMC Emerg Med. 2011 ;11 :16\nAmerican College of Medical Toxicology, American Academy of Clinical Toxicology, American Association of Poison Control Centers, European Association of Poison Control Centres, International Society on Toxinology, Asia Pacific Association of Medical Toxicology. Pressure immobilization after North American crotalinae snake envenomation. J Med Toxicol. 2011;7 (4): 3 22\u20133\nHoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR. Goldfrank' s Toxicologic Emergencies, 10th Edition. China: McGraw -Hill Education; 2015\nLavonas EJ, Ruha AM, Banner W, et al. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of evidence-informed consensus workshop. BMC Emerg Med. 2011; 11:2\nPrestwich H, Jenner R. Best evidence topic report. Treatment of jellyfish stings in UK coastal waters: vinegar or sodium bicarbonate? Emerg Med J. 2007;24 (9):6 64\n\n________________________ Go To TOC\n\nToxins and Environmental Bites and Envenomation Rev. March 2022 293\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n6. Ward N. Evidence-based treatment of jellyfish stings in North America and Hawaii. Ann Emerg Med. 2012; 60(4):399\u2013414.\n\n7.", "start_char_idx": 667192, "end_char_idx": 671279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72b7497b-2899-4c2a-95f5-245037f81c02": {"__data__": {"id_": "72b7497b-2899-4c2a-95f5-245037f81c02", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df8c28d5-68b9-4a2b-bac6-f889ef058960", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "fe19c52050ab58af7489a1fba5b0a9358b8c9a5d424ef3a10604e80608199056", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdbe6b3e-f76a-416d-8bd9-659c8f90ddd4", "node_type": "1", "metadata": {}, "hash": "62003949859b669dec82af37747a4051c83907c54e5d586dbba892b45bfaab62", "class_name": "RelatedNodeInfo"}}, "text": "Unified treatment algorithm for the management of crotaline snakebite in the United States: results of evidence-informed consensus workshop. BMC Emerg Med. 2011; 11:2\nPrestwich H, Jenner R. Best evidence topic report. Treatment of jellyfish stings in UK coastal waters: vinegar or sodium bicarbonate? Emerg Med J. 2007;24 (9):6 64\n\n________________________ Go To TOC\n\nToxins and Environmental Bites and Envenomation Rev. March 2022 293\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n6. Ward N. Evidence-based treatment of jellyfish stings in North America and Hawaii. Ann Emerg Med. 2012; 60(4):399\u2013414.\n\n7. Weinstein SA, Dart RC, Stables A. Envenomations: an overview of clinical toxinology for the primary care physician. Am Fam Physician. 2009;80(8):793\u2013802\n\nRevision Date March 11, 2022\n\n________________________\n\nGo To TOC\n\nToxins and Environmental\n\nBites and Envenomation\n\nRev. March 2022\n\n294\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Calcium Channel Blocker Poisoning/Overdose\n\n### Aliases\n\nAnti-hypertensive\n\n### Patient Care Goals\n\nReduce GI absorption of oral agents with some form of binding agent (activated charcoal) especially for extended release\nEarly airway protection is required as patients may have rapid mental status deterioration\nAssure adequate ventilation, oxygenation, and correction of hypoperfusion\n\n### Patient Presentation\n\nCalcium channel blockers interrupt the movement of calcium across cell membranes. Calcium channel blockers are used to manage hypertension, certain rate-related arrhythmias, prevent cerebral vasospasm, and angina pectoris. Patients may present with:\n\nBradycardia\nHypotension\nDecreased AV nodal conduction\nCardiogenic shock\nHyperglycemia\n\n### Inclusion Criteria\n\nPatients who have may have taken/been administered calcium channel blockers\n\nCalcium channel blocker examples:\n\nAmlodipine (Norvasc\u00ae)\nDiltiazem (Cardizem\u00ae, Tiazac\u00ae)\nFelodipine\nlsradipine\nNicardipine\nNifedipine (Adalat CC\u00ae, Afeditab CR\u00ae, Procardia\u00ae)\nNisoldipine (Sular\u00ae)\nVerapamil (Calan\u00ae, Verelan\u00ae)\n\n### Exclusion Criteria\n\nNone noted\n\n### Patient Management\n\n#### Assessment\n\nAssess ABCDs and, if indicated, expose, and then cover to assure retention of body heat\nVital signs including temperature\nApply a cardiac monitor, examine rhythm strip for arrhythmias, and consider obtaining a 12-lead EKG\nCheck blood glucose level\nMonitor pulse oximetry and EtCO2 for respiratory decompensation\nIdentify specific medication taken (noting immediate release vs. sustained release formulations), time of ingestion, and quantity\n\n________________________\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nCalcium Channel Blocker Poisoning/Overdose\n\n295\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Treatment and Interventions\n\nConsider activated charcoal without sorbitol (1 g/kg) PO only if within the first hour of ingestion, if indicated per the time of ingestion.", "start_char_idx": 670645, "end_char_idx": 673586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdbe6b3e-f76a-416d-8bd9-659c8f90ddd4": {"__data__": {"id_": "bdbe6b3e-f76a-416d-8bd9-659c8f90ddd4", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72b7497b-2899-4c2a-95f5-245037f81c02", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "9a4deb4fd23f7b513a517831c9487c9ee5fabca045a958267540a96b195151fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "547143f7-db83-4697-96fd-c28eb0f3bc82", "node_type": "1", "metadata": {}, "hash": "87c9c9e14fab0e7c0defa12797747b955120c634134cf4ab3a5e182bb4c5c05a", "class_name": "RelatedNodeInfo"}}, "text": "sustained release formulations), time of ingestion, and quantity\n\n________________________\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nCalcium Channel Blocker Poisoning/Overdose\n\n295\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Treatment and Interventions\n\nConsider activated charcoal without sorbitol (1 g/kg) PO only if within the first hour of ingestion, if indicated per the time of ingestion. If risk of rapid decreasing mental status, do not administer oral agent without adequately protecting the airway\nConsider atropine sulfate for symptomatic bradycardia\n\nAdult: atropine 1 mg IV q 5 minutes to maximum of 3 mg\nPediatric: atropine 0.02 mg/kg (0.5 mg maximum) q 5 minutes, maximum total dose 1 mg\n\nConsider calcium gluconate or calcium chloride\n\nCalcium gluconate\n\nAdult: Calcium gluconate 2\u20136 g slow IVP over 10 minutes\nPediatric: Calcium gluconate 60 mg/kg IVP over 10 minutes\n\nCalcium chloride\n\nAdult: Calcium chloride 0.5\u20131 g slow IVP (50 mg/minute)\nPediatric: Calcium chloride 20 mg/kg (0.2 mL/kg) slow IVP over 10 minutes (50 mg/mL) Maximum dose 1 g or 10 mL (Calcium gluconate is preferred as Calcium chloride has increased risk of tissue damage in pediatrics)\n\nConsider IV fluid bolus (normal saline or lactated Ringer's) 20 mL/kg up to 2 liters\nConsider vasopressors after adequate fluid resuscitation for the hypotensive patient [See Shock Guideline for adult vs. pediatric dosing]\nIf atropine, calcium, and vasopressors have failed in the symptomatic bradycardia patient, consider:\n\nAdult: Glucagon 5 mg IVP, then 1 mg q 5 minutes IVP (may require 5\u201315 mg to see effect)\nPediatric:\n\nGlucagon 1 mg IVP (25\u201340 kg); q 5 minutes as necessary\nGlucagon 0.5 mg IVP (less than 25 kg); q 5 minutes as necessary\n\nConsider transcutaneous pacing if refractory to initial pharmacologic interventions\nIf seizure, consider midazolam (benzodiazepine of choice). [See Seizures Guideline for adult vs. pediatric dosing]\n\n## Patient Safety Considerations\n\nTranscutaneous pacing may not always capture nor correct hypotension when capture is successful.\n\n## Notes/Educational Pearls\n\n### Key Considerations\n\nWhile most calcium channel blockers cause bradycardia, dihydropyridine class calcium channel blockers (e.g., nifedipine, amlodipine) can cause a reflex tachycardia (torsade de pointes) early in the ingestion. The patient can become bradycardic as the intoxication worsens\n\n________________________\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nCalcium Channel Blocker Poisoning/Overdose\n\n296\n---\nNASEMSO\n\nNASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n2. The avoidance of administering calcium chloride or calcium gluconate to a patient on cardiac glycosides (e.g.,\ndigoxin) as this may precipitate toxicity and associate fatal arrhythmias is felt to be a historical belief and not\nsupported\n\n3. Glucagon has a side effect of increased vomiting at these doses and ondansetron prophylaxis should be considered\n\n4. A single pill can kill a toddler. It is very important that a careful assessment of medications the toddler could\nhave access to is done by EMS and suspect medications brought into the ED\n\n5. Calcium channel blockers can cause many types of rhythms that can range from sinus bradycardia to complete heart\nblock\n\n6. Hyperglycemia is the result of the blocking of L-type calcium channels in the pancreas. This can help differentiate\nthese ingestions from beta-blockers. There may also be a relationship between the severity of the ingestion and the\nextent of the hyperglycemia\n\n7. Atropine may have little or no effect (likely to be more helpful in mild overdoses)\n\nHypotension and bradycardia may be mutually exclusive, and the blood pressure may not respond to correction of\nbradycardia\n\n## Pertinent Assessment Findings\n\n1. Close monitoring of EKG changes and dysrhythmias\n\n2.", "start_char_idx": 673162, "end_char_idx": 677012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "547143f7-db83-4697-96fd-c28eb0f3bc82": {"__data__": {"id_": "547143f7-db83-4697-96fd-c28eb0f3bc82", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdbe6b3e-f76a-416d-8bd9-659c8f90ddd4", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "55f03e90e65ce20d7fe12c3fc99a11ecbe72ef2d1e9edaa65f620ec6c62abfad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ca98578-7a73-4367-a1ef-5e5bece82d63", "node_type": "1", "metadata": {}, "hash": "61dca8660422477cb387989e45f1d985c47797ed69b7d0af5ecc159c88948a03", "class_name": "RelatedNodeInfo"}}, "text": "It is very important that a careful assessment of medications the toddler could\nhave access to is done by EMS and suspect medications brought into the ED\n\n5. Calcium channel blockers can cause many types of rhythms that can range from sinus bradycardia to complete heart\nblock\n\n6. Hyperglycemia is the result of the blocking of L-type calcium channels in the pancreas. This can help differentiate\nthese ingestions from beta-blockers. There may also be a relationship between the severity of the ingestion and the\nextent of the hyperglycemia\n\n7. Atropine may have little or no effect (likely to be more helpful in mild overdoses)\n\nHypotension and bradycardia may be mutually exclusive, and the blood pressure may not respond to correction of\nbradycardia\n\n## Pertinent Assessment Findings\n\n1. Close monitoring of EKG changes and dysrhythmias\n\n2. Serial frequent assessments are essential as these patients often have rapid deterioration with profound hypotension\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914217\u2014Medical - Calcium Channel Blocker Poisoning/Overdose\n\n## Key Documentation Elements\n\nRepeat evaluation and documentation of signs and symptoms as patient clinical conditions may deteriorate rapidly\nIdentification of possible etiology of poisoning\nTime of symptoms onset and time of initiation of exposure-specific treatments\nTherapy and response to therapy\n\n## Performance Measures\n\nEarly airway management in the rapidly deteriorating patient\nAccurate exposure history\n\nTime ingestion/exposure\nRoute of exposure\nQuantity of medication or toxin taken (safely collect all possible mediations or agents)\nAlcohol or other intoxicant taken\n\nAppropriate protocol selection and management\nMultiple frequent documented reassessments\n\n## References\n\nAshraf M, Chaudhary K, Nelson J, Thompson W. Massive overdose of sustained- release verapamil: a case report and\nreview of literature. Am J Med Sci. 1995;310(6):258\u201363\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nCalcium Channel Blocker Poisoning/Overdose\n\n297\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Toxins and Environmental - Calcium Channel Blocker Poisoning/Overdose\n\nRevision Date: March 11, 2022\n\n2. Hoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR. Goldfrank\u2019s Toxicologic Emergencies, 10th Edition.\nChina: McGraw-Hill Education; 2015\n\n3. Levine M. Critical care management of verapamil and diltiazem overdose with a focus on vasopressors: a 25-year\nexperience at a single center. Ann Emerg Med. 2013;62(3):252\u20138\n\n4. Levine M, Boyer EW, Pozner CN, et al. Assessment of hyperglycemia after calcium channel blocker overdoses\ninvolving diltiazem or verapamil. Crit Care Med. 2007;35(9):2071\u20135\n\n5. Levine M, Nikkanen H, Pallin DJ. The effects of intravenous calcium in patient are with digoxin toxicity. J Emerg\nMed. 2011;40(1);41\u20136\n\n6. Marraffa JM, Cohen J, Howland MA. Antidotes for toxicological emergencies. Am J Health Syst Pharm.\n2012;69(3):199\u2013212\n\n7. Olsen KR, Erdman AR, Woolf AD, et al. Calcium channel blocker ingestion: an evidence-based consensus guideline\nfor out-of-hospital management. Clin Toxicol (Phila). 2005;(7):797\u2013822\n\n8. Olsen K. What is the best treatment for acute calcium channel blocker overdose? Ann Emerg Med. 2013;62(3):259\u201361\n\n9. Shepherd G. Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers. Am J Health Syst\nPharm. 2006;63(19):1828\u201335. Review. Erratum in: Am J Health Syst Pharm. 2008;65(17):1592\n\n10. St-Onge M, Anseeuw K, Cantrell FL, et al. Experts consensus recommendations for the management of calcium\nchannel blocker poisoning in adults. Crit Care Med. 2017;45(3): e306\u201315\n\n11.", "start_char_idx": 676169, "end_char_idx": 679891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ca98578-7a73-4367-a1ef-5e5bece82d63": {"__data__": {"id_": "4ca98578-7a73-4367-a1ef-5e5bece82d63", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "547143f7-db83-4697-96fd-c28eb0f3bc82", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "6aeb5a631c42a6c94de619143ba00ddf044c1cb8f0934fd13a8d5f8e88b78251", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95809b13-84ed-4a84-aa5d-c2d92ef30a04", "node_type": "1", "metadata": {}, "hash": "6e2e9bc2c3777e1a0e8a928e0d4b43052977d9738d14a5f60e21d8b5df0d2fa4", "class_name": "RelatedNodeInfo"}}, "text": "Clin Toxicol (Phila). 2005;(7):797\u2013822\n\n8. Olsen K. What is the best treatment for acute calcium channel blocker overdose? Ann Emerg Med. 2013;62(3):259\u201361\n\n9. Shepherd G. Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers. Am J Health Syst\nPharm. 2006;63(19):1828\u201335. Review. Erratum in: Am J Health Syst Pharm. 2008;65(17):1592\n\n10. St-Onge M, Anseeuw K, Cantrell FL, et al. Experts consensus recommendations for the management of calcium\nchannel blocker poisoning in adults. Crit Care Med. 2017;45(3): e306\u201315\n\n11. St-Onge M, Dub\u00e9 PA, Gosselin S, et al. Treatment for calcium channel blocker poisoning: a systematic review.\nClin Toxicol (Phila). 2014;52(9):926\u201344\n\n________________________ Go To TOC\n\nRev. March 2022\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Carbon Monoxide/Smoke Inhalation\n\n### Aliases\n\nCO\n\n### Patient Care Goals\n\nRemove patient from toxic environment.\nAssure adequate ventilation, oxygenation, and correction of hypoperfusion.\nConsider use of environmental carbon monoxide (CO) monitors on \"first in\" bags to assist in detection of occult CO toxicity.\n\n### Patient Presentation\n\nCarbon monoxide is a colorless, odorless gas which has a high affinity for binding to red cell hemoglobin, thus preventing the binding of oxygen to the hemoglobin, leading to tissue hypoxia (although pulse oximetry may appear to be normal). A significant reduction in oxygen delivery to tissues and organs occurs with carbon monoxide poisoning. Carbon monoxide is also a cellular toxin which can result in delayed or persistent neurologic sequelae in significant exposures. With any form of combustion (fire/smoke [e.g., propane, kerosene, or charcoal stoves or heaters], combustion engines [e.g., generators, lawn mowers, motor vehicles, home heating systems]), carbon monoxide will be generated. People in a fire may also be exposed to cyanide from the combustion of some synthetic materials. Cyanide toxicity may need to be considered in the hemodynamically unstable patient removed from a fire.\n\n### Inclusion Criteria\n\nPatients exposed to carbon monoxide may present with a spectrum of symptoms:\n\nMild intoxication:\n\nNausea\nFatigue\nHeadache\nVertigo\nLightheadedness\n\nModerate to severe:\n\nAltered mental status\nTachypnea\nTachycardia\nConvulsion\nCardiopulmonary arrest\n\n### Exclusion Criteria\n\nNone noted\n\n### Patient Management\n\n#### Assessment\n\nRemove patient from toxic environment\nAssess ABCDs and, if indicated, expose patient and re-cover to assure retention of body heat\nVital signs (pulse, blood pressure, respiratory rate, neurologic status assessment) temperature, and O2 saturation, and EtCO2 if available\n\nGo To TOC\n\n### Toxins and Environmental\n\nRev.", "start_char_idx": 679347, "end_char_idx": 682083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95809b13-84ed-4a84-aa5d-c2d92ef30a04": {"__data__": {"id_": "95809b13-84ed-4a84-aa5d-c2d92ef30a04", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ca98578-7a73-4367-a1ef-5e5bece82d63", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "da38a9c5932e0918156ea9ebfa994fa179fa522f9b23742845c348f9a9741008", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a22e37b-54b8-4b90-a44f-1131c4c3f46d", "node_type": "1", "metadata": {}, "hash": "93e84432568b08b01bea56322643adfae2b55b80bfdf6687f0e9d57a70eb3f85", "class_name": "RelatedNodeInfo"}}, "text": "Cyanide toxicity may need to be considered in the hemodynamically unstable patient removed from a fire.\n\n### Inclusion Criteria\n\nPatients exposed to carbon monoxide may present with a spectrum of symptoms:\n\nMild intoxication:\n\nNausea\nFatigue\nHeadache\nVertigo\nLightheadedness\n\nModerate to severe:\n\nAltered mental status\nTachypnea\nTachycardia\nConvulsion\nCardiopulmonary arrest\n\n### Exclusion Criteria\n\nNone noted\n\n### Patient Management\n\n#### Assessment\n\nRemove patient from toxic environment\nAssess ABCDs and, if indicated, expose patient and re-cover to assure retention of body heat\nVital signs (pulse, blood pressure, respiratory rate, neurologic status assessment) temperature, and O2 saturation, and EtCO2 if available\n\nGo To TOC\n\n### Toxins and Environmental\n\nRev. March 2022\n\nCalcium Channel Blocker Poisoning/Overdose\n\n299\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Treatment Protocol\n\nApply a cardiac monitor, examine rhythm strip for arrhythmias, and obtain a 12-lead EKG if available\nCheck blood glucose level\nMonitor pulse oximetry and EtCO2 for respiratory decompensation\nPatient pertinent history\nPatient physical examination\n\n## Treatment and Interventions\n\n100% oxygen via non-rebreather mask or high flow oxygen by nasal cannula (HFNC) or CPAP or bag valve mask or\nadvanced airway as indicated\nIf seizure, treat per Seizures Guideline\nConsider transporting patients with severe carbon monoxide poisoning directly to a facility with hyperbaric\noxygen capabilities if feasible and patient does not meet criteria for other specialty care (e.g., trauma or\nburn)\n\n## Patient Safety Considerations\n\nConsider affixing a carbon monoxide detector to an equipment bag that is routinely taken into scene (if it\nsignals alarm, don appropriate respiratory protection and exit scene) to assist with detection of occult CO\ntoxicity\nRemove patient and response personnel from potentially hazardous environment as soon as possible\nProvide instruction to the patient, the patient's family, and other appropriate bystanders to not enter the\nenvironment (e.g., building, car) where the carbon monoxide exposure occurred until the source of the poisoning\nhas been eliminated\nDo not look for cherry red skin coloration as an indication of carbon monoxide poisoning, as this is an unusual\nfinding\nCO oximeter devices may yield inaccurate low/normal results for patients with CO poisoning. All patients with\nprobable or suspected CO poisoning should be transported to the nearest appropriate hospital based on their\npresenting signs and symptoms\n\n## Notes/Educational Pearls\n\n### Key Considerations\n\nPulse oximetry is inaccurate due to the carbon monoxide binding with hemoglobin\nAs maternal carboxyhemoglobin levels do not accurately reflect fetal carboxyhemoglobin levels, pregnant patients\nare more likely to be treated with hyperbaric oxygen\nConsider cyanide toxicity if carbon monoxide poisoning is from a fire\n\n### Pertinent Assessment Findings\n\nEarly and repeat assessment of patient's mental status and motor function are extremely useful in determining\nresponse to therapy and the need for hyperbaric therapy\nIdentification of possible etiology of poisoning\nTime of symptom onset and time of initiation of exposure-specific treatment\nResponse to therapy\n\n________________________ Go To TOC\n\nToxins and Environmental Rev.", "start_char_idx": 681314, "end_char_idx": 684672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a22e37b-54b8-4b90-a44f-1131c4c3f46d": {"__data__": {"id_": "4a22e37b-54b8-4b90-a44f-1131c4c3f46d", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95809b13-84ed-4a84-aa5d-c2d92ef30a04", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "e6d37fdc74fd53b03a379b75550085ad2bb0350529d562ca570409eadca68bbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f196db6c-c458-4c3c-8d17-ac0ab9465e3f", "node_type": "1", "metadata": {}, "hash": "05b8ec399b68f37a25fba7d9c3fca174947ba641af37adbd1cf7436702ec243c", "class_name": "RelatedNodeInfo"}}, "text": "All patients with\nprobable or suspected CO poisoning should be transported to the nearest appropriate hospital based on their\npresenting signs and symptoms\n\n## Notes/Educational Pearls\n\n### Key Considerations\n\nPulse oximetry is inaccurate due to the carbon monoxide binding with hemoglobin\nAs maternal carboxyhemoglobin levels do not accurately reflect fetal carboxyhemoglobin levels, pregnant patients\nare more likely to be treated with hyperbaric oxygen\nConsider cyanide toxicity if carbon monoxide poisoning is from a fire\n\n### Pertinent Assessment Findings\n\nEarly and repeat assessment of patient's mental status and motor function are extremely useful in determining\nresponse to therapy and the need for hyperbaric therapy\nIdentification of possible etiology of poisoning\nTime of symptom onset and time of initiation of exposure-specific treatment\nResponse to therapy\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 300\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914167\u2014Exposure - Carbon Monoxide\n9914173\u2014Exposure - Smoke Inhalation\n\n### Key Documentation Elements\n\nIf using an environmental carbon monoxide detector, record the level detected\nEvidence of soot or burns around the face, nares, or pharynx\nEarly and repeat assessment of patient's mental status and motor function are extremely useful in determining response to therapy and the need for hyperbaric therapy\nAccurate exposure history\n\nTime of ingestion/exposure\nRoute of exposure\nQuantity of medication or toxin taken (safely collect all possible mediations or agents)\nAlcohol or other intoxicant taken\n\nSigns and symptoms of other patients encountered at same location if present\n\n### Performance Measures\n\nEarly airway management in the rapidly deteriorating patient\nAccurate exposure history\n\nTime of ingestion/exposure\nRoute of exposure\nQuantity of medication or toxin taken (safely collect all possible mediations or agents)\nAlcohol or other intoxicant taken\n\nAppropriate protocol selection and management\nMultiple frequent documented reassessments\n\n### References\n\nBuckley NA, Juurlink DN, Isbister G, Bennett MH, Lavonas EJ. Hyperbaric oxygen for carbon monoxide poisoning. Cochrane Database Syst Rev. 2011 Apr 13;(4): CD002041\nClinical Policy: Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department with Acute Carbon Monoxide Poisoning. ACEP Clinical Policies Subcommittee (Writing Committees) on Carbon Monoxide Poisoning, American College of Emergency Physicians; Ann Emerg Med. 2017;69:98\u2013107\nHampson N. Practice Recommendations: the diagnosis, management, and prevention of carbon monoxide poisoning. Am J Respir Crit Care Med. 2012;186(11):1095\u2013101\nHigh Flow Nasal Cannula is superior than CPAP in carbon monoxide poisoning\nHoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR. Goldfrank\u2019s Toxicologic Emergencies, 10th Edition. China: McGraw-Hill Education; 2015\nHampson NB. Pulse oximetry in severe carbon monoxide poisoning. Chest. 1998;114(4):1036\u201341\nJones A. Recent advances in the management of poisoning. Ther Drug Monit. 2002;24(1):150\u20135\nKaraman K, Golcuk Y, Y\u0131ld\u0131r\u0131m B, Acar E. Am J Emerg Med. 2020 Oct 2: S0735-6757(20)30879-2. doi: 10.1016/j.ajem.2020.09.084. Bahad\u0131r Caglar 1, Suha Serin 2, Gokhan Yilmaz 3, Alper\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nTorun 4, Ismet Parlak The Impact of Treatment with Continuous Positive Airway Pressure on Acute Carbon Monoxide\nPoisoning Prehosp Disaster Med. 2019 Dec;34(6):588\u2013591. doi: 10.1017/S1049023X19005028. Epub 2019 Oct 22. PMID:\n31637993\n\n9.", "start_char_idx": 683733, "end_char_idx": 687481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f196db6c-c458-4c3c-8d17-ac0ab9465e3f": {"__data__": {"id_": "f196db6c-c458-4c3c-8d17-ac0ab9465e3f", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a22e37b-54b8-4b90-a44f-1131c4c3f46d", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "20555cd2ca7a014cf7f08fa5de9c8913d30e3b0faade0c96a2349e5e9360a7da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "182780ec-7bf9-4666-bb0b-75b8036439d2", "node_type": "1", "metadata": {}, "hash": "70984812fe25cd336f802084e07481a534a21dabf75b3c7d066047e3a8328e6e", "class_name": "RelatedNodeInfo"}}, "text": "2020 Oct 2: S0735-6757(20)30879-2. doi: 10.1016/j.ajem.2020.09.084. Bahad\u0131r Caglar 1, Suha Serin 2, Gokhan Yilmaz 3, Alper\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nTorun 4, Ismet Parlak The Impact of Treatment with Continuous Positive Airway Pressure on Acute Carbon Monoxide\nPoisoning Prehosp Disaster Med. 2019 Dec;34(6):588\u2013591. doi: 10.1017/S1049023X19005028. Epub 2019 Oct 22. PMID:\n31637993\n\n9. Touger M, Birnbaum A, Wang J, Chou K, Pearson D, Bijur P. Performance of the RAD-57 pulse co-oximeter compared\nwith standard laboratory carboxyhemoglobin measurement. Ann Emerg Med. 2010;56(4):382\u20138\n\nRevision Date\n\nMarch 11, 2022\n\n________________________\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nCalcium Channel Blocker Poisoning/Overdose\n\n302\n---\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Opioid Poisoning/Overdose\n\n#### Aliases\n\nCarfentanil, Dilaudid\u00ae, Drug abuse, Fentanyl, Heroin, Hydrocodone, Hydromorphone, Methadone, Morphine, Opiate,\nOpioid, Overdose, Oxycodone, Oxycontin\u00ae, Percocet\u00ae, Percodan\u00ae, U-47700, Vicodin\u00ae\n\n#### Patient Care Goals\n\nRapid recognition and intervention of a clinically significant opioid poisoning or overdose\nPrevention of respiratory and/or cardiac arrest\n\n#### Patient Presentation\n\n##### Inclusion Criteria\n\nPatients exhibiting decreased mental status, and respiratory depression of all age groups with known or suspected\nopioid use or abuse. Lack of miosis (pinpoint pupils) is not a reliable sign for ruling out opioid exposure, although\nits presence is consistent with such exposure\n\n##### Exclusion Criteria\n\nPatients with altered mental status exclusively from other causes (e.g., head injury, or hypoglycemia)\n\n#### Patient Management\n\nDon the appropriate PPE. Note that opioids have minimal vapor pressure and do not pose an exposure risk to\nrescuers unless aerosolized or ingested\nTherapeutic interventions to support the patient's airway, breathing, and circulation should be initiated prior to\nthe administration of naloxone\nIf possible, identify specific medication taken (including immediate release versus sustained release) time of\ningestion, and quantity\nObtain and document pertinent cardiovascular history or other prescribed medications for underlying disease\nBe aware that unsecured hypodermic needles may be on scene if the intravenous route may have been used by the\npatient, and that there is a higher risk of needle sticks during the management of this patient population which may\nalso have an increased incidence of blood-borne pathogens\nNaloxone, an opioid antagonist, should be considered for administration to patients with respiratory depression in a\nconfirmed or suspected opioid overdose\nNaloxone administration via the intravenous route provides more predictable bioavailability and flexibility in\ndosing and titration\nNaloxone administration via the intranasal or intramuscular routes or as a nebulized solution provide additional\noptions of medication delivery\nIf naloxone was administered to the patient prior to the arrival of EMS, obtain the dose and route through which it\nwas administered and, if possible, bring the devices containing the dispensed naloxone with the patient along with all\nother medications on scene\n\n________________________\n\nGo To TOC\n\n### Toxins and Environmental\n\nRev. March 2022\n\n### Opioid Poisoning/Overdose\n\n303\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Assessment\n\n1. Assess the patient's airway, breathing, circulation, and mental status\n\n2. Support the patient's airway by positioning, oxygen administration, and ventilator assistance with a bag valve\nmask if necessary\n\n3. Assess the patient for other etiologies of altered mental status including hypoxia (pulse oximetry less than\n94%), hypoglycemia, hypotension, and traumatic head injury\n\n4.", "start_char_idx": 687048, "end_char_idx": 690904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "182780ec-7bf9-4666-bb0b-75b8036439d2": {"__data__": {"id_": "182780ec-7bf9-4666-bb0b-75b8036439d2", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f196db6c-c458-4c3c-8d17-ac0ab9465e3f", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "66b1cb09fc2f2aa9bfbf1de356df6f106485ed5d8085406b9305caa3016baf03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7abb64d-ecb9-446f-b6a0-32feba4452f7", "node_type": "1", "metadata": {}, "hash": "c61bdff08ab68650433a71afd16e48ebc95ee4c58c58ada23724164c496e1e80", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n### Opioid Poisoning/Overdose\n\n303\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Assessment\n\n1. Assess the patient's airway, breathing, circulation, and mental status\n\n2. Support the patient's airway by positioning, oxygen administration, and ventilator assistance with a bag valve\nmask if necessary\n\n3. Assess the patient for other etiologies of altered mental status including hypoxia (pulse oximetry less than\n94%), hypoglycemia, hypotension, and traumatic head injury\n\n4. Legally prescribed opioids are also manufactured as an adhesive patch for transdermal absorption, and if found,\nshould be removed from the skin\n\n## Treatments and Interventions\n\n1. Critical resuscitation (opening and/or maintaining the airway, provision of oxygen, ensuring adequate circulation)\nshould be performed prior to naloxone administration\n\n2. If the patient has respiratory depression from a confirmed or suspected opioid overdose, consider naloxone\nadministration\n\na. The administration of the initial dose or subsequent doses can be incrementally titrated until respiratory\ndepression is reversed\n\n3. Naloxone can be administered via the IV, IM, IN, or ETT routes. As the ETT route is not very effective, its use\nshould be reserved for dire circumstances with a patient in extremis with no other choice\n\na. Adults: The typical initial adult dose ranges between 0.4\u20132 mg IV, IM, up to a dose of 4 mg IN or 5 mg ETT\n\nb. Pediatrics: The pediatric dose of naloxone is 0.1 mg/kg IV, IM, IN, or ETT\n\ni. Maximum dose of 2 mg IV, IM, or ETT\n\nii. Maximum dose of 4 mg IN\n\n4. Naloxone can be administered via the IV, IM, IN, or ETT routes. As the ETT route is not very effective, its use\nshould be reserved for dire circumstances with a patient in extremis with no other choice\n\na. Adults: The typical initial adult dose ranges between 0.4\u20132 mg IV, IM, up to a dose of 4 mg IN or 5 mg ETT\n\nb. Pediatrics: The pediatric dose of naloxone is 0.1 mg/kg IV, IM, IN, or ETT\n\ni. Maximum dose of 2 mg IV, IM, or ETT\n\nii. Maximum dose of 4 mg IN\n\nc. Naloxone provided to laypersons and non-medical first responders via public access programs or prescriptions may\nbe provided as a pre-measured dose in an auto-injector or nasal spray or as a pre-measured, but variable, dose and/or\nconcentration in a needleless syringe with a mucosal atomization device (MAD) on the hub\n\nd. Naloxone auto-injectors contain 0.4 mg/0.4 mL or 2 mg/0.4 mL\n\ni. The cartons of naloxone auto-injectors prescribed to laypersons contain two naloxone auto-injectors and one\ntrainer\n\ne. Naloxone nasal spray is manufactured in a single-use bottle that contains 4 mg/0.1 mL\n\nf. For the intranasal route when naloxone is administered via a needleless syringe (preferably with MAD on the hub),\ndivide administration of the dose equally between the nostrils to a maximum of 1 mL per nostril\n\ng. The administration of naloxone can be titrated until adequate respiratory effort is achieved if administered with a\nsyringe IV, IM, IN, or ETT\n\nh. Naloxone has no benefit in the treatment of cardiac arrest. Do not delay other\n\nToxins and Environmental\n\nOpioid Poisoning/Overdose\n\nRev.", "start_char_idx": 690379, "end_char_idx": 693545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7abb64d-ecb9-446f-b6a0-32feba4452f7": {"__data__": {"id_": "b7abb64d-ecb9-446f-b6a0-32feba4452f7", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "182780ec-7bf9-4666-bb0b-75b8036439d2", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "f1aef59f0e87d8d0a994771762be3c51b7ed624421ffdbd49f9225c8f646ddea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b23df02-efed-499a-ad31-077d7f011f61", "node_type": "1", "metadata": {}, "hash": "bb55ee18ffa5c83b39704e240472bbb244861b65c669aee8ee21e12b907ae27e", "class_name": "RelatedNodeInfo"}}, "text": "Do not delay other\n\nToxins and Environmental\n\nOpioid Poisoning/Overdose\n\nRev. March 2022\n\n304\n\nGo To TOC\n---\n## National Model EMS Clinical Guidelines Version 3.0\n\nInterventions such as chest compressions and ventilations\n\n### Key Considerations\n\nThe essential feature of opioid overdose requiring EMS intervention is respiratory depression or apnea, managed by ventilation followed by naloxone\nSome opioids have additional toxic effects (i.e., methadone can produce QT prolongation and tramadol can produce seizures)\nOveruse and abuse of prescribed and illegal opioids has led to an increase in accidental and intentional opioid overdoses\nOpioid combinations:\n\nSome opioids are manufactured as a combination of analgesics with acetaminophen, acetylsalicylic acid (aspirin), or other substances\nIn the scenario of an overdose, there is a potential for multiple drug toxicities\nExamples of opioid combination analgesics:\n\nVicodin\u00ae is a combination of acetaminophen and hydrocodone\nPercocet\u00ae is a combination of acetaminophen and oxycodone\nPercodan\u00ae is a combination of aspirin and oxycodone\nSuboxone\u00ae is a combination of buprenorphine and naloxone\n\nHigh-potency opioids:\n\nFentanyl is 50\u2013100 times more potent than morphine. It is legally manufactured in an injectable and oral liquid, tablet, and transdermal (worn as a patch) forms however much of the fentanyl adulterating the heroin supply are illegal fentanyl analogs such as acetyl fentanyl\nCarfentanil is 10,000 times more potent than morphine\n\nIt is legally manufactured in a liquid form; however, a powder or tablet is the\n\n### Patient Safety Considerations\n\nClinical duration of naloxone\n\nThe clinical opioid reversal effect of naloxone is limited and may end within an hour whereas opioids often have a duration of 4 hours or longer\nMonitor the patient for recurrent respiratory depression and decreased mental status\n\nOpioid withdrawal\n\nPatients with altered mental status secondary to an opioid overdose may become agitated or violent following naloxone administration due to opioid withdrawal therefore the goal is to use the lowest dose as possible to avoid precipitating withdrawal\nBe prepared for this potential scenario and take the appropriate measures in advance to ensure and maintain scene safety\n\nEMS clinicians should be prepared to initiate airway management before, during, and after naloxone administration and to provide appropriate airway support until the patient has adequate respiratory effort\n\n### Notes/Educational Pearls\n\nSome notes and educational pearls content here...\n\nToxins and Environmental | Rev. March 2022 | Opioid Poisoning/Overdose | 305\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nmost common form of this drug that is illegally produced\n\nii. In the concentration in which it is legally manufactured (3 mg/mL), an intramuscular dose of 2 mL of carfentanil will sedate an elephant\n\nc. Synthetic opioids (i.e., W-18 are 10,000 times more potent than morphine) many synthetic opioids are not detectable by routine toxicology screening assays\n\n### 6. The IN route has the benefit of no risk of needle stick to the clinician\n\n### 7. Patients with opioid overdose from fentanyl or fentanyl analogs may rapidly exhibit chest wall rigidity and require positive end expiratory pressure (PEEP), in addition to multiple and/or larger doses of naloxone, to achieve adequate ventilation\n\n### Pertinent Assessment Findings\n\nThe primary clinical indication for the use of opioid medications is analgesia\nIn the opioid overdose scenario, signs and symptoms include:\n\nMiosis (pinpoint pupils)\nRespiratory depression\nDecreased mental status\n\nAdditional assessment precautions:\n\nThe risk of respiratory arrest with subsequent cardiac arrest from an opioid overdose as well as hypoxia (pulse oximetry less than 94%), hypercarbia, and aspiration may be increased when other substances such as alcohol, benzodiazepines, or other medications have also been taken by the patient\nPediatric Considerations: The signs and symptoms of an opioid overdose may also be seen in newborns who have been delivered from a mother with recent or chronic opioid use.", "start_char_idx": 693468, "end_char_idx": 697628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b23df02-efed-499a-ad31-077d7f011f61": {"__data__": {"id_": "0b23df02-efed-499a-ad31-077d7f011f61", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7abb64d-ecb9-446f-b6a0-32feba4452f7", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "cb907dc01b7d029e755fe102f1cec51645d0a388e767736a137a3521ebb3a639", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb9c554f-88e7-47ef-96c0-b7c88c3d5e05", "node_type": "1", "metadata": {}, "hash": "84f2af69d1945b9355088088e0844b39d8f86131646a11874d80bbe98a7b7760", "class_name": "RelatedNodeInfo"}}, "text": "Patients with opioid overdose from fentanyl or fentanyl analogs may rapidly exhibit chest wall rigidity and require positive end expiratory pressure (PEEP), in addition to multiple and/or larger doses of naloxone, to achieve adequate ventilation\n\n### Pertinent Assessment Findings\n\nThe primary clinical indication for the use of opioid medications is analgesia\nIn the opioid overdose scenario, signs and symptoms include:\n\nMiosis (pinpoint pupils)\nRespiratory depression\nDecreased mental status\n\nAdditional assessment precautions:\n\nThe risk of respiratory arrest with subsequent cardiac arrest from an opioid overdose as well as hypoxia (pulse oximetry less than 94%), hypercarbia, and aspiration may be increased when other substances such as alcohol, benzodiazepines, or other medications have also been taken by the patient\nPediatric Considerations: The signs and symptoms of an opioid overdose may also be seen in newborns who have been delivered from a mother with recent or chronic opioid use. Neonates who have been administered naloxone for respiratory depression due to presumed intrauterine opioid exposure may be narcotic dependent and should be monitored closely for seizures\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914219\u2014Medical - Opioid Poisoning/Overdose\n\n### Key Documentation Elements\n\nRapid and accurate identification of signs and symptoms of opioid poisoning\nAirway management\nPulse oximetry (oxygen saturation) and, if available, capnometry or capnography\nBlood glucose assessment\nNaloxone dose and route of administration\nClinical response to medication administration\nNumber of doses of naloxone to achieve a clinical response\n\n### Performance Measures\n\nClinical improvement after prehospital administration of naloxone\nThe performance and ongoing assessment of airway management\nFrequency of patients who develop adverse effects or complications (recurrent respiratory depression or decreased mental status, aspiration pneumonia or pulmonary edema)\nNumber of patients who refuse transport following naloxone administration\n\nToxins and Environmental\n\nOpioid Poisoning/Overdose\n\nRev. March 2022\n\n306\n\nGo To TOC\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n# References\n\n1. American College of Medical Toxicology and the American Academy of Clinical Toxicology, Preventing Occupational\nFentanyl and Fentanyl Analog Exposure to Emergency Responders,\nhttps://www.acmt.net/_Library/Positions/Fentanyl_PPE_Emergency_Responders_.pdf.\nAccessed March 11, 2022\n2. Burns G, DeRienz RT, Baker DD, Casavant M, Spiller HA. Could chest wall rigidity be a factor in rapid death\nfrom illicit fentanyl abuse? Clin Toxicol. 2016;54(5):420\u20133\n3. Drugs@FDA: FDA Approved Drug Products. FDA.gov.\nhttps://www.accessdata.fda.gov/scripts/cder/daf/.\nNew Drug Application (NDA) #208411. Accessed March 11, 2022\n4. Drugs@FDA: FDA Approved Drug Products. FDA.gov.\nhttps://www.accessdata.fda.gov/scripts/cder/daf/.\nNew Drug Application (NDA) #209862. Accessed March 11, 2022\n5. Fentanyl: Preventing Occupational Exposure to Emergency Responders. Atlanta, GA: Centers for Disease Control\nand Prevention, the National Institute for Occupational Safety and Health; Updated November 28, 2016\n6. Hoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR. Goldfrank\u2019s Toxicologic Emergencies, 10th Edition.\nChina: McGraw-Hill Education; 2015\n7. Marx JA et al. Rosen\u2019s Emergency Medicine: Concepts and Clinical Practice, 2014 2052\u20132056\n8. Nelson, LS et al. Goldfrank\u2019s Toxicologic Emergencies, 2014, 559\u2013578\n9. Title 21 United States Code (USC) Controlled Substance Act, Section 812. Springfield, VA: US Department of\nJustice, Drug Enforcement Administration\n\nRevision Date: March 11, 2022\n\n________________________ Go To TOC\n\n## Toxins and Environmental Opioid Poisoning/Overdose\n\nRev.", "start_char_idx": 696629, "end_char_idx": 700506, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb9c554f-88e7-47ef-96c0-b7c88c3d5e05": {"__data__": {"id_": "bb9c554f-88e7-47ef-96c0-b7c88c3d5e05", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b23df02-efed-499a-ad31-077d7f011f61", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "f1db712cf7e8e4a03e4f296495d87c044a87fd2edc83e8f4f5dc33ce77b70588", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e80edf3-85ca-432c-9447-b5d431ef6d20", "node_type": "1", "metadata": {}, "hash": "56074efbd17775039988a3015e8375ea32ef45439e0f23f1253d3a8b21499bdc", "class_name": "RelatedNodeInfo"}}, "text": "Hoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR. Goldfrank\u2019s Toxicologic Emergencies, 10th Edition.\nChina: McGraw-Hill Education; 2015\n7. Marx JA et al. Rosen\u2019s Emergency Medicine: Concepts and Clinical Practice, 2014 2052\u20132056\n8. Nelson, LS et al. Goldfrank\u2019s Toxicologic Emergencies, 2014, 559\u2013578\n9. Title 21 United States Code (USC) Controlled Substance Act, Section 812. Springfield, VA: US Department of\nJustice, Drug Enforcement Administration\n\nRevision Date: March 11, 2022\n\n________________________ Go To TOC\n\n## Toxins and Environmental Opioid Poisoning/Overdose\n\nRev. March 2022\n\n307\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# Airway Respiratory Irritants\n\n## Aliases\n\nAirway injury, Respiratory injury, Chemical respiratory Injury, Respiratory irritant, Toxic inhalation\n\n## Patient Care Goals\n\nRapid recognition of the signs and symptoms of confirmed or suspected airway respiratory irritants\n\n## Patient Presentation\n\n### Inclusion Criteria\n\nInhalation of a variety of gases, mists, fumes, aerosols, or dusts may cause irritation or injury to the airways, pharynx, lung, asphyxiation, or other systemic effects\nInhaled airway/respiratory irritant agents will interact with the mucous membranes, upper and lower airways based on solubility, concentration, particle size, and duration of exposure\nThe less soluble and smaller the particle size of the agent the deeper it will travel into the airway and respiratory systems the inhaled toxic agent will go before reacting with adjoining tissues thus causing a greater delay in symptom onset\n\n### Signs and Symptoms\n\nAs the type, severity and rapidity of signs and symptom onset depends on agent, water solubility, concentration, particle size, and duration of exposure, the below signs and symptoms are often overlapping and escalating in severity\nMany airways and respiratory irritant agents have \"warning properties\" such as identifiable or unpleasant smells or irritation to eyes or airways\nSome agents do not have clear warning properties and will often have delayed onset of any sign or symptom:\n\nUnusual odor/smell\nTearing or itchy eyes\nBurning sensation and burns to the nose, pharynx, and respiratory tract\nSneezing\nGeneral excitation\nCough\nChest tightness\nNausea\nShortness of breath/dyspnea\nWheezing\nStridor\nDyspnea on exertion\nDizziness Upper\nChange in voice\nAirway obstructions include laryngospasm and laryngeal edema\nPulmonary edema (non-cardiogenic)\nSeizures\nCardiopulmonary arrest\n\nHigh water solubility/highly irritating (oral/nasal and pharynx, particle size greater than\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022\n\nAirway Respiratory Irritants 308\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n5. Intermediate water solubility (bronchus and bronchiole, particle size 5\u201310 micrometers)\n\n|a.|Chlorine|\n|---|---|\n\n6. Low water solubility/less irritating (alveolar, particle size less than 5 micrometers)\n\n|a.|Cadmium fume|\n|---|---|\n|b.|Fluorine|\n|c.|Hydrogen sulfide (rotten egg odor; olfactory fatigue)|\n|d.|Mercury fume|\n|e.|Mustard gas (also delayed blistering skin manifestations)|\n|f.|Nickel carbonyl|\n|g.|Ozone|\n|h.|Phosgene|\n\n7. Asphyxia agents (two categories)\n\n|a.|Oxygen deprivation below 19.5% oxygen atmosphere (\"simple asphyxiants\")|\n|---|---|\n| |Any gas that reduces oxygen fraction or displaces oxygen from the inspired air|\n| |i. Argon|\n| |ii. Carbon dioxide|\n| |iii. Ethane|\n| |iv. Helium|\n| |v. Methane|\n| |vi. Natural gas (e.g., heptane, propane)|\n| |vii. Nitrogen|\n| |viii. Nitrogen dioxide (delayed symptom onset)|\n|b.|Chemical interfering with oxygen delivery of utilization (\"chemical asphyxiants\")|\n| |i.", "start_char_idx": 699918, "end_char_idx": 703597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e80edf3-85ca-432c-9447-b5d431ef6d20": {"__data__": {"id_": "9e80edf3-85ca-432c-9447-b5d431ef6d20", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb9c554f-88e7-47ef-96c0-b7c88c3d5e05", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "2645e6f6ad8ae053e52cbdc5b939a47427d30b2f517cb89a1c1baf1d9cd1aaeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "434127b6-661a-4fb4-9190-7d84d683c97f", "node_type": "1", "metadata": {}, "hash": "68609de7d4b82d833ca3a90b0854171d6c7023d24eacfc02fb6c091a9ca961b5", "class_name": "RelatedNodeInfo"}}, "text": "Asphyxia agents (two categories)\n\n|a.|Oxygen deprivation below 19.5% oxygen atmosphere (\"simple asphyxiants\")|\n|---|---|\n| |Any gas that reduces oxygen fraction or displaces oxygen from the inspired air|\n| |i. Argon|\n| |ii. Carbon dioxide|\n| |iii. Ethane|\n| |iv. Helium|\n| |v. Methane|\n| |vi. Natural gas (e.g., heptane, propane)|\n| |vii. Nitrogen|\n| |viii. Nitrogen dioxide (delayed symptom onset)|\n|b.|Chemical interfering with oxygen delivery of utilization (\"chemical asphyxiants\")|\n| |i. Carbon monoxide [See Carbon Monoxide/Smoke Exposure Guideline]|\n| |ii. Cyanide [See Cyanide Exposure Guideline]|\n| |iii. Hydrogen sulfide|\n\n8. Inhalants of abuse\n\n|a.|These agents or substances are a diverse class of substances that include volatile solvents, aerosols, and gases|\n|---|---|\n|b.|These chemicals are intentionally inhaled to produce a state that resembles alcohol intoxication with initial         excitation, drowsiness, lightheadedness, and agitation|\n|c.|Users of these inhaled agents are often called huffers, sniffers, baggers, or snorters|\n| |i. These individuals often present after inhaling an aerosol or gas with a loss of consciousness and the presence         of the aerosol can or residue/paint around or in the mouth, nose, and oral pharynx|\n\n________________________ Go To TOC\n\nToxins and Environmental Airway Respiratory Irritants Rev. March 2022 309\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nd. Common household products that are used as inhalants of abuse\n\ni. Volatile solvents\n\n|1. Paint remover|\n|---|\n|2. Degreasers|\n|3. Dry-cleaning fluids|\n|4. Gasoline|\n|5. Lighter fluid|\n|6. Correction fluid|\n|7. Felt tip markers|\n|8. Glue|\n\nii. Cosmetic/paint spray\n\n|1. Deodorant spray|\n|---|\n|2. Vegetable oil spray|\n|3. Fabric protector spray|\n|4. Spray paint|\n\niii. Propellants/asphyxiants/nitrous oxide\n\n|1. Propane gas|\n|---|\n|2. Balloon tanks (helium)|\n|3. Computer keyboard cleaner|\n|4. Ether|\n|5. Halothane|\n|6. Chloroform|\n|7. Butane|\n|8. Propane|\n|9. Whipped cream dispensers|\n\n9. Riot Control Agents [See Riot Control Agent Guideline]\n\n10. A prototype agent is identified with each region of the effected airway respiratory track for mild to moderate\nexposures, as severe concentrated exposures of many of these agents overlap in signs and symptoms \u2014 the deeper the\nsymptoms are in the respiratory track and the slower the rate of symptom onset the less water soluble the airway\nrespiratory irritant\n\na. Nasal and oral pharynx irritation: highly water-soluble agents (ammonia)\n\nb. Bronchial irritation (chlorine)\n\nc. Acute pulmonary edema/deep alveolar injury: poorly water soluble (phosgene)\n\nd. Direct neurotoxin (hydrogen sulfide)\n\ne. Asphyxia agent with additional symptoms (nitrogen dioxide \u2014 Silo Filler's disease)\n\nf. Inhalants of abuse (volatile solvents, cosmetics/paints, propellants/asphyxiants/nitrous oxide)\n\ng. Riot control agents [See Riot Control Agent Guideline]\n\nh. Anticholinesterase inhibitors [See Acetylcholinesterase Inhibitors Guideline]\n\n11. Ammonia\n\na. Immediate detection of unique sharp smell\n\nb. Nasal pharyngeal burning/irritation sensation\n\nc. Ocular tearing and irritation\n\nd. Sneezing\n\ne. Altered mental status \u2014 sleepy to agitated\n\nf. Cough\n\n________________________ Go To TOC\n\nToxins and Environmental Airway Respiratory Irritants Rev. March 2022 310\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n12.", "start_char_idx": 703105, "end_char_idx": 706528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "434127b6-661a-4fb4-9190-7d84d683c97f": {"__data__": {"id_": "434127b6-661a-4fb4-9190-7d84d683c97f", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e80edf3-85ca-432c-9447-b5d431ef6d20", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "74a678c320ada7f11f8da13379ca1353628c0902d5edaf4e76e16fa9706f0b88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d58d043-4f92-4584-9a95-db18d0194ae0", "node_type": "1", "metadata": {}, "hash": "f8f53fc503e244100ca7b1563c11a61a1961b7832774aa5f35394a2f6b8d31b5", "class_name": "RelatedNodeInfo"}}, "text": "Ammonia\n\na. Immediate detection of unique sharp smell\n\nb. Nasal pharyngeal burning/irritation sensation\n\nc. Ocular tearing and irritation\n\nd. Sneezing\n\ne. Altered mental status \u2014 sleepy to agitated\n\nf. Cough\n\n________________________ Go To TOC\n\nToxins and Environmental Airway Respiratory Irritants Rev. March 2022 310\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n12. Chlorine\n\na. All the above (ammonia)\nb. Increased likelihood of the following\n\ni. Bronchiole burns\nii. Bronchospasm wheezing\niii. Non-cardiac pulmonary edema develops within 6\u201324 hours of higher exposures\n\n13. Phosgene\n\na. Often have none of the above symptoms for first half hour to several hours then are much milder until more\nsevere lower respiratory tract symptoms develop\n\ni. Only warning is report of \"fresh mowed hay\" odor\nii. Mild airway irritation or drying\niii. Mild eye irritation\niv. Fatigue\nv. Chest tightness\nvi. Dyspnea/tachypnea\nvii. Significant delay up to 24 hours for\n\n1. Exertional dyspnea\n2. Bronchospasm wheezing\n3. Hypoxia\n4. Severe non-cardiac pulmonary edema\n5. Cardiopulmonary arrest\n\n14. Hydrogen sulfide \u2014 A direct neurotoxin and is rapidly absorbed through lung generating systemic effects\n\na. Distinctive rotten egg smell which rapidly causes olfactory fatigue/loss of sense of smell\nb. Cough\nc. Shortness of breath\nd. Rapid alternations in cognition or consciousness\ne. Bronchiole and lung hemorrhage/hemoptysis\nf. Non-cardiac pulmonary edema\ng. Hydrogen sulfide is known as the \"knock down\" gas because of near immediate and sudden loss of consciousness\nwith high concentrations\nh. Asphyxia\ni. Death\n\n15. Nitrogen dioxide (also called Silo Filler's disease)\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Toxins and Environmental Airway Respiratory Irritants\n\n16. Inhalants of abuse (i.e., felt tip markers, spray paint)\n\na. Physical presences of paint or residue on individual from the inhaled agent\nb. Slurred speech\nc. Altered mental status (excitation, drowsiness to unconsciousness)\nd. Loss of consciousness\ne. Cardiac dysrhythmias\nf. Cardiopulmonary arrest\n\n### Patient Management\n\nDon appropriate PPE \u2014 respiratory protection critical\nRemove patient from the toxic environment\n\na. Remove the patient's clothing that may retain gases or decontaminate if liquid or solid contamination\nb. Flush irrigated effected/burned areas\n\nRapidly assess the patient's respiratory status, mental status, and oxygenation\nAdminister (humidified if available) oxygen\nEstablish intravenous access (if possible)\nApply a cardiac monitor (if available)\nContinuous and ongoing patient reassessment is critical\n\n### Assessment\n\nMake sure the scene is safe as many gases are heavier than air and will build up in low lying areas. This is\nespecially true of hydrogen sulfide and it's \"knock down\" effect of the initial unprotected responder and\nsubsequence casualties associated with unprotected rescuers attempting to safe the first downed responder\nConsider BSI or appropriate PPE\nRemove patient from toxic environment\nDecontaminate\nAssess ABCD and if indicated, expose the patient, and then cover the patient to assure retention of body heat\nVital signs (pulse, blood pressure, respiratory rate, neurologic status assessment) which include temperature\n\n________________________\n\nGo To TOC\n\nRev. March 2022\n\n312\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Toxins and Environmental - Airway Respiratory Irritants\n\n7. Place cardiac monitor and examine rhythm strip for arrhythmia potentials (consider 12-lead EKG)\n\n8. Check blood glucose Level\n\n9. Monitor pulse oximetry and EtCO2 for respiratory decompensation\n\n10. Perform carboxyhemoglobin and cyanide device assessment, if available\n\n11. Identify specific suspected agent if possible\n\n12. Pertinent cardiovascular history or other prescribed medications for underlying disease\n\n13. Patient pertinent history\n\n14.", "start_char_idx": 706140, "end_char_idx": 710083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d58d043-4f92-4584-9a95-db18d0194ae0": {"__data__": {"id_": "4d58d043-4f92-4584-9a95-db18d0194ae0", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "434127b6-661a-4fb4-9190-7d84d683c97f", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "9c0c149a714dfd79af72fdf74bddafe667ebabf24cb4cfda6f526e4b9fdc20b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18a79015-7dd2-43b2-9df3-39072348e97e", "node_type": "1", "metadata": {}, "hash": "cff3cb41dce1d550ec748c50915d6441863b8b9e56ae991765e543a34837fc45", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n312\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Toxins and Environmental - Airway Respiratory Irritants\n\n7. Place cardiac monitor and examine rhythm strip for arrhythmia potentials (consider 12-lead EKG)\n\n8. Check blood glucose Level\n\n9. Monitor pulse oximetry and EtCO2 for respiratory decompensation\n\n10. Perform carboxyhemoglobin and cyanide device assessment, if available\n\n11. Identify specific suspected agent if possible\n\n12. Pertinent cardiovascular history or other prescribed medications for underlying disease\n\n13. Patient pertinent history\n\n14. Patient physical examination\n\n## Treatment and Interventions\n\n1. Assure a patent airway\n\n2. Administer (humidified if available) oxygen and if hypoventilation, toxic inhalation, or desaturation noted, support\nbreathing\n\na. Maintain the airway and assess for airway burns, stridor, or airway edema and if indicated, perform intubation early\n(recommendation to avoid supraglottic airways \u2014 cricothyrotomy may be required in rare severe cases\n\nb. Non-invasive ventilation techniques\n\ni. Use continuous CPAP, BiPAP, intermittent positive pressure breathing (IPPB), HFNC, and/or bilevel nasal CPAP for\nsevere respiratory distress or impending respiratory failure\n\nii. Use bag-valve-mask (BVM) ventilation in the setting of hypoventilation, respiratory failure, or arrest\n\n3. While albuterol 2.5 mg nebulized is usually sufficient for mild wheezing without clinical distress, albuterol 5 mg\nnebulized (or 6 puffs metered dose inhaler) should be administered to all patients in respiratory distress with signs\nof bronchospasm either by basic life support BLS or ALS clinicians. This medication should be repeated at this dose\nwith unlimited frequency for ongoing distress\n\n4. Ipratropium 0.5 mg nebulized should be given up to 3 doses, in conjunction with albuterol\n\n5. Initiate IV access for infusion of lactated Ringer's or normal saline and obtain blood samples in effort to record\npre-treatment levels, e.g., via point-of-care testing, associated with EMS management (e.g., glucose, lactate, cyanide)\n\n6. Fluid bolus (20 mL/kg) if evidence of hypoperfusion\n\n7. If the patient is experiencing significant pain, administer IV/IO analgesics\n\na. Morphine sulfate 0.1 mg/kg IV or IO\n\nb. Fentanyl 1 mcg/kg IV or IO\n\n8. Eye irrigation early\n\n9. Treat topical chemical burns [See appropriate Toxins and Environmental Section guideline(s)]\n\n10. In severe respiratory irritation, in particular hydrogen sulfide, with altered mental status and no improvement with\nremoval from the toxic environment, administer oxygen (humidified if available) as appropriate with a target of achieving\n94\u201398% saturation. Consider consultation for transfer to a tertiary care hospital. If carbon monoxide is a confirmed\nor suspected element of the inhalant, a facility with hyperbaric oxygen capabilities is preferred\n\n________________________ Go To TOC\n\nRev. March 2022\n\n313\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Medication Administration\n\n1. If wheezing is present, consider administering inhaled albuterol (2.5\u20135 mg) as nebulized, or four to eight puffs metered dose inhaler\n\n2. Ipratropium 0.5 mg nebulized should be given in conjunction with albuterol, up to three doses\n\n### Patient Safety Considerations\n\n1. Generally, speaking to patients with exposure to highly soluble airway/respiratory irritants you will find that they have self-extricated due to the warning properties such as the smell, rapidity of onset of irritation, and other symptoms\n\n2. The less soluble agents may generate only an odor (e.g., mowed hay smell for Phosgene) and will have delayed serious symptoms such as acute pulmonary edema, hypoxia, and shortness of breath with minimal exertion\n\n### Notes/Educational Pearls\n\nKey Considerations\n\n1.", "start_char_idx": 709479, "end_char_idx": 713323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18a79015-7dd2-43b2-9df3-39072348e97e": {"__data__": {"id_": "18a79015-7dd2-43b2-9df3-39072348e97e", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d58d043-4f92-4584-9a95-db18d0194ae0", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "cd4b9ffb7ef062a443139e5232cbc0dab20162f510e1a33cb30346ab21c2b3d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2face4b7-6f07-479a-8169-11c8b114894b", "node_type": "1", "metadata": {}, "hash": "1b13bb44bb2c99ca32dfc5b7bec71d4ea17c35e1f3540f67b33860dda78b12a1", "class_name": "RelatedNodeInfo"}}, "text": "If wheezing is present, consider administering inhaled albuterol (2.5\u20135 mg) as nebulized, or four to eight puffs metered dose inhaler\n\n2. Ipratropium 0.5 mg nebulized should be given in conjunction with albuterol, up to three doses\n\n### Patient Safety Considerations\n\n1. Generally, speaking to patients with exposure to highly soluble airway/respiratory irritants you will find that they have self-extricated due to the warning properties such as the smell, rapidity of onset of irritation, and other symptoms\n\n2. The less soluble agents may generate only an odor (e.g., mowed hay smell for Phosgene) and will have delayed serious symptoms such as acute pulmonary edema, hypoxia, and shortness of breath with minimal exertion\n\n### Notes/Educational Pearls\n\nKey Considerations\n\n1. Airway respiratory irritants can exacerbate underlying reactive airway diseases (e.g., asthma, chronic obstructive pulmonary disease (COPD)) and precipitate or exacerbate bronchospasm, respiratory distress, and hypoxia\n\n2. As patients may be off gassing (particularly hydrogen sulfide and hydrogen cyanide) in the back of the transport vehicle, it is important to have adequate ventilation of the patient compartment\n\n3. Removal from the toxic environment, oxygen (humidified if available), general supportive therapy, bronchodilators, respiratory support, and rapid transport are core elements of care as there are no specific antidotes for any of these inhaled agents except for heavy metals that may be chelated in-hospital after agent identification\n\n4. Hydrogen sulfide causes the cells responsible for the sense of smell to be stunned into inaction and therefore with a very short exposure will shut down and the exposed victim will not perceive the smell, yet the victim continues to absorb the gas as it is still present\n\n5. Inhaled agents have become popular as a means of committing suicide. If there is some form of suicide signage, hoses, or buckets of substances visible as you arrive at the vehicle or residence, immediately retreat to well ventilated area and don self-contained breathing apparatus (SCBA) before opening the vehicle or making entry as these gases may be highly concentrated and potentially lethal to EMS responders\n\n6. Household bathroom, kitchen, and oven cleaners when mixed can generate various airway respiratory irritants (ammonia, chloramine, and chlorine gas releases are particularly common). A very common exposure is to chloramine, a gas liberated when bleach (hypochlorite) and ammonia are combined. Chloramine then hydrolyzes in the distal airways and alveoli to ammonia and hypochlorous acid\n\n7. Sudden sniffing death can result from a single use of inhalant of abuse\n\na. Some inhalants can cause cardiac arrest due to dysrhythmias from irritated myocardium\n\nb. This syndrome most often is associated with abuse of butane, propane, and effects of the chemicals in the aerosols\n\n### Pertinent Assessment Findings\n\n1. Patient may describe a specific odor (chlorine swimming pool smell, ammonia smell,\n\n________________________\n\nGo To TOC\n\nToxins and Environmental\n\nAirway Respiratory Irritants\n\nRev.", "start_char_idx": 712544, "end_char_idx": 715666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2face4b7-6f07-479a-8169-11c8b114894b": {"__data__": {"id_": "2face4b7-6f07-479a-8169-11c8b114894b", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18a79015-7dd2-43b2-9df3-39072348e97e", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "5e2e0fc10064110f03fce05410810af2b27a67b8b5425e38ceedb82e7fc6b134", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb5374f9-ece3-4db3-8927-63ed09f1a2e6", "node_type": "1", "metadata": {}, "hash": "829b536d22a60cbd88fca59b6462b44427f3137b1a2f549fbab9cc65007de34d", "class_name": "RelatedNodeInfo"}}, "text": "A very common exposure is to chloramine, a gas liberated when bleach (hypochlorite) and ammonia are combined. Chloramine then hydrolyzes in the distal airways and alveoli to ammonia and hypochlorous acid\n\n7. Sudden sniffing death can result from a single use of inhalant of abuse\n\na. Some inhalants can cause cardiac arrest due to dysrhythmias from irritated myocardium\n\nb. This syndrome most often is associated with abuse of butane, propane, and effects of the chemicals in the aerosols\n\n### Pertinent Assessment Findings\n\n1. Patient may describe a specific odor (chlorine swimming pool smell, ammonia smell,\n\n________________________\n\nGo To TOC\n\nToxins and Environmental\n\nAirway Respiratory Irritants\n\nRev. March 2022\n\n314\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nFresh mowed hay smell (phosgene) which may be helpful but should not be relied upon as the human nose is a poor discriminator of scent\n\n### Assessment\n\nHistory of exposure\nRespiratory distress (retractions, wheezing, stridor)\nDecreased oxygen saturation\nSkin color\nNeurologic status assessment\nReduction in work of breathing after treatment\nImproved oxygenation after breathing\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914033\u2014Exposure - Airway/Inhalation Irritants\n9914139\u2014Medical - Respiratory Distress/Asthma/COPD/Reactive Airway\n\n#### Key Documentation Elements\n\nDocument key aspects of the exam to assess for a change after each intervention:\nRespiratory rate\nOxygen saturation\nUse of accessory muscles or tracheal tugging\nBreath sounds\nAir entry/stridor\nMental status\nColor\nReduction of burning sensation in airway/pharynx\n\n#### Performance Measures\n\nClinical improvement in patient and response to therapy\nSurvival rates of victims\nLong term sequelae of the victims\nNo EMS clinicians injured while managing these incidents\n\n### References\n\nAinsile G. Inhalational injuries produced by smoke and nitrogen dioxide. Respir Med. 1993; 87:169\u201374\nArwood R, Hammond J, Ward GG. Ammonia inhalation. J Trauma. 1985; 25:444\u20137\nBaydala L, Canadian Paediatric Society, First Nations, Inuit and M\u00e9tis Health Committee. Inhalant Abuse. Paediatr\nChild Health. 2010;15(7):443\u20138\nChenuel B, Sonobe T, Haouzi P. Effects of infusion of human methemoglobin solution following hydrogen sulfide\npoisoning. Clin Toxicol (Phila). 2015;53(2):93\u2013101\nChlorine Toxicity. Emedicine.medscape.com. www.emedicine.com\nUpdated Dec 11, 2015. Accessed March 11, 2022\nD\u2019Alessandro A, Kuschner W, Wong H, et al. Exaggerated responses to chlorine inhalation among persons with\nnonspecific airway hyperreactivity. Chest. 1996; 109:331\u20137\nDouglas WW, Hepper NGG, Colby TV. Silo-filler\u2019s disease. Mayo Clin Proc. 1989; 64:291\u2013304\n\n________________________ Go To TOC\n\nToxins and Environmental Airway Respiratory Irritants Rev. March 2022 315\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n8. Fuller DC, Suruda AJ. Occupationally related hydrogen sulfide deaths in the United States from 1984 to 1994. J\nOccup Environ Med. 2000;42(9):939\u201342\n\n9. Gorguner M, Akgun M. Acute Inhalation Injury. Eurasian J Med. 2010;42(1):28\u201335\n\n10. Guloglu C, Kara IH, Erten PG. Acute accidental exposure to chlorine gas in the Southeast of Turkey: a study of\n106 cases. Environ Res. 2002; 88:89\u201393\n\n11. Haouzi P, Chenuel B, Sonobe T. High-dose hydroxocobalamin administered after H2S exposure counteracts sulfide\npoisoning induced cardiac depression in sheep.", "start_char_idx": 714957, "end_char_idx": 718477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb5374f9-ece3-4db3-8927-63ed09f1a2e6": {"__data__": {"id_": "bb5374f9-ece3-4db3-8927-63ed09f1a2e6", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2face4b7-6f07-479a-8169-11c8b114894b", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "38f5c5aa706072b1b23d03aa50546bd02c4cdf21134f65af21756202fd546fa7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "325551bf-cd86-471a-be73-e7c314b050db", "node_type": "1", "metadata": {}, "hash": "aad5e9063c1207ccd8ef257079cd3cd25eea11d39ffdcc4cbaae19e560dd4b8d", "class_name": "RelatedNodeInfo"}}, "text": "Fuller DC, Suruda AJ. Occupationally related hydrogen sulfide deaths in the United States from 1984 to 1994. J\nOccup Environ Med. 2000;42(9):939\u201342\n\n9. Gorguner M, Akgun M. Acute Inhalation Injury. Eurasian J Med. 2010;42(1):28\u201335\n\n10. Guloglu C, Kara IH, Erten PG. Acute accidental exposure to chlorine gas in the Southeast of Turkey: a study of\n106 cases. Environ Res. 2002; 88:89\u201393\n\n11. Haouzi P, Chenuel B, Sonobe T. High-dose hydroxocobalamin administered after H2S exposure counteracts sulfide\npoisoning induced cardiac depression in sheep. Clin Toxicol (Phila). 2015 Jan;51(1): 28\u201336\n\n12. Hydrogen Sulfide Toxicity. Emedicine.medcape.com. http://www.emedicine.com/emerg/topic258.htm Updated\nDecember 29, 2016. Accessed March 11, 2022\n\n13. Issley S, Lang E. Ammonia Toxicity. Emedicine.medscape.com. http://www.emedicine.com/emerg/topic846.htm Updated\nDecember 29, 2015. Accessed March 11, 2022\n\n14. Leduc D, Gris G, Lheureux P, et al. Acute and long-term respiratory damage following inhalation of ammonia.\nThorax. 1992; 47:755\u20137\n\n15. Lim SC, Yang JY, Jang AS, et al. Acute lung injury after phosgene inhalation. Korean J Intern Med. 1996;\n11:87\u201392\n\n16. Mowry JB, Spyker DA, Brooks DE, Zimmerman A, Schauben JL. 2015 Annual Report of the American Association of\nPoison Control Centers' National Poison Data System (NPDS): 33rd Annual Report. Clin Toxicol (Phila). 2016;(10):924\u20131109\n\n17. Newman LS, Gottschall EB. Toxic Inhalational Lung Injury. In: Albert RK, Spiro SG, Jett JR, ed. Clinical\nRespiratory Medicine. 2nd Edition. Philadelphia, PA: Mosby; 2004:759\u201364\n\n18. Noltkamper D, Burgher SW. Toxicity Phosgene 2006. Available at: https://www.ncbi.nlm.nih.gov/books/NBK537213/. Accessed\nMarch 11, 2022\n\n19. Phosgene Toxicity. Emedicine.medscape.com. https://www.ncbi.nlm.nih.gov/books/NBK537213/. Accessed\nMarch 11, 2022\n\n20. Reiffenstein RJ, Hulbert WC, Roth SH. Toxicology of hydrogen sulfide. Ann Rev Pharmacol Toxicol. 1992;\n32:109\u201334\n\n21. Sams RN, Carver HW 2nd, Catanese C, Gilson T. Suicide with hydrogen sulfide. Am J Forensic Med Pathol. 2013;\n34(2):81\u20132\n\n22. Truscott A. Suicide fad threatens neighbors, rescuers. CMAJ. 2008 Aug 12;179(4):312\u20133\n\n23. Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci. 2001; 59:5\u201316\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nToxins and Environmental Airway Respiratory Irritants Rev.", "start_char_idx": 717930, "end_char_idx": 720334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "325551bf-cd86-471a-be73-e7c314b050db": {"__data__": {"id_": "325551bf-cd86-471a-be73-e7c314b050db", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb5374f9-ece3-4db3-8927-63ed09f1a2e6", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "d3787febcec20cd1b71ed2dd633fbc1d31de80e4684d0f003930ab9594dfc2ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad6609e2-4bd6-44b9-bfa9-bffa78f18567", "node_type": "1", "metadata": {}, "hash": "8c215a496a72ea2bfe873f7b5d3eafb47414ac69908ff60b0a839114d1eb1396", "class_name": "RelatedNodeInfo"}}, "text": "Toxicology of hydrogen sulfide. Ann Rev Pharmacol Toxicol. 1992;\n32:109\u201334\n\n21. Sams RN, Carver HW 2nd, Catanese C, Gilson T. Suicide with hydrogen sulfide. Am J Forensic Med Pathol. 2013;\n34(2):81\u20132\n\n22. Truscott A. Suicide fad threatens neighbors, rescuers. CMAJ. 2008 Aug 12;179(4):312\u20133\n\n23. Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci. 2001; 59:5\u201316\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nToxins and Environmental Airway Respiratory Irritants Rev. March 2022 316\n---\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Riot Control Agents\n\n#### Aliases\n\nChemical crowd control agents\n\nHarassing agents\n\nLacrimators\n\nOleoresin capsicum (OC, pepper spray)\n\n|2-Chloroacetophenone (CN, Mace\u00ae)|o-chlorobenzylidene malononitrile (CS)|Tear gas|\n|---|---|---|\n\n#### Patient Care Goals\n\nAddress side effects of exposed individuals\nDecontamination of affected individuals\nMinimize effect to clinician\n\n#### Patient Presentation\n\n##### Inclusion Criteria\n\nExposure to identifiable agents that are not intended to cause significant injury or fatality\n\n##### Exclusion Criteria\n\nExposure to chlorine, phosgene, ammonia, or other agents that are intended to cause significant injury or fatality\nExposure to an unknown agent\n\n#### Patient Management\n\n##### Assessment\n\nAssess scene safety: evaluate for hazards to EMS personnel, patient, bystanders\n\nDetermine riot control agent being used\nDon appropriate PPE\nDetermine number of patients\n\nNote symptoms exhibited by the exposed individual\nExamine as appropriate to complaints\n\n##### Treatment and Interventions\n\nMove affected individuals from contaminated environment into fresh air if possible\nRemove contaminated clothing as able\nHave patient remove contact lenses if appropriate\nIrrigation with water or saline may facilitate resolution of symptoms and is recommended for decontamination of\ndermal and ocular exposure\nIf patient is in respiratory distress, go to Respiratory Section\nIf patient is wheezing, go to Bronchospasm Guideline\nFor persistent pain of the eye or skin, go to Topical Chemical Burn Guideline\nExposed individuals who are persistently symptomatic warrant further evaluation and treatment per local standards\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nRiot Control Agents\n\n317\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Patient Safety Considerations\n\n1. Toxicity is related to duration of exposure and concentration of agent used (exposure in non-ventilated space)\n\n2. Patients with pre-existing pulmonary conditions (e.g., asthma, COPD) may be prone to more severe respiratory effects\n\n3. Traumatic injury may result when exposed individuals are in proximity to the device used to disperse the riot control agent (e.g., hose/stream under pressure, riot control agent projectile, grenade)\n\n## Notes/Educational Pearls\n\n### Key Considerations\n\n1. CN, CS, and OC are the most encountered riot control agents\n\n2. CN, CS, and OC have a high safety ratio. All three have a high median lethal concentration (LCt50) and a low median effective concentration (ECt50)\n\n3. Toxicity is related to time of exposure and concentration of agent used (exposure in non-ventilated space)\n\n4. Symptoms that may be experienced after exposure:\n\na. Eyes: tearing, pain, conjunctivitis, blurred vision\nb. Nose/mouth/throat: rhinorrhea, burning/pain, trouble swallowing, drooling\nc. Lungs: chest tightness, coughing, choking sensation, wheezing, dyspnea\nd. Skin: burning, redness, dermatitis\ne. GI: nausea and vomiting are rare and may be posttussive\n\n5. Symptoms begin within seconds of exposure, are self-limited and are best treated by removing patient from ongoing exposure. Symptoms frequently decrease over time (15\u201345 minutes) after exposure ends\n\n### Pertinent Assessment Findings\n\n1. Riot control agent used\n\n2. Symptoms of exposed\n\n3. Lung sounds\n\n4.", "start_char_idx": 719805, "end_char_idx": 723736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad6609e2-4bd6-44b9-bfa9-bffa78f18567": {"__data__": {"id_": "ad6609e2-4bd6-44b9-bfa9-bffa78f18567", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "325551bf-cd86-471a-be73-e7c314b050db", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "46a510972967e76aadbe588ef6dbe21479186507a4bd0c2d610de46c92e2af75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc48a589-3ca6-4f8c-9990-381bf7af79c2", "node_type": "1", "metadata": {}, "hash": "ee241b4d604b99c9dc6db752bf3293673392599e8ef43138ed34fdc126af088a", "class_name": "RelatedNodeInfo"}}, "text": "Symptoms that may be experienced after exposure:\n\na. Eyes: tearing, pain, conjunctivitis, blurred vision\nb. Nose/mouth/throat: rhinorrhea, burning/pain, trouble swallowing, drooling\nc. Lungs: chest tightness, coughing, choking sensation, wheezing, dyspnea\nd. Skin: burning, redness, dermatitis\ne. GI: nausea and vomiting are rare and may be posttussive\n\n5. Symptoms begin within seconds of exposure, are self-limited and are best treated by removing patient from ongoing exposure. Symptoms frequently decrease over time (15\u201345 minutes) after exposure ends\n\n### Pertinent Assessment Findings\n\n1. Riot control agent used\n\n2. Symptoms of exposed\n\n3. Lung sounds\n\n4. Evidence of other traumatic injuries\n\n## Quality Improvement\n\n### Key Documentation Elements\n\nType of riot control agent if known\nSymptoms being treated\nTreatment provided\nResponse to treatment\n\n### Performance Measures\n\nRiot control agent identified before making patient contact and providing treatment\nPPE used by responders\nAffected individuals removed from ongoing exposure\nContaminated clothing and contact lenses removed as able\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Riot Control Agents 318\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n## References\n\n|1.|Barry JD, Hennessy R, McManus JG Jr. A randomized controlled trial comparing treatment regimens for acute         pain for topical oleoresin capsaicin (pepper spray) exposure in adult volunteers. Prehosp Emerg Care. 2008         Oct\u2013Dec;12(4):432\u20137|\n|---|---|\n|2.|Dimitroglou Y, Rachiotis G, Hadjichristodoulou C. Exposure to the Riot Control Agent CS and Potential Health         Effects: A Systematic Review of the Evidence. Int. J. Environ. Res. Public Health 2015, 12(2), 1397\u20131411|\n|3.|Menezes RG, Hussain SA, Rameez MA, Kharoshah MA, Madadin M, Anwar N, Senthilkumaran S, Chemical crowd         control agents. Med Leg J. 2016 Mar;84(1):22\u20135|\n|4.|Riot-control agents. Army.mil. https://medcoe.army.mil/borden-field-mgt-of-cb-casualties. Accessed March 11,         2022|\n|5.|Riot control agents. Fas.org. https://fas.org/nuke/guide/usa/doctrine/army/mmcch/RiotAgnt.htm. Accessed         August 29, 2017|\n|6.|Riot control agents/tear gas. CDC.gov. https://emergency.cdc.gov/agent/riotcontrol/factsheet.asp. Accessed         March 11, 2022|\n|7.|Schep LJ, Slaughter RJ, McBride DI. Riot control agents: the tear gases CN, CS and OC- a medical review. J R         Army Med Corps. 2015 Jun;161(2):94\u20139. http://jramc.bmj.com/content/161/2/94.long. Epub 2013 Dec 30. Accessed         March 11, 2022|\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Riot Control Agents 319\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Hyperthermia/Heat Exposure\n\n### Aliases\n\nHeat cramps\n\nHeat edema\n\nHeat exhaustion\n\nHeat stroke\n\nHeat syncope\n\nHyperthermia\n\n### Definitions\n\n|Heat Cramps:|are muscle cramps usually in the legs and abdominal wall. Patient temperature is normal|\n|---|---|\n|Heat Exhaustion:|has both salt and water depletion usually of a gradual onset. As it progresses tachycardia, hypotension, elevated         temperature, and very painful cramps occur. Symptoms of headache, nausea, and vomiting occur. Heat exhaustion can         progress to heat stroke|\n|Heat Stroke:|occurs when the cooling mechanism of the body ceases due to temperature overload and/or electrolyte imbalances.         Patient core temperature is usually greater than 104\u00b0F.", "start_char_idx": 723074, "end_char_idx": 726616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc48a589-3ca6-4f8c-9990-381bf7af79c2": {"__data__": {"id_": "cc48a589-3ca6-4f8c-9990-381bf7af79c2", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad6609e2-4bd6-44b9-bfa9-bffa78f18567", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "18d56c4461c727ed68f370c94f36e4b8fae429ac380aba0989a86b99f909084e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dea17a3-171a-42b8-8102-c350832c7102", "node_type": "1", "metadata": {}, "hash": "fadf6e236595305bf158c06286de8846a12714199cfe5fc054515cef81d1f0b3", "class_name": "RelatedNodeInfo"}}, "text": "Patient temperature is normal|\n|---|---|\n|Heat Exhaustion:|has both salt and water depletion usually of a gradual onset. As it progresses tachycardia, hypotension, elevated         temperature, and very painful cramps occur. Symptoms of headache, nausea, and vomiting occur. Heat exhaustion can         progress to heat stroke|\n|Heat Stroke:|occurs when the cooling mechanism of the body ceases due to temperature overload and/or electrolyte imbalances.         Patient core temperature is usually greater than 104\u00b0F. When no thermometer is available, it is distinguished from         heat exhaustion by altered level of consciousness, seizures, or coma|\n|Heat Syncope:|transient loss of consciousness with spontaneous return to normal mentation, attributable to heat exposure|\n\n### Patient Care Goals\n\nCooling and rehydration\nMitigate high-risk for decompensation\nMitigate high-risk for agitation and uncooperative behavior\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nHeat cramps\nHeat exhaustion\nHeat stroke\nHeat syncope\nHeat edema\nStimulant drug abuse\nDelirium with agitated behavior [See Agitated or Violent Patient/Behavioral Emergency Guideline]\n\n#### Exclusion Criteria\n\nFever from infectious or inflammatory conditions\nMalignant hyperthermia\nSerotonin syndrome\nNeuroleptic malignant syndrome\n\n### Patient Management\n\n#### Assessment\n\nPatient Assessment:\n\nAge\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022\n\nHyperthermia/Heat Exposure 320\n---\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Toxins and Environmental Hyperthermia/Heat Exposure\n\n1. Patient Assessment:\n\na. History of exposure\nb. Oral intake\nc. Medications\nd. Alcohol\ne. Illicit drugs\nf. Overdose\ng. Withdrawal risk\n\n2. Environmental Assessment:\n\na. Ambient temperature and humidity\nb. Exertion level\nc. Length of time at risk\nd. Attire (clothing worn)\ne. Confined space\n\ni. Pediatric Considerations: Children left in cars who show signs of altered mental status and elevated body\ntemperature should be presumed to have hyperthermia\n\n3. Associated Symptoms:\n\na. Cramps\nb. Headache\nc. Orthostatic symptoms\nd. Nausea\ne. Weakness\nf. Mental status changes, including\n\ni. Confusion\nii. Coma\niii. Seizures\niv. Psychosis\n\n4. Vital signs:\n\na. Core temperature: usually 104\u00b0F or greater (if thermometer available)\nb. Skin:\n\ni. Flushed and hot\nii. Dry or sweaty\niii. Signs of first or second degree burns from sun exposure\n\nc. Other signs of poor perfusion/shock\n\nTreatment and Interventions\n\nMove victim to a cool area and shield from the sun or any external heat source\nRemove as much clothing as is practical and loosen any restrictive garments\nIf alert and oriented, give small sips of cool liquids\nIf altered mental status, check blood glucose level\nManage airway as indicated\nPlace on cardiac monitor and record ongoing vital signs (pulse, blood pressure, respiratory rate, neurologic status\nassessment)\nIf core temperature is greater than 104\u00b0F (40\u00b0C) or if altered mental status is present, begin active cooling\nby:\n\na. Ice bath immersion provides the most rapid cooling mechanism\nb. If ice bath immersion is not available, consider the following:\n\ni. Tarp-assisted cooling with oscillation\nii. Rotating ice water-soaked towels or sheets\n\nGo To TOC\n\n________________________\n\nRev. March 2022\n\n321\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\niii. Continually misting the exposed skin with tepid water while fanning the victim\n\niv.", "start_char_idx": 726099, "end_char_idx": 729583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dea17a3-171a-42b8-8102-c350832c7102": {"__data__": {"id_": "8dea17a3-171a-42b8-8102-c350832c7102", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc48a589-3ca6-4f8c-9990-381bf7af79c2", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "e43d5b7d785021dcf2ab8598d8609b81f2fbb300547f2eec75889808942ce0b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "509b7404-7fac-4152-855b-6cd1cbfdadba", "node_type": "1", "metadata": {}, "hash": "4d336fc22dd9ea367a312ee0c359febf509ed0bfa0d82faf66eb65d4cfc4fc8e", "class_name": "RelatedNodeInfo"}}, "text": "Rotating ice water-soaked towels or sheets\n\nGo To TOC\n\n________________________\n\nRev. March 2022\n\n321\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\niii. Continually misting the exposed skin with tepid water while fanning the victim\n\niv. Truncal ice packs may be used, but are less effective than evaporation\n\nv. DO NOT apply wet cloths or wet clothing, as they may trap heat and prevent evaporative cooling\n\nIf shivering occurs during cooling and prevents effective cooling, benzodiazepines may be considered:\n\nAdult:\n\n|Midazolam|2.5 mg IV/IN, may repeat once in 5 minutes|OR|5 mg IM may repeat once in 10 minutes|\n|---|---|---|---|\n|Lorazepam|1 mg IV, may repeat once in 5 minutes|OR|2 mg IM, may repeat once in 10 minutes|\n|Diazepam|2 mg IV, may repeat once in 5 minutes|\n\nPediatric:\n\n|Midazolam (single maximum dose 1 mg)|0.5 mg/kg IV, maximum single dose 2 mg, may repeat once in 10 minutes|OR|0.2 mg/kg IN/IM, maximum single dose 10 mg|\n|---|---|---|---|\n|Lorazepam (single maximum dose 1 mg)|0.1 mg/kg IV/IM|\n|Diazepam|0.1 mg/kg IV (maximum single dose 2.5 mg)|May repeat once, for maximum total IV/IM dose 5 mg|OR|0.5 mg/kg PR (maximum single dose 10 mg)|May repeat once for maximum total PR dose 20 mg|\n\n8. Cooling efforts should continue until the patient's temperature is less than 102.2\u00b0F (39\u00b0C) or, if continuous\ntemperature monitoring is not available, until the patient demonstrates improvement in mental status\n\n9. Establish IV access for patients suffering from heat stroke \u2014 give cool fluids at 20 mL/kg boluses and reduce to\n10 mL/kg/hr boluses when vitals are stable\n\n10. Monitor for arrhythmia and cardiovascular collapse [See Cardiovascular Section]\n\n11. Treat seizures, per the Seizures Guideline\n\n12. All patients suffering from life threatening heat illness (including heat stroke) should be transported to the\nhospital\n\n## Patient Safety Considerations\n\nConsider use of physical securing devices [See Agitated or Violent Patient/Behavioral Emergency Guideline] to\nprotect vascular access sites.\n\n________________________ Go To TOC\n\nToxins and Environmental Rev.", "start_char_idx": 729312, "end_char_idx": 731433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "509b7404-7fac-4152-855b-6cd1cbfdadba": {"__data__": {"id_": "509b7404-7fac-4152-855b-6cd1cbfdadba", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dea17a3-171a-42b8-8102-c350832c7102", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "71b2ce6277be93368858e3b4547b6f561a24071db36ee28e3863de60617d5ebf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcfe8dfd-b23d-4542-9943-5e9120852dc6", "node_type": "1", "metadata": {}, "hash": "f6b21466d303c48663ded866f2c12a976a6416c91f86306cbde08ad73e378976", "class_name": "RelatedNodeInfo"}}, "text": "Cooling efforts should continue until the patient's temperature is less than 102.2\u00b0F (39\u00b0C) or, if continuous\ntemperature monitoring is not available, until the patient demonstrates improvement in mental status\n\n9. Establish IV access for patients suffering from heat stroke \u2014 give cool fluids at 20 mL/kg boluses and reduce to\n10 mL/kg/hr boluses when vitals are stable\n\n10. Monitor for arrhythmia and cardiovascular collapse [See Cardiovascular Section]\n\n11. Treat seizures, per the Seizures Guideline\n\n12. All patients suffering from life threatening heat illness (including heat stroke) should be transported to the\nhospital\n\n## Patient Safety Considerations\n\nConsider use of physical securing devices [See Agitated or Violent Patient/Behavioral Emergency Guideline] to\nprotect vascular access sites.\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Hyperthermia/Heat Exposure 322\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Notes/Educational Pearls\n\nKey Considerations\n\nPatients at risk for heat emergencies include neonates, infants, geriatric patients, and patients with mental illness\nContributory risk factors may come from:\n\nPrescription and over-the-counter herbal supplements\nCold medications\nHeart medications\nDiuretics\nPsychiatric medications\nDrug abuse\nAccidental or intentional drug overdose\n\nHeat exposure can occur either due to increased environmental temperatures or prolonged exercise or a combination of both\n\nEnvironments with temperature greater than 90\u00b0F and humidity greater than 60% present the most risk\n\nHeat stroke is associated with cardiac arrhythmias independent of drug ingestion/overdose Heat stroke has also been associated with cerebral edema\nFor patients with signs and symptoms of heat stroke, rapid cooling takes priority over other interventions (e.g., cardiac monitoring, IV access)\nDo not forget to look for other causes of altered mental status such as low blood glucose level, or, in the proper circumstances (i.e., endurance exercise events), consider exercise associated hyponatremia (EAH), especially in the patient with altered mental status, normal blood glucose, and normal temperature\nControversy: shivering may occur while treating heat stroke\n\nIt is uncertain how harmful shivering is to heat stroke patients\nCooling should be continued until the above temperature and mental status goals are met\nTreat shivering as above\nResearch does not demonstrate the value of one benzodiazepine over another in shivering patients or any value of other medications\n\nHyperthermia not from environmental factors has a differential that includes the following:\n\nFever and delirium\nHyperthyroid storm\nDelirium tremens (DTs)\nCNS lesion or tumor\nAdverse drug event: neuroleptic malignant syndrome, malignant hyperthermia\nMental status changes without hyperthermia in the correct circumstances could be exercise associated hyponatremia\n\nThere is no evidence supporting EMS obtaining orthostatic vital signs as a clinical indicator\n\n## Pertinent Assessment Findings\n\nWarning signs: fever, altered mental status\nBlood glucose level for AMS\n\n________________________\n\nGo To TOC\n\nToxins and Environmental\n\nHyperthermia/Heat Exposure\n\nRev. March 2022\n\n323\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914027\u2014Environmental - Heat Exposure/Heat Exhaustion\n9914029\u2014Environmental - Heat Stroke/Heat Exposure\n\n### Key Documentation Elements\n\nPatient assessment includes all types of medication/drug use and detailed past medical history\nEnvironmental assessment performed\nCooling interventions considered and implemented\nDecision-making regarding securing devices\nDecision-making regarding monitoring ABCs (Airway, Breathing, Circulation)\n\n### Performance Measures\n\nBlood glucose level obtained\nFluids given for hypotension\nAttempts to reduce core temperature\nTime from arrival at scene to when active cooling by immersion is started\nAll decompensations during EMS care reviewed\n\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nHypoglycemia\u201401: Treatment Administered for Hypoglycemia.", "start_char_idx": 730562, "end_char_idx": 734846, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcfe8dfd-b23d-4542-9943-5e9120852dc6": {"__data__": {"id_": "fcfe8dfd-b23d-4542-9943-5e9120852dc6", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "509b7404-7fac-4152-855b-6cd1cbfdadba", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "113a0c4db2ecef22b8cf7e40f9dfcaca2bf4b35c038fdb888174bbb8ea137443", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f72b190-57d5-47bc-b152-ed7eb7a3f8df", "node_type": "1", "metadata": {}, "hash": "208aece27cfb275e2fd9357d62c685346019c83f8ad55162ae5335cecc5c0ece", "class_name": "RelatedNodeInfo"}}, "text": "Measure of patients who received treatment to correct their hypoglycemia\n\nPediatrics\u201403: Documentation of Estimated Weight in Kilograms\n\n### References\n\nBelval, L., Casa, D., Adams, W., Chiampas, G., Holschen, J., Hosokawa, Y., Jardine, J., Kane, S., Labotz, M., Lemieux, R., McClaine, K., Nye, N., O'Connor, F., Prine, B., Raukar, N., Smith, M. and Stearns, R., 2022. Consensus Statement- Prehospital Care of Exertional Heat Stroke.\nBouchama A, Knochel JP. Heat Stroke. NEJM. 2002;346(25):1978\u201388\nBouchama A, Dehbi M, Chaves-Carballo E. Cooling and hemodynamic management in heatstroke: practical recommendation. Crit Care Lond Engl. 2007;11(3): R54\nBrugger H, Bouzat P, Pasquier M, Mair P, Fieler J, Darocha T, Blancher M, de Riedmatten M, Falk M, Paal P, Strapazzon G, Zafren K, Brodmann Maeder M. Cut-off values of serum potassium and core temperature at hospital admission for extracorporeal rewarming of avalanche victims in cardiac arrest: A retrospective multi-centre study. Resuscitation. 2019;139:222\u2013229. doi: 10.1016/j.resuscitation.2019.04.025\nEpstein, Y., Yanovich, R. \u201cHeatstroke\u201d N Engl J Med 2019;380:2449-59. www.nejm.org/doi/pdf/10.1056/NEJMra1810762?articleTools=true. Accessed March 11, 2022\nHeled Y, Rav-Acha M, Shani Y et al. The \u201cGolden Hour\u201d for heatstroke treatment. Mil Med, 2004 169(3)184\u2013186\nLipman G, Eifling K, Ellis MA, et. al. Wilderness Medical Society practice guidelines for the prevention and treatment of heat-related illness. Wilderness Environ Med.\n\n## Toxins and Environmental Hyperthermia/Heat Exposure\n\nRev. March 2022\n\n324\n\n________________________\n\nGo To TOC\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n2013;24(4):351\u201361\n\nLuhring, K. E., Butts, C. L., Smith, C. R., Bonacci, J. A., Ylanan, R. C., Ganio, M. S., & McDermott, B. P. (2016).\nCooling Effectiveness of a Modified Cold-Water Immersion Method After Exercise-Induced Hyperthermia. Journal of\nathletic training, 51(11), 946\u2013951. https://doi.org/10.4085/1062-6050-51.12.07.\nAccessed March 11, 2022\n\nPaal P, Gordon L, Strapazzon G, Brodmann Maeder M, Putzer G, Walpoth B, Wanscher M, Brown D, Holzer M, Broessner\nG, Brugger H. Accidental hypothermia- an update: The content of this review is endorsed by the International\nCommission for Mountain Emergency Medicine (ICAR MEDCOM). Scand J Trauma Resusc Emerg Med. 2016;24:111. doi:\n10.1186/s13049-016-0303-7\n\nROBERT GAUER, MD, BRYCE K. MEYERS, DO, MPH, Heat Related Illnesses. Am Fam Physician. 2019 Apr 15;99(8):482\u2013489\n\nThe Futility of Orthostatic Measurements. Lifeinthefastlane.com. https://litfl.com/the-futility-of-orthostatic-measurements/.\nPublished January 14, 2014. Accessed March 11, 2022\n\nVicario SJ, Okabajue R, Haltom T. Rapid cooling in classic heatstroke treatment: effect on mortality rates. Am J\nEmerg Med. 1986;4(5):394\u20138\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nToxins and Environmental Hyperthermia/Heat Exposure Rev.", "start_char_idx": 734848, "end_char_idx": 737798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f72b190-57d5-47bc-b152-ed7eb7a3f8df": {"__data__": {"id_": "7f72b190-57d5-47bc-b152-ed7eb7a3f8df", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcfe8dfd-b23d-4542-9943-5e9120852dc6", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "57ce1e589619b02c4279558e391a55da638a1f98b8e41dfd83c1bd955b99f89c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bddc74c-3192-4eeb-84cb-7ab375b0d84b", "node_type": "1", "metadata": {}, "hash": "654590028bc9f9b5dbb06e8342b5c091cb93cb794d6f506166e74a07667be0a2", "class_name": "RelatedNodeInfo"}}, "text": "Am Fam Physician. 2019 Apr 15;99(8):482\u2013489\n\nThe Futility of Orthostatic Measurements. Lifeinthefastlane.com. https://litfl.com/the-futility-of-orthostatic-measurements/.\nPublished January 14, 2014. Accessed March 11, 2022\n\nVicario SJ, Okabajue R, Haltom T. Rapid cooling in classic heatstroke treatment: effect on mortality rates. Am J\nEmerg Med. 1986;4(5):394\u20138\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nToxins and Environmental Hyperthermia/Heat Exposure Rev. March 2022 325\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Hypothermia/Cold Exposure\n\n### Aliases\n\nCold induced injuries, Frost bite, Hypothermia\n\n### Patient Care Goals\n\nMaintain hemodynamic stability\nPrevent further heat loss\nRewarm the patient in a safe manner\nAppropriate management of hypothermia induced cardiac arrest\nPrevent loss of limbs\n\n### Patient Presentation\n\nPatients may suffer from hypothermia due to exposure to a cold environment (increased heat loss) or may suffer\nfrom a primary illness or injury that, in combination with cold exposure (heat loss in combination with decreased\nheat production), leads to hypothermia\nPatients may suffer systemic effects from cold (hypothermia) or localized effects (i.e., frostbite)\nPatients with mild hypothermia will have normal mental status, shivering, and may have normal vital signs while\npatients with moderate to severe hypothermia will manifest mental status changes, eventual loss of shivering and\nprogressive bradycardia, hypotension, and decreased respiratory status\nPatients with frostbite will develop numbness involving the affected body part along with a \"clumsy\" feeling along\nwith areas of blanched skin \u2014 later findings include a \"woody\" sensation, decreased or loss of sensation, bruising\nor blister formation, or a white and waxy appearance to affected tissue\n\n### Inclusion Criteria\n\nPatients suffering systemic or localized cold injuries.\n\n### Exclusion Criteria\n\nPatients without cold exposure\nPatients with cold exposure but no symptoms referable to hypothermia or frostbite\n\n### Patient Management\n\n#### Assessment\n\nPatient assessment should begin with attention to the primary survey, looking for evidence of circulatory\ncollapse and ensuring effective respirations\n\nThe patient suffering from moderate or severe hypothermia may have severe alterations in vital signs\nincluding weak and extremely slow pulses, profound hypotension, and decreased respirations\nThe rescuer may need to evaluate the hypothermic patient for a pulse for longer than the normothermic\npatient (up to 60 seconds)\n\nHistory: along with standard SAMPLE \u2014 type history, additional patient history should include:\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n### 3. Hypothermia Severity Categorization\n\na. Attention to any associated injury or illness\n\nb. Duration of cold exposure\n\nc. Ambient temperature\n\nd. Treatments initiated before EMS arrival\n\nThere are several means to categorize the severity of hypothermia based on either core body temperature readings or clinical evaluation. If possible and reliable, EMS clinicians should perform core body temperature measurements and categorize patients into one of the three follow levels of hypothermia:\n\n|Level|Temperature Range|\n|---|---|\n|Mild|32.1\u00b0\u201335\u00b0C/89.8\u00b0\u201395\u00b0F|\n|Moderate|28.1\u00b0\u201332\u00b0C/82.5\u00b0\u201389.7\u00b0F|\n|Severe|24\u00b0\u201328\u00b0C/75.2\u00b0\u201382.4\u00b0F|\n|Profound|less than 24\u00b0C (75.2\u00b0F)|\n\nEqually important is the patient's clinical presentation and the signs or symptoms the patient is experiencing \u2014 the above temperature-based categorization should be balanced against these clinical findings\n\nMild: vital signs not depressed; normal mental status; shivering is preserved; body maintains the ability to attempt to control temperature\n\nModerate/Severe: progressive bradycardia, hypotension, and decreased respirations, alterations in mental status with eventual coma, shivering will be lost in moderate hypothermia (generally between 30\u00b0\u201331\u00b0C (86\u00b0-87.8\u00b0F), and general slowing of bodily functions; the body loses the ability to thermo-regulate\n\n### Treatment and Interventions\n\n1. Maintain patient and rescuer safety\n\n2. Manage airway per the Airway Management Guideline\n\n3.", "start_char_idx": 737311, "end_char_idx": 741507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bddc74c-3192-4eeb-84cb-7ab375b0d84b": {"__data__": {"id_": "5bddc74c-3192-4eeb-84cb-7ab375b0d84b", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f72b190-57d5-47bc-b152-ed7eb7a3f8df", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "78c19cd0f55c353faee5c91e6ea3e7e1be9b8659fa711fc788ba2f323e01dfb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "792001b1-621e-4e93-850f-d4d4f7eee655", "node_type": "1", "metadata": {}, "hash": "6ac9a372a64b6fb8bb24e4cf5cf42e349691db8084691d7a4108ef4f640ea41c", "class_name": "RelatedNodeInfo"}}, "text": "Maintain patient and rescuer safety\n\n2. Manage airway per the Airway Management Guideline\n\n3. Mild hypothermia:\n\na. Remove the patient from the environment and prevent further heat loss by removing wet clothes and drying skin, insulate from the ground, shelter the patient from wind and wet conditions, and insulate the patient with dry clothing or a hypothermia wrap/blanket. Cover the patient with a vapor barrier and, if available, move the patient to a warm environment\n\nb. Hypothermic patients have decreased oxygen needs and may not require supplemental oxygen\n\ni. If oxygen is deemed necessary, it should be warmed to a maximum temperature between 40\u00b0\u201342\u00b0C (104\u00b0\u2013108\u00b0F) and humidified if possible\n\nc. Provide beverages or foods containing glucose if feasible and patient is awake and able to manage airway independently\n\nd. Vigorous shivering can substantially increase heat production \u2014 shivering should be fueled by caloric replacement\n\ne. Consider field-rewarming methods such as placement of large heat packs or heat blankets (chemical or electric if feasible) to the anterior chest or wrapped around the patient's thorax if large enough \u2014 forced air warming blankets (e.g., Bair Hugger\u00ae) can be an effective field rewarming method if available\n\nf. Monitor frequently \u2014 if temperature or level of consciousness decreases, refer to severe hypothermia\n\ng. Consider IV access\n\ni. Indications for IV access and IV fluids in the mildly hypothermic patient are\n\nToxins and Environmental\n\nHypothermia/Cold Exposure\n\nRev. March 2022\n\n327\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nsimilar to those of the non-hypothermic patient\n\nIV fluids, if administered, should be warmed, ideally to 42\u00b0C (107.6\u00b0F)\n\nBolus therapy is preferable to continuous drip\n\nIf alterations in mental status, consider measuring blood glucose and treat as indicated (treat per Hypoglycemia\nGuideline or Hyperglycemia Guideline) and assess for other causes of alterations of mentation\n\nTransport to a hospital capable of rewarming the patient\n\n### 4. Moderate or severe hypothermia:\n\nPerform ABCs (Airway, Breathing, Circulation), pulse checks for patients suffering hypothermia should be performed\nfor 60 seconds, and obtain core temperature, if possible, for patients exhibiting signs or symptoms of\nmoderate/severe hypothermia\n\nCore temperatures can be measured by esophageal probe, if one is available, the patient's airway is secured, and\nthe clinician has been trained in its insertion and use.\n\nRectal temperatures may also be used, with caution to avoid worsening the hypothermia by undressing the patient\n(e.g., done in a warm environment such as a heated ambulance)\n\nIf neither esophageal nor rectal thermometers are available, an epitympanic field thermometer with an isolating\near cap may be used, but is generally less accurate\n\nManage airway as needed\n\nPrevent further heat loss by removing the patient from the environment and removing wet clothes and drying skin,\ninsulate from the ground, shelter the patient from wind and wet conditions, and insulate the patient with dry\nclothing or a hypothermia wrap/blanket. Cover the patient with a vapor barrier and, if available, move the patient\nto a warm environment\n\nInitiate field-rewarming methods such as placement of large heat packs or heat blankets (chemical or electric if\nfeasible) to the anterior chest or wrapped around the patient's thorax if large enough\n\nHandle the patient gently\n\nApply cardiac monitor or AED if available\n\nEstablish IV and provide warmed isotonic crystalloid bolus. Repeat as necessary\n\nIf alterations in mental status, consider measuring blood glucose and treat as indicated (treat per Hypoglycemia\nGuideline or Hyperglycemia Guideline) and assess\n\n________________________\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nHypothermia/Cold Exposure\n\n328\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nfor other causes of alterations of mentation\n\nTransport as soon as possible to a hospital capable of resuscitation. If cardiac arrest develops consider transport to a center capable of extracorporeal circulation (ECMO) or cardiopulmonary bypass (if feasible)\nWarm the patient compartment of the ambulance to at least 24\u00b0C (75.2\u00b0F) during transport\n\n5.", "start_char_idx": 741414, "end_char_idx": 745707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "792001b1-621e-4e93-850f-d4d4f7eee655": {"__data__": {"id_": "792001b1-621e-4e93-850f-d4d4f7eee655", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bddc74c-3192-4eeb-84cb-7ab375b0d84b", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "89286683d7b05fc3b76d25ded693a38ce85048a01d45f08ea339bfc751d3a617", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52ff2706-6c8b-4998-a57b-3df0f649c2dd", "node_type": "1", "metadata": {}, "hash": "bdc3c143593ec214cb181ef4d124622da6abea110e835b2fd92b510b34fc6039", "class_name": "RelatedNodeInfo"}}, "text": "Repeat as necessary\n\nIf alterations in mental status, consider measuring blood glucose and treat as indicated (treat per Hypoglycemia\nGuideline or Hyperglycemia Guideline) and assess\n\n________________________\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nHypothermia/Cold Exposure\n\n328\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nfor other causes of alterations of mentation\n\nTransport as soon as possible to a hospital capable of resuscitation. If cardiac arrest develops consider transport to a center capable of extracorporeal circulation (ECMO) or cardiopulmonary bypass (if feasible)\nWarm the patient compartment of the ambulance to at least 24\u00b0C (75.2\u00b0F) during transport\n\n5. Frost bite:\n\nIf the patient has evidence of frostbite, and ambulation/travel is necessary for evacuation or safety, avoid rewarming of extremities until definitive treatment is possible. Additive injury occurs when the area of frostbite is rewarmed then inadvertently refrozen. Only initiate rewarming if refreezing is absolutely preventable\n\nIf rewarming is feasible and refreezing can be prevented use circulating warm water (37\u00b0\u201339\u00b0C/98.6\u00b0\u2013102\u00b0F) to affected body part, thaw injury completely. If warm water is not available, rewarm frostbitten parts by contact with non-affected body surfaces. Do not rub or cause physical trauma.\nAfter rewarming, cover injured parts with loose sterile dressing. If blisters are causing significant pain, and the clinician is so trained, these may be aspirated, however, should not be de-roofed. Do not allow injury to refreeze. Treat per the Pain Management Guideline.\n\nPatient Safety Considerations\n\nGiven the additive effects of additional cold stress, the patient should be removed from the cold environment as soon as operationally feasible\nIn patients suffering from moderate to severe hypothermia, it is critical to not allow these patients to stand or exercise as this may cause circulatory collapse\nDevices that self-generate heat (e.g., heat packs) that are being utilized during the rewarming process should be wrapped in a barrier to avoid direct contact with the skin and to prevent burns. Available evidence suggests that heat packs with peak temperatures above 45\u00b0C (113\u00b0F) are most likely to cause burns. In patients who are unresponsive, or unable to recognize a developing injury, please check the area in which the heating pad is placed regularly to ensure no tissue damage occurs.\n\nNotes/Educational Pearls\n\nKey Considerations\n\nConsiderations in cardiac arrest\n\nThe following are contraindications for initiation of resuscitation in the hypothermic patient:\n\nObvious fatal injuries (such as decapitation)\nThe patient exhibits signs of being frozen (such as ice formation in the airway)\nChest wall rigidity such that compressions are impossible\nDanger to rescuers or rescuer exhaustion\nAvalanche victims buried for 35 minutes or longer with airway obstruction by ice or snow\n\nFixed and dilated pupils, apparent rigor mortis, and dependent lividity may not be contraindication for resuscitation in the severely hypothermic patient\nThe mainstay of therapy in severe hypothermia and cardiac arrest should be effective chest compressions and attempts at rewarming. Chest compressions\n\nGo To TOC\n\nToxins and Environmental\n\nHypothermia/Cold Exposure\n\nRev. March 2022\n\n329\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n1. should be provided at the same rate as in normothermic patients\n\n2. The temperature at which defibrillation should first be attempted in the severely hypothermic cardiac arrest victim\nand the number of defibrillation attempts is unclear. There are different approaches regarding resuscitation of the hypothermic\narrest patient\n\na. Per the American Heart Association (AHA), if the patient has a shockable rhythm (VF/VT), defibrillation should be attempted.\nIt is reasonable to continue defibrillation attempts per AHA protocols concurrently with rewarming strategies\n\nb. The state of Alaska's 2014 guidance on management of hypothermic patients in cardiac arrest advises that defibrillation\nshould be attempted once, followed by 2 minutes of chest compressions, then rhythm and pulse checks\n\ni. If defibrillation is unsuccessful and the patient's core temperature is less than 30\u00b0C (86\u00b0F), do not make further attempts\nat defibrillation until the core temperature has increased to greater than 30\u00b0C (86\u00b0F)\n\nii.", "start_char_idx": 744987, "end_char_idx": 749417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52ff2706-6c8b-4998-a57b-3df0f649c2dd": {"__data__": {"id_": "52ff2706-6c8b-4998-a57b-3df0f649c2dd", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "792001b1-621e-4e93-850f-d4d4f7eee655", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "fa77eece9182a4b6a69f1e40002c84981d1e85fcc547115d8ce40eedcf7b1f07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c20f7eba-bab5-4b9a-81dd-9fa4a4b2be6b", "node_type": "1", "metadata": {}, "hash": "adcd48443f63cc517173279c4882eb361b6c4803432aa3ea21c5d296f38d26d3", "class_name": "RelatedNodeInfo"}}, "text": "There are different approaches regarding resuscitation of the hypothermic\narrest patient\n\na. Per the American Heart Association (AHA), if the patient has a shockable rhythm (VF/VT), defibrillation should be attempted.\nIt is reasonable to continue defibrillation attempts per AHA protocols concurrently with rewarming strategies\n\nb. The state of Alaska's 2014 guidance on management of hypothermic patients in cardiac arrest advises that defibrillation\nshould be attempted once, followed by 2 minutes of chest compressions, then rhythm and pulse checks\n\ni. If defibrillation is unsuccessful and the patient's core temperature is less than 30\u00b0C (86\u00b0F), do not make further attempts\nat defibrillation until the core temperature has increased to greater than 30\u00b0C (86\u00b0F)\n\nii. Continue CPR and attempt to rewarm the patient\n\nc. An alternate strategy, per the Wilderness Medical Society's accidental hypothermia guideline, suggests that if the patient's\ncore temperature is below 30\u00b0C (86\u00b0F), attempt defibrillation once, then wait until the patient has been rewarmed at least 1\u00b0\u20132\u00b0C\nor to 30\u00b0C (86\u00b0F) before attempting additional shocks. It is noted that the likelihood of successful defibrillation increases\nwith every one-degree increase in temperature\n\nd. If defibrillation is unsuccessful and the patient's core temperature is greater than 30\u00b0C (86\u00b0F), follow guidelines for\nnormothermic patients\n\ne. If available monitors reveal asystole, CPR alone is the mainstay of therapy\n\nf. If monitoring reveals an organized rhythm (other than VF or VT) and no pulses are detected, do not start CPR, but continue\nto monitor\n\ni. While this may represent pulseless electrical activity (PEA), this may also represent situations in which the patient's\npulses are not detectable but remain effective due to decreased metabolic needs\n\nii. In the case of PEA, the rhythm will deteriorate rapidly to asystole, in which case, CPR should be initiated\n\niii. Given the potential to cause VF with chest compressions, the Alaska guidance offers that it is better to maintain effective\ncardiac activity than to start CPR and cause VF\n\n3. Manage the airway per standard care in cardiac arrest victims [See Cardiac Arrest Guideline]\n\na. In the absence of advanced airways, ventilate the patient at the same rate as a normothermic patient\n\nb. If the patient has an advanced airway, ventilate at half the rate recommended for a normothermic patient to prevent hyperventilation.\nIf EtCO2 is available, ventilate to maintain normal EtCO2 levels\n\n4. There is little evidence to guide use of medications in severe hypothermia with cardiac arrest, however 2010 AHA updates to\nadvanced cardiac life support recommend use of vasopressors according to standard ACLS protocols while the 2014 Alaska guidelines\nand the Wilderness Medical Society's accidental hypothermia guideline for the management of hypothermic patients advises medications\nshould be withheld until the patient's core temperature is greater than 30\u00b0C (86\u00b0F)\n\na. Above 30\u00b0C (86\u00b0F), intervals between medication provision should be doubled until the\n\nToxins and Environmental\n\nHypothermia/Cold Exposure\n\nRev.", "start_char_idx": 748646, "end_char_idx": 751783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c20f7eba-bab5-4b9a-81dd-9fa4a4b2be6b": {"__data__": {"id_": "c20f7eba-bab5-4b9a-81dd-9fa4a4b2be6b", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52ff2706-6c8b-4998-a57b-3df0f649c2dd", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "6870f47223e2cb7da36adf4c7606cf898a3fd897cebd695a26c10719d8058d5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f23fc7d-7226-4a59-9650-a4e5a9a9c4e5", "node_type": "1", "metadata": {}, "hash": "85cc9514d8e39a3e976e09f8d36b05b2609d971592ee010806adc96c66a509de", "class_name": "RelatedNodeInfo"}}, "text": "If EtCO2 is available, ventilate to maintain normal EtCO2 levels\n\n4. There is little evidence to guide use of medications in severe hypothermia with cardiac arrest, however 2010 AHA updates to\nadvanced cardiac life support recommend use of vasopressors according to standard ACLS protocols while the 2014 Alaska guidelines\nand the Wilderness Medical Society's accidental hypothermia guideline for the management of hypothermic patients advises medications\nshould be withheld until the patient's core temperature is greater than 30\u00b0C (86\u00b0F)\n\na. Above 30\u00b0C (86\u00b0F), intervals between medication provision should be doubled until the\n\nToxins and Environmental\n\nHypothermia/Cold Exposure\n\nRev. March 2022\n\n330\n\nGo To TOC\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\npatient reaches 35\u00b0C (95\u00b0F), at which time, normal medication intervals may be adopted\n\nUpon ROSC, treat per Adult Post-ROSC Care Guideline\nPatients with severe hypothermia and arrest may benefit from resuscitation even after prolonged downtime, and survival with intact neurologic function has been observed even after prolonged resuscitation\n\nPatients should not be considered deceased until rewarming has been attempted\n\nIf a hypothermic patient clearly suffered cardiac arrest and subsequently became hypothermic afterward with prolonged down time between arrest and rescue, there is no rationale for initiating resuscitation and warming the patient\n\n### Pertinent Assessment Findings\n\nIdentification of associated traumatic injuries (when present)\nIdentification of localized freezing injuries\nPatient core temperature (when available)\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914023 \u2013 Environmental - Cold Exposure\n9914025 \u2013 Environmental - Frostbite/Cold Injury\n9914031 \u2013 Environmental - Hypothermia\n\n#### Key Documentation Elements\n\nDuration of cold exposure\nAmbient temperature and recent range of temperatures\nRewarming attempts or other therapies performed prior to EMS arrival\nPatient use of alcohol/drugs\n\n#### Performance Measures\n\nPatient core temperature and means of measurement (when available)\nPresence of cardiac dysrhythmias\nDocumentation of associated trauma (when present)\nBlood glucose level obtained\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nHypoglycemia\u201401: Treatment Administered for Hypoglycemia\nTrauma\u201401: Pain Assessment of Injured Patients\n\n### References\n\nAlaska Emergency Medical Services. State of Alaska Cold Injury Guidelines \u2013 2014. Anchorage, AK: Department of Health and Social Services, Division of Public Health; July 15, 2014.\nBrown DJ, Brugger H, Boyd J, Paal P. Accidental Hypothermia. NEJM. 2012;367(2):1930\u20138\nCasa DJ, DeMartini JK, Bergeron MF, Csillan D, Eichner ER, Lopez RM, Ferrara MS, Miller KC, O'Connor F, Sawka MN, Yeargin SW. National Athletic Trainers' Association Position Statement: Exertional Heat Illnesses. J Athl Train. 2015 Sep;50(9):986-1000.\n\n________________________ Go To TOC\n\nToxins and Environmental\n\nHypothermia/Cold Exposure\n\nRev. March 2022\n\n331\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\ndoi: 10.4085/1062-6050-50.9.07. Erratum in: J Athl Train. 2017 Apr;52(4):401. PMID: 26381473; PMCID:\nPMC4639891\n\n4. Dow, Jennifer MD, MHA Giesbrecht, Gordon G. PhD Danzl, Daniel F. MD Zafren, Ken MD Bennett, Brad L. PhD\nGrissom, Colin K. MD\n\nHttps://pubmed.ncbi.nlm.nih.gov/31326282/ December 1, 2019.\n\n5. McIntosh SE, Hamonko M, Freer L, et al. Wilderness Medical Society guidelines for the prevention and treatment\nof frostbite. Dec 1, 2019.https://www.wemjournal.org/issue/S1080-6032(19)X0006-X\n\n6. Venden Hoek et al. Part 12: cardiac arrest in special situations. 2010 American Heart Association guidelines for\ncardiopulmonary resuscitation and emergency cardiovascular care. Circulation.", "start_char_idx": 751095, "end_char_idx": 755031, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f23fc7d-7226-4a59-9650-a4e5a9a9c4e5": {"__data__": {"id_": "9f23fc7d-7226-4a59-9650-a4e5a9a9c4e5", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c20f7eba-bab5-4b9a-81dd-9fa4a4b2be6b", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "b3067dcb6cd6262f972b5f095084c8ac493ad4c45b712b7daf64d48d8c9dbb65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12d4f45e-74ca-4008-a0ed-28f655fae283", "node_type": "1", "metadata": {}, "hash": "2c00456a05028e75651c82772af5c63c0ed5a464edbfb9ad6791a66551b35f43", "class_name": "RelatedNodeInfo"}}, "text": "Dow, Jennifer MD, MHA Giesbrecht, Gordon G. PhD Danzl, Daniel F. MD Zafren, Ken MD Bennett, Brad L. PhD\nGrissom, Colin K. MD\n\nHttps://pubmed.ncbi.nlm.nih.gov/31326282/ December 1, 2019.\n\n5. McIntosh SE, Hamonko M, Freer L, et al. Wilderness Medical Society guidelines for the prevention and treatment\nof frostbite. Dec 1, 2019.https://www.wemjournal.org/issue/S1080-6032(19)X0006-X\n\n6. Venden Hoek et al. Part 12: cardiac arrest in special situations. 2010 American Heart Association guidelines for\ncardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122;(18 Suppl 3): S829\u201361.\n\n7. Panchal et al. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for\nCardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020;142:S366\u2013S468.\n\n8. Brugger H, Bouzat P, Pasquier M, Mair P, Fieler J, Darocha T, Blancher M, de Riedmatten M, Falk M, Paal P,\nStrapazzon G, Zafren K, Brodmann Maeder M. Cut-off values of serum potassium and core temperature at hospital\nadmission for extracorporeal rewarming of avalanche victims in cardiac arrest: A retrospective multi-centre study.\nResuscitation. 2019;139:222\u2013229. doi: 10.1016/j.resuscitation.2019.04.025\n\n9. Paal P, Gordon L, Strapazzon G, Brodmann Maeder M, Putzer G, Walpoth B, Wanscher M, Brown D, Holzer M, Broessner\nG, Brugger H. Accidental hypothermia-an update: The content of this review is endorsed by the International\nCommission for Mountain Emergency Medicine (ICAR MEDCOM). Scand J Trauma Resusc Emerg Med. 2016;24:111. doi:\n10.1186/s13049-016-0303-7\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\n## Toxins and Environmental Hypothermia/Cold Exposure 332\n\nRev. March 2022\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Drowning\n\n### Aliases\n\nFatal drowning\n\nNon-fatal drowning\n\nImmersion\n\nSubmersion\n\nNear-drowning\n\n### Patient Care Goals\n\nRapid assessment and management of life-threatening injuries\nRescue from the water-based environment\nTransport patients suffering from drowning for hospital evaluation unless field arrest resuscitation termination\nguidelines apply.\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nPatients suffering from drowning or drowning events independent of presence or absence of symptoms\n\n#### Exclusion Criteria\n\nWhen protocol is inapplicable.\n\n### Patient Management\n\n#### Assessment\n\nHistory should include circumstances leading to the submersion, details of mechanism of injury, time under water\nPrimary survey should include aggressive airway management and restoration of adequate oxygenation and ventilation.\nUnlike the CAB strategy used in standard cardiac arrest, patients suffering cardiac arrest from drowning require an ABCs\n(Airway, Breathing, Circulation) approach with prompt airway management and supplemental breathing\nHistory, mechanism of injury and exam should include consideration of possible c-spine injury. Manage c-spine if\nevaluation suggests injury to the cervical spine\nAssess for other associated injury such as injury to the head or dive-related emergency\n\n#### Treatment and Interventions\n\nEnsure scene safety for patient and rescuers.", "start_char_idx": 754455, "end_char_idx": 757653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12d4f45e-74ca-4008-a0ed-28f655fae283": {"__data__": {"id_": "12d4f45e-74ca-4008-a0ed-28f655fae283", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f23fc7d-7226-4a59-9650-a4e5a9a9c4e5", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "083c26053e92ec80c849d76abec70d71f7500681df49ff489d76a5bde0b04f49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cee667e-a67a-40b9-b2a3-596a2882f35b", "node_type": "1", "metadata": {}, "hash": "399caa18e2d384ae1f783ea80653a647751fc3625d1585951cfcd34ec159a972", "class_name": "RelatedNodeInfo"}}, "text": "### Patient Presentation\n\n#### Inclusion Criteria\n\nPatients suffering from drowning or drowning events independent of presence or absence of symptoms\n\n#### Exclusion Criteria\n\nWhen protocol is inapplicable.\n\n### Patient Management\n\n#### Assessment\n\nHistory should include circumstances leading to the submersion, details of mechanism of injury, time under water\nPrimary survey should include aggressive airway management and restoration of adequate oxygenation and ventilation.\nUnlike the CAB strategy used in standard cardiac arrest, patients suffering cardiac arrest from drowning require an ABCs\n(Airway, Breathing, Circulation) approach with prompt airway management and supplemental breathing\nHistory, mechanism of injury and exam should include consideration of possible c-spine injury. Manage c-spine if\nevaluation suggests injury to the cervical spine\nAssess for other associated injury such as injury to the head or dive-related emergency\n\n#### Treatment and Interventions\n\nEnsure scene safety for patient and rescuers. Remove patient from water as soon as possible\n\nPractice the safest water rescue technique possible, given circumstances on scene\nEvacuate to land or a watercraft as soon as possible\nIf there is a delay to accessing shore or a rescue boat, initiate in-water basic life support consisting of\nventilation only\n\nManage airway per the Airway Management Guideline\nFollow Cardiac Arrest Guideline as indicated with consideration of ABCs (Airway, Breathing, Circulation) strategy\nfor drowning victims in cardiac arrest\n\nInitiate 5 rescue breaths followed by 30 chest compressions\nAfter the initial 5 breaths, use ratio of 30 compressions to 2 breaths\n\nIf mechanism or history suggest cervical spine injury, manage c-spine, per the Spinal\n\nGo To TOC\n\n### Toxins and Environmental\n\nRev. March 2022\n\n### Drowning\n\n333\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Care Guideline\n\nMonitor vital signs (pulse, blood pressure, respiratory rate, neurologic status assessment) including oxygen saturations\nIf O2 saturations are less than 92%, administer oxygen as appropriate with a target of achieving 94\u201398% saturation. Consider positive pressure ventilation in patients with signs or symptoms of respiratory difficulty\nConsider hypothermia, treat per Hypothermia/Cold Exposure Guideline\nIf the victim was involved in underwater diving and uncertainty exists regarding the most appropriate therapy, consider contacting medical direction and discussing need for hyperbaric treatment. Include discussion regarding:\n\nSubmersion time\nGreatest depth achieved\nAscent rate\nGas mix\n\nEstablish IV access\nFluid bolus as indicated\nAdvanced airway management as indicated. Consider CPAP in awake patients with respiratory distress\nCardiac monitor\n\n## Patient Safety Considerations\n\nAvoidance of hyperoxygenation of the drowning victim\nRescuer safety considerations\n\n## Notes/Educational Pearls\n\n### Key Considerations\n\nThe World Health Organization definition of drowning is \" the process of experiencing respiratory impairment from submersion/immersion in liquid\"\nDrowning is further defined in the following categories:\n\nNon-fatal drowning: patients rescued from drowning\nFatal drowning: any death, acutely or subacutely, resulting from drowning\n\nSubmersion refers to situations in which the patient's airway is underwater. Immersion refers to situations in which the patient's body is in water, but the patient's airway remains out of the water\nPediatric Considerations:\n\nDrowning is a common cause of death in children\nRisk factors for drowning include male gender, age less than 14 years old, alcohol use, lack of supervision, and risky behavior\n\nRescue efforts should be coordinated between all responding agencies to ensure patient is rapidly accessed and removed from the water\nInitiation of in-water ventilations may increase survival. In-water chest compressions are futile\nThe European Resuscitation Council recommends five initial breaths be provided to the drowning victim\n\nThe initial ventilations may be more difficult to achieve as water in the airways may impede alveolar expansion\nIf cardiac arrest after 5 rescue breaths, refer to Cardiac Arrest Guideline.\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Drowning 334\n---\n## National Model EMS Clinical Guidelines Version 3.0\n\n8. Active efforts to expel water from the airway (by abdominal thrusts or other means) should be avoided as they delay resuscitative efforts and increase the potential for vomiting and aspiration\n\n9.", "start_char_idx": 756625, "end_char_idx": 761168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cee667e-a67a-40b9-b2a3-596a2882f35b": {"__data__": {"id_": "2cee667e-a67a-40b9-b2a3-596a2882f35b", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12d4f45e-74ca-4008-a0ed-28f655fae283", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "7e722e85afee91f09426444fa3a31156a15a71309c0e6f57eacd932f3ca3755f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05319213-e034-405d-916f-acc33384a011", "node_type": "1", "metadata": {}, "hash": "419df320c542c7d39eed8c45ebf6f0e8e12d254c6120972718333c132e9d9293", "class_name": "RelatedNodeInfo"}}, "text": "In-water chest compressions are futile\nThe European Resuscitation Council recommends five initial breaths be provided to the drowning victim\n\nThe initial ventilations may be more difficult to achieve as water in the airways may impede alveolar expansion\nIf cardiac arrest after 5 rescue breaths, refer to Cardiac Arrest Guideline.\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Drowning 334\n---\n## National Model EMS Clinical Guidelines Version 3.0\n\n8. Active efforts to expel water from the airway (by abdominal thrusts or other means) should be avoided as they delay resuscitative efforts and increase the potential for vomiting and aspiration\n\n9. Long-standing teaching has suggested that rescuers should always assume c-spine injury in victims of drowning\n\nThe 2010 American Heart Association update on special circumstances in cardiac arrest notes that routine c-spine precautions in all victims of drowning is likely unnecessary unless the mechanism or injury, history, or physical exam suggests a cervical spine injury\nMechanisms of injury highly suggestive of cervical spine injury include diving, water skiing, surfing, or watercraft accidents\n\n10. Uncertainty exists regarding survival in cold water drowning; however, recent literature suggests the following:\n\nIf water temperature is less than 43\u00b0F (6\u00b0C) and the patient is submerged with evidence of cardiac arrest:\n\nSurvival is possible for submersion time less than 90 minutes and resuscitative efforts should be initiated\nSurvival is not likely for submersion time greater than 90 minutes and clinicians may consider not initiating resuscitation or termination of resuscitation on scene\n\nIf water temperature is greater than 43\u00b0F (6\u00b0C) and the patient is submerged with evidence of cardiac arrest:\n\nSurvival is possible for submersion time less than 30 minutes and resuscitative efforts should be initiated\nSurvival is not likely for submersion time greater than 30 minutes and clinicians may consider not initiating resuscitation or termination of resuscitation on scene\n\n11. Patients may develop subacute respiratory difficulty after drowning and therefore all victims of drowning should be transported for observation\n\n12. Decompression illness may have a variety of presentations depending on system affected (e.g., skin, joint(s), pulmonary, neurologic), and can occur even when a diver does not exceed dive table limits\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914091 \u2013 Injury - Diving Emergencies\n9914093 \u2013 Injury - Drowning/Near Drowning\n\n### Key Documentation Elements\n\nMechanism of injury or history suggesting cervical spine injury\nSubmersion time\nWater temperature\nActivities leading to drowning\nConsider a standardized data collection metrics such as the Utstein drowning data reporting elements\n\n### Performance Measures\n\nRecognition and appropriate care of pulmonary/respiratory complaints\n\nToxins and Environmental Drowning 335 Rev. March 2022\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nCervical spine management when appropriate\nAdherence to Cardiac Arrest (VF/VT/Asystole/PEA) Guideline\n\nReferences\n\nHarris M. ABC of resuscitation, near drowning. BMJ. 2003;327(7427):1336\u20138\nIdris AH, Berg RA, Bierens J, et al. Recommended guidelines for uniform reporting of data from drowning: The\n\u201cUtstein Style.\u201d Circulation. 2003;108(20):2565\u201374\nLayon J, Modell JH. Drowning, update 2009. Anesthesiology. 2009;110(6):1390\u2013401\nOlshaker J. Submersion. Emerg Med Clin N Am. 2004;22(2):357\u201367\nPerkins, Olasveengen et al. BLS Task Force March 15, 2021, Resuscitation\nhttps://costr.ilcor.org/document/drowning-tfsr-costr Drowning BLS Systematic Review. Accessed March 11, 2022\nSzpilman D, Bierens JJ, Handley AJ, Orlowski JP. Drowning. N Engl J Med. 2012;366(22):2102\u201310\nVanden Hoek T, Morrison LJ, Shuster M, et al. Part 12: Cardiac arrest in special situations. 2010 American Heart\nAssociation guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation.", "start_char_idx": 760488, "end_char_idx": 764586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05319213-e034-405d-916f-acc33384a011": {"__data__": {"id_": "05319213-e034-405d-916f-acc33384a011", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cee667e-a67a-40b9-b2a3-596a2882f35b", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "4159ce581c6a3d77eeda111977bd03ec59ce2a01b20defea107d57cbcd1d1721", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1fb7cf0-faab-420b-b017-60c5e17c2a8b", "node_type": "1", "metadata": {}, "hash": "7ba14bf56e06f22b6aa0e7f336e1843821518e294bdfd21b746eba7781663f90", "class_name": "RelatedNodeInfo"}}, "text": "Emerg Med Clin N Am. 2004;22(2):357\u201367\nPerkins, Olasveengen et al. BLS Task Force March 15, 2021, Resuscitation\nhttps://costr.ilcor.org/document/drowning-tfsr-costr Drowning BLS Systematic Review. Accessed March 11, 2022\nSzpilman D, Bierens JJ, Handley AJ, Orlowski JP. Drowning. N Engl J Med. 2012;366(22):2102\u201310\nVanden Hoek T, Morrison LJ, Shuster M, et al. Part 12: Cardiac arrest in special situations. 2010 American Heart\nAssociation guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122(18\nSuppl 3): S829\u201361\n\nRevision Date\n\nMarch 11, 2022\n\n________________________ Go To TOC\n\nToxins and Environmental\n\nDrowning\n\nRev. March 2022\n\n336\n---\n## Dive (SCUBA) Injury/Accidents\n\n### Aliases\n\nBarotrauma, Bends, Squeeze\n\n### Patient Care Goals\n\nRapid assessment and management of life-threatening injuries\nRescue from the water-based environment\nTransport patients suffering from self-contained underwater breathing apparatus (SCUBA) diving injury/illness\nfor hospital evaluation and consideration of repressurization/hyperbaric oxygen therapy (HBOT)\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nPatients with history of recent (within 48 hours) SCUBA diving activity who are exhibiting potential signs and/or\nsymptoms of dive related illness/injury, regardless of dive table compliance. NOTE: SCUBA-related complications may\noccur anywhere, particularly when divers travel by air within 24-hours of diving\n\n#### Exclusion Criteria\n\nPatients without history of recent (within 48 hours) SCUBA diving exposure\n\n### Patient Management\n\n#### Assessment\n\nHistory should include circumstances leading to the complaint, details of mechanism of injury, time under water,\ndepth of dive, compliance with dive tables/decompression stops, gas mixture used, and water temperature (if\navailable)\nBe alert for signs of barotrauma (pulmonary barotrauma, arterial gas embolism, pneumothorax, pneumomediastinum,\near/sinus/dental barotrauma, dysrhythmias, skin mottling or erythema, neurologic signs and symptoms etc.) and/or\ndecompression sickness (joint pain, mental status change, other neurologic symptoms including paralysis) or nitrogen\nnarcosis (confusion, intoxication).\nAssess for other associated injury such as injury to the head or spine (if mechanism and symptoms suggest), marine\nenvenomation, hypothermia, or other injury\n\n#### Treatment and Interventions\n\nIf a SCUBA accident includes associated drowning/near-drowning [See Drowning Guideline ]\nManage airway as indicated and provide 100% oxygen\nIf air embolism suspected, place in left lateral recumbent position (patient lying with the left side down, knees\ndrawn upward, and flat)\n\nTrendelenburg position is sometimes recommended to help trap the air in the dependent right ventricle, and may\nbe useful if a central venous catheter is being used to withdraw the air, but this position may increase cerebral\nedema\n\nMonitor vital signs including oxygen saturations and cardiac rhythm (if possible)\nAdminister oxygen as appropriate with a target of achieving 94\u201398% saturation\n\nGo To TOC\n\n________________________\n\nRev. March 2022\n\nDive (SCUBA) Injury/Accidents\n\n337\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\na. Use positive pressure ventilation (e.g., CPAP) carefully in patients for whom pulmonary barotrauma is a consideration [See Airway Management Guideline] and if signs or symptoms of tension pneumothorax are present perform needle decompression\n\n6. Patients with symptoms suspicious for decompression illness, should be placed on supplemental oxygen regardless of saturations to enhance washout of inert gasses\n\n7. Assess for hypothermia, treat per Hypothermia/Cold Exposure Guideline\n\n8. Consider contacting medical direction and discussing need for hyperbaric treatment and primary transport to facility with hyperbaric oxygen therapy (HBOT) capability \u2014 include discussion regarding factors such as submersion time, greatest depth achieved, ascent rate, and gas mix\n\n9. Establish IV access\n\n10. Fluid bolus as indicated\n\n## Patient Safety Considerations\n\n1.", "start_char_idx": 764054, "end_char_idx": 768147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1fb7cf0-faab-420b-b017-60c5e17c2a8b": {"__data__": {"id_": "f1fb7cf0-faab-420b-b017-60c5e17c2a8b", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05319213-e034-405d-916f-acc33384a011", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "959c5d3744cb8ebe698a2fc3e62faf665c1b2acecca9da6ab8ca7b460af4ab65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b3d43df-9ab3-44e5-bdd3-d1da43112b1c", "node_type": "1", "metadata": {}, "hash": "ce416e17bd7744f356496376315250b2c594286855de4a916a5a318c06cc3a5a", "class_name": "RelatedNodeInfo"}}, "text": "Patients with symptoms suspicious for decompression illness, should be placed on supplemental oxygen regardless of saturations to enhance washout of inert gasses\n\n7. Assess for hypothermia, treat per Hypothermia/Cold Exposure Guideline\n\n8. Consider contacting medical direction and discussing need for hyperbaric treatment and primary transport to facility with hyperbaric oxygen therapy (HBOT) capability \u2014 include discussion regarding factors such as submersion time, greatest depth achieved, ascent rate, and gas mix\n\n9. Establish IV access\n\n10. Fluid bolus as indicated\n\n## Patient Safety Considerations\n\n1. If the patient is still in the water, seek safest and most rapid means of removal safe (within your scope of training) while minimizing risk of further injury\n\n2. Seek assistance early for special rescue/extrication and transportation needs\n\n3. Check for multiple patients (e.g., group dive table calculation error(s) or contaminated dive gases)\n\n## Notes/Educational Pearls Key Considerations\n\n1. Rescue efforts should be coordinated between all responding agencies to ensure that the patient is rapidly accessed and safely removed from the water if diver unable to do so themselves\n\n2. If air medical transport is necessary, the patient should be transported with the cabin pressurized to lowest possible altitude. If an unpressurized aircraft is used (i.e., most helicopter emergency medical services (HEMS)), patient should be flown at the lowest safe altitude possible\n\n3. Decompression illness may have a variety of presentations depending on system affected (e.g., skin, joint(s), pulmonary, neurologic)\n\n4. SCUBA accidents/incidents can result in a variety of issues, including barotrauma, air embolism and decompression illness\n\n5. Decompression illness may have a variety of presentations depending on system affected (e.g., skin, joint(s), pulmonary, neurologic), and can occur even when a diver does not exceed dive table limits\n\n6. Do not attempt to disassemble, turn off, or modify any of the dive equipment. The dive computer may provide a clue about the patient\u2019s exposure to depth\n\n## Pertinent Assessment Findings\n\n1. Vital signs findings\n\n2. Neurologic status assessment findings\n\n3. Respiratory assessment findings (i.e., oxygen saturation, respiratory rate)\n\n4. Subcutaneous emphysema\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Dive (SCUBA) Injury/Accidents 338\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914091 \u2013 Injury - Diving Emergencies\n9914211 \u2013 Injury - SCUBA Injury/Accidents\n\n### Key Documentation Elements\n\nWater temperature, if available\nDive history\n\nNumber of dives in recent history (days)\n\"Bottom time\" in dives\nDive profiles\nMaximum depth\nRate of ascent\nSafety stops utilized if any\nDive gas (i.e., air vs. mixed gases such as Nitrox, Heliox or Trimix)\n\nTiming of onset of symptoms\nHistory of altitude exposure after diving (air travel)\nAny associated injuries or exposures\n\n### Performance Measures\n\nRecognition and appropriate care of pulmonary/respiratory complaints\nPatient transported to nearest appropriate facility (HBOT if available and indicated)\nNeed for HBOT recognized and communicated to receiving facility if indicated\n\n### References\n\nChandy D, Weinhouse GL. Complications of SCUBA diving. Post TW, ed. UpToDate. Waltham, MA: UpToDate. (Accessed March 15, 2021)\nDoolette DJ, Mitchell SJ. Recreational technical diving part 2: decompression from deep technical dives. Diving Hyperb Med. 2013;43(2):96\u2013104\nFAA Aeronautical Information Manual\u2014Decompression Sickness after Scuba Diving. https://www.faa.gov/air_traffic/publications/atpubs/aim_html/chap8_section_1.html. Accessed March 11, 2022\nFock A, Harris R, Slade M. Oxygen exposure and toxicity in recreational technical divers. Diving Hyperb Med. 2013;43(2):67\u201371\nFock AW. Analysis of recreational closed-circuit rebreather deaths 1998\u20132010. Diving Hyperb Med. 2013;43(2):78\u201385\nGordy S, Rowell S. Vascular Air Embolism.", "start_char_idx": 767536, "end_char_idx": 771666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b3d43df-9ab3-44e5-bdd3-d1da43112b1c": {"__data__": {"id_": "5b3d43df-9ab3-44e5-bdd3-d1da43112b1c", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1fb7cf0-faab-420b-b017-60c5e17c2a8b", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "e46c1d18471664c3acc32826790731fa6030c76a7d6841f5befd75f01ac42053", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38caee37-180e-4b0c-9dc3-0038efc65b84", "node_type": "1", "metadata": {}, "hash": "55eb5e76527002f23962a90a27e07c90b77ce1a75119191d2ea94153d93de72b", "class_name": "RelatedNodeInfo"}}, "text": "Recreational technical diving part 2: decompression from deep technical dives. Diving Hyperb Med. 2013;43(2):96\u2013104\nFAA Aeronautical Information Manual\u2014Decompression Sickness after Scuba Diving. https://www.faa.gov/air_traffic/publications/atpubs/aim_html/chap8_section_1.html. Accessed March 11, 2022\nFock A, Harris R, Slade M. Oxygen exposure and toxicity in recreational technical divers. Diving Hyperb Med. 2013;43(2):67\u201371\nFock AW. Analysis of recreational closed-circuit rebreather deaths 1998\u20132010. Diving Hyperb Med. 2013;43(2):78\u201385\nGordy S, Rowell S. Vascular Air Embolism. Int J Crit Iln Inj Sci. 2013;3(1):73\u20136\nMadden D, Lozo M, Dujic Z, Ljubkovic M. Exercise after SCUBA diving increases the incidence of arterial gas embolism. J Appl Physiol (1985). 2013;115(5):716\u201322\nMitchell SJ, Doolette DJ. Recreational technical diving part 1: an introduction to technical diving methods and activities. Diving Hyperb Med. 2013;43(2):86\u201393\nMuth C-M, Tetzlaff K. [Scuba diving and the heart. Cardiac aspects of sport scuba diving]. Herz. 2044;29(4):406\u201313\nSykes O, Clark JE. Patent foramen ovale and scuba diving: a practical guide for physicians on when to refer for screening. Extrem Physiol Med. 2013;2(1):10\n\n________________________Go To TOC\n\n## Toxins and Environmental Dive (SCUBA) Injury/Accidents\n\nRev. March 2022\n\n339\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n11. T\u00fcrkmen N, Okan A, Sel\u00e7uk C, B\u00fclent E, Murat SG, Umit NG. Scuba diver deaths due to air embolism: two case\nreports. Soud L\u00e9k. 2013;58(2):26\u20138\n\n12. Vann RD, Gerth PJ, Denoble CF, Pieper CF, Thalmann ED. Experimental trials to assess the risks of\ndecompression sickness in flying after diving. Undersea Hyberb Med. 2004 Winter;3(4):431\u201344\n\n13. Winkler BE, Muth CM, Kaehler W, Froeba G, Georgieff M, Koch A. Rescue of drowning victims and divers: Is\nmechanical ventilation possible underwater? A pilot studies. Diving Hyperb Med. 2013;43(2):72\u20137\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Dive (SCUBA) Injury/Accidents 340\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Altitude Illness\n\n### Aliases\n\nAcute mountain sickness (AMS)\n\nAltitude sickness\n\nHigh altitude cerebral edema (HACE)\n\nHigh altitude pulmonary edema (HAPE)\n\n### Definitions\n\n|1.|Acute mountain sickness: Headache plus one or more of the following: anorexia, nausea or vomiting, fatigue or weakness, dizziness or lightheadedness or difficulty sleeping. (In infants and young children, symptoms include pallor, fussiness, vomiting, decreased appetite, poor sleep, decreased playfulness.) These symptoms must occur in the setting of recent arrival to high altitude (generally considered greater than 5000 \u2013 7000 feet)|\n|---|---|\n|2.|High altitude pulmonary edema (HAPE): Progressive dyspnea, cough, hypoxia, and weakness in high altitude environments (considered greater than 8000 feet). (In infants and young children, symptoms again include pallor, fussiness, vomiting, decreased appetite, poor sleep, decreased playfulness.)", "start_char_idx": 771083, "end_char_idx": 774185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38caee37-180e-4b0c-9dc3-0038efc65b84": {"__data__": {"id_": "38caee37-180e-4b0c-9dc3-0038efc65b84", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b3d43df-9ab3-44e5-bdd3-d1da43112b1c", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "b920dc862e9efee3358a2847fb27cf402f662e91c12dd87cc7ed6f84275fc781", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5374afa9-5f59-48ba-9ff0-6353db66dec9", "node_type": "1", "metadata": {}, "hash": "e05250183bab2df92c6af4b86de0a8cd0145739c00b385e81126f0ca0680cddf", "class_name": "RelatedNodeInfo"}}, "text": "(In infants and young children, symptoms include pallor, fussiness, vomiting, decreased appetite, poor sleep, decreased playfulness.) These symptoms must occur in the setting of recent arrival to high altitude (generally considered greater than 5000 \u2013 7000 feet)|\n|---|---|\n|2.|High altitude pulmonary edema (HAPE): Progressive dyspnea, cough, hypoxia, and weakness in high altitude environments (considered greater than 8000 feet). (In infants and young children, symptoms again include pallor, fussiness, vomiting, decreased appetite, poor sleep, decreased playfulness.) Patients may or may not exhibit new symptoms if acute mountain sickness precedes symptoms of HAPE|\n|3.|High altitude cerebral edema (HACE): Heralded by mental status changes in patients with symptoms of acute mountain sickness including altered mentation, ataxia, or stupor and progressing to coma. Typically seen in high altitude environments (greater than 8000 feet)|\n|4.|Feet to meters conversion reference:|\n\n|Feet|Meters|\n|---|---|\n|8000 ft|Approximately 2400 m|\n|7000 ft|Approximately 2100 m|\n|5000 ft|Approximately 1500 m|\n|1000 ft|Approximately 300 m|\n|500 ft|Approximately 150 m|\n\n### Patient Care Goals\n\nImprove oxygenation through a combination of descent and supplemental O2\nSafe but rapid transport from the high-altitude environment to a lower altitude environment\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nPatients suffering from altitude illness, including\n\nAcute mountain sickness\nHigh altitude pulmonary edema\nHigh altitude cerebral edema\n\n#### Exclusion Criteria\n\nWhen protocol is inapplicable.\n\nGo To TOC\n\n## Toxins and Environmental\n\nAltitude Illness\n\nRev. March 2022\n\n341\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Patient Management\n\n### Assessment\n\nAssessment should target the signs and symptoms of altitude illness but should also consider alternate causes of these symptoms\n\n### Treatment and Interventions\n\nEnsure scene safety for rescuers\nStop ascent\n\nPatients with acute mountain sickness only may remain at their current altitude and initiate symptomatic therapy\nPatients with HACE or HAPE should initiate descent\n\nPerform ABCs (Airway, Breathing, Circulation) and manage airway as necessary\nAdminister supplemental oxygen, if available, with goal to keep oxygen saturations 90%\nDescend to lower altitude. Descent is the mainstay of therapy and is the definitive therapy for all altitude related illnesses. Descent should be initiated as soon as scene conditions permit\n\nIf severe respiratory distress is present and pulmonary edema is found on exam, clinician should start positive pressure ventilation\nEstablish IV and perform fluid bolus with goal to maintain systolic BP greater than 90 mmHg\nMonitor cardiac rhythm\n\nDescent should always be the primary treatment strategy for patients suffering from altitude illness, especially patients suffering from HACE and HAPE. If decent is not possible, or if medical direction permits, the EMS clinician may consider the following possible therapies \u2014 portable hyperbaric chambers are effective for the management of severe altitude illness. However, they should not be used in lieu of decent, only as an alternative should descent be unfeasible.\n\nAcute mountain sickness\n\nIbuprofen or acetaminophen for pain [See Pain Management Guideline]\nOndansetron 4 mg IV, PO, or sublingual every 6 hours for vomiting [See Nausea-Vomiting Guideline]\nAcetazolamide: up to 250 mg PO twice a day\n\nPediatric dosing is 2.5 mg/kg to a maximum of 125 mg, given twice a day\nAcetazolamide speeds acclimatization and therefore helps in treating acute mountain sickness\n\nDexamethasone 4 mg IM, IV, or PO q 6 hours until symptoms resolve\n\nPediatric dosing is 0.15 mg/kg IM, IV, or PO q 6 hours; maximum single dose is 4 mg.\nDexamethasone helps treat the symptoms of acute mountain sickness and may be used as an adjunctive therapy in severe acute mountain sickness when the above measures alone do not ameliorate the symptoms. In these circumstances, patients should also initiate descent, as dexamethasone does not facilitate acclimatization\n\nHACE: All therapies listed below should be considered as adjunctive to descent.", "start_char_idx": 773613, "end_char_idx": 777814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5374afa9-5f59-48ba-9ff0-6353db66dec9": {"__data__": {"id_": "5374afa9-5f59-48ba-9ff0-6353db66dec9", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38caee37-180e-4b0c-9dc3-0038efc65b84", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "121aa923b6cbade7586a6be7ccc31a27db2dd0af39460aa5b5e2d9ef87c89f57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70386e3e-0ffd-4dca-aeb5-f6b2e432cc98", "node_type": "1", "metadata": {}, "hash": "b4631479a63d21c0d2950289a4d2f499ebe9476fc808c95f89b18bf3d0b2507d", "class_name": "RelatedNodeInfo"}}, "text": "Dexamethasone helps treat the symptoms of acute mountain sickness and may be used as an adjunctive therapy in severe acute mountain sickness when the above measures alone do not ameliorate the symptoms. In these circumstances, patients should also initiate descent, as dexamethasone does not facilitate acclimatization\n\nHACE: All therapies listed below should be considered as adjunctive to descent. Descent should always be the primary treatment modality\n\nDexamethasone: 8 mg IM, IV, or PO once followed by 4 mg q 6 hours\n\nPediatric dosing: 0.15 mg/kg/dose every 6 hours\n\n________________________ Go To TOC\n\nToxins and Environmental\n\nAltitude Illness\n\nRev. March 2022\n\n342\n---\nNASEMSO\n\nNASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## 2. Dexamethasone helps treat the symptoms of HACE and should be initiated in HACE. In these circumstances, patients should also initiate descent\n\nii. Consider use of acetazolamide at the above dosing\n\n### c. HAPE: All therapies listed below should be considered as adjunctive to descent. Descent should always be the primary treatment modality\n\ni. Nifedipine: Adult 30 mg ER (extended-release) PO twice a day. Pediatric: 0.5 mg/kg (max single dose 20 mg), extended-release PO every 8 hours\n\nii. If nifedipine is not available:\n\niii. Tadalafil: 10 mg PO twice daily may be used OR\n\ni. Sildenafil: 50 mg PO three times a day may be used\n\nii. Multiple pulmonary vasodilators should not be used concurrently\n\n## Patient Safety Considerations\n\n1. The high-altitude environment is inherently dangerous. Rescuers must balance patient needs with patient safety and safety for the responders\n\n2. Rapid descent by a minimum of 500\u20131000 feet is a priority, however rapidity of descent must be balanced by current environmental conditions and other safety considerations\n\n## Notes/Educational Pearls\n\nKey Considerations\n\n1. Patients suffering from altitude illness have exposed themselves to a dangerous environment. By entering the same environment, clinicians are exposing themselves to the same altitude exposure. Be vigilant in looking for symptoms of altitude illness amongst rescuers\n\n2. Descent of 500\u20131000 feet is often enough to see improvements in patient conditions\n\n3. Patients with HAPE are suffering from non-cardiogenic pulmonary edema and may benefit from positive pressure ventilation via either bag assisted ventilation, CPAP, or other means of positive pressure ventilation\n\n4. Patients suffering from altitude illness are commonly dehydrated and require IV fluids \u2014 once resuscitation is complete and the patient requires no further fluid boluses, maintain IV fluids at 125 mL/hr\n\n5. HAPE is the most lethal of all altitude illnesses\n\n6. Consider alternate causes of symptoms of AMS \u2014 the symptoms of AMS may be caused by alternate etiologies such as carbon monoxide poisoning (in patients cooking within enclosed areas), dehydration, exhaustion, hypoglycemia, hyponatremia\n\n7. Children with the following are at greater risk for altitude illness:\n\na. Those with a concurrent upper or lower respiratory tract infection or otitis media.\n\nb. Full term infants less than 6 weeks of age, or preterm infants less than 46 weeks post conceptual age\n\nc. Congenital heart disease\n\nd. Down syndrome, especially those with obstructive sleep apnea\n\ne. Those with bronchopulmonary dysplasia (BPD), cystic fibrosis, sickle cell anemia, severe scoliosis, and neuromuscular diseases\n\nf. Premature infants beyond 46-weeks with a history of oxygen requirement, PBD or pulmonary hypertension\n\n________________________ Go To TOC\n\nToxins and Environmental Rev.", "start_char_idx": 777415, "end_char_idx": 781015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70386e3e-0ffd-4dca-aeb5-f6b2e432cc98": {"__data__": {"id_": "70386e3e-0ffd-4dca-aeb5-f6b2e432cc98", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5374afa9-5f59-48ba-9ff0-6353db66dec9", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "0864d4ecae2ab8b99c4e228b2660734cb285b59ebd7f6b399a33e3681ae0eac4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ff5cb4c-5f6e-4c95-9f62-3ec45ae59fea", "node_type": "1", "metadata": {}, "hash": "383069829f0eb3acee24711f5be2bc42216183d94147adbb3c67b56992daef4b", "class_name": "RelatedNodeInfo"}}, "text": "Children with the following are at greater risk for altitude illness:\n\na. Those with a concurrent upper or lower respiratory tract infection or otitis media.\n\nb. Full term infants less than 6 weeks of age, or preterm infants less than 46 weeks post conceptual age\n\nc. Congenital heart disease\n\nd. Down syndrome, especially those with obstructive sleep apnea\n\ne. Those with bronchopulmonary dysplasia (BPD), cystic fibrosis, sickle cell anemia, severe scoliosis, and neuromuscular diseases\n\nf. Premature infants beyond 46-weeks with a history of oxygen requirement, PBD or pulmonary hypertension\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Altitude Illness 343\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\ng. Children who live at high altitude when they descend to lower altitude, then return home are at risk for HAPE\n\n## Pertinent Assessment Findings\n\nConsider airway management needs in the patient with severe alteration in mental status\nHAPE will present with increasing respiratory distress and rales on exam\nHACE will present with mental status changes, ataxia, and progressing to coma\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914021 \u2013 Environmental - Altitude Sickness\n\n## Key Documentation Elements\n\nPatient's itinerary, including starting altitude, highest altitude gained and rate of ascent\nPresence (or absence) of prophylaxis against altitude (including medications such as acetazolamide, sildenafil)\nTotal altitude descended\n\n## Performance Measures\n\nMechanism of treatment for acute mountain sickness, HACE, or HAPE\nMedical decision-making regarding treatment choice (i.e., weather, inability to descend)\n\n## References\n\nBarry P, et al. Clinical review: altitude illness. BMJ, 2003\nBartsch P, Swenseon ER. Acute high-altitude illness. N Engl J Med. 2013; 368:2294\u2013302\nGallagher SA, Hackett PH. High-altitude illness. Emerg Med Clin N Am. 2004;22(2):329\u201355\nGallagher SA, Hackett P. Acute Mountain sickness and high-altitude cerebral edema. Post TW, ed. UpToDate. Waltham,\nMA: UpToDate. (Accessed March 15, 2021)\nHackett P, Gallagher. High altitude disease: unique pediatric considerations. Post TW, ed. UpToDate. Waltham, MA:\nUpToDate. (Accessed March 15, 2021)\nImray C, Wright A, Subudhi A, Roach R. Acute Mountain sickness: pathophysiology, prevention and treatment. Prog\nCardiovasc Dis. 2010;52(6):467\u201384\nJackson Hole Fire/EMS. Operations Manual: Altitude illness. Jackson Hole, WY: Teton County\nLuks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society consensus guidelines for the prevention and\ntreatment of acute altitude illness. Wilderness Environ Med. 2010;25(4 Suppl): S4\u201314\nLuks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society Practice guidelines for the prevention and\ntreatment of acute altitude illness: 2014 update. Wilderness Environ Med. 2014;25(4 Suppl): S4\u201314\nWest JB. High-altitude medicine. Am J Respir Crit Care Med. 2012;186(12):1229\u201337\n\nRevision Date: March 11, 2022\n\n________________________ Go To TOC\n\nToxins and Environmental Rev.", "start_char_idx": 780354, "end_char_idx": 783487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ff5cb4c-5f6e-4c95-9f62-3ec45ae59fea": {"__data__": {"id_": "4ff5cb4c-5f6e-4c95-9f62-3ec45ae59fea", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70386e3e-0ffd-4dca-aeb5-f6b2e432cc98", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "4158db85d24ae3000bcd51d2861e897df3c880025ca27540bb74672435cd6942", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e13093d-54f6-4e0f-8ade-e1246a76a0f5", "node_type": "1", "metadata": {}, "hash": "1c298702ba6e4c32400164049642c6faf69746315fd320918c03ca20366e0e37", "class_name": "RelatedNodeInfo"}}, "text": "Operations Manual: Altitude illness. Jackson Hole, WY: Teton County\nLuks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society consensus guidelines for the prevention and\ntreatment of acute altitude illness. Wilderness Environ Med. 2010;25(4 Suppl): S4\u201314\nLuks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society Practice guidelines for the prevention and\ntreatment of acute altitude illness: 2014 update. Wilderness Environ Med. 2014;25(4 Suppl): S4\u201314\nWest JB. High-altitude medicine. Am J Respir Crit Care Med. 2012;186(12):1229\u201337\n\nRevision Date: March 11, 2022\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Altitude Illness 344\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Conducted Electrical Weapon Injury (i.e., TASER\u00ae)\n\n### Aliases\n\nTased\n\n### Patient Care Goals\n\nManage the condition that triggered the application of the conducted electrical weapon with special attention to patients meeting criterion for delirium with agitated behavior [See Agitated or Violent Patient/Behavioral Emergency Guideline]\n\nEnsure patient is appropriately secured or restrained with assistance of law enforcement to protect the patient and clinicians [See Agitated or Violent Patient/Behavioral Emergency Guideline]\n\nPerform comprehensive trauma and medical assessment for injuries (e.g., from falls or altercations or concomitant medical issues)\n\nIf discharged from a distance, up to two single barbed darts (13 mm length) should be located\n\nDo not remove barbed dart from sensitive areas (head, neck, hands, feet, or genitals)\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nPatient received either a weapon\u2019s direct-contact discharge or struck by the barbed dart of a conducted electrical weapon\n\nPatient may have sustained fall or physical confrontation trauma\n\nPatient may be under the influence of toxic substances and or may have underlying medical or psychiatric disorder\n\n#### Exclusion Criteria\n\nNone noted\n\n### Patient Management\n\n#### Assessment\n\nOnce patient has been appropriately secured or restrained with assistance of law enforcement, perform primary and secondary assessment including 3-lead EKG, pulse oximeter, and consider 12-lead EKG\n\nEvaluate patient for evidence of delirium with agitated behavior manifested by varied combination of agitation, reduced pain sensitivity, elevated temperature, persistent struggling, or hallucinosis\n\n#### Treatment and Interventions\n\nMake sure patient is appropriately secured with assistance of law enforcement to protect the patient and staff. Consider psychologic management medications if patient struggling against physical devices and may harm themselves or others\n\nSome EMS agencies treat all barbed darts as a foreign body and leave them for physician removal while others allow EMS or law enforcement to remove barbed darts except for\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nConducted Electrical Weapon Injury (i.e., TASER\u00ae)\n\n345\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nsensitive areas (head, neck, hands, feet, or genitals). Follow local protocols, including those of law enforcement for evidence collection and retention.\n\n3. Treat medical and traumatic injury\n\n### Patient Safety Considerations\n\n1. Before removal of the barbed dart, make sure the cartridge has been removed from the conducted electrical weapon\n\n2. Patient should not be restrained in the prone, face down, or hog-tied position as respiratory compromise is a significant risk\n\n3. The patient may have underlying pathology before being tased (refer to appropriate guidelines for managing the underlying medical/traumatic pathology)\n\n4. Perform a comprehensive assessment with special attention looking for signs and symptoms of active medical decompensation\n\n5. Transport the patient to the hospital\n\n6. EMS clinicians who respond for a conducted electrical weapon patient should not perform a \"medical clearance\" for law enforcement to then take the patient to a nonmedical facility\n\n### Notes/Educational Pearls\n\nKey Considerations\n\n1. Conducted electrical weapon can be discharged in three fashions:\n\na. Direct contact without the use of the darts\n\nb. A single dart with addition contact by direct contact of weapon\n\nc. From a distance up to 35 feet with two darts\n\n2. The device delivers 19 pulses per second with an average current per pulse of 2.1 milliamps which, in combination with toxins/drugs, patient's underlying diseases, excessive physical exertion, and trauma, may precipitate arrhythmias.", "start_char_idx": 782835, "end_char_idx": 787395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e13093d-54f6-4e0f-8ade-e1246a76a0f5": {"__data__": {"id_": "1e13093d-54f6-4e0f-8ade-e1246a76a0f5", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ff5cb4c-5f6e-4c95-9f62-3ec45ae59fea", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "6072a6909a5c25e943e6a34e99cae6cae92da35476657d5b02009b8d01aa1d72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "590ea2b3-1acb-4bc4-8f00-0d11cd8e100a", "node_type": "1", "metadata": {}, "hash": "e25205f02fe0b6d1fd4e874154cc4207d27f75eb484d44a2dbbdfc900d0e7dc9", "class_name": "RelatedNodeInfo"}}, "text": "Perform a comprehensive assessment with special attention looking for signs and symptoms of active medical decompensation\n\n5. Transport the patient to the hospital\n\n6. EMS clinicians who respond for a conducted electrical weapon patient should not perform a \"medical clearance\" for law enforcement to then take the patient to a nonmedical facility\n\n### Notes/Educational Pearls\n\nKey Considerations\n\n1. Conducted electrical weapon can be discharged in three fashions:\n\na. Direct contact without the use of the darts\n\nb. A single dart with addition contact by direct contact of weapon\n\nc. From a distance up to 35 feet with two darts\n\n2. The device delivers 19 pulses per second with an average current per pulse of 2.1 milliamps which, in combination with toxins/drugs, patient's underlying diseases, excessive physical exertion, and trauma, may precipitate arrhythmias. Thus, consider cardiac monitoring and 12-lead EKG assessment\n\n3. Drive Stun is a direct weapon two-point contact which is designed to generate pain and not incapacitate the subject. Only local muscle groups are stimulated with the Drive Stun technique\n\n### Pertinent Assessment Findings\n\n1. Thoroughly assess the patient for trauma as the patient may have fallen from standing or higher\n\n2. Ascertain if more than one TASER\u00ae cartridge was used (by one or more officers, in effort to identify total number of possible darts and contacts)\n\n### Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914203 \u2013 Injury - Conducted Electrical Weapon (e.g., Taser)\n\nKey Documentation Elements\n\nIf darts removed, document the removal location in the patient care report\nPhysical exam trauma findings\nCardiac rhythm and changes\nNeurologic status assessment findings\n\nGo To TOC\n\n## Toxins and Environmental\n\nConducted Electrical Weapon Injury (i.e., TASER\u00ae)\n\nRev. March 2022\n\n346\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Performance Measures\n\nComprehensive patient documentation as this is a complex patient\nAbnormal findings or vital signs were addressed\nPatient received cardiac monitoring and/or 12-lead EKG evaluation\nIf indicated, review for appropriate securing technique\n\n## References\n\n|1.|Ho JD, Dawes DM, Buttman LL, Moscati RM, Janchar TA, Miner JR. Prolonged TASER use on exhausted humans does not worsen markers of acidosis. Am J Emerg Med. 2009;27(4):413\u20138|\n|---|---|\n|2.|Ho JD, Dawes DM, Cole JC, et al. Corrigendum to \u2018\u2018lactate and pH evaluation in exhausted humans with prolonged TASER X26 exposure or continued exertion.\u2019\u2019 Forensic Sci Int. 2009;190(1\u20133):80\u20136|\n|3.|Ho JD, Dawes DM, Cole JB, Hottinger JC, Overton KG, Miner JR. Lactate, and pH evaluation in exhausted humans with prolonged TASER X26 exposure or continued exertion. Forensic Sci Int. 2009;190(1\u20133):80\u20136|\n|4.|Ho JD, Dawes DM, Nelson RS, et al. Acidosis and catecholamine evaluation following simulated law enforcement \u2018\u2018use of force\u2019\u2019 encounters. Acad Emerg Med. 2010;17(7): e60\u20138|\n|5.|Ho JD, Dawes DM, Nystrom PC, et al. Markers of acidosis and stress in a sprint versus a conducted electrical weapon. Forensic Sci Int. 2013;233(1\u20133):84\u20139|\n|6.|Kroll MW, Adamec J, Wetli CV, Williams HE. Fatal traumatic brain injury with electrical weapon falls. J Forensic Legal Med. 2016; 43:12\u201319|\n|7.|Kroll MW, Ritter MB, Kennedy EA, Silverman NK, et al. Eye injuries from electrical weapon probes: Incidents, prevalence and legal implications. J Forensic Legal Med. 2018; 55:52\u201357|\n|8.|Kroll MW, Ritter MB, Kennedy EA, Siegal NK, et al. Eye injury from electrical weapon probes: Mechanisms and treatment. Am J Emerg Med. 2018; 37:427\u2013432|\n|9.|Kunz SN, Calkins HG, Adamec J, Kroll MW.", "start_char_idx": 786526, "end_char_idx": 790246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "590ea2b3-1acb-4bc4-8f00-0d11cd8e100a": {"__data__": {"id_": "590ea2b3-1acb-4bc4-8f00-0d11cd8e100a", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e13093d-54f6-4e0f-8ade-e1246a76a0f5", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "c866786b76b22f960c8ffe7f9de45ffc5265215dc2a5129c9789b3d783e031c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "301f1ef3-abbf-43a4-a9ed-db41588bec7c", "node_type": "1", "metadata": {}, "hash": "0e8a2bea7e11c3ab3cbddbaa40c51f81c91a0c29ed02c860dddc74dfcef43ee5", "class_name": "RelatedNodeInfo"}}, "text": "Forensic Sci Int. 2013;233(1\u20133):84\u20139|\n|6.|Kroll MW, Adamec J, Wetli CV, Williams HE. Fatal traumatic brain injury with electrical weapon falls. J Forensic Legal Med. 2016; 43:12\u201319|\n|7.|Kroll MW, Ritter MB, Kennedy EA, Silverman NK, et al. Eye injuries from electrical weapon probes: Incidents, prevalence and legal implications. J Forensic Legal Med. 2018; 55:52\u201357|\n|8.|Kroll MW, Ritter MB, Kennedy EA, Siegal NK, et al. Eye injury from electrical weapon probes: Mechanisms and treatment. Am J Emerg Med. 2018; 37:427\u2013432|\n|9.|Kunz SN, Calkins HG, Adamec J, Kroll MW. Adrenergic and metabolic effects of electrical weapons: review and meta-analysis of human data. Intl J Legal Med. 2018; 132:1469\u20131475|\n|10.|Kunz SN, Calkins H, Adamec J, Kroll MW. Cardiac and skeletal muscle effects of electrical weapons: a review of human and animal studies. Forens Sci Med Pathol. 2018; 14:358\u2013366|\n|11.|Kunz SN, Adamec J. A comparative brief on conducted electrical weapon safety. Wien Med Wochenschr 2019; 169:185\u2013192|\n|12.|Pinto DS, Clardy PF. Environmental and weapon-related electrical injuries. Uptodate.com [Internet]. January 22, 2020. Accessed March 31, 2021|\n|13.|Stevenson R, Drummond-Smith I. Medical Implications of Conducted Electrical Devices in Law Enforcement. J Forens Leg Med. Published online June 10, 2020;73:101948|\n|14.|Vilke G, Chan T, Bozeman WP, Childers R. Emergency Department Evaluation After Conducted Energy Weapon Use: Review of the Literature for the Clinician. J Emerg Med. 2019;57(5):740\u2013746|\n|15.|White Paper Report on Excited Delirium Syndrome. ACEP Excited Delirium Task Force, American College of Emergency Physicians; September 10, 2009|\n\n## Revision Date\n\nMarch 11, 2022\n\n________________________\n\nGo To TOC\n\n### Toxins and Environmental Conducted Electrical Weapon Injury (i.e., TASER\u00ae)\n\nRev. March 2022\n\n347\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Electrical Injuries\n\n### Aliases\n\nElectrical burns\n\nElectrocution\n\n### Patient Care Goals\n\nPrevent additional harm to patient\nIdentify life threatening issues such as dysrhythmias and cardiac arrest\nIdentify characteristics of electrical source to communicate to receiving facility (voltage, amperage, alternating\ncurrent [AC] versus direct current [DC])\nUnderstand that deep tissue injury can be far greater than external appearance\nHave high index of suspicion for associated trauma due to patient being thrown\nDetermine most appropriate disposition for the patient as many will require burn center care and some may require\ntrauma center care\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nExposure to electrical current (AC or DC).\n\n#### Exclusion Criteria\n\nNone noted\n\n### Patient Management\n\n#### Assessment\n\nVerify scene is secure. The electrical source must be disabled prior to assessment\nPerform primary survey with specific focus on dysrhythmias or cardiac arrest\u2014apply a continuous cardiac monitor\nand obtain 12-lead EKG as soon as feasible\nIdentify all sites of burn injury. If the patient became part of the circuit, there will be an additional site near\nthe contact with ground. Electrical burns are often full thickness and involve significant deep tissue damage, and\nthere may be multiple burn sites\nAssess for potential associated trauma and note if the patient was thrown from contact point.", "start_char_idx": 789677, "end_char_idx": 793016, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "301f1ef3-abbf-43a4-a9ed-db41588bec7c": {"__data__": {"id_": "301f1ef3-abbf-43a4-a9ed-db41588bec7c", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "590ea2b3-1acb-4bc4-8f00-0d11cd8e100a", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "b6e1de837ca7a8792fc0f6909ccf8413fdb39940a69f6628292d99219b5a5bc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "053147ef-9e39-49ea-9a2d-a9e5809be524", "node_type": "1", "metadata": {}, "hash": "dd7b94fb208126aefc769b8d45ca219b3e8be7e0dad998e570bb516ee723b8a0", "class_name": "RelatedNodeInfo"}}, "text": "#### Exclusion Criteria\n\nNone noted\n\n### Patient Management\n\n#### Assessment\n\nVerify scene is secure. The electrical source must be disabled prior to assessment\nPerform primary survey with specific focus on dysrhythmias or cardiac arrest\u2014apply a continuous cardiac monitor\nand obtain 12-lead EKG as soon as feasible\nIdentify all sites of burn injury. If the patient became part of the circuit, there will be an additional site near\nthe contact with ground. Electrical burns are often full thickness and involve significant deep tissue damage, and\nthere may be multiple burn sites\nAssess for potential associated trauma and note if the patient was thrown from contact point. If patient has\naltered mental status, assume trauma was involved and treat accordingly\nAssess for potential compartment syndrome from significant extremity tissue damage\nDetermine characteristics of source if possible (AC or DC, voltage, amperage, time of injury)\n\n#### Treatment and Interventions\n\nIdentify dysrhythmias or cardiac arrest \u2014 even patients who appear dead (particularly dilated pupils) may have\ngood outcomes with prompt intervention [see appropriate guideline for additional information and patient\nassessment/treatment]\nApply spinal motion restriction if associated trauma suspected [See Trauma Section]\nApply dry dressing to any wounds\nRemove constricting clothing and jewelry since additional swelling is possible\nAdminister IV fluid resuscitation. Remember that external appearance will underestimate the degree of tissue\ninjury but that electrical injuries do not generally require as much fluid as thermal burn injuries\n\n________________________\n\nGo To TOC\n\n### Toxins and Environmental\n\nRev. March 2022\n\n### Electrical Injuries\n\n348\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n6. Electrical injuries may be associated with significant pain, treat per Pain Management Guideline\n\n7. Electrical injury patients should be taken to a burn center whenever possible since these injuries can involve considerable tissue damage\n\n8. When there is significant associated trauma, this takes priority, if local trauma resources and burn resources are not in the same facility\n\n### Patient Safety Considerations\n\n1. Verify no additional threat to patient\n\n2. Shut off electrical power\n\n3. Move patient to shelter if electrical storm activity still in area\n\n### Notes/Educational Pearls\n\nKey Considerations\n\n1. Electrical current causes injury through three main mechanisms:\n\na. Direct tissue damage, altering cell membrane resting potential, and eliciting tetany in skeletal and/or cardiac muscles\n\nb. Conversion of electrical energy into thermal energy, causing massive tissue destruction and coagulative necrosis\n\nc. Mechanical injury with direct trauma resulting from falls or violent muscle contraction\n\n2. Anticipate atrial and/or ventricular dysrhythmias as well as cardiac arrest\n\n3. The mortality related to electrical injuries is impacted by several factors:\n\na. Route current takes through the body- current traversing the heart has higher mortality\n\nb. Type of current (AC vs. DC)\n\ni. AC is more likely to cause cardiac dysrhythmias while DC is more likely to cause deep tissue burns however either type of current can cause any injury\n\nii. DC typically causes one muscle contraction while AC can cause repeated contractions\n\niii. Both types of current can cause involuntary muscle contractions that do not allow the victim to let go of the electrical source\n\niv. AC is more likely to cause ventricular fibrillation while DC is more likely to cause asystole\n\nc. The amount of current impacts mortality more than the voltage\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Electrical Injuries 349\n---\n# NASEMSO\n\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Current level Probable Effect on Human Body of 120 V, 60 Hz AC for 1 second (Milliamperes)\n\n|Current (Milliamperes)|Effect|\n|---|---|\n|1mA|Perception level. Slight tingling sensation. Still dangerous if wet conditions.|\n|5mA|Slight shock felt; not painful but disturbing. Average individual can let go. However, strong involuntary         reactions to shocks in this range may lead to injuries.|\n|6mA\u201316mA|Painful shock, begin to lose muscular control. Commonly referred to as the freezing current or \"let-go\" range.|\n|17mA\u201399mA|Extreme pain, respiratory arrest, severe muscular contractions. Individual cannot let go. Death is possible.|\n|100mA\u20132000mA|Ventricular fibrillation (uneven, uncoordinated pumping of the heart). Muscular contraction and nerve damage         begins to occur.", "start_char_idx": 792343, "end_char_idx": 796966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "053147ef-9e39-49ea-9a2d-a9e5809be524": {"__data__": {"id_": "053147ef-9e39-49ea-9a2d-a9e5809be524", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "301f1ef3-abbf-43a4-a9ed-db41588bec7c", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "cfb58f4e68583e9aaca1eb1ef740a18b834c8d83770204cadf13031038cb7b51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6768563-f8f2-4888-b4c3-8ad41cad23ff", "node_type": "1", "metadata": {}, "hash": "39916ef42c3cf747376849078c2f0b207fd3c12dadc108b1b27ae8de1f8532a3", "class_name": "RelatedNodeInfo"}}, "text": "Slight tingling sensation. Still dangerous if wet conditions.|\n|5mA|Slight shock felt; not painful but disturbing. Average individual can let go. However, strong involuntary         reactions to shocks in this range may lead to injuries.|\n|6mA\u201316mA|Painful shock, begin to lose muscular control. Commonly referred to as the freezing current or \"let-go\" range.|\n|17mA\u201399mA|Extreme pain, respiratory arrest, severe muscular contractions. Individual cannot let go. Death is possible.|\n|100mA\u20132000mA|Ventricular fibrillation (uneven, uncoordinated pumping of the heart). Muscular contraction and nerve damage         begins to occur. Death is likely.|\n|> 2,000mA|Cardiac arrest, internal organ damage, and severe burns. Death is probable.|\n\nSource: https://www.osha.gov/SLTC/etools/construction/electrica!_incidents/eleccurrent.html\n\n## Pertinent Assessment Findings\n\nIdentification of potential trauma concomitant with electrical injury\nPresence of cardiac dysrhythmias\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914095 \u2013 Injury - Electrical Injuries\n\n## Key Documentation Elements\n\nCharacteristics of electrical current\nDowntime if found in cardiac arrest\nPositioning of the patient with respect to the electrical source\nAccurate description of external injuries\nDocument presence or absence of associated trauma\n\n## Performance Measures\n\nConfirmation of scene safety\nDocumentation of electrical source and voltage if known\nDocumentation of cardiac monitoring\nDocumentation of appropriate care of associated traumatic injuries\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nTrauma\u201401: Pain Assessment of Injured Patients\n\n## References\n\nElectrical Injuries. Emedicince.medscape.com.\n\n________________________ Go To TOC\n\nToxins and Environmental\n\nElectrical Injuries\n\nRev. March 2022\n\n350\n---\n## National Model EMS Clinical Guidelines Version 3.0\n\nhttp://emedicine.medscape.com/article/433682-overview. Updated February 8, 2017. Accessed March 11, 2022\n\nPham TN, Gibran NS. Thermal and electrical injuries. Surg Clin North Am. 2007;87(1):185\u2013206\nPrice TG, Cooper MA. Electrical and lightning injuries. In Hockenberger R, ed. Rosen's Emergency Medicine, 9th Edition. 2009\n\nRevision Date: March 11, 2022\n\n________________________ Go To TOC\n\n### Toxins and Environmental Electrical Injuries Rev. March 2022\n\n351\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Lightning/Lightning Strike Injury\n\n### Aliases\n\nLightning burn\n\n### Patient Care Goals\n\nIdentify patient(s) as lightning strike victim(s)\nMove to safe area\nInitiate immediate resuscitation of cardiac arrest victim(s), within limits of mass casualty care, also known as \"reverse triage\"\nCardiac monitoring during transport\nTreat associated traumatic injuries\n\n### Patient Presentation\n\nLightning strikes may happen in a variety of environmental conditions\n\nMost commonly they occur in outdoor or wilderness circumstances\nGolf courses, exposed mountains or ledges and farms/fields all present conditions that increase risk of lightning strike, when hazardous meteorological conditions exist\n\nLacking bystander observations or history, it is not always immediately apparent that patient has been the victim of a lightning strike\nSubtle findings such as injury patterns might suggest lightning injury\n\n### Inclusion Criteria\n\nPatients of all ages who have been the victim of lightning strike injury\n\n### Exclusion Criteria\n\nNo recommendations\n\n### Patient Management\n\n#### Assessment\n\nRespiratory\n\nApnea\nAgonal respirations\nRespiratory paralysis\n\nCardiovascular\n\nDysrhythmias\nTransient hypertension\n\nNeurologic\n\nSeizures\nConfusion\nParalysis\nParaplegia\nVertigo/dizziness\nParesthesias\nAmnesia\nMemory deficits\n\nGo To TOC\n\n### Toxins and Environmental\n\nRev. March 2022\n\n## Lightning/Lightning Strike Injury\n\n352\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Lightning/Lightning Strike Injury\n\ni. Anxiety\n\nj. Fixed/dilated pupils possible (autonomic dysfunction)\n\n4.", "start_char_idx": 796337, "end_char_idx": 800450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6768563-f8f2-4888-b4c3-8ad41cad23ff": {"__data__": {"id_": "b6768563-f8f2-4888-b4c3-8ad41cad23ff", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "053147ef-9e39-49ea-9a2d-a9e5809be524", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "490bdaae77a365edeba121a8d08664da3ab03a019c60ed24a7b563af9d7b73fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "316858bc-b366-46c2-8760-670ab4b880d0", "node_type": "1", "metadata": {}, "hash": "d73e35b262c8fe600ca71cf474a1516a0f10cf1982b577c1481268d040bc5f21", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n## Lightning/Lightning Strike Injury\n\n352\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## Lightning/Lightning Strike Injury\n\ni. Anxiety\n\nj. Fixed/dilated pupils possible (autonomic dysfunction)\n\n4. Skin\n\na. Ferning or fern-like superficial skin burn (\"Lichtenberg figures\")\n\nb. Vascular instability may result in cool, mottled extremities\n\nc. Frequent first and/or second-degree burns\n\nd. Third degree burns less common\n\n5. Patient may be in full cardiopulmonary arrest or have only respiratory arrest, as injury is a result of DC current\n\n6. May have stroke-like findings as a result of neurologic insult\n\n7. May have secondary traumatic injury as a result of overpressurization, blast or missile injury\n\n8. Fixed/dilated pupils may be a sign of neurologic insult, rather than a sign of death/impending death. Should not be used as a solitary, independent sign of death for the purpose of discontinuing resuscitation in this patient population\n\n### Treatment and Interventions\n\n1. Assure patent airway \u2014 if in respiratory arrest only, manage airway as appropriate\n\n2. If in cardiopulmonary arrest, treat per Cardiac Arrest Guideline\n\n3. Consider IV initiation \u2014 avoid initiation through burned skin\n\n4. Monitor EKG. Be alert for potential arrhythmias. Consider 12-lead EKG, when available\n\n5. Consider early pain management for burns or associated traumatic injury [See Pain Management Guideline]\n\n### Patient Safety Considerations\n\n1. Recognize that repeat strike is a risk. Patient and rescuer safety is paramount\n\n2. Victims do not carry or discharge a current, so the patient is safe to touch and treat\n\n### Notes/Educational Pearls\n\nKey Considerations\n\n1. Lightning strike cardiopulmonary arrest patients have a high rate of successful resuscitation, if initiated early, in contrast to general cardiac arrest statistics\n\n2. There may be multiple victims\n\n3. If multiple victims, cardiac arrest patients whose injury was witnessed or thought to be recent should be treated first and aggressively (reverse from traditional triage practices)\n\na. Patients suffering cardiac arrest from lightning strike initially suffer a combined cardiac and respiratory arrest\n\nb. Return of spontaneous circulation may precede resolution of respiratory arrest\n\nc. Patients may be successfully resuscitated if provided proper cardiac and respiratory support, highlighting the value of \"reverse triage\"\n\n4. It may not be immediately apparent that the patient is a lightning strike victim\n\n5. Injury pattern and secondary physical exam findings may be key in identifying patient as a victim of lightning strike\n\n6. Lightning strike is a result of very high voltage, very short duration DC current exposure\n\n________________________\n\nGo To TOC\n\nToxins and Environmental\n\nRev. March 2022\n\nLightning/Lightning Strike Injury\n\n353\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## Pertinent Assessment Findings\n\nPresence of thermal or non-thermal burns\nEvidence of trauma\nEvidence of focal neurologic deficits\n\n## Quality Improvement\n\nAssociated NEMSIS Protocol(s) (eProtocol.01) (for additional information, go to www.nemsis.org)\n\n9914209 \u2013 Injury - Lightning/Lightning Strike\n\n## Key Documentation Elements\n\nInitial airway status\nInitial cardiac rhythm\nNeurologic exam (initial and repeat)\nAssociated/secondary injuries\nPain scale documentation/pain management\n\n## Performance Measures\n\nCardiopulmonary issues addressed early and documented appropriately\nPatient transported to closest appropriate facility\nPain scale documented and treated per guidelines (when appropriate)\nNational EMS Quality Alliance (NEMSQA) Performance Measures (for additional information, see www.nemsqa.org)\n\nTrauma\u201401: Pain Assessment of Injured Patients\n\n## References\n\nAnderson DR, Gillberg JM, Torrey JW, Koneru JN. Lightning induced inappropriate ICD shock: an unusual case of\nelectromagnetic interference. Pacing Clin Electrophysiol. 2012;35(6): e159\u201362\nArnoldo BD, Purdue GF. The diagnosis and management of electrical injuries. Hand Clin. 2009;25(4):469\u201379\nBlumenthal R. Secondary missile injury from lightning strike. Am J Forensic Med Pathol. 2012;33(1):83\u20135\nBlumenthal R, Jandrell IR, West NJ. Does a sixth mechanism exist to explain lightning injuries?", "start_char_idx": 800220, "end_char_idx": 804508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "316858bc-b366-46c2-8760-670ab4b880d0": {"__data__": {"id_": "316858bc-b366-46c2-8760-670ab4b880d0", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6768563-f8f2-4888-b4c3-8ad41cad23ff", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "67a15ede93fcd4997f283a1604739906d98649b3987115258b23ca0fda179b38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "287ac444-df08-41e0-a01e-c8aef2afa6ce", "node_type": "1", "metadata": {}, "hash": "506e70cf91323d509408557b58f5be69c1499b0a7dbeb51bcf0cfe07d1b55b1d", "class_name": "RelatedNodeInfo"}}, "text": "Lightning induced inappropriate ICD shock: an unusual case of\nelectromagnetic interference. Pacing Clin Electrophysiol. 2012;35(6): e159\u201362\nArnoldo BD, Purdue GF. The diagnosis and management of electrical injuries. Hand Clin. 2009;25(4):469\u201379\nBlumenthal R. Secondary missile injury from lightning strike. Am J Forensic Med Pathol. 2012;33(1):83\u20135\nBlumenthal R, Jandrell IR, West NJ. Does a sixth mechanism exist to explain lightning injuries? Investigating a\npossible new injury mechanism to determine the cause of injuries related to close lightning flashes. Am J Forensic\nMed Pathol. 2012;33(3):222\u20136\nBrunner FX. [Bilateral tympanic membrane perforation caused by a lightning accident]. HNO. 1984;32(10):429\u201330\nCenters for Disease Control and Prevention (CDC). Lightning-associated deaths \u2013 United States, 1980\u20131995. MMWR\nMorb Mortal Wkly Rep. 1998 May 22;47(19):391\u201394\nCherington M, Kurtzman R, Krider EP, Yarnell PR. Mountain medical mystery: unwitnessed death of a healthy young\nman, caused by lightning. Am J Forensic Med Pathol. 2001;22(3):296\u20138\nCooper MA. Emergent care of lightning and electrical injuries. Semin Neurol. 1995;15(3):268\u201378\nCooper MA. A fifth mechanism of lightning injury. Acad Emerg Med. 2002;9(2):172\u20134\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Lightning/Lightning Strike Injury 354\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n10. Davis C, Engeln A, Johnson E, et al; Wilderness Medical Society. Wilderness Medical Society practice guidelines\nfor the prevention and treatment of lightning injuries. Wilderness Environ Med. 2012;23(3):260\u20139\n\n11. Davis C, Engeln A, Johnson E, et al; Wilderness Medical Society Practice Guidelines for the Prevention and Treatment\nof Lightning Injuries: 2014 Update - Wilderness & Environmental Medicine (wemjournal.org) https://doi.org/10.1016/j.wem.2014.08.011. Accessed March 11,\n2022\n\n12. Desai BK, Fairclough R. A case of a speech impediment following a near lightning strike. Int J Emerg Med. 2011; 4:60\n\n13. Dronacahrya L, Poudel R. Lightning induced atrial fibrillation. Kathmandu Univ Med J (KUMJ). 2008;6(24):514\u20135\n\n14. Duclos PJ, Sanderson LM, Klontz KC. Lightning-related mortality, and morbidity in Florida. Public Health Rep.\n1990;105(3):276\u201382\n\n15. Dundon BK, Puri R, Leong DP, Worthley MI. Takotsubo cardiomyopathy following lightning strike. BMJ. 2008;\n25:460\u20131\n\n16. Fontanarosa PB. Electrical shock and lightning strike. Ann Emerg Med. 1993;22(2 Pt 2):378\u201387\n\n17. Forster SA, Silva IM, Ramos MLC, Gragnani A, Ferreira LM. Lightning burn \u2013 review and case report. Burns.\n2013;39(2): e8\u201312\n\n18. Glunci\u0107 I, Roje Z, Glunci\u0107 V, Poljak K. Ear injuries caused by lightning: report of 18 cases. J Laryngol Otol.\n2001;115(1):4\u20138\n\n19. Guardiola B, Planella M, Ferreruela M, Velasco J, P\u00e9rez-B\u00e1rcena J, Llompart-Pou JA. [Brain injury secondary to\nlightning strike]. Med Intensiva. 2013;37(5):367\u20138\n\n20. Haraldsson PO, Bergstedt M. [Unconsciousness and persistent tinnitus caused by lightning injury to the ear during\ntelephoning]. L\u00e4kartidningen.", "start_char_idx": 804064, "end_char_idx": 807150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "287ac444-df08-41e0-a01e-c8aef2afa6ce": {"__data__": {"id_": "287ac444-df08-41e0-a01e-c8aef2afa6ce", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "316858bc-b366-46c2-8760-670ab4b880d0", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "5a154cbb2e7c8a996e6ca76caf241025f88ad297a52e9f281f7667a8b384da36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb8eff95-18df-4789-84d8-9afe0c1482f2", "node_type": "1", "metadata": {}, "hash": "067903ee7dbd040b7dda2eb9114526e2e6606a6df81a65637a4da0198f4f4718", "class_name": "RelatedNodeInfo"}}, "text": "Lightning burn \u2013 review and case report. Burns.\n2013;39(2): e8\u201312\n\n18. Glunci\u0107 I, Roje Z, Glunci\u0107 V, Poljak K. Ear injuries caused by lightning: report of 18 cases. J Laryngol Otol.\n2001;115(1):4\u20138\n\n19. Guardiola B, Planella M, Ferreruela M, Velasco J, P\u00e9rez-B\u00e1rcena J, Llompart-Pou JA. [Brain injury secondary to\nlightning strike]. Med Intensiva. 2013;37(5):367\u20138\n\n20. Haraldsson PO, Bergstedt M. [Unconsciousness and persistent tinnitus caused by lightning injury to the ear during\ntelephoning]. L\u00e4kartidningen. 1983;80(19):2024\n\n21. Hinkelbein J, Spelten O, Wetsch WA. [Lightning strikes and lightning injuries in prehospital emergency medicine.\nRelevance, results, and practical implications]. Unfallchirurg. 2013;116(1):74\u20139\n\n22. Jefferiss WR. Three cases of lightning-stroke. Br Med J. 1876;1(786):102\n\n23. Kaliszan M, Karnecki K, Jankowski Z. [A case of fatal lightning stroke at an unusual site \u2013 the city center]. Arch\nMed Sa\u0327dowej Kryminol. 2012;62(3):208\u201312\n\n24. Kleinschmidt-DeMasters, BK. Neuropathology of lightning-strike injuries. Semin Neurol. 1995;15(4):323\u20138\n\n25. Ko SH, Chun W, Kim HC. Delayed spinal cord injury following electrical burns: a 7-year experience. Burns.\n2004;30(7):691\u20135\n\n26. Kubilius D, Rimdeika R. Simultaneous lightning injury in a group of people: case report. Burns. 2012;38(3): e9\u201312\n\n27. Lane JR. Clinical lecture on injuries from lightning. Br Med J. 1872;2(605):114\u20136\n\n28. Leiria TLL, Pires LM, Kruse ML, de Lima GG. Struck by lightning: a case of nature-induced pre- excited atrial\nfibrillation. Circ Arrhythm Electrophysiol. 2013;6(2): e20\u20131\n\n29. Levy DR, Akiyama T. Lightning-induced ventricular fibrillation. Cardiology J. 2007;14(1):91\u20134\n\n30. Lichtenberg R, Dries D, Ward K, Marshall W, Scanlon P. Cardiovascular effects of lightning strikes. J Am Coll\nCardiol. 1993;21(2):531\u20136\n\n31. Lightning Safety Awareness. Boston, MA: American Meteorological Society; April 29, 2002.\n\n32. Lightning-related Medical Encounters, Active and Reserve Components, U.S. Armed Forces, January 2009-August\n2012. MSMR. 2012;19(9):18\u20139\n\n33. McIntyre WF, Simpson CS, Redfearn DP, Abdollah H, Baranchuk A. The lightning heart: a case report and brief\nreview of the cardiovascular complications of lightning injury. Indian Pacing Toxins and Environmental Rev. March\n2022\n\nLightning/Lightning Strike Injury 355\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n34. Modayil PC, Lloyd GW, Mallik A, Bowdler DA. Inner ear damage following electric current and lightning injury: a\nliterature review. Eur Arch Otorhinolaryngol. 2014;271(5):855\u201361\n\n35. Mora-Maga\u00f1a I, Collado-Corona MA, Toral-Marti\u00f1\u00f2n R, Cano A. Acoustic trauma caused by lightning. Int J Pediatr\nOtorhinolaryngol. 1996;35(1):59\u201369\n\n36. Myung N-S, Lee I-W, Goh E-K, Kong S-K. Cochlear implantation for severe sensorineural hearing loss caused by\nlightning.", "start_char_idx": 806637, "end_char_idx": 809508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb8eff95-18df-4789-84d8-9afe0c1482f2": {"__data__": {"id_": "bb8eff95-18df-4789-84d8-9afe0c1482f2", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "287ac444-df08-41e0-a01e-c8aef2afa6ce", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "e5b1e6c7862fc7886da8e9ce08eb8da5912e9e6074a58e78fa5b312a6d6a8695", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d47bdbd4-451d-45a8-875b-cfb6e9df257a", "node_type": "1", "metadata": {}, "hash": "6be46829b913b311d2748369788eea9df255410f16abe3c31e165c3053882248", "class_name": "RelatedNodeInfo"}}, "text": "Modayil PC, Lloyd GW, Mallik A, Bowdler DA. Inner ear damage following electric current and lightning injury: a\nliterature review. Eur Arch Otorhinolaryngol. 2014;271(5):855\u201361\n\n35. Mora-Maga\u00f1a I, Collado-Corona MA, Toral-Marti\u00f1\u00f2n R, Cano A. Acoustic trauma caused by lightning. Int J Pediatr\nOtorhinolaryngol. 1996;35(1):59\u201369\n\n36. Myung N-S, Lee I-W, Goh E-K, Kong S-K. Cochlear implantation for severe sensorineural hearing loss caused by\nlightning. Am J Otolaryngol. 2012;33(6):767\u20139\n\n37. Navarrete N. Severe rhabdomyolysis without renal injury associated with lightning strike. J Burn Care Res.\n2013;34(3): e209\u201312\n\n38. O\u2019Keefe Gatewood M, Zane RD. Lightning injuries. Emerg Med Clin N Am. 2004;22(2):369\u2013403.\n\n39. Parsaik AK, Jahlskog JE, Singer W, et al. Central hyperadrenergic state after lightning strike. Clin Auton Res.\n2013;23(4):169\u2013173\n\n40. Pedersen ML, B\u00fclent U, Morten NL, Carl P. [Survival following lightning strike and treatment of sequelae]. Ugeskr\nLaeger. 2011;173(15):1138\u20139\n\n41. Pfortmueller CA, Yikun Y, Haberkern M, Wuest E, Zimmermann H, Exadaktylos AK. Injuries, sequelae, and treatment\nof lightning-induced injuries: 10 years of experience at a Swiss trauma center. Emerg Med Int. 2012; 2012:167698\n\n42. Russell KW, Cochran AL, Sagar TM, Morris SE, McDevitt MC. Lightning burns. J Burn Care Res. 2013;35(6): e436\u20138\n\n43. Slesinger TL, Bank M, Drumheller BC, et al. Immediate cardiac arrest and subsequent development of cardiogenic\nshock caused by lightning strike. J Trauma. 2010;68(1): e5\u20137\n\n44. Soomaroo L, Murray V. Weather and environmental hazards at mass gatherings. PLoS Curr 2012;4: e4fca9ee30afc4\n\n45. Thacker MTF, Lee R, Sabogal RI, Henderson A. Overview of deaths associated with natural events, United States,\n1979\u20132004. Disasters. 2008;32(2):303\u201315\n\n46. Thomson EM, Thomas MH. Lightning injuries in sports and recreation. Curr Sports Med Rep. 2013;12(2):120\u20134\n\n47. Walsh KM. Lightning and severe thunderstorms in event management. Curr Sports Med Rep. 2012;11(3):131\u20134\n\n48. Walsh KM, Cooper MA, Holle R, Rakov VA, Roeder WP, Ryan M; National Athletic Trainers\u2019 Association. National\nAthletic Trainers\u2019 Association position statement: lightning safety for athletics and recreation. J Athl Train.\n2013;48(2):258\u201370\n\n49. Wankhede AG, Sariya DR. Damage due to lightning when it strikes the face. Foren Sci Int. 2013;224(1\u20133): e1\u20133\n\n50. Ward NJ, Little JH, Higgins GL III. Man with confusion and resolved paralysis. Lightning strike injury. Ann Emerg\nMed. 2012;59(4):335, 340\n\n51. Wiesenthal L, Jacoby A, Davis KP, Campagne D, Snowden B, Hughes S. Lightning safety awareness of visitors in\nthree California national parks. Wilderness Environ Med. 2011;22(3):257\u201361\n\n52. Zimmermann C, Cooper MA, Holle RL. Lightning safety guidelines. Ann Emerg Med. 2002;39(6):660\u20134\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nToxins and Environmental Rev.", "start_char_idx": 809056, "end_char_idx": 811955, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d47bdbd4-451d-45a8-875b-cfb6e9df257a": {"__data__": {"id_": "d47bdbd4-451d-45a8-875b-cfb6e9df257a", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb8eff95-18df-4789-84d8-9afe0c1482f2", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "05674b418d9b2c4304e4af1deac69bebf30835a1226faf7ffdbb0750d5109e46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee852c4c-7e25-424d-a503-28a158b59444", "node_type": "1", "metadata": {}, "hash": "7eeb46035d3c483e9ad25820944c694ba5e0854be0843faeda7bdbe5cd025dd5", "class_name": "RelatedNodeInfo"}}, "text": "Damage due to lightning when it strikes the face. Foren Sci Int. 2013;224(1\u20133): e1\u20133\n\n50. Ward NJ, Little JH, Higgins GL III. Man with confusion and resolved paralysis. Lightning strike injury. Ann Emerg\nMed. 2012;59(4):335, 340\n\n51. Wiesenthal L, Jacoby A, Davis KP, Campagne D, Snowden B, Hughes S. Lightning safety awareness of visitors in\nthree California national parks. Wilderness Environ Med. 2011;22(3):257\u201361\n\n52. Zimmermann C, Cooper MA, Holle RL. Lightning safety guidelines. Ann Emerg Med. 2002;39(6):660\u20134\n\nRevision Date March 11, 2022\n\n________________________ Go To TOC\n\nToxins and Environmental Rev. March 2022 Lightning/Lightning Strike Injury 356\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# APPENDICES\n\n## I. Author, Reviewer and Staff Information\n\n### Authors\n\nCo-Principal Investigators\n\nCarol A. Cunningham, MD\nState Medical Director\nOhio Department of Public Safety, Division of EMS\nAssociate Professor of Emergency Medicine, Northeast Ohio Medical University\nDepartment of Emergency Medicine, Cleveland Clinic Akron General\nRichard Kamin, MD\nEMS Program Director\nAssociate Professor of Emergency Medicine\nUniversity of CT Health Center\nMedical Director\nConnecticut Department of Health, Office of EMS\n\n### Workgroup Authors\n\nGail H. Bradley, MD,\nMedical Director, Bureau of EMS and Trauma System\nArizona Department of Health Services\nSabina Braithwaite, MD, MPH, NRP\nProfessor of Emergency Medicine, Washington University in St Louis\nMedical Director, AirEvac Lifeteam Missouri / Arkansas\nMissouri State EMS Medical Director\nJon Burstein, MD\nState EMS Medical Director\nOffice of EMS, MA Dept of Public Health\nM. Riccardo Colella, DO, MPH\nProfessor and Chief, Division of EMS Medicine\nDepartment of Emergency Medicine\nMedical College of Wisconsin\nToni K. Gross, MD, MPH\nChief, Pediatric Emergency Medicine, Children\u2019s Hospital New Orleans\nProfessor of Pediatrics, Tulane University School of Medicine\nClinical Associate Professor of Pediatrics, LSU Health Sciences Center New Orleans\nDouglas F. Kupas, MD\nCommonwealth EMS Medical Director\n\n________________________Go To TOC\n\nAPPENDICES Rev. March 2022 357\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nBureau of EMS\n\nPennsylvania Department of Health\n\nProfessor of Emergency Medicine\n\nLewis Katz School of Medicine at Temple University\n\nDavid Lehrfeld, MD\n\nMedical Director\n\nOregon Health Authority\n\nEmergency Medical Services & Trauma Systems\n\nMichael Levy, MD\n\nChief Medical Officer Anchorage Areawide EMS, Anchorage Alaska\n\nMedical Director for Emergency Programs State of Alaska\n\nAffil Assoc Prof WWAMI School of Health Univ of Alaska Anchorage\n\nGeorge Lindbeck, MD\n\nAssociate Professor of Emergency Medicine\n\nDirector, Emergency Medical Services Fellowship\n\nUniversity of Virginia\n\nSharon Malone, MD\n\nMedical Director\n\nEmergency Medical Task Force (EMTF-2)\n\nMedical Director for North Central Texas Trauma Advisory Council (NCTTRAC)\n\nJulian Mapp MD, MBA, MPH\n\nAssistant Research Director\n\nWellSpan Health\n\nTom McGinnis, MHA, EMT-P\n\nChief, EMS Division\n\nCalifornia EMS Authority\n\nKyle N. Remick, MD\n\nEMS Committee\n\nAmerican College of Surgeons \u2013 Committee on Trauma\n\nProfessor of Surgery\n\nUniformed Services University School of Medicine\n\nCurtis Sandy, MD\n\nEMS Director\n\nPortneuf Medical Center\n\nChair Idaho EMS Physician Commission\n\nJ. Matthew Sholl, MD, MPH\n\nAssociate Professor\n\nDirector, Division of EMS\n\nDepartment of Emergency Medicine\n\n________________________\n\nGo To TOC\n\n## APPENDICES\n\nRev.", "start_char_idx": 811340, "end_char_idx": 814909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee852c4c-7e25-424d-a503-28a158b59444": {"__data__": {"id_": "ee852c4c-7e25-424d-a503-28a158b59444", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d47bdbd4-451d-45a8-875b-cfb6e9df257a", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "a26e2deab689efabe702028c1670726e9dfac51c2e5ddea3a112c4d86afd3e67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ee8b7ad-9655-40f2-acbf-5d802afe50b0", "node_type": "1", "metadata": {}, "hash": "2cf09fac716d50a89757627a78899658cdd3a28fe3307892c2d383f20039a2b9", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n### I. Author, Reviewer and Staff Information\n\n358\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nMaine Medical Center\n\nTufts University School of Medicine\n\nState Medical Director, Maine EMS\n\nMaine Department of Public Safety\n\nPeter P. Taillac, MD\n\nClinical Professor University of Utah School of Medicine\n\nState EMS Medical Director Utah Bureau of EMS and Preparedness Utah Department of Health\n\nLynn White, MS\n\nNational Director of Research and Evidence Based Practice Global Medical Response\n\n### Contributing Authors\n\nJennifer Anders, MD Johns Hopkins Children's Center\n\nNoah Bernhardson, MD Medical Director Southeast Fire Department\n\nLorin Browne, DO Children's Wisconsin - Milwaukee Hospital\n\nPatricia Casey, RN, NRP STARS Program SSM Health Cardinal Glennon Children\u2019s Hospital\n\nMark Cicero, MD Yale New Haven Children's Hospital\n\nShea Duerring, MD University of Alabama at Birmingham\n\nGreg Faris, MD Riley Hospital for Children\n\nJennifer Fishe, MD UF Health Jacksonville\n\nPeter Fischer, MD, MS, NRP Associate Professor College of Medicine - Memphis\n\n________________________ Go To TOC\n\n### APPENDICES\n\nRev. March 2022\n\n### I. Author, Reviewer and Staff Information\n\n359\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### Department of Surgery\n\n### Division of Trauma/Surgical Critical Care\n\nSusan Fuchs, MD - Lurie Children's Hospital\n\nMarianne Gausche-Hill, MD - LA County EMS\n\nAndrew Hogan, MD - UT Southwestern Medical Center\n\nSteven Laffey, MD - Professor of Pediatrics, Director of Clinical Operations \u2013 Pediatric Emergency Medicine, SSM Health Cardinal Glennon Children\u2019s Hospital\n\nSuzan Mazor, MD - Seattle Children's Hospital\n\nRonna Miller, MD - UT Southwestern Medical Center\n\nStacey Noel, MD - C. S. Mott Children's Hospital\n\nKaren O'Connell, MD - Children's National Medical Center\n\nLara Rappaport, MD - Denver Health\n\nDavid Rayburn, MD - Children's Hospital New Orleans\n\nLauren Riney, DO - Cincinnati Children's Hospital\n\nMichael Schauf, MD - Neonatal/Pediatric Transport Team, Albany Medical Center, New York, Air Med Air Ambulance, Birmingham, Alabama\n\nManish Shah, MD - Texas Children's Hospital\n\nJeffery Siegler, MD, EMT-P - EMS Physician, Assistant Professor\n\n## APPENDICES\n\nRev. March 2022\n\n### I. Author, Reviewer and Staff Information\n\n360\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nDepartment of Emergency Medicine\n\nWashington University School of Medicine\n\n### Authors\n\nJessica Wall, MD\nSeattle Children's Hospital\n\nCaleb Ward, MD\nChildren's National Medical Center\n\nElizabeth Weinstein, MD\nRiley Hospital for Children\n\n### Technical Reviewers\n\nWilliam Heuser, PharmD, MS, BCCCP, EMT-P, FP-C\nResearch Coordinator/Assistant Professor\nHofstra Northwell School of Nursing and Physician Assistant Studies\n\nTimothy T. Pieh, MD\nMedical Director, Emergency Medicine\nMaine General Medical Center\n\nAmy Raubenolt, MD, MPH, MEd\nEMS Medical Director\nCleveland Clinic Akron General\nAssociate Professor of Emergency Medicine\nNortheast Ohio Medical University\n\nJames C. Suozzi, DO, NRP\nAssociate Medical Director/EMS\nCheshire Medical Center/Dartmouth Hitchcock \u2013 Keene NH\nMedical Director, New Hampshire Bureau of EMS\n\nKate Zimmerman, DO\nAssociate State EMS Medical Director\nDepartment of Emergency Medicine\nMaine Medical Center\n\n### Key Federal Partners for Project\n\nJon Krohmer, MD\nDirector, Office of Emergency Medical Services\nNational Highway Traffic Safety Administration\n\nTheresa Morrison-Quinata\nDivision of Child, Adolescent and Family Health (DCAFH) Maternal and Child Health Bureau\nHealth Resources and Services Administration\n\n## APPENDICES\n\nRev.", "start_char_idx": 814910, "end_char_idx": 818681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ee8b7ad-9655-40f2-acbf-5d802afe50b0": {"__data__": {"id_": "0ee8b7ad-9655-40f2-acbf-5d802afe50b0", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee852c4c-7e25-424d-a503-28a158b59444", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "3b005b79a8816e966bcae8bd3ddb393b8a7069e6092c99c114cf512487e4c28f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1bbf538-19da-4eaa-a283-12ec27565ef8", "node_type": "1", "metadata": {}, "hash": "954c0a7cc456ffe36245c197e7d7ea1fda03fc61a1242b6d211e3b7ed5f91694", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n### I. Author, Reviewer and Staff Information\n\n361\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nMax Sevareid\nOffice of Emergency Medical Services\nNational Highway Traffic Safety Administration\nAlternate Cooperative Agreement Project Manager\n\nGamunu Wijetunge\nOffice of Emergency Medical Services\nNational Highway Traffic Safety Administration\nCooperative Agreement Project Manager\n\n### Project Staff\n\nAndy Gienapp\nProgram Manager\nGuidelines Project Manager\nNational Association of State EMS Officials\n\nAlisa Williams\nProgram Manager\nGuidelines Project Technical Writer/Editor\nNational Association of State EMS Officials\n\nGo To TOC\n\n### APPENDICES\n\nRev. March 2022\n\n### I. Author, Reviewer and Staff Information\n\n362\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n## II. Universal Documentation Guideline\n\n### Aliases\n\nNEMSIS, Documentation\n\n### Patient Care Goals\n\nSupport continuity of patient care and continuous performance improvement (CPI) of patient care through meeting minimum documentation standards for all EMS events where a patient was encountered\nThis guideline defines minimum standards and inclusions used and referenced throughout this document under the \u201cQuality Improvement\u201d section of each guideline\nThe National EMS Information System (NEMSIS) submission requirements, state and local EMS systems, and EMS billing reimbursement services will have more extensive minimum requirements that exceed this guideline (For additional information, go to www.nemsis.org)\nThis guideline can be used as a starting point for systems looking to more formally define documentation requirements\n\n### Patient Presentation\n\n#### Inclusion Criteria\n\nAll EMS events where a patient was encountered, and one or more clinical guideline was used to determine patient treatment and/or disposition.\n\n#### Exclusion Criteria\n\nNone noted\n\n### Toolkit for Key Categories of Data Elements\n\n#### Incident Demographics\n\nIncident Demographics include the type of incident, location, time, dispatch information, response resources and patient/incident disposition of the EMS event\n\nThis information will always apply and be available, even if the responding unit never arrives on scene (is cancelled) or never makes patient contact\nIncident demographics are important for filtering incident types and outcomes when doing CPI reviews, providing aggregate descriptive data, and billing for reimbursement\n\nMinimum Incident Demographic Fields include:\n\nIncident Times\n\neTimes.03\u2014Unit Notified by Dispatch Date/Time (NEMSIS mandatory)\neTimes.05\u2014Unit En Route Date/Time (Unit responding)\neTimes.06\u2014Unit Arrived on Scene Date/Time (If arrived)\neTimes.07\u2014Arrived at Patient Date/Time (If patient contact made)\neTimes.09\u2014Unit Left Scene Date/Time (Unit Transporting Time, if applicable)\neTimes.11\u2014Patient Arrived at Destination Date/Time (If applicable)\neTimes.13\u2014Unit Back in Service Date/Time (NEMSIS mandatory)\n\neResponse.05\u2014Type of Service Requested (i.e., 911 vs interfacility)\neResponse.07\u2014Primary Role of the Unit (i.e., Transport or non-transport)\neDispatch.01\u2014Complaint Reported by Dispatch (Dispatch reason from EMD)\nCrew Responding:\n\neCrew.01\u2014Crew Member ID (Crew name or license # depending on software)\neCrew.02\u2014Crew Member Level (License level for this call)\n\n________________________ Go To TOC\n\n### APPENDICES\n\nRev. March 2022\n\n## II. Universal Documentation Guideline\n\n363\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## II. Universal Documentation Guideline\n\niii. eCrew.03\u2014Crew Member Response Role (i.e., Primary or secondary care giver)\n\nf. eScene.09\u2014Incident Location Type\n\ni. Used for multiple purposes, including CARES (Cardiac Arrest Registry to Enhance Survival)\n\ng. Response Modes (e.g., lights and sirens)\n\ni. eResponse.23\u2014Response Mode to Scene\n\nii. eResponse.24\u2014Additional Response Mode Descriptors\n\nh. Delays:\n\ni. eResponse.09\u2014Type of Response Delay\n\nii. eResponse.10\u2014Type of Scene Delay\n\n## Patient Demographics and Medical History\n\nPatient demographics in this section include the minimum information required for CPI review and do not include\nprotected health information (PHI) or patient identifiable information. Local systems may require additional PHI to\nsupport EMS reimbursement and link local level CPI reviews to specific incidents or outcome data.", "start_char_idx": 818682, "end_char_idx": 823094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1bbf538-19da-4eaa-a283-12ec27565ef8": {"__data__": {"id_": "d1bbf538-19da-4eaa-a283-12ec27565ef8", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ee8b7ad-9655-40f2-acbf-5d802afe50b0", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8f5475a42b778328390c999f2eb2843aafbbc1420e6a69ac383964fb574ea62e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be163f8a-f99c-46b0-9f8d-aad7093e34f0", "node_type": "1", "metadata": {}, "hash": "1d6eb306c4d728406d43bfcff996a9c56305965b02836be10935e5ad3c061ff7", "class_name": "RelatedNodeInfo"}}, "text": "Universal Documentation Guideline\n\niii. eCrew.03\u2014Crew Member Response Role (i.e., Primary or secondary care giver)\n\nf. eScene.09\u2014Incident Location Type\n\ni. Used for multiple purposes, including CARES (Cardiac Arrest Registry to Enhance Survival)\n\ng. Response Modes (e.g., lights and sirens)\n\ni. eResponse.23\u2014Response Mode to Scene\n\nii. eResponse.24\u2014Additional Response Mode Descriptors\n\nh. Delays:\n\ni. eResponse.09\u2014Type of Response Delay\n\nii. eResponse.10\u2014Type of Scene Delay\n\n## Patient Demographics and Medical History\n\nPatient demographics in this section include the minimum information required for CPI review and do not include\nprotected health information (PHI) or patient identifiable information. Local systems may require additional PHI to\nsupport EMS reimbursement and link local level CPI reviews to specific incidents or outcome data.\n\n### Minimum Patient Demographic and History Fields include:\n\na. ePatient.13\u2014Gender\n\nb. ePatient.15\u2014Age\n\nc. ePatient.16\u2014Age Units\n\nd. eHistory.06\u2014Medication Allergies\n\ne. eHistory.07\u2014Environmental/Food Allergies\n\nf. eHistory.08\u2014Medical/Surgical History\n\ng. eHistory.12\u2014Current Medications\n\nh. eHistory.17\u2014Alcohol/Drug Use Indicators\n\ni. eHistory.01\u2014Barriers to Patient Care\n\nj. eExam.01\u2014Estimated Body Weight in Kilograms\n\nk. eExam.02\u2014Length-based Tape Measure\n\n## Patient Complaints and Symptoms\n\n1. Patient and situational history for this EMS event generally addresses issues leading up to EMS being requested\nand include patient complaints, SAMPLE history, signs or symptoms, barriers and confounders, onset times, and trauma\nand cardiac arrest historical information\n\n2. Patient Complaints, Signs and Symptoms, and Key Related Times:\n\na. eSituation.02\u2014Possible Injury\n\nb. Patient Complaint Group\n\ni. eSituation.03\u2014Complaint Type\n\nii. eSituation.04 \u2013 Complaint\n\niii. eSituation.05\u2014Duration of Complaint\n\niv. eSituation.06\u2014Time Units of Duration of Complaint\n\nc. eSituation.07\u2014Chief Complaint Anatomic Location\n\nd. eSituation.08\u2014Chief Complaint Organ System\n\ne. Signs and Symptoms\n\ni. eSituation.01\u2014Date/Time of Symptom Onset\n\nii. eSituation.09\u2014Primary Symptom [Single Choice]\n\niii. eSituation.10\u2014Other Associated Symptoms [Choose All that Apply]\n\nf. eSituation.18\u2014Date/Time Last Known Well (Stroke/CVA)\n\n________________________ Go To TOC\n\nAPPENDICES Rev. March 2022\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nSituational History for this EMS Event\n\n3. SAMPLE History\n\nNOTE: Although many assessment guidelines refer to this history mnemonic, many electronic patient care report\n(ePCR) systems do not collect this information in a tool organized specifically in this group, but rather throughout\nthe EMS record in the appropriate areas to the topics\n\na. Symptoms\n\ni. eSituation.09\u2014Primary Symptom AND\n\nii. eSituation.10\u2014Other Associated Symptoms\n\nb. Allergies\n\ni. eHistory.06\u2014Medication Allergies AND\n\nii. eHistory.07\u2014Environmental/Food Allergies\n\na. Medications\n\ni. eHistory.12\u2014Current Medications\n\nb. Past medical and surgical history\n\ni. eHistory.08\u2014Medical/Surgical History\n\nc. Last Oral Intake\n\ni. eHistory.19\u2014Last Oral Intake (if software configured to collect) and/or\n\nii. eNarrative.01\u2014Patient Care Report Narrative\n\nd. Events leading to activation of EMS\n\ni. eSituation.17\u2014Patient Activity and/or\n\nii. eNarrative.01\u2014Patient Care Report Narrative\n\n4. Barriers and Situational Confounders\n\na. eHistory.01\u2014Barriers to Patient Care\n\nb. eHistory.17\u2014Alcohol/Drug Use Indicators\n\n5. Stroke\n\na. eSituation.18\u2014Date/Time Last Known Well (Stroke/CVA)\n\n6. Trauma History and Situation\n\na. eSituation.02\u2014Possible Injury (Yes/No\u2014based on mechanism, not listing an actual injury)\n\nb. eInjury.01\u2014Cause of Injury\n\ni. Known to clinicians as Mechanism of Injury; values are from ICD-10\n\nii.", "start_char_idx": 822247, "end_char_idx": 826017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be163f8a-f99c-46b0-9f8d-aad7093e34f0": {"__data__": {"id_": "be163f8a-f99c-46b0-9f8d-aad7093e34f0", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1bbf538-19da-4eaa-a283-12ec27565ef8", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "d9a00e0becfe3863b89cb2cc415cd3d7fa121379a1780a0d090092641494fa6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1330769-5221-4b15-8f72-4b352c249455", "node_type": "1", "metadata": {}, "hash": "afb506de2b09e524daefe966bd28e1ff50dc923b1cce920b30a49707a5a2fe87", "class_name": "RelatedNodeInfo"}}, "text": "eNarrative.01\u2014Patient Care Report Narrative\n\nd. Events leading to activation of EMS\n\ni. eSituation.17\u2014Patient Activity and/or\n\nii. eNarrative.01\u2014Patient Care Report Narrative\n\n4. Barriers and Situational Confounders\n\na. eHistory.01\u2014Barriers to Patient Care\n\nb. eHistory.17\u2014Alcohol/Drug Use Indicators\n\n5. Stroke\n\na. eSituation.18\u2014Date/Time Last Known Well (Stroke/CVA)\n\n6. Trauma History and Situation\n\na. eSituation.02\u2014Possible Injury (Yes/No\u2014based on mechanism, not listing an actual injury)\n\nb. eInjury.01\u2014Cause of Injury\n\ni. Known to clinicians as Mechanism of Injury; values are from ICD-10\n\nii. Intent is included where possible in ICD-10, but is no longer a separate field as it was in NEMSIS v2\n\nc. eInjury.03\u2014Trauma Center Criteria (per the ACS-COT 2022 National Guideline for Field Triage of Injured Patients)\n\nd. eInjury.04\u2014Vehicular, Pedestrian, or Other Injury Risk Factor (per the ACS-COT 2022 National Guideline for Field\nTriage of Injured Patients)\n\ne. eInjury.07\u2014Use of Occupant Safety Equipment\n\nf. Destination Pre-Arrival Alerts (e.g., trauma alerts)\n\ni. eDisposition.24\u2014Destination Team Pre-Arrival Alert or Activation\n\nii. eDisposition.25\u2014Date/Time of Destination Pre-Arrival Alert or Activation\n\n7. Cardiac Arrest History and Situation\n\nNOTE: The following fields meet the needs of Utstein Criteria reports and many of the fields\n\n________________________ Go To TOC\n\nAPPENDICES Rev. March 2022\n\n## II. Universal Documentation Guideline\n\n365\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nin CARES. CARES has additional custom fields that may be available from your software vendor.\n\na. eArrest.01\u2014Cardiac Arrest [Yes/No]\n\nb. eArrest.02\u2014Cardiac Arrest Etiology\n\nc. eArrest.03\u2014Resuscitation Attempted By EMS\n\nd. eArrest.04\u2014Arrest Witnessed By\n\ne. eArrest.05\u2014CPR Care Provided Prior to EMS Arrival\n\nf. eArrest.06\u2014Who Provided CPR Prior to EMS Arrival\n\ng. eArrest.07\u2014AED Use Prior to EMS Arrival\n\nh. eArrest.08\u2014Who Used AED Prior to EMS Arrival\n\ni. eArrest.09\u2014Type of CPR Provided\n\nj. eArrest.11\u2014First Monitored Arrest Rhythm of the Patient\n\nk. eArrest.12\u2014Any Return of Spontaneous Circulation\n\nl. eArrest.14\u2014Date/Time of Cardiac Arrest\n\nm. eArrest.15\u2014Date/Time Resuscitation Discontinued\n\nn. eArrest.16\u2014Reason CPR/Resuscitation Discontinued\n\no. eArrest.17\u2014Cardiac Rhythm on Arrival at Destination\n\np. eArrest.18\u2014End of EMS Cardiac Arrest Event\n\nq. eScene.02\u2014Other EMS or Public Safety Agencies at Scene\n\nr. eScene.03\u2014Other EMS or Public Safety Agency ID Number\n\ns. eScene.04\u2014Type of Other Service at Scene\n\n## Clinician Impressions and Incident/Patient Disposition\n\n1. Clinician Impressions (Clinician Field Working Diagnosis)\n\na. eSituation.11\u2014Clinician's Primary Impression [Single Choice]\n\ni. The word \u201cPrimary\u201d causes a great deal of understandable confusion with this field, this should be the diagnosis\nof the most acute (primary) problem NOT NECESSARILY THE FIRST problem that was wrong with the patient, or their initial\ncomplaint\n\nb. eSituation.12\u2014Clinician's Secondary Impressions [Choose all that Apply]\n\n2. Incident/Patient Disposition\n\na. eSituation.13\u2014Initial Patient Acuity (Intended to be prior to EMS care)\n\nb. eDisposition.19\u2014Final Patient Acuity (Intended to be after EMS care)\n\nc. eDisposition.12\u2014Incident/Patient Disposition\n\nd. eDisposition.16\u2014EMS Transport Method\n\ne. Transport Mode (i.e., use of lights and sirens)\n\ni. eDisposition.17\u2014Transport Mode from Scene\n\nii.", "start_char_idx": 825417, "end_char_idx": 828856, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1330769-5221-4b15-8f72-4b352c249455": {"__data__": {"id_": "f1330769-5221-4b15-8f72-4b352c249455", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be163f8a-f99c-46b0-9f8d-aad7093e34f0", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "e8b70a9b053e03df0bc57ef18e4d19c35b1c1fff8bc9e44f6e90a67b7260829b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03a9d552-7665-468e-aa4e-ea67146e55aa", "node_type": "1", "metadata": {}, "hash": "2e64940567c127d10dba39651090cac208b8e743fabea0b995f132ca2727c7cd", "class_name": "RelatedNodeInfo"}}, "text": "Incident/Patient Disposition\n\na. eSituation.13\u2014Initial Patient Acuity (Intended to be prior to EMS care)\n\nb. eDisposition.19\u2014Final Patient Acuity (Intended to be after EMS care)\n\nc. eDisposition.12\u2014Incident/Patient Disposition\n\nd. eDisposition.16\u2014EMS Transport Method\n\ne. Transport Mode (i.e., use of lights and sirens)\n\ni. eDisposition.17\u2014Transport Mode from Scene\n\nii. eDisposition.18\u2014Additional Transport Mode Descriptors\n\nf. eDisposition.01\u2014Destination/Transferred To, Name\n\ni. Intended by NEMSIS to be the destination facility or the Agency transferred to, although many ePCR systems only\ncollect this as the destination facility because of the complexity of mixing facilities and services in the same field\n\n## Assessments and Exams\n\n1. Exams\n\nBy definition, use of NEMSIS eExam fields is optional; they are, however, available for both state and local EMS system\nuse.\n\na. Many systems do not require use of these fields as they can be time-consuming to enter, often too detailed (i.e.,\nthere is no value for whole arm, it would need to be\n\n________________________ Go To TOC\n\nAPPENDICES Rev. March 2022\n\n## II. Universal Documentation Guideline\n\n366\n---\nNASEMSO National Model EMS Clinical Guidelines Version 3.0\n\nentered as shoulder, upper arm, elbow, forearm and wrist with separate exam findings for each component, meaning a single exam finding of paralysis for an arm would take ten steps to enter) and the same information is often reflected in the clinician\u2019s narrative.\n\nb. However, there is some utility in targeted use of these fields for certain situations such as stroke, spinal exams, and trauma without needing to enter all the fields in each record.\n\n2. Capacity Assessment Group This can be used to support documentation of patient capacity for refusal of care and/or transport, participation in advanced spinal assessments, or support for treatment decisions by EMS clinicians. NOTE: The Capacity Assessment Group does not provide a legal definition of capacity and should not be used as such. It is intended only to assist the EMS clinician in documenting the most basic exam and history findings in order to determine capacity. Many additional factors must be considered when determining capacity including the situation, patient medical history, medical conditions, and consultation with medical direction.\n\na. Barriers and situational confounders [Both only single entry] i. eHistory.01\u2014Barriers to Patient Care ii. eHistory.17\u2014Alcohol/Drug Use Indicators\n\nb. Glasgow Coma Score (GCS) Vitals Group [see Vitals section] [serial entries allowed]\n\nc. eVitals.26\u2014Level of Responsiveness (AVPU) [serial entries allowed]\n\nd. eExam.19\u2014Mental Status Assessment [serial entries allowed]\n\ne. eExam.20\u2014Neurological Assessment [serial entries allowed]\n\n3. Stroke Assessments a. Initial Vitals b. eSituation.18\u2014Date/Time Last Known Well (Stroke/CVA) c. Stroke Score Group d. eExam.19\u2014Mental Status Assessment e. eExam.20\u2014Neurological Assessment (Speech, facial droop, arm drift, unilateral weakness) f. eVitals.31\u2014Reperfusion Checklist (May not apply if service area does not use due to lack of consensus on a standard reperfusion checklist, or acceptance by EMS if used)\n\n4. Spinal Injury/Exam a. Capacity Assessment Group b. Back and Spine Assessment Group i. eExam.13\u2014Back and Spine Assessment Finding Location ii. eExam.14\u2014Back and Spine Assessment c. Extremity Assessment Group i. eExam.15\u2014Extremity Assessment Finding Location ii. eExam.16\u2014Extremities Assessment\n\n5. 12-lead EKG Acquisition a. eTimes.06\u2014Unit Arrived on Scene Date/Time b. eTimes.07\u2014Arrived at Patient Date/Time c. EKG Rhythm Group [see Vitals section] d. Attach 12-lead graphic ePCR (through direct integration linkage with EKG monitor or attachment of scanned printout as allowed/available in software) e. 12-lead-EKG Procedure-documented under Procedures Performed Group\n\n6. Trauma/Injury\n\nGo To TOC\n\nAPPENDICES Rev. March 2022 II. Universal Documentation Guideline 367\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nThe exam fields have many useful values for documenting trauma (deformity, bleeding, burns, etc.).", "start_char_idx": 828486, "end_char_idx": 832618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03a9d552-7665-468e-aa4e-ea67146e55aa": {"__data__": {"id_": "03a9d552-7665-468e-aa4e-ea67146e55aa", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1330769-5221-4b15-8f72-4b352c249455", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "84491714fcda35124b8ba49ffe9cda363887f993a11cee6a76c6ad1bf1568b45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6184f38-a493-4641-9867-f75845bd5b41", "node_type": "1", "metadata": {}, "hash": "db31d465087f6650561d320051a7f772b095624a8979fae86cf4bca40e23551e", "class_name": "RelatedNodeInfo"}}, "text": "eExam.16\u2014Extremities Assessment\n\n5. 12-lead EKG Acquisition a. eTimes.06\u2014Unit Arrived on Scene Date/Time b. eTimes.07\u2014Arrived at Patient Date/Time c. EKG Rhythm Group [see Vitals section] d. Attach 12-lead graphic ePCR (through direct integration linkage with EKG monitor or attachment of scanned printout as allowed/available in software) e. 12-lead-EKG Procedure-documented under Procedures Performed Group\n\n6. Trauma/Injury\n\nGo To TOC\n\nAPPENDICES Rev. March 2022 II. Universal Documentation Guideline 367\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nThe exam fields have many useful values for documenting trauma (deformity, bleeding, burns, etc.). Use of targeted\ndocumentation of injured areas can be helpful, particularly in cases of more serious trauma. Because of the endless\npossible variations where this could be used, specific fields will not be defined here. Note, however that the exam\nfields use a specific and useful Pertinent Negative called \u201cExam Finding Not Present.\u201d This can be used to document\nthat the clinician actually performed the assessment but did not find any injury/abnormality.\n\n## Vitals\n\n1. Vitals Date/Time Group\n\na. eVitals.01\u2014Date/Time Vital Signs Taken\n\nb. eVitals.02\u2014Obtained Prior to this Unit's EMS Care\n\n2. Glasgow Coma Score (GCS) Group\n\na. Vitals Date/Time Group\n\nb. eVitals.19\u2014Glasgow Coma Score-Eye\n\nc. eVitals.20\u2014Glasgow Coma Score-Verbal\n\nd. eVitals.21\u2014Glasgow Coma Score-Motor\n\ne. eVitals.22\u2014Glasgow Coma Score-Qualifier\n\nf. eVitals.23\u2014Total Glasgow Coma Score\n\n3. EKG Rhythm Group\n\na. Vitals Date/Time Group\n\nb. eVitals.03\u2014Cardiac Rhythm/Electrocardiography (EKG)\n\nc. eVitals.04\u2014EKG Type\n\nd. eVitals.05\u2014Method of EKG Interpretation\n\n4. Temperature Group\n\na. Vitals Date/Time Group\n\nb. eVitals.24\u2014Temperature\n\nc. eVitals.25\u2014Temperature Method\n\n5. Pain Scale Group\n\na. Vitals Date/Time Group\n\nb. eVitals.27\u2014Pain Scale Score\n\nc. eVitals.28\u2014Pain Scale Type\n\n6. Stroke Score Group\n\na. Vitals Date/Time Group\n\nb. eVitals.29\u2014Stroke Scale Score\n\nc. eVitals.30\u2014Stroke Scale Type\n\n7. Additional Vitals Options\n\nAll should have a value in the Vitals Date/Time Group and can be documented individually or as an add-on to basic,\nstandard, or full vitals\n\na. eVitals.09\u2014Mean Arterial Pressure\n\nb. eVitals.13\u2014Pulse Rhythm\n\nc. eVitals.15\u2014Respiratory Effort\n\nd. eVitals.16\u2014End Tidal Carbon Dioxide (EtCO2)\n\ne. eVitals.17\u2014Carbon Monoxide (CO)\n\nf. eVitals.18\u2014Blood glucose Level\n\ng. eVitals.26\u2014Level of Responsiveness (AVPU)\n\nh. Vitals.32\u2014APGAR\n\n8. Routine Vitals \u2013 Includes the following vital signs:\n\n________________________ Go To TOC\n\nAPPENDICES Rev. March 2022\n\n## II. Universal Documentation Guideline\n\n368\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## II. Universal Documentation Guideline\n\na. Vitals Date/Time Group\n\nb. Blood Pressure\n\nc. eVitals.06\u2014SBP (Systolic Blood Pressure)\n\nd. eVitals.07\u2014DBP (Diastolic Blood Pressure)\n\ne. eVitals.10\u2014Heart Rate\n\nf. eVitals.12\u2014Pulse Oximetry\n\ng. eVitals.14\u2014Respiratory Rate\n\nh. eVitals.26\u2014Level of Responsiveness (AVPU)\n\ni. Pain Scale Group\n\n9.", "start_char_idx": 831938, "end_char_idx": 835059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6184f38-a493-4641-9867-f75845bd5b41": {"__data__": {"id_": "b6184f38-a493-4641-9867-f75845bd5b41", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03a9d552-7665-468e-aa4e-ea67146e55aa", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "1fe64ce17b74a0567a805e5d63a5cb6473d02055c455f7e48a395e05170e9425", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5144c4bc-c318-413d-b751-09541e4c8fb4", "node_type": "1", "metadata": {}, "hash": "42d031643e58fe7d2bd852f12367b6a7f4bbda9b1cf5df609bfd8fe6719e4fcf", "class_name": "RelatedNodeInfo"}}, "text": "Routine Vitals \u2013 Includes the following vital signs:\n\n________________________ Go To TOC\n\nAPPENDICES Rev. March 2022\n\n## II. Universal Documentation Guideline\n\n368\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## II. Universal Documentation Guideline\n\na. Vitals Date/Time Group\n\nb. Blood Pressure\n\nc. eVitals.06\u2014SBP (Systolic Blood Pressure)\n\nd. eVitals.07\u2014DBP (Diastolic Blood Pressure)\n\ne. eVitals.10\u2014Heart Rate\n\nf. eVitals.12\u2014Pulse Oximetry\n\ng. eVitals.14\u2014Respiratory Rate\n\nh. eVitals.26\u2014Level of Responsiveness (AVPU)\n\ni. Pain Scale Group\n\n9. Initial Vitals\n\na. Routine Vitals\n\nb. eVitals.18\u2014Blood glucose Level\n\nc. Glasgow Coma Score (GCS) Group\n\nd. Temperature Group\n\n10. Full Vitals\n\na. Initial Vitals\n\nb. eVitals.13\u2014Pulse Rhythm\n\nc. eVitals.15\u2014Respiratory Effort\n\nd. eVitals.16\u2014End Tidal Carbon Dioxide (EtCO2) (If available and applicable)\n\ne. EKG Rhythm Group (If available and applicable)\n\nMedications Given\n\n1. eMedications.01\u2014Date/Time Medication Administered\n\n2. eMedications.02\u2014Medication Administered Prior to this Unit's EMS Care\n\n3. eMedications.03\u2014Medication Given\n\na. Pertinent Negatives (medication qualifiers) allowed\n\ni. Contraindication Noted\n\nii. Medication Already Taken\n\niii. Denied By Order\n\niv. Refused\n\nv. Medication Allergy\n\nvi. Unable to Complete\n\n4. eMedications.04\u2014Medication Administered Route\n\n5. eMedications.05\u2014Medication Dosage\n\n6. eMedications.06\u2014Medication Dosage Units\n\n7. eMedications.07\u2014Response to Medication [see Definitions of Medication Response below]\n\n8. eMedications.08\u2014Medication Complication\n\n9. eMedications.09\u2014Medication Crew (Healthcare Professionals) ID (Name or license #)\n\n10. eMedications.10\u2014Role/Type of Person Administering Medication (License level)\n\nProcedures Performed\n\n1. eProcedures.01\u2014Date/Time Procedure Performed\n\n2. eProcedures.02\u2014Procedure Performed Prior to this Unit's EMS Care\n\n3. eProcedures.03 \u2013 Procedure\n\na. Pertinent Negatives Allowed\n\ni. Contraindication Noted\n\nii. Refused\n\niii. Denied By Order\n\nGo To TOC\n\n## APPENDICES\n\nRev. March 2022\n\n369\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### iv. Unable to Complete\n\n4. eProcedures.04\u2014Size of Procedure Equipment\n\n5. eProcedures.05\u2014Number of Procedure Attempts (This should always be \u201c1\u201d with each attempt at a procedure\ndocumented separately with appropriate date/time stamp)\n\n6. eProcedures.06\u2014Procedure Successful\n\n7. eProcedures.07\u2014Procedure Complication\n\n8. eProcedures.08\u2014Response to Procedure [see Definitions for Response to Procedures below]\n\n9. eProcedures.09\u2014Procedure Crew Members ID\n\n10. eProcedures.10\u2014Role/Type of Person Performing the Procedure\n\n11. eProcedures.13\u2014Vascular Access Location (If applicable)\n\n### Narrative\n\nThe use of the narrative is essential to an effective and complete Patient Care Record. It summarizes the incident\nhistory and care in a manner that is easily digested between caregivers for continuity of care and provides a place\nfor EMS to document facts that do not fit into fixed data fields [see Narrative Section under Notes/Educational\nPearls (below) for more detail]\n\n### Notes/Educational Pearls\n\nDocumenting Signs and Symptoms Versus Clinician Impressions\n\n1. Signs and Symptoms\n\na. Signs and Symptoms should support the clinician impressions, treatment guidelines and overall care given. A\nsymptom is something the patient experiences and tells the clinician; it is subjective. A sign is something the\nclinician sees; it is objective.\n\nb. Symptoms should not be confused with clinician impressions.", "start_char_idx": 834447, "end_char_idx": 838028, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5144c4bc-c318-413d-b751-09541e4c8fb4": {"__data__": {"id_": "5144c4bc-c318-413d-b751-09541e4c8fb4", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6184f38-a493-4641-9867-f75845bd5b41", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "3291d25412a0186d5d7a4f9460d2df567e52e312237ff6d50ee97b009d8b1067", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dda1f4e2-b735-4b4e-985a-8627419c5587", "node_type": "1", "metadata": {}, "hash": "ae3d8ffd61d128613f8e826affd203806744f1222402780d89c16ecbfb5c5feb", "class_name": "RelatedNodeInfo"}}, "text": "It summarizes the incident\nhistory and care in a manner that is easily digested between caregivers for continuity of care and provides a place\nfor EMS to document facts that do not fit into fixed data fields [see Narrative Section under Notes/Educational\nPearls (below) for more detail]\n\n### Notes/Educational Pearls\n\nDocumenting Signs and Symptoms Versus Clinician Impressions\n\n1. Signs and Symptoms\n\na. Signs and Symptoms should support the clinician impressions, treatment guidelines and overall care given. A\nsymptom is something the patient experiences and tells the clinician; it is subjective. A sign is something the\nclinician sees; it is objective.\n\nb. Symptoms should not be confused with clinician impressions. The clinician impressions are the EMS working field\ndiagnosis of the patient\u2019s actual medical condition.\n\n2. Clinician Impressions\n\na. There is often a great deal of confusion on the part of EMS clinicians about the difference between symptoms and\nclinician impressions. Clinician impressions should be supported by symptoms but not be the symptoms except on rare\noccasions where they may be the same (i.e., weakness when no etiology for the weakness can be determined by the EMS\nclinician).\n\nb. Correctly documenting impressions is essential to many aspects of EMS data use, such as EMS reimbursement, reports\nof incident types, specialty registries (e.g., CARES) and CPI reviews. EMS agencies could literally lose money or\nequipment and staffing resources if the clinicians are incorrectly entering clinician impressions. Addressing this\nissue should be an essential part of the record Quality Assurance and CPI process and documentation training.\n\nc. Example of documenting symptoms versus impressions:\n\ni. An opiate overdose patient who received naloxone and had a positive response. This patient would have possible\nSymptoms of altered mental status, unconscious, respiratory distress, and respiratory failure/apnea. All 4 of these\nsymptoms are available as clinician impressions, however the correct impression for this patient would be whatever\nvariation of \u201cDrug Overdose Opiates or Heroin\u201d impression(s) are setup in the local ePCR system being used. This\nimpression will specifically define the call as an overdose with opiates, rather than a case where one of the symptoms\nwas also used as an impression when the use of naloxone and other\n\n________________________ Go To TOC\n\n### APPENDICES\n\nRev. March 2022\n\n## II. Universal Documentation Guideline\n\n370\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nassessments and diagnostic tools could not determine an etiology for the symptom(s).\n\n## Narrative\n\nThe various data fields within the ePCR are important as they provide a means of uniformly entering incident data\nthat can be used for importing into billing software or hospital records, transmitting between EMS systems or creating\ndescriptive reports, or conducting research. In most cases, at a local, state, or national level, if something wasn\u2019t\ndocumented in the appropriate data field, it didn\u2019t happen or exist. However, the Narrative plays several essential\nroles in the PCR.\n\nRole of the Narrative\n\nProvides an efficient and effective means to share patient information for continuity of care between EMS\nservices and EMS and hospital staff. The narrative summarizes the incident history and care in a manner that is\neasily digested between caregivers.\nProvides a place for EMS to document facts that do not fit into fixed data fields. Specifically, this would\ninclude the detailed history of the scene, what the patient may have done or said or other aspects of thecal that\nonly the clinician saw, heard, or did. The Narrative is the place for the EMS clinician to \u201cpaint the picture\u201d for\nall others to more fully understand the incident.\nProvides a standard means to add essential details about medical history, exams, treatments, patient response,\nand changes in patient condition that can\u2019t otherwise be effectively or clearly communicated.\n\nNarrative Formats\nDocumentation by EMS clinicians demonstrates a wide variation of training and practice reinforcement. Most\ntraining programs provide limited instruction on how to properly document operational and clinical processes, and\nalmost no practice. Most clinicians learn this skill on the job, and often proficient mentors are sparse. Therefore,\nit is essential that the EMS clinician uses a standard format to ensure they are consistent and complete in their\ndocumentation. There are three standard formats for EMS documentation. EMS clinicians should choose the best match\nfor them, master the format, and be consistent in its use.\n\nMedical Narrative: This format is the one most new EMS clinicians use as it is intuitive and easy to learn.", "start_char_idx": 837307, "end_char_idx": 842077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dda1f4e2-b735-4b4e-985a-8627419c5587": {"__data__": {"id_": "dda1f4e2-b735-4b4e-985a-8627419c5587", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5144c4bc-c318-413d-b751-09541e4c8fb4", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "688eb8fcee7ce4e60a34185f94315145e25ad8bab1a9304791f3d84302263f1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae013a5a-6816-4183-bcff-ab09d23142ac", "node_type": "1", "metadata": {}, "hash": "5c4fc01e24377db36c9f481ef2e15a07d9b5347d7f5d546146512b37be51e1dd", "class_name": "RelatedNodeInfo"}}, "text": "Provides a standard means to add essential details about medical history, exams, treatments, patient response,\nand changes in patient condition that can\u2019t otherwise be effectively or clearly communicated.\n\nNarrative Formats\nDocumentation by EMS clinicians demonstrates a wide variation of training and practice reinforcement. Most\ntraining programs provide limited instruction on how to properly document operational and clinical processes, and\nalmost no practice. Most clinicians learn this skill on the job, and often proficient mentors are sparse. Therefore,\nit is essential that the EMS clinician uses a standard format to ensure they are consistent and complete in their\ndocumentation. There are three standard formats for EMS documentation. EMS clinicians should choose the best match\nfor them, master the format, and be consistent in its use.\n\nMedical Narrative: This format is the one most new EMS clinicians use as it is intuitive and easy to learn. Some\nmore experienced clinicians use it as they find telling the story from start to finish works best to organize their\nthoughts. A drawback to this method is that it is easy to forget to include facts because of the lack of\nstructure.\nSOAP: This format stands for Subjective, Objective, Assessment, Plan. This is a format that is very common in\nthe medical field.\nCHART: This format stands for Complaint, History, Assessment, Rx (Treatment) and Transport. Each section\u2019s\ncontent is clearly defined and consistent in format. It minimizes the likelihood of forgetting information and\nensures documentation is consistent between records and clinicians. CHART is the format most recommended as best\npractice by EMS legal authorities and is considered the standard in many EMS systems. A variation is DCHART,\nwhere the \u201cD\u201d stands for Dispatch (reason).\n\nMedications Given Showing Positive Action Using Pertinent Negatives\n\nFor medications that are required by protocol (i.e., aspirin for cardiac chest pain), pertinent negatives should be\nused to show that a medication protocol was considered but was satisfied by other than clinician action.\n\n________________________ Go To TOC\n\nAPPENDICES Rev. March 2022\n\n## II. Universal Documentation Guideline 371\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nExample: EMS is called to a patient for cardiac chest pain. The patient has already taken 324 mg of aspirin by the time EMS arrives per 911 pre-arrival instructions. EMS clinicians should document this as a medication given, prior-to-arrival, with the best estimated time, and qualify the medication as \u201cMedication Already Taken\u201d using the pertinent negative.\n\nDefinitions for Response to Medications\n\nImproved:\n\na. The medication had its intended therapeutic effect and the patient's symptoms decreased or clinical condition improved or resolved (the word \"effective\" could generally be substituted for \"improved\").\n\nb. If a patient had the intended therapeutic response to the medication, but a side effect that caused a clinical deterioration in another body system, then \"Improved\" should be chosen and the side effects documented as a complication (i.e., nitroglycerin improved chest pain but dropped the blood pressure).\n\nUnchanged:\n\na. The medication was ineffective and had no intended therapeutic effect or had a sub-therapeutic and unnoticeable effect, AND\n\nb. The patient condition did not deteriorate.\n\nWorse:\n\na. The patient condition deteriorated or continued to deteriorate because either the medication:\n\ni. Was ineffective and had no intended therapeutic effect; OR\n\nii. Had a sub-therapeutic effect that was unable to stop or reverse the decline in patient condition; OR\n\niii. Was the wrong medication for the clinical situation and the therapeutic effect caused the condition to worsen (i.e., giving glucose to a patient with hyperglycemia/diabetic ketoacidosis).\n\nDefinitions for Response to Procedures\n\nNot Applicable:\n\nThe nature of the procedure has no direct expected clinical response (i.e., patient assessment, 12-lead EKG acquisition).\n\nImproved:\n\na. The procedure performed had the intended effective outcome and/or the patient's symptoms decreased, or clinical condition improved or resolved (i.e., defibrillation resolved VF into a perfusing rhythm; intubation controlled the airway and allowed effective management of breathing).\n\nb. An effective procedure that caused an improvement in the patient condition may also have resulted in a procedure complication and the complication should be documented (i.e., intubation caused minor airway trauma, but the intubation successfully secured the airway).\n\nUnchanged:\n\na. The procedure performed did not have the clinical effect intended, but did not directly worsen the patient's symptoms or clinical condition (i.e., attempted defibrillation and\n\n________________________\n\nGo To TOC\n\nAPPENDICES\n\nRev. March 2022\n\n## II.", "start_char_idx": 841119, "end_char_idx": 846004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae013a5a-6816-4183-bcff-ab09d23142ac": {"__data__": {"id_": "ae013a5a-6816-4183-bcff-ab09d23142ac", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dda1f4e2-b735-4b4e-985a-8627419c5587", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "32659b1f6e2d11943b2ba66ca86b58a5afd8a881bab02825a70f8ba3dd7ba17b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c66dae90-73dd-45c5-bd42-a112fbb68f37", "node_type": "1", "metadata": {}, "hash": "b675ace8eed1d272f797fb3304289e5f864c71de5101f65c101e121274daae5d", "class_name": "RelatedNodeInfo"}}, "text": "Improved:\n\na. The procedure performed had the intended effective outcome and/or the patient's symptoms decreased, or clinical condition improved or resolved (i.e., defibrillation resolved VF into a perfusing rhythm; intubation controlled the airway and allowed effective management of breathing).\n\nb. An effective procedure that caused an improvement in the patient condition may also have resulted in a procedure complication and the complication should be documented (i.e., intubation caused minor airway trauma, but the intubation successfully secured the airway).\n\nUnchanged:\n\na. The procedure performed did not have the clinical effect intended, but did not directly worsen the patient's symptoms or clinical condition (i.e., attempted defibrillation and\n\n________________________\n\nGo To TOC\n\nAPPENDICES\n\nRev. March 2022\n\n## II. Universal Documentation Guideline\n\n372\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nthe person remained in VF);\n\nor\n\nb. Had a sub-therapeutic effect and the symptoms continued (i.e., a bandage applied to a bleeding wound failed to stop\nthe bleeding);\n\nor\n\nc. The nature of the procedure has no direct expected clinical response (i.e., patient assessment).\n\nNOTE: \"Not Applicable\" would also be appropriate to choose for these cases\n\n4. Worse:\n\na. The results of the procedure performed lead to a worsening of the patient's symptoms or condition (e.g., defibrillation\nconverted VF into asystole, application of a splint caused significant increase in pain or loss of sensation and pulses).\n\nb. In the case of worsening condition, documentation of the procedure complications may also be appropriate.\n\nc. NOTE: Just because a patient got worse, doesn\u2019t necessarily mean the clinician performed the procedure incorrectly.\n\nNEMSIS Data Standards and Limitations\n\n1. NEMSIS is a national dataset and standard used by all EMS software systems. (For additional information, go to www.nemsis.org.) Currently there are three versions of the data standard available for\ndocumentation and in which data is stored:\n\na. NEMSIS Version 2.2.1 (v2.2.1)\n\ni. Adopted in 2006, there have been no changes since release\n\nii. Most states or systems have used this standard since its release, and the majority of most states\u2019 data available\nsince approximately 2016 is in this format.\n\niii. NEMSIS accepted v2.2.1 data through 12/31/2016, and some states may continue to collect data in this standard\nuntil they transition to NEMSIS v3 standards.\n\nb. NEMSIS Version 3 (v3)\n\ni. NEMSIS v3 was created and finalized in 2011 to replace v2.2.1 in order to allow the dataset to become more flexible\nfor updates and adopt technical standards making linkage to other health records possible.\n\n1. NEMSIS v3.3.4 was released in March 2014 and was the first version in production where live data was collected by\nservices and states and subsequently submitted to NEMSIS. NEMSIS will continue to accept v3.3.4 data until 12/31/2017.\n\n2. NEMSIS v3.4, released in March 2015, included both changed elements and many added values to existing elements.\nNEMSIS has been accepting data from this version concurrently with V3.3.4 data. As of August 2021, v3.4 will be the only\nstandard and V3.3.4 will be phased out. All documentation guidelines found in this document are based on the NEMSIS\nv3.4 dataset and standard.\n\n2. Mandatory and Required Elements\n\nb. Mandatory: NEMSIS makes certain elements or fields mandatory so, if not included, the record cannot be properly\nstored or moved electronically. These fields require real data and do not accept Nil (Blank) values, Not Values, or\nPertinent Negatives.\n\nc. Required: NEMSIS requires these elements or fields to be completed or the record cannot be properly stored or moved\nelectronically. However, required fields allow Nil (blank) values, Not Values, or Pertinent Negatives to be entered and\nsubmitted.\n\n________________________ Go To TOC\n\nAPPENDICES Rev. March 2022\n\nII. Universal Documentation Guideline 373\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n### 3.", "start_char_idx": 845171, "end_char_idx": 849239, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c66dae90-73dd-45c5-bd42-a112fbb68f37": {"__data__": {"id_": "c66dae90-73dd-45c5-bd42-a112fbb68f37", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae013a5a-6816-4183-bcff-ab09d23142ac", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "11a4c67fc5a10ed0562b3eb16f233184e2a3c6c76fc7d8e1c3ff87ff7de052dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef6c0fba-cc33-4d7a-9d09-0f7e671e3175", "node_type": "1", "metadata": {}, "hash": "cca7b0a2ba112f92c23f639c516a6b9ca74d2d2c50d5481cbbf3b4b196788bd4", "class_name": "RelatedNodeInfo"}}, "text": "All documentation guidelines found in this document are based on the NEMSIS\nv3.4 dataset and standard.\n\n2. Mandatory and Required Elements\n\nb. Mandatory: NEMSIS makes certain elements or fields mandatory so, if not included, the record cannot be properly\nstored or moved electronically. These fields require real data and do not accept Nil (Blank) values, Not Values, or\nPertinent Negatives.\n\nc. Required: NEMSIS requires these elements or fields to be completed or the record cannot be properly stored or moved\nelectronically. However, required fields allow Nil (blank) values, Not Values, or Pertinent Negatives to be entered and\nsubmitted.\n\n________________________ Go To TOC\n\nAPPENDICES Rev. March 2022\n\nII. Universal Documentation Guideline 373\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n### 3. Not Values, Nil, and Pertinent Negatives\n\nb. Not Values (NV), Nil, and Pertinent Negatives (PN) are values that are attributes of certain NEMSIS elements designed to clarify a null data entry or qualify data entry into the element with which the NV, Nil, or PN is associated.\n\nc. Not Values available are \u201cNot Applicable\u201d and \u201cNot Recorded\u201d\n\ni. Some NEMSIS rules require one of these values to be entered when data is imported/exported if there is no other data in a field (e.g., at least one medication given must have a value, if no medications are given, then the software system must insert \u201cNot Applicable\u201d in the medications field when exporting)\n\nii. At times the EMS clinician use of \u201cNot Applicable\u201d is appropriate documentation (e.g., using \u201cNot Applicable\u201d under eInjury.03\u2014Trauma Center Criteria, per the ACS-COT 2022 National Guideline for the Field Triage of Injured Patients, when transporting a patient with a simple sprained ankle)\n\nd. Nil Values are blank values\n\ni. Values can be left blank, which can either be an accidental or purposeful omission of data.\n\nii. Value fields can appropriately and purposefully be left blank if there was nothing to enter (e.g., a procedure field left blank if no patient was encountered).\n\ne. Pertinent Negatives are attributes or qualifiers for both elements and fields. There are 11 possible Pertinent Negative values and the available list for each field varies as appropriate to the field. Two examples of the use of Pertinent Negatives are:\n\ni. Documenting non-administration of ASA for chest pain by the EMS clinician with the Pertinent Negative of \u201cMedication Already Taken\u201d to show evidence that this treatment requirement was met.\n\nii. Documenting assessment of, and lack of a gunshot wound to the chest with the qualifier of \u201cChest --> gunshot wound --> Exam Finding Not Present\u201d in the examination section (previously you could only document a positive finding of a gunshot wound with was no way to document that you looked and did not find one).\n\n### 4. NEMSIS Element and Value Name Formats\n\nb. NEMSIS Elements/Fields are organized into groups with other related elements/fields\n\ni. There are two parent datasets: Demographic (designated by a \u201cd\u201d) and EMS (designated by an \u201ce\u201d). The majority of the documentation in any ePCR falls in the \u201ce\u201d section. The Demographic dataset is intended to be descriptive of the EMS agencies and system characteristics for correlation at a larger research level, rather than for use in operational CPI reviews.\n\nii. The element numbering structure reflects the dataset and the text group name of the element\n\n### 5. Example: \u201ceVitals.06\u2014SBP (Systolic Blood Pressure)\u201d where \u201ce\u201d is the EMS dataset and \u201cVitals\u201d is the dataset grouping for all elements related to Vitals and the number is the number assigned to a specific element.\n\nb. \u201ceVitals.06\u201d is used to store the data in the background and \u201cSBP (Systolic Blood Pressure)\u201d is what clinicians and reviewers see.\n\nc. Values are designated by a code and text name.\n\n________________________ Go To TOC\n\n### APPENDICES\n\nRev. March 2022\n\n### II. Universal Documentation Guideline\n\n374\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n#### i. The codes are generally derived from various sources such as ICD-10, SNOMED, or RxNorm and are used to store\nand move the data in the system\u2019s background.\n\n#### ii.", "start_char_idx": 848409, "end_char_idx": 852619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef6c0fba-cc33-4d7a-9d09-0f7e671e3175": {"__data__": {"id_": "ef6c0fba-cc33-4d7a-9d09-0f7e671e3175", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c66dae90-73dd-45c5-bd42-a112fbb68f37", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "96490035f11f53832f7993b2d436c7fed0058bc44bd01859f59b024b46dd1ee5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c22fcf0b-3a5e-464f-824a-d4cc09fa7d4f", "node_type": "1", "metadata": {}, "hash": "c4477d6dfb5a846d0db3686c1a929fb355f8087cc8f2cf98b47cdf094274dd45", "class_name": "RelatedNodeInfo"}}, "text": "b. \u201ceVitals.06\u201d is used to store the data in the background and \u201cSBP (Systolic Blood Pressure)\u201d is what clinicians and reviewers see.\n\nc. Values are designated by a code and text name.\n\n________________________ Go To TOC\n\n### APPENDICES\n\nRev. March 2022\n\n### II. Universal Documentation Guideline\n\n374\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n#### i. The codes are generally derived from various sources such as ICD-10, SNOMED, or RxNorm and are used to store\nand move the data in the system\u2019s background.\n\n#### ii. Codes are not seen by the EMS clinician in the ePCR, but rather the clinician will see text names. Some software\nsystems allow the visible text name to be modified or relabeled to meet local standards or nomenclature; This feature\ncan help improve data quality by making documentation easier for the clinician.\n\n#### iii. An example of a value code and name for cardiac chest pain, found under the element \u201ceProtocols.01\u2014Protocols\nUsed\u201d is \u201c9914117 \u2013 Medical-Cardiac Chest Pain\u201d.\n\n#### d. All minimum general documentation guideline requirements are identified using the NEMSIS element, values codes,\nand names to allow application across a variety of ePCR software labels for these fields.\n\n### 6. Custom Elements/Fields and Values\n\n#### b. The NEMSIS Standard provides a data format for software vendors to create custom elements or values requested\nby states or local systems.\n\n#### c. States or local systems may create new elements or value extensions for existing NEMSIS elements to meet regional\nneeds (e.g., adding additional protocol name values not on the NEMSIS list).\n\n### Airway Confirmation Fields\n\nSpecific use of the NEMSIS airway confirmation fields in documentation will not be detailed at this time due to current\noperational and technical challenges all states, local systems, and ePCR software vendors are experiencing.\n\nThe NEMSIS airway confirmation fields were closely modeled on the \u201cRecommended Guidelines for Uniform Reporting\nof Data from Out-of-Hospital Airway Management: Position Statement of the National Association of EMS Physicians\u201d\nand the fields and values could provide excellent and appropriately useful data to evaluate airway management. However,\nthe technical structure of the fields has made their practical use limited as all the data is collected as a separate,\nself-contained group, rather than as part of the procedures group. This means EMS clinicians would need to enter much\nof the same information twice in the ePCR, in both the procedures area and airway confirmation section (when, who\ndid it, what device was used, and complications). Furthermore, the airway group can only be entered once per ePCR,\nso the fields cannot be used again if more than one airway was required (e.g., one airway became ineffective and needed\nto be replaced with a different type of airway). Many states and ePCR software vendors have been struggling with how\nto make these fields functional for use by only using a portion of them or looking to add mirrored custom values that\nare directly linked to procedures performed. However, solutions are currently far from practical, functional, effective,\nor uniform in how they are being implemented or used across various systems.\n\n### References\n\nNational Association of EMS Officials, Data Mangers Council. Extended data definitions, NEMSIS Version 3.4.0.\nhttps://www.nasemso.org/Councils/DataManagers/documents/Extended-Data-Definitions_v3_Final.pdf\nPublished May 2016.\nNational EMS Information System Technical Assistance Center. NEMSIS data dictionary, NHTSA v3.4.0, Build 160713\nCritical Patch 2, EMS Data Standard.\n\n________________________\n\nGo To TOC\n\n### APPENDICES\n\nRev. March 2022\n\n## II. Universal Documentation Guideline\n\n375\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nhttps://nemsis.org/media/nemsis_v3/release-3.4.0/DataDictionary/PDFHTML/DEMEMS/NEMSISDataDictionary.pdf. Updated July 13, 2016.\n\n3. Wang HE, Domeier RM, Kupas DF, Greenwood MJ, O'Connor RE. Recommended guidelines for uniform reporting of data from out-of-hospital airway management: position statement of the national association of EMS physicians. Prehosp Emerg Care 2004;8(1):58-72.\n\nRevision Date\n\nMarch 11, 2022\n\n________________________\n\nGo To TOC\n\nAPPENDICES\n\nRev. March 2022\n\n## II.", "start_char_idx": 852071, "end_char_idx": 856398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c22fcf0b-3a5e-464f-824a-d4cc09fa7d4f": {"__data__": {"id_": "c22fcf0b-3a5e-464f-824a-d4cc09fa7d4f", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef6c0fba-cc33-4d7a-9d09-0f7e671e3175", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "1c264d10fd4f19fb2a846d72c78137a9eb97fa1cee896e808980e648da482142", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbae228d-276d-492f-bd05-518d623a5f26", "node_type": "1", "metadata": {}, "hash": "421550c2c595c8d23738725bc815a3ab8715762e0cad56867616b2efdd3030b8", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n## II. Universal Documentation Guideline\n\n375\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nhttps://nemsis.org/media/nemsis_v3/release-3.4.0/DataDictionary/PDFHTML/DEMEMS/NEMSISDataDictionary.pdf. Updated July 13, 2016.\n\n3. Wang HE, Domeier RM, Kupas DF, Greenwood MJ, O'Connor RE. Recommended guidelines for uniform reporting of data from out-of-hospital airway management: position statement of the national association of EMS physicians. Prehosp Emerg Care 2004;8(1):58-72.\n\nRevision Date\n\nMarch 11, 2022\n\n________________________\n\nGo To TOC\n\nAPPENDICES\n\nRev. March 2022\n\n## II. Universal Documentation Guideline\n\n376\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### III. Medications\n\nThe project team considered the use of Institute for Safe Medication Practices (ISMP) Tall Man Letters methodology\nto avoid the miscommunication of lookalike drug names. Upon review of the list and the limited number of medications\ncarried by EMS, as well as the expected use of this document, it was elected not to institute this measure into our\nmedication list. We recommend EMS agencies consider incorporating these measures into practice where appropriate.\n\nAdditional information regarding Tall Man Letters can be found on the ISMP website:\nhttp://www.ismp.org/tools/tallmanletters.pdf and the US\nFood and Drug Administration website:\nhttp://www.fda.gov/Drugs/DrugSafety/MedicationErrors/ucm164587.htm.\n\nReference: Trade names, class, pharmacologic action and contraindications (relative and absolute) information from\nthe website http://www.medscape.com, accessed October 23, 2021. Additional\nreferences include the 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency\nCardiovascular Care, position statements from the American Academy of Clinical Toxicology and the European\nAssociation of Poison Control Centers\n(http://clintox.org/documents/positionpapers/Cathartics.pdf),\nand the article: Rodrigo GJ, Pollack CV, Rodrigo C, Rowe BH. Heliox for non-intubated acute asthma patients.\nCochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD002884.\n\nNOTE: Not all contraindications listed on the http://www.medscape.com website\nwere included for the purposes of this document. Contraindications which were not pertinent to EMS clinicians were\nnot included for the purposes of streamlining this document.\n\n### Medication List\n\n|Acetazolamide|Name \u2014 Diamox Sequels\u00ae|\n|---|---|\n| |Class \u2014 Carbonic anhydrase inhibitors|\n| |Pharmacologic Action\u2014Inhibits hydrogen ion excretion in renal tubule, increasing sodium, potassium, bicarbonate,         and water excretion and producing alkaline diuresis|\n| |Indications \u2014 Acute mountain sickness|\n| |Contraindications \u2014 Known hypokalemia/hyponatremia, hypersensitivity to acetazolamide or sulfa, liver disease,         renal disease, cirrhosis, long term administration in patients with chronic, noncongestive angle-closure glaucoma|\n|Acetaminophen|Name \u2014 There are multiple over-the-counter medications, as well as scheduled drugs, that include acetaminophen         (Tylenol\u00ae) as an active ingredient|\n| |Class \u2014 Analgesics, antipyretic, other|\n| |Pharmacologic Action\u2014May work peripherally to block pain impulse generation; may also inhibit prostaglandin         synthesis in CNS|\n| |Indications\u2014Pain control, fever control|\n| |Contraindications\u2014Hypersensitivity, severe acute liver disease|\n|Acetic acid (vinegar)|Name\u2014Vinegar|\n| |Class \u2014 Other|\n\n________________________ Go To TOC\n\nAPPENDICES Rev. March 2022\n\nIII.", "start_char_idx": 855777, "end_char_idx": 859355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbae228d-276d-492f-bd05-518d623a5f26": {"__data__": {"id_": "cbae228d-276d-492f-bd05-518d623a5f26", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c22fcf0b-3a5e-464f-824a-d4cc09fa7d4f", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "4f80dbca48376b87a64dbfb74e0684690240ef2de85c9efaab31bb42c99038c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a7d110e-2a45-457a-99df-fbc22fdbf4c4", "node_type": "1", "metadata": {}, "hash": "105bfae27f30b998a508173fbf5fec6be48b9459f2ff424e3513989278216c11", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nIII. Medications 377\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n## Pharmacologic Action\n\n\u2014 Stabilizes nematocyst discharge in non-United States jellyfish thus decreasing pain\n\n### Indications\n\nPain control for jellyfish envenomation (outside of the United States (US))\n\n### Contraindications\n\nMay increase nematocyst discharge for US jellyfish and therefore should be used outside of the US only\n\n## Acetylcysteine\n\nName\u2014Mucomyst\u00ae, Acetadote\u00ae\n\nClass \u2014 Antidotes, other\n\n### Pharmacologic Action\n\nActs as sulfhydryl group donor to restore liver glutathione; may also scavenge free radicals to prevent delayed hepatotoxicity as antioxidant; encourages sulfation pathway of metabolism for acetaminophen\n\n### Indications\n\nAntidote for acetaminophen overdose\n\n### Contraindications\n\nAcute asthma\n\nWARNING: Nausea and vomiting are common adverse effects following the oral administration of acetylcysteine\n\n## Activated Charcoal\n\nName \u2014 Actidose-Aqua\u00ae\n\nClass \u2014 Antidotes, other\n\n### Pharmacologic Action\n\nAdsorbs a variety of drugs and chemicals (e.g., physical binding of a molecule to the surface of charcoal particles); desorbtion of bound particles may occur unless the ratio of charcoal to toxin is extremely high\n\n### Indications\n\nOverdose and poisoning\n\n### Contraindications\n\nUnprotected airway (beware of aspiration), caustic ingestions, intestinal obstruction\n\n## Adenosine\n\nName \u2014 Adenocard\u00ae\n\nClass \u2014 Antidysrhythmics\n\n### Pharmacologic Action\n\nSlows conduction through AV node and interrupts AV reentry pathways, which restore normal sinus symptoms\n\n### Indications\n\nConversion of regular, narrow complex tachycardia \u2013 stable supraventricular tachycardia (SVT) or regular, monomorphic wide complex tachycardia\n\n### Contraindications\n\nHypersensitivity, second- or third-degree AV Block (except those on pacemakers), sick sinus syndrome, atrial flutter or fibrillation, ventricular tachycardia\n\n## Albuterol\n\nName \u2014 Proventil\u00ae, Ventolin\u00ae, Proair\u00ae, Accuneb\u00ae\n\nClass \u2014 Beta-2 agonist\n\n### Pharmacologic Action\n\nBeta-2 receptor agonist with some beta-1 activity; relaxes bronchial smooth muscle with little effect on heart rate\n\n### Indications\n\nBronchospastic lung disease\n\n### Contraindications\n\nHypersensitivity, tachycardia secondary to heart condition\n\n## Amiodarone\n\nName \u2014 Pacerone\u00ae, Cordarone\u00ae, Nexterone\u00ae\n\nClass \u2014 Class III antidysrhythmics\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nPharmacologic Action \u2014 Class III antidysrhythmic agent, which inhibits adrenergic stimulation; affects sodium, potassium, and calcium channels; markedly prolongs action potential and repolarization; decreases AV conduction and sinus node function\n\nIndications \u2014 Management of regular wide complex tachycardia in stable patients, irregular wide complex tachycardia in stable patients, and as antidysrhythmic for the management of ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT)\n\nContraindications \u2014 Hypersensitivity, Severe sinus node dysfunction, second degree or third-degree heart block or bradycardia causing syncope (except with functioning artificial pacemaker), cardiogenic shock\n\nWARNING: Avoid during breastfeeding\n\nAmyl Nitrite\n\nName \u2014 component of the Cyanide Antidote Kit\u00ae\n\nClass \u2014 Cyanide antidote\n\nPharmacologic Action \u2014 Reacts with hemoglobin to form methemoglobin, an oxidized form of hemoglobin incapable of oxygen transport but with high affinity for cyanide. Cyanide preferentially binds to methemoglobin over cytochrome a3, forming the nontoxic cyanomethemoglobin\n\nIndications \u2014 Acute cyanide toxicity\n\nContraindications \u2014 None in the case of suspected pure cyanide toxicity noted, documented hypersensitivity, suspected or confirmed smoke inhalation and/or carbon monoxide poisoning\n\nWARNING: There is a risk of worsening hypoxia due to methemoglobin formation\n\nAspirin\n\nName \u2014 Multiple over-the-counter medications, as well as scheduled drugs, include aspirin as an active ingredient.", "start_char_idx": 859339, "end_char_idx": 863340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a7d110e-2a45-457a-99df-fbc22fdbf4c4": {"__data__": {"id_": "1a7d110e-2a45-457a-99df-fbc22fdbf4c4", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbae228d-276d-492f-bd05-518d623a5f26", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "d7bad91280ff5de7afa1e352844ec68a10cc4075283828d0f10da2911cbcb21d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de30defa-b6e4-4c02-8bf6-4d821664b776", "node_type": "1", "metadata": {}, "hash": "e4a10e0fe589932d9f7a21caf56c6b9d50dfdf7b788ce4d0d26d7d149352d873", "class_name": "RelatedNodeInfo"}}, "text": "Cyanide preferentially binds to methemoglobin over cytochrome a3, forming the nontoxic cyanomethemoglobin\n\nIndications \u2014 Acute cyanide toxicity\n\nContraindications \u2014 None in the case of suspected pure cyanide toxicity noted, documented hypersensitivity, suspected or confirmed smoke inhalation and/or carbon monoxide poisoning\n\nWARNING: There is a risk of worsening hypoxia due to methemoglobin formation\n\nAspirin\n\nName \u2014 Multiple over-the-counter medications, as well as scheduled drugs, include aspirin as an active ingredient. These include, but are not limited to, Bayer Buffered Aspirin\u00ae, Alka-Seltzer with Aspirin\u00ae, Ascriptin\u00ae, Bayer Women\u2019s Low Dose\u00ae, Ecotrin\u00ae\n\nClass \u2014 Antiplatelet agent, non-steroidal anti-inflammatory drug (NSAID)\n\nPharmacologic Action \u2014 Inhibits synthesis of prostaglandin by cyclooxygenase; inhibits platelet aggregation; has antipyretic and analgesic activity\n\nIndications \u2014 Antiplatelet agent for the care of patients suspected of suffering from an acute coronary syndrome\n\nContraindications \u2014 Hypersensitivity to aspirin or NSAIDs (aspirin-associated hypersensitivity reactions include aspirin-induced urticarial or aspirin-intolerant asthma), bleeding GI ulcers, hemolytic anemia from pyruvate kinase (PK) and glucose-6-phosphate dehydrogenase (G6PD) deficiency, hemophilia, hemorrhagic diathesis, hemorrhoids, lactating mother, nasal polyps associated with asthma, sarcoidosis, thrombocytopenia, ulcerative colitis\n\nAtropine\n\nName \u2014 Atropen\u00ae, a component of Mark I\u00ae kits and DuoDote\u00ae\n\nClass \u2014 Anticholinergic, toxicity antidotes\n\nPharmacologic Action \u2014 Competitively inhibits action of acetylcholinesterase on autonomic effectors innervated by postganglionic nerves\n\nIndications \u2014 Management of nerve agent toxicity, symptomatic bradycardia (primary or related to toxin ingestion), organophosphate and carbamate insecticide toxicity\n\nNOTE: Ineffective in hypothermic bradycardia\n\nContraindications \u2014 No absolute contraindications for ACLS, documented hypersensitivity in non- ACLS/nerve agent/organophosphate scenarios\n\n________________________\n\nGo To TOC\n\nAPPENDICES\n\nRev. March 2022\n\nIII. Medications\n\n379\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n## RELATIVE CONTRAINDICATIONS:\n\nNarrow-angle glaucoma, GI obstruction, severe ulcerative colitis, toxic megacolon, bladder outlet obstruction,\nmyasthenia gravis, hemorrhage w/cardiovascular instability, thyrotoxicosis\n\n## Calcium Chloride\n\n|Name|Calcium Chloride|\n|---|---|\n|Class|Antidotes, other; calcium salts|\n|Pharmacologic Action|Bone mineral component; cofactor in enzymatic reactions, essential for neurotransmission, muscle contraction,         and many signal transduction pathways|\n|Indications|For use in topical burns (hydrofluoric acid) or for use in calcium channel blocker overdose|\n|Contraindications|Hypercalcemia, documented hypersensitivity, life-threatening cardiac arrhythmias may occur in known or         suspected severe hypokalemia|\n\nWARNING: There is a risk for digitalis toxicity.", "start_char_idx": 862812, "end_char_idx": 865840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de30defa-b6e4-4c02-8bf6-4d821664b776": {"__data__": {"id_": "de30defa-b6e4-4c02-8bf6-4d821664b776", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a7d110e-2a45-457a-99df-fbc22fdbf4c4", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "edd2fef6f5d24c7a115b856b60cbea9b83308f8ff8b28a0c73c253f1ba1ebfcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca75fa2d-ecab-4b75-b875-3eefa9cac1c3", "node_type": "1", "metadata": {}, "hash": "c0f55b71b527392539a88db4def8734ae6903bf4e5ce2b76a9328e07ca3856c6", "class_name": "RelatedNodeInfo"}}, "text": "Be cautious of peripheral IV use as significant tissue necrosis at\ninjection site may occur\n\n## Calcium Gluconate\n\n|Name|Gluconate\u00ae|\n|---|---|\n|Class|Antidotes, other; calcium salts|\n|Pharmacologic Action|Bone mineral component; cofactor in enzymatic reactions, essential for neurotransmission, muscle contraction,         and many signal transduction pathways|\n|Indications|For use in topical burns (hydrofluoric acid) or for use in calcium channel blocker overdose|\n|Contraindications|Hypercalcemia, documented hypersensitivity, sarcoidosis, life-threatening cardiac arrhythmias may occur in         known or suspected severe hypokalemia|\n\nWARNING: There is a risk for digitalis toxicity\n\n## Cimetidine\n\n|Name|Tagamet\u00ae|\n|---|---|\n|Class|Histamine H2 antagonist|\n|Pharmacologic Action|blocks H2-receptors of gastric parietal cells, leading to inhibition of gastric secretions|\n|Indications|For the management of gastric or duodenal ulcers, gastroesophageal reflux, as an adjunct in the treatment of         urticarial and/or pruritis in patients suffering from allergic reaction|\n|Contraindications|Hypersensitivity to cimetidine or other H2-receptor antagonists|\n\n## Dexamethasone\n\n|Name|Decadron\u00ae, Dexasone\u00ae|\n|---|---|\n|Class|Corticosteroid, anti-inflammatory drugs|\n|Pharmacologic Action|Potent glucocorticoid with minimal to no mineralocorticoid activity Decreases inflammation by suppressing         migration of polymorphonuclear leukocytes (PMNs) and reducing capillary permeability; stabilizes cell and         lysosomal membranes, increases surfactant synthesis, increases serum vitamin A concentration, and inhibits         prostaglandin and proinflammatory cytokines; suppresses lymphocyte proliferation through direct cytolysis,         inhibits mitosis, breaks down granulocyte aggregates, and improves pulmonary microcirculation|\n|Indications|Used in the management of croup and bronchospasm, as well as the management of patients suffering from high         altitude cerebral edema (HACE)|\n|Contraindications|Documented hypersensitivity, systemic fungal infection, cerebral malaria|\n\n## Dextrose\n\nGo To TOC\n\n### APPENDICES\n\nRev. March 2022\n\n### III. Medications\n\n380\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n|Name|Class|Pharmacologic Action|Indications|Contraindications|\n|---|---|---|---|---|\n|D50W, DGlucose, glucose|Glucose-elevating agents; metabolic and endocrine, other|Parenteral dextrose is oxidized to carbon dioxide and water, and provides 3.4 kilocalories/gram of d-glucose|Used for the management of hypoglycemia|Hyperglycemia, anuria, diabetic coma, intracranial or intraspinal hemorrhage, dehydrated patients with delirium, glucose-galactose malabsorption syndrome, and documented hypersensitivity|\n|Valium, Diastat, AcuDial|Benzodiazepine, anticonvulsants, skeletal muscle relaxants, anxiolytic|Modulates postsynaptic effects of GABA-A transmission, resulting in an increase in presynaptic inhibition. Appears to act on part of the limbic system, as well as on the thalamus and hypothalamus, to induce a calming effect|For use in agitated or violent patients, as well as for the management of seizures|Documented hypersensitivity, severe respiratory depression|\n|Includes Cardizem, Dilacor, Diltiaz|Calcium channel blocker, antidysrhythmic type IV|Inhibits extracellular calcium ion influx across membranes of myocardial cells and vascular smooth muscle cells, resulting in inhibition of cardiac and vascular smooth muscle contraction and thereby dilating main coronary and systemic arteries; no effect on serum calcium concentrations; substantial inhibitory effects on cardiac conduction system, acting principally at AV node, with some effects at sinus node|For management of narrow complex tachycardias|Documented hypersensitivity, Wolff-Parkinson-White syndrome, Lown-Ganong-Levine syndrome, symptomatic severe hypotension (systolic BP less than 90 mmHg), sick sinus syndrome (if no pacemaker), second- and third-degree heart block (if no pacemaker present), and complete heart block.", "start_char_idx": 865841, "end_char_idx": 869900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca75fa2d-ecab-4b75-b875-3eefa9cac1c3": {"__data__": {"id_": "ca75fa2d-ecab-4b75-b875-3eefa9cac1c3", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de30defa-b6e4-4c02-8bf6-4d821664b776", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "56104da15211a935c0280f46e4c4cdcbb4994ee29f91590857963c4995737428", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8abea84-fbe2-4f3e-926d-f3f6a3fa15a9", "node_type": "1", "metadata": {}, "hash": "71b63c55078f926651361ff05429feea70e23415c4b955532ddfdc1fe6849161", "class_name": "RelatedNodeInfo"}}, "text": "Contraindications for IV administration: Use in newborns (because of benzyl alcohol), concomitant beta-blocker therapy, cardiogenic shock, ventricular tachycardia (must determine whether origin is supraventricular or ventricular)|\n|Benadryl|Antihistamine - first generation|Histamine H1-receptor antagonist of effector cells in respiratory tract, blood vessels, and GI smooth muscle|For urticarial and/or pruritis in the management of patients suffering from allergic reaction as well as for the management of patents suffering from dystonia/akathisia|Documented hypersensitivity, use controversial in lower respiratory tract disease (such as acute asthma), premature infants and neonates|\n|Intropin|Inotropic agent; catecholamine; pressor| | | |\n\n________________________\n\nGo To TOC\n\n## APPENDICES\n\nRev. March 2022\n\n### III. Medications\n\n381\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n# National Model EMS Clinical Guidelines Version 3.0\n\nPharmacologic Action \u2014 Endogenous catecholamine, acting on both dopaminergic and adrenergic neurons. Low dose stimulates mainly dopaminergic receptors, producing renal and mesenteric vasodilation; higher dose stimulates both beta-1-adrenergic and dopaminergic receptors, producing cardiac stimulation and renal vasodilation; large dose stimulates alpha-adrenergic receptors\n\nIndications \u2014 As a pressor agent used in the management of shock\n\nContraindications \u2014 Hypersensitivity to dopamine, pheochromocytoma, ventricular fibrillation, uncorrected tachyarrhythmias\n\nWARNING: Dopamine is a vesicant and can cause severe tissue damage if extravasation occurs\n\n## Droperidol\n\nName \u2014 Inapsine\u00ae\n\nClass \u2014 Antiemetic agents; antipsychotic\n\nPharmacologic Action \u2014 Antiemesis: dopamine receptor blockade in brain, predominantly dopamine-2 receptor. When reuptake is prevented, a strong antidopaminergic, antiserotonergic response occurs. Droperidol reduces motor activity, anxiety, and causes sedation; also possesses adrenergic blocking, antifibrillatory, antihistaminic, and anticonvulsive properties\n\nIndications \u2014 For use in the patient with acute delirium or psychosis\n\nContraindications \u2014 Hypersensitivity, known or suspected prolonged QT interval; QTc interval greater than 450 msec in females or greater than 440 msec in males\n\nWARNING: Use with caution in patients with bradycardia, cardiac disease, concurrent MAO inhibitor therapy, Class I and Class III dysrhythmics or other drugs that prolong the QT interval and cause electrolyte disturbances due to its adverse cardiovascular effects, e.g., QT prolongation, hypotension, tachycardia, and torsades de pointes\n\n## Epinephrine\n\nName \u2014 EpiPen\u00ae, TwinJect\u00ae, Adrenaclick\u00ae, Auvi-Q, Adrenalin\u00ae, AsthmaNefrin\u00ae, Vaponefrin\u00ae\n\nClass \u2014 Alpha/beta adrenergic agonist\n\nPharmacologic Action \u2014 Strong alpha-adrenergic effects, which cause an increase in cardiac output and heart rate, a decrease in renal perfusion and peripheral vascular resistance, and a variable effect on BP, resulting in systemic vasoconstriction and increased vascular permeability. Strong beta-1- and moderate beta-2-adrenergic effects, resulting in bronchial smooth muscle relaxation. Secondary relaxation effect on smooth muscle of stomach, intestine, uterus, and urinary bladder\n\nIndications \u2014 For use in the management of patients suffering anaphylaxis, shock, cardiac arrest, bradycardia, or in the nebulized form for croup/bronchiolitis and IM form for refractory acute asthma\n\nContraindications \u2014 Hypersensitivity, cardiac dilatation and coronary insufficiency\n\n## Famotidine\n\nName \u2014 Pepcid\u00ae\n\nClass \u2014 Histamine H2 antagonist\n\nPharmacologic Action \u2014 Blocks H2 receptors of gastric parietal cells, leading to inhibition of gastric secretions\n\nIndications \u2014 For the management of gastric or duodenal ulcers, gastroesophageal reflux, as an adjunct in the treatment of urticarial and/or pruritus in patients suffering from allergic reaction\n\nContraindications \u2014 Hypersensitivity to famotidine or other H2-receptor antagonists\n\n## Fentanyl\n\nName \u2014Currently only available in the generic form (formerly Sublimaze\u00ae)\n\nClass \u2014 Synthetic opioid, opioid analgesics\n\nAPPENDICES Rev. March 2022 III.", "start_char_idx": 869901, "end_char_idx": 874059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8abea84-fbe2-4f3e-926d-f3f6a3fa15a9": {"__data__": {"id_": "a8abea84-fbe2-4f3e-926d-f3f6a3fa15a9", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca75fa2d-ecab-4b75-b875-3eefa9cac1c3", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "275067ad0d8b12ed5da9e342fe1eb305e2d81bd273dc569453685f822623c682", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cd11053-59b9-4bd1-aa0f-ce84f91393d4", "node_type": "1", "metadata": {}, "hash": "0cb0e0c865ed81da6b61422d243217f6c39d83cbea77047422a780cc3b8050bb", "class_name": "RelatedNodeInfo"}}, "text": "March 2022 III. Medications 382\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nPharmacologic Action \u2014 Narcotic agonist-analgesic of opiate receptors; inhibits ascending pain pathways, thus altering response to pain; increases pain threshold; produces analgesia, respiratory depression, and sedation\n\nIndications \u2014 Management of acute pain\n\nContraindications \u2014 Hypersensitivity\n\nWARNING: Should be used with caution in the elderly and in patients with hypotension, suspected gastrointestinal obstruction, head injury, and concomitant CNS depressants\n\nGlucagon\n\nName \u2014 GlucaGen\u00ae, Glucagon Emergency Kit\u00ae, GlucaGen HypoKit\u00ae\n\nClass \u2014 Hypoglycemia antidotes, glucose-elevating agents, other antidotes (e.g., beta-blocker or calcium channel blocker overdose)\n\nPharmacologic Action \u2014 Insulin antagonist. Stimulates cAMP synthesis to accelerate hepatic glycogenolysis and gluconeogenesis. Glucagon also relaxes smooth muscles of GI tract\n\nIndications \u2014 For the management of hypoglycemic patients as well as patients suffering symptomatic bradycardia after beta blocker or calcium channel blocker overdose\n\nContraindications \u2014 Hypersensitivity, pheochromocytoma, insulinoma\n\nWARNING: Nausea and vomiting are common adverse effects following the administration of glucagon\n\nHaloperidol\n\nName \u2014 Haldol\u00ae, Haldol Decanoate\u00ae, Haloperidol LA\u00ae, Peridol\u00ae\n\nClass \u2014 First generation antipsychotic\n\nPharmacologic Action \u2014 Antagonizes dopamine-1 and dopamine-2 receptors in brain; depresses reticular activating system and inhibits release of hypothalamic and hypophyseal hormones\n\nIndications \u2014 For the management of acute psychosis or agitated/violent behavior refractory to non-pharmacologic interventions\n\nContraindications \u2014 Documented hypersensitivity, Severe CNS depression (including coma), neuroleptic malignant syndrome, poorly controlled seizure disorder, Parkinson\u2019s disease\n\nWARNING: Risk of sudden death, torsades de pointes, and prolonged QT interval from off-label IV administration of higher than recommended dose. Continuous cardiac monitoring is required if administering IV\n\nHelium Gas Mixture\n\nName \u2014 Heliox\u00ae\n\nClass \u2014 Optional method of oxygen delivery\n\nPharmacology \u2014 Less resistant than atmospheric air which may reduce the patient\u2019s work of breathing by increasing tendency to laminar flow and reducing resistance to turbulent flow\n\nIndications \u2014 Persistent or severe bronchospasm in non-intubated patients with obstructive airway disease or pediatric patients with croup that is unresponsive to all other evidence-based medical interventions.\n\nContraindications \u2014 None\n\nHydralazine\n\nName \u2014 No listed brand name\n\nClass \u2014 Vasodilator\n\nPharmacology \u2014 Direct vasodilator at the level of arterioles, with little effect on veins. Decreases systemic resistance.\n\nIndications \u2014 Severe hypertension with pre-eclampsia symptoms\n\nAPPENDICES\n\nIII. Medications\n\nRev.", "start_char_idx": 874044, "end_char_idx": 876929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cd11053-59b9-4bd1-aa0f-ce84f91393d4": {"__data__": {"id_": "0cd11053-59b9-4bd1-aa0f-ce84f91393d4", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8abea84-fbe2-4f3e-926d-f3f6a3fa15a9", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8f9d091638e362c1ef130466a47e12b2ea5c797422dcbe99d4325053a3c8741e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a1c028c-1af7-46de-afc8-4d3e3802f39d", "node_type": "1", "metadata": {}, "hash": "a492a8b14d55dbcf4c5a62c25e8e1b7a40a0ca8f495b92af3327b765e61a6145", "class_name": "RelatedNodeInfo"}}, "text": "Continuous cardiac monitoring is required if administering IV\n\nHelium Gas Mixture\n\nName \u2014 Heliox\u00ae\n\nClass \u2014 Optional method of oxygen delivery\n\nPharmacology \u2014 Less resistant than atmospheric air which may reduce the patient\u2019s work of breathing by increasing tendency to laminar flow and reducing resistance to turbulent flow\n\nIndications \u2014 Persistent or severe bronchospasm in non-intubated patients with obstructive airway disease or pediatric patients with croup that is unresponsive to all other evidence-based medical interventions.\n\nContraindications \u2014 None\n\nHydralazine\n\nName \u2014 No listed brand name\n\nClass \u2014 Vasodilator\n\nPharmacology \u2014 Direct vasodilator at the level of arterioles, with little effect on veins. Decreases systemic resistance.\n\nIndications \u2014 Severe hypertension with pre-eclampsia symptoms\n\nAPPENDICES\n\nIII. Medications\n\nRev. March 2022\n---\n# NASEMSO\n\n# National Model EMS Clinical Guidelines Version 3.0\n\n## Hydrocortisone succinate\n\n|Name|Cortef\u00ae, SoluCortef\u00ae|\n|---|---|\n|Class|Corticosteroid|\n|Pharmacologic Action|Glucocorticoid; elicits mild mineralocorticoid activity and moderate anti-inflammatory effects; controls or prevents inflammation by controlling rate of protein synthesis, suppressing migration of polymorphonuclear leukocytes (PMNs) and fibroblasts, and reversing capillary permeability|\n|Indications|For the management of adrenal insufficiency|\n|Contraindications|Untreated serious infections (except tuberculous meningitis or septic shock), idiopathic thrombocytopenic purpura, intrathecal administration (injection), documented hypersensitivity|\n\n## Hydromorphone\n\n|Name|Dilaudid\u00ae|\n|---|---|\n|Class|Synthetic opiate, opioid analgesic|\n|Pharmacology|Narcotic agonist-analgesic of opiate receptors; inhibits ascending pain pathways, thus altering response to pain; increases pain threshold; produces analgesia, respiratory depression, and sedation|\n|Indications|Management of acute pain|\n|Contraindications|Hypersensitivity|\n|WARNING|Should be used with caution in the elderly and in patients with hypotension, suspected gastrointestinal obstruction, head injury, and concomitant CNS depressants|\n\n## Hydroxocobalamin\n\n|Name|Cyanokit\u00ae|\n|---|---|\n|Class|Cyanide antidote|\n|Pharmacologic Action|Vitamin B12 with hydroxyl group complexed to cobalt which can be displaced by cyanide resulting in cyanocobalamin that is renally excreted|\n|Indications|For the management of cyanide toxicity|\n|Contraindications|Documented hypersensitivity|\n|WARNING|Will cause discoloration of the skin and urine, can interfere with pulse oximetry. Due to its interference with certain diagnostic blood tests, the performance of prehospital phlebotomy is preferable prior to the administration of hydroxocobalamin|\n\n## Ibuprofen\n\n|Name|There are multiple over-the-counter medications that include ibuprofen, such as Advil\u00ae, Motrin\u00ae|\n|---|---|\n|Class|Non-steroidal anti-inflammatory drug (NSAID)|\n|Pharmacologic Action|Inhibits synthesis of prostaglandins in body tissues by inhibiting at least 2 cyclo-oxygenase (COX) isoenzymes, COX-1 and COX-2. May inhibit chemotaxis, alter lymphocyte activity, decrease proinflammatory cytokine activity, and inhibit neutrophil aggregation; these effects may contribute to anti-inflammatory activity|\n|Indications|For the acute management of pain or as an antipyretic|\n|Contraindications|Aspirin allergy; perioperative pain in setting of coronary artery bypass graft (CABG) surgery; preterm infants with untreated proven or suspected infection; bleeding with active intracranial|\n\n________________________\n\nGo To TOC\n\n## APPENDICES\n\nRev. March 2022\n\n### III. Medications\n\n384\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nIII.", "start_char_idx": 876083, "end_char_idx": 879795, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a1c028c-1af7-46de-afc8-4d3e3802f39d": {"__data__": {"id_": "4a1c028c-1af7-46de-afc8-4d3e3802f39d", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cd11053-59b9-4bd1-aa0f-ce84f91393d4", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "d06a0af4dc24098fbb2401126dce24da4dc1c5f818262e7ffbf0697e59e2e871", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8387343-4baf-4167-a241-ad3a25091c81", "node_type": "1", "metadata": {}, "hash": "54601735bf4c06d38a867162f7b36233df588c8511d3a481f38fcd5e67805cb5", "class_name": "RelatedNodeInfo"}}, "text": "May inhibit chemotaxis, alter lymphocyte activity, decrease proinflammatory cytokine activity, and inhibit neutrophil aggregation; these effects may contribute to anti-inflammatory activity|\n|Indications|For the acute management of pain or as an antipyretic|\n|Contraindications|Aspirin allergy; perioperative pain in setting of coronary artery bypass graft (CABG) surgery; preterm infants with untreated proven or suspected infection; bleeding with active intracranial|\n\n________________________\n\nGo To TOC\n\n## APPENDICES\n\nRev. March 2022\n\n### III. Medications\n\n384\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nIII. Medications 385\n\n|Name|Atrovent\u00ae|\n|---|---|\n|Class|Anticholinergics, respiratory|\n|Pharmacologic Action|Anticholinergic (parasympatholytic) agent; inhibits vagally mediated reflexes by antagonizing acetylcholine         action; prevents increase in intracellular calcium concentration that is caused by interaction of acetylcholine         with muscarinic receptors on bronchial smooth muscle|\n|Indications|For the management of asthma and chronic obstructive pulmonary disease (COPD)|\n|Contraindications|Documented hypersensitivity to ipratropium, atropine, or derivatives.|\n\n|Name|No brand name available|\n|---|---|\n|Class|Secondary alcohol|\n|Pharmacology|In addition to traditional role as antiseptic, may be used as antiemetic|\n|Indications|Nausea and vomiting|\n|Contraindications|None|\n\n|Name|Ketalar\u00ae|\n|---|---|\n|Class|General anesthetics, systemic|\n|Pharmacologic Action|Produces dissociative anesthesia. Blocks N-methyl D-aspartate (NMDA) receptor|\n|Indications|For the management of agitated or violent behavior|\n|Contraindications|Hypersensitivity RELATIVE/CONTROVERSIAL CONTRAINDICATIONS: Head trauma, intracranial mass/hemorrhage,         hypertension, angina, and stroke, underlying psychiatric disorder WARNING: Overdose may lead to panic attacks         and aggressive behavior; rarely seizures, increased ICP, and cardiac arrest. Very similar in chemical makeup to         PCP (phencyclidine), but it is shorter acting and less toxic|\n\n|Name|Toradol\u00ae|\n|---|---|\n|Class|Non-steroidal anti-inflammatory drug (NSAID)|\n|Pharmacologic Action|Inhibits synthesis of prostaglandins in body tissues by inhibiting at least 2 cyclo-oxygenase (COX) isoenzymes,         COX-1 and COX-2. May inhibit chemotaxis, alter lymphocyte activity, decrease proinflammatory cytokine activity,         and inhibit neutrophil aggregation; these effects may contribute to anti-inflammatory activity|\n|Indications|For the acute management of moderately severe pain|\n|Contraindications|Allergy to aspirin, ketorolac, or other NSAIDS; women who are in active labor or are breastfeeding, significant         renal impairment particularly when associated with volume depletion, previous or current GI bleeding,         intracranial bleeding, coagulation defects, patients with a high-risk of bleeding|\n\n|Name|Trandate\u00ae|\n|---|---|\n---\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nClass \u2014 Beta-blockers, alpha activity\n\nPharmacology \u2014 Nonselective beta blocker with intrinsic sympathomimetic activity; also, alpha blocker\n\nIndications \u2014 severe hypertension with pre-eclampsia symptoms\n\nContraindications \u2014 Asthma or obstructive airway disease, severe bradycardia, second-degree or third-degree heart block (without pacemaker), cardiogenic shock, bronchial asthma, uncompensated cardiac failure, hypersensitivity, sinus bradycardia, sick sinus syndrome without permanent pacemaker; conditions associated with prolonged and severe hypotension. Use with caution in patients taking calcium channel blockers. Hypotension with or without syncope may occur, monitor. Consider pre-existing conditions, such as, sick sinus syndrome before initiating therapy. Use caution in patients with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges; treatment with epinephrine in patients taking beta-blockers may be ineffective or promote undesirable effects.", "start_char_idx": 879147, "end_char_idx": 883207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8387343-4baf-4167-a241-ad3a25091c81": {"__data__": {"id_": "b8387343-4baf-4167-a241-ad3a25091c81", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a1c028c-1af7-46de-afc8-4d3e3802f39d", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "404bed608ab1ae60a2defad3c3b0c023f2545bc3eefbc577f591aec9dc839db1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af2dc654-25ff-4759-b6be-2068914f8083", "node_type": "1", "metadata": {}, "hash": "4b922b99dcc5dad936ea9111e4c9055130d0d594aa67f43bbdbc754a49cf3943", "class_name": "RelatedNodeInfo"}}, "text": "Use with caution in patients taking calcium channel blockers. Hypotension with or without syncope may occur, monitor. Consider pre-existing conditions, such as, sick sinus syndrome before initiating therapy. Use caution in patients with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges; treatment with epinephrine in patients taking beta-blockers may be ineffective or promote undesirable effects. Use with caution in patients with myasthenia gravis, psoriasis, or psychiatric illness (may cause or exacerbate CNS depression)\n\nLidocaine\n\nName \u2014 Lidocaine CV\u00ae, Lidopen\u00ae, Xylocaine\u00ae\n\nClass \u2014 Class Ib antidysrhythmics\n\nPharmacologic Action \u2014 Class 1b antidysrhythmic; combines with fast sodium channels and thereby inhibits recovery after repolarization, resulting in decreasing myocardial excitability and conduction velocity\n\nIndications \u2014 For the management of refractory or recurrent ventricular fibrillation or pulseless VT\n\nContraindications \u2014 Hypersensitivity to lidocaine or amide-type local anesthetic, Adams-Stokes syndrome, SA/AV/intraventricular heart block in the absence of artificial pacemaker. nitro (CHF), cardiogenic shock, second- and third-degree heart block (if no pacemaker is present), Wolff-Parkinson-White Syndrome\n\nLorazepam\n\nName \u2014 Ativan\u00ae\n\nClass \u2014 Anticonvulsants, other; antianxiety agent; anxiolytics; benzodiazepines\n\nPharmacologic Action \u2014 Sedative hypnotic with short onset of effects and relatively long half-life; by increasing the action of gamma-aminobutyric acid (GABA), which is a major inhibitory neurotransmitter in the brain, lorazepam may depress all levels of the CNS, including limbic and reticular formation\n\nIndications \u2014 For the management of seizures, uncontrolled shivering in hypothermia, and for the management of agitated or violent patients suffering behavioral emergencies\n\nContraindications \u2014 Documented hypersensitivity, acute narrow angle glaucoma, severe respiratory depression, sleep apnea\n\nMagnesium sulfate\n\nName \u2014 MgSO4\n\nClass \u2014 Class V antidysrhythmic, electrolyte\n\nPharmacologic Action \u2014 Depresses CNS, blocks peripheral neuromuscular transmission, produces anticonvulsant effects; decreases amount of acetylcholine released at end-plate by motor nerve impulse. Slows rate of sinoatrial (SA) node impulse formation in myocardium and prolongs conduction time. Promotes movement of calcium, potassium, and sodium in and out of cells and stabilizes excitable membranes\n\nIndications \u2014 For the management of torsades de pointes or for severe bronchoconstriction with impending respiratory failure, seizure during the third trimester of pregnancy or in the postpartum patient\n\n________________________ Go To TOC\n\nAPPENDICES Rev. March 2022\n\nIII. Medications 386\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n## Contraindications\n\nHypersensitivity, myocardial damage, diabetic coma, heart block, hypermagnesemia, hypercalcemia\n\n### Methylprednisolone\n\nName \u2014 Medrol\u00ae, Medrol Dosepak\u00ae, DepoMedrol\u00ae, SoluMedrol\u00ae\n\nClass \u2014 Corticosteroid, anti-inflammatory agent\n\nPharmacologic Action \u2014 Potent glucocorticoid with minimal to no mineralocorticoid activity. Modulates\ncarbohydrate, protein, and lipid metabolism and maintenance of fluid and electrolyte homeostasis.", "start_char_idx": 882736, "end_char_idx": 886057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af2dc654-25ff-4759-b6be-2068914f8083": {"__data__": {"id_": "af2dc654-25ff-4759-b6be-2068914f8083", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8387343-4baf-4167-a241-ad3a25091c81", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "ba088e56d5632bab025cfe12c395a051d59067ef8c990dcc69a93120303af50c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62f01751-8868-4ae7-8262-0df65a02a61e", "node_type": "1", "metadata": {}, "hash": "16562f04d5db3c81929e1ee09b1a1991d4d2f7cd3cb7f6a7e6b81d63d7837e1b", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nIII. Medications 386\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n## Contraindications\n\nHypersensitivity, myocardial damage, diabetic coma, heart block, hypermagnesemia, hypercalcemia\n\n### Methylprednisolone\n\nName \u2014 Medrol\u00ae, Medrol Dosepak\u00ae, DepoMedrol\u00ae, SoluMedrol\u00ae\n\nClass \u2014 Corticosteroid, anti-inflammatory agent\n\nPharmacologic Action \u2014 Potent glucocorticoid with minimal to no mineralocorticoid activity. Modulates\ncarbohydrate, protein, and lipid metabolism and maintenance of fluid and electrolyte homeostasis. Controls or\nprevents inflammation by controlling rate of protein synthesis, suppressing migration of polymorphonuclear\nleukocytes (PMNs) and fibroblasts, reversing capillary permeability, and stabilizing lysosomes at cellular level\n\nIndications \u2014 For the management of acute bronchospastic disease as well as for adrenal insufficiency\n\nContraindications \u2014 Untreated serious infections, documented hypersensitivity, IM route is contraindicated in\nidiopathic thrombocytopenic purpura, traumatic brain injury (high doses)\n\n### Metoclopramide\n\nName \u2014 Reglan\u00ae, Metozolv ODT\u00ae\n\nClass \u2014 Antiemetic agent, prokinetic agent\n\nPharmacologic Action \u2014 Blocks dopamine receptors (at high dose) and serotonin receptors in chemoreceptor\ntrigger zone of CNS; and sensitizes tissues to acetylcholine; increases upper GI motility but not secretions;\nincreases lower esophageal sphincter tone\n\nIndications \u2014 For the management of nausea and vomiting\n\nContraindications \u2014 Hypersensitivity to metoclopramide or procainamide, GI hemorrhage, mechanical obstruction,\nperforation, history of seizures, pheochromocytoma. Other drugs causing extrapyramidal symptoms (e.g.,\nphenothiazines, butyrophenones)\n\n### Metoprolol\n\nName \u2014 Lopressor\u00ae, Toprol XL\u00ae\n\nClass \u2014 Beta blocker, beta-1 selective\n\nPharmacologic Action \u2014 Blocks response to beta-adrenergic stimulation; cardio selective for beta-1 receptors at\nlow doses, with little or no effect on beta-2 receptors\n\nIndications \u2014 For management of narrow complex tachycardias\n\nContraindications \u2014 Hypersensitivity. When administered for hypertension or angina: Sinus bradycardia, 2nd or 3rd\ndegree AV block, cardiogenic shock, sick sinus syndrome (unless permanent pacemaker in place), severe peripheral\nvascular disease, pheochromocytoma. When administered for myocardial infarction: Severe sinus bradycardia with\nheart rate less than 45 beats/minute, systolic BP less than 100 mmHg, significant first-degree heart block (PR\ninterval at least 0.24 seconds), moderate-to-severe cardiac failure\n\nWARNING: May cause 1st, 2nd, or 3rd degree AV block\n\n### Midazolam\n\nName \u2014 Versed\u00ae\n\nClass \u2014 Anticonvulsants, other; antianxiety agent; anxiolytics; benzodiazepines\n\nPharmacologic Action \u2014 Binds receptors at several sites within the CNS, including the limbic system and reticular\nformation; effects may be mediated through gabba-aminobutyric acid (GABA) receptor system; increase in neuronal\nmembrane permeability to chloride ions enhances the inhibitory effects of GABA; the shift in chloride ions causes\nhyperpolarization (less excitability) and stabilization of the neuronal membrane\n\n________________________\n\nGo To TOC\n\n## APPENDICES\n\nRev. March 2022\n\n### III.", "start_char_idx": 885496, "end_char_idx": 888734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62f01751-8868-4ae7-8262-0df65a02a61e": {"__data__": {"id_": "62f01751-8868-4ae7-8262-0df65a02a61e", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af2dc654-25ff-4759-b6be-2068914f8083", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "fd39922203262a49bd5f7114d7816a240db6faace25dfc9ff690e5321b4fe9b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9631a34f-a0bf-4223-b105-125997254604", "node_type": "1", "metadata": {}, "hash": "077c93bce3d8103dacf8517b697f2ce8e5958350b60aaa4eb67a7a6e25bca9bf", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n### III. Medications\n\n387\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nIndications \u2014 For the management of seizures, uncontrolled shivering in hypothermia, and for the management of agitated or violent patients suffering behavioral emergencies\n\nContraindications \u2014 Documented hypersensitivity, severe respiratory depression, sleep apnea\n\nWARNING: May cause respiratory depression, arrest, or apnea\n\n|Name|MS Contin\u00ae, Avinza\u00ae, Depodur\u00ae, Duramorph\u00ae, Infumorph\u00ae, Astramorph\u00ae, Kadian\u00ae, MSO4|\n|---|---|\n|Class|Opioid analgesic|\n|Pharmacologic Action|Narcotic agonist-analgesic of opiate receptors; inhibits ascending pain pathways, thus altering response to pain; produces analgesia, respiratory depression, and sedation; suppresses cough by acting centrally in medulla|\n|Indications|Management of acute pain|\n|Contraindications|Hypersensitivity, paralytic ileus, toxin-mediated diarrhea, respiratory depression, acute or severe bronchial asthma, upper airway obstruction, GI obstruction (extended release), hypercarbia (immediate release tablets/solution), upper airway obstruction (epidural/intrathecal), heart failure due to chronic lung disease, head injuries, brain tumors, deliriums tremens, seizure disorders, during labor when premature birth anticipated (injectable formulation), cardiac arrhythmia, increased intracranial or cerebrospinal pressure, acute alcoholism, use after biliary tract surgery, surgical anastomosis (suppository formulation)|\n\nName \u2014 Narcan\u00ae\n\nClass \u2014 Opioid reversal agent\n\nPharmacologic Action \u2014 Competitive opioid antagonist; synthetic congener of oxymorphone\n\nIndications \u2014 Reversal of acute opioid toxicity\n\nContraindications \u2014 Hypersensitivity\n\nWARNING: Administration of naloxone can result in the sudden onset of opiate withdrawal (agitation, tachycardia, pulmonary edema, nausea, vomiting, and, in neonates, seizures)\n\nName \u2014 Procardia\u00ae, Adalat CC\u00ae, Nifedical\u00ae\n\nClass \u2014 Calcium channel blocker\n\nPharmacologic Action \u2014 Calcium-channel blocker; inhibits transmembrane influx of extracellular calcium ions across myocardial and vascular smooth muscle cell membranes without changing serum calcium concentrations; this results in inhibition of cardiac and vascular smooth muscle contraction, thereby dilating main coronary and systemic arteries. Vasodilation with decreased peripheral resistance and increased heart rate\n\nIndications \u2014 For the management of high-altitude pulmonary edema (HAPE)\n\nContraindications \u2014 Hypersensitivity to nifedipine or other calcium-channel blockers, cardiogenic shock, concomitant administration with strong CYP3A4 inducers (e.g., rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, St. John's wort) significantly reduces nifedipine efficacy, Immediate release preparation (sublingually or orally) for urgent or emergent hypertension\n\nName \u2014 N2O\n\nClass \u2014 Weak inhalational anesthetic\n\nPharmacologic Action \u2014 Its analgesic mechanism of action is described as opioid in nature and may involve a number of spinal neuromodulators. The anxiolytic effect is similar to that of\n\nGo To TOC\n\nAPPENDICES\n\nRev. March 2022\n\nIII. Medications\n\n388\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nbenzodiazepine and may involve gamma aminobutyric (GABA) receptors. The anesthesia mechanism may involve GABA and possibly N-methyl-D-aspartate receptors as well.[6] In general, the effect of nitrous oxide ceases as soon as the inhalation stops, with no residual effect\n\n### Indications\n\nAnalgesia in the patient who is capable of self-administration of this medication\n\n### Contraindications\n\nSignificant respiratory compromise, suspected abnormal air-filled cavities (e.g., pneumothorax, bowel obstruction, air embolism)\n\nRELATIVE CONTRAINDICATIONS: History of stroke, hypotension, pregnancy, known cardiac conditions, known vitamin B12 deficiency\n\n### Nitroglycerin\n\nName \u2014 Nitrostat\u00ae, Nitrolingual Pumpspray\u00ae, NitroQuick\u00ae\n\nClass \u2014 Nitrates, anti-anginal\n\n#### Pharmacologic Action\n\nOrganic nitrate which causes systemic venodilation, decreasing preload.", "start_char_idx": 888714, "end_char_idx": 892800, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9631a34f-a0bf-4223-b105-125997254604": {"__data__": {"id_": "9631a34f-a0bf-4223-b105-125997254604", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62f01751-8868-4ae7-8262-0df65a02a61e", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "aa61a93a9a0760b9b9cd72518bbd2e966d63c92646a4bfda5f850c3cfeaffef0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0e4ced8-b15f-45aa-a2d4-5b57b2469e12", "node_type": "1", "metadata": {}, "hash": "462114fc58a19becd13db4f6ee27e3fa8e60daa6979851641f52615f3477eb02", "class_name": "RelatedNodeInfo"}}, "text": "The anesthesia mechanism may involve GABA and possibly N-methyl-D-aspartate receptors as well.[6] In general, the effect of nitrous oxide ceases as soon as the inhalation stops, with no residual effect\n\n### Indications\n\nAnalgesia in the patient who is capable of self-administration of this medication\n\n### Contraindications\n\nSignificant respiratory compromise, suspected abnormal air-filled cavities (e.g., pneumothorax, bowel obstruction, air embolism)\n\nRELATIVE CONTRAINDICATIONS: History of stroke, hypotension, pregnancy, known cardiac conditions, known vitamin B12 deficiency\n\n### Nitroglycerin\n\nName \u2014 Nitrostat\u00ae, Nitrolingual Pumpspray\u00ae, NitroQuick\u00ae\n\nClass \u2014 Nitrates, anti-anginal\n\n#### Pharmacologic Action\n\nOrganic nitrate which causes systemic venodilation, decreasing preload. Cellular mechanism: nitrate enters vascular smooth muscle and converted to nitric oxide (NO) leading to activation of cyclic guanosine monophosphate (cGMP) and vasodilation. Relaxes smooth muscle via dose-dependent dilation of arterial and venous beds to reduce both preload and afterload, and myocardial O2 demand. Also improves coronary collateral circulation. Lower BP, increases heart rate, occasional paradoxical bradycardia\n\n#### Indications\n\nAs an anti-anginal medication for the management of chest pain as well as a reducer of preload for patients suffering from acute pulmonary edema\n\n#### Contraindications\n\nHypersensitivity, acute myocardial infarction, severe anemia, recent use of erectile dysfunction medications (sildenafil (Viagra\u00ae \u2014 within last 24 hours), tadalafil (Cialis\u00ae \u2014 within last 48 hours), vardenafil (Levitra\u00ae \u2014 within last 48 hours), or other phopsphodiesterase-5 inhibitors). There is potential for dangerous hypotension, narrow angle glaucoma (controversial: may not be clinically significant). Nitrates are contraindicated in the presence of hypotension (SBP less than 90 mmHg or \u226530 mmHg below baseline), extreme bradycardia (less than 50 BPM), tachycardia in the absence of heart failure (greater than 100 BPM), and right ventricular infarction\n\n### Norepinephrine\n\nName \u2014 Levophed\u00ae, Levarterenol\u00ae\n\nClass \u2014 Alpha/beta adrenergic agonist\n\n#### Pharmacologic Action\n\nStrong beta-1 and alpha-adrenergic effects and moderate beta-2 effects, which increase cardiac output and heart rate, decrease renal perfusion and peripheral vascular resistance, and cause variable BP effects\n\n#### Indications\n\nAs a pressor agent used in the management of shock\n\n#### Contraindications\n\nHypersensitivity, hypotension due to blood volume deficit, peripheral vascular thrombosis (except for lifesaving procedures)\n\nRELATIVE CONTRAINDICATIONS: concomitant use with some general anesthetics: chloroform, trichloroethylene, cyclopropane, halothane\n\nWARNING: Norepinephrine is a vesicant and can cause severe tissue damage if extravasation occurs. Do not use in the same IV line as alkaline solutions as these may deactivate it\n\n### Olanzapine\n\nName \u2014 Zyprexa\u00ae\n\nClass \u2014 Antipsychotic, second generation, antimanic agents\n\n#### Pharmacologic Action\n\nMay act through combination of dopamine and serotonin type 2 receptor site antagonism\n\n## APPENDICES\n\n## III. Medications\n\n389\n\nRev. March 2022\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nIndications \u2014 For the management of agitated or violent patients suffering a behavioral emergency\n\nContraindications \u2014 Documented hypersensitivity\n\nWARNING: Patients are at risk for severe sedation (including coma) or delirium after each injection and must be observed for at least 3 hours in registered facility with ready access to emergency response services. Patients are at significant risk of severe sedation when olanzapine is administered with benzodiazepines or to patients who have are taking benzodiazepines\n\nOndansetron\n\n|Name|Zofran\u00ae, Zofran ODT\u00ae, Zuplenz\u00ae|\n|---|---|\n|Class|Antiemetic, selective 5-HT3 antagonist|\n|Pharmacologic Action|Mechanism not fully characterized; selective 5-HT3 receptor antagonist; binds to 5-HT3 receptors both in periphery and in CNS, with primary effects in GI tract.", "start_char_idx": 892011, "end_char_idx": 896089, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0e4ced8-b15f-45aa-a2d4-5b57b2469e12": {"__data__": {"id_": "a0e4ced8-b15f-45aa-a2d4-5b57b2469e12", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9631a34f-a0bf-4223-b105-125997254604", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "f5ef926876347522a2544adbf54b056cde689d3f7980e5bd39b3bf5465b12e2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fa65883-c39b-49c5-9cc8-3ce0161c6d05", "node_type": "1", "metadata": {}, "hash": "d25b02fcce228e3c439bc8fe092758696519ed9f94eb8c56203b5babd4488dab", "class_name": "RelatedNodeInfo"}}, "text": "Patients are at significant risk of severe sedation when olanzapine is administered with benzodiazepines or to patients who have are taking benzodiazepines\n\nOndansetron\n\n|Name|Zofran\u00ae, Zofran ODT\u00ae, Zuplenz\u00ae|\n|---|---|\n|Class|Antiemetic, selective 5-HT3 antagonist|\n|Pharmacologic Action|Mechanism not fully characterized; selective 5-HT3 receptor antagonist; binds to 5-HT3 receptors both in periphery and in CNS, with primary effects in GI tract. Has no effect on dopamine receptors and therefore does not cause extrapyramidal symptoms|\n|Indications|For the management of nausea or vomiting|\n\nNOTE: EKG monitoring is recommended in patients who have electrolyte abnormalities, CHF, or bradyarrhythmias or who are also receiving other medications that cause QT prolongation\n\nContraindications \u2014 Hypersensitivity, coadministration with apomorphine; combination reported to cause profound hypotension and loss of consciousness\n\nWARNING: May cause dose-dependent QT prolongation, avoid in patients with congenital long QT syndrome\n\nOxymetazoline\n\n|Name|Afrin\u00ae, Duramist Plus\u00ae, Dristan 12 Hr\u00ae, Sinarest 12 Hour\u00ae, Vicks Sinus 12 Hour\u00ae|\n|---|---|\n|Class|Decongestants, intranasal|\n|Pharmacologic Action|Alpha-adrenergic agonist; stimulates alpha-adrenergic receptors and produces vasoconstriction in the arterioles of the nasal mucosa|\n|Indications|For the management of epistaxis in the patient suffering facial trauma|\n\nContraindications \u2014 Hypersensitivity\n\nPotassium iodide\n\n|Name|Pima Syrup\u00ae, SSKI\u00ae, ThyroSafe\u00ae, ThyroShield\u00ae|\n|---|---|\n|Class|Antidotes, other; antithyroid agents|\n|Pharmacologic Action|As a thyroid protective agent: Systemically circulating potassium iodide is readily taken up by thyroid gland by sodium/iodide transporter in basal membrane; blocking the thyroid uptake of radioactive isotopes of iodine; concentration gradient of thyroid gland to plasma is 20\u201450:1|\n|Indications|Indicated during environmental radiation emergency to block uptake of radioactive iodine isotopes in thyroid and reduce risk of thyroid cancer|\n\nContraindications \u2014 Iodine sensitivity (although allergy to radiocontrast media, contact dermatitis from iodine-containing antibacterials, allergy to seafood should not be considered evidence of potassium iodide allergy), hyperthyroidism, respiratory failure\n\nPrednisone\n\n|Name|Deltasone\u00ae, Rayos\u00ae, Sterapred\u00ae|\n|---|---|\n|Class|Corticosteroid|\n|Pharmacologic Action|Glucocorticosteroid which also elicits mild mineralocorticoid activity and dose dependent moderate-to-significant anti-inflammatory effects|\n|Indications|WILL NEED TO REVIEW EVERY PLACE PREDNISONE IS MENTIONED IN THE PROTOCOLS|\n\n________________________ Go To TOC\n\nAPPENDICES Rev. March 2022\n\nIII.", "start_char_idx": 895642, "end_char_idx": 898346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fa65883-c39b-49c5-9cc8-3ce0161c6d05": {"__data__": {"id_": "6fa65883-c39b-49c5-9cc8-3ce0161c6d05", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0e4ced8-b15f-45aa-a2d4-5b57b2469e12", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "9410bbeb8510b142417c251dd73d31475a651b2c7f0fd6b042df7ac0329b44d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "897af07f-4bbd-4172-a260-a5d8bb3f2510", "node_type": "1", "metadata": {}, "hash": "9c65dc9833478421a542735f6dfbfdffbbf26ba9753e2394e0de7f6cbe48a2e2", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nIII. Medications 390\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nContraindications \u2013 Avoid in untreated severe infections, documented hypersensitivity, or active varicella and fungal infections\n\n|Name|Pediapred\u00ae, FloPred\u00ae, Orapred\u00ae, Millipred\u00ae, Prelone Syrup\u00ae, Veripred\u00ae|\n|---|---|\n|Class|Corticosteroid|\n|Pharmacologic Action|Glucocorticosteroid which also elicits mild mineralocorticoid activity and dose dependent moderate-to-significant anti-inflammatory effects|\n|Indications|WILL NEED TO REVIEW EVERY PLACE PREDNISONE IS MENTIONED IN THE PROTOCOLS|\n|Contraindications|Avoid in untreated severe infections, documented hypersensitivity, or active varicella and fungal infections|\n\n|Name|Protopam\u00ae, 2PAM Antidote\u00ae, Pralidoxime Auto Injector\u00ae, a component of Mark I\u00ae kits and DuoDote\u00ae|\n|---|---|\n|Class|Cholinergic, toxicity antidote|\n|Pharmacologic Action|Binds to organophosphates and breaks alkyl phosphate-cholinesterase bond to restore activity of acetylcholinesterase|\n|Indications|For the management of toxicity caused by organophosphate insecticides and related nerve gases (e.g., tabun, sarin, soman)|\n|Contraindications|Documented hypersensitivity|\n\n|Name|Pronestyl\u00ae, Procanbid\u00ae|\n|---|---|\n|Class|Class Ia antidysrhythmic|\n|Pharmacologic Action|Class Ia (membrane stabilizing) antidysrhythmic agent; inhibits recovery after repolarization resulting in decreasing myocardial excitability and conduction velocity. Direct membrane depressant that decreases conduction velocity, prolongs refractoriness, decreases automaticity and reduces repolarization abnormalities|\n|Indications|For the management of stable patients with regular, wide complex tachycardia|\n|Contraindications|Hypersensitivity to procainamide or other ingredients, complete heart block, second- or third-degree AV block, systemic lupus erythematosus (SLE), torsades de pointes RELATIVE CONTRAINDICATION: Patients with QT prolongation|\n\n|Name|Compazine\u00ae|\n|---|---|\n|Class|Antiemetic agent; antipsychotics, phenothiazine|\n|Pharmacologic Action|Antiemetic: antidopaminergic effect, blocking dopamine receptors in the brain, blocking vagus nerve in GI tract. Antipsychotic: Blocking mesolimbic dopamine receptors, and blocking alpha-adrenergic receptors (D1 and D2) in brain|\n|Indications|For the management of nausea and vomiting|\n|Contraindications|Documented hypersensitivity to phenothiazines, coma, severe CNS depression, concurrent use of large amounts of CNS depressants, poorly controlled seizure disorder, subcortical brain damage, pediatric surgery, children less than 2 years or weighing less than 9 kg|\n\nName \u2014 Revatio\u00ae, Viagra\u00ae\n\nAPPENDICES\n\nIII. Medications\n\nRev.", "start_char_idx": 898330, "end_char_idx": 901021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "897af07f-4bbd-4172-a260-a5d8bb3f2510": {"__data__": {"id_": "897af07f-4bbd-4172-a260-a5d8bb3f2510", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fa65883-c39b-49c5-9cc8-3ce0161c6d05", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "eb5f4aadedb10fd67465e8c0c0015fc725dfbc0f1d77f4b14bc942b04058eb41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c0b4cd7-60fc-45b2-9e6d-1cd679734c3e", "node_type": "1", "metadata": {}, "hash": "dc86cd43c8a2f02f4f3147d2210f703ba6921bd9d62eeb817467d55973297937", "class_name": "RelatedNodeInfo"}}, "text": "Antipsychotic: Blocking mesolimbic dopamine receptors, and blocking alpha-adrenergic receptors (D1 and D2) in brain|\n|Indications|For the management of nausea and vomiting|\n|Contraindications|Documented hypersensitivity to phenothiazines, coma, severe CNS depression, concurrent use of large amounts of CNS depressants, poorly controlled seizure disorder, subcortical brain damage, pediatric surgery, children less than 2 years or weighing less than 9 kg|\n\nName \u2014 Revatio\u00ae, Viagra\u00ae\n\nAPPENDICES\n\nIII. Medications\n\nRev. March 2022\n\n391\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\nClass \u2014 Pulmonary artery hypertension therapy, PDE-5 inhibitors; phosphodiesterase-5 enzyme inhibitor\n\nPharmacologic Action \u2014 Inhibits PDE-5, increasing cyclic guanosine monophosphate (cGMP) to allow smooth-muscle relaxation\n\nIndications \u2014 As an adjunct to descent in the management of high-altitude pulmonary edema (HAPE)\n\nContraindications \u2014 Concomitant use of organic nitrates in any form (e.g., nitroglycerin, isosorbide, illicit \u201cpoppers\u201d) either regularly or intermittently, increases risk of severe or potentially fatal hypotension, hypersensitivity\n\nWARNING: Hypotension may occur due to vasodilation\n\nSodium Bicarbonate\n\nName \u2014 Bicarb\n\nClass \u2014 Antidote, other\n\nPharmacologic Action \u2014 Increases blood and urinary pH by releasing a bicarbonate ion, which in turn neutralizes hydrogen ion concentrations\n\nIndications \u2014 For the management of cardiac arrest in cases in which either hyperkalemia or tricyclic antidepressant (TCA) overdose are suspected as contributory, QRS prolongation in known or suspected TCA overdose\n\nContraindications \u2014 Documented hypersensitivity, severe pulmonary edema, known alkalosis, hypernatremia, or hypocalcemia\n\nSodium Nitrite\n\nName \u2014 Nithiodote\u00ae\n\nClass \u2014 Cyanide antidote\n\nPharmacologic Action \u2014 Nitrites create methemoglobins to bind to cyanide\n\nIndications \u2014 For the management of cyanide toxicity\n\nContraindications \u2014 Documented hypersensitivity, suspected or confirmed smoke inhalation and/or carbon monoxide poisoning\n\nWARNING: There is a risk of worsening hypoxia due to methemoglobin formation. In addition, sodium nitrite can cause serious adverse reactions and death from hypotension and methemoglobin formation. Monitor to ensure adequate perfusion and oxygenation during treatment with sodium nitrite\n\nSodium Thiosulfate\n\nName\u2014 Nithiodote\u00ae\n\nClass \u2014 Cyanide antidote\n\nPharmacologic Action \u2014 Thiosulfate is sulfur donor utilized by rhodanese to convert cyanide to less toxic thiocyanate\n\nIndications \u2014 For the management of cyanide toxicity\n\nContraindications \u2014 Documented hypersensitivity\n\nSorbitol\n\nName \u2014 Sorbitol\n\nClass \u2014 Laxatives, osmotic\n\nPharmacologic Action \u2014 Polyalcoholic sugar with hyperosmotic effects\n\nIndications \u2014 Administered for the management of patients suffering from toxic ingestions\n\nContraindications \u2014 Acute abdominal pain, nausea, vomiting, or other symptoms of appendicitis or undiagnosed abdominal pain, documented hypersensitivity\n\nWARNING: Sorbitol is no longer recommended to be given with activated charcoal\n\nAPPENDICES\n\nRev. March 2022\n\nIII. Medications\n\n392\n---\n# NASEMSO\n\n# NASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n|Name|Cialis\u00ae, Adcirca\u00ae|\n|---|---|\n|Class|Pulmonary artery hypertension therapy, PDE-5 inhibitors; phosphodiesterase-5 enzyme inhibitor|\n|Pharmacologic Action|Pulmonary arterial hypertension (PAH): inhibits PDE-5, increasing cyclic guanosine monophosphate (cGMP) to allow relaxation of pulmonary vascular smooth-muscle cells and vasodilation of pulmonary vasculature|\n|Indications|As an adjunct to descent in the management of high-altitude pulmonary edema (HAPE)|\n|Contraindications|Concomitant use of any form of organic nitrates (e.g., nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, illicit \"poppers\"), either regularly or intermittently; may potentiate hypotensive effect of nitrates.", "start_char_idx": 900504, "end_char_idx": 904431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c0b4cd7-60fc-45b2-9e6d-1cd679734c3e": {"__data__": {"id_": "8c0b4cd7-60fc-45b2-9e6d-1cd679734c3e", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "897af07f-4bbd-4172-a260-a5d8bb3f2510", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "4258ba33add60f17cc0dcc6204510cbe28aa49e6271be3863d65f68031a460b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a60b7ae8-db95-45e4-868d-411a6f58ef0a", "node_type": "1", "metadata": {}, "hash": "f895be5df8662e15147ccf847cdd0e23034862c6401a335b4e85ab1c76868a2c", "class_name": "RelatedNodeInfo"}}, "text": "Hypersensitivity, including Stevens-Johnson syndrome and exfoliative dermatitis|\n\nWARNING: Hypotension may occur due to vasodilation\n\n|Name|Geodon\u00ae|\n|---|---|\n|Class|Second generation antipsychotic|\n|Pharmacologic Action|Acts as antagonist at dopamine-2 and serotonin type 1 and 2 (5HT1D, 5HT2A) receptors; acts as agonist at serotonin 5HT1A receptor; moderately inhibits reuptake of norepinephrine and serotonin; has alpha-blocking and antihistaminic activity|\n|Indications|For the management of agitated or violent patients suffering a behavioral emergency|\n|Contraindications|Documented hypersensitivity, any drugs or conditions that prolong QT interval, recent acute myocardial infarction, uncompensated heart failure|\n\n________________________ Go To TOC\n\nAPPENDICES Rev. March 2022 III. Medications 393\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n## IV. Approved Abbreviations\n\nThe following is the Project\u2019s list of approved medical abbreviations used in this document. The Drug.com article \u201cMedical Abbreviations on Pharmacy Prescriptions\u201d at https://www.drugs.com/article/prescription-abbreviations.html is considered the reference of authority.\n\n|Abbreviation|Description|\n|---|---|\n|ACS|acute coronary syndrome|\n|AED|automatic external defibrillator|\n|A-FIB|atrial fibrillation|\n|ALS|advanced life support|\n|AMS|altered mental status|\n|ASA|aspirin|\n|AV|atrioventricular|\n|AVPU|alert, verbal, pain, unresponsive (neurological status measure)|\n|BiPAP|bi-level positive airway pressure|\n|BLS|basic life support|\n|BP|blood pressure|\n|BPM|beats per minute|\n|BSA|body surface area|\n|BSI|body substance isolation|\n|BVM|bag-valve-mask|\n|CABG|coronary artery bypass graft|\n|CAD|coronary artery disease|\n|CARES|Cardiac Arrest Registry to Enhance Survival|\n|CC|chief complaint|\n|CDC|Centers for Disease Control and Prevention|\n|CHF|congestive heart failure|\n|CNS|central nervous system|\n|CO|carbon monoxide|\n|CO2|carbon dioxide|\n|COPD|chronic obstructive pulmonary disease|\n|CP|chest pain|\n|CPAP|continuous positive airway pressure|\n|CPI|continuous performance improvement|\n|CPR|cardiopulmonary resuscitation|\n|C-SECTION|caesarean section|\n|C-SPINE|cervical spine|\n\n________________________ Go To TOC\n\n## APPENDICES\n\nRev. March 2022\n\n## IV.", "start_char_idx": 904432, "end_char_idx": 906693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a60b7ae8-db95-45e4-868d-411a6f58ef0a": {"__data__": {"id_": "a60b7ae8-db95-45e4-868d-411a6f58ef0a", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c0b4cd7-60fc-45b2-9e6d-1cd679734c3e", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "19994d77a65b77a5d233c86a2172571c8cfaaaeeeb792093250ca5d61653cc17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "693ee3df-41dd-4ff0-8bac-31eef592b4ef", "node_type": "1", "metadata": {}, "hash": "f1eeeba4d0d3a9bc3e89b50106b5e54608395cfbe02f70e0ec9a87c5b4db727d", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n## IV. Approved Abbreviations\n\n394\n---\n# NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n|Abbreviation|Meaning|\n|---|---|\n|CT|cat scan, Cardiac Technician|\n|CVA|cerebrovascular accident (stroke)|\n|D5W|5% dextrose in water|\n|DKA|diabetic ketoacidosis|\n|DNI|do not intubate|\n|DNR|do not resuscitate|\n|DT|delirium tremens|\n|Dx|diagnosis|\n|ECPR|extracorporeal cardiopulmonary resuscitation|\n|EEG|electroencephalogram|\n|EENT|eye, ear, nose, and throat|\n|EGD|extraglottic device|\n|EKG|electrocardiogram|\n|EMS|emergency medical services|\n|EMT|emergency medical technician|\n|ePCR|electronic patient call/care record/report|\n|ET|endotracheal|\n|ETA|estimated time of arrival|\n|EtCO2|end-tidal carbon dioxide; end-tidal capnography|\n|ETOH|ethanol (alcohol)|\n|ETT|endotracheal tube|\n|FBAO|foreign body airway obstruction|\n|FiO2|fraction of inspired oxygen|\n|g|gram(s)|\n|GI|gastrointestinal|\n|gtt|drops|\n|GU|genitourinary|\n|GYN|gynecology (gynecological)|\n|HFNC|high flow nasal cannula|\n|HR|heart rate (hour)|\n|ICU|intensive care unit|\n|IM|intramuscular|\n|IO|intraosseous|\n|IPPB|intermittent positive pressure breathing|\n|IV|intravenous|\n|IVP|intravenous push|\n|J|joules|\n|JVD|jugular vein distension|\n\nGo To TOC\n\n## APPENDICES\n\nRev. March 2022\n\n### IV.", "start_char_idx": 906675, "end_char_idx": 907939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "693ee3df-41dd-4ff0-8bac-31eef592b4ef": {"__data__": {"id_": "693ee3df-41dd-4ff0-8bac-31eef592b4ef", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a60b7ae8-db95-45e4-868d-411a6f58ef0a", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "7cda110e3cac9fa39f3dc914a990806c62fa426c169d711d794862bf8c97d453", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9220026d-2817-42c4-a3a7-095f18210c16", "node_type": "1", "metadata": {}, "hash": "a1b1127b3f9b61198935584bf14ab6cb775ca08c91cd405e69f03dd949443779", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\n### IV. Approved Abbreviations\n\n395\n---\n|kg|kilogram|\n|---|---|\n|KVO|keep vein open|\n|L|liter|\n|LMA|laryngeal mask airway|\n|LPM|liters per minute|\n|LR|lactated Ringer\u2019s|\n|MAT|multifocal atrial tachycardia|\n|mcg|microgram(s)|\n|MED|medicine|\n|mg|milligram(s)|\n|mg/dL|milligrams per deciliter|\n|MI|myocardial infarction (heart attack)|\n|mL|milliliter|\n|mmHg|millimeters of mercury|\n|mmol|millimole|\n|MOLST|medical orders for life-sustaining treatment|\n|MS|mental status|\n|msec|millisecond|\n|MVC|motor vehicle crash|\n|N/V|nausea/vomiting|\n|NC|nasal cannula|\n|NRB|non-rebreather|\n|NS|normal saline|\n|NSR|normal sinus rhythm|\n|OB/GYN|obstetrics/gynecology|\n|O2|oxygen|\n|P|pulse|\n|PAC|premature atrial contraction|\n|PCR|Patient call/care record/report|\n|PE|pulmonary embolus|\n|PEA|pulseless electrical activity|\n|PO|orally|\n|POLST|physician orders for life-sustaining treatment|\n|PPE|personal protection equipment|\n|prn|as needed|\n|PVC|premature ventricular contraction|\n|q|every (e.g., q 3-5 minutes)|\n|RR|respiratory rate|\n---\nNASEMSO\n\nNational Model EMS Clinical Guidelines Version 3.0\n\n|RSI|rapid sequence intubation|\n|---|---|\n|Rx|medicine|\n|sat|saturation|\n|SBP|systolic blood pressure|\n|SC|subcutaneous|\n|SCBA|self-contained breathing apparatus|\n|SCUBA|self-contained underwater breathing apparatus|\n|SGD|supraglottic device|\n|SL|sublingual|\n|SOB|shortness of breath|\n|ST|sinus tachycardia|\n|SVT|supraventricular tachycardia|\n|T|temperature|\n|TBSA|total body surface area|\n|TCA|tricyclic antidepressants|\n|TIA|transient ischemic attack|\n|TID|three times a day|\n|TKO|to keep open|\n|VF|ventricular fibrillation|\n|VS|vital signs|\n|VT|ventricular tachycardia|\n|y/o|years old (years old)|\n\nAPPENDICES Rev. March 2022 IV. Approved Abbreviations 397\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### V. Burn and Burn Fluid Charts\n\nBurn Size Chart 1\n\n| | |18|\n|---|---|---|\n| |18| |\n|18| | |\n| | |18|\n| |13.5|73.5|\n\nSource: Used with permission, University of Utah Burn Center\n\nTotal Body Surface Area\n\n________________________\n\nAPPENDICES\n\nV. Burn and Burn Fluid Charts\n\nRev. March 2022\n\n398\n\nGo To TOC\n---\n# Burn Size Chart 2\n\nRule of 9's for adults\n\nPalmar surface (including fingers) equals 1% of child's body surface.", "start_char_idx": 907920, "end_char_idx": 910170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9220026d-2817-42c4-a3a7-095f18210c16": {"__data__": {"id_": "9220026d-2817-42c4-a3a7-095f18210c16", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "693ee3df-41dd-4ff0-8bac-31eef592b4ef", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "bdaa67fe3d9cb23523aaab66619438ac1087c2341f9033eb5b24523860d39d3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "871a98a7-4a42-431b-8c91-cb8218432b0c", "node_type": "1", "metadata": {}, "hash": "e92158071d14918dcbac4d901917a1d409be30e4917807dae3d8229ebd2085c7", "class_name": "RelatedNodeInfo"}}, "text": "March 2022 IV. Approved Abbreviations 397\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### V. Burn and Burn Fluid Charts\n\nBurn Size Chart 1\n\n| | |18|\n|---|---|---|\n| |18| |\n|18| | |\n| | |18|\n| |13.5|73.5|\n\nSource: Used with permission, University of Utah Burn Center\n\nTotal Body Surface Area\n\n________________________\n\nAPPENDICES\n\nV. Burn and Burn Fluid Charts\n\nRev. March 2022\n\n398\n\nGo To TOC\n---\n# Burn Size Chart 2\n\nRule of 9's for adults\n\nPalmar surface (including fingers) equals 1% of child's body surface.\n\nSource: American Heart Association, Pediatric Advanced Life Support Textbook, 2013\n\n|Content|Page Number|\n|---|---|\n|APPENDICES|399|\n---\n## NASEMSO National Model EMS Clinical Guidelines Version 3.0\n\n|Percentage of Total Body Surface Area by Age, Anatomic Structure, and Body Habitus|\n|---|\n\n|Adult| | |Child| |\n|---|---|---|---|---|\n|Anatomic Structure|Surface Area| |Anatomic Structure|Surface Area|\n|Anterior head|4.5%| |Anterior head|9%|\n|Posterior head|4.5%| |Posterior head|9%|\n|Anterior torso|18%| |Anterior torso|18%|\n|Posterior torso|18%| |Posterior torso|18%|\n|Anterior leg, each|9%| |Anterior leg, each|6.75%|\n|Posterior leg, each|9%| |Posterior leg, each|6.75%|\n|Anterior arm, each|4.5%| |Anterior arm, each|4.5%|\n|Posterior arm, each|4.5%| |Posterior arm, each|4.5%|\n|Genitalia, perineum|1%| |Genitalia/perineum|1%|\n\n|Adult \u2013 Obese| | |Infant| |\n|---|---|---|---|---|\n|80 kg| | |10 kg| |\n|Anatomic Structure|Surface Area| |Anatomic Structure|Surface Area|\n|Head and neck|2%| |Head and neck|20%|\n|Anterior torso|25%| |Anterior torso|16%|\n|Posterior torso|25%| |Posterior torso|16%|\n|Leg, each|20%| |Leg, each|16%|\n|Arm, each|5%| |Arm, each|8%|\n|Genitalia/perineum|0%| |Genitalia/perineum|1%|\n\n________________________\n\nGo To TOC\n\n### APPENDICES\n\nRev. March 2022\n\n### V. Burn and Burn Fluid Charts\n\n|Content|Page number|\n|---|---|\n|Burn and Burn Fluid Charts|400|\n---\nNASEMSO\n\nNASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\nParkland Formula\n\nFor patients who require fluid resuscitation, consider use of the Parkland formula to calculate the volume of normal saline or lactated Ringer\u2019s solution that should be administered intravenously to ensure hemodynamic stability.\n\nVolume of Intravenous Fluid required in the first 24 hours (in mL) = (4 X patient weight in kg) X (Percentage of total body surface area burned)\n\nThe first half of the volume of fluid should be administered over the first 8 hours following the burn with the remaining fluid administered over the following 16 hours.\n\nFor pediatric patients, a weight-based assessment tool (length-based tape or other system) should be used to provide a more accurate estimate of the patient\u2019s weight. Likewise, the total body surface area (BSA) estimates are different for pediatric patients compared to adults due to larger head and trunk size. For children, the palmar surface of the hand (not including the fingers is approximately equal to 1% BSA. The guidelines listed above will provide assistance during the estimation of the percentage of total body surface area burned for patients of various ages and body habitus.\n\n________________________\n\nGo To TOC\n\n## APPENDICES Rev.", "start_char_idx": 909633, "end_char_idx": 912836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "871a98a7-4a42-431b-8c91-cb8218432b0c": {"__data__": {"id_": "871a98a7-4a42-431b-8c91-cb8218432b0c", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9220026d-2817-42c4-a3a7-095f18210c16", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "9406177848c9b66cb27af90e77b6d87f18ccfc1b13e7a9a6bc0d38cabdabfe32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6b6078c-b089-4fae-8dd3-e5490fe5baac", "node_type": "1", "metadata": {}, "hash": "e87b774d7ffbfa724d3e0ab2c6897e61c33f0720ce847ea863910aaa4e9e5557", "class_name": "RelatedNodeInfo"}}, "text": "Volume of Intravenous Fluid required in the first 24 hours (in mL) = (4 X patient weight in kg) X (Percentage of total body surface area burned)\n\nThe first half of the volume of fluid should be administered over the first 8 hours following the burn with the remaining fluid administered over the following 16 hours.\n\nFor pediatric patients, a weight-based assessment tool (length-based tape or other system) should be used to provide a more accurate estimate of the patient\u2019s weight. Likewise, the total body surface area (BSA) estimates are different for pediatric patients compared to adults due to larger head and trunk size. For children, the palmar surface of the hand (not including the fingers is approximately equal to 1% BSA. The guidelines listed above will provide assistance during the estimation of the percentage of total body surface area burned for patients of various ages and body habitus.\n\n________________________\n\nGo To TOC\n\n## APPENDICES Rev. March 2022\n\n### V. Burn and Burn Fluid Charts 401\n---\n# NASEMSO\n\n# NASEMSO\n\n## National Model EMS Clinical Guidelines\n\n### Version 3.0\n\nBurn Injury IV Fluid Rates\n\nInfusion Rate > 30 KG\n\n'Fluld of cholce LR/NS,DO NOT use dextrose contalning flulds\n\n|Wt (lbs)|Wt (kg)|TBSA (%)|8 Hrs of Care|60 gtt|20 gtt|15 gtt|10 gtt|\n|---|---|---|---|---|---|---|---|\n|66| | |15|35|450|15|\n|616|70|Jan|JQ| |45 @|\n| |44i| |750|464|47|\n| |JI|Jwm|J|1|Sm|\n|f6|3i|37i|14i4|26|\n| |4502| |M6|75 0|\n|3|Am|J_|Jnm|Fn|\n| |JL|JL|li2|\n|FF| | | | | | | |\n|Goi|G|145|450|6645|4kZ|\n|475| |98|64 $|\n|4|{q|J0| |\n|\"|545|65|\n|744|7|1i76|154|\n|Jo|30|3|3|3|\n|30|300| |39n0|\n|G| |Qnm|1150|\n|J|J75|L7i|418|42/|\n|3|545|545|Lzi|375|\n|7nn|W|175 0|MlS7|\n|Jn|10z0|067|17im|\n|L1i| | | | | | | |\n|Lli|Gni|fn|J061|1e|\n|ll6|1n| |Jil|\n|lli| | | | | | | |\n|3|M|445|4i|350|J|350|\n|198|3|675|625|175|16B|4Z5|\n|199|4|90| |445 0|\n|9|44i|L4i|Ji|1i|\n|193| | | |45n|\n|JI| | | |4LZ|\n|30|JI|EqI|Jniz_|Ji|\n|7L|Jn| |J8ZS|J75|\n|J0|JMI|J_|I_|Jll_|\n|J_|Ji|lui_|14_|Jli1_|\n|D|JI|6L_| | | | | |\n|0|J|275|775|647|42|\n|MQ| |350|Jaul|26|\n|J| | |206 2|\n|J|1|I|J066|14|Jau|\n|50|Ll75|1375|317|444L|\n|J4|J_|JI|942|12|FL|\n|J4I|30|GnI|fm|Jul|Je|949|\n|J| |875|Jm| |JAMM|\n|J4|4_| | | | | | |\n|764|JAI|501|JeM|FMH|\n|A|J|J65o|\n\nPatients with traumatic injuries may require additional fluids.\n\n________________________\n\nGo To TOC\n\nAPPENDICES\n\nRev.", "start_char_idx": 911872, "end_char_idx": 914204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6b6078c-b089-4fae-8dd3-e5490fe5baac": {"__data__": {"id_": "e6b6078c-b089-4fae-8dd3-e5490fe5baac", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "871a98a7-4a42-431b-8c91-cb8218432b0c", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "a776daaeccad50887caf951c00047d5baf8e58a027b494d683ae2dc75a960f37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f763fe1-8e09-45f7-b808-2160e2062a17", "node_type": "1", "metadata": {}, "hash": "8857d56993cf146410361030cc5186dcd2d830e241220d9ce1882bd073f3ea85", "class_name": "RelatedNodeInfo"}}, "text": "________________________\n\nGo To TOC\n\nAPPENDICES\n\nRev. March 2022\n\nV. Burn and Burn Fluid Charts\n\n402\n---\nNASEMSO\n\nNASEMSO\n\nNational Model EMS Clinical Guidelines\n\nVersion 3.0\n\nBurn Injury IV Fluid Rates\n\nFluid Infusion Rate < 30 KG\n\n\"Fluld of cholce LRYNS,DO NOT use dextrose contalning flulds\n\n|Wt (lbs)|Wt (kg)|TBSA|Hrs of can|60 gtt/min|20 gtt/min|15 gtt/min|10 gtt/min|\n|---|---|---|---|---|---|---|---|\n|0|0|436|43|0|3|\n|3|1|#5|75| | | | |\n|3|1|JiA|47|4|LL| | |\n|50|20|0|45|41*|157| | |\n|\n\nSource: Used with permission, University of Utah Burn Center (https://crisisstandardsofcare.utah.edu).\n\n________________________\n\nGo To TOC\n\nAPPENDICES\n\nRev. March 2022\n\nV. Burn and Burn Fluid Charts\n\n403\n---\n# NASEMSO\n\n## National Model EMS Clinical Guidelines Version 3.0\n\n### VI. Neurologic Status Assessment\n\nNeurologic status assessment involves establishing a baseline and then trending any change in patient neurologic status. Glasgow Coma Score (GCS) is frequently used, but there are often errors in applying and calculating this score. With this in consideration, Glasgow Coma Score may not be more valid than a simpler field approach. Either AVPU (Alert, Verbal, Painful, Unresponsive) or only the motor component of the GCS may more effectively serve in this capacity.\n\n#### Glasgow Coma Score\n\n|Points|Pediatric|Adult|\n|---|---|---|\n|1|No eye opening|No eye opening|\n|2|Eye opening to pain|Eye opening to pain|\n|3|Eye opening to verbal|Eye opening to verbal|\n|4|Eyes open spontaneously|-|\n|1|No vocalization|No verbal response|\n|2|Inconsolable, agitated|Incomprehensible sounds|\n|3|Inconsistently consolable, moaning|Inappropriate words|\n|4|Cries but consolable, inappropriate interactions|Confused|\n|5|Smiles, oriented to sounds, follows objects, interacts|Oriented|\n|1|No motor response|No motor response|\n|2|Extension to pain|-|\n|3|Flexion to pain|-|\n|4|Withdraws from pain|-|\n|5|Localizes pain|-|\n|6|Obeys commands|-|\n\n#### Table X: AVPU\n\nA: The patient is alert\n\nV: The patient responds to verbal stimulus\n\nP: The patient responds to painful stimulus\n\nU: The patient is completely unresponsive\n\n________________________ Go To TOC\n\n### APPENDICES Rev. March 2022\n\n### VI. Neurologic Status Assessment 404\n---\n## National Model EMS Clinical Guidelines - Version 3.0\n\n### VII. Abnormal Vital Signs\n\n|Age|Heart Rate|Respiratory Rate|Systolic BP|Temp (\u00b0C)|\n|---|---|---|---|---|\n|0 d \u2013 1 mo|>205|>60|38|\n|>= 1 mo \u2013 3 mo|>205|>60|38|\n|>= 3 mo \u2013 1 yr|>190|>60|38.5|\n|>= 1 yr \u2013 2 yr|>190|>40|38.5|\n|>= 2 yr \u2013 4 yr|>140|>40|38.5|\n|>= 4 yr \u2013 6 yr|>140|>34|38.5|\n|>= 6 yr \u2013 10 yr|>140|>30|38.5|\n|>= 10 yr \u2013 13 yr|>100|>30|38.5|\n|> 13 yr|>100|>16|38.5|\n\n________________________ Go To TOC\n\nAPPENDICES Rev. March 2022\n\nVII. Abnormal Vital Signs 405\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## VIII. Evidence-Based Guidelines: GRADE Methodology\n\nAn Overview of GRADE Methodology\n\nAlthough engagement in quality EMS research has increased significantly, the demand for evidence-based quality\nprehospital research continues to exceed its availability.", "start_char_idx": 914151, "end_char_idx": 917216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f763fe1-8e09-45f7-b808-2160e2062a17": {"__data__": {"id_": "2f763fe1-8e09-45f7-b808-2160e2062a17", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6b6078c-b089-4fae-8dd3-e5490fe5baac", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "d80785d6b1c97390fd88111896ebf39a0b26fae75d54266f4d147598782415cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "579fc8b1-66fb-4aa7-95a8-a46340cb77e4", "node_type": "1", "metadata": {}, "hash": "9b90ef2dcee9ebe67cd0788df1a5cc5feac2d965ba1dca4f9d72985fe4c54de1", "class_name": "RelatedNodeInfo"}}, "text": "March 2022\n\nVII. Abnormal Vital Signs 405\n---\n# National Model EMS Clinical Guidelines Version 3.0\n\n## VIII. Evidence-Based Guidelines: GRADE Methodology\n\nAn Overview of GRADE Methodology\n\nAlthough engagement in quality EMS research has increased significantly, the demand for evidence-based quality\nprehospital research continues to exceed its availability. The need for evidence-based prehospital patient care\nprotocols was clearly recognized by the Institute of Medicine of the National Academies and clearly stated in 2007\nin The Future of Emergency Care: Emergency Medical Services at the Crossroads.\n\nThe Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology is a transparent\nprocess where the available research is reviewed and assessed by a panel of subject matter experts. Following this\nthorough review process, the available research is reviewed and graded for its validity based upon the assessment of\nthe workgroup, and an evidence-based guideline (EBG) is developed based upon the outcome of the workgroup.\n\nThe Federal Interagency Committee on Emergency Medical Services (FICEMS) and the National EMS Advisory Council\n(NEMSAC) approved a National Prehospital Evidence-based Guideline Model Process for the development,\nimplementation, and evaluation of evidence-based guidelines. This Model Process recommends the use of the GRADE\nmethodology for the guideline development tool. The six process steps of the GRADE EBG development tool are:\n\nAssemble the expert panel and provide GRADE training\nDefine the EBG content area and establish the specific clinical questions to address in patient, intervention,\ncomparison, and outcome (PICO) format\nPrioritize outcomes to facilitate systematic literature searches\nCreate GRADE tables (or evidence profiles) for each PICO question\nVet and endorse GRADE evidence tables and draft recommendations\nSynthesize recommendations into an EMS protocol and visual algorithm\n\nSome evidence-based guidelines cited in this document were created for and released by NHTSA; however, the GRADE\nmethodology is not proprietary to NHTSA or any other organization. Local, regional, and state EMS agencies and EMS\nsystems are encouraged to support the ongoing need for quality prehospital care, improved patient outcome, and the\ngrowing demand for EBGs for EMS.\n\nReferences:\n\nBrown KM. The development of evidence-based prehospital guidelines using a GRADE-based methodology, Prehospital\nEmergency Care, 2014, Suppl 1:3-14, 2014\n\n________________________ Go To TOC\n\n## APPENDICES\n\nRev. March 2022\n\n## VIII. Evidence-Based Guidelines: GRADE Methodology\n\n406\n---\n# NASEMSO National Model EMS Clinical Guidelines\n\n## Version 3.0\n\n### IX. 2022 National Guideline for the Field Triage of Injured Patients\n\n#### National Guideline for the Field Triage of Injured Patients\n\n#### RED CRITERIA\n\n|Injury Patterns|High Risk for Serious Injury|All Patients|\n|---|---|---|\n|Penetrating injuries to head, neck, torso, and proximal extremities| | |\n|Skull deformity, suspected skull fracture| | |\n|Suspected spinal injury with new motor or sensory loss| | |\n|Chest wall instability, deformity, suspected flail chest| | |\n|Suspected pelvic fracture| | |\n|Suspected fracture of two or more proximal long bones| | |\n|Crushed, degloved, mangled; or pulseless extremity| | |\n|Amputation proximal to wrist or ankle| | |\n|Active bleeding requiring a tourniquet or wound packing with continuous pressure| | |\n|Patients meeting any one of the above RED criteria should be transported to the highest-level trauma center available within the geographic constraints of the regional trauma system| | |\n\n#### YELLOW CRITERIA\n\n|Mechanism of Injury|Moderate Risk for Serious Injury|EMS Judgement|\n|---|---|---|\n|High-Risk Auto Crash| | |\n|Partial or complete ejection| | |\n|Significant intrusion (including roof)| | |\n|Death in passenger compartment| | |\n|Child (Age 0-9) unrestrained or in unsecured child safety seat| | |\n|Fall from height > 10 feet (all ages)| | |\n|Patients meeting any one of the YELLOW CRITERIA WHO DO NOT MEET RED CRITERIA should be preferentially transported to a trauma center, as available within the geographic constraints of the regional trauma system| | |\n\nNote: \"Low-level\" refers to less than 10 feet including ground level falls (need not be the highest-level trauma center)\n\nSource: The American College of Surgeons Committee on Trauma (ACS COT), 2022\n\n________________________\n\nGo To TOC\n\n### APPENDICES\n\n### IX.", "start_char_idx": 916858, "end_char_idx": 921344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "579fc8b1-66fb-4aa7-95a8-a46340cb77e4": {"__data__": {"id_": "579fc8b1-66fb-4aa7-95a8-a46340cb77e4", "embedding": null, "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afb9b040-6326-42a5-83fb-cf44aa93e06d", "node_type": "4", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "8afc2f9fe08e4373037cd36e14992b2b89aec741cc4a125ba0e2066450601100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f763fe1-8e09-45f7-b808-2160e2062a17", "node_type": "1", "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}, "hash": "3c900dcda2e7f3b5d70298bc879a1c83a5ac2bd651f5c9bf78f26763ae1bdc91", "class_name": "RelatedNodeInfo"}}, "text": "2022 National Guideline for the Field Triage of Injured Patients\n\nRev. March 2022\n\n407", "start_char_idx": 921345, "end_char_idx": 921431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/ref_doc_info": {"afb9b040-6326-42a5-83fb-cf44aa93e06d": {"node_ids": ["1036a4f8-3485-4d30-a6cb-aa4f9bc3a0a5", "052cbc8d-fa9f-42fb-83e9-5766d8e788a4", "43458db4-244a-48b3-8e1d-af78647d3291", "d80d93c7-46e6-4a61-bae0-ebca359a0f81", "4158e382-6845-4f03-9e03-1bb0da38247c", "c685d16f-0229-44b6-a640-095ba85eb828", "19fb4a23-a91f-476a-82c9-8a3e749927fb", "f4953596-7d02-4fe0-8879-9e16292174ab", "236b8a33-9489-48f1-ae41-b2025f3ccdaf", "7f5fc362-b2f0-41bd-b2a3-1c0c6e3b9830", "1ad76d80-f31b-433e-bc05-c6580728a784", "1ac7f708-6fc9-4cd4-8800-0e058f5f38ee", "4489c10f-77ce-47f6-ba54-5265142fac28", "ddb3c7a4-47d7-46b0-b4ba-962f9da7b55b", "a6ca6a4a-ad94-41e2-9994-d92271b399aa", "99135879-8373-4bb8-8700-abfc7ed740b6", "0b151272-b5f3-46f1-9fa4-8281dc1b54f3", "ecafb81d-90b8-4b6c-9cad-5cdf3884e661", "eb46cca4-1e07-48d1-b2b0-a9e5c2e17106", "a9692c7a-ee28-44ac-b19b-1bd19e41c25b", "ad805fd6-1618-4255-a9cc-6be22582b2fd", "aede0b6a-4ecb-491a-8d8c-290df566cb1a", "25c75933-341f-4f40-bff4-164b65b2d1f2", "d5186346-bc1c-456b-8eca-6e392508db4a", "1b8cbd76-01c7-443f-ad43-0b4ccd2350ef", "449a6cce-d131-41e8-9502-e32a621694bf", "103d247a-c0df-4b31-b219-83173b72fb65", "e8d2eacc-9f37-4d14-ba67-dfcf08f7d1ee", "c5b0e74a-7ae2-4afb-b7fc-8cee366a3e91", "b17bc647-e238-4e04-a2c5-cc6659c0c0f0", "8479a90a-1221-4e8b-abcf-7fc084c4021c", "f4448a73-5eb5-4ba1-8068-5bfda83b79cb", "45c4adb3-6a9d-47c1-b73e-add0b14a913c", "daa465cc-2819-48f3-aa86-5d356cd5d569", "ee99db64-dd02-4b8b-b523-3f332e1a9456", "59c7b1bd-6874-4dc4-a60b-d76951e40ca5", "69ba04b1-ec0b-4f35-9c26-0dc6e2180114", "e32cab25-cf9e-4ce9-bc0a-1763e97caf72", "24a37567-78f2-405e-ab36-09f0f98f53a7", "49c0e777-a6c0-4529-974a-1d52c86e4cd8", "40baa07a-bdda-403d-b422-81e5ef472ba7", "4a587a50-e6bc-4dcb-90fa-2f15d08c055a", "14d7c90d-0e4a-4de3-b1d1-6fd8b1bd90bb", "71f7b1c0-17cc-4e46-ba75-d40b74faf6cf", "6f2369d1-2979-4dfa-97cc-197840df09bc", "0bfa73c0-65f0-4b6b-bd9d-bb1d70cd71e6", "8b8c5c2b-d62f-4c3d-b88c-ff0b905bb01f", "f4d8731f-de36-422e-b47c-dde8f7d43c3a", "e54d1f30-7e17-4486-a9d6-9c317842cca2", "00529685-51ce-451c-9738-58689422bda1", "eb23ea85-cec7-47c9-b7ac-c1994897aa74", "9cb11c9f-ab42-4032-9247-42891281c397", "937519ce-0dad-48f6-8445-232d1f32866e", "61f7f586-3fbd-4224-9f4d-ee339ef1ba5a", "68d17695-6053-4a48-af47-35705201d333", "0d3f64cc-bd9f-4fd3-a1b9-3a10ed44b518", "9be33f89-e3d7-44cc-a1dc-67347895e4c1", "91d2c834-1bb8-459b-a791-c98887609019", "d16802c4-9be4-46da-9d90-7b95036ad451", "1a0fd09c-bdda-4bd5-90a5-c829def51fda", "690b7103-f38e-46da-8511-f9e7835a084c", "acb4dec0-79a4-454e-9289-7cdfd94ceb21", "30f154ac-54d0-457c-af30-6373dace70ba", "6a4be7fb-c4e3-4b91-bf58-ffbb5cd7248d", "961e12af-4d2f-4f75-8018-8e3ababf2bd7", "9407dfbb-c851-4b9d-9004-7d81b463b5e3", "c161b1ee-d189-455b-b78b-d089d9154a45", "3b67ef33-19f3-4cb6-8fb3-d6d9259afe2f", "a177ca05-4dea-44f4-970e-ee783b7bfc0a", "0ffec63e-c37c-4c72-a712-3b7fccaef9d2", "9692b485-7b15-4800-9659-f813ae362532", "28ac60bc-bda8-4b08-9942-5edd029b9670", "dcaeca5c-1ee8-430a-b687-58e0a3fbd310", "288eccf3-d9f1-4b5f-b044-b3a3675208cd", "6b69d05c-f395-4901-91a4-5faccc2bc2fc", "56edb2ea-d832-48e1-a724-94a83e10b95d", "649ce2f9-13db-4093-815f-4d5af1186966", "bfdedacb-6f1d-4f5e-b6ee-75f18a47fa8c", "4a3edce0-e362-4db2-92d1-94bbf0f25f97", "cfd4b491-08f1-4d60-991a-3eda0c66750c", "b71c35c2-6518-44ff-b2aa-949152b438ca", "5080571c-37c9-4a9c-b04b-c760b4384c72", "e368f399-145d-4986-8c5e-ae5edf99d1d5", "ba1ba382-5680-4b70-a172-f20f39d3bb6e", "9cb65691-478a-473a-a029-9031f6181067", "36601084-14f5-4891-8843-cf3da093f2e2", "e08820ea-03f2-4a04-8f1e-5c0d71cfb10d", "ced1544d-e977-49eb-8e8c-8e4cbe90fdec", "1a3b97b9-209d-46ef-a814-1918e1b13f3f", "76f7a18e-9e55-4515-9a86-faabbfbcbd4e", "75a48158-a4bc-4389-a621-57493449b494", "7dca7282-c74c-4730-b0c3-c7facfe84305", "0a0a3d38-b758-4655-978a-349506737657", "ddc8d27b-f612-4146-8ed4-87c59233eec7", "28150757-f102-44c2-81a0-4a3d80492343", "9fd9ffa0-ff02-4dad-9d1a-43b06a4f2526", "42409b83-d018-4272-8c0e-0b419cae7e82", "e6e4c1ed-008e-43c0-9157-6a944babce8f", "fafb8693-ecdb-4afc-b535-4ed2d173d0a5", "936e113b-929f-4223-8c9b-818105a8cc6b", "1b241987-b338-4b9d-8276-91acd4d8a4e4", "47f9d7a3-2e00-4c5c-a277-57af3f134ee2", "43d54893-d8e8-4be2-845a-935680a75dc3", "2f6ef761-f940-4459-a9e9-aa0324c39d73", "cbd14bdd-47db-47d3-8db0-9cf973e24878", "4117d508-400d-456d-b3f1-52d90a14a586", "39ecc645-2496-4cab-97f7-339e1dff17bb", "8ca16fd9-8388-4140-b3c5-d260c925b00b", "f395d788-fb73-4df3-b4d7-a9b7e7295919", "2d0f803e-a067-4c27-8108-2d5ee25030e8", "85d49957-ae50-466a-8c85-6d029bf7295f", "685897a8-6be3-45c8-9972-c7e3dee7c261", "e919736f-026a-497d-a57a-d9e914102879", "62fbd0d4-0d75-4298-8ab6-3d8b39d03334", "5e62b029-8891-4b2b-b0bb-d9c998a907dc", "f8dadadf-2830-4e78-a001-1bdfab2bf5fb", "4066d87e-0092-45ec-b530-31e17778ef3e", "f3888ea3-4c0d-491a-bc9d-4df171f4602a", "e4e1aa3d-c9b9-4dfb-b74e-941e7d91ce55", "972c0f03-1969-4128-96a5-cc324384f60c", "57edc9ec-0116-4bc5-aece-44adab3723a4", "f5aaa0ab-09ee-4a4b-ac0f-3afee52f7b6b", "2a769a85-a4a1-4035-a56e-651cbbb29a3a", "1ca669ab-3103-419f-954a-6a9bed6946f1", "ed28d78a-bfe1-4e4d-aeb6-f735250f7d43", "7d9bc5ff-f858-4ca5-a1a7-02609294c7a2", "94507c4d-a376-4aee-940c-f069bda93e75", "bbed5a8c-886c-4f8e-a434-3e8635945b52", "cc81e3a0-aa8a-4556-9b03-c0a093c91302", "a9355efb-ad67-44eb-b4ca-72994217a088", "9b2fe97e-e211-426c-abf6-a9ff248071ab", "b0fee0bb-948b-41b4-a18f-204cb0140cb3", "c6630ff4-f3ef-4204-9883-711d7685995a", "00a56089-0956-4078-8a0a-02b888f08c2c", "11e0291a-7412-4c7b-906f-27ad7188631e", "cfaa5827-9140-45c1-a536-639ea9fdf92e", "1053b498-b6b2-4e1d-a0ba-d0ad8da908ae", "60c0aaa9-5f40-4fbc-bdd8-6fe51181f6a2", "d415fc58-0e1d-4d0a-bcbc-f61170701876", "2adb8e6f-9152-4417-8ddd-4748f3ab3d6e", "dd78f9cd-07c6-4f4c-92ba-3ce65df77e9b", "37306512-b166-48ce-8ec1-6d617a833ac9", "3c29c57a-b9c0-4f36-ac8d-2ec9a1f2b020", "8c8fe47b-c642-4052-8f16-d2c8d2ce9458", "0fbcd7b5-6e4b-4a84-8f71-02ce8ce7173b", "c84f13da-ce73-47e9-aadd-31d13db6533e", "54fe4d0d-8f14-439d-adab-cafb9c57d862", "e0f20e7a-9885-4a78-b9f5-d6c7b02b1dfb", "3eb08217-0b56-40e7-b585-d9cd98dd376b", "fccb0447-15d5-462d-b4fa-fb371fe7192d", "d0e57b5b-06e8-4917-88de-19c754283d0b", "39c76bfa-1c0d-459d-b92b-aafeb82c530f", "b59ee300-57d8-4a28-94aa-1c9a3d7f93ad", "32e8a32f-4e2d-4dea-9c55-f16df2df9a98", "27feed5c-1a29-4060-9413-32a8e1c84ccd", "9887439d-a408-4ca3-8fcb-1c8234128c66", "04a9b834-4bf4-4a4f-a360-4514a947785b", "f3bb362e-b548-4a6b-b0ee-36cca203cbce", "50e1fbc6-ce92-4407-b3ee-1236bf051cb6", "713c32b8-2196-49a5-9a53-ca53a0676fde", "255105fb-6aef-4034-b7c8-19428baa2b26", "4ef969b0-03f1-469f-8653-e2cbc4668112", "1a4812e1-28d6-468f-86ac-8ce53cebd625", "14b7a12a-641e-4648-9dca-60a535a97025", "b3d574ea-c88e-4e89-a6d1-e85ac3587dfb", "b7dd20e2-c7fa-46fe-9ab0-ef6f2e374f23", "ee974b0e-438c-4280-b3e6-ec22c700d4dc", "653f14f5-48db-4fa7-b2ca-754d8a7f4497", "3d71dba8-8788-40f7-b748-b1efe293bfc2", "40a9ed84-8fbc-464a-b243-576444978912", "4820a60d-7c6e-422c-8fb4-d65d67aaad21", "d8f545c2-4b4d-499d-be28-520d710af962", "e7a52c70-826c-44e8-abef-54480625ddfb", "e224655b-9379-4af3-99b0-5d50cb96489f", "532068e0-122a-408d-9acc-6be26d94d2a6", "7cd6511e-bc6a-4254-baec-f7b36239c34e", "848dd453-5336-4ef9-b445-4508dcbb0ad4", "990c7852-628c-49d8-b18f-141e7e0d4417", "65d74546-e665-421f-a2d2-f6ae5d2544de", "019ef2a0-55d9-4563-8be3-bcb58b6810ea", "980db64e-92c2-47c0-8d6c-f1d967bd5535", "4d1e1223-80da-4d4e-92c9-7c998f55e656", "9937b0e1-4130-432e-8d55-cc1aea6411f9", "53916f59-fff6-497f-82c6-4b7831eed5c1", "43c217ae-86ed-4b41-aa49-efe0219b8ef4", "3ad3447d-121a-4927-b435-36ded6bdc526", "18e5cd46-9c56-48b3-a643-27847ea52e77", "d00b99f9-6510-463a-90b9-1f8e3745dc11", "43e6c42e-71b3-4523-a906-d599c04a21fd", "57481040-2e71-4a0b-b48b-7be0a81156f8", "501aa4df-f3f5-409d-adbd-ea2532add26f", "0fcb2b47-0b13-4d84-893a-961eee50260d", "3b8517c0-5e2c-4ff2-8847-77ebe7162328", "1dce9361-c062-49ba-809a-3183a280c0c8", "ffb16ab1-8580-4243-a4c9-7d31c12a621b", "73637211-3e06-4849-a900-ba6c48bf8e5e", "99c04a38-ede0-4d32-97d5-7dadfd17ace1", "2a0c2f99-1b79-412c-9dcf-007eba999855", "ae640b64-0210-4262-936c-6ca16f261f76", "0a5edce9-d52a-4176-91b9-8b64198a61fc", "bedabdb3-df05-4d9f-a051-cef8ffa5f871", "5aae2931-fc70-4fe0-a893-ad7f219dae57", "9dba4efe-88d4-4301-87fc-e0cefea78bd6", "d50917b1-8db6-496f-abb6-272260bb0986", "447c65af-0137-497f-946d-b395640da62b", "fca67361-d74c-4b9b-b58b-894379487234", "8b36e6fd-cb6b-4055-a0bb-44e3be63eb43", "629a39b7-a00e-4058-b941-a8dfa0f516f3", "040a1177-7e5f-4891-9d1b-fe7d3b12463d", "b59f1c00-1560-4736-9c6a-13ff264e444f", "48959635-c9a5-4b2e-b695-55d12cc9b70c", "df8c28d5-68b9-4a2b-bac6-f889ef058960", "72b7497b-2899-4c2a-95f5-245037f81c02", "bdbe6b3e-f76a-416d-8bd9-659c8f90ddd4", "547143f7-db83-4697-96fd-c28eb0f3bc82", "4ca98578-7a73-4367-a1ef-5e5bece82d63", "95809b13-84ed-4a84-aa5d-c2d92ef30a04", "4a22e37b-54b8-4b90-a44f-1131c4c3f46d", "f196db6c-c458-4c3c-8d17-ac0ab9465e3f", "182780ec-7bf9-4666-bb0b-75b8036439d2", "b7abb64d-ecb9-446f-b6a0-32feba4452f7", "0b23df02-efed-499a-ad31-077d7f011f61", "bb9c554f-88e7-47ef-96c0-b7c88c3d5e05", "9e80edf3-85ca-432c-9447-b5d431ef6d20", "434127b6-661a-4fb4-9190-7d84d683c97f", "4d58d043-4f92-4584-9a95-db18d0194ae0", "18a79015-7dd2-43b2-9df3-39072348e97e", "2face4b7-6f07-479a-8169-11c8b114894b", "bb5374f9-ece3-4db3-8927-63ed09f1a2e6", "325551bf-cd86-471a-be73-e7c314b050db", "ad6609e2-4bd6-44b9-bfa9-bffa78f18567", "cc48a589-3ca6-4f8c-9990-381bf7af79c2", "8dea17a3-171a-42b8-8102-c350832c7102", "509b7404-7fac-4152-855b-6cd1cbfdadba", "fcfe8dfd-b23d-4542-9943-5e9120852dc6", "7f72b190-57d5-47bc-b152-ed7eb7a3f8df", "5bddc74c-3192-4eeb-84cb-7ab375b0d84b", "792001b1-621e-4e93-850f-d4d4f7eee655", "52ff2706-6c8b-4998-a57b-3df0f649c2dd", "c20f7eba-bab5-4b9a-81dd-9fa4a4b2be6b", "9f23fc7d-7226-4a59-9650-a4e5a9a9c4e5", "12d4f45e-74ca-4008-a0ed-28f655fae283", "2cee667e-a67a-40b9-b2a3-596a2882f35b", "05319213-e034-405d-916f-acc33384a011", "f1fb7cf0-faab-420b-b017-60c5e17c2a8b", "5b3d43df-9ab3-44e5-bdd3-d1da43112b1c", "38caee37-180e-4b0c-9dc3-0038efc65b84", "5374afa9-5f59-48ba-9ff0-6353db66dec9", "70386e3e-0ffd-4dca-aeb5-f6b2e432cc98", "4ff5cb4c-5f6e-4c95-9f62-3ec45ae59fea", "1e13093d-54f6-4e0f-8ade-e1246a76a0f5", "590ea2b3-1acb-4bc4-8f00-0d11cd8e100a", "301f1ef3-abbf-43a4-a9ed-db41588bec7c", "053147ef-9e39-49ea-9a2d-a9e5809be524", "b6768563-f8f2-4888-b4c3-8ad41cad23ff", "316858bc-b366-46c2-8760-670ab4b880d0", "287ac444-df08-41e0-a01e-c8aef2afa6ce", "bb8eff95-18df-4789-84d8-9afe0c1482f2", "d47bdbd4-451d-45a8-875b-cfb6e9df257a", "ee852c4c-7e25-424d-a503-28a158b59444", "0ee8b7ad-9655-40f2-acbf-5d802afe50b0", "d1bbf538-19da-4eaa-a283-12ec27565ef8", "be163f8a-f99c-46b0-9f8d-aad7093e34f0", "f1330769-5221-4b15-8f72-4b352c249455", "03a9d552-7665-468e-aa4e-ea67146e55aa", "b6184f38-a493-4641-9867-f75845bd5b41", "5144c4bc-c318-413d-b751-09541e4c8fb4", "dda1f4e2-b735-4b4e-985a-8627419c5587", "ae013a5a-6816-4183-bcff-ab09d23142ac", "c66dae90-73dd-45c5-bd42-a112fbb68f37", "ef6c0fba-cc33-4d7a-9d09-0f7e671e3175", "c22fcf0b-3a5e-464f-824a-d4cc09fa7d4f", "cbae228d-276d-492f-bd05-518d623a5f26", "1a7d110e-2a45-457a-99df-fbc22fdbf4c4", "de30defa-b6e4-4c02-8bf6-4d821664b776", "ca75fa2d-ecab-4b75-b875-3eefa9cac1c3", "a8abea84-fbe2-4f3e-926d-f3f6a3fa15a9", "0cd11053-59b9-4bd1-aa0f-ce84f91393d4", "4a1c028c-1af7-46de-afc8-4d3e3802f39d", "b8387343-4baf-4167-a241-ad3a25091c81", "af2dc654-25ff-4759-b6be-2068914f8083", "62f01751-8868-4ae7-8262-0df65a02a61e", "9631a34f-a0bf-4223-b105-125997254604", "a0e4ced8-b15f-45aa-a2d4-5b57b2469e12", "6fa65883-c39b-49c5-9cc8-3ce0161c6d05", "897af07f-4bbd-4172-a260-a5d8bb3f2510", "8c0b4cd7-60fc-45b2-9e6d-1cd679734c3e", "a60b7ae8-db95-45e4-868d-411a6f58ef0a", "693ee3df-41dd-4ff0-8bac-31eef592b4ef", "9220026d-2817-42c4-a3a7-095f18210c16", "871a98a7-4a42-431b-8c91-cb8218432b0c", "e6b6078c-b089-4fae-8dd3-e5490fe5baac", "2f763fe1-8e09-45f7-b808-2160e2062a17", "579fc8b1-66fb-4aa7-95a8-a46340cb77e4"], "metadata": {"file_path": "./static/National-Model-EMS-Clinical-Guidelines_2022.pdf"}}}}